CA3137804A1 - Phage and transduction particles - Google Patents
Phage and transduction particles Download PDFInfo
- Publication number
- CA3137804A1 CA3137804A1 CA3137804A CA3137804A CA3137804A1 CA 3137804 A1 CA3137804 A1 CA 3137804A1 CA 3137804 A CA3137804 A CA 3137804A CA 3137804 A CA3137804 A CA 3137804A CA 3137804 A1 CA3137804 A1 CA 3137804A1
- Authority
- CA
- Canada
- Prior art keywords
- phage
- dna
- cell
- composition
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 374
- 230000026683 transduction Effects 0.000 title claims abstract description 128
- 238000010361 transduction Methods 0.000 title claims abstract description 128
- 108020004414 DNA Proteins 0.000 claims abstract description 400
- 239000000203 mixture Substances 0.000 claims abstract description 378
- 241000894006 Bacteria Species 0.000 claims abstract description 239
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 229
- 238000000034 method Methods 0.000 claims abstract description 190
- 239000013612 plasmid Substances 0.000 claims abstract description 111
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 68
- 231100000331 toxic Toxicity 0.000 claims abstract description 52
- 230000002588 toxic effect Effects 0.000 claims abstract description 52
- 210000004027 cell Anatomy 0.000 claims description 535
- 238000004806 packaging method and process Methods 0.000 claims description 190
- 230000001580 bacterial effect Effects 0.000 claims description 119
- 101710172711 Structural protein Proteins 0.000 claims description 100
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 239000013598 vector Substances 0.000 claims description 76
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 69
- 239000002773 nucleotide Substances 0.000 claims description 68
- 125000003729 nucleotide group Chemical group 0.000 claims description 67
- 241000282414 Homo sapiens Species 0.000 claims description 66
- 241001465754 Metazoa Species 0.000 claims description 62
- 108020005004 Guide RNA Proteins 0.000 claims description 59
- 230000010076 replication Effects 0.000 claims description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 42
- 101710163270 Nuclease Proteins 0.000 claims description 40
- 108700039887 Essential Genes Proteins 0.000 claims description 34
- 244000005700 microbiome Species 0.000 claims description 28
- 210000000349 chromosome Anatomy 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 24
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 20
- 230000003362 replicative effect Effects 0.000 claims description 19
- 230000003828 downregulation Effects 0.000 claims description 15
- 230000022534 cell killing Effects 0.000 claims description 13
- 230000002463 transducing effect Effects 0.000 claims description 12
- 241001137855 Caudovirales Species 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 9
- 230000009089 cytolysis Effects 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 90
- 230000002068 genetic effect Effects 0.000 abstract description 15
- 230000007613 environmental effect Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 description 84
- 239000003242 anti bacterial agent Substances 0.000 description 69
- 241000894007 species Species 0.000 description 65
- 150000007523 nucleic acids Chemical class 0.000 description 58
- 230000003115 biocidal effect Effects 0.000 description 54
- 108020004707 nucleic acids Proteins 0.000 description 48
- 102000039446 nucleic acids Human genes 0.000 description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 description 36
- 108091033409 CRISPR Proteins 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 30
- 241000588724 Escherichia coli Species 0.000 description 28
- 241000193403 Clostridium Species 0.000 description 26
- 238000010354 CRISPR gene editing Methods 0.000 description 24
- 241000736262 Microbiota Species 0.000 description 24
- 230000001939 inductive effect Effects 0.000 description 22
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 108700010839 phage proteins Proteins 0.000 description 19
- 230000002950 deficient Effects 0.000 description 17
- 239000013605 shuttle vector Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 239000006166 lysate Substances 0.000 description 16
- 230000002101 lytic effect Effects 0.000 description 16
- 230000001276 controlling effect Effects 0.000 description 15
- 230000007918 pathogenicity Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 230000008685 targeting Effects 0.000 description 15
- 108010040614 terminase Proteins 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 14
- 244000005709 gut microbiome Species 0.000 description 13
- 230000004543 DNA replication Effects 0.000 description 12
- 241000589516 Pseudomonas Species 0.000 description 12
- 241000194017 Streptococcus Species 0.000 description 12
- 210000000234 capsid Anatomy 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 241000588748 Klebsiella Species 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 241000607142 Salmonella Species 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 229960000268 spectinomycin Drugs 0.000 description 10
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 10
- 229960005322 streptomycin Drugs 0.000 description 10
- 241000702192 Escherichia virus P2 Species 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 9
- 229960000318 kanamycin Drugs 0.000 description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 9
- 229930182823 kanamycin A Natural products 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000002689 soil Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 238000010459 TALEN Methods 0.000 description 8
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 101100497181 Comamonas sp. (strain NCIMB 9872) cpnB gene Proteins 0.000 description 7
- 108010061833 Integrases Proteins 0.000 description 7
- 241000187747 Streptomyces Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 241000589634 Xanthomonas Species 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 108060003760 HNH nuclease Proteins 0.000 description 6
- 102000029812 HNH nuclease Human genes 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 6
- 241001496920 Tenacibaculum Species 0.000 description 6
- 241000607598 Vibrio Species 0.000 description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 229960004099 azithromycin Drugs 0.000 description 6
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- 241000187362 Actinomadura Species 0.000 description 5
- 241000186063 Arthrobacter Species 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 101100497194 Comamonas testosteroni cpnA gene Proteins 0.000 description 5
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 241000589248 Legionella Species 0.000 description 5
- 208000007764 Legionnaires' Disease Diseases 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 241000607768 Shigella Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 230000017363 positive regulation of growth Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- -1 such as a Cas Proteins 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 241000186046 Actinomyces Species 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 244000061176 Nicotiana tabacum Species 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 241001428633 Phage P4 satellite Species 0.000 description 4
- 241000702072 Podoviridae Species 0.000 description 4
- 241000605861 Prevotella Species 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- 241000702202 Siphoviridae Species 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 241000701521 Tectiviridae Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 241000193445 [Clostridium] stercorarium Species 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 4
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000004009 herbicide Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- JEOQACOXAOEPLX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1.OC(=O)[C@@H](N)CCCN=C(N)N JEOQACOXAOEPLX-WCCKRBBISA-N 0.000 description 3
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 3
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000021612 Bacillus halotolerans Species 0.000 description 3
- 241001221145 Bacteroides pyogenes Species 0.000 description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000157902 Brachybacterium Species 0.000 description 3
- 241000206594 Carnobacterium Species 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 241000186542 Clostridium baratii Species 0.000 description 3
- 241000688734 Clostridium estertheticum Species 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 241000701520 Corticoviridae Species 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 241000702221 Cystoviridae Species 0.000 description 3
- 230000003682 DNA packaging effect Effects 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000760358 Enodes Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 241000589565 Flavobacterium Species 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 3
- 241000702394 Inoviridae Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 3
- 241000714210 Leviviridae Species 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000863391 Methylophilus Species 0.000 description 3
- 241001467578 Microbacterium Species 0.000 description 3
- 241000702318 Microviridae Species 0.000 description 3
- 241000701553 Myoviridae Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 241001659629 Virgibacillus Species 0.000 description 3
- 241000589506 Xanthobacter Species 0.000 description 3
- 241000607734 Yersinia <bacteria> Species 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 210000003578 bacterial chromosome Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 230000002363 herbicidal effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 230000001320 lysogenic effect Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000005065 mining Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 2
- 241001430271 Acetitomaculum Species 0.000 description 2
- 241001495178 Acetivibrio Species 0.000 description 2
- 244000235858 Acetobacter xylinum Species 0.000 description 2
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 2
- 241000588853 Acidiphilium Species 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 241000187844 Actinoplanes Species 0.000 description 2
- 241000841740 Actinotalea Species 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 2
- 241000607574 Aeromonas veronii Species 0.000 description 2
- 241000702460 Akkermansia Species 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 2
- 241001147780 Alicyclobacillus Species 0.000 description 2
- 241000358067 Alkalibacillus haloalkaliphilus Species 0.000 description 2
- 241000722955 Anaerobiospirillum Species 0.000 description 2
- 241000379991 Anaerococcus Species 0.000 description 2
- 241000337031 Anaeromyxobacter Species 0.000 description 2
- 241000555286 Aneurinibacillus Species 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 241000192705 Aphanothece Species 0.000 description 2
- 241001135699 Arcanobacterium Species 0.000 description 2
- 241001135163 Arcobacter Species 0.000 description 2
- 241000589941 Azospirillum Species 0.000 description 2
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 2
- 241001032451 Bacillus indicus Species 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 241000588676 Bergeriella denitrificans Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000498637 Brevibacillus agri Species 0.000 description 2
- 241000193764 Brevibacillus brevis Species 0.000 description 2
- 241000534628 Brevibacillus centrosporus Species 0.000 description 2
- 241000534630 Brevibacillus choshinensis Species 0.000 description 2
- 241000193417 Brevibacillus laterosporus Species 0.000 description 2
- 241000534614 Brevibacillus parabrevis Species 0.000 description 2
- 241000534616 Brevibacillus reuszeri Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- 241000168061 Butyrivibrio proteoclasticus Species 0.000 description 2
- 241001645400 Caldanaerobius Species 0.000 description 2
- 241000178334 Caldicellulosiruptor Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 241000520057 Catellatospora Species 0.000 description 2
- 241000588917 Citrobacter koseri Species 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000193167 Clostridium cochlearium Species 0.000 description 2
- 241001147706 Clostridium sardiniense Species 0.000 description 2
- 241000863004 Cystobacter Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000702197 Enterobacteria phage P4 Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241001608234 Faecalibacterium Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 241001509401 Gordonia rubripertincta Species 0.000 description 2
- 108050008753 HNH endonucleases Proteins 0.000 description 2
- 102000000310 HNH endonucleases Human genes 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 2
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 241000026993 Jeotgalibacillus Species 0.000 description 2
- 241000579722 Kocuria Species 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241001236203 Lonsdalea quercina Species 0.000 description 2
- 102100035304 Lymphotactin Human genes 0.000 description 2
- 241000206589 Marinobacter Species 0.000 description 2
- 241001633954 Microbacterium oxydans Species 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 102100023897 NADPH-cytochrome P450 reductase Human genes 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 241000167284 Natranaerobius Species 0.000 description 2
- 241000579725 Nesterenkonia Species 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 241000178959 Paenibacillus durus Species 0.000 description 2
- 241000227676 Paenibacillus thiaminolyticus Species 0.000 description 2
- 241001238056 Paraburkholderia ginsengisoli Species 0.000 description 2
- 241000866630 Paraburkholderia graminis Species 0.000 description 2
- 241000193390 Parageobacillus thermoglucosidasius Species 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 108050005751 Portal proteins Proteins 0.000 description 2
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 2
- 101710143509 Pre-histone-like nucleoprotein Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 241000588671 Psychrobacter Species 0.000 description 2
- 241000981915 Quatrionicoccus Species 0.000 description 2
- 108090000951 RNA polymerase sigma 70 Proteins 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- 101710197208 Regulatory protein cro Proteins 0.000 description 2
- 241000192031 Ruminococcus Species 0.000 description 2
- 241000187560 Saccharopolyspora Species 0.000 description 2
- 241000192023 Sarcina Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000438283 Staphylococcus aureus RF122 Species 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 241001234013 Staphylococcus vitulinus Species 0.000 description 2
- 241000191973 Staphylococcus xylosus Species 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 241000589262 Tatlockia micdadei Species 0.000 description 2
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 2
- 241000658698 Tepidanaerobacter Species 0.000 description 2
- 241001581232 Tepidibacter Species 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 241001467018 Typhis Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241001661387 Umezawaea tangerina Species 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 241000498583 Ureibacillus thermosphaericus Species 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 241001655291 Williamsia Species 0.000 description 2
- 241000043486 Yokenella Species 0.000 description 2
- 241000824405 Zeaxanthinibacter Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 101150062912 cct3 gene Proteins 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 238000000424 optical density measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 101150095178 pacA gene Proteins 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 101150075675 tatC gene Proteins 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 208000002918 testicular germ cell tumor Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 1
- 101150016096 17 gene Proteins 0.000 description 1
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- 101710183434 ATPase Proteins 0.000 description 1
- 241000201856 Abiotrophia defectiva Species 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241001133252 Acaricomes Species 0.000 description 1
- 241001133251 Acaricomes phytoseiuli Species 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 241001420322 Acetanaerobacterium Species 0.000 description 1
- 241000204555 Acetitomaculum ruminis Species 0.000 description 1
- 241001495177 Acetivibrio cellulolyticus Species 0.000 description 1
- 241001109646 Acetivibrio ethanolgignens Species 0.000 description 1
- 241001112780 Acetoanaerobium Species 0.000 description 1
- 241001223493 Acetoanaerobium noterae Species 0.000 description 1
- 241000193451 Acetoanaerobium sticklandii Species 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 244000283763 Acetobacter aceti Species 0.000 description 1
- 235000007847 Acetobacter aceti Nutrition 0.000 description 1
- 241000776564 Acetobacter cerevisiae Species 0.000 description 1
- 241001310540 Acetobacter cibinongensis Species 0.000 description 1
- 241001497693 Acetobacter estunensis Species 0.000 description 1
- 241000209191 Acetobacter fabarum Species 0.000 description 1
- 241000023769 Acetobacter ghanensis Species 0.000 description 1
- 241001497546 Acetobacter lovaniensis Species 0.000 description 1
- 241000776559 Acetobacter malorum Species 0.000 description 1
- 241000813193 Acetobacter nitrogenifigens Species 0.000 description 1
- 241000924390 Acetobacter oeni Species 0.000 description 1
- 241001310537 Acetobacter orientalis Species 0.000 description 1
- 241000452744 Acetobacter senegalensis Species 0.000 description 1
- 241001468161 Acetobacterium Species 0.000 description 1
- 241000511260 Acetobacterium bakii Species 0.000 description 1
- 241000511218 Acetobacterium carbinolicum Species 0.000 description 1
- 241001633096 Acetobacterium dehalogenans Species 0.000 description 1
- 241000511217 Acetobacterium fimetarium Species 0.000 description 1
- 241000511216 Acetobacterium malicum Species 0.000 description 1
- 241000511215 Acetobacterium paludosum Species 0.000 description 1
- 241000915445 Acetobacterium tundrae Species 0.000 description 1
- 241000511222 Acetobacterium wieringae Species 0.000 description 1
- 241001468163 Acetobacterium woodii Species 0.000 description 1
- 241000549912 Acetofilamentum Species 0.000 description 1
- 241001135190 Acetohalobium Species 0.000 description 1
- 241001135192 Acetohalobium arabaticum Species 0.000 description 1
- 241000245942 Acetomicrobium Species 0.000 description 1
- 241000245947 Acetomicrobium flavidum Species 0.000 description 1
- 241000394635 Acetomicrobium mobile Species 0.000 description 1
- 241000204396 Acetonema Species 0.000 description 1
- 241000204392 Acetonema longum Species 0.000 description 1
- 241000549924 Acetothermus Species 0.000 description 1
- 241001603747 Acetothermus paucivorans Species 0.000 description 1
- 241001148575 Acholeplasma axanthum Species 0.000 description 1
- 241000881835 Acholeplasma brassicae Species 0.000 description 1
- 241000078099 Acholeplasma cavigenitalium Species 0.000 description 1
- 241000078104 Acholeplasma granularum Species 0.000 description 1
- 241000078105 Acholeplasma hippikon Species 0.000 description 1
- 241000203022 Acholeplasma laidlawii Species 0.000 description 1
- 241000203057 Acholeplasma modicum Species 0.000 description 1
- 241000078102 Acholeplasma morum Species 0.000 description 1
- 241000078103 Acholeplasma multilocale Species 0.000 description 1
- 241001495110 Acholeplasma oculi Species 0.000 description 1
- 241001537153 Acholeplasma palmae Species 0.000 description 1
- 241000078106 Acholeplasma parvum Species 0.000 description 1
- 241000319470 Acholeplasma pleciae Species 0.000 description 1
- 241000984021 Acholeplasma vituli Species 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241001453369 Achromobacter denitrificans Species 0.000 description 1
- 241001611471 Achromobacter insolitus Species 0.000 description 1
- 241001250076 Achromobacter piechaudii Species 0.000 description 1
- 241001611468 Achromobacter spanius Species 0.000 description 1
- 241000920672 Acidaminobacter Species 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241000604450 Acidaminococcus fermentans Species 0.000 description 1
- 241001116699 Acidaminococcus intestini Species 0.000 description 1
- 241001261672 Acidicaldus organivorans Species 0.000 description 1
- 241000521593 Acidimicrobium Species 0.000 description 1
- 241000521595 Acidimicrobium ferrooxidans Species 0.000 description 1
- 241001290773 Acidiphilium acidophilum Species 0.000 description 1
- 241000588848 Acidiphilium angustum Species 0.000 description 1
- 241000876838 Acidiphilium multivorum Species 0.000 description 1
- 241001468101 Acidiphilium organovorum Species 0.000 description 1
- 241000673694 Acidisoma Species 0.000 description 1
- 241000673697 Acidisoma sibiricum Species 0.000 description 1
- 241000673693 Acidisoma tundrae Species 0.000 description 1
- 241000501787 Acidisphaera Species 0.000 description 1
- 241000501798 Acidisphaera rubrifaciens Species 0.000 description 1
- 241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 1
- 241000605272 Acidithiobacillus thiooxidans Species 0.000 description 1
- 241001468182 Acidobacterium Species 0.000 description 1
- 241001464782 Acidobacterium capsulatum Species 0.000 description 1
- 241001478307 Acidomonas Species 0.000 description 1
- 241000589210 Acidomonas methanolica Species 0.000 description 1
- 241001134629 Acidothermus Species 0.000 description 1
- 241001134630 Acidothermus cellulolyticus Species 0.000 description 1
- 241000726119 Acidovorax Species 0.000 description 1
- 241001311655 Acidovorax anthurii Species 0.000 description 1
- 241000697956 Acidovorax caeni Species 0.000 description 1
- 241001600127 Acidovorax cattleyae Species 0.000 description 1
- 241001600126 Acidovorax citrulli Species 0.000 description 1
- 241000006386 Acidovorax defluvii Species 0.000 description 1
- 241000218592 Acidovorax delafieldii Species 0.000 description 1
- 241000726118 Acidovorax facilis Species 0.000 description 1
- 241001453304 Acidovorax konjaci Species 0.000 description 1
- 241001600692 Acidovorax temperans Species 0.000 description 1
- 241001127180 Acidovorax valerianellae Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241001165345 Acinetobacter baylyi Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241001165347 Acinetobacter gerneri Species 0.000 description 1
- 241001148231 Acinetobacter haemolyticus Species 0.000 description 1
- 241000122229 Acinetobacter johnsonii Species 0.000 description 1
- 241000122231 Acinetobacter radioresistens Species 0.000 description 1
- 241001556023 Acinetobacter schindleri Species 0.000 description 1
- 241000271152 Acinetobacter soli Species 0.000 description 1
- 241001165356 Acinetobacter tandoii Species 0.000 description 1
- 241001165355 Acinetobacter tjernbergiae Species 0.000 description 1
- 241001165358 Acinetobacter towneri Species 0.000 description 1
- 241001556024 Acinetobacter ursingii Species 0.000 description 1
- 241000508783 Acinetobacter venetianus Species 0.000 description 1
- 241000295662 Acrocarpospora Species 0.000 description 1
- 241001495392 Acrocarpospora corrugata Species 0.000 description 1
- 244000309567 Acrodontium simplex Species 0.000 description 1
- 241000488066 Actibacter Species 0.000 description 1
- 241000488069 Actibacter sediminis Species 0.000 description 1
- 241000921775 Actinoalloteichus Species 0.000 description 1
- 241001348202 Actinoalloteichus spitiensis Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000606730 Actinobacillus capsulatus Species 0.000 description 1
- 241000498564 Actinobacillus delphinicola Species 0.000 description 1
- 241000498208 Actinobacillus indolicus Species 0.000 description 1
- 241000606801 Actinobacillus lignieresii Species 0.000 description 1
- 241000498210 Actinobacillus porcinus Species 0.000 description 1
- 241001065789 Actinobacillus scotiae Species 0.000 description 1
- 241000606793 Actinobacillus seminis Species 0.000 description 1
- 241000948980 Actinobacillus succinogenes Species 0.000 description 1
- 241000606791 Actinobacillus ureae Species 0.000 description 1
- 241001291962 Actinobaculum Species 0.000 description 1
- 241001164718 Actinobaculum massiliense Species 0.000 description 1
- 241000186043 Actinobaculum suis Species 0.000 description 1
- 241000832184 Actinocatenispora Species 0.000 description 1
- 241000756769 Actinocatenispora rupis Species 0.000 description 1
- 241000592981 Actinocorallia Species 0.000 description 1
- 241000202388 Actinocorallia aurantiaca Species 0.000 description 1
- 241000921530 Actinocorallia aurea Species 0.000 description 1
- 241000034954 Actinocorallia cavernae Species 0.000 description 1
- 241000202372 Actinocorallia glomerata Species 0.000 description 1
- 241000201765 Actinocorallia libanotica Species 0.000 description 1
- 241000651961 Actinomadura alba Species 0.000 description 1
- 241000187257 Actinomadura atramentaria Species 0.000 description 1
- 241000368680 Actinomadura catellatispora Species 0.000 description 1
- 241000862440 Actinomadura chibensis Species 0.000 description 1
- 241000789908 Actinomadura chokoriensis Species 0.000 description 1
- 241000201754 Actinomadura citrea Species 0.000 description 1
- 241000201753 Actinomadura coerulea Species 0.000 description 1
- 241000187255 Actinomadura echinospora Species 0.000 description 1
- 241000972646 Actinomadura hibisca Species 0.000 description 1
- 241000364961 Actinomadura latina Species 0.000 description 1
- 241001327993 Actinomadura livida Species 0.000 description 1
- 241000157189 Actinomadura oligospora Species 0.000 description 1
- 241000157202 Actinomadura pelletieri Species 0.000 description 1
- 241000199759 Actinomadura rubrobrunea Species 0.000 description 1
- 241000187253 Actinomadura rugatobispora Species 0.000 description 1
- 241000157203 Actinomadura umbrina Species 0.000 description 1
- 241000199757 Actinomadura vinacea Species 0.000 description 1
- 241000592895 Actinomadura viridilutea Species 0.000 description 1
- 241000592900 Actinomadura viridis Species 0.000 description 1
- 241000511656 Actinomyces georgiae Species 0.000 description 1
- 241000511654 Actinomyces gerencseriae Species 0.000 description 1
- 241000511583 Actinomyces howellii Species 0.000 description 1
- 241000132732 Actinomyces johnsonii Species 0.000 description 1
- 241000511582 Actinomyces meyeri Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241001464988 Actinomyces neuii Species 0.000 description 1
- 241000186066 Actinomyces odontolyticus Species 0.000 description 1
- 241000132734 Actinomyces oris Species 0.000 description 1
- 241000900280 Actinomyces radingae Species 0.000 description 1
- 241000511581 Actinomyces slackii Species 0.000 description 1
- 241000900275 Actinomyces turicensis Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 241000219205 Actinoplanes auranticolor Species 0.000 description 1
- 241000183230 Actinoplanes consettensis Species 0.000 description 1
- 241000183229 Actinoplanes deccanensis Species 0.000 description 1
- 241000183228 Actinoplanes derwentensis Species 0.000 description 1
- 241000187841 Actinoplanes digitatis Species 0.000 description 1
- 241000183221 Actinoplanes humidus Species 0.000 description 1
- 241000183219 Actinoplanes italicus Species 0.000 description 1
- 241000983982 Actinoplanes liguriensis Species 0.000 description 1
- 241000183236 Actinoplanes lobatus Species 0.000 description 1
- 241000187843 Actinoplanes missouriensis Species 0.000 description 1
- 241000183243 Actinoplanes palleronii Species 0.000 description 1
- 241001495438 Actinoplanes philippinensis Species 0.000 description 1
- 241000183261 Actinoplanes rectilineatus Species 0.000 description 1
- 241000511219 Actinoplanes regularis Species 0.000 description 1
- 241000187840 Actinoplanes utahensis Species 0.000 description 1
- 241000187793 Actinopolyspora halophila Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000123663 Actinosynnema Species 0.000 description 1
- 241000609850 Actinotignum schaalii Species 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000193798 Aerococcus Species 0.000 description 1
- 241000252859 Aerococcus sanguinicola Species 0.000 description 1
- 241000193795 Aerococcus urinae Species 0.000 description 1
- 241000500353 Aerococcus urinaeequi Species 0.000 description 1
- 241000609146 Aerococcus urinaehominis Species 0.000 description 1
- 241000193792 Aerococcus viridans Species 0.000 description 1
- 241001506298 Aeromonas bestiarum Species 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241001245632 Aeromonas encheleia Species 0.000 description 1
- 241000607513 Aeromonas eucrenophila Species 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 241000607552 Aeromonas jandaei Species 0.000 description 1
- 241000607548 Aeromonas media Species 0.000 description 1
- 241001223881 Aeromonas popoffii Species 0.000 description 1
- 241000607522 Aeromonas sobria Species 0.000 description 1
- 241001660768 Agrococcus citreus Species 0.000 description 1
- 241000202696 Agrococcus jenensis Species 0.000 description 1
- 241001467490 Agromyces Species 0.000 description 1
- 241000134715 Agromyces fucosus Species 0.000 description 1
- 241000824754 Agromyces hippuratus Species 0.000 description 1
- 241001467494 Agromyces ramosus Species 0.000 description 1
- 241000016254 Agromyces rhizospherae Species 0.000 description 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 241001208525 Albidovulum Species 0.000 description 1
- 241001485466 Albidovulum inexpectatum Species 0.000 description 1
- 241000588813 Alcaligenes faecalis Species 0.000 description 1
- 241000611272 Alcanivorax Species 0.000 description 1
- 241000611270 Alcanivorax borkumensis Species 0.000 description 1
- 241000908790 Alcanivorax jadensis Species 0.000 description 1
- 241001179699 Algicola Species 0.000 description 1
- 241000640374 Alicyclobacillus acidocaldarius Species 0.000 description 1
- 241000193412 Alicyclobacillus acidoterrestris Species 0.000 description 1
- 241001347567 Alicyclobacillus vulcanalis Species 0.000 description 1
- 241000162693 Alishewanella Species 0.000 description 1
- 241000162694 Alishewanella fetalis Species 0.000 description 1
- 241001143270 Alkalicoccus saliphilus Species 0.000 description 1
- 241000197729 Alkaliphilus Species 0.000 description 1
- 241001111556 Alkaliphilus oremlandii Species 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 241001655243 Allochromatium Species 0.000 description 1
- 241000190857 Allochromatium vinosum Species 0.000 description 1
- 241000186033 Alloiococcus Species 0.000 description 1
- 241000186032 Alloiococcus otitis Species 0.000 description 1
- 241000722558 Allokutzneria Species 0.000 description 1
- 241001540743 Allokutzneria albata Species 0.000 description 1
- 241001288806 Alloprevotella tannerae Species 0.000 description 1
- 241001400674 Altererythrobacter Species 0.000 description 1
- 241000226889 Alteribacillus iranensis Species 0.000 description 1
- 241000916411 Alteribacillus persepolensis Species 0.000 description 1
- 241001458906 Alysiella Species 0.000 description 1
- 241001657419 Alysiella crassa Species 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 241001430273 Aminobacter Species 0.000 description 1
- 241001621848 Aminobacterium Species 0.000 description 1
- 241001621844 Aminobacterium mobile Species 0.000 description 1
- 241001621927 Aminomonas Species 0.000 description 1
- 241001621924 Aminomonas paucivorans Species 0.000 description 1
- 241000936849 Ammoniphilus Species 0.000 description 1
- 241000936844 Ammoniphilus oxalaticus Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241001147782 Amphibacillus Species 0.000 description 1
- 241000193373 Amphibacillus xylanus Species 0.000 description 1
- 241000772392 Amphritea balenae Species 0.000 description 1
- 241000187643 Amycolatopsis Species 0.000 description 1
- 241001289517 Amycolatopsis alba Species 0.000 description 1
- 241001464404 Amycolatopsis albidoflavus Species 0.000 description 1
- 241001289519 Amycolatopsis coloradensis Species 0.000 description 1
- 241001430311 Amycolatopsis lurida Species 0.000 description 1
- 241001468213 Amycolatopsis mediterranei Species 0.000 description 1
- 241000839543 Amycolatopsis rifamycinica Species 0.000 description 1
- 241000173880 Amycolatopsis rubida Species 0.000 description 1
- 241001289518 Amycolatopsis sulphurea Species 0.000 description 1
- 241001246350 Amycolatopsis tolypomycina Species 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 description 1
- 241001629573 Anaeroarcus Species 0.000 description 1
- 241001633957 Anaeroarcus burkinensis Species 0.000 description 1
- 241001499237 Anaerobacillus alkalidiazotrophicus Species 0.000 description 1
- 241001673109 Anaerobacillus arseniciselenatis Species 0.000 description 1
- 241000039815 Anaerobacillus macyae Species 0.000 description 1
- 241000786447 Anaerobiospirillum thomasii Species 0.000 description 1
- 241001464907 Anaerococcus hydrogenalis Species 0.000 description 1
- 241001464884 Anaerococcus lactolyticus Species 0.000 description 1
- 241001464890 Anaerococcus prevotii Species 0.000 description 1
- 241001464898 Anaerococcus tetradius Species 0.000 description 1
- 241001464864 Anaerococcus vaginalis Species 0.000 description 1
- 241000193457 Anaerocolumna aminovalerica Species 0.000 description 1
- 241001424158 Anaerocolumna jejuensis Species 0.000 description 1
- 241001446754 Anaerocolumna xylanovorans Species 0.000 description 1
- 241000511612 Anaerofilum Species 0.000 description 1
- 241001621846 Anaeromusa acidaminophila Species 0.000 description 1
- 241000246079 Anaerorhabdus furcosa Species 0.000 description 1
- 241001629581 Anaerosinus Species 0.000 description 1
- 241001227086 Anaerostipes Species 0.000 description 1
- 241000319947 Anaerotignum lactatifermentans Species 0.000 description 1
- 241001509481 Anaerotignum neopropionicum Species 0.000 description 1
- 241001136167 Anaerotignum propionicum Species 0.000 description 1
- 241001013579 Anaerotruncus Species 0.000 description 1
- 241000823109 Anaerovirgula Species 0.000 description 1
- 241001558988 Anaerovorax Species 0.000 description 1
- 241001185613 Ancalomicrobium Species 0.000 description 1
- 241001569694 Ancalomicrobium adetum Species 0.000 description 1
- 241000862972 Ancylobacter Species 0.000 description 1
- 241000586489 Ancylobacter aquaticus Species 0.000 description 1
- 241001281729 Aneurinibacillus thermoaerophilus Species 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 241001610717 Angulomicrobium tetraedrale Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241001626813 Anoxybacillus Species 0.000 description 1
- 241001626810 Anoxybacillus pushchinoensis Species 0.000 description 1
- 241000320697 Aquabacterium Species 0.000 description 1
- 241001222023 Aquabacterium commune Species 0.000 description 1
- 241001222025 Aquabacterium parvum Species 0.000 description 1
- 241001600693 Aquaspirillum polymorphum Species 0.000 description 1
- 241000589940 Aquaspirillum serpens Species 0.000 description 1
- 241001109946 Aquimarina Species 0.000 description 1
- 241000605104 Aquimarina latercula Species 0.000 description 1
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 1
- 241000863007 Archangium Species 0.000 description 1
- 241000863009 Archangium gephyra Species 0.000 description 1
- 241001135164 Arcobacter butzleri Species 0.000 description 1
- 241001501366 Arcobacter halophilus Species 0.000 description 1
- 241001135166 Arcobacter nitrofigilis Species 0.000 description 1
- 241001135723 Arcobacter skirrowii Species 0.000 description 1
- 241000204358 Arhodomonas aquaeolei Species 0.000 description 1
- 241000607469 Arsenophonus Species 0.000 description 1
- 241000607467 Arsenophonus nasoniae Species 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241001524194 Arthrobacter agilis Species 0.000 description 1
- 241000185996 Arthrobacter citreus Species 0.000 description 1
- 241000186074 Arthrobacter globiformis Species 0.000 description 1
- 241000186001 Arthrobacter pascens Species 0.000 description 1
- 241000185993 Arthrobacter ramosus Species 0.000 description 1
- 241000024410 Arthrobacter woluwensis Species 0.000 description 1
- 241001147785 Asaccharospora irregularis Species 0.000 description 1
- 241000308413 Asaia Species 0.000 description 1
- 241000308412 Asaia bogorensis Species 0.000 description 1
- 241001482139 Asanoa Species 0.000 description 1
- 241000520065 Asanoa ferruginea Species 0.000 description 1
- 241001291839 Asticcacaulis Species 0.000 description 1
- 241001291837 Asticcacaulis biprosthecium Species 0.000 description 1
- 241001313491 Asticcacaulis excentricus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001377138 Atlantibacter subterranea Species 0.000 description 1
- 241000965595 Atopobacter Species 0.000 description 1
- 241000965596 Atopobacter phocae Species 0.000 description 1
- 241000193818 Atopobium Species 0.000 description 1
- 241001531201 Atopobium fossor Species 0.000 description 1
- 241000193815 Atopobium minutum Species 0.000 description 1
- 241000193836 Atopobium rimae Species 0.000 description 1
- 241001633064 Atopobium vaginae Species 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 241000606767 Avibacterium paragallinarum Species 0.000 description 1
- 241000726110 Azoarcus Species 0.000 description 1
- 241001148574 Azoarcus indigens Species 0.000 description 1
- 241001478311 Azoarcus tolulyticus Species 0.000 description 1
- 241000330868 Azoarcus toluvorans Species 0.000 description 1
- 241001239322 Azohydromonas Species 0.000 description 1
- 241001446526 Azohydromonas australica Species 0.000 description 1
- 241000193033 Azohydromonas lata Species 0.000 description 1
- 241000408718 Azomonas insignis Species 0.000 description 1
- 241000973037 Azomonas macrocytogenes Species 0.000 description 1
- 241000894008 Azorhizobium Species 0.000 description 1
- 241000894009 Azorhizobium caulinodans Species 0.000 description 1
- 241000973036 Azorhizophilus paspali Species 0.000 description 1
- 241001478325 Azospirillum halopraeferens Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000681683 Azotobacter beijerinckii Species 0.000 description 1
- 241000589152 Azotobacter chroococcum Species 0.000 description 1
- 241000408717 Azotobacter nigricans Species 0.000 description 1
- 241000973041 Azotobacter salinestris Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001183283 Bacillus aeolius Species 0.000 description 1
- 241001150382 Bacillus aerius Species 0.000 description 1
- 241001150378 Bacillus aerophilus Species 0.000 description 1
- 241000513399 Bacillus aidingensis Species 0.000 description 1
- 241000193376 Bacillus akibai Species 0.000 description 1
- 241000193375 Bacillus alcalophilus Species 0.000 description 1
- 241000285020 Bacillus algicola Species 0.000 description 1
- 241001391484 Bacillus alkalinitrilicus Species 0.000 description 1
- 241000287345 Bacillus alkalisediminis Species 0.000 description 1
- 241000924888 Bacillus alkalitelluris Species 0.000 description 1
- 241001150381 Bacillus altitudinis Species 0.000 description 1
- 241000496456 Bacillus alveayuensis Species 0.000 description 1
- 241001143891 Bacillus aquimaris Species 0.000 description 1
- 241000331867 Bacillus asahii Species 0.000 description 1
- 241000193410 Bacillus atrophaeus Species 0.000 description 1
- 241001363720 Bacillus aurantiacus Species 0.000 description 1
- 241000193409 Bacillus azotoformans Species 0.000 description 1
- 241000193408 Bacillus badius Species 0.000 description 1
- 241000223009 Bacillus bataviensis Species 0.000 description 1
- 241000193416 Bacillus benzoevorans Species 0.000 description 1
- 241001470576 Bacillus beringensis Species 0.000 description 1
- 241000452296 Bacillus berkeleyi Species 0.000 description 1
- 241001113888 Bacillus beveridgei Species 0.000 description 1
- 241000966273 Bacillus boroniphilus Species 0.000 description 1
- 241001323694 Bacillus butanolivorans Species 0.000 description 1
- 241000006380 Bacillus carboniphilus Species 0.000 description 1
- 241000845425 Bacillus cecembensis Species 0.000 description 1
- 241001382004 Bacillus chagannorensis Species 0.000 description 1
- 241001646894 Bacillus chungangensis Species 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241001328122 Bacillus clausii Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000678616 Bacillus coahuilensis Species 0.000 description 1
- 241001468256 Bacillus cohnii Species 0.000 description 1
- 241001560509 Bacillus cytotoxicus Species 0.000 description 1
- 241001219427 Bacillus daliensis Species 0.000 description 1
- 241000480228 Bacillus decisifrondis Species 0.000 description 1
- 241000365704 Bacillus decolorationis Species 0.000 description 1
- 241000944721 Bacillus deserti Species 0.000 description 1
- 241000268545 Bacillus eiseniae Species 0.000 description 1
- 241000363514 Bacillus enclensis Species 0.000 description 1
- 241000166175 Bacillus endoradicis Species 0.000 description 1
- 241001364843 Bacillus farraginis Species 0.000 description 1
- 241000193414 Bacillus fastidiosus Species 0.000 description 1
- 241000547610 Bacillus fengqiuensis Species 0.000 description 1
- 241000193747 Bacillus firmus Species 0.000 description 1
- 241000006381 Bacillus flexus Species 0.000 description 1
- 241000495374 Bacillus foraminis Species 0.000 description 1
- 241001364845 Bacillus fordii Species 0.000 description 1
- 241001364844 Bacillus fortis Species 0.000 description 1
- 241001610592 Bacillus galactosidilyticus Species 0.000 description 1
- 241001328119 Bacillus gibsonii Species 0.000 description 1
- 241001357357 Bacillus gottheilii Species 0.000 description 1
- 241000006382 Bacillus halodurans Species 0.000 description 1
- 241000226881 Bacillus halosaccharovorans Species 0.000 description 1
- 241000602818 Bacillus hemicellulosilyticus Species 0.000 description 1
- 241001589339 Bacillus hemicentroti Species 0.000 description 1
- 241000794699 Bacillus herbersteinensis Species 0.000 description 1
- 241001328132 Bacillus horikoshii Species 0.000 description 1
- 241000186551 Bacillus horneckiae Species 0.000 description 1
- 241000040462 Bacillus huizhouensis Species 0.000 description 1
- 241001245216 Bacillus hwajinpoensis Species 0.000 description 1
- 241001661600 Bacillus idriensis Species 0.000 description 1
- 241001515794 Bacillus infernus Species 0.000 description 1
- 241000038661 Bacillus isabeliae Species 0.000 description 1
- 241001357355 Bacillus kochii Species 0.000 description 1
- 241000795180 Bacillus kokeshiiformis Species 0.000 description 1
- 241000756349 Bacillus korlensis Species 0.000 description 1
- 241001092457 Bacillus kribbensis Species 0.000 description 1
- 241001523399 Bacillus krulwichiae Species 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000698515 Bacillus ligniniphilus Species 0.000 description 1
- 241001643767 Bacillus litoralis Species 0.000 description 1
- 241000775876 Bacillus luciferensis Species 0.000 description 1
- 241001280075 Bacillus luteolus Species 0.000 description 1
- 241000448737 Bacillus luteus Species 0.000 description 1
- 241001143890 Bacillus marisflavi Species 0.000 description 1
- 241001032346 Bacillus marmarensis Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241001208143 Bacillus mesonae Species 0.000 description 1
- 241000193398 Bacillus methanolicus Species 0.000 description 1
- 241001249117 Bacillus mojavensis Species 0.000 description 1
- 241000194106 Bacillus mycoides Species 0.000 description 1
- 241001354640 Bacillus nanhaiisediminis Species 0.000 description 1
- 241000210691 Bacillus nealsonii Species 0.000 description 1
- 241001662157 Bacillus niabensis Species 0.000 description 1
- 241000006385 Bacillus niacini Species 0.000 description 1
- 241000223014 Bacillus novalis Species 0.000 description 1
- 241000587861 Bacillus oceanisediminis Species 0.000 description 1
- 241000344824 Bacillus okhensis Species 0.000 description 1
- 241000963702 Bacillus okuhidensis Species 0.000 description 1
- 241001536371 Bacillus oleronius Species 0.000 description 1
- 241001120919 Bacillus oshimensis Species 0.000 description 1
- 241000783579 Bacillus pakistanensis Species 0.000 description 1
- 241001126986 Bacillus panacisoli Species 0.000 description 1
- 241001643941 Bacillus paraflexus Species 0.000 description 1
- 241000331092 Bacillus patagoniensis Species 0.000 description 1
- 241000226913 Bacillus persicus Species 0.000 description 1
- 241001425962 Bacillus pervagus Species 0.000 description 1
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 description 1
- 241000428714 Bacillus plakortidis Species 0.000 description 1
- 241001429228 Bacillus pocheonensis Species 0.000 description 1
- 241001365187 Bacillus polygoni Species 0.000 description 1
- 241001328129 Bacillus pseudalcaliphilus Species 0.000 description 1
- 241001328127 Bacillus pseudofirmus Species 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000194104 Bacillus psychrosaccharolyticus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241001658955 Bacillus purgationiresistens Species 0.000 description 1
- 241000040009 Bacillus qingshengii Species 0.000 description 1
- 241000835167 Bacillus safensis Species 0.000 description 1
- 241000798395 Bacillus salarius Species 0.000 description 1
- 241000560147 Bacillus selenatarsenatis Species 0.000 description 1
- 241000798847 Bacillus seohaeanensis Species 0.000 description 1
- 241001304324 Bacillus shacheensis Species 0.000 description 1
- 241000040345 Bacillus shackletonii Species 0.000 description 1
- 241001302493 Bacillus siralis Species 0.000 description 1
- 241000193399 Bacillus smithii Species 0.000 description 1
- 241000656516 Bacillus solimangrovi Species 0.000 description 1
- 241000460252 Bacillus songklensis Species 0.000 description 1
- 241000266830 Bacillus sonorensis Species 0.000 description 1
- 241000202341 Bacillus sporothermodurans Species 0.000 description 1
- 241001150380 Bacillus stratosphericus Species 0.000 description 1
- 241000821243 Bacillus subterraneus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241001345152 Bacillus thermocopriae Species 0.000 description 1
- 241001336886 Bacillus thermolactis Species 0.000 description 1
- 241000770536 Bacillus thermophilus Species 0.000 description 1
- 241000102674 Bacillus thioparans Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000905228 Bacillus tianshenii Species 0.000 description 1
- 241001249119 Bacillus vallismortis Species 0.000 description 1
- 241000563903 Bacillus velezensis Species 0.000 description 1
- 241000223012 Bacillus vireti Species 0.000 description 1
- 241000602824 Bacillus wakoensis Species 0.000 description 1
- 241000311516 Bacillus xiaoxiensis Species 0.000 description 1
- 241000025044 Bacillus zhanjiangensis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000217846 Bacteroides caccae Species 0.000 description 1
- 241001032450 Bacteroides cellulosilyticus Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 241001122267 Bacteroides salyersiae Species 0.000 description 1
- 241000204294 Bacteroides stercoris Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241000271813 Balnearium Species 0.000 description 1
- 241000271826 Balnearium lithotrophicum Species 0.000 description 1
- 241001277519 Balneatrix Species 0.000 description 1
- 241001277523 Balneatrix alpica Species 0.000 description 1
- 241000800368 Balneola Species 0.000 description 1
- 241000841175 Balneola vulgaris Species 0.000 description 1
- 241000927512 Barnesiella Species 0.000 description 1
- 241000927510 Barnesiella viscericola Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000511683 Bartonella alsatica Species 0.000 description 1
- 241000606685 Bartonella bacilliformis Species 0.000 description 1
- 241000567117 Bartonella clarridgeiae Species 0.000 description 1
- 241001464950 Bartonella doshiae Species 0.000 description 1
- 241000606070 Bartonella elizabethae Species 0.000 description 1
- 241001464952 Bartonella grahamii Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241001464955 Bartonella vinsonii Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000053357 Bavariicoccus Species 0.000 description 1
- 241000186553 Bavariicoccus seileri Species 0.000 description 1
- 241000604933 Bdellovibrio Species 0.000 description 1
- 241000604931 Bdellovibrio bacteriovorus Species 0.000 description 1
- 241000774461 Bdellovibrio exovorus Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241000588882 Beijerinckia Species 0.000 description 1
- 241000616862 Belliella Species 0.000 description 1
- 241000616876 Belliella baltica Species 0.000 description 1
- 241001459699 Belnapia Species 0.000 description 1
- 241001459701 Belnapia moabensis Species 0.000 description 1
- 241000235122 Bensingtonia naganoensis Species 0.000 description 1
- 241001648895 Bergeriella <Ciliophora> Species 0.000 description 1
- 241001661339 Beutenbergia cavernae Species 0.000 description 1
- 241001378078 Bhargavaea ginsengi Species 0.000 description 1
- 241001553294 Bibersteinia Species 0.000 description 1
- 241000218561 Bibersteinia trehalosi Species 0.000 description 1
- 241000186013 Bifidobacterium asteroides Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001312348 Bifidobacterium boum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241001495388 Bifidobacterium choerinum Species 0.000 description 1
- 241000186021 Bifidobacterium cuniculi Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241001312342 Bifidobacterium gallinarum Species 0.000 description 1
- 241000186156 Bifidobacterium indicum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186150 Bifidobacterium minimum Species 0.000 description 1
- 241001312954 Bifidobacterium pullorum Species 0.000 description 1
- 241001312356 Bifidobacterium ruminantium Species 0.000 description 1
- 241001311520 Bifidobacterium saeculare Species 0.000 description 1
- 241001302264 Bifidobacterium subtile Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241001495171 Bilophila Species 0.000 description 1
- 241001495172 Bilophila wadsworthia Species 0.000 description 1
- 241001167521 Biostraticola tofi Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000794227 Bizionia Species 0.000 description 1
- 241000815539 Bizionia argentinensis Species 0.000 description 1
- 241000333975 Bizionia psychrotolerans Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000586490 Blastobacter Species 0.000 description 1
- 241000607159 Blastochloris Species 0.000 description 1
- 241000190944 Blastochloris viridis Species 0.000 description 1
- 241000943710 Blastococcus endophyticus Species 0.000 description 1
- 241000981098 Blastococcus saxobsidens Species 0.000 description 1
- 241001626906 Blastomonas Species 0.000 description 1
- 241001478330 Blastomonas natatoria Species 0.000 description 1
- 241000589957 Blastopirellula marina Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 241001464894 Blautia producta Species 0.000 description 1
- 241001038648 Blautia wexlerae Species 0.000 description 1
- 241001394284 Bogoriella <ascomycete lichen> Species 0.000 description 1
- 241000565336 Bogoriella caseilytica Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241001477981 Bordetella hinzii Species 0.000 description 1
- 241001495147 Bordetella holmesii Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000359246 Bordetella petrii Species 0.000 description 1
- 241000543043 Bordetella trematum Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241001579546 Borreliella americana Species 0.000 description 1
- 241001478201 Borreliella japonica Species 0.000 description 1
- 241000427199 Bosea <angiosperm> Species 0.000 description 1
- 241000610438 Bosea minatitlanensis Species 0.000 description 1
- 241000519601 Bosea thiooxidans Species 0.000 description 1
- 241000157894 Brachybacterium faecium Species 0.000 description 1
- 241000482171 Brachybacterium horti Species 0.000 description 1
- 241000719300 Brachybacterium rhamnosum Species 0.000 description 1
- 241001658772 Brachyspira alvinipulli Species 0.000 description 1
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
- 241000722022 Brachyspira innocens Species 0.000 description 1
- 241001658774 Brachyspira murdochii Species 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 241000031361 Bradornis pallidus Species 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- 241001378169 Bradyrhizobium canariense Species 0.000 description 1
- 241000033231 Bradyrhizobium denitrificans Species 0.000 description 1
- 241001148114 Bradyrhizobium elkanii Species 0.000 description 1
- 241000159535 Bradyrhizobium liaoningense Species 0.000 description 1
- 241000178956 Bradyrhizobium oligotrophicum Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001236205 Brenneria Species 0.000 description 1
- 241001236204 Brenneria alni Species 0.000 description 1
- 241000556421 Brenneria nigrifluens Species 0.000 description 1
- 241000556446 Brenneria salicis Species 0.000 description 1
- 241000191775 Brevibacillus borstelensis Species 0.000 description 1
- 241000534612 Brevibacillus formosus Species 0.000 description 1
- 241001623592 Brevibacillus gelatini Species 0.000 description 1
- 241000718329 Brevibacillus invocatus Species 0.000 description 1
- 241001660615 Brevibacillus massiliensis Species 0.000 description 1
- 241000630118 Brevibacillus panacihumi Species 0.000 description 1
- 241001209722 Brevibacillus sediminis Species 0.000 description 1
- 241001468177 Brevibacillus thermoruber Species 0.000 description 1
- 241000285038 Brevibacterium celere Species 0.000 description 1
- 241000186162 Brevibacterium epidermidis Species 0.000 description 1
- 241001482309 Brevibacterium jeotgali Species 0.000 description 1
- 241000520039 Brevibacterium mcbrellneri Species 0.000 description 1
- 241000520042 Brevibacterium otitidis Species 0.000 description 1
- 241000692373 Brevibacterium paucivorans Species 0.000 description 1
- 241001478252 Brevinema Species 0.000 description 1
- 241001478253 Brevinema andersonii Species 0.000 description 1
- 241000339786 Brevundimonas abyssalis Species 0.000 description 1
- 241000059180 Brevundimonas humi Species 0.000 description 1
- 241001261626 Brevundimonas subvibrioides Species 0.000 description 1
- 241001423733 Brevundimonas vancanneytii Species 0.000 description 1
- 241001261625 Brevundimonas variabilis Species 0.000 description 1
- 241000131418 Brevundimonas vesicularis Species 0.000 description 1
- 241000206605 Brochothrix Species 0.000 description 1
- 241000206603 Brochothrix campestris Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001156809 Bryobacter Species 0.000 description 1
- 241001646647 Burkholderia ambifaria Species 0.000 description 1
- 241000790236 Burkholderia anthina Species 0.000 description 1
- 241000371430 Burkholderia cenocepacia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241001646389 Burkholderia dolosa Species 0.000 description 1
- 241001135516 Burkholderia gladioli Species 0.000 description 1
- 241000589638 Burkholderia glumae Species 0.000 description 1
- 241000020731 Burkholderia multivorans Species 0.000 description 1
- 241000134107 Burkholderia plantarii Species 0.000 description 1
- 241000866604 Burkholderia pyrrocinia Species 0.000 description 1
- 241000371422 Burkholderia stabilis Species 0.000 description 1
- 241000581608 Burkholderia thailandensis Species 0.000 description 1
- 241000134846 Bursaphelenchus tusciae Species 0.000 description 1
- 241001622847 Buttiauxella Species 0.000 description 1
- 241001622848 Buttiauxella agrestis Species 0.000 description 1
- 241001622825 Buttiauxella ferragutiae Species 0.000 description 1
- 241001622816 Buttiauxella gaviniae Species 0.000 description 1
- 241001622818 Buttiauxella izardii Species 0.000 description 1
- 241001622812 Buttiauxella noackiae Species 0.000 description 1
- 241000605902 Butyrivibrio Species 0.000 description 1
- 241001102661 Butyrivibrio hungatei Species 0.000 description 1
- 238000010455 CRISPR delivery Methods 0.000 description 1
- 241000866631 Caballeronia glathei Species 0.000 description 1
- 241001488656 Caenimonas koreensis Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000199490 Caldalkalibacillus Species 0.000 description 1
- 241001068246 Caldalkalibacillus uzonensis Species 0.000 description 1
- 241001058118 Caldanaerobacter Species 0.000 description 1
- 241001157085 Caldanaerobacter subterraneus Species 0.000 description 1
- 241000815917 Caldanaerobius fijiensis Species 0.000 description 1
- 241000511681 Caldicellulosiruptor kristjanssonii Species 0.000 description 1
- 241000556413 Caldicellulosiruptor owensensis Species 0.000 description 1
- 241000316922 Caldicoprobacter faecalis Species 0.000 description 1
- 241001147798 Caloramator fervidus Species 0.000 description 1
- 241000589985 Campylobacter curvus Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000606208 Campylobacter gracilis Species 0.000 description 1
- 241001137866 Campylobacter helveticus Species 0.000 description 1
- 241001290832 Campylobacter hominis Species 0.000 description 1
- 241000589872 Campylobacter hyointestinalis Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000589986 Campylobacter lari Species 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 241000589992 Campylobacter showae Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000207187 Candidatus Legionella jeonii Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000190890 Capnocytophaga Species 0.000 description 1
- 241001135194 Capnocytophaga canimorsus Species 0.000 description 1
- 241001135159 Capnocytophaga cynodegmi Species 0.000 description 1
- 241000190888 Capnocytophaga gingivalis Species 0.000 description 1
- 241000190566 Capnocytophaga granulosa Species 0.000 description 1
- 241000190564 Capnocytophaga haemolytica Species 0.000 description 1
- 241000190885 Capnocytophaga ochracea Species 0.000 description 1
- 241000190882 Capnocytophaga sputigena Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 102100024644 Carbonic anhydrase 4 Human genes 0.000 description 1
- 101710167916 Carbonic anhydrase 4 Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000907319 Carnimonas Species 0.000 description 1
- 241000907317 Carnimonas nigrificans Species 0.000 description 1
- 241000206593 Carnobacterium divergens Species 0.000 description 1
- 241000206599 Carnobacterium funditum Species 0.000 description 1
- 241000206592 Carnobacterium gallinarum Species 0.000 description 1
- 241001468185 Caryophanon Species 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 241000520061 Catellatospora citrea Species 0.000 description 1
- 241000358114 Catenococcus thiocycli Species 0.000 description 1
- 241000292566 Catenuloplanes crispus Species 0.000 description 1
- 241000976749 Catenuloplanes indicus Species 0.000 description 1
- 241001467488 Catenuloplanes japonicus Species 0.000 description 1
- 241001645051 Catenuloplanes nepalensis Species 0.000 description 1
- 241001645047 Catenuloplanes niger Species 0.000 description 1
- 241001147794 Cellulosilyticum lentocellum Species 0.000 description 1
- 241000186221 Cellulosimicrobium cellulans Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000007190 Chlamydia Infections Diseases 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000611330 Chryseobacterium Species 0.000 description 1
- 241000589585 Chryseobacterium balustinum Species 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241000949030 Citrobacter farmeri Species 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000949040 Citrobacter gillenii Species 0.000 description 1
- 241000949041 Citrobacter murliniae Species 0.000 description 1
- 241000949031 Citrobacter rodentium Species 0.000 description 1
- 241000949032 Citrobacter sedlakii Species 0.000 description 1
- 241000920610 Citrobacter youngae Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000186584 Clostridioides mangenotii Species 0.000 description 1
- 241001656810 Clostridium aceticum Species 0.000 description 1
- 241001290510 Clostridium acetireducens Species 0.000 description 1
- 241000193401 Clostridium acetobutylicum Species 0.000 description 1
- 241000306283 Clostridium acidisoli Species 0.000 description 1
- 241000414748 Clostridium aciditolerans Species 0.000 description 1
- 241000402146 Clostridium aestuarii Species 0.000 description 1
- 241000306276 Clostridium akagii Species 0.000 description 1
- 241001215936 Clostridium algifaecis Species 0.000 description 1
- 241001519498 Clostridium algoriphilum Species 0.000 description 1
- 241000274838 Clostridium amylolyticum Species 0.000 description 1
- 241000719667 Clostridium arbusti Species 0.000 description 1
- 241001147768 Clostridium argentinense Species 0.000 description 1
- 241000186522 Clostridium aurantibutyricum Species 0.000 description 1
- 241001656809 Clostridium autoethanogenum Species 0.000 description 1
- 241000915466 Clostridium bowmanii Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000193455 Clostridium cadaveris Species 0.000 description 1
- 241001611022 Clostridium carboxidivorans Species 0.000 description 1
- 241000779795 Clostridium cavendishii Species 0.000 description 1
- 241001509496 Clostridium celatum Species 0.000 description 1
- 241000193169 Clostridium cellulovorans Species 0.000 description 1
- 241001147787 Clostridium chartatabidum Species 0.000 description 1
- 241000206044 Clostridium chauvoei Species 0.000 description 1
- 241000291085 Clostridium chromiireducens Species 0.000 description 1
- 241000788977 Clostridium colicanis Species 0.000 description 1
- 241001147788 Clostridium collagenovorans Species 0.000 description 1
- 241000193165 Clostridium cylindrosporum Species 0.000 description 1
- 241000272479 Clostridium diolis Species 0.000 description 1
- 241001656808 Clostridium disporicum Species 0.000 description 1
- 241000328950 Clostridium drakei Species 0.000 description 1
- 241001200944 Clostridium estertheticum subsp. laramiense Species 0.000 description 1
- 241000186571 Clostridium fallax Species 0.000 description 1
- 241001509499 Clostridium felsineum Species 0.000 description 1
- 241000193161 Clostridium formicaceticum Species 0.000 description 1
- 241001239391 Clostridium ganghwense Species 0.000 description 1
- 241000360099 Clostridium gasigenes Species 0.000 description 1
- 241000123594 Clostridium grantii Species 0.000 description 1
- 241001656807 Clostridium haemolyticum Species 0.000 description 1
- 241001509473 Clostridium homopropionicum Species 0.000 description 1
- 241000126598 Clostridium huakuii Species 0.000 description 1
- 241000779784 Clostridium hydrogeniformans Species 0.000 description 1
- 241001509477 Clostridium intestinale Species 0.000 description 1
- 241001072406 Clostridium isatidis Species 0.000 description 1
- 241000186570 Clostridium kluyveri Species 0.000 description 1
- 241000186566 Clostridium ljungdahlii Species 0.000 description 1
- 241001331740 Clostridium lundense Species 0.000 description 1
- 241001468167 Clostridium magnum Species 0.000 description 1
- 241000186565 Clostridium malenominatum Species 0.000 description 1
- 241001495412 Clostridium maximum Species 0.000 description 1
- 241000491294 Clostridium nitrophenolicum Species 0.000 description 1
- 241000186581 Clostridium novyi Species 0.000 description 1
- 241000186580 Clostridium oceanicum Species 0.000 description 1
- 241001147791 Clostridium paraputrificum Species 0.000 description 1
- 241000203642 Clostridium pascui Species 0.000 description 1
- 241000193469 Clostridium pasteurianum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000915467 Clostridium psychrophilum Species 0.000 description 1
- 241001147704 Clostridium puniceum Species 0.000 description 1
- 241000408944 Clostridium putrefaciens Species 0.000 description 1
- 241001509317 Clostridium quinii Species 0.000 description 1
- 241001656801 Clostridium roseum Species 0.000 description 1
- 241000429427 Clostridium saccharobutylicum Species 0.000 description 1
- 241001508458 Clostridium saccharoperbutylacetonicum Species 0.000 description 1
- 241001656793 Clostridium sartagoforme Species 0.000 description 1
- 241000186587 Clostridium scatologenes Species 0.000 description 1
- 241001041716 Clostridium schirmacherense Species 0.000 description 1
- 241000193466 Clostridium septicum Species 0.000 description 1
- 241000193463 Clostridium sp. ATCC 29733 Species 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 241000186524 Clostridium subterminale Species 0.000 description 1
- 241001318996 Clostridium sulfidigenes Species 0.000 description 1
- 241001396684 Clostridium tagluense Species 0.000 description 1
- 241001308971 Clostridium tepidiprofundi Species 0.000 description 1
- 241000186528 Clostridium tertium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000186520 Clostridium tetanomorphum Species 0.000 description 1
- 241001147721 Clostridium thermobutyricum Species 0.000 description 1
- 241001147708 Clostridium thermopalmarium Species 0.000 description 1
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 1
- 241000264391 Clostridium uliginosum Species 0.000 description 1
- 241000192020 Clostridium ventriculi Species 0.000 description 1
- 241000511746 Clostridium vincentii Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186308 Corynebacterium stationis Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- 241000203813 Curtobacterium Species 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000219206 Dactylosporangium roseum Species 0.000 description 1
- 241000218946 Dactylosporangium thailandense Species 0.000 description 1
- 241000520036 Dactylosporangium vinaceum Species 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 241000565686 Dehalobacter Species 0.000 description 1
- 241000940696 Deinococcus caeni Species 0.000 description 1
- 241000192091 Deinococcus radiodurans Species 0.000 description 1
- 241001453175 Deinococcus radiophilus Species 0.000 description 1
- 241001313305 Dendrosporobacter quercicolus Species 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241001535083 Dialister Species 0.000 description 1
- 244000101366 Diplotaxis muralis Species 0.000 description 1
- 241000192534 Dolichospermum flos-aquae Species 0.000 description 1
- 241001143779 Dorea Species 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 101100321993 Drosophila melanogaster pix gene Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108700042349 E coli ygcB Proteins 0.000 description 1
- 241001430190 Eggerthia catenaformis Species 0.000 description 1
- 241000336502 Elsinoe arachidis Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000881810 Enterobacter asburiae Species 0.000 description 1
- 241000982938 Enterobacter cancerogenus Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000982936 Enterobacter cloacae subsp. dissolvens Species 0.000 description 1
- 241001217893 Enterobacter ludwigii Species 0.000 description 1
- 241001493237 Enterobacter mori Species 0.000 description 1
- 241000737206 Enterobacter soli Species 0.000 description 1
- 101000954958 Enterobacteria phage T4 Fibritin Proteins 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001645942 Erwinia carnegieana Species 0.000 description 1
- 241000556426 Erwinia rhapontici Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 101100149960 Escherichia phage P2 lysB gene Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241001350695 Ethanoligenens Species 0.000 description 1
- 241000193456 Eubacterium barkeri Species 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000186589 Faecalicatena orotica Species 0.000 description 1
- 241000404113 Fangia hongkongensis Species 0.000 description 1
- 241000661429 Fastidiosipila Species 0.000 description 1
- 241000661434 Fastidiosipila sanguinis Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001376287 Fictibacillus arsenicus Species 0.000 description 1
- 241001065721 Fictibacillus barbaricus Species 0.000 description 1
- 241001024488 Fictibacillus macauensis Species 0.000 description 1
- 241001179476 Fictibacillus nanhaiensis Species 0.000 description 1
- 241000496163 Fictibacillus rigui Species 0.000 description 1
- 241000845813 Fictibacillus solisalsi Species 0.000 description 1
- 241001147710 Filifactor villosus Species 0.000 description 1
- 241000101451 Flavobacterium croceum Species 0.000 description 1
- 241001020619 Flavobacterium cucumis Species 0.000 description 1
- 241000101455 Flavobacterium defluvii Species 0.000 description 1
- 241000335415 Flavobacterium degerlachei Species 0.000 description 1
- 241000101452 Flavobacterium filum Species 0.000 description 1
- 241000405386 Flavobacterium frigidarium Species 0.000 description 1
- 241001134569 Flavonifractor plautii Species 0.000 description 1
- 241000589282 Fluoribacter dumoffii Species 0.000 description 1
- 241000589278 Fluoribacter gormanii Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000604959 Francisella persica Species 0.000 description 1
- 241001135321 Francisella philomiragia Species 0.000 description 1
- 241001106040 Franconibacter helveticus Species 0.000 description 1
- 241000070950 Franconibacter pulveris Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241001238246 Gaetbulibacter saemankumensis Species 0.000 description 1
- 241000606562 Gallibacterium anatis Species 0.000 description 1
- 241000351213 Gallicola Species 0.000 description 1
- 241000220678 Gallicola barnesae Species 0.000 description 1
- 241001627088 Garciella Species 0.000 description 1
- 241001627085 Garciella nitratireducens Species 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 241001468249 Geobacillus thermocatenulatus Species 0.000 description 1
- 241001468175 Geobacillus thermodenitrificans Species 0.000 description 1
- 241001468176 Geobacillus thermoleovorans Species 0.000 description 1
- 241000948428 Geobacillus vulcani Species 0.000 description 1
- 241001135750 Geobacter Species 0.000 description 1
- 241000290396 Geobacter bemidjiensis Species 0.000 description 1
- 241000168711 Geobacter chapellei Species 0.000 description 1
- 241000010919 Geobacter grbiciae Species 0.000 description 1
- 241001269822 Geobacter lovleyi Species 0.000 description 1
- 241001135751 Geobacter metallireducens Species 0.000 description 1
- 241000863672 Geobacter pelophilus Species 0.000 description 1
- 241000723998 Geobacter pickeringii Species 0.000 description 1
- 241001494297 Geobacter sulfurreducens Species 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000032681 Gluconacetobacter Species 0.000 description 1
- 241001524188 Glutamicibacter nicotianae Species 0.000 description 1
- 241000157899 Glutamicibacter uratoxydans Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241001337904 Gordonia <angiosperm> Species 0.000 description 1
- 241000186530 Gottschalkia acidurici Species 0.000 description 1
- 241000193467 Gottschalkia purinilyticum Species 0.000 description 1
- 241000777639 Gracilibacillus dipsosauri Species 0.000 description 1
- 241000695160 Gracilibacter Species 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000329524 Guggenheimella Species 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 241000606788 Haemophilus haemolyticus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606824 Haemophilus paracuniculus Species 0.000 description 1
- 241000606822 Haemophilus parahaemolyticus Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 241000588731 Hafnia Species 0.000 description 1
- 241000588729 Hafnia alvei Species 0.000 description 1
- 241000824743 Hahella ganghwensis Species 0.000 description 1
- 241000862436 Halalkalibacillus Species 0.000 description 1
- 241000862437 Halalkalibacillus halophilus Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 241000186568 Hathewaya limosa Species 0.000 description 1
- 241001147793 Hathewaya proteolytica Species 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000033197 Hemibarbus labeo Species 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 241000972946 Hespellia Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 241001674997 Hungatella hathewayi Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000063180 Idiomarina fontislapidosi Species 0.000 description 1
- 241000948245 Idiomarina loihiensis Species 0.000 description 1
- 241000063177 Idiomarina ramblicola Species 0.000 description 1
- 241000769126 Idiomarina seosinensis Species 0.000 description 1
- 241001669091 Idiomarina zobellii Species 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 241000172412 Ignatzschineria Species 0.000 description 1
- 241000172414 Ignatzschineria larvae Species 0.000 description 1
- 241001183629 Ilumatobacter fluminis Species 0.000 description 1
- 241000411968 Ilyobacter Species 0.000 description 1
- 241000261919 Ilyobacter delafieldii Species 0.000 description 1
- 241000411973 Ilyobacter insuetus Species 0.000 description 1
- 241000411974 Ilyobacter polytropus Species 0.000 description 1
- 241000411982 Ilyobacter tartaricus Species 0.000 description 1
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 241000037075 Intestinibacter bartlettii Species 0.000 description 1
- 241001478125 Janibacter terrae Species 0.000 description 1
- 241001139251 Jannaschia Species 0.000 description 1
- 241001139252 Jannaschia helgolandensis Species 0.000 description 1
- 241000831706 Jannaschia pohangensis Species 0.000 description 1
- 241000784339 Jannaschia rubra Species 0.000 description 1
- 241001148465 Janthinobacterium Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000268967 Jejuia Species 0.000 description 1
- 241000346880 Jejuia pallidilutea Species 0.000 description 1
- 241000026999 Jeotgalicoccus halotolerans Species 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 241000396557 Kaistia Species 0.000 description 1
- 241000396559 Kaistia adipata Species 0.000 description 1
- 241000452738 Kaistia soli Species 0.000 description 1
- 241000186778 Kandleria vitulina Species 0.000 description 1
- 241000048242 Kangiella Species 0.000 description 1
- 241000048244 Kangiella aquimarina Species 0.000 description 1
- 241000048245 Kangiella koreensis Species 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241001212817 Kerstersia gyiorum Species 0.000 description 1
- 241000789902 Kiloniella Species 0.000 description 1
- 241000789944 Kiloniella laminariae Species 0.000 description 1
- 241000498833 Kluyvera ascorbata Species 0.000 description 1
- 241000881812 Kluyvera intermedia Species 0.000 description 1
- 241000191953 Kocuria varians Species 0.000 description 1
- 241001245439 Kosakonia cowanii Species 0.000 description 1
- 241000796977 Kosakonia radicincitans Species 0.000 description 1
- 241000186809 Kurthia Species 0.000 description 1
- 241000186035 Kurthia zopfii Species 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 241000833408 Labedella Species 0.000 description 1
- 241000833388 Labedella gwakjiensis Species 0.000 description 1
- 241001582688 Labrenzia Species 0.000 description 1
- 241001116661 Labrenzia aggregata Species 0.000 description 1
- 241001235237 Labrenzia alba Species 0.000 description 1
- 241000558763 Labrenzia alexandrii Species 0.000 description 1
- 241000770727 Labrenzia marina Species 0.000 description 1
- 241000149139 Laceyella putida Species 0.000 description 1
- 241001233595 Lachnobacterium Species 0.000 description 1
- 241000933069 Lachnoclostridium phytofermentans Species 0.000 description 1
- 241001134638 Lachnospira Species 0.000 description 1
- 241000186717 Lactobacillus acetotolerans Species 0.000 description 1
- 241000110061 Lactobacillus acidifarinae Species 0.000 description 1
- 241000028630 Lactobacillus acidipiscis Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000186716 Lactobacillus agilis Species 0.000 description 1
- 241001507052 Lactobacillus algidus Species 0.000 description 1
- 241001647783 Lactobacillus amylolyticus Species 0.000 description 1
- 241000186714 Lactobacillus amylophilus Species 0.000 description 1
- 241000168643 Lactobacillus amylotrophicus Species 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 241000316282 Lactobacillus antri Species 0.000 description 1
- 241000186723 Lactobacillus bifermentans Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000489238 Lactobacillus camelliae Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000902616 Lactobacillus ceti Species 0.000 description 1
- 241001061980 Lactobacillus coleohominis Species 0.000 description 1
- 241001468197 Lactobacillus collinoides Species 0.000 description 1
- 241000933456 Lactobacillus composti Species 0.000 description 1
- 241000838743 Lactobacillus concavus Species 0.000 description 1
- 241000186842 Lactobacillus coryniformis Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000861211 Lactobacillus crustorum Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000500356 Lactobacillus dextrinicus Species 0.000 description 1
- 241000790171 Lactobacillus diolivorans Species 0.000 description 1
- 241000976279 Lactobacillus equi Species 0.000 description 1
- 241001026944 Lactobacillus equigenerosi Species 0.000 description 1
- 241000186841 Lactobacillus farciminis Species 0.000 description 1
- 241000831741 Lactobacillus farraginis Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000015236 Lactobacillus fornicalis Species 0.000 description 1
- 241000186839 Lactobacillus fructivorans Species 0.000 description 1
- 241001493843 Lactobacillus frumenti Species 0.000 description 1
- 241000370757 Lactobacillus fuchuensis Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000316283 Lactobacillus gastricus Species 0.000 description 1
- 241000950383 Lactobacillus ghanensis Species 0.000 description 1
- 241000866684 Lactobacillus graminis Species 0.000 description 1
- 241000111368 Lactobacillus hammesii Species 0.000 description 1
- 241000925032 Lactobacillus harbinensis Species 0.000 description 1
- 241000914114 Lactobacillus hayakitensis Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- 241001468190 Lactobacillus homohiochii Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241001343376 Lactobacillus ingluviei Species 0.000 description 1
- 241001640457 Lactobacillus intestinalis Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000316281 Lactobacillus kalixensis Species 0.000 description 1
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000674808 Lactobacillus kitasatonis Species 0.000 description 1
- 241001339775 Lactobacillus kunkeei Species 0.000 description 1
- 241001134654 Lactobacillus leichmannii Species 0.000 description 1
- 241000520745 Lactobacillus lindneri Species 0.000 description 1
- 241000751214 Lactobacillus malefermentans Species 0.000 description 1
- 241000186851 Lactobacillus mali Species 0.000 description 1
- 241000016642 Lactobacillus manihotivorans Species 0.000 description 1
- 241000414465 Lactobacillus mindensis Species 0.000 description 1
- 241000394636 Lactobacillus mucosae Species 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 241001635183 Lactobacillus nagelii Species 0.000 description 1
- 241000468580 Lactobacillus namurensis Species 0.000 description 1
- 241000938545 Lactobacillus nantensis Species 0.000 description 1
- 241001150383 Lactobacillus oligofermentans Species 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 241000216456 Lactobacillus panis Species 0.000 description 1
- 241000692795 Lactobacillus pantheris Species 0.000 description 1
- 241001105994 Lactobacillus parabrevis Species 0.000 description 1
- 241001643453 Lactobacillus parabuchneri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000972176 Lactobacillus paracollinoides Species 0.000 description 1
- 241000831743 Lactobacillus parafarraginis Species 0.000 description 1
- 241001643449 Lactobacillus parakefiri Species 0.000 description 1
- 241001647418 Lactobacillus paralimentarius Species 0.000 description 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241001448603 Lactobacillus perolens Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241001495404 Lactobacillus pontis Species 0.000 description 1
- 241000220680 Lactobacillus psittaci Species 0.000 description 1
- 241000692139 Lactobacillus rennini Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001438705 Lactobacillus rogosae Species 0.000 description 1
- 241000602084 Lactobacillus rossiae Species 0.000 description 1
- 241000186870 Lactobacillus ruminis Species 0.000 description 1
- 241000318646 Lactobacillus saerimneri Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000186868 Lactobacillus sanfranciscensis Species 0.000 description 1
- 241001424195 Lactobacillus satsumensis Species 0.000 description 1
- 241000915257 Lactobacillus secaliphilus Species 0.000 description 1
- 241000186867 Lactobacillus sharpeae Species 0.000 description 1
- 241000755777 Lactobacillus siliginis Species 0.000 description 1
- 241001599932 Lactobacillus spicheri Species 0.000 description 1
- 241001643448 Lactobacillus suebicus Species 0.000 description 1
- 241000489237 Lactobacillus thailandensis Species 0.000 description 1
- 241000316280 Lactobacillus ultunensis Species 0.000 description 1
- 241000751212 Lactobacillus vaccinostercus Species 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 241001456524 Lactobacillus versmoldensis Species 0.000 description 1
- 241000692127 Lactobacillus vini Species 0.000 description 1
- 241000110060 Lactobacillus zymae Species 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 241000396668 Lechevalieria Species 0.000 description 1
- 241000970318 Lechevalieria aerocolonigenes Species 0.000 description 1
- 241000189574 Legionella adelaidensis Species 0.000 description 1
- 241001135524 Legionella anisa Species 0.000 description 1
- 241000307152 Legionella beliardensis Species 0.000 description 1
- 241001135525 Legionella birminghamensis Species 0.000 description 1
- 241001148222 Legionella brunensis Species 0.000 description 1
- 241001409867 Legionella busanensis Species 0.000 description 1
- 241001135527 Legionella cincinnatiensis Species 0.000 description 1
- 241001441459 Legionella clemsonensis Species 0.000 description 1
- 241000189592 Legionella donaldsonii Species 0.000 description 1
- 241000425109 Legionella drancourtii Species 0.000 description 1
- 241000747302 Legionella dresdenensis Species 0.000 description 1
- 241000381228 Legionella drozanskii Species 0.000 description 1
- 241000189485 Legionella fairfieldensis Species 0.000 description 1
- 241000189481 Legionella gratiana Species 0.000 description 1
- 241000307151 Legionella gresilensis Species 0.000 description 1
- 241000589240 Legionella hackeliae Species 0.000 description 1
- 241000708794 Legionella impletisoli Species 0.000 description 1
- 241000589261 Legionella israelensis Species 0.000 description 1
- 241000589274 Legionella jamestowniensis Species 0.000 description 1
- 241000589276 Legionella jordanis Species 0.000 description 1
- 241000189478 Legionella lansingensis Species 0.000 description 1
- 241000189475 Legionella londiniensis Species 0.000 description 1
- 241000589264 Legionella longbeachae Species 0.000 description 1
- 241000381284 Legionella lytica Species 0.000 description 1
- 241001148226 Legionella monrovica Species 0.000 description 1
- 241001534810 Legionella moravica Species 0.000 description 1
- 241001437053 Legionella nagasakiensis Species 0.000 description 1
- 241000189498 Legionella nautarum Species 0.000 description 1
- 241000376856 Legionella norrlandica Species 0.000 description 1
- 241001148224 Legionella oakridgensis Species 0.000 description 1
- 241000189497 Legionella parisiensis Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000189496 Legionella quateirensis Species 0.000 description 1
- 241000189495 Legionella quinlivanii Species 0.000 description 1
- 241000381256 Legionella rowbothamii Species 0.000 description 1
- 241000589272 Legionella rubrilucens Species 0.000 description 1
- 241001135522 Legionella sainthelensi Species 0.000 description 1
- 241000189518 Legionella santicrucis Species 0.000 description 1
- 241000189517 Legionella shakespearei Species 0.000 description 1
- 241001222702 Legionella taurinensis Species 0.000 description 1
- 241000122902 Legionella tucsonensis Species 0.000 description 1
- 241000998049 Legionella tunisiensis Species 0.000 description 1
- 241001135523 Legionella wadsworthii Species 0.000 description 1
- 241000937844 Legionella waltersii Species 0.000 description 1
- 241000189514 Legionella worsleiensis Species 0.000 description 1
- 241000170964 Legionella yabuuchiae Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000881808 Lelliottia amnigena Species 0.000 description 1
- 244000309491 Leptothyrium zeae Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000371304 Listeria aquatica Species 0.000 description 1
- 241000215688 Listeria booriae Species 0.000 description 1
- 241000371308 Listeria cornellensis Species 0.000 description 1
- 241000452253 Listeria fleischmannii Species 0.000 description 1
- 241000371306 Listeria floridensis Species 0.000 description 1
- 241000371298 Listeria grandensis Species 0.000 description 1
- 241000186806 Listeria grayi Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- 241001120504 Listeria marthii Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000390917 Listeria newyorkensis Species 0.000 description 1
- 241000371296 Listeria riparia Species 0.000 description 1
- 241001554615 Listeria rocourtiae Species 0.000 description 1
- 241000186807 Listeria seeligeri Species 0.000 description 1
- 241000186814 Listeria welshimeri Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001167717 Lysinibacillus odysseyi Species 0.000 description 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 241000973040 Macrococcus Species 0.000 description 1
- 241000973039 Macrococcus bovicus Species 0.000 description 1
- 241000973043 Macrococcus caseolyticus Species 0.000 description 1
- 241001509487 Maledivibacter halophilus Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000662215 Marinobacter algicola Species 0.000 description 1
- 241001358049 Massilia Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 241000043362 Megamonas Species 0.000 description 1
- 241000921347 Meiothermus Species 0.000 description 1
- 241000589496 Meiothermus ruber Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241001467579 Microbacterium arborescens Species 0.000 description 1
- 241001468201 Microbacterium barkeri Species 0.000 description 1
- 241001468202 Microbacterium liquefaciens Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000191951 Micrococcus lylae Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 101710167711 Minor tail protein Proteins 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000509624 Mitsuokella Species 0.000 description 1
- 241001147402 Monachus Species 0.000 description 1
- 241000193459 Moorella thermoacetica Species 0.000 description 1
- 241000186544 Moorella thermoautotrophica Species 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000588630 Moraxella nonliquefaciens Species 0.000 description 1
- 241001478294 Moraxella osloensis Species 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000948981 Muribacter muris Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 241000520669 Nakamurella multipartita Species 0.000 description 1
- 241000862996 Nannocystis Species 0.000 description 1
- 241000790438 Nannocystis pusilla Species 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 241001650546 Natranaerobius trueperi Species 0.000 description 1
- 241000588654 Neisseria cinerea Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588649 Neisseria lactamica Species 0.000 description 1
- 241000588659 Neisseria mucosa Species 0.000 description 1
- 241000588645 Neisseria sicca Species 0.000 description 1
- 241001136170 Neisseria subflava Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241001277524 Neptunomonas Species 0.000 description 1
- 241001026748 Neptunomonas japonica Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010071579 Neuronal neuropathy Diseases 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 241001478326 Niveispirillum irakense Species 0.000 description 1
- 241001021462 Nocardia argentinensis Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 208000007684 Occupational Stress Diseases 0.000 description 1
- 241000287240 Oceanibulbus Species 0.000 description 1
- 241000287241 Oceanibulbus indolifex Species 0.000 description 1
- 241001663458 Oceanicaulis Species 0.000 description 1
- 241001663457 Oceanicaulis alexandrii Species 0.000 description 1
- 241001348358 Oceanicola Species 0.000 description 1
- 241001348356 Oceanicola granulosus Species 0.000 description 1
- 241000625725 Oceanimonas baumannii Species 0.000 description 1
- 241000742637 Oceaniserpentilla haliotis Species 0.000 description 1
- 241000290213 Oceanisphaera Species 0.000 description 1
- 241000739061 Oceanisphaera donghaensis Species 0.000 description 1
- 241000290203 Oceanisphaera litoralis Species 0.000 description 1
- 241001246353 Oceanithermus Species 0.000 description 1
- 241000316381 Oceanithermus desulfurans Species 0.000 description 1
- 241000634765 Oceanobacillus caeni Species 0.000 description 1
- 241000605012 Oceanospirillum Species 0.000 description 1
- 241000605010 Oceanospirillum linum Species 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 241000089925 Oribacterium Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001509479 Oxalophagus oxalicus Species 0.000 description 1
- 241000178986 Oxobacter Species 0.000 description 1
- 241001509483 Oxobacter pfennigii Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 241000157908 Paenarthrobacter aurescens Species 0.000 description 1
- 241000157904 Paenarthrobacter ilicis Species 0.000 description 1
- 241001147838 Paenarthrobacter nicotinovorans Species 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241000611836 Paenibacillus alginolyticus Species 0.000 description 1
- 241000178961 Paenibacillus alvei Species 0.000 description 1
- 241001337872 Paenibacillus chitinolyticus Species 0.000 description 1
- 241000611787 Paenibacillus chondroitinus Species 0.000 description 1
- 241000611789 Paenibacillus curdlanolyticus Species 0.000 description 1
- 241000881862 Paenibacillus edaphicus Species 0.000 description 1
- 241001337870 Paenibacillus ehimensis Species 0.000 description 1
- 241000611788 Paenibacillus kobensis Species 0.000 description 1
- 241000193418 Paenibacillus larvae Species 0.000 description 1
- 241001310335 Paenibacillus lentimorbus Species 0.000 description 1
- 241000178960 Paenibacillus macerans Species 0.000 description 1
- 241000689135 Paenibacillus macquariensis Species 0.000 description 1
- 241000881860 Paenibacillus mucilaginosus Species 0.000 description 1
- 241001144206 Paenibacillus odorifer Species 0.000 description 1
- 241000193397 Paenibacillus pabuli Species 0.000 description 1
- 241000611735 Paenibacillus peoriae Species 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 241001310339 Paenibacillus popilliae Species 0.000 description 1
- 241000178958 Paenibacillus validus Species 0.000 description 1
- 241001147789 Paeniclostridium ghonii Species 0.000 description 1
- 241000193465 Paeniclostridium sordellii Species 0.000 description 1
- 241000157907 Paeniglutamicibacter sulfureus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 241001446614 Papillibacter Species 0.000 description 1
- 241000930993 Paraburkholderia caledonica Species 0.000 description 1
- 241000930992 Paraburkholderia fungorum Species 0.000 description 1
- 241000861159 Paraburkholderia ginsengiterrae Species 0.000 description 1
- 241000866634 Paraburkholderia phenazinium Species 0.000 description 1
- 241000176271 Paraburkholderia rhizosphaerae Species 0.000 description 1
- 241001615782 Paraburkholderia silvatlantica Species 0.000 description 1
- 241000480193 Paraburkholderia soli Species 0.000 description 1
- 241000318919 Paraburkholderia tropica Species 0.000 description 1
- 241001647379 Parachlamydia Species 0.000 description 1
- 241000193157 Paraclostridium bifermentans Species 0.000 description 1
- 241001057811 Paracoccus <mealybug> Species 0.000 description 1
- 241001478308 Paracoccus alcaliphilus Species 0.000 description 1
- 241001105493 Parageobacillus thermantarcticus Species 0.000 description 1
- 241001427615 Paramaledivibacter caminithermalis Species 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 241001478329 Pararhizobium capsulatum Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000531155 Pectobacterium Species 0.000 description 1
- 241000943942 Pectobacterium aroidearum Species 0.000 description 1
- 241001148142 Pectobacterium atrosepticum Species 0.000 description 1
- 241000982891 Pectobacterium cacticida Species 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 241000556406 Pectobacterium wasabiae Species 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000022034 Penile disease Diseases 0.000 description 1
- 241000186529 Peptoclostridium litorale Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241001495084 Phylo Species 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 241000193804 Planococcus <bacterium> Species 0.000 description 1
- 241000193802 Planococcus citreus Species 0.000 description 1
- 241000351212 Planomicrobium Species 0.000 description 1
- 241000589579 Planomicrobium okeanokoites Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 241000606999 Plesiomonas shigelloides Species 0.000 description 1
- 241000881813 Pluralibacter gergoviae Species 0.000 description 1
- 241001621838 Pluralibacter pyrinus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 241001302521 Prevotella albensis Species 0.000 description 1
- 241001041813 Prevotella amnii Species 0.000 description 1
- 241000987248 Prevotella bergensis Species 0.000 description 1
- 241001135215 Prevotella bivia Species 0.000 description 1
- 241001646114 Prevotella brevis Species 0.000 description 1
- 241001135217 Prevotella buccae Species 0.000 description 1
- 241001135209 Prevotella denticola Species 0.000 description 1
- 241001135219 Prevotella disiens Species 0.000 description 1
- 241001482483 Prevotella histicola Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000124542 Prevotella maculosa Species 0.000 description 1
- 241001141018 Prevotella marshii Species 0.000 description 1
- 241001141020 Prevotella micans Species 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- 241001135261 Prevotella oralis Species 0.000 description 1
- 241001135262 Prevotella oris Species 0.000 description 1
- 241001135263 Prevotella oulorum Species 0.000 description 1
- 241000864367 Prevotella pallens Species 0.000 description 1
- 241000331195 Prevotella salivae Species 0.000 description 1
- 241001430102 Prevotella stercorea Species 0.000 description 1
- 241001135264 Prevotella veroralis Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241001656788 Propionispira Species 0.000 description 1
- 241000008321 Propionispira paucivorans Species 0.000 description 1
- 241000008322 Propionispira raffinosivorans Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 241000185994 Pseudarthrobacter oxydans Species 0.000 description 1
- 241000521450 Pseudarthrobacter sulfonivorans Species 0.000 description 1
- 241000519590 Pseudoalteromonas Species 0.000 description 1
- 241000202386 Pseudobutyrivibrio Species 0.000 description 1
- 241000409196 Pseudoglutamicibacter albus Species 0.000 description 1
- 241000024403 Pseudoglutamicibacter cumminsii Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000168225 Pseudomonas alcaligenes Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589755 Pseudomonas mendocina Species 0.000 description 1
- 241000589630 Pseudomonas pseudoalcaligenes Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 241001272810 Pseudooceanicola batsensis Species 0.000 description 1
- 241000184247 Pseudoramibacter Species 0.000 description 1
- 241000193420 Psychrobacillus insolitus Species 0.000 description 1
- 241000577491 Psychrobacillus psychrodurans Species 0.000 description 1
- 241001049173 Psychrobacter faecalis Species 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241001315311 Quadrisphaera Species 0.000 description 1
- 241001315309 Quadrisphaera granulorum Species 0.000 description 1
- 241000186548 Quinella ovalis Species 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 241001406310 Ralstonia insidiosa Species 0.000 description 1
- 241001513398 Ralstonia mannitolilytica Species 0.000 description 1
- 241000589625 Ralstonia pickettii Species 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- 241000358078 Ramlibacter tataouinensis Species 0.000 description 1
- 241000321184 Raoultella Species 0.000 description 1
- 241000531124 Raoultella ornithinolytica Species 0.000 description 1
- 241000588746 Raoultella planticola Species 0.000 description 1
- 241000588756 Raoultella terrigena Species 0.000 description 1
- 241001301196 Rathayibacter toxicus Species 0.000 description 1
- 241001467570 Rathayibacter tritici Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 241000185992 Rhizobium viscosum Species 0.000 description 1
- 241000191025 Rhodobacter Species 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- 241001134718 Rhodoferax Species 0.000 description 1
- 241001440631 Rhodoferax ferrireducens Species 0.000 description 1
- 241001135520 Robbsia andropogonis Species 0.000 description 1
- 241000186567 Romboutsia lituseburensis Species 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- 241000379619 Ruegeria Species 0.000 description 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 1
- 241001451093 Rummeliibacillus pycnus Species 0.000 description 1
- 241001147744 Saccharococcus thermophilus Species 0.000 description 1
- 241000187792 Saccharomonospora Species 0.000 description 1
- 241000125139 Saccharomonospora azurea Species 0.000 description 1
- 241000125140 Saccharomonospora cyanea Species 0.000 description 1
- 241000187810 Saccharomonospora viridis Species 0.000 description 1
- 241001303116 Saccharophagus Species 0.000 description 1
- 241001670248 Saccharophagus degradans Species 0.000 description 1
- 241001468198 Saccharopolyspora gregorii Species 0.000 description 1
- 241000187558 Saccharopolyspora hirsuta Species 0.000 description 1
- 241000187581 Saccharopolyspora hordei Species 0.000 description 1
- 241001134661 Saccharopolyspora rectivirgula Species 0.000 description 1
- 241000868102 Saccharopolyspora spinosa Species 0.000 description 1
- 241000868105 Saccharopolyspora taberi Species 0.000 description 1
- 241000204094 Saccharothrix australiensis Species 0.000 description 1
- 241001468203 Saccharothrix coeruleofusca Species 0.000 description 1
- 241001478477 Saccharothrix espanaensis Species 0.000 description 1
- 241001468274 Saccharothrix mutabilis Species 0.000 description 1
- 241001478482 Saccharothrix syringae Species 0.000 description 1
- 241001478458 Saccharothrix texasensis Species 0.000 description 1
- 241001282575 Salegentibacter Species 0.000 description 1
- 241001282574 Salegentibacter salegens Species 0.000 description 1
- 241001023238 Salibacterium halochares Species 0.000 description 1
- 241000105345 Salibacterium qingdaonense Species 0.000 description 1
- 241001042899 Salimicrobium Species 0.000 description 1
- 241000501795 Salimicrobium album Species 0.000 description 1
- 241000006383 Salimicrobium halophilum Species 0.000 description 1
- 241001312748 Salinibacter Species 0.000 description 1
- 241001312746 Salinibacter ruber Species 0.000 description 1
- 241000193000 Salinicoccus Species 0.000 description 1
- 241001343894 Salinicoccus alkaliphilus Species 0.000 description 1
- 241000026995 Salinicoccus hispanicus Species 0.000 description 1
- 241000193022 Salinicoccus roseus Species 0.000 description 1
- 241000426682 Salinispora Species 0.000 description 1
- 241000426680 Salinispora arenicola Species 0.000 description 1
- 241000426681 Salinispora tropica Species 0.000 description 1
- 241000499381 Salinivibrio costicola Species 0.000 description 1
- 241001292348 Salipaludibacillus agaradhaerens Species 0.000 description 1
- 241000747359 Salipaludibacillus neizhouensis Species 0.000 description 1
- 241000894029 Salisediminibacterium locisalis Species 0.000 description 1
- 241000533331 Salmonella bongori Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 241000191112 Saprospira Species 0.000 description 1
- 241000191110 Saprospira grandis Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241001453170 Sebaldella Species 0.000 description 1
- 241000606178 Sebaldella termitidis Species 0.000 description 1
- 241001136691 Seinonella Species 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000763413 Shuttleworthia Species 0.000 description 1
- 241001105882 Siccibacter turicensis Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000976732 Solibacillus isronensis Species 0.000 description 1
- 241001291918 Solibacillus silvestris Species 0.000 description 1
- 241001478896 Sphaerotilus natans Species 0.000 description 1
- 241000190872 Sphingobacterium mizutaii Species 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000168515 Sporobacter Species 0.000 description 1
- 241001446760 Sporobacterium Species 0.000 description 1
- 241000605063 Sporohalobacter lortetii Species 0.000 description 1
- 241001464969 Sporolactobacillus laevolacticus Species 0.000 description 1
- 241000193413 Sporosarcina globispora Species 0.000 description 1
- 241000193395 Sporosarcina pasteurii Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241001147687 Staphylococcus auricularis Species 0.000 description 1
- 241001147736 Staphylococcus capitis Species 0.000 description 1
- 241001147695 Staphylococcus caprae Species 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 241000201854 Staphylococcus chromogenes Species 0.000 description 1
- 241001147698 Staphylococcus cohnii Species 0.000 description 1
- 241001220267 Staphylococcus condimenti Species 0.000 description 1
- 241000520126 Staphylococcus delphini Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001617353 Staphylococcus fleurettii Species 0.000 description 1
- 241000192085 Staphylococcus gallinarum Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241000191982 Staphylococcus hyicus Species 0.000 description 1
- 241001147689 Staphylococcus kloosii Species 0.000 description 1
- 241001379473 Staphylococcus leei Species 0.000 description 1
- 241000147121 Staphylococcus lentus Species 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 241000010986 Staphylococcus lutrae Species 0.000 description 1
- 241000432394 Staphylococcus lyticans Species 0.000 description 1
- 241000507187 Staphylococcus massiliensis Species 0.000 description 1
- 241000192101 Staphylococcus muscae Species 0.000 description 1
- 241001582999 Staphylococcus nepalensis Species 0.000 description 1
- 241000193817 Staphylococcus pasteuri Species 0.000 description 1
- 241000236551 Staphylococcus petrasii Species 0.000 description 1
- 241000681475 Staphylococcus pettenkoferi Species 0.000 description 1
- 241001220301 Staphylococcus piscifermentans Species 0.000 description 1
- 241000794282 Staphylococcus pseudintermedius Species 0.000 description 1
- 241001368129 Staphylococcus pseudolugdunensis Species 0.000 description 1
- 241001044486 Staphylococcus rostri Species 0.000 description 1
- 241001464905 Staphylococcus saccharolyticus Species 0.000 description 1
- 241000192097 Staphylococcus sciuri Species 0.000 description 1
- 241000967959 Staphylococcus simiae Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241001503679 Staphylococcus stepanovicii Species 0.000 description 1
- 241000861996 Staphylococcus succinus Species 0.000 description 1
- 241000192086 Staphylococcus warneri Species 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000194007 Streptococcus canis Species 0.000 description 1
- 241000602664 Streptococcus devriesei Species 0.000 description 1
- 241000193992 Streptococcus downei Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000194050 Streptococcus ferus Species 0.000 description 1
- 241001473878 Streptococcus infantarius Species 0.000 description 1
- 241000194056 Streptococcus iniae Species 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000782300 Streptococcus oralis subsp. tigurinus Species 0.000 description 1
- 241000197578 Streptococcus orisratti Species 0.000 description 1
- 241000193991 Streptococcus parasanguinis Species 0.000 description 1
- 241000960362 Streptococcus peroris Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 241000194051 Streptococcus vestibularis Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000970227 Streptomyces fimbriatus Species 0.000 description 1
- 241000187438 Streptomyces fradiae Species 0.000 description 1
- 241000971004 Streptomyces fulvissimus Species 0.000 description 1
- 241000187217 Streptomyces griseoruber Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 241000187389 Streptomyces lavendulae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241001136694 Subdoligranulum Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 241001656784 Syntrophococcus Species 0.000 description 1
- 241000143014 T7virus Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 241001413771 Tenacibaculum discolor Species 0.000 description 1
- 241001509489 Terrisporobacter glycolicus Species 0.000 description 1
- 241000186582 Terrisporobacter mayombei Species 0.000 description 1
- 206010071574 Testicular autoimmunity Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000105512 Thalassobacter stenotrophicus Species 0.000 description 1
- 241000521326 Thalassobius gelatinovorus Species 0.000 description 1
- 241001665566 Thalassocola Species 0.000 description 1
- 241001147805 Thermoanaerobacter thermocopriae Species 0.000 description 1
- 241000193447 Thermoanaerobacter thermohydrosulfuricus Species 0.000 description 1
- 241000193446 Thermoanaerobacterium thermosaccharolyticum Species 0.000 description 1
- 241001468159 Thermoanaerobacterium thermosulfurigenes Species 0.000 description 1
- 241001291204 Thermobacillus Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 241000167944 Tissierella praeacuta Species 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000078013 Trichormus variabilis Species 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241001147795 Tyzzerella nexilis Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000862962 Uliginosibacterium Species 0.000 description 1
- 241000862965 Uliginosibacterium gangwonense Species 0.000 description 1
- 241000674806 Ulvibacter Species 0.000 description 1
- 241000305338 Ulvibacter litoralis Species 0.000 description 1
- 241001603532 Umezawaea Species 0.000 description 1
- 241000587091 Undibacterium Species 0.000 description 1
- 241000586989 Undibacterium pigrum Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 241000248785 Ureibacillus terrenus Species 0.000 description 1
- 241001489064 Ureibacillus thermophilus Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000207194 Vagococcus Species 0.000 description 1
- 241001626532 Vagococcus carniphilus Species 0.000 description 1
- 241001052205 Vagococcus elongatus Species 0.000 description 1
- 241000507624 Vagococcus fessus Species 0.000 description 1
- 241000207193 Vagococcus fluvialis Species 0.000 description 1
- 241001609646 Vagococcus lutrae Species 0.000 description 1
- 241000207192 Vagococcus salmoninarum Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241001478283 Variovorax Species 0.000 description 1
- 241000084929 Variovorax boronicumulans Species 0.000 description 1
- 241000721373 Variovorax dokdonensis Species 0.000 description 1
- 241001478284 Variovorax paradoxus Species 0.000 description 1
- 241000168661 Variovorax soli Species 0.000 description 1
- 241001533207 Veillonella atypica Species 0.000 description 1
- 241001048169 Veillonella caviae Species 0.000 description 1
- 241001488327 Veillonella criceti Species 0.000 description 1
- 241001533204 Veillonella dispar Species 0.000 description 1
- 241001116698 Veillonella montpellierensis Species 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- 241001488326 Veillonella ratti Species 0.000 description 1
- 241001048168 Veillonella rodentium Species 0.000 description 1
- 241000665148 Venenivibrio stagnispumantis Species 0.000 description 1
- 241001447270 Verminephrobacter Species 0.000 description 1
- 241001447269 Verminephrobacter eiseniae Species 0.000 description 1
- 241000207196 Verrucomicrobium Species 0.000 description 1
- 241000207195 Verrucomicrobium spinosum Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000332146 Vibrio aerogenes Species 0.000 description 1
- 241001135143 Vibrio aestuarianus Species 0.000 description 1
- 241001231453 Vibrio albensis Species 0.000 description 1
- 241000607594 Vibrio alginolyticus Species 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 241000607323 Vibrio campbellii Species 0.000 description 1
- 241000607296 Vibrio cincinnatiensis Species 0.000 description 1
- 241001407018 Vibrio coralliilyticus Species 0.000 description 1
- 241000219284 Vibrio cyclitrophicus Species 0.000 description 1
- 241000607306 Vibrio diazotrophicus Species 0.000 description 1
- 241000607291 Vibrio fluvialis Species 0.000 description 1
- 241001234514 Vibrio halioticoli Species 0.000 description 1
- 241000607618 Vibrio harveyi Species 0.000 description 1
- 241001268204 Vibrio ichthyoenteri Species 0.000 description 1
- 241000607334 Vibrio mediterranei Species 0.000 description 1
- 241001135144 Vibrio metschnikovii Species 0.000 description 1
- 241000501793 Vibrio mytili Species 0.000 description 1
- 241000607365 Vibrio natriegens Species 0.000 description 1
- 241001148073 Vibrio navarrensis Species 0.000 description 1
- 241000607359 Vibrio nereis Species 0.000 description 1
- 241001135139 Vibrio ordalii Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000896074 Vibrio pectenicida Species 0.000 description 1
- 241001490532 Vibrio penaeicida Species 0.000 description 1
- 241000607269 Vibrio proteolyticus Species 0.000 description 1
- 241000876831 Vibrio shilonii Species 0.000 description 1
- 241001148079 Vibrio splendidus Species 0.000 description 1
- 241001148039 Vibrio tubiashii Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000193406 Virgibacillus halodenitrificans Species 0.000 description 1
- 241001327123 Virgibacillus marismortui Species 0.000 description 1
- 241000193396 Virgibacillus pantothenticus Species 0.000 description 1
- 241000862002 Virgibacillus salexigens Species 0.000 description 1
- 241000065508 Viridibacillus arenosi Species 0.000 description 1
- 241000065502 Viridibacillus arvi Species 0.000 description 1
- 241001451077 Viridibacillus neidei Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 241000975185 Weissella cibaria Species 0.000 description 1
- 241000186675 Weissella confusa Species 0.000 description 1
- 241000186838 Weissella halotolerans Species 0.000 description 1
- 241000202218 Weissella hellenica Species 0.000 description 1
- 241000186837 Weissella kandleri Species 0.000 description 1
- 241000384856 Weissella koreensis Species 0.000 description 1
- 241000010758 Weissella soli Species 0.000 description 1
- 241000028633 Weissella thailandensis Species 0.000 description 1
- 241000186882 Weissella viridescens Species 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 241001630928 Williamsia marianensis Species 0.000 description 1
- 241000827162 Winogradskyella Species 0.000 description 1
- 241000604961 Wolbachia Species 0.000 description 1
- 241000605939 Wolinella succinogenes Species 0.000 description 1
- 241000216454 Xanthobacter agilis Species 0.000 description 1
- 241000589495 Xanthobacter flavus Species 0.000 description 1
- 241000865160 Xanthobacter tagetidis Species 0.000 description 1
- 241000589951 Xanthobacter viscosus Species 0.000 description 1
- 241000589655 Xanthomonas citri Species 0.000 description 1
- 241000567013 Xanthomonas codiaei Species 0.000 description 1
- 241001472254 Xanthomonas fuscans Species 0.000 description 1
- 241000293040 Xanthomonas gardneri Species 0.000 description 1
- 241000566987 Xanthomonas hortorum Species 0.000 description 1
- 241000566985 Xanthomonas hyacinthi Species 0.000 description 1
- 241000411046 Xanthomonas perforans Species 0.000 description 1
- 241000194062 Xanthomonas phaseoli Species 0.000 description 1
- 241000566994 Xanthomonas pisi Species 0.000 description 1
- 241000567011 Xanthomonas theicola Species 0.000 description 1
- 241000589643 Xanthomonas translucens Species 0.000 description 1
- 241001640585 Xenophilus azovorans Species 0.000 description 1
- 241000607757 Xenorhabdus Species 0.000 description 1
- 241000123583 Xenorhabdus beddingii Species 0.000 description 1
- 241000123579 Xenorhabdus bovienii Species 0.000 description 1
- 241001041741 Xenorhabdus cabanillasii Species 0.000 description 1
- 241001041739 Xenorhabdus doucetiae Species 0.000 description 1
- 241001041740 Xenorhabdus griffiniae Species 0.000 description 1
- 241001041746 Xenorhabdus hominickii Species 0.000 description 1
- 241000123581 Xenorhabdus poinarii Species 0.000 description 1
- 241000329465 Xylanibacterium Species 0.000 description 1
- 241000329466 Xylanibacterium ulmi Species 0.000 description 1
- 241000204366 Xylella Species 0.000 description 1
- 241000204362 Xylella fastidiosa Species 0.000 description 1
- 241000529915 Xylophilus Species 0.000 description 1
- 241000529917 Xylophilus ampelinus Species 0.000 description 1
- 241000287049 Yaniella Species 0.000 description 1
- 241000839298 Yaniella flava Species 0.000 description 1
- 241000287074 Yaniella halotolerans Species 0.000 description 1
- 241000844081 Yeosuana Species 0.000 description 1
- 241000844082 Yeosuana aromativorans Species 0.000 description 1
- 241000607475 Yersinia bercovieri Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000290086 Yersinia entomophaga Species 0.000 description 1
- 241001148127 Yersinia frederiksenii Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241001148128 Yersinia rohdei Species 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- 241000317522 Youngiibacter multivorans Species 0.000 description 1
- 241001185312 Zavarzinia Species 0.000 description 1
- 241001513148 Zavarzinia compransoris Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000100581 Zhihengliuella Species 0.000 description 1
- 241000172243 Zobellia Species 0.000 description 1
- 241000893379 Zobellia galactanivorans Species 0.000 description 1
- 241001282535 Zobellia uliginosa Species 0.000 description 1
- 241000589651 Zoogloea Species 0.000 description 1
- 241000589153 Zoogloea ramigera Species 0.000 description 1
- 241000123669 Zoogloea resiniphila Species 0.000 description 1
- 241001029157 Zunongwangia Species 0.000 description 1
- 241000944737 Zunongwangia profunda Species 0.000 description 1
- 241001464778 Zymobacter Species 0.000 description 1
- 241001464780 Zymobacter palmae Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 1
- 241000543168 [Actinobacillus] rossii Species 0.000 description 1
- 241001327213 [Bacillus] clarkii Species 0.000 description 1
- 241001673106 [Bacillus] selenitireducens Species 0.000 description 1
- 241001468250 [Bacillus] thermocloacae Species 0.000 description 1
- 241001517045 [Bacillus] vedderi Species 0.000 description 1
- 241000204291 [Bacteroides] coagulans Species 0.000 description 1
- 241000514948 [Bacteroides] pectinophilus Species 0.000 description 1
- 241001509492 [Clostridium] aerotolerans Species 0.000 description 1
- 241001118737 [Clostridium] aldenense Species 0.000 description 1
- 241001147803 [Clostridium] aldrichii Species 0.000 description 1
- 241000360105 [Clostridium] algidixylanolyticum Species 0.000 description 1
- 241001604192 [Clostridium] alkalicellulosi Species 0.000 description 1
- 241000193458 [Clostridium] aminophilum Species 0.000 description 1
- 241001350461 [Clostridium] amygdalinum Species 0.000 description 1
- 241000342876 [Clostridium] asparagiforme Species 0.000 description 1
- 241001246487 [Clostridium] bolteae Species 0.000 description 1
- 241000277654 [Clostridium] caenicola Species 0.000 description 1
- 241001147804 [Clostridium] celerecrescens Species 0.000 description 1
- 241001147786 [Clostridium] cellobioparum Species 0.000 description 1
- 241000193453 [Clostridium] cellulolyticum Species 0.000 description 1
- 241001147772 [Clostridium] cellulosi Species 0.000 description 1
- 241001118742 [Clostridium] citroniae Species 0.000 description 1
- 241000854263 [Clostridium] clariflavum Species 0.000 description 1
- 241000186561 [Clostridium] clostridioforme Species 0.000 description 1
- 241001509494 [Clostridium] colinum Species 0.000 description 1
- 241000408908 [Clostridium] fimetarium Species 0.000 description 1
- 241000696045 [Clostridium] glycyrrhizinilyticum Species 0.000 description 1
- 241000030487 [Clostridium] hiranonis Species 0.000 description 1
- 241000229117 [Clostridium] hungatei Species 0.000 description 1
- 241000030493 [Clostridium] hylemonae Species 0.000 description 1
- 241000985249 [Clostridium] indolis Species 0.000 description 1
- 241000193462 [Clostridium] innocuum Species 0.000 description 1
- 241000193158 [Clostridium] josui Species 0.000 description 1
- 241001098250 [Clostridium] lavalense Species 0.000 description 1
- 241000186569 [Clostridium] leptum Species 0.000 description 1
- 241001621904 [Clostridium] methoxybenzovorans Species 0.000 description 1
- 241001656805 [Clostridium] methylpentosum Species 0.000 description 1
- 241001147790 [Clostridium] papyrosolvens Species 0.000 description 1
- 241000193460 [Clostridium] piliforme Species 0.000 description 1
- 241001522212 [Clostridium] populeti Species 0.000 description 1
- 241001509315 [Clostridium] rectum Species 0.000 description 1
- 241000685809 [Clostridium] saccharogumia Species 0.000 description 1
- 241001656794 [Clostridium] saccharolyticum Species 0.000 description 1
- 241001147801 [Clostridium] scindens Species 0.000 description 1
- 241001147717 [Clostridium] sphenoides Species 0.000 description 1
- 241001147796 [Clostridium] spiroforme Species 0.000 description 1
- 241000186586 [Clostridium] sporosphaeroides Species 0.000 description 1
- 241001147802 [Clostridium] stercorarium subsp. thermolacticum Species 0.000 description 1
- 241001351214 [Clostridium] straminisolvens Species 0.000 description 1
- 241000913097 [Clostridium] sufflavum Species 0.000 description 1
- 241001147719 [Clostridium] termitidis Species 0.000 description 1
- 241001147797 [Clostridium] thermoalcaliphilum Species 0.000 description 1
- 241001656792 [Clostridium] thermosuccinogenes Species 0.000 description 1
- 241000191758 [Clostridium] ultunense Species 0.000 description 1
- 241001147712 [Clostridium] xylanolyticum Species 0.000 description 1
- 241000543172 [Haemophilus] felis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 208000030798 agammaglobulinemia 5 Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229940044726 anaerococcus tetradius Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025719 ankylosing spondylitis 3 Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 208000032217 autosomal dominant agammaglobulinemia 5 Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940092528 bartonella bacilliformis Drugs 0.000 description 1
- 229940092527 bartonella clarridgeiae Drugs 0.000 description 1
- 229940092526 bartonella elizabethae Drugs 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 229940092522 bartonella vinsonii Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940055012 brevibacterium stationis Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 229960002615 dalfopristin Drugs 0.000 description 1
- 108700028430 dalfopristin Proteins 0.000 description 1
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940012229 genone Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 208000014136 immunodeficiency 16 Diseases 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 101150033534 lysA gene Proteins 0.000 description 1
- 101150035025 lysC gene Proteins 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 101150032784 pacB gene Proteins 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 208000008142 parkinson disease 16 Diseases 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000004391 petroleum recovery Methods 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 235000021489 probiotic drink Nutrition 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000012629 purifying agent Substances 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 208000012233 scrotal disease Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 101150054961 terA gene Proteins 0.000 description 1
- 101150096590 terB gene Proteins 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10141—Use of virus, viral particle or viral elements as a vector
- C12N2795/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the production of phage and transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these. The particles are particularly useful for delivering toxic payloads into target bacteria for antibacterial action. Embodiments enable production of highly pure compositions of such particles for medical or environmental use and for containment of the particles, which may be useful for containing antibacterial action.
Description
PHAGE AND TRANSDUCTION PARTICLES
TECHNICAL FIELD
[0001] The invention relates to the production of phage and transduction particles comprising phage proteins using DNAs (eg, plasmids and helper phage, or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these. The particles are particularly useful for delivering toxic payloads into target bacteria for antibacterial action. Embodiments enable production of highly pure compositions of such particles for medical or environmental use and for containment of the particles, which may be useful for containing antibacterial action, controlling dosing or reducing the risk of acquisition of undesirable foreign genes.
BACKGROUND
TECHNICAL FIELD
[0001] The invention relates to the production of phage and transduction particles comprising phage proteins using DNAs (eg, plasmids and helper phage, or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these. The particles are particularly useful for delivering toxic payloads into target bacteria for antibacterial action. Embodiments enable production of highly pure compositions of such particles for medical or environmental use and for containment of the particles, which may be useful for containing antibacterial action, controlling dosing or reducing the risk of acquisition of undesirable foreign genes.
BACKGROUND
[0002] The use of helper phage to package phagemid DNA into phage virus particles is known. An example is the M13K07 helper phage, a derivative of M13, used in E coli host cells. Other examples are R408 and CM13.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0003] The invention relates to tbe production of phage and transduction particles and provides:-
[0004] In a First Configuration A kit comprising a) A first DNA; and b) One or more second DNAs;
Wherein (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle comprising a copy of the first DNA;
(ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
(iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle;
and (iv) the second DNA is devoid of a nucleotide sequence (eg, a packaging signal) required for packaging the second DNA into phage particles;
wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
There is also provided A method of producing phage, the method comprising expressing in a cell comprising the DNAs the phage protein genes, wherein packaged phage are produced that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
Wherein (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle comprising a copy of the first DNA;
(ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
(iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle;
and (iv) the second DNA is devoid of a nucleotide sequence (eg, a packaging signal) required for packaging the second DNA into phage particles;
wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
There is also provided A method of producing phage, the method comprising expressing in a cell comprising the DNAs the phage protein genes, wherein packaged phage are produced that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
[0005] In a Seond Configuration A population of helper phage, wherein the helper phage are capable of packaging first phage, wherein the first phage are different from the helper phage and the helper phage are incapable of self-replication.
[0006] In a third Configuration A composition comprising a population of first phage, wherein the first phage require helper phage according to the First Configuration for replication; and wherein less than [20%] of total phage comprised by the composition are such helper phage.
[0007] In a Fourth Configuration
[0008] A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising (a) Providing DNA comprising a packaging signal;
(b) Introducing the DNA into a host bacterial cell;
(c) Wherein the host bacterial cell comprises helper phage or wherein helper phage are introduced into the bacterial cell simultaneously or sequentially with step (b);
(d) Wherein the helper phage are according to the invention;
(e) Causing or allowing the helper phage to produce phage proteins, wherein the packaging signal is recognised in the host cell, whereby first phage are produced using the proteins, the first phage packaging the DNA;
(f) Wherein helper phage replication in the host cell is inhibited or reduced, thereby limiting the availability of helper phage;
(g) Optionally lysing the host cell and obtaining the first phage;
(h) Thereby producing a composition comprising first phage which require the helper phage for replication, wherein propagation of first phage is prevented or reduced by the limitation of helper phage availability.
(b) Introducing the DNA into a host bacterial cell;
(c) Wherein the host bacterial cell comprises helper phage or wherein helper phage are introduced into the bacterial cell simultaneously or sequentially with step (b);
(d) Wherein the helper phage are according to the invention;
(e) Causing or allowing the helper phage to produce phage proteins, wherein the packaging signal is recognised in the host cell, whereby first phage are produced using the proteins, the first phage packaging the DNA;
(f) Wherein helper phage replication in the host cell is inhibited or reduced, thereby limiting the availability of helper phage;
(g) Optionally lysing the host cell and obtaining the first phage;
(h) Thereby producing a composition comprising first phage which require the helper phage for replication, wherein propagation of first phage is prevented or reduced by the limitation of helper phage availability.
[0009] In a Fifth Configuration A phage production system, for producing phage (eg, the first phage of any preceding claim) comprising a nucleotide sequence of interest (NSI-phage), the system comprising components (i) to (iii):-(i) A first DNA;
(ii) A second DNA; and (iii) a NSI-phage production factor (NPF) or an expressible nucleotide sequence that encodes a NPF;
Wherein a) The first DNA encodes a helper phage (eg, said first helper phage recited in any preceding claim);
b) The second DNA comprises the nucleotide sequence of interest (NSI);
c) When the system is comprised by a bacterial host cell, helper phage proteins are expressed from the first DNA to form phage that package the second DNA in the presence of the NPF, thereby producing NSI-phage;
d) The system is devoid of a helper phage production factor (HPF) that is required for forming phage that package the first DNA, or is devoid of an expressible nucleotide sequence that encodes a functional HPF; or the system comprises a nucleotide sequence that comprises or encodes a functional HPF, the system further comprising means for targeted inactivation in the host cell of the HPF
sequence to eliminate or minimise production of helper phage comprising the first DNA; and Whereby the system is capable of producing a product comprising a population of NSI-phage, wherein each NSI-phage requires a said helper phage for propagation, wherein the NSI-phage in the product are not mixed with helper phage or less than [20%] of total phage comprised by the product are said helper phage.
The invention also provides:_
(ii) A second DNA; and (iii) a NSI-phage production factor (NPF) or an expressible nucleotide sequence that encodes a NPF;
Wherein a) The first DNA encodes a helper phage (eg, said first helper phage recited in any preceding claim);
b) The second DNA comprises the nucleotide sequence of interest (NSI);
c) When the system is comprised by a bacterial host cell, helper phage proteins are expressed from the first DNA to form phage that package the second DNA in the presence of the NPF, thereby producing NSI-phage;
d) The system is devoid of a helper phage production factor (HPF) that is required for forming phage that package the first DNA, or is devoid of an expressible nucleotide sequence that encodes a functional HPF; or the system comprises a nucleotide sequence that comprises or encodes a functional HPF, the system further comprising means for targeted inactivation in the host cell of the HPF
sequence to eliminate or minimise production of helper phage comprising the first DNA; and Whereby the system is capable of producing a product comprising a population of NSI-phage, wherein each NSI-phage requires a said helper phage for propagation, wherein the NSI-phage in the product are not mixed with helper phage or less than [20%] of total phage comprised by the product are said helper phage.
The invention also provides:_
[0010] A composition for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a first phage genome, wherein in the cell the MGE
is mobilised using proteins encoded by the phage and replication of first is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent.
is mobilised using proteins encoded by the phage and replication of first is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent.
[0011] A nucleic acid vector comprising the MGE integrated therein, wherein the vector is capable of transferring the MGE or a copy thereof into a host bacterial cell.
[0012] A non-self replicative transduction particle comprising said MGE or vector of the invention.
[0013] A composition comprising a plurality of transduction particles, wherein each particle comprises a MGE or vector according to the invention, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein (i)target cells are killed by the antibacterial agent;
(ii) growth or proliferation of target cells is reduced; or (iii)target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
(ii) growth or proliferation of target cells is reduced; or (iii)target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
[0014] A composition comprising a plurality of non-self replicative transduction particles, wherein each particle comprises a MGE or plasmid according to the invention, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein the agent is a CRISPR/Cas system and the component comprises a nucleic acid encoding a crRNA or a guide RNA that is operable with a Cas in a target bacterial cell to guide the Cas to a target nucleic acid sequence of the cell to modify the sequence, whereby (i)target cells are killed by the antibacterial agent;
(ii)growth or proliferation of target cells is reduced; or (iii)target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
(ii)growth or proliferation of target cells is reduced; or (iii)target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
[0015] A method of producing a plurality of transduction particles, the method comprising combining the composition of the invention with host bacterial cells of said first species, wherein the cells comprise the first phage, allowing a plurality of said MGEs to be introduced into host cells and culturing the host cells under conditions in which first phage-encoded proteins are expressed and MGE copies are packaged by first phage proteins to produce a plurality of transduction particles, and optionally separating the transduction particles from cells and obtaining a plurality of transduction particles separated from cells.
[0016] A bacterial host cell comprising a first phage and a MGE, vector or particle of the invention, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
[0017] A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition of the invention, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
[0018] A bacterial host cell comprising a first phage and a MGE, vector or particle of the invention, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
[0019] A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition of the invention, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
[0020] A bacterial host cell comprising a MGE, vector or particle of the invention and nucleic acid under the control of one or more inducible promoters, wherein the nucleic acid encodes all structural proteins necessary to produce a transduction particle that packages a copy of the MGE or plasmid, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
[0021] A plasmid comprising (a) A nucleotide sequence encoding an antibacterial agent or component thereof for expression in target bacterial cells;
(b) A constitutive promoter for controlling the expression of the agent or component;
(c) An optional terS nucleotide sequence;
(d) An origin of replication (on); and (e) A phage packaging sequence (optionally pac, cos or a homologue thereof); and the plasmid being devoid of (f) All nucleotide sequences encoding phage structural proteins necessary for the production of a transduction particle (optionally a phage), or the plasmid being devoid of at least one of such sequences; and (g) Optionally terL.
(b) A constitutive promoter for controlling the expression of the agent or component;
(c) An optional terS nucleotide sequence;
(d) An origin of replication (on); and (e) A phage packaging sequence (optionally pac, cos or a homologue thereof); and the plasmid being devoid of (f) All nucleotide sequences encoding phage structural proteins necessary for the production of a transduction particle (optionally a phage), or the plasmid being devoid of at least one of such sequences; and (g) Optionally terL.
[0022] A bacterial host cell comprising the genome of a helper phage that is incapable of self-replication, optionally wherein the genome is present as a prophage, and a plasmid according to the invention, wherein the helper phage is operable to package copies of the plasmid in transduction particles, wherein the particles are capable of infecting bacterial target cells to which the antibacterial agent is toxic.
[0023] A method of making a plurality of transduction particles, the method comprising culturing a plurality of host cells according to the invention, optionally inducing a lytic cycle of the helper phage, and incubating the cells under conditions wherein transducing particles comprising packaged copies of the plasmid are created, and optionally separating the particles from the cells to obtain a plurality of transduction particles.
[0024] A plurality of transduction particles obtainable by the method of the invention for use in medicine, eg, for treating or preventing an infection of a human or animal subject by target bacterial .. cells, wherein transducing particles are administered to the subject for infecting target cells and killing the cells using the antibacterial agent.
[0025] A method of making a plurality of transduction particles, the method comprising (a) Producing host cells whose genomes comprise nucleic acid encoding structural proteins necessary to produce transduction particles that can package first DNA, wherein the genomes are devoid of a phage packaging signal, wherein the expression of the proteins is under the control of inducible promoter(s);
(b) Producing first DNA encoding an antibacterial agent or a component thereof, wherein the DNA comprises a phage packaging signal;
(c) Introducing the DNA into the host cells;
(d) Inducing production of the structural proteins in host cells, whereby transduction particles are produced that package the DNA;
(e) Optionally isolating a plurality of the transduction particles; and (0 Optionally formulating the particles into a pharmaceutical composition for administration to a .. human or animal for medical use.
(b) Producing first DNA encoding an antibacterial agent or a component thereof, wherein the DNA comprises a phage packaging signal;
(c) Introducing the DNA into the host cells;
(d) Inducing production of the structural proteins in host cells, whereby transduction particles are produced that package the DNA;
(e) Optionally isolating a plurality of the transduction particles; and (0 Optionally formulating the particles into a pharmaceutical composition for administration to a .. human or animal for medical use.
[0026] A plurality of transduction particles obtainable by the method.
[0027] A host bacterial cell comprising
28 a) A first DNA; and b) One or more second DNAs;
wherein (i) the DNAs together comprise all genes required to produce a transduction particle comprising a copy of the first DNA packaged by phage structural proteins;
(ii) the first DNA is devoid of at least one functional essential gene (eg, encoding a phage structural protein) required to produce the particle; and wherein the one or more second DNAs comprises said functional essential gene(s);
(iii) the first DNA comprises a phage packaging signal for producing the particle; and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1: The genetic map of P2 genome with non-essential genes boxed;
wherein (i) the DNAs together comprise all genes required to produce a transduction particle comprising a copy of the first DNA packaged by phage structural proteins;
(ii) the first DNA is devoid of at least one functional essential gene (eg, encoding a phage structural protein) required to produce the particle; and wherein the one or more second DNAs comprises said functional essential gene(s);
(iii) the first DNA comprises a phage packaging signal for producing the particle; and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1: The genetic map of P2 genome with non-essential genes boxed;
[0029] Figure 2: Schematic of SaPIbov1;
[0030] Figure 3: (A) Maps of P2 and P4¨ genomic architecture and regulatory network of phage P2 and satellite phage P4; the grey boxed region in P2 was deleted and replaced with a a kanamycin marker sequence, and the box shown in dashed lines shows the region of P4 including the cos site that was included in the CGV; (B) p94 genomic map;
[0031] Figure 4: Schematic view of the SA100 production srain ¨ the defective helper phage will only turn on phage production following induction; since the phage packaging DNA sequence has .. been removed from the helper and placed on the CGVTM, only CGVTM molecules will be packaged into the synthetic phage particles;
[0032] Figure 5: Efficiency of infection ¨ percent infected EMG-2 cells with increasing ratio (MOT) of SA100 particles to EMG-2;
[0033] Figure 6: CGVTM delivery by SA100 ¨ total CFU and CGVTm-containing CFU
after infection of MG1655_pks cells (A) with SA100 containing p114 or p94 or X1-blue_pks cells (B) containing p114;
after infection of MG1655_pks cells (A) with SA100 containing p114 or p94 or X1-blue_pks cells (B) containing p114;
[0034] Figure 7: Killing of target cells by SA100-delivered CGVTM - killing efficiency of the two target strains by SA100 delivered CGV5TM (2nd, 4th and 6th bars) using wild-type and optimised copy number CGVTM compared to non-infected controls;
[0035] Figure 8: Plotted is the abundance as expressed in colony forming units (CFU) per 5 milliliter faecal sample (n=15). Two groups, CRISPR induced and non-induced are shown. No difference was observed between the groups when the CFU was deteremined on agar plates containing streptomycin;
and
and
[0036] Figure 9: Plotted is the abundance as expressed in colony forming units (CFU) per 5 milliliter faecal sample (n=15). Two groups, CRISPR induced and non-induced are shown.
The statistical difference is calculated using the Student t-test, showing a statistically significant increase in abundance after 48 hours in the CRISPR non-induced group (p-value=0.011) on agar plates supplemented with spectinomycin and streptomycin. This shows that the CGV
(containing a spectonomycin marker) can be delivered by non-self-replicative particles SA100.
The statistical difference is calculated using the Student t-test, showing a statistically significant increase in abundance after 48 hours in the CRISPR non-induced group (p-value=0.011) on agar plates supplemented with spectinomycin and streptomycin. This shows that the CGV
(containing a spectonomycin marker) can be delivered by non-self-replicative particles SA100.
[0037] Figure 10:
1. CRISPR system is inserted into a phage genome containing at least packaging signal and DNA replication module thereby generating a vector, such as a plasmid (we call a CRISPR Guided VectorTM, CGV); the CRISPR system may comprise nucleic acid encoding a Cas (eg, Cas3 or Cas9) and/or one or more crRNAs or gRNAs, optionally also Cascade proteins when the Cas is Cas3;
2. Essential gene(s) are removed or mutated in phage and the function provided by expression in trans from a plasmid (or this may instead be from essential genes integrated in the chromosome of a host bacterial cell (aka the production strain));
3. CGV is replicated and packaged in phage-like transduction particles encoded by functions encoded on CGV, but at least one essential function being expressed in trans from plasmid or chromosome; and 4. Production via propagation cycles on production strain. Propagation on other bacterial strains is advantageously prevented.
DETAILED DESCRIPTION
1. CRISPR system is inserted into a phage genome containing at least packaging signal and DNA replication module thereby generating a vector, such as a plasmid (we call a CRISPR Guided VectorTM, CGV); the CRISPR system may comprise nucleic acid encoding a Cas (eg, Cas3 or Cas9) and/or one or more crRNAs or gRNAs, optionally also Cascade proteins when the Cas is Cas3;
2. Essential gene(s) are removed or mutated in phage and the function provided by expression in trans from a plasmid (or this may instead be from essential genes integrated in the chromosome of a host bacterial cell (aka the production strain));
3. CGV is replicated and packaged in phage-like transduction particles encoded by functions encoded on CGV, but at least one essential function being expressed in trans from plasmid or chromosome; and 4. Production via propagation cycles on production strain. Propagation on other bacterial strains is advantageously prevented.
DETAILED DESCRIPTION
[0038] The invention relates to tbe production of phage using DNAs (eg, plasmids with helper phage), as well as the phage, helper phage, compositions and methods involving these. The invention finds utility, for example, for containing phage in environments ex vivo and in vivo, reducing the risk of acquisition of antibiotic resistance or other genes by phage, as well as controlling dosing of phage in an environment. The contamination of useful phage populations by helper phage may in examples also be restricted or eliminated, thereby controlling phage propagation and enhancing the proportion of desired phage in phage compositions, such as medicaments, herbicides and other agents where phage may usefully be used. Thus, the invention provides the following embodiments.
[0039] A kit comprising a) A first DNA; and b) One or more second DNAs;
Wherein (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle or a transduction particle comprising a copy of the first DNA;
(ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
(iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle;
and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into phage particles;
wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
Wherein (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle or a transduction particle comprising a copy of the first DNA;
(ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
(iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle;
and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into phage particles;
wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
[0040] For example the second DNA is devoid of a packaging signal for packaging second DNA.
Additionally or alternatively, the second DNA is devoid of a nucleotide sequence required for replication of helper phage. Optionally, the nucleotide sequence enodes a sigma factor or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication when the second DNA is comprised by a helper prophage.
Additionally or alternatively, the second DNA is devoid of a nucleotide sequence required for replication of helper phage. Optionally, the nucleotide sequence enodes a sigma factor or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication when the second DNA is comprised by a helper prophage.
[0041] In an example, the second DNA is comprised by an M13 or M13-based helper phage. M13 encodes the following proteins required for phage packaging:-a) pill: host recognition b) pV: coat protein c) pVII, pVIII, pIX: membrane proteins d) pI, pIV, pXI: Channel for translocating the phage to the extracellular space.
[0042] In this example, the second DNA is devoid of one or more of the genes coding for these proteins, eg, is devoid of a gene endoding pill, a gene encoding pV, a gene endoding pVII, a gene endoding pVIII, a gene endoding pIX, a gene endoding pI, a gene endoding pIV
and/or a gene endoding XI.
and/or a gene endoding XI.
[0043] In an embodiment, the phage particle of (i) is capable of infecting a target bacterium, the phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, or wherein the NSI comprises a regulatory element that is operable in the target bacterium. In an example, the NSI is capable of recombination with the target cell chromosome or an episome comprised by the target cell to modify the chromosome or episome.
Optionally, this is carried out in a method wherein the chromosome or episome is cut (eg, at a predetermined site using a guided nuclease, such as a Cas, TALEN, zinc finger or meganuclease; or a restriction endonuclease) and simultaneously or sequentially the cell is infected by a phage particle that comprises the first DNA, wherein the DNA is introduced into the cell and the NSI or a sequence thereof is introduced into the chromosome or episome at or adjacent the cut site. In an example the first DNA comprises one or more components of a CRISPR/Cas system operable to perform the cutting (eg, comprising at least a nucleotide sequence encoding a guide RNA or crRNA for targeting the site to be cut) and further comprising the NSI.
Optionally, this is carried out in a method wherein the chromosome or episome is cut (eg, at a predetermined site using a guided nuclease, such as a Cas, TALEN, zinc finger or meganuclease; or a restriction endonuclease) and simultaneously or sequentially the cell is infected by a phage particle that comprises the first DNA, wherein the DNA is introduced into the cell and the NSI or a sequence thereof is introduced into the chromosome or episome at or adjacent the cut site. In an example the first DNA comprises one or more components of a CRISPR/Cas system operable to perform the cutting (eg, comprising at least a nucleotide sequence encoding a guide RNA or crRNA for targeting the site to be cut) and further comprising the NSI.
[0044] In an embodiment, the presence in the target bacterium of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genome, or downregulation thereof.
[0045] In an embodiment, the presence in the target bacterium of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of the target cell, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genome, or upregulation thereof.
[0046] In an embodiment, the NSI encodes a component of a CRISPR/Cas system that is toxic to the target bacterium.
[0047] In an embodiment, the DNA is a first DNA as defined in any preceding paragraph.
[0048] In an embodiment, the first DNA is comprised by a vector (eg, a plasmid or shuttle vector).
[0049] In an embodiment, the second DNA is comprised by a vector (eg, a plasmid or shuttle vector), helper phage (eg, a helper phagemid) or is integrated in the genome of a host bacterial cell.
[0050] An embodiment provides a bacterial cell comprising the first and second DNAs. Optionally, the cell is devoid of a functional CRISPR/Cas system before transfer therein of a first DNA, eg, a first DNA comprising a component of a CRISPR/Cas system that is toxic to the target bacterium. An embodiment provides an antibacterial composition comprising a plurality of cells, wherein each cell is optionally according to this paragraph, for administration to a human or animal subject for medical use.
[0051] A method of producing phage is provided, the method comprising expressing in a host bacterial cell the phage protein genes, wherein packaged phage are produced that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles. Optionally, the method comprises isolating the phage particles.
[0052] A composition comprising a population of phage particles obtainable by the method is provided for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the phage are capable of infecting and killing the target cells.
[0053] A method of treating an environment ex vivo, the method comprising exposing the environment to a population of phage particles obtainable by the method is provided, wherein the environment comprises target bacteria and the phage infect and kill the target bacteria. In an example thje subject is further administered an agent simultaneously or sequentially with the phage administration. In an example, the agent is a herbicide, pesticide, insecticide, plant fertilizer or cleaning agent.
[0054] Optionally, the method is for containing the treatment in the environment.
[0055] Optionally, the method is for controlling the dosing of the phage treatment in the environment.
[0056] Optionally, the method is for reducing the risk of acquisition of foreign gene sequence(s) by the phage in the environment.
[0057] A method of treating an infection of target bacteria in a human or animal subject is provided, the method comprising exposing the bacteria to a population of phage particles obtainable by the production method, wherein the phage infect and kill the target bacteria.
[0058] Optionally, the method for treating is for containing the treatment in the subject.
[0059] Optionally, the method for treating is for containing the treatment in the environment in which the subject exists.
[0060] Optionally, the method for treating is for controlling the dosing of the phage treatment in the subject.
[0061] Optionally, the method for treating is for reducing the risk of acquisition of foreign gene sequence(s) by the phage in the subject.
[0062] Optionally, the method for treating is for reducing the risk of acquisition of foreign gene sequence(s) by the phage in the environment in which the subject exists.
[0063] Optionally, target bacteria herein are comprised by a microbiome of the subject, eg, a gut microbiome. Altertnatively, the microbiome is a skin, scalp, hair, eye, ear, oral, throat, lung, blood, rectal, anal, vaginal, scrotal, penile, nasal or tongue microbiome.
[0064] In an example thje subject is further administered a medicament simultaneously or sequentially with the phage administration. In an example, the medicament is an antibiotic, antibody, immune checkpoint inhibitor (eg, an anti-PD-1, anti-PD-Li or anti-CTLA4 antibody), adoptive cell therapy (eg, CAR-T therapy) or a vaccine.
[0065] In an example, the invention employs helper phage for packaging the phage nucleic acid of interest. Thus, the invention provides the following illustrative Aspects:-1. A population of helper phage, wherein the helper phage are capable of packaging first phage nucleic acid to produce first phage particles, wherein the first phage are different from the helper phage and the helper phage are incapable themselves of producing helper phage particles.
2. A composition comprising a population of first phage, wherein the first phage require helper phage according to Aspect 1 for replication of first phage particles; and optionally wherein less than 20, 15, 10, 5, 4, 3,2, 1, 0.5, 0.4, 0.2 or 0.1% of total phage particles comprised by the composition are particles of such helper phage.
In an example the composition comprises helper phage and less than 1% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.5% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.1% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.01% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.0001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.00001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.000001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.0000001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.00000001% of total phage particles comprised by the composition are particles of such helper phage.
In an example, the population comprises at least 10,104' 105 or 106 phage particles, as indicated a transduction assay, for example. In an example, the population comprises at least 10 phage particles and eg, no more than 1014 particles. In an example, the population comprises at least 104 phage particles and eg, no more than 1014 particles. In an example, the population comprises at least 105 phage particles and eg, no more than 1014 particles. In an example, the population comprises at least 106 phage particles and eg, no more than 1014 particles. To have a measure of the first phage concentration, for example, one can perform a standard transduction assay when the first phage genome contains an antibiotic marker. Thus, in this case the first phage are capable of infecting target bacteria and in a sample of lml the population comprises at least 103,104' 105 or 106 transducing particles, which can be determined by infecting susceptible bacteria at a multiplicity of infection <0.1 and determining the number of infected cells by plating on a selective agar plate corresponding to the antibiotic marker in vitro at 20 to 37 degrees centigrade, eg, at 20 or 37 degrees centrigrade.
Optionally at least 99.9, 99.8, 99.7, 99.6, 99.5, 99.4, 99.3, 99.2, 99.1, 90, 85, 80, 70, 60, 50 or 40% of total phage particles comprised by the composition are particles of first phage.
In an example, the first phage genome comprises an fl origin of replication.
In an example, the helper phage are E coli phage. In an example, the first phage are E co/i, C dificile, Streptococcus, Klebsiella, Pseudomonas, Acitenobacter, Enterobacteracea, Firmicutes or Bacteroidetes phage. In an example, the helper phage are engineered M13 phage.
In an example, the first phage genome comprises a phagemid, wherein the phagemid comprises a packaging signal for packaging first phage particles in the presence of the helper phage.
The first phage particles may contain a nucleotide sequence of interest (NSI), eg, as defined herein, such as a NSI that encodes a component of a CRISPR/Cas system operable in target bacteria that can be infected by the first phage particles. Once inside the target bacteria, the first phage DNA is incapable of being packaged to form first phage particles in the absence of the helper phage. This usefully contains the activity of the first phage genome and its encoded products (protieins and/or nucleic acid), as well as limits or controls dosing of the NSI and its encoded products in an environment comprising the target bacteria that have been exposed to the first phage. This is useful, for example to control the medical treatment of an environment comprised by a human or animal subject, plant or other environment (eg, soil or a foodstiff or food ingredient).
3. The helper phage or composition of any preceding Aspect, wherein the genome of each first phage is devoid of genes encoding first phage structural proteins.
4. The composition of Aspect 2 or 3, wherein the composition comprises helper phage DNA.
5. The composition of Aspect 4, wherein the DNA comprises helper DNA
fragments.
6. The helper phage or composition of any one preceding Aspect, wherein the helper phage are in the form of prophage.
Thus, the prophage is integrated in the chromosome of a host cell.
Examples of phage structural proteins are phage coat proteins, collar proteins and phage tail fibre proteins.
7. The composition of any one of Aspects 2 or 3, wherein the composition comprises no helper phage DNA comprising a sequence of 20 contiguous nucleotides or more (eg, from 20 to 25, 30, 35, 40, 50 or 100 nucleotides), eg, no helper phage DNA.
This can be determined, for example, using DNA probes (designed on the basis of the known heper phge genome sequence) with PCR, as is conventional. In an example, the composition may comprise residual helper prophage DNA, but essentially otherwise is devoid of helper DNA.
8. The composition of any one of Aspects 2 to 5 and 7, wherein the helper phage are capable of infecting host bacteria and the composition does not comprise host bacteria.
9. The composition of any one of Aspects 2 to 8, wherein the composition is a lysate of host bacterial cells, wherein the lysate comprises helper prophage DNA, eg, such DNA comprises 20 contiguous nucleotides or more (eg, from 20 to 25, 30, 35, 40, 50 or 100 nucleotides) of helper phage DNA.
10. The composition of any one of Aspects 2 to 8, wherein the composition is a lysate of host bacterial cells, wherein the lysate has been processed (eg, filtered) to remove all or some helper phage DNA; or the composition is a lysate of host bacterial cells that is devoid of cellular material.
11. The composition of any one of Aspects 2 to 10, wherein the composition does not comprise helper phage particles.
12. The composition of any one of Aspects 2 to 11, wherein at least 95%
(eg, 100%) of phage particles comprised by the composition are first phage particles.
In another embodiment, the composition comprises second phage particles, wherein the second phage .. are different from the first phage and are not helper phage.
13. The composition of any one of Aspects 2 to 12, wherein the population comprises at least 103, 104, 105 or 106 phage particles, as indicated in a transduction assay.
14. The helper phage or composition of any preceding Aspect, wherein the first phage are capable of replicating in host bacteria in the presence of the helper phage (eg, helper prophage), wherein the first phage comprise antibacterial means for killing target bacteria of a first strain or species, wherein the target bacteria are of a different strain or species and the antibacterial means is not operable to kill the target bacteria.
15. A composition comprising a population of phage, the population comprising (a) A first sub-population of first phage that require a helper phage for packaging the first phage;
(b) A second sub-population of phage comprising the helper phage, wherein the helper phage are as recited in any preceding Aspect.
16. The helper phage or composition of any preceding Aspect, wherein the helper phage are phagemids.
17. A composition comprising (a) A population of helper phage as recited in any preceding Aspect; and (b) A population of nucleic acid vectors comprising vector DNA that comprises a first phage packaging signal;
(c) wherein the helper phage are capable of packaging the vector DNA to produce first phage.
18. The composition of Aspect 17, wherein the vectors are phage.
19. The composition of Aspect 17, wherein the vectors are plasmids or phagemids.
20. The composition of Aspect 19, the vectors are shuttle vectors (eg, pUC
vectors) that can be replicated in first bacteria, wherein the vectors can further be replicated and packaged into first phage in second bacteria (host bacteria) in the presence of the helper phage, wherein the first bacteria are of a strain or species that is different to the strain or species of the host bacteria.
21. The composition of Aspect 20, wherein the first phage are capable of infecting third bacteria .. of a strain or species that is different to the second (and optionally also the first) bacteria.
22. The composition of any one of Aspects 17 to 21, wherein the first phage are capable of replicating in host bacteria in the presence of the helper phage (eg, helper prophage), wherein the first phage comprise antibacterial means for killing target bacteria of a first strain or species, wherein the host bacteria are of a different strain or species and the antibacterial means is not operable to kill the host bacteria.
23. The helper phage or composition of any preceding Aspect, wherein the genome is devoid of a packaging signal (eg, SEQ ID NO: 2 below), wherein the helper phage are incapable of self-replication.
24. The helper phage or composition of Aspect 23, wherein the signal is a pac or cos sequence.
25. The helper phage or composition of any preceding Aspect, wherein the helper phage genome is capable of replication in a host cell.
Thus, the genome is capable of nucleic acid replication but not packaging of helper phage.
26. The helper phage or composition of any one of Aspects 1 to 24, wherein the genome is devoid of a nucleotide sequence required for production of helper phage particles.
27. The helper phage or composition of Aspect 26, wherein the nucleotide sequence enodes a sigma factor (eg, sigma-70) or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA
replication.
28. The helper phage or composition of any preceding Aspect, wherein the helper phage are temperate phage.
29. The helper phage or composition of any one of Aspects 1 to 27, wherein the helper phage are lytic phage.
30. The helper phage or composition of any preceding Aspect, wherein the first phage are capable of infecting target bacteria, the first phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA (eg, gRNA or crRNA) in target bacteria, or wherein the NSI
comprises a regulatory element that is operable in target bacteria.
31. The helper phage or composition of Aspect 30, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genomes, or downregulation thereof.
32. The helper phage or composition of Aspect 30, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of target cells, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genomes, or upregulation thereof.
33. An antibacterial composition according to any one of Aspects 2 to 32, wherein the first phage are capable of infecting target bacteria and each first phage comprises engineered antibacterial means for killing target bacteria.
By use of the term "engineered" it will be readily apparent to the skilled addressee that the relevant means has been introduced and is not naturally-occurring in the phage. For example, the means is recombinant, artificial or synthetic.
34. The composition of Aspect 14, 22 or 33, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
35. The composition of caim 34, wherein the component(s) comprise (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria; (ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
In an example, a Cas herein is a Cas9. In an example, a Cas herein is a Cas3.
The Cas may be identical to a Cas encoded by the target bacteria.
36. The composition of any one of Aspects 14, 22 or 33 to 35, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease.
37. The helper phage or composition of any preceding Aspect, wherein the helper phage is for use in medicine practised on a human or animal subject, or the composition is a pharmaceutical composition for use in medicine practised on a human or animal subject.
In an example, the animak is a livestock or companion pet animal (eg, a cow, pig, goat, sheep, horse, dog, cat or rabbit). In an example, the animal is an insect (an insect at any stage of its lifecycle, eg, egg, larva or pupa). In an example, the animal is a protozoan. In an example, the animal is a cephalopod.
38. The composition of any one of Aspects 2 to 36, wherein the composition is a herbicide, pesticide, food or beverage processing agent, food or beverage additive, petrochemical or fuel processing agent, water purifying agent, cosmetic additive, detergent additive or environmental (eg, soil) additive or cleaning agent.
39. The helper phage or composition of any one of Aspects 1 to 37 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by the target bacteria and the target bacteria are comprised by the subject, the method comprising administering the composition to the subject, whereby the target bacteria are exposed to the antibacterial means and killed and propagation of the first phage is contained.
The inability of the first phage to self-replicate and to require helper phage or second DNA to do this usefully provides containment in the location (eg, gut) of action of the composition and/or in the environment of the subject, eg, when exposed to secretions such as urine and faeces of the subject that otherwise may contain replicated first phage. Inability of the helper phage or second DNA to self-package limits availability of factors required by the first phage to form packaged particles, hence providing containment by limiting first phage propagation. This may be useful, for example, to contain an antibacterial acitivity provided by the first phage, such as a CRISPR/Cas killing principle.
40. A bacterial cell or a plurality of bacterial cells comprising the helper phage or composition of any preceding Aspect, wherein the first phage are capable of replication in the presence of the helper phage in the cell.
The cell may, for example, act as a carrier for the genome of the first phage, wherein the first phage DNA is capable of horizontal transfer from the carrier to the target bacteria once the carrier bacteria have been administered to an environment to be treated, eg, a soil or a human gut or other environment described herein. In an example, the environment is comprised by a human or animal subject and the carrier are commensal or probiotic in the subject. For example the carrier bacteria are Lactobacillus (eg, L reuteri or L lactis), E coli or Streptococcus (eg, S
thermophilus) bacteria. The horizontal transfer can be transfer of a plasmid (such as a conjugative plasmid) to the target bacteria or first phage infection of the target bacteria, wherein the first phage have been prior packaged in the carrier. The use of a carrier is useful too for oral administration or other routes where the carrier can provide protection for the phage, helper or composition from the acid stomach or other harsh environments in the subject. Furthermore, the carrier can be formulated into a beverage, for example, a probiotic drink, eg, an adapted Yakult (trademark), Actimel (trademark), Kevita (trademark), Activia (trademark), Jarrow (trademark) or similar drink for human consumption.
41. The cell(s) of Aspect 40 for administration to a human or animal subject for medical use, comprising killing target bacteria using first phage, wherein the target bacteria mediate as disease or condition in the subject.
In an example, when the subject is a human, the subject is not an embryo.
42. The cell(s) of Aspect 41, wherein the cell(s) comprises helper phage and is symbiotic or probiotic in the subject.
43. A method of killing target bacteria in an environment, optionally wherein the method is not practised on a human or animal body, wherein the method comprises exposing the environment to the cell(s) according to Aspect 42, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, wherein the environment is or has been exposed to first phage or said vectors to produce first phage in the presence of the helper phage, wherein the first phage are capable of replication in the environment and kill target bacteria.
44. The cell(s) or method of any one of Aspects 40 to 43, wherein the cell is an E coli, Lactobacillus (eg, L lactis or retueri) or Streptococcus (eg, thermophilus) cell.
45. The cell(s) or method of Aspects 40 to 44 wherein the subject is administered or has been administered a cell comprising first phage.
46. The composition of any one of Aspects 2 to 45 in combination with a target bacterial cell wherein the first phage are capable of infecting the target bacterial cell.
47. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills target bacteria, for containment of the antibacterial in an environment, eg, containment ex vivo; or containment in a human or animal subject comprising the environment.
48. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills the target bacteria, for reducing the risk of acquisition by the first phage of foreign genes.
For example, this is useful for reducing the risk of antibiotic resistance genes by the phage, such as when the phage are in the presence of other phage or plasmids in the environment.
49. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills the target bacteria, for reducing the risk of acquisition by the first phage of one or more antibiotic resistance genes.
50. A method of reducing the risk of acquisition by first phage of foreign genes, the method comprising (a) Providing the composition of any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and (b) Exposing target bacteria to the composition, wherein the first phage infect the target bacteria;
(c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby reducing the risk of acquisition of first phage of foreign genes (eg, antibiotic resistance genes).
51. A method of containing an antibacterial activity in an environment (e.g., ex vivo), the method comprising (a) Providing an antibacterial composition according to any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and (b) Exposing target bacteria in the environment to the composition, wherein the bacteria are exposed to the first phage and antibacterial means and are killed;
(c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby containing the antibacterial activity.
52. A method of controlling the dosing of first phage in an environment (e.g., ex vivo), the method comprising (a) Providing an antibacterial composition according to any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and (b) Exposing target bacteria in the environment to the composition, wherein the bacteria are infected by first phage;
(c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby controlling dosing of first phage in the environment.
53. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is a human or animal microbiome, e.g., a gut microbiome.
54. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is a microbiome of soil; a plant, part of a part (e.g., a leaf, fruit, vegetable or flower) or plant product (e.g., pulp); water; a waterway; a fluid; a foodstuff or ingredient thereof; a beverage or ingredient thereof; a medical device; a cosmetic; a detergent; blood; a bodily fluid; a medical apparatus; an industrial apparatus; an oil rig; a petrochemical processing, storage or transport apparatus; a vehicle or a container.
55. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is an ex vivo bodily fluid (e.g., urine, blood, blood product, sweat, tears, sputum or spit), bodily solid (e.g., faeces) or tissue of a human or animal subject that has been administered the composition.
56. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is an in vivo bodily fluid (e.g., urine, blood, blood product, sweat, tears, sputum or spit), bodily solid (e.g., faeces) or tissue of a human or animal subject that has been administered the composition.
57. A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising (a) Providing DNA comprising a packaging signal;
(b) Introducing the DNA into a host bacterial cell;
(c) Wherein the host bacterial cell comprises helper phage or wherein helper phage are introduced into the bacterial cell simultaneously or sequentially with step (b);
(d) Wherein the helper phage are according to any preceding Aspect;
(e) Causing or allowing the helper phage to produce phage coat proteins, wherein the packaging signal is recognised in the host cell, whereby first phage are produced using the proteins, the first phage packaging the DNA;
(0 Wherein helper phage particle production in the host cell is inhibited or reduced, thereby limiting the availability of helper phage particles;
(g) Optionally lysing the host cell and obtaining the first phage;
(h) Thereby producing a composition comprising first phage which require the helper phage for replication, wherein further production of first phage particles is prevented or reduced by the limitation of helper phage availability in the composition.
In an embodiment, the DNA is comprised by a phagemid or cloning vector (eg, a shuttle vector, eg, a pUC vector).
There may be a modest amount of helper phage DNA replication to enable first phage protein production efficiently, or should replication of helper phage DNA may be eliminated totally eliminated.
58. The method of Aspect 57, wherein in (c) the helper phage are prophage integrated in the bacterial cell chromosome.
59. The method of Aspect 59, wherein (e) comprises inducing replication of helper phage DNA
and/or expression of the proteins, eg, using UV, mitomycin.
60. The method of any one of Aspects 57 to 59, wherein (g) comprises further separating the first phage from cellular material or helper phage DNA.
61. The method of any one of Aspects 57 to 60, wherein the composition comprises a population of first phage particles, wherein the composition does not comprise helper phage DNA and/or particles.
62. The method of any one of Aspects 57 to 61, wherein the DNA of (a) comprises engineered antibacterial means for killing target bacteria.
63. The method of Aspect 62, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
64. The method of Aspect 63, wherein the component(s) comprise (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas (eg, Cas9, Cas3, Cpfl, CasX or CasY) nuclease-encoding DNA sequence; and/or (iii) a DNA
sequence encoding one or more components of Cascade (eg, CasA).
65. The method of any one of Aspects 62 to 64, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease.
2. A composition comprising a population of first phage, wherein the first phage require helper phage according to Aspect 1 for replication of first phage particles; and optionally wherein less than 20, 15, 10, 5, 4, 3,2, 1, 0.5, 0.4, 0.2 or 0.1% of total phage particles comprised by the composition are particles of such helper phage.
In an example the composition comprises helper phage and less than 1% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.5% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.1% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.01% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.0001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.00001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.000001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.0000001% of total phage particles comprised by the composition are particles of such helper phage. In an example the composition comprises helper phage and less than 0.00000001% of total phage particles comprised by the composition are particles of such helper phage.
In an example, the population comprises at least 10,104' 105 or 106 phage particles, as indicated a transduction assay, for example. In an example, the population comprises at least 10 phage particles and eg, no more than 1014 particles. In an example, the population comprises at least 104 phage particles and eg, no more than 1014 particles. In an example, the population comprises at least 105 phage particles and eg, no more than 1014 particles. In an example, the population comprises at least 106 phage particles and eg, no more than 1014 particles. To have a measure of the first phage concentration, for example, one can perform a standard transduction assay when the first phage genome contains an antibiotic marker. Thus, in this case the first phage are capable of infecting target bacteria and in a sample of lml the population comprises at least 103,104' 105 or 106 transducing particles, which can be determined by infecting susceptible bacteria at a multiplicity of infection <0.1 and determining the number of infected cells by plating on a selective agar plate corresponding to the antibiotic marker in vitro at 20 to 37 degrees centigrade, eg, at 20 or 37 degrees centrigrade.
Optionally at least 99.9, 99.8, 99.7, 99.6, 99.5, 99.4, 99.3, 99.2, 99.1, 90, 85, 80, 70, 60, 50 or 40% of total phage particles comprised by the composition are particles of first phage.
In an example, the first phage genome comprises an fl origin of replication.
In an example, the helper phage are E coli phage. In an example, the first phage are E co/i, C dificile, Streptococcus, Klebsiella, Pseudomonas, Acitenobacter, Enterobacteracea, Firmicutes or Bacteroidetes phage. In an example, the helper phage are engineered M13 phage.
In an example, the first phage genome comprises a phagemid, wherein the phagemid comprises a packaging signal for packaging first phage particles in the presence of the helper phage.
The first phage particles may contain a nucleotide sequence of interest (NSI), eg, as defined herein, such as a NSI that encodes a component of a CRISPR/Cas system operable in target bacteria that can be infected by the first phage particles. Once inside the target bacteria, the first phage DNA is incapable of being packaged to form first phage particles in the absence of the helper phage. This usefully contains the activity of the first phage genome and its encoded products (protieins and/or nucleic acid), as well as limits or controls dosing of the NSI and its encoded products in an environment comprising the target bacteria that have been exposed to the first phage. This is useful, for example to control the medical treatment of an environment comprised by a human or animal subject, plant or other environment (eg, soil or a foodstiff or food ingredient).
3. The helper phage or composition of any preceding Aspect, wherein the genome of each first phage is devoid of genes encoding first phage structural proteins.
4. The composition of Aspect 2 or 3, wherein the composition comprises helper phage DNA.
5. The composition of Aspect 4, wherein the DNA comprises helper DNA
fragments.
6. The helper phage or composition of any one preceding Aspect, wherein the helper phage are in the form of prophage.
Thus, the prophage is integrated in the chromosome of a host cell.
Examples of phage structural proteins are phage coat proteins, collar proteins and phage tail fibre proteins.
7. The composition of any one of Aspects 2 or 3, wherein the composition comprises no helper phage DNA comprising a sequence of 20 contiguous nucleotides or more (eg, from 20 to 25, 30, 35, 40, 50 or 100 nucleotides), eg, no helper phage DNA.
This can be determined, for example, using DNA probes (designed on the basis of the known heper phge genome sequence) with PCR, as is conventional. In an example, the composition may comprise residual helper prophage DNA, but essentially otherwise is devoid of helper DNA.
8. The composition of any one of Aspects 2 to 5 and 7, wherein the helper phage are capable of infecting host bacteria and the composition does not comprise host bacteria.
9. The composition of any one of Aspects 2 to 8, wherein the composition is a lysate of host bacterial cells, wherein the lysate comprises helper prophage DNA, eg, such DNA comprises 20 contiguous nucleotides or more (eg, from 20 to 25, 30, 35, 40, 50 or 100 nucleotides) of helper phage DNA.
10. The composition of any one of Aspects 2 to 8, wherein the composition is a lysate of host bacterial cells, wherein the lysate has been processed (eg, filtered) to remove all or some helper phage DNA; or the composition is a lysate of host bacterial cells that is devoid of cellular material.
11. The composition of any one of Aspects 2 to 10, wherein the composition does not comprise helper phage particles.
12. The composition of any one of Aspects 2 to 11, wherein at least 95%
(eg, 100%) of phage particles comprised by the composition are first phage particles.
In another embodiment, the composition comprises second phage particles, wherein the second phage .. are different from the first phage and are not helper phage.
13. The composition of any one of Aspects 2 to 12, wherein the population comprises at least 103, 104, 105 or 106 phage particles, as indicated in a transduction assay.
14. The helper phage or composition of any preceding Aspect, wherein the first phage are capable of replicating in host bacteria in the presence of the helper phage (eg, helper prophage), wherein the first phage comprise antibacterial means for killing target bacteria of a first strain or species, wherein the target bacteria are of a different strain or species and the antibacterial means is not operable to kill the target bacteria.
15. A composition comprising a population of phage, the population comprising (a) A first sub-population of first phage that require a helper phage for packaging the first phage;
(b) A second sub-population of phage comprising the helper phage, wherein the helper phage are as recited in any preceding Aspect.
16. The helper phage or composition of any preceding Aspect, wherein the helper phage are phagemids.
17. A composition comprising (a) A population of helper phage as recited in any preceding Aspect; and (b) A population of nucleic acid vectors comprising vector DNA that comprises a first phage packaging signal;
(c) wherein the helper phage are capable of packaging the vector DNA to produce first phage.
18. The composition of Aspect 17, wherein the vectors are phage.
19. The composition of Aspect 17, wherein the vectors are plasmids or phagemids.
20. The composition of Aspect 19, the vectors are shuttle vectors (eg, pUC
vectors) that can be replicated in first bacteria, wherein the vectors can further be replicated and packaged into first phage in second bacteria (host bacteria) in the presence of the helper phage, wherein the first bacteria are of a strain or species that is different to the strain or species of the host bacteria.
21. The composition of Aspect 20, wherein the first phage are capable of infecting third bacteria .. of a strain or species that is different to the second (and optionally also the first) bacteria.
22. The composition of any one of Aspects 17 to 21, wherein the first phage are capable of replicating in host bacteria in the presence of the helper phage (eg, helper prophage), wherein the first phage comprise antibacterial means for killing target bacteria of a first strain or species, wherein the host bacteria are of a different strain or species and the antibacterial means is not operable to kill the host bacteria.
23. The helper phage or composition of any preceding Aspect, wherein the genome is devoid of a packaging signal (eg, SEQ ID NO: 2 below), wherein the helper phage are incapable of self-replication.
24. The helper phage or composition of Aspect 23, wherein the signal is a pac or cos sequence.
25. The helper phage or composition of any preceding Aspect, wherein the helper phage genome is capable of replication in a host cell.
Thus, the genome is capable of nucleic acid replication but not packaging of helper phage.
26. The helper phage or composition of any one of Aspects 1 to 24, wherein the genome is devoid of a nucleotide sequence required for production of helper phage particles.
27. The helper phage or composition of Aspect 26, wherein the nucleotide sequence enodes a sigma factor (eg, sigma-70) or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA
replication.
28. The helper phage or composition of any preceding Aspect, wherein the helper phage are temperate phage.
29. The helper phage or composition of any one of Aspects 1 to 27, wherein the helper phage are lytic phage.
30. The helper phage or composition of any preceding Aspect, wherein the first phage are capable of infecting target bacteria, the first phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA (eg, gRNA or crRNA) in target bacteria, or wherein the NSI
comprises a regulatory element that is operable in target bacteria.
31. The helper phage or composition of Aspect 30, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genomes, or downregulation thereof.
32. The helper phage or composition of Aspect 30, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of target cells, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genomes, or upregulation thereof.
33. An antibacterial composition according to any one of Aspects 2 to 32, wherein the first phage are capable of infecting target bacteria and each first phage comprises engineered antibacterial means for killing target bacteria.
By use of the term "engineered" it will be readily apparent to the skilled addressee that the relevant means has been introduced and is not naturally-occurring in the phage. For example, the means is recombinant, artificial or synthetic.
34. The composition of Aspect 14, 22 or 33, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
35. The composition of caim 34, wherein the component(s) comprise (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria; (ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
In an example, a Cas herein is a Cas9. In an example, a Cas herein is a Cas3.
The Cas may be identical to a Cas encoded by the target bacteria.
36. The composition of any one of Aspects 14, 22 or 33 to 35, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease.
37. The helper phage or composition of any preceding Aspect, wherein the helper phage is for use in medicine practised on a human or animal subject, or the composition is a pharmaceutical composition for use in medicine practised on a human or animal subject.
In an example, the animak is a livestock or companion pet animal (eg, a cow, pig, goat, sheep, horse, dog, cat or rabbit). In an example, the animal is an insect (an insect at any stage of its lifecycle, eg, egg, larva or pupa). In an example, the animal is a protozoan. In an example, the animal is a cephalopod.
38. The composition of any one of Aspects 2 to 36, wherein the composition is a herbicide, pesticide, food or beverage processing agent, food or beverage additive, petrochemical or fuel processing agent, water purifying agent, cosmetic additive, detergent additive or environmental (eg, soil) additive or cleaning agent.
39. The helper phage or composition of any one of Aspects 1 to 37 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by the target bacteria and the target bacteria are comprised by the subject, the method comprising administering the composition to the subject, whereby the target bacteria are exposed to the antibacterial means and killed and propagation of the first phage is contained.
The inability of the first phage to self-replicate and to require helper phage or second DNA to do this usefully provides containment in the location (eg, gut) of action of the composition and/or in the environment of the subject, eg, when exposed to secretions such as urine and faeces of the subject that otherwise may contain replicated first phage. Inability of the helper phage or second DNA to self-package limits availability of factors required by the first phage to form packaged particles, hence providing containment by limiting first phage propagation. This may be useful, for example, to contain an antibacterial acitivity provided by the first phage, such as a CRISPR/Cas killing principle.
40. A bacterial cell or a plurality of bacterial cells comprising the helper phage or composition of any preceding Aspect, wherein the first phage are capable of replication in the presence of the helper phage in the cell.
The cell may, for example, act as a carrier for the genome of the first phage, wherein the first phage DNA is capable of horizontal transfer from the carrier to the target bacteria once the carrier bacteria have been administered to an environment to be treated, eg, a soil or a human gut or other environment described herein. In an example, the environment is comprised by a human or animal subject and the carrier are commensal or probiotic in the subject. For example the carrier bacteria are Lactobacillus (eg, L reuteri or L lactis), E coli or Streptococcus (eg, S
thermophilus) bacteria. The horizontal transfer can be transfer of a plasmid (such as a conjugative plasmid) to the target bacteria or first phage infection of the target bacteria, wherein the first phage have been prior packaged in the carrier. The use of a carrier is useful too for oral administration or other routes where the carrier can provide protection for the phage, helper or composition from the acid stomach or other harsh environments in the subject. Furthermore, the carrier can be formulated into a beverage, for example, a probiotic drink, eg, an adapted Yakult (trademark), Actimel (trademark), Kevita (trademark), Activia (trademark), Jarrow (trademark) or similar drink for human consumption.
41. The cell(s) of Aspect 40 for administration to a human or animal subject for medical use, comprising killing target bacteria using first phage, wherein the target bacteria mediate as disease or condition in the subject.
In an example, when the subject is a human, the subject is not an embryo.
42. The cell(s) of Aspect 41, wherein the cell(s) comprises helper phage and is symbiotic or probiotic in the subject.
43. A method of killing target bacteria in an environment, optionally wherein the method is not practised on a human or animal body, wherein the method comprises exposing the environment to the cell(s) according to Aspect 42, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, wherein the environment is or has been exposed to first phage or said vectors to produce first phage in the presence of the helper phage, wherein the first phage are capable of replication in the environment and kill target bacteria.
44. The cell(s) or method of any one of Aspects 40 to 43, wherein the cell is an E coli, Lactobacillus (eg, L lactis or retueri) or Streptococcus (eg, thermophilus) cell.
45. The cell(s) or method of Aspects 40 to 44 wherein the subject is administered or has been administered a cell comprising first phage.
46. The composition of any one of Aspects 2 to 45 in combination with a target bacterial cell wherein the first phage are capable of infecting the target bacterial cell.
47. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills target bacteria, for containment of the antibacterial in an environment, eg, containment ex vivo; or containment in a human or animal subject comprising the environment.
48. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills the target bacteria, for reducing the risk of acquisition by the first phage of foreign genes.
For example, this is useful for reducing the risk of antibiotic resistance genes by the phage, such as when the phage are in the presence of other phage or plasmids in the environment.
49. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills the target bacteria, for reducing the risk of acquisition by the first phage of one or more antibiotic resistance genes.
50. A method of reducing the risk of acquisition by first phage of foreign genes, the method comprising (a) Providing the composition of any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and (b) Exposing target bacteria to the composition, wherein the first phage infect the target bacteria;
(c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby reducing the risk of acquisition of first phage of foreign genes (eg, antibiotic resistance genes).
51. A method of containing an antibacterial activity in an environment (e.g., ex vivo), the method comprising (a) Providing an antibacterial composition according to any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and (b) Exposing target bacteria in the environment to the composition, wherein the bacteria are exposed to the first phage and antibacterial means and are killed;
(c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby containing the antibacterial activity.
52. A method of controlling the dosing of first phage in an environment (e.g., ex vivo), the method comprising (a) Providing an antibacterial composition according to any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and (b) Exposing target bacteria in the environment to the composition, wherein the bacteria are infected by first phage;
(c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby controlling dosing of first phage in the environment.
53. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is a human or animal microbiome, e.g., a gut microbiome.
54. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is a microbiome of soil; a plant, part of a part (e.g., a leaf, fruit, vegetable or flower) or plant product (e.g., pulp); water; a waterway; a fluid; a foodstuff or ingredient thereof; a beverage or ingredient thereof; a medical device; a cosmetic; a detergent; blood; a bodily fluid; a medical apparatus; an industrial apparatus; an oil rig; a petrochemical processing, storage or transport apparatus; a vehicle or a container.
55. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is an ex vivo bodily fluid (e.g., urine, blood, blood product, sweat, tears, sputum or spit), bodily solid (e.g., faeces) or tissue of a human or animal subject that has been administered the composition.
56. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is an in vivo bodily fluid (e.g., urine, blood, blood product, sweat, tears, sputum or spit), bodily solid (e.g., faeces) or tissue of a human or animal subject that has been administered the composition.
57. A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising (a) Providing DNA comprising a packaging signal;
(b) Introducing the DNA into a host bacterial cell;
(c) Wherein the host bacterial cell comprises helper phage or wherein helper phage are introduced into the bacterial cell simultaneously or sequentially with step (b);
(d) Wherein the helper phage are according to any preceding Aspect;
(e) Causing or allowing the helper phage to produce phage coat proteins, wherein the packaging signal is recognised in the host cell, whereby first phage are produced using the proteins, the first phage packaging the DNA;
(0 Wherein helper phage particle production in the host cell is inhibited or reduced, thereby limiting the availability of helper phage particles;
(g) Optionally lysing the host cell and obtaining the first phage;
(h) Thereby producing a composition comprising first phage which require the helper phage for replication, wherein further production of first phage particles is prevented or reduced by the limitation of helper phage availability in the composition.
In an embodiment, the DNA is comprised by a phagemid or cloning vector (eg, a shuttle vector, eg, a pUC vector).
There may be a modest amount of helper phage DNA replication to enable first phage protein production efficiently, or should replication of helper phage DNA may be eliminated totally eliminated.
58. The method of Aspect 57, wherein in (c) the helper phage are prophage integrated in the bacterial cell chromosome.
59. The method of Aspect 59, wherein (e) comprises inducing replication of helper phage DNA
and/or expression of the proteins, eg, using UV, mitomycin.
60. The method of any one of Aspects 57 to 59, wherein (g) comprises further separating the first phage from cellular material or helper phage DNA.
61. The method of any one of Aspects 57 to 60, wherein the composition comprises a population of first phage particles, wherein the composition does not comprise helper phage DNA and/or particles.
62. The method of any one of Aspects 57 to 61, wherein the DNA of (a) comprises engineered antibacterial means for killing target bacteria.
63. The method of Aspect 62, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
64. The method of Aspect 63, wherein the component(s) comprise (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas (eg, Cas9, Cas3, Cpfl, CasX or CasY) nuclease-encoding DNA sequence; and/or (iii) a DNA
sequence encoding one or more components of Cascade (eg, CasA).
65. The method of any one of Aspects 62 to 64, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease.
66. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for antibacterial treatment of target bacteria in a human or animal subject whereby the antibacterial treatment is contained in the subject.
67. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for antibacterial treatment of target bacteria in a gut of a human or animal subject whereby the antibacterial activity in one or more bodily excretions of the subject is reduced.
This is useful as a safety measure to reduce or eliminate first phage activity outside the subject.
This is useful as a safety measure to reduce or eliminate first phage activity outside the subject.
68. The helper phage, composition or cell(s) of Aspect 67, wherein the antibacterial activity in one or more bodily excretions of the subject is eliminated.
69. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for controlling the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
Usefully, propagation of the first phage is restricted or eliminated, so dosing in the subject can be controlled, or even pre-determined within a narrow expected range. This is useful, for example, for medicaments comprising the first phage or composition, and may be aid approval of such medicines before FDA and simiar authorities.
Alternatively, the dosing is dosing of an environment, such as soil etc disclosed herein, wherein limitation of the first phage or composition activity is also desirable to limit spread of activities in natural and other terrains.
Usefully, propagation of the first phage is restricted or eliminated, so dosing in the subject can be controlled, or even pre-determined within a narrow expected range. This is useful, for example, for medicaments comprising the first phage or composition, and may be aid approval of such medicines before FDA and simiar authorities.
Alternatively, the dosing is dosing of an environment, such as soil etc disclosed herein, wherein limitation of the first phage or composition activity is also desirable to limit spread of activities in natural and other terrains.
70. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for fixing the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
71. A phage production system, for producing phage (eg, the first phage of any preceding Aspect) comprising a nucleotide sequence of interest (NSI-phage), the system comprising components (i) to (iii):-(a) A first DNA;
(b) A second DNA; and (c) a NSI-phage production factor (NPF) or an expressible nucleotide sequence that encodes a NPF;
Wherein (d) The first DNA encodes a helper phage (eg, said first helper phage recited in any preceding Aspect);
(e) The second DNA comprises the nucleotide sequence of interest (NSI);
(0 When the system is comprised by a bacterial host cell, helper phage proteins are expressed from the first DNA to form phage that package the second DNA in the presence of the NPF, thereby producing NSI-phage; and (g) The system is devoid of a helper phage production factor (HPF) that is required for forming helper phage particles that package the first DNA, or is devoid of an expressible nucleotide sequence that encodes a functional HPF; or the system comprises a nucleotide sequence that comprises or encodes a functional HPF, the system further comprising means for targeted inactivation in the host cell of the HPF sequence to eliminate or minimise production of helper phage comprising the first DNA;
Whereby the system is capable of producing a product comprising a population of NSI-phage, wherein each NSI-phage requires a said helper phage for propagation, optionally wherein the NSI-phage in the product are not mixed with helper phage or less than 20% of total phage comprised by the product are said helper phage.
The invention includes within its concept relatively low level of helper phage particle production if there is a residual capability of helper phage to replicate to produce particles, such as for example in the case that a helper phage packaging signal or other HPF nucleotide sequence in the helper phage genome is mutated (eg, by deletion, substitution or addition of nucleotides therein) to knock down the ability to form phage particles. Preferably, there is no production of helper phage particles, such as by deleting all or part of the sequence from the helper phage genome or inactivating the sequence.
(b) A second DNA; and (c) a NSI-phage production factor (NPF) or an expressible nucleotide sequence that encodes a NPF;
Wherein (d) The first DNA encodes a helper phage (eg, said first helper phage recited in any preceding Aspect);
(e) The second DNA comprises the nucleotide sequence of interest (NSI);
(0 When the system is comprised by a bacterial host cell, helper phage proteins are expressed from the first DNA to form phage that package the second DNA in the presence of the NPF, thereby producing NSI-phage; and (g) The system is devoid of a helper phage production factor (HPF) that is required for forming helper phage particles that package the first DNA, or is devoid of an expressible nucleotide sequence that encodes a functional HPF; or the system comprises a nucleotide sequence that comprises or encodes a functional HPF, the system further comprising means for targeted inactivation in the host cell of the HPF sequence to eliminate or minimise production of helper phage comprising the first DNA;
Whereby the system is capable of producing a product comprising a population of NSI-phage, wherein each NSI-phage requires a said helper phage for propagation, optionally wherein the NSI-phage in the product are not mixed with helper phage or less than 20% of total phage comprised by the product are said helper phage.
The invention includes within its concept relatively low level of helper phage particle production if there is a residual capability of helper phage to replicate to produce particles, such as for example in the case that a helper phage packaging signal or other HPF nucleotide sequence in the helper phage genome is mutated (eg, by deletion, substitution or addition of nucleotides therein) to knock down the ability to form phage particles. Preferably, there is no production of helper phage particles, such as by deleting all or part of the sequence from the helper phage genome or inactivating the sequence.
72. A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising (a) Providing in host cells the system of Aspect 71;
(b) Causing or allowing the helper phage proteins to be produced, whereby the second DNA is packaged to produce first phage; and (c) Optionally lysing the host cells and obtaining a composition comprising first phage.
(b) Causing or allowing the helper phage proteins to be produced, whereby the second DNA is packaged to produce first phage; and (c) Optionally lysing the host cells and obtaining a composition comprising first phage.
73. The method of Aspect 72, wherein step (c) comprises separating the first phage from cellular material.
74. The method of Aspect 72 or 73, wherein the composition comprises a population of first phage, wherein less than 20, 10, 5, 4, 3, 2, 1, 0.5 or 0.1% of total phage comprised by the composition are helper phage.
75. The method of any one of Aspects 72 to 74, wherein the second DNA
comprises engineered antibacterial means for killing target bacteria.
comprises engineered antibacterial means for killing target bacteria.
76. The method of Aspect 75, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
77. The method of Aspect 76 wherein the component(s) comprise (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
78. The method of any one of Aspects 75 to 77, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease
79. The system of method of any one of Aspects 71 to 78, wherein the first phage are capable of infecting target bacteria, the NSI being capable of expressing a protein or RNA in target bacteria, or wherein the NSI comprises a regulatory element that is operable in target bacteria.
80. The system or method of Aspect 79, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genomes, or downregulation thereof.
81. The system or method of Aspect 79, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of target cells, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genomes, or upregulation thereof.
82. The system of method of any one of Aspects 71 to 81, wherein each of the NPF and HPF is a packaging signal, eg, SEQ ID NO: 2 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99%
identical thereto, or is a homologue from a different species.
identical thereto, or is a homologue from a different species.
83. The system of method of Aspect 82, wherein each signal is a pac or cos sequence, or is a homologue.
84. The system of method of any one of Aspects 71 to 81, wherein the HPF is a nucleotide sequence required for replication of helper phage.
85. The system of method of any one of Aspects 71 to 81, wherein the HPF
enodes a sigma factor (eg, sigma-70) or comprises a sigma factor recognition site, a DNA
polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication, a helper phage integrase, a helper phage excissionase or a helper phage origin of replication,
enodes a sigma factor (eg, sigma-70) or comprises a sigma factor recognition site, a DNA
polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication, a helper phage integrase, a helper phage excissionase or a helper phage origin of replication,
86. A composition comprising a population of first phage obtainable by the method of any one of Aspects 72 to 85, wherein the genome of each first phage is devoid of genes encoding phage proteins.
87. The composition of Aspect 86, wherein the first phage comprise antibacterial means as recited in any one of Aspects 75 to 78.
88. The composition of Aspect 87, comprising DNA identical to the first DNA
or fragments thereof.
or fragments thereof.
89. The composition of Aspect 88, wherein the DNA of the composition is identical to the first DNA and is devoid of a helper phage packaging signal.
90. The composition of any one of Aspects 86 to 89 for antibacterial treatment of target bacteria in a human or animal subject whereby the antibacterial treatment is contained in the subject.
91. The composition of any one of Aspects 86 to 89 for antibacterial treatment of target bacteria in a gut of a human or animal subject whereby the antibacterial activity in one or more bodily excretions of the subject is reduced.
92. The composition of Aspect 91, wherein the antibacterial activity in one or more bodily excretions of the subject is eliminated.
93. The composition of any one of Aspects 86 to 89 for controlling the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
94. The composition of any one of Aspects 86 to 89 for fixing the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
95. An isolated DNA comprising all structural protein genes of a helper phage genome that are required for producing phage particles, wherein the DNA is devoid of a helper phage production factor (HPF) that is required for producing packaged helper phage, optionally wherein the DNA
comprises one or more promoters for expression of the genes when the DNA is integrated in the genone of a host bacterial cell.
comprises one or more promoters for expression of the genes when the DNA is integrated in the genone of a host bacterial cell.
96. The DNA of Aspect 95, wherein the DNA is devoid of any phage packaging signals.
97. The DNA of Aspect 95 or 96, wherein the HPF is a sigma factor-encoding nucleotide sequence or comprises a sigma factor recognition site, a DNA polymerisation recognition site, a promoter of a gene required for helper phage DNA replication, a helper phage integrase-encoding nucleotide sequence, a helper phage excissionase-encoding nucleotide sequence or a helper phage origin of replication.
98. The DNA of any one of Aspects 95 to 97, wherein the DNA comprises a nucleotide sequence encoding a CRISPR/Cas system repressor.
99. The DNA of any one of Aspects 95 to 98, wherein the DNA is integrated in the chromosome of a host bacterial cell, wherein the genes are expressible in the host cell.
100. The DNA of Aspect 99, wherein the cell is devoid of an active CRISPR/Cas system.
101. The DNA of any one of Aspects 95 to 100 in combination with a second DNA, wherein the second DNA comprises the HPF.
102. The DNA of any one of Aspects 95 to 100 in combination with a second DNA, wherein the second DNA comprises a phage packaging signal and optionally the first DNA is devoid of a phage packaging signal.
103. The DNA of Aspect 101 or 102, wherein the second DNA is comprised by a phagemid or a plasmid (eg, a shuttle vector).
[0066] In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medical container, eg, a syringe, vial, IV bag, inhaler, eye dropper or nebulizer. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a sterile container. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medically-compatible container. In an example, the kit, DNA(s), first first phage, helper phage or composition is comprised by a fermentation vessel, eg, a metal, glass or plastic vessel.
[0067] In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medicament, e,g in combination with instructions or a packaging label with directions to administer the medicament by oral, IV, subcutaneous, intranasal, intraocular, vaginal, topical, rectal or inhaled administration to a human or animal subject. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an oral medicament formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an intranasal or ocular medicament formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a personal hygiene composition (eg, shampoo, soap or deodorant) or cosmetic formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a detergent formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a cleaning formulation, eg, for cleaning a medical or industrial device or apparatatus. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by foodstuff, foodstuff ingredient or foodstuff processing agent. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by beverage, beverage ingredient or beverage processing agent. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medical bandage, fabric, plaster or swab. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a herbicide or pesticide. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an insecticide.
[0068] In an example, the first phage is a is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae virus. In an example, the helper phage is a is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae virus. In an example, the helper phage is a filamentous M13, a Noviridae, a tailed phage (eg, a Myoviridae, Siphoviridae or Podoviridae), or a non-tailed phage (eg, a Tectiviridae).
[0069] In an example, both the first and helper phage are Corticoviridae. In an example, both the first and helper phage are Cystoviridae. In an example, both the first and helper phage are Inoviridae.
In an example, both the first and helper phage are Leviviridae. In an example, both the first and helper phage are Microviridae. In an example, both the first and helper phage are Podoviridae. In an example, both the first and helper phage are Siphoviridae. In an example, both the first and helper phage are Tectiviridae.
[0070] In an example, the CRISPR/Cas component(s) are component(s) of a Type I
CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type II CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type III CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type IV CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type V CRISPR/Cas system. In an example, the CRISPR/Cas component(s) comprise a Cas9-encoding nucleotide sequence (eg, S pyogenes Cas9, S aureus Cas9 or S thermophilus Cas9). In an example, the CRISPR/Cas component(s) comprise a Cas3-encoding nucleotide sequence (eg, E
coli Cas3, C
difficile Cas3 or Salmonella Cas3). In an example, the CRISPR/Cas component(s) comprise a Cpf-encoding nucleotide sequence. In an example, the CRISPR/Cas component(s) comprise a CasX-encoding nucleotide sequence. In an example, the CRISPR/Cas component(s) comprise a CasY-encoding nucleotide sequence.
[0071] In an example, the first DNA, first phage or vector encode a CRISPR/Cas component or protein of interest from a nucleotide sequence comprising a promoter that is operable in the target bacteria.
[0072] In an example, the host bacteria and/or target bacteria are E coli. In an example, the host bacteria and/or target bacteria are C dificile (eg, the vector is a shuttle vector operable in E coli and the host bacteria are C dificile). In an example, the host bacteria and/or target bacteria are Streptococcus, such as S the rmophilus (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Streptococcus). In an example, the host bacteria and/or target bacteria are Pseudomonas, such as P aeruginosa (eg, the vector is a shuttle vector operable in E coli and the host bacteria are P
aeruginosa). In an example, the host bacteria and/or target bacteria are Klebsiella (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Klebsiella). In an example, the host bacteria and/or target bacteria are Salmonella, eg, S typhimurium (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Salmonella).
[0073] Optionally, host and/or target bacteria is a gram negative bacterium (eg, a spirilla or vibrio).
Optionally, host and/or target bacteria is a gram positive bacterium.
Optionally, host and/or target bacteria is a mycoplasma, chlamydiae, spirochete or mycobacterium. Optionally, host and/or target bacteria is a Streptococcus (eg, pyo genes or thermophilus). Optionally, host and/or target bacteria is a Staphylococcus (eg, aureus, eg, MRSA). Optionally, host and/or target bacteria is an E. coli (eg, 0157: H7) host, eg, wherein the Cas is encoded by the vecor or an endogenous host Cas nuclease activity is de-repressed. Optionally, host and/or target bacteria is a Pseudomonas (eg, aeruginosa).
Optionally, host and/or target bacteria is a Vibro (eg, cholerae (eg, 0139) or vulnificus). Optionally, host and/or target bacteria is a Neisseria (eg, gonnorrhoeae or meningitidis).
Optionally, host and/or target bacteria is a Bordetella (eg, pertussis). Optionally, host and/or target bacteria is a Haemophilus (eg, influenzae). Optionally, host and/or target bacteria is a Shigella (eg, dysenteriae). Optionally, host and/or target bacteria is a Brucella (eg, abortus). Optionally, host and/or target bacteria is a Francisella host. Optionally, host and/or target bacteria is a Xanthomonas host. Optionally, host and/or target bacteria is a Agro bacterium host. Optionally, host and/or target bacteria is a Erwinia host. Optionally, host and/or target bacteria is a Legionella (eg, pneumophila). Optionally, host and/or target bacteria is a Listeria (eg, monocytogenes). Optionally, host and/or target bacteria is a Campylobacter (eg, jejuni). Optionally, host and/or target bacteria is a Yersinia (eg, pestis).
Optionally, host and/or target bacteria is a Borelia (eg, burgdorferi).
Optionally, host and/or target bacteria is a Helicobacter (eg, pylori). Optionally, host and/or target bacteria is a Clostridium (eg, dificile or botulinum). Optionally, host and/or target bacteria is a Erlichia (eg, chaffeensis).
Optionally, host and/or target bacteria is a Salmonella (eg, typhi or enterica, eg, serotype typhimurium, eg, DT 104). Optionally, host and/or target bacteria is a Chlamydia (eg, pneumoniae).
Optionally, host and/or target bacteria is a Parachlamydia host. Optionally, host and/or target bacteria is a Cotynebacterium (eg, amycolatum). Optionally, host and/or target bacteria is a Klebsiella (eg, pneumoniae). Optionally, host and/or target bacteria is an Enterococcus (eg, faecalis or faecim, eg, linezolid-resistant). Optionally, host and/or target bacteria is an Acinetobacter (eg, baumannii, eg, multiple drug resistant).
Further examples of target cells and targeting of antibiotic resistance in such cells using the present invention are as follows:-1. Optionally the target bacteria are Staphylococcus aureus cells, eg, resistant to an antibiotic selected from methicillin, vancomycin, linezolid, daptomycin, quinupristin, dalfopristin and teicoplanin.
2. Optionally the target bacteria are Pseudomonas aeuroginosa cells, eg, resistant to an antibiotic selected from cephalosporins (eg, ceftazidime), carbapenems (eg, imipenem or meropenem), fluoroquinolones, aminoglycosides (eg, gentamicin or tobramycin) and colistin.
3. Optionally the target bacteria are Klebsiella (eg, pneumoniae) cells, eg, resistant to carbapenem.
4. Optionally the target bacteria are Streptoccocus (eg, thermophilus, pneumoniae or pyogenes) cells, eg, resistant to an antibiotic selected from erythromycin, clindamycin, beta-lactam, macrolide, amoxicillin, azithromycin and penicillin.
5. Optionally the target bacteria are Salmonella (eg, serotype Typhi) cells, eg, resistant to an antibiotic selected from ceftriaxone, azithromycin and ciprofloxacin.
6. Optionally the target bacteria are Shigella cells, eg, resistant to an antibiotic selected from ciprofloxacin and azithromycin.
7. Optionally the target bacteria are mycobacterium tuberculosis cells, eg, resistant to an antibiotic selected from Resistance to isoniazid (INH), rifampicin (RMP), fluoroquinolone, amikacin, kanamycin and capreomycin and azithromycin.
8. Optionally the target bacteria are Enterococcus cells, eg, resistant to vancomycin.
9. Optionally the target bacteria are Enterobacteriaceae cells, eg, resistant to an antibiotic selected from a cephalosporin and carbapenem.
10. Optionally the target bacteria are E. coli cells, eg, resistant to an antibiotic selected from trimethoprim, itrofurantoin, cefalexin and amoxicillin.
11. Optionally the target bacteria are Clostridium (eg, dificile) cells, eg, resistant to an antibiotic selected from fluoroquinolone antibiotic and carbapenem.
12. Optionally the target bacteria are Neisseria gonnorrhoea cells, eg, resistant to an antibiotic selected from cefixime (eg, an oral cephalosporin), ceftriaxone (an injectable cephalosporin), azithromycin and tetracycline.
13. Optionally the target bacteria are Acinetoebacter baumannii cells, eg, resistant to an antibiotic selected from beta-lactam, meropenem and a carbapenem.
14. Optionally the target bacteria are Campylobacter cells, eg, resistant to an antibiotic selected from ciprofloxacin and azithromycin.
15. Optionally, the target cell(s) produce Beta (13)-lactamase.
16. Optionally, the target cell(s) are bacterial cells that are resistant to an antibiotic recited in any one of examples 1 to 14.
Mobile Genetic Elements, Genomic Islands, Pathogenicity Islands etc.
[0072] Genetic variation of bacteria and archaea can be achieved through mutations, rearrangements and horizontal gene transfers and recombinations. Increasing genome sequence data have demonstrated that, besides the core genes encoding house-keeping functions such as essential metabolic activities, information processing, and bacterial structural and regulatory components, a vast number of accessory genes encoding antimicrobial resistance, toxins, and enzymes that contribute to adaptation and survival under certain environmental conditions are acquired by horizontal gene transfer of mobile genetic elements (MGEs). Mobile genetic elements are a heterogeneous group of molecules that include plasmids, bacteriophages, genomic islands, chromosomal cassettes, pathogenicity islands, and integrative and conjugative elements. Genomic islands are relatively large segments of DNA ranging from 10 to 200 kb often integrated into tRNA
gene clusters flanked by 16-20 bp direct repeats. They are recognized as discrete DNA segments acquired by horizontal gene transfer since they can differ from the rest of the chromosome in terms of GC content (%G+C) and codon usage.
[0073] Pathogenicity islands (PTIs) are a subset of horizontally transferred genetic elements known as genomic islands. There exists a particular family of highly mobile PTIs in Staphylococcus aureus that are induced to excise and replicate by certain resident prophages.
These PTIs are packaged into small headed phage-like particles and are transferred at frequencies commensurate with the plaque-forming titer of the phage. This process is referred to as the SaPI
excision replication-packaging (ERP) cycle, and the high-frequency SaPI transfer is referred to as SaPI-specific transfer (SPST) to distinguish it from classical generalized transduction (CGT). The SaPIs have a highly conserved genetic organization that parallels that of bacteriophages and clearly distinguishes them from all other horizontally acquired genomic islands. The SaPThencoded and SaPIbov2-encoded integrases are used for both excision and integration of the corresponding elements, and it is assumed that the same is true for the other SaPIs. Phage 80a can induce several different SaPIs, including SaPI1, SaPI2, and SaPIbovl, whereas 911 can induce SaPIbovl but neither of the other two SaPIs.
[0074] Reference is made to "Staphylococcal pathogenicity island DNA packaging system involving cos-site packaging and phage-encoded HNH endonucleases", Quiles-Puchalt et al, PNAS April 22, 2014. 111(16) 6016-6021. Staphylococcal pathogenicity islands (SaPIs) are highly mobile and carry and disseminate superantigen and other virulence genes. It was reported that SaPIs hijack the packaging machinery of the phages they victimise, using two unrelated and complementary mechanisms. Phage packaging starts with the recognition in the phage DNA of a specific sequence, termed "pac" or "cos" depending on the phage type. The SaPI strategies involve carriage of the helper phage pac- or cos-like sequences in the SaPI genome, which ensures SaPI
packaging in full-sized phage particles, depending on the helper phage machinery. These strategies interfere with phage reproduction, which ultimately is a critical advantage for the bacterial population by reducing the number of phage particles.
[0075] Staphylococcal pathogenicity islands (SaPIs) are the prototypical members of a widespread family of chromosomally located mobile genetic elements that contribute substantially to intra- and interspecies gene transfer, host adaptation, and virulence. The key feature of their mobility is the induction of SaPI excision and replication by certain helper phages and their efficient encapsidation into phage-like infectious particles. Most SaPIs use the headful packaging mechanism and encode small terminase subunit (TerS) homologs that recognize the SaPI-specific pac site and determine SaPI
packaging specificity. Several of the known SaPIs do not encode a recognizable TerS homolog but are nevertheless packaged efficiently by helper phages and transferred at high frequencies. Quiles-Puchalt et al report that one of the non¨terS-coding SaPIs, SaPIbov5, and found that it uses two different, undescribed packaging strategies. SaPIbov5 is packaged in full-sized phage-like particles either by typical pac-type helper phages, or by cos-type phages¨i.e., it has both pac and cossites and uses the two different phage-coded TerSs. This is an example of SaPI packaging by a cos phage, and in this, it resembles the P4 plasmid of Escherichia coll. Cos-site packaging in Staphylococcus aureus is additionally unique in that it requires the HNH nuclease, carried only by cos phages, in addition to the large terminase subunit, for cos-site cleavage and melting.
[0076] Characterization of several of the phage-inducible SaPIs and their helper phages has established that the pac (or headful) mechanism is used for encapsidation. In keeping with this concept, some SaPIs encode a homolog of TerS, which complexes with the phage-coded large terminase subunit TerL to enable packaging of the SaPI DNA in infectious particles composed of phage proteins. These also contain a morphogenesis (cpm) module that causes the formation of small capsids commensurate with the small SaPI genomes. Among the SaPI sequences first characterized, there were several that did not include either a TerS homolog or a cpm homolog, and the same is true of several subsequently identified SaPIs from bovine sources and for many phage-inducible chromosomal islands from other species. It was assumed, for these several islands, either that they were defective derivatives of elements that originally possessed these genes, or that terS
and cpm genes were present but not recognized by homology.
[0077] Quiles-Puchalt et al observed that an important feature of 4SLT/SaPIbov5 packaging is the requirement for an HNH nuclease, which is encoded next to the OSLT terminase module. Proteins carrying HNH domains are widespread in nature, being present in organisms of all kingdoms. The HNH motif is a degenerate small nucleic acid-binding and cleavage module of about 30-40 aa residues and is bound by a single divalent metal ion. The HNH motif has been found in a variety of enzymes playing important roles in many different cellular processes, including bacterial killing;
DNA repair, replication, and recombination; and processes related to RNA. HNH
endonucleases are present in a number of cos-site bacteriophages of Gram-positive and -negative bacteria, always adjacent to the genes encoding the terminases and other morphogenetic proteins. Quiles-Puchalt et al have demonstrated that the HNH nucleases encoded by 4)12 and the closely related OSLT have nonspecific nuclease activity and are required for the packaging of these phages and of SaPIbov5.
Quiles-Puchalt et al have shown that HNH and TerL are jointly required for cos-site cleavage.
Quiles-Puchalt et al have also observed that only cos phages of Gram-negative as well as of Gram-positive bacteria encode HNH nucleases, consistent with a special requirement for cos-site cleavage as opposed to pac-site cleavage, which generates flush-ended products. The demonstration that HNH
nuclease activity is required for some but not other cos phages suggests that there is a difference between the TerL proteins of the two types of phages¨one able to cut both strands and the other needing a second protein to enable the generation of a double-stranded cut.
[0078] The invention, also involves, in certain configurations the use of mobile genetic elements (MGEs). Thus, there are provided the following Clauses. Any of the other configurations, Aspects, Examples or description of the invention above or elsewhere herein are combinable mutatis mutandis with any of these Clauses:-1. A composition for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a first phage genome, wherein in the cell the MGE
is mobilised using proteins encoded by the phage and replication of first is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent.
In the alternative, instead of a bacteria, the host cell is a archaeal cell and instead of a phage there is a virus that is capable of infecting the archaeal cell.
In an example, the MGE is capable of integration into the genome of the host cell comprising the genome of a first phage, for example integration in the chromosome of the host cell and/or an episome thereof.
Optionally, the MGE inhibits first phage replication.
In an example, first phage replication is totally inhibited. In an example, it is reduced by at least 50, 60, 70, 80 or 90% compared to replication in the absence of the MGE in host cells. This can be assessed by a standard in vitro plaque assay to determine the relative amount of first phage plaque formation.
Optionally, in the presence of the agent, (i)host cells are killed by the antibacterial agent;
(ii) growth or proliferation of host cells is reduced; and/or (iii)host cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
2. The composition of Clause 1, wherein the agent is toxic to cells of the same species or strain as the host cell.
3. The composition of Clause 1 or 2, wherein the agent is toxic to cells of a species or strain that is different from the strain or species of the host cell.
4. The composition of Clause 1, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
5. The composition of Clause 4, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and cells of the same species as the host cell comprise a target sequence that is cut by the nuclease, wherein the target sequence has been removed or altered in the host cell whereby the nuclease is not capable of cutting the target sequence.
Viruses undergo lysogenic and lytic cycles in a host cell. If the lysogenic cycle is adopted, the phage chromosome can be integrated into the bacterial chromosome, or it can establish itself as a stable plasmid in the host, where it can remain dormant for long periods of time. If the lysogen is induced, the phage genome is excised from the bacterial chromosome and initiates the lytic cycle, which culminates in lysis of the cell and the release of phage particles. The lytic cycle leads to the production of new phage particles which are released by lysis of the host.
6. The composition of any preceding Clause, wherein the first phage is a temperate phage.
7. The composition of any preceding Clause, wherein the first cell comprises the first phage as a prophage.
8. The composition of any one of Clauses 1 to 5, wherein the first phage is a lytic phage.
9. The composition of any preceding Clause, wherein in the presence of a first phage the mobilisation of the MGE causes host cell lysis.
10. The composition of any preceding Clause, wherein the MGE is capable of being packaged in transduction particles that comprise some, but not all, structural proteins of the first phage.
"Transduction particles" may be phage or smaller than phage and are particles that are capable of transducing nucleic acid encoding the antibiotic or component thereof or other DNA into target bacterial cells.
In some examples, instead of a nucleic acid encoding an antibiotic or component thereof, there is used a nucleic acid sequence of interest (eg, any NSI disclosed herein) that encodes a protein or RNA of interest for expression in the cell into which transduction from a transduction particle can take place.
Examples of structural proteins are phage proteins selected from one, more or all of the major head and tail proteins, the portal protein, tail fibre proteins, and minor tail proteins.
The MGE comprises a packaging signal sequence operable with proteins encoded by the first phage to package the MGE (or at least nucleic acid thereof encoding the agent or one or more components thereof) into transduction particles that are capable of infecting host cells of the same species or strain as the first host cell.
11. The composition of any preceding Clause, wherein mobilisation of the MGE comprises packaging of copies of the MGE or nucleic acid encoding the agent or component into transduction particles that are capable of transferring the copies into target bacterial cells for antibacterial treatment of the target cells.
12. The composition of Clause 10 or 11, wherein the transduction particles are particles of second phage that are capable of infecting cells of said first species or strain.
13. The composition of any one of Clauses 10 to 12, wherein the transduction particles are non-self replicative particles.
A "non-self replicative transduction particle" refers to a particle, (eg, a phage or phage-like particle;
or a particle produced from a genomic island (eg, a SaPI) or a modified version thereof) capable of delivering a nucleic acid molecule encoding an antibacterial agent or component (or any protein or RNA) into a bacterial cell, but does not package its own replicated genome into the transduction particle. In an alternative herein, instead of a phage, there is used or packaged a virus that infects an animal, human, plant or yeast cell. For example, an adenovirus when the cell is a human cell.
14. The composition of any preceding Clause, wherein the MGE is devoid of genes encoding phage structural proteins.
Optionally, the MGE is devoid of one or more phage genes rinA, terS and terL.
In an example, in a host cell a protein complex comprising the small terminase (encoded by terS) and large terminase (encoded by terL) proteins is able to recognise and cleave a double-stranded DNA
molecule of the MGE at or near the pac site (cos site or other packaging signal sequence comprised by the MGE), and this allows the MGE or plasmid DNA molecule to be packaged into a phage capsid.
When first phage as prophage in the host cell is induced, the lytic cycle of the phage produces the phage's structural proteins and the phage's large terminase protein. The MGE
or plasmid is replicated, and the small terminase protein encoded by the MGE or plasmid is expressed.
The replicated MGE or plasmid DNA containing the terS (and the nucleotide sequence encoding the antibacterial agent or component) are packaged into phage capsids, resulting in non-self replicative transduction particles carrying only MGE or plasmid DNA.
15. The composition of any one of Clauses 1 to 13, wherein the MGE
comprises phage structural genes and a packaging signal sequence and the first phage is devoid of a packaging signal sequence.
16. The composition of any preceding Clause, wherein the MGE is a modified version of a MGE
that is naturally found in bacterial cells of the first species or strain.
17. The composition of any preceding Clause, wherein the MGE comprises a modified genomic island.
Optionally, the genomic island is an island that is naturally found in bacterial cells of the first species or strain. In an example, the genomic island is selected from the group consisting of a SaPI, a SaPI1, a SaPI2, a SaPIbov 1 and a SaPibov2 genomic island.
18. The composition of any preceding Clause, wherein the MGE comprises a modified pathogenicity island.
Optionally, the pathogenicity island is an island that is naturally found in bacterial cells of the first species or strain, eg, a Staphylococcus SaPI or a Vibro PLE or a P. aeruginosa pathogenicity island (eg, a PAPI or a PAGI, eg, PAPI-1, PAGI-5, PAGI-6, PAGI-7, PAGI-8, PAGI-9, PAGI-10, or PAGI-19. The composition of Clause 18, wherein the pathogenicity island is a SaPI (S aureus pathogenicity island).
20. The composition of Clause 19, wherein the first phage is 011, 80a, 012 or 0SLT.
Staphylococcus phage 80a appears to mobilise all known SaPIs. Thus, in an example, the MGE
comprises a modified SaPI and the first phage is a 80a.
21. The composition of Clause 18, wherein the pathogenicity island is a V.
cholerae PLE (phage-inducible chromosomal island-like element) and optionally the first phage is ICP1.
22. The composition of Clause 18, wherein the pathogenicity island is a E
coli PLE.
23. The composition of any one of Clauses 1 to 16, wherein the MGE
comprises P4 DNA, eg, a P4 packaging signal sequence.
24. The composition of Clause 23, wherein the first phage are P2 phage or a modified P2 phage that is self-replicative defective; optionally present as a prophage.
25. The composition of any preceding Clause, wherein the MGE comprises a pacA gene of the Enterobacteriaceae bacteriophage Pl.
26. The composition of any preceding Clause, wherein the MGE comprises a packaging initiation site sequence, optionally a packaging initiation site sequence of Pl.
27. The composition of any preceding Clause, wherein the MGE comprises a nucleotide sequence that is beneficial to cells of the first species or strain, optionally encoding a protein that is beneficial to cells of the first species or strain.
This is useful where, not only does the presence of the MGE reduce first phage replication in the host cell, but also the MGE is taken up and may provide a survival, growth or other benefit to the host cell, promoting uptake and/or retention of MGEs by host cells. In an example, expression of the antibacterial agent in the host cell is under the control of an inducible promoter or weak promoter to allow for a period where uptake of MGEs into host cells may be favoured owing to the presence of the nucleotide sequence that is beneficial to cells of the first species or strain.
28. The composition of any preceding Clause, wherein the MGE is devoid of rinA.
29. The composition of any preceding Clause, wherein the MGE is is devoid of terL.
30. The composition of any preceding Clause, wherein the MGE comprises a terS or a homologue thereof, and optionally is devoid of any other terminase gene.
The terS homologues are sequences which, like terS, recognise the SaPI-specific pac site (or other packaging sequence) comprised by the MGE or plasmid and determine packaging specificity for packaging the MGE.
Examples of terminase genes are pacA, pacB, terA, terB and terL.
31. The composition of any preceding Clause, wherein the first phage is a pac-type phage (eg, 011 or 80a) operable with a pac comprised by the MGE.
32. The composition of any one of Clauses 1 to 30, wherein the first phage is a cos-type phage (eg, 012 or 0SLT) operable with a cos comprised by the MGE.
Optionally, the phage is P2. Optionally, the first phage is a T7 or T7-like phage that recognises direct repeat sequences comprised by the MGE for packaging.
33. The composition of any preceding Clause, wherein the plasmid or MGE
comprises a pac and/or cos sequence or a homologue thereof.
34. The composition of any preceding Clause, wherein the plasmid or MGE
comprises a terS or a homologue thereof and optionally devoid of terL.
The terS homologues are sequences which, like terS, recognise the SaPI-specific pac site (or other packaging sequence) comprised by the MGE or plasmid and determine packaging specificity for packaging the MGE.
In an example, the terS comprises the sequence of SEQ ID NO: 1.
35. The composition of Clause 34, wherein the terS is a S aureus bacteriophage 980a terS or a bacteriophage 911 terS.
36. The composition of any preceding Clause, wherein the MGE is a modified SaPIbov 1 or SaPIbov5 and is devoid of a terS.
37. The composition of any preceding Clause, wherein the first phage is devoid of a functional packaging signal sequence and the MGE comprises a packaging signal sequence operable with proteins encoded by the first phage for producing transduction particles that package copies of the MGE or copies of a nucleic acid encoding the agent or component.
38. The composition of any preceding Clause, wherein the MGE or plasmid comprises a Ppi or homologue, which is capable of complexing with first phage TerS, thereby blocking function of the TerS.
39. The composition of any preceding Clause, wherein the MGE comprises a morphogenesis (cpm) module.
40. The composition of any preceding Clause, wherein the MGE comprises cpmA
and/or cpmB.
Optionally the cpmA and B are from any SaPI disclosed herein. In an example any SaPI is a SaPI
disclosed in Table 2 and optionally the host cell or target cell is any corresponding Staphylococcus disclosed in the table.
41. The composition of any preceding Clause, wherein the MGE or first phage comprises one, more or all genes cpl, cp2, and cp3.
In an example, the MGE comprises a modified SaPI and comprises one, more or all genes cpl, cp2, and cp3.
42. The composition of any preceding Clause, wherein the MGE or first phage encodes a HNH
nuclease.
43. The composition of any preceding Clause, wherein the MGE or first phage comprises an integrase gene that encodes an integrase for excising the MGE and integrating the MGE into a bacterial cell genome.
44. The composition of any preceding Clause, wherein the MGE is devoid of a functional integrase gene, and the first phage or host cell genome (eg, bacterial chromosome or a bacterial episome) comprises a functional integrase gene.
45. The composition of any preceding Clause, wherein the transcription of MGE nucleic acid is under the control of a constitutive promoter, for transcription of copies of the agent or component in a host cell.
Optionally, Constitutive transcription and production of the agent in target cells may be used where the target cells should be killed, eg, in medical settings.
Optionally, the transcription of MGE nucleic acid is under the control of an inducible promoter, for transcription of copies of the agent or component in a host cell. This may be useful, for example, to control switching on of the antibacterial activity against target bacterial cells, such as in an environment (eg, soil or water) or in an industrial culture or fermentation container containing the target cells. For example, the target cells may be useful in an industrial process (eg, for fermentation, eg, in the brewing or dairy industry) and the induction enables the process to be controlled (eg, stopped or reduced) by using the antibacterial agent against the target bacteria.
46. The composition of Clause 45, wherein the promoter is foreign to the host cell.
47. The composition of Clause 45 or 46, wherein the promoter comprises a nucleotide sequence that is at least 80% identical to an endogenous promoter sequence of the host cell.
48. The composition of any preceding Clause comprising a nucleic acid that is separate from the MGE, wherein the nucleic acid comprises all genes necessary for producing first phage particles.
49. The composition of any one of Clauses 1 to 47 comprising a nucleic acid that is separate from the MGE, wherein the nucleic acid comprises less than, all genes necessary for producing first phage particles, but comprises genes encoding structural proteins for production of transduction particles that package MGE nucleic acid encoding the antibacterial agent or one or more components thereof.
When the agent comprises a plurality of components, eg, wherein the agent is a CRISPR/Cas system, or is a CRISPR array encoding crRNA or a nucleic acid encoding a guide RNA
(eg, single guide RNA) operable with a Cas in host cells, wherein the crRNA or gRNA guides the Cas to a target sequence in the host cell to modify the target (eg, cut it or repress transcription from it).
50. The composition of Clause 48 or 49, wherein the genes are comprised by the host cell chromosome and/or one or more host cell episome(s).
51. The composition of Clause 50, wherein the genes are comprised by a chromosomally-integrated prophage of the first phage.
52. The composition of any preceding Clause, wherein the agent is a guided nuclease system or a component thereof, wherein the agent is capable of recognising and cutting host cell DNA (eg, chromosomal DNA).
In examples, such cutting causes one or more of the following:-(i)The host cell is killed by the antibacterial agent;
(ii) growth or proliferation of the host cell is reduced; and/or (iii)The host cell is sensitised to an antibiotic, whereby the antibiotic is toxic to the cell.
53. The composition of Clause 52, wherein the guided nuclease system is selected from a CRISPR/Cas system, TALEN system, meganuclease system or zinc finger system.
54. The composition of Clause 52, wherein the system is a CRISPR/Cas system and each MGE
encodes a (a) CRISPR array encoding crRNA or (b) a nucleic acid encoding a guide RNA (gRNA, eg, single guide RNA), wherein the crRNA or gRNA is operable with a Cas in target bacterial cells, wherein the crRNA or gRNA guides the Cas to a target nucleic acid sequence in the host cell to modify the target sequence (eg, cut it or repress transcription from it).
Optionally, the Cas is a Cas encoded by a functional endogenous nucleic acid of a host cell. For example, the target is comprised by a DNA or RNA of the host cell.
55. The composition of Clause 52, wherein the system is a CRISPR/Cas system and each MGE
encodes a Cas (eg, a Cas nuclease) that is operable in a target bacterial cells to modify a target nucleic acid sequence comprised by the target cell.
56. The composition of Clause 53, 54 or 55, wherein the Cas is a Cas3, Cas9, Cas13, CasX, CasY
or Cpfl.
57. The composition of any one of Clauses 52 to 56, wherein the system is a CRISPR/Cas system and each MGE encodes one or more Cascade Cas (eg, Cas, A, B, C, D and E).
58. The composition of any one of Clauses 52 to 57, wherein each MGE
further encodes a Cas3 that is operable in a target bacterial cell with the Cascade Cas.
59. The composition of any preceding Clause, wherein the first species or strain is a gram positive species or strain.
60. The composition of any one of Clauses 1 to 58, wherein the first species or strain is a gram negative species or strain.
61. The composition of any preceding Clause, wherein the first species or strain is selected from Table 1.
In an example, the first species of strain is a Staphylococcus (eg, S aureus) species or strain and optionally the MGE is a modified SaPI; and optionally the first phage is a 980a or 911. In an example, the first species of strain is a Vibrio (eg, V cholerae) species or strain and optionally the MGE is Vibrio (eg, V cholerae) PLE.
62. The composition of any preceding Clause, wherein the first species or strain is selected from Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.
These are species that P2 phage can infect. Thus, in an embodiment, the MGE
comprises one or more P4 sequences (eg, a P4 packaging sequence) and the first phage is P2. Thus, the MGE is packaged by P2 structural proteins and the resultant transduction particles can infect a broad spectrum of species, ie, two or more of Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.
63. A nucleic acid vector comprising a MGE integrated therein, wherein the MGE is according to any preceding Clause and the vector is capable of transferring the MGE or a copy thereof into a host bacterial cell.
Suitable vectors are plasmids (eg, conjugative plasmids) or viruses (eg, phage or packaged phagemids).
64. The vector of Clause 63, wherein the vector is a shuttle vector.
A shuttle vector is a vector (usually a plasmid) constructed so that it can propagate in two different host species. Therefore, DNA inserted into a shuttle vector can be tested or manipulated in two different cell types.
65. The vector of Clause 63, wherein the vector is a plasmid, wherein the plasmid is capable of being transformed into a host bacterial cell comprising a first phage.
66. A non-self replicative transduction particle comprising said MGE or vector of any preceding .. Clause.
By "non-replicative" it is meant that the MGE is not capable by itself of self-replicating. For example, the MGE is devoid of one or more nucleotide sequences encoding a protein (eg, a structural protein) that is necessary to produce a transduction particle comprising a copy of the MGE.
67. A composition comprising a plurality of transduction particles, wherein each particle comprises a MGE or vector according to any one of Clauses 1 to 65, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
In an example, the reduction in growth or proliferation of host cells is at least 50, 60, 70, 80, 90 or 95%. The antibiotic can be any antibiotic disclosed herein.
68. The composition of Clause 67, wherein the agent is a guided nuclease system or a component thereof, wherein the agent is capable of recognising and cutting host cell DNA
(eg, chromosomal DNA) whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
69. A composition comprising a plurality of non-self replicative transduction particles, wherein each particle comprises a MGE or plasmid according to any one of Clauses 1 to 65, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein the agent is a CRISPR/Cas system and the component comprises a nucleic acid encoding a crRNA or a guide RNA
that is operable with a Cas in a target bacterial cell to guide the Cas to a target nucleic acid sequence of the cell to modify the sequence, whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
In an example, the reduction in growth or proliferation of host cells is at least 50, 60, 70, 80, 90 or 95%. The antibiotic can be any antibiotic disclosed herein.
70. A kit comprising the composition of Clause 69 and said antibiotic.
71. The composition of Clause 69, wherein the composition comprises said antibiotic.
72. The composition of any one of Clauses 67 to 69, wherein less than 10%
of transduction particles comprise by the composition are first phage particles.
73. The composition of any one of Clauses 67 to 69, wherein no first phage particles are present in the composition.
74. The MGE, vector, particle, composition or kit of any preceding Clause for medical use in a human or animal patient.
75. The MGE, vector, particle, composition or kit of any preceding Clause for treating or preventing an infection by target bacterial cells in a human or animal patient, wherein the antibacterial agent is toxic to the target cells.
76. The MGE, vector, particle, composition or kit of any preceding Clause for treating or preventing an infection by target bacterial cells in a human or animal patient, wherein in the presence of the antibacterial agent a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; and/or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
77. A method of producing a plurality of transduction particles, the method comprising combining the composition of any one of Clauses 1 to 62, 67 to 69 and 71 to 76 with host bacterial cells of said first species, wherein the cells comprise the first phage, allowing a plurality of said MGEs to be introduced into host cells and culturing the host cells under conditions in which first phage-encoded proteins are expressed and MGE copies are packaged by first phage proteins to produce a plurality of transduction particles, and optionally separating the transduction particles from cells and obtaining a plurality of transduction particles separated from cells.
78. The method of Clause 77, comprising separating the transduction particles from any first phage, optionally by filtering or centrifugation, thereby obtaining a plurality of transduction particles in the absence of first phage.
79. The method of Clause 77 or 78, wherein the particles encode a guided nuclease system (optionally a CRISPR/Cas system) or component thereof for cutting a target nucleic acid sequence comprised by target bacterial cells.
80. The method of Clause 79, wherein the sequence is comprised by an antibiotic resistance gene and the method comprises combining the plurality of particles with said antibiotic in a kit or a mixture.
81. The method of any one of Clauses 77 to 80, wherein said conditions comprise induction of a lytic cycle of the first phage.
82. A bacterial host cell comprising a first phage and a MGE, vector or particle as recited in any one of Clauses 1 to 66, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
83. A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition as recited in any one of Clauses 1 to 62, 67 to 69 and 71 to 76, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
84. The cell of Clause 83, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and cells of the same species as the host cell comprise a target sequence that is cut by the nuclease, wherein the target sequence has been removed or altered in the host cell whereby the nuclease is not capable of cutting the target sequence.
85. A bacterial host cell comprising a first phage and a MGE, vector or particle as recited in any one of Clauses 1 to 66, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE
is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
86. A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition as recited in any one of Clauses 1 to 62, 67 to 69 and 71 to 76, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
87. The cell of Clause 86, wherein the first phage is a prophage.
88. A bacterial host cell comprising a MGE, vector or particle as recited in any one of Clauses 1 to 66 and nucleic acid under the control of one or more inducible promoters, wherein the nucleic acid encodes all structural proteins necessary to produce a transduction particle that packages a copy of the MGE or plasmid, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
89. The cell of Clause 88, wherein the structural proteins are structural proteins of a lytic phage.
90. The cell of Clause 88 or 89, wherein the nucleic acid comprises terS
and/or terL.
91. The cell of any one of Clauses 88 to 90, wherein the host and second cells are of the same species and the host cell has been engineered so that the antibiotic is not toxic to the host cell.
92. The cell of any one of Clauses 88 to 91, wherein the nucleic acid is comprised by a plasmid.
93. The cell of any one of Clauses 88 to 92, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and the second cells comprise a target sequence that is cut by the nuclease, wherein the target sequence is absent in the genome of the host cell whereby the nuclease is not capable of cutting the host cell genome.
94. The composition, vector, particle, kit or method of any preceding Clause, wherein the cell, host cell or target cell is selected from a Staphylococcal, Vibrio, Pseudomonas, Clostridium, E coli, Helicobacter, Klebsiella and Salmonella cell.
95. A plasmid comprising a. A nucleotide sequence encoding an antibacterial agent or component thereof for expression in target bacterial cells;
b. A constitutive promoter for controlling the expression of the agent or component;
c. An optional terS nucleotide sequence;
d. An origin of replication (on); and e. A phage packaging sequence (optionally pac, cos or a homologue thereof);
and f. the plasmid being devoid of g. All nucleotide sequences encoding phage structural proteins necessary for the production of a transduction particle (optionally a phage), or the plasmid being devoid of at least one of such sequences; and h. Optionally terL.
96. The plasmid of Clause 95, wherein the antibacterial agent is a CRISPR/Cas system and the plasmid encodes a crRNa or guide RNA (eg, single gRNA) that is operable with a Cas in the target cells to guide the Cas to a target nucleotide sequence to modify (eg, cut) the sequence, whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
97. The plasmid of Clause 95 or 96, wherein the antibacterial agent is a CRISPR/Cas system and the plasmid encodes a Cas that is operable with a crRNa or guide RNA (eg, single gRNA) in the target cells to guide the Cas to a target nucleotide sequence to modify (eg, cut) the sequence, whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
98. The plasmid of Clause 97, wherein the plasmid further encodes said crRNA or gRNA.
99. A host cell comprising the plasmid of any one of Clauses 95 to 98, wherein the host cell does not comprise the target nucleotide sequence.
100. The host cell of Clause 99, wherein the cell is capable of replicating the plasmid and packaging the replicated plasmid in transduction particles that are capable of infecting target bacterial cells.
101. The host cell of Clause 99 or 100, wherein the host cell comprises, integrated in the cell chromosome and/or one or more episomes of the cell, a. A terL;
b. An optional terS; and c. Expressible nucleotide sequences encoding all structural proteins necessary for the production of transduction particles that package copies of the plasmid;
d. wherein the chromosome and episomes of the cell (other than said plasmid) are devoid of a phage packaging sequence, wherein the phage packaging sequence comprised by the plasmid is operable together with the product of said terS and terL in the production of packaged plasmid.
102. The cell of Clause 101, wherein the terL, optional terS and nucleotide sequences encoding the structural proteins are comprised by a phage (optionally a prophage) genome in the host cell.
103. A bacterial host cell comprising the genome of a helper phage that is incapable of self-replication, optionally wherein the genome is present as a prophage, and a plasmid according to any one of Clauses 95 to 98, wherein the helper phage is operable to package copies of the plasmid in transduction particles, wherein the particles are capable of infecting bacterial target cells to which the antibacterial agent is toxic.
[0066] In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medical container, eg, a syringe, vial, IV bag, inhaler, eye dropper or nebulizer. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a sterile container. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medically-compatible container. In an example, the kit, DNA(s), first first phage, helper phage or composition is comprised by a fermentation vessel, eg, a metal, glass or plastic vessel.
[0067] In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medicament, e,g in combination with instructions or a packaging label with directions to administer the medicament by oral, IV, subcutaneous, intranasal, intraocular, vaginal, topical, rectal or inhaled administration to a human or animal subject. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an oral medicament formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an intranasal or ocular medicament formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a personal hygiene composition (eg, shampoo, soap or deodorant) or cosmetic formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a detergent formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a cleaning formulation, eg, for cleaning a medical or industrial device or apparatatus. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by foodstuff, foodstuff ingredient or foodstuff processing agent. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by beverage, beverage ingredient or beverage processing agent. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medical bandage, fabric, plaster or swab. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a herbicide or pesticide. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an insecticide.
[0068] In an example, the first phage is a is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae virus. In an example, the helper phage is a is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae virus. In an example, the helper phage is a filamentous M13, a Noviridae, a tailed phage (eg, a Myoviridae, Siphoviridae or Podoviridae), or a non-tailed phage (eg, a Tectiviridae).
[0069] In an example, both the first and helper phage are Corticoviridae. In an example, both the first and helper phage are Cystoviridae. In an example, both the first and helper phage are Inoviridae.
In an example, both the first and helper phage are Leviviridae. In an example, both the first and helper phage are Microviridae. In an example, both the first and helper phage are Podoviridae. In an example, both the first and helper phage are Siphoviridae. In an example, both the first and helper phage are Tectiviridae.
[0070] In an example, the CRISPR/Cas component(s) are component(s) of a Type I
CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type II CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type III CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type IV CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type V CRISPR/Cas system. In an example, the CRISPR/Cas component(s) comprise a Cas9-encoding nucleotide sequence (eg, S pyogenes Cas9, S aureus Cas9 or S thermophilus Cas9). In an example, the CRISPR/Cas component(s) comprise a Cas3-encoding nucleotide sequence (eg, E
coli Cas3, C
difficile Cas3 or Salmonella Cas3). In an example, the CRISPR/Cas component(s) comprise a Cpf-encoding nucleotide sequence. In an example, the CRISPR/Cas component(s) comprise a CasX-encoding nucleotide sequence. In an example, the CRISPR/Cas component(s) comprise a CasY-encoding nucleotide sequence.
[0071] In an example, the first DNA, first phage or vector encode a CRISPR/Cas component or protein of interest from a nucleotide sequence comprising a promoter that is operable in the target bacteria.
[0072] In an example, the host bacteria and/or target bacteria are E coli. In an example, the host bacteria and/or target bacteria are C dificile (eg, the vector is a shuttle vector operable in E coli and the host bacteria are C dificile). In an example, the host bacteria and/or target bacteria are Streptococcus, such as S the rmophilus (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Streptococcus). In an example, the host bacteria and/or target bacteria are Pseudomonas, such as P aeruginosa (eg, the vector is a shuttle vector operable in E coli and the host bacteria are P
aeruginosa). In an example, the host bacteria and/or target bacteria are Klebsiella (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Klebsiella). In an example, the host bacteria and/or target bacteria are Salmonella, eg, S typhimurium (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Salmonella).
[0073] Optionally, host and/or target bacteria is a gram negative bacterium (eg, a spirilla or vibrio).
Optionally, host and/or target bacteria is a gram positive bacterium.
Optionally, host and/or target bacteria is a mycoplasma, chlamydiae, spirochete or mycobacterium. Optionally, host and/or target bacteria is a Streptococcus (eg, pyo genes or thermophilus). Optionally, host and/or target bacteria is a Staphylococcus (eg, aureus, eg, MRSA). Optionally, host and/or target bacteria is an E. coli (eg, 0157: H7) host, eg, wherein the Cas is encoded by the vecor or an endogenous host Cas nuclease activity is de-repressed. Optionally, host and/or target bacteria is a Pseudomonas (eg, aeruginosa).
Optionally, host and/or target bacteria is a Vibro (eg, cholerae (eg, 0139) or vulnificus). Optionally, host and/or target bacteria is a Neisseria (eg, gonnorrhoeae or meningitidis).
Optionally, host and/or target bacteria is a Bordetella (eg, pertussis). Optionally, host and/or target bacteria is a Haemophilus (eg, influenzae). Optionally, host and/or target bacteria is a Shigella (eg, dysenteriae). Optionally, host and/or target bacteria is a Brucella (eg, abortus). Optionally, host and/or target bacteria is a Francisella host. Optionally, host and/or target bacteria is a Xanthomonas host. Optionally, host and/or target bacteria is a Agro bacterium host. Optionally, host and/or target bacteria is a Erwinia host. Optionally, host and/or target bacteria is a Legionella (eg, pneumophila). Optionally, host and/or target bacteria is a Listeria (eg, monocytogenes). Optionally, host and/or target bacteria is a Campylobacter (eg, jejuni). Optionally, host and/or target bacteria is a Yersinia (eg, pestis).
Optionally, host and/or target bacteria is a Borelia (eg, burgdorferi).
Optionally, host and/or target bacteria is a Helicobacter (eg, pylori). Optionally, host and/or target bacteria is a Clostridium (eg, dificile or botulinum). Optionally, host and/or target bacteria is a Erlichia (eg, chaffeensis).
Optionally, host and/or target bacteria is a Salmonella (eg, typhi or enterica, eg, serotype typhimurium, eg, DT 104). Optionally, host and/or target bacteria is a Chlamydia (eg, pneumoniae).
Optionally, host and/or target bacteria is a Parachlamydia host. Optionally, host and/or target bacteria is a Cotynebacterium (eg, amycolatum). Optionally, host and/or target bacteria is a Klebsiella (eg, pneumoniae). Optionally, host and/or target bacteria is an Enterococcus (eg, faecalis or faecim, eg, linezolid-resistant). Optionally, host and/or target bacteria is an Acinetobacter (eg, baumannii, eg, multiple drug resistant).
Further examples of target cells and targeting of antibiotic resistance in such cells using the present invention are as follows:-1. Optionally the target bacteria are Staphylococcus aureus cells, eg, resistant to an antibiotic selected from methicillin, vancomycin, linezolid, daptomycin, quinupristin, dalfopristin and teicoplanin.
2. Optionally the target bacteria are Pseudomonas aeuroginosa cells, eg, resistant to an antibiotic selected from cephalosporins (eg, ceftazidime), carbapenems (eg, imipenem or meropenem), fluoroquinolones, aminoglycosides (eg, gentamicin or tobramycin) and colistin.
3. Optionally the target bacteria are Klebsiella (eg, pneumoniae) cells, eg, resistant to carbapenem.
4. Optionally the target bacteria are Streptoccocus (eg, thermophilus, pneumoniae or pyogenes) cells, eg, resistant to an antibiotic selected from erythromycin, clindamycin, beta-lactam, macrolide, amoxicillin, azithromycin and penicillin.
5. Optionally the target bacteria are Salmonella (eg, serotype Typhi) cells, eg, resistant to an antibiotic selected from ceftriaxone, azithromycin and ciprofloxacin.
6. Optionally the target bacteria are Shigella cells, eg, resistant to an antibiotic selected from ciprofloxacin and azithromycin.
7. Optionally the target bacteria are mycobacterium tuberculosis cells, eg, resistant to an antibiotic selected from Resistance to isoniazid (INH), rifampicin (RMP), fluoroquinolone, amikacin, kanamycin and capreomycin and azithromycin.
8. Optionally the target bacteria are Enterococcus cells, eg, resistant to vancomycin.
9. Optionally the target bacteria are Enterobacteriaceae cells, eg, resistant to an antibiotic selected from a cephalosporin and carbapenem.
10. Optionally the target bacteria are E. coli cells, eg, resistant to an antibiotic selected from trimethoprim, itrofurantoin, cefalexin and amoxicillin.
11. Optionally the target bacteria are Clostridium (eg, dificile) cells, eg, resistant to an antibiotic selected from fluoroquinolone antibiotic and carbapenem.
12. Optionally the target bacteria are Neisseria gonnorrhoea cells, eg, resistant to an antibiotic selected from cefixime (eg, an oral cephalosporin), ceftriaxone (an injectable cephalosporin), azithromycin and tetracycline.
13. Optionally the target bacteria are Acinetoebacter baumannii cells, eg, resistant to an antibiotic selected from beta-lactam, meropenem and a carbapenem.
14. Optionally the target bacteria are Campylobacter cells, eg, resistant to an antibiotic selected from ciprofloxacin and azithromycin.
15. Optionally, the target cell(s) produce Beta (13)-lactamase.
16. Optionally, the target cell(s) are bacterial cells that are resistant to an antibiotic recited in any one of examples 1 to 14.
Mobile Genetic Elements, Genomic Islands, Pathogenicity Islands etc.
[0072] Genetic variation of bacteria and archaea can be achieved through mutations, rearrangements and horizontal gene transfers and recombinations. Increasing genome sequence data have demonstrated that, besides the core genes encoding house-keeping functions such as essential metabolic activities, information processing, and bacterial structural and regulatory components, a vast number of accessory genes encoding antimicrobial resistance, toxins, and enzymes that contribute to adaptation and survival under certain environmental conditions are acquired by horizontal gene transfer of mobile genetic elements (MGEs). Mobile genetic elements are a heterogeneous group of molecules that include plasmids, bacteriophages, genomic islands, chromosomal cassettes, pathogenicity islands, and integrative and conjugative elements. Genomic islands are relatively large segments of DNA ranging from 10 to 200 kb often integrated into tRNA
gene clusters flanked by 16-20 bp direct repeats. They are recognized as discrete DNA segments acquired by horizontal gene transfer since they can differ from the rest of the chromosome in terms of GC content (%G+C) and codon usage.
[0073] Pathogenicity islands (PTIs) are a subset of horizontally transferred genetic elements known as genomic islands. There exists a particular family of highly mobile PTIs in Staphylococcus aureus that are induced to excise and replicate by certain resident prophages.
These PTIs are packaged into small headed phage-like particles and are transferred at frequencies commensurate with the plaque-forming titer of the phage. This process is referred to as the SaPI
excision replication-packaging (ERP) cycle, and the high-frequency SaPI transfer is referred to as SaPI-specific transfer (SPST) to distinguish it from classical generalized transduction (CGT). The SaPIs have a highly conserved genetic organization that parallels that of bacteriophages and clearly distinguishes them from all other horizontally acquired genomic islands. The SaPThencoded and SaPIbov2-encoded integrases are used for both excision and integration of the corresponding elements, and it is assumed that the same is true for the other SaPIs. Phage 80a can induce several different SaPIs, including SaPI1, SaPI2, and SaPIbovl, whereas 911 can induce SaPIbovl but neither of the other two SaPIs.
[0074] Reference is made to "Staphylococcal pathogenicity island DNA packaging system involving cos-site packaging and phage-encoded HNH endonucleases", Quiles-Puchalt et al, PNAS April 22, 2014. 111(16) 6016-6021. Staphylococcal pathogenicity islands (SaPIs) are highly mobile and carry and disseminate superantigen and other virulence genes. It was reported that SaPIs hijack the packaging machinery of the phages they victimise, using two unrelated and complementary mechanisms. Phage packaging starts with the recognition in the phage DNA of a specific sequence, termed "pac" or "cos" depending on the phage type. The SaPI strategies involve carriage of the helper phage pac- or cos-like sequences in the SaPI genome, which ensures SaPI
packaging in full-sized phage particles, depending on the helper phage machinery. These strategies interfere with phage reproduction, which ultimately is a critical advantage for the bacterial population by reducing the number of phage particles.
[0075] Staphylococcal pathogenicity islands (SaPIs) are the prototypical members of a widespread family of chromosomally located mobile genetic elements that contribute substantially to intra- and interspecies gene transfer, host adaptation, and virulence. The key feature of their mobility is the induction of SaPI excision and replication by certain helper phages and their efficient encapsidation into phage-like infectious particles. Most SaPIs use the headful packaging mechanism and encode small terminase subunit (TerS) homologs that recognize the SaPI-specific pac site and determine SaPI
packaging specificity. Several of the known SaPIs do not encode a recognizable TerS homolog but are nevertheless packaged efficiently by helper phages and transferred at high frequencies. Quiles-Puchalt et al report that one of the non¨terS-coding SaPIs, SaPIbov5, and found that it uses two different, undescribed packaging strategies. SaPIbov5 is packaged in full-sized phage-like particles either by typical pac-type helper phages, or by cos-type phages¨i.e., it has both pac and cossites and uses the two different phage-coded TerSs. This is an example of SaPI packaging by a cos phage, and in this, it resembles the P4 plasmid of Escherichia coll. Cos-site packaging in Staphylococcus aureus is additionally unique in that it requires the HNH nuclease, carried only by cos phages, in addition to the large terminase subunit, for cos-site cleavage and melting.
[0076] Characterization of several of the phage-inducible SaPIs and their helper phages has established that the pac (or headful) mechanism is used for encapsidation. In keeping with this concept, some SaPIs encode a homolog of TerS, which complexes with the phage-coded large terminase subunit TerL to enable packaging of the SaPI DNA in infectious particles composed of phage proteins. These also contain a morphogenesis (cpm) module that causes the formation of small capsids commensurate with the small SaPI genomes. Among the SaPI sequences first characterized, there were several that did not include either a TerS homolog or a cpm homolog, and the same is true of several subsequently identified SaPIs from bovine sources and for many phage-inducible chromosomal islands from other species. It was assumed, for these several islands, either that they were defective derivatives of elements that originally possessed these genes, or that terS
and cpm genes were present but not recognized by homology.
[0077] Quiles-Puchalt et al observed that an important feature of 4SLT/SaPIbov5 packaging is the requirement for an HNH nuclease, which is encoded next to the OSLT terminase module. Proteins carrying HNH domains are widespread in nature, being present in organisms of all kingdoms. The HNH motif is a degenerate small nucleic acid-binding and cleavage module of about 30-40 aa residues and is bound by a single divalent metal ion. The HNH motif has been found in a variety of enzymes playing important roles in many different cellular processes, including bacterial killing;
DNA repair, replication, and recombination; and processes related to RNA. HNH
endonucleases are present in a number of cos-site bacteriophages of Gram-positive and -negative bacteria, always adjacent to the genes encoding the terminases and other morphogenetic proteins. Quiles-Puchalt et al have demonstrated that the HNH nucleases encoded by 4)12 and the closely related OSLT have nonspecific nuclease activity and are required for the packaging of these phages and of SaPIbov5.
Quiles-Puchalt et al have shown that HNH and TerL are jointly required for cos-site cleavage.
Quiles-Puchalt et al have also observed that only cos phages of Gram-negative as well as of Gram-positive bacteria encode HNH nucleases, consistent with a special requirement for cos-site cleavage as opposed to pac-site cleavage, which generates flush-ended products. The demonstration that HNH
nuclease activity is required for some but not other cos phages suggests that there is a difference between the TerL proteins of the two types of phages¨one able to cut both strands and the other needing a second protein to enable the generation of a double-stranded cut.
[0078] The invention, also involves, in certain configurations the use of mobile genetic elements (MGEs). Thus, there are provided the following Clauses. Any of the other configurations, Aspects, Examples or description of the invention above or elsewhere herein are combinable mutatis mutandis with any of these Clauses:-1. A composition for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a first phage genome, wherein in the cell the MGE
is mobilised using proteins encoded by the phage and replication of first is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent.
In the alternative, instead of a bacteria, the host cell is a archaeal cell and instead of a phage there is a virus that is capable of infecting the archaeal cell.
In an example, the MGE is capable of integration into the genome of the host cell comprising the genome of a first phage, for example integration in the chromosome of the host cell and/or an episome thereof.
Optionally, the MGE inhibits first phage replication.
In an example, first phage replication is totally inhibited. In an example, it is reduced by at least 50, 60, 70, 80 or 90% compared to replication in the absence of the MGE in host cells. This can be assessed by a standard in vitro plaque assay to determine the relative amount of first phage plaque formation.
Optionally, in the presence of the agent, (i)host cells are killed by the antibacterial agent;
(ii) growth or proliferation of host cells is reduced; and/or (iii)host cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
2. The composition of Clause 1, wherein the agent is toxic to cells of the same species or strain as the host cell.
3. The composition of Clause 1 or 2, wherein the agent is toxic to cells of a species or strain that is different from the strain or species of the host cell.
4. The composition of Clause 1, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
5. The composition of Clause 4, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and cells of the same species as the host cell comprise a target sequence that is cut by the nuclease, wherein the target sequence has been removed or altered in the host cell whereby the nuclease is not capable of cutting the target sequence.
Viruses undergo lysogenic and lytic cycles in a host cell. If the lysogenic cycle is adopted, the phage chromosome can be integrated into the bacterial chromosome, or it can establish itself as a stable plasmid in the host, where it can remain dormant for long periods of time. If the lysogen is induced, the phage genome is excised from the bacterial chromosome and initiates the lytic cycle, which culminates in lysis of the cell and the release of phage particles. The lytic cycle leads to the production of new phage particles which are released by lysis of the host.
6. The composition of any preceding Clause, wherein the first phage is a temperate phage.
7. The composition of any preceding Clause, wherein the first cell comprises the first phage as a prophage.
8. The composition of any one of Clauses 1 to 5, wherein the first phage is a lytic phage.
9. The composition of any preceding Clause, wherein in the presence of a first phage the mobilisation of the MGE causes host cell lysis.
10. The composition of any preceding Clause, wherein the MGE is capable of being packaged in transduction particles that comprise some, but not all, structural proteins of the first phage.
"Transduction particles" may be phage or smaller than phage and are particles that are capable of transducing nucleic acid encoding the antibiotic or component thereof or other DNA into target bacterial cells.
In some examples, instead of a nucleic acid encoding an antibiotic or component thereof, there is used a nucleic acid sequence of interest (eg, any NSI disclosed herein) that encodes a protein or RNA of interest for expression in the cell into which transduction from a transduction particle can take place.
Examples of structural proteins are phage proteins selected from one, more or all of the major head and tail proteins, the portal protein, tail fibre proteins, and minor tail proteins.
The MGE comprises a packaging signal sequence operable with proteins encoded by the first phage to package the MGE (or at least nucleic acid thereof encoding the agent or one or more components thereof) into transduction particles that are capable of infecting host cells of the same species or strain as the first host cell.
11. The composition of any preceding Clause, wherein mobilisation of the MGE comprises packaging of copies of the MGE or nucleic acid encoding the agent or component into transduction particles that are capable of transferring the copies into target bacterial cells for antibacterial treatment of the target cells.
12. The composition of Clause 10 or 11, wherein the transduction particles are particles of second phage that are capable of infecting cells of said first species or strain.
13. The composition of any one of Clauses 10 to 12, wherein the transduction particles are non-self replicative particles.
A "non-self replicative transduction particle" refers to a particle, (eg, a phage or phage-like particle;
or a particle produced from a genomic island (eg, a SaPI) or a modified version thereof) capable of delivering a nucleic acid molecule encoding an antibacterial agent or component (or any protein or RNA) into a bacterial cell, but does not package its own replicated genome into the transduction particle. In an alternative herein, instead of a phage, there is used or packaged a virus that infects an animal, human, plant or yeast cell. For example, an adenovirus when the cell is a human cell.
14. The composition of any preceding Clause, wherein the MGE is devoid of genes encoding phage structural proteins.
Optionally, the MGE is devoid of one or more phage genes rinA, terS and terL.
In an example, in a host cell a protein complex comprising the small terminase (encoded by terS) and large terminase (encoded by terL) proteins is able to recognise and cleave a double-stranded DNA
molecule of the MGE at or near the pac site (cos site or other packaging signal sequence comprised by the MGE), and this allows the MGE or plasmid DNA molecule to be packaged into a phage capsid.
When first phage as prophage in the host cell is induced, the lytic cycle of the phage produces the phage's structural proteins and the phage's large terminase protein. The MGE
or plasmid is replicated, and the small terminase protein encoded by the MGE or plasmid is expressed.
The replicated MGE or plasmid DNA containing the terS (and the nucleotide sequence encoding the antibacterial agent or component) are packaged into phage capsids, resulting in non-self replicative transduction particles carrying only MGE or plasmid DNA.
15. The composition of any one of Clauses 1 to 13, wherein the MGE
comprises phage structural genes and a packaging signal sequence and the first phage is devoid of a packaging signal sequence.
16. The composition of any preceding Clause, wherein the MGE is a modified version of a MGE
that is naturally found in bacterial cells of the first species or strain.
17. The composition of any preceding Clause, wherein the MGE comprises a modified genomic island.
Optionally, the genomic island is an island that is naturally found in bacterial cells of the first species or strain. In an example, the genomic island is selected from the group consisting of a SaPI, a SaPI1, a SaPI2, a SaPIbov 1 and a SaPibov2 genomic island.
18. The composition of any preceding Clause, wherein the MGE comprises a modified pathogenicity island.
Optionally, the pathogenicity island is an island that is naturally found in bacterial cells of the first species or strain, eg, a Staphylococcus SaPI or a Vibro PLE or a P. aeruginosa pathogenicity island (eg, a PAPI or a PAGI, eg, PAPI-1, PAGI-5, PAGI-6, PAGI-7, PAGI-8, PAGI-9, PAGI-10, or PAGI-19. The composition of Clause 18, wherein the pathogenicity island is a SaPI (S aureus pathogenicity island).
20. The composition of Clause 19, wherein the first phage is 011, 80a, 012 or 0SLT.
Staphylococcus phage 80a appears to mobilise all known SaPIs. Thus, in an example, the MGE
comprises a modified SaPI and the first phage is a 80a.
21. The composition of Clause 18, wherein the pathogenicity island is a V.
cholerae PLE (phage-inducible chromosomal island-like element) and optionally the first phage is ICP1.
22. The composition of Clause 18, wherein the pathogenicity island is a E
coli PLE.
23. The composition of any one of Clauses 1 to 16, wherein the MGE
comprises P4 DNA, eg, a P4 packaging signal sequence.
24. The composition of Clause 23, wherein the first phage are P2 phage or a modified P2 phage that is self-replicative defective; optionally present as a prophage.
25. The composition of any preceding Clause, wherein the MGE comprises a pacA gene of the Enterobacteriaceae bacteriophage Pl.
26. The composition of any preceding Clause, wherein the MGE comprises a packaging initiation site sequence, optionally a packaging initiation site sequence of Pl.
27. The composition of any preceding Clause, wherein the MGE comprises a nucleotide sequence that is beneficial to cells of the first species or strain, optionally encoding a protein that is beneficial to cells of the first species or strain.
This is useful where, not only does the presence of the MGE reduce first phage replication in the host cell, but also the MGE is taken up and may provide a survival, growth or other benefit to the host cell, promoting uptake and/or retention of MGEs by host cells. In an example, expression of the antibacterial agent in the host cell is under the control of an inducible promoter or weak promoter to allow for a period where uptake of MGEs into host cells may be favoured owing to the presence of the nucleotide sequence that is beneficial to cells of the first species or strain.
28. The composition of any preceding Clause, wherein the MGE is devoid of rinA.
29. The composition of any preceding Clause, wherein the MGE is is devoid of terL.
30. The composition of any preceding Clause, wherein the MGE comprises a terS or a homologue thereof, and optionally is devoid of any other terminase gene.
The terS homologues are sequences which, like terS, recognise the SaPI-specific pac site (or other packaging sequence) comprised by the MGE or plasmid and determine packaging specificity for packaging the MGE.
Examples of terminase genes are pacA, pacB, terA, terB and terL.
31. The composition of any preceding Clause, wherein the first phage is a pac-type phage (eg, 011 or 80a) operable with a pac comprised by the MGE.
32. The composition of any one of Clauses 1 to 30, wherein the first phage is a cos-type phage (eg, 012 or 0SLT) operable with a cos comprised by the MGE.
Optionally, the phage is P2. Optionally, the first phage is a T7 or T7-like phage that recognises direct repeat sequences comprised by the MGE for packaging.
33. The composition of any preceding Clause, wherein the plasmid or MGE
comprises a pac and/or cos sequence or a homologue thereof.
34. The composition of any preceding Clause, wherein the plasmid or MGE
comprises a terS or a homologue thereof and optionally devoid of terL.
The terS homologues are sequences which, like terS, recognise the SaPI-specific pac site (or other packaging sequence) comprised by the MGE or plasmid and determine packaging specificity for packaging the MGE.
In an example, the terS comprises the sequence of SEQ ID NO: 1.
35. The composition of Clause 34, wherein the terS is a S aureus bacteriophage 980a terS or a bacteriophage 911 terS.
36. The composition of any preceding Clause, wherein the MGE is a modified SaPIbov 1 or SaPIbov5 and is devoid of a terS.
37. The composition of any preceding Clause, wherein the first phage is devoid of a functional packaging signal sequence and the MGE comprises a packaging signal sequence operable with proteins encoded by the first phage for producing transduction particles that package copies of the MGE or copies of a nucleic acid encoding the agent or component.
38. The composition of any preceding Clause, wherein the MGE or plasmid comprises a Ppi or homologue, which is capable of complexing with first phage TerS, thereby blocking function of the TerS.
39. The composition of any preceding Clause, wherein the MGE comprises a morphogenesis (cpm) module.
40. The composition of any preceding Clause, wherein the MGE comprises cpmA
and/or cpmB.
Optionally the cpmA and B are from any SaPI disclosed herein. In an example any SaPI is a SaPI
disclosed in Table 2 and optionally the host cell or target cell is any corresponding Staphylococcus disclosed in the table.
41. The composition of any preceding Clause, wherein the MGE or first phage comprises one, more or all genes cpl, cp2, and cp3.
In an example, the MGE comprises a modified SaPI and comprises one, more or all genes cpl, cp2, and cp3.
42. The composition of any preceding Clause, wherein the MGE or first phage encodes a HNH
nuclease.
43. The composition of any preceding Clause, wherein the MGE or first phage comprises an integrase gene that encodes an integrase for excising the MGE and integrating the MGE into a bacterial cell genome.
44. The composition of any preceding Clause, wherein the MGE is devoid of a functional integrase gene, and the first phage or host cell genome (eg, bacterial chromosome or a bacterial episome) comprises a functional integrase gene.
45. The composition of any preceding Clause, wherein the transcription of MGE nucleic acid is under the control of a constitutive promoter, for transcription of copies of the agent or component in a host cell.
Optionally, Constitutive transcription and production of the agent in target cells may be used where the target cells should be killed, eg, in medical settings.
Optionally, the transcription of MGE nucleic acid is under the control of an inducible promoter, for transcription of copies of the agent or component in a host cell. This may be useful, for example, to control switching on of the antibacterial activity against target bacterial cells, such as in an environment (eg, soil or water) or in an industrial culture or fermentation container containing the target cells. For example, the target cells may be useful in an industrial process (eg, for fermentation, eg, in the brewing or dairy industry) and the induction enables the process to be controlled (eg, stopped or reduced) by using the antibacterial agent against the target bacteria.
46. The composition of Clause 45, wherein the promoter is foreign to the host cell.
47. The composition of Clause 45 or 46, wherein the promoter comprises a nucleotide sequence that is at least 80% identical to an endogenous promoter sequence of the host cell.
48. The composition of any preceding Clause comprising a nucleic acid that is separate from the MGE, wherein the nucleic acid comprises all genes necessary for producing first phage particles.
49. The composition of any one of Clauses 1 to 47 comprising a nucleic acid that is separate from the MGE, wherein the nucleic acid comprises less than, all genes necessary for producing first phage particles, but comprises genes encoding structural proteins for production of transduction particles that package MGE nucleic acid encoding the antibacterial agent or one or more components thereof.
When the agent comprises a plurality of components, eg, wherein the agent is a CRISPR/Cas system, or is a CRISPR array encoding crRNA or a nucleic acid encoding a guide RNA
(eg, single guide RNA) operable with a Cas in host cells, wherein the crRNA or gRNA guides the Cas to a target sequence in the host cell to modify the target (eg, cut it or repress transcription from it).
50. The composition of Clause 48 or 49, wherein the genes are comprised by the host cell chromosome and/or one or more host cell episome(s).
51. The composition of Clause 50, wherein the genes are comprised by a chromosomally-integrated prophage of the first phage.
52. The composition of any preceding Clause, wherein the agent is a guided nuclease system or a component thereof, wherein the agent is capable of recognising and cutting host cell DNA (eg, chromosomal DNA).
In examples, such cutting causes one or more of the following:-(i)The host cell is killed by the antibacterial agent;
(ii) growth or proliferation of the host cell is reduced; and/or (iii)The host cell is sensitised to an antibiotic, whereby the antibiotic is toxic to the cell.
53. The composition of Clause 52, wherein the guided nuclease system is selected from a CRISPR/Cas system, TALEN system, meganuclease system or zinc finger system.
54. The composition of Clause 52, wherein the system is a CRISPR/Cas system and each MGE
encodes a (a) CRISPR array encoding crRNA or (b) a nucleic acid encoding a guide RNA (gRNA, eg, single guide RNA), wherein the crRNA or gRNA is operable with a Cas in target bacterial cells, wherein the crRNA or gRNA guides the Cas to a target nucleic acid sequence in the host cell to modify the target sequence (eg, cut it or repress transcription from it).
Optionally, the Cas is a Cas encoded by a functional endogenous nucleic acid of a host cell. For example, the target is comprised by a DNA or RNA of the host cell.
55. The composition of Clause 52, wherein the system is a CRISPR/Cas system and each MGE
encodes a Cas (eg, a Cas nuclease) that is operable in a target bacterial cells to modify a target nucleic acid sequence comprised by the target cell.
56. The composition of Clause 53, 54 or 55, wherein the Cas is a Cas3, Cas9, Cas13, CasX, CasY
or Cpfl.
57. The composition of any one of Clauses 52 to 56, wherein the system is a CRISPR/Cas system and each MGE encodes one or more Cascade Cas (eg, Cas, A, B, C, D and E).
58. The composition of any one of Clauses 52 to 57, wherein each MGE
further encodes a Cas3 that is operable in a target bacterial cell with the Cascade Cas.
59. The composition of any preceding Clause, wherein the first species or strain is a gram positive species or strain.
60. The composition of any one of Clauses 1 to 58, wherein the first species or strain is a gram negative species or strain.
61. The composition of any preceding Clause, wherein the first species or strain is selected from Table 1.
In an example, the first species of strain is a Staphylococcus (eg, S aureus) species or strain and optionally the MGE is a modified SaPI; and optionally the first phage is a 980a or 911. In an example, the first species of strain is a Vibrio (eg, V cholerae) species or strain and optionally the MGE is Vibrio (eg, V cholerae) PLE.
62. The composition of any preceding Clause, wherein the first species or strain is selected from Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.
These are species that P2 phage can infect. Thus, in an embodiment, the MGE
comprises one or more P4 sequences (eg, a P4 packaging sequence) and the first phage is P2. Thus, the MGE is packaged by P2 structural proteins and the resultant transduction particles can infect a broad spectrum of species, ie, two or more of Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.
63. A nucleic acid vector comprising a MGE integrated therein, wherein the MGE is according to any preceding Clause and the vector is capable of transferring the MGE or a copy thereof into a host bacterial cell.
Suitable vectors are plasmids (eg, conjugative plasmids) or viruses (eg, phage or packaged phagemids).
64. The vector of Clause 63, wherein the vector is a shuttle vector.
A shuttle vector is a vector (usually a plasmid) constructed so that it can propagate in two different host species. Therefore, DNA inserted into a shuttle vector can be tested or manipulated in two different cell types.
65. The vector of Clause 63, wherein the vector is a plasmid, wherein the plasmid is capable of being transformed into a host bacterial cell comprising a first phage.
66. A non-self replicative transduction particle comprising said MGE or vector of any preceding .. Clause.
By "non-replicative" it is meant that the MGE is not capable by itself of self-replicating. For example, the MGE is devoid of one or more nucleotide sequences encoding a protein (eg, a structural protein) that is necessary to produce a transduction particle comprising a copy of the MGE.
67. A composition comprising a plurality of transduction particles, wherein each particle comprises a MGE or vector according to any one of Clauses 1 to 65, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
In an example, the reduction in growth or proliferation of host cells is at least 50, 60, 70, 80, 90 or 95%. The antibiotic can be any antibiotic disclosed herein.
68. The composition of Clause 67, wherein the agent is a guided nuclease system or a component thereof, wherein the agent is capable of recognising and cutting host cell DNA
(eg, chromosomal DNA) whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
69. A composition comprising a plurality of non-self replicative transduction particles, wherein each particle comprises a MGE or plasmid according to any one of Clauses 1 to 65, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein the agent is a CRISPR/Cas system and the component comprises a nucleic acid encoding a crRNA or a guide RNA
that is operable with a Cas in a target bacterial cell to guide the Cas to a target nucleic acid sequence of the cell to modify the sequence, whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
In an example, the reduction in growth or proliferation of host cells is at least 50, 60, 70, 80, 90 or 95%. The antibiotic can be any antibiotic disclosed herein.
70. A kit comprising the composition of Clause 69 and said antibiotic.
71. The composition of Clause 69, wherein the composition comprises said antibiotic.
72. The composition of any one of Clauses 67 to 69, wherein less than 10%
of transduction particles comprise by the composition are first phage particles.
73. The composition of any one of Clauses 67 to 69, wherein no first phage particles are present in the composition.
74. The MGE, vector, particle, composition or kit of any preceding Clause for medical use in a human or animal patient.
75. The MGE, vector, particle, composition or kit of any preceding Clause for treating or preventing an infection by target bacterial cells in a human or animal patient, wherein the antibacterial agent is toxic to the target cells.
76. The MGE, vector, particle, composition or kit of any preceding Clause for treating or preventing an infection by target bacterial cells in a human or animal patient, wherein in the presence of the antibacterial agent a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; and/or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
77. A method of producing a plurality of transduction particles, the method comprising combining the composition of any one of Clauses 1 to 62, 67 to 69 and 71 to 76 with host bacterial cells of said first species, wherein the cells comprise the first phage, allowing a plurality of said MGEs to be introduced into host cells and culturing the host cells under conditions in which first phage-encoded proteins are expressed and MGE copies are packaged by first phage proteins to produce a plurality of transduction particles, and optionally separating the transduction particles from cells and obtaining a plurality of transduction particles separated from cells.
78. The method of Clause 77, comprising separating the transduction particles from any first phage, optionally by filtering or centrifugation, thereby obtaining a plurality of transduction particles in the absence of first phage.
79. The method of Clause 77 or 78, wherein the particles encode a guided nuclease system (optionally a CRISPR/Cas system) or component thereof for cutting a target nucleic acid sequence comprised by target bacterial cells.
80. The method of Clause 79, wherein the sequence is comprised by an antibiotic resistance gene and the method comprises combining the plurality of particles with said antibiotic in a kit or a mixture.
81. The method of any one of Clauses 77 to 80, wherein said conditions comprise induction of a lytic cycle of the first phage.
82. A bacterial host cell comprising a first phage and a MGE, vector or particle as recited in any one of Clauses 1 to 66, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
83. A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition as recited in any one of Clauses 1 to 62, 67 to 69 and 71 to 76, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
84. The cell of Clause 83, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and cells of the same species as the host cell comprise a target sequence that is cut by the nuclease, wherein the target sequence has been removed or altered in the host cell whereby the nuclease is not capable of cutting the target sequence.
85. A bacterial host cell comprising a first phage and a MGE, vector or particle as recited in any one of Clauses 1 to 66, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE
is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
86. A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition as recited in any one of Clauses 1 to 62, 67 to 69 and 71 to 76, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
87. The cell of Clause 86, wherein the first phage is a prophage.
88. A bacterial host cell comprising a MGE, vector or particle as recited in any one of Clauses 1 to 66 and nucleic acid under the control of one or more inducible promoters, wherein the nucleic acid encodes all structural proteins necessary to produce a transduction particle that packages a copy of the MGE or plasmid, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
89. The cell of Clause 88, wherein the structural proteins are structural proteins of a lytic phage.
90. The cell of Clause 88 or 89, wherein the nucleic acid comprises terS
and/or terL.
91. The cell of any one of Clauses 88 to 90, wherein the host and second cells are of the same species and the host cell has been engineered so that the antibiotic is not toxic to the host cell.
92. The cell of any one of Clauses 88 to 91, wherein the nucleic acid is comprised by a plasmid.
93. The cell of any one of Clauses 88 to 92, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and the second cells comprise a target sequence that is cut by the nuclease, wherein the target sequence is absent in the genome of the host cell whereby the nuclease is not capable of cutting the host cell genome.
94. The composition, vector, particle, kit or method of any preceding Clause, wherein the cell, host cell or target cell is selected from a Staphylococcal, Vibrio, Pseudomonas, Clostridium, E coli, Helicobacter, Klebsiella and Salmonella cell.
95. A plasmid comprising a. A nucleotide sequence encoding an antibacterial agent or component thereof for expression in target bacterial cells;
b. A constitutive promoter for controlling the expression of the agent or component;
c. An optional terS nucleotide sequence;
d. An origin of replication (on); and e. A phage packaging sequence (optionally pac, cos or a homologue thereof);
and f. the plasmid being devoid of g. All nucleotide sequences encoding phage structural proteins necessary for the production of a transduction particle (optionally a phage), or the plasmid being devoid of at least one of such sequences; and h. Optionally terL.
96. The plasmid of Clause 95, wherein the antibacterial agent is a CRISPR/Cas system and the plasmid encodes a crRNa or guide RNA (eg, single gRNA) that is operable with a Cas in the target cells to guide the Cas to a target nucleotide sequence to modify (eg, cut) the sequence, whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
97. The plasmid of Clause 95 or 96, wherein the antibacterial agent is a CRISPR/Cas system and the plasmid encodes a Cas that is operable with a crRNa or guide RNA (eg, single gRNA) in the target cells to guide the Cas to a target nucleotide sequence to modify (eg, cut) the sequence, whereby a. target cells are killed by the antibacterial agent;
b. growth or proliferation of target cells is reduced; or c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
98. The plasmid of Clause 97, wherein the plasmid further encodes said crRNA or gRNA.
99. A host cell comprising the plasmid of any one of Clauses 95 to 98, wherein the host cell does not comprise the target nucleotide sequence.
100. The host cell of Clause 99, wherein the cell is capable of replicating the plasmid and packaging the replicated plasmid in transduction particles that are capable of infecting target bacterial cells.
101. The host cell of Clause 99 or 100, wherein the host cell comprises, integrated in the cell chromosome and/or one or more episomes of the cell, a. A terL;
b. An optional terS; and c. Expressible nucleotide sequences encoding all structural proteins necessary for the production of transduction particles that package copies of the plasmid;
d. wherein the chromosome and episomes of the cell (other than said plasmid) are devoid of a phage packaging sequence, wherein the phage packaging sequence comprised by the plasmid is operable together with the product of said terS and terL in the production of packaged plasmid.
102. The cell of Clause 101, wherein the terL, optional terS and nucleotide sequences encoding the structural proteins are comprised by a phage (optionally a prophage) genome in the host cell.
103. A bacterial host cell comprising the genome of a helper phage that is incapable of self-replication, optionally wherein the genome is present as a prophage, and a plasmid according to any one of Clauses 95 to 98, wherein the helper phage is operable to package copies of the plasmid in transduction particles, wherein the particles are capable of infecting bacterial target cells to which the antibacterial agent is toxic.
104. The cell of Clause 103, wherein the host cell is a cell of first species or strain and the target cells are of the same species or strain, and optionally wherein the hosts cell is an engineered cell that to which the antibacterial agent is not toxic.
105. The cell of Clause 103, wherein the host cell is a cell of first species or strain and the target cells are of a different species or strain, wherein the antibacterial agent is not toxic to the host cell.
106. A method of making a plurality of transduction particles, the method comprising culturing a plurality of host cells according to any one of Clauses 103 to 105, optionally inducing a lytic cycle of the helper phage, and incubating the cells under conditions wherein transducing particles comprising packaged copies of the plasmid are created, and optionally separating the particles from the cells to obtain a plurality of transduction particles.
107. A plurality of transduction particles obtainable by the method of Clause 106 for use in medicine, eg, for treating or preventing an infection of a human or animal subject by target bacterial cells, wherein transducing particles are administered to the subject for infecting target cells and killing the cells using the antibacterial agent.
108. A method of making a plurality of transduction particles, the method comprising i.Producing host cells whose genomes comprise nucleic acid encoding structural proteins necessary to produce transduction particles that can package first DNA, wherein the genomes are devoid of a phage packaging signal, wherein the expression of the proteins is under the control of inducible promoter(s);
ii.Producing first DNA encoding an antibacterial agent or a component thereof (eg, as defined in any preceding Clause), wherein the DNA comprises a phage packaging signal;
iii.Introducing the DNA into the host cells;
iv.Inducing production of the structural proteins in host cells, whereby transduction particles are produced that package the DNA;
v.Optionally isolating a plurality of the transduction particles; and vi.Optionally formulating the particles into a pharmaceutical composition for administration to a human or animal for medical use.
ii.Producing first DNA encoding an antibacterial agent or a component thereof (eg, as defined in any preceding Clause), wherein the DNA comprises a phage packaging signal;
iii.Introducing the DNA into the host cells;
iv.Inducing production of the structural proteins in host cells, whereby transduction particles are produced that package the DNA;
v.Optionally isolating a plurality of the transduction particles; and vi.Optionally formulating the particles into a pharmaceutical composition for administration to a human or animal for medical use.
109. The method of Clause 108, wherein the DNA comprises a MGE as defined in any preceding Clause.
110. The method of Clause 108 or 109, wherein the structural proteins are P2 phage proteins and optionally the packaging signal is a P4 phage packaging signal.
111. The method of Clause 108 or 109, wherein the DNA comprises a modified SaPI or a genomic island DNA.
112. The method of any one of Clauses 108 to 111, wherein the cells in step (iv) comprise a gene encoding a helper phage activator, optionally wherein the activator is a P4 phage delta or ogr protein when the structural proteins are P2 proteins; or the activator is a SaPI rinA, ptiA, ptiB or ptiM when the MGE comprises a modified SaPI; and optionally the expression of the activator(s) is controlled by an inducible promoter, eg, a T7 promoter.
113. The method of any one of Clauses 108 to 112, wherein the packaging signal is P4 phage Sid and/or psu; or the signal is SaPI cpmA and/or cpmB.
This is useful for packaging DNAs into smaller capsids.
This is useful for packaging DNAs into smaller capsids.
114. The method of any one of Clauses 108 to 113, wherein the cell genomes comprise prophages, wherein each prophage comprises said nucleic acid encoding structural proteins.
115. The method of Clause 114, wherein the prophages are P2 prophages devoid of cos and optionally one, more or all genes selected from int, cox orf78, B, oif80, oif81, oif82, orf83, A, oif91, tin, old, orf30 andfun(Z); and optionally the packaging signal of (ii) is a cos or P4 packaging signal.
116. The method of Clause 114 or 115, wherein the prophages are P2 prophages devoid of cos and comprising genes from Q to S, V to G and Fr to ogr.
117. The method of Clause 114, wherein the prophages are phill prophages devoid of a packaging signal and comprising gene 29 (terS) to gene 53 (lysin); and optionally the packaging signal of (ii) is a phill packaging signal.
118. A plurality of transduction particles obtainable by the method of any one of Clauses 108 to 117.
119. The particles of Clause 118 for administration to a human or animal for medical use.
Further Concepts of the invention are as follows:-[0079] The present invention is optionally for an industrial or domestic use, or is used in a method for such use. For example, it is for or used in agriculture, oil or petroleum industry, food or drink industry, clothing industry, packaging industry, electronics industry, computer industry, environmental industry, chemical industry, aeorspace industry, automotive industry, biotechnology industry, medical industry, healthcare industry, dentistry industry, energy industry, consumer products industry, pharmaceutical industry, mining industry, cleaning industry, forestry industry, fishing .. industry, leisure industry, recycling industry, cosmetics industry, plastics industry, pulp or paper industry, textile industry, clothing industry, leather or suede or animal hide industry, tobacco industry or steel industry.
[0080] The present invention is optionally for use in an industry or the environment is an industrial environment, wherein the industry is an industry of a field selected from the group consisting of the medical and healthcare; pharmaceutical; human food; animal food; plant fertilizers; beverage; dairy;
meat processing; agriculture; livestock farming; poultry farming; fish and shellfish farming;
veterinary; oil; gas; petrochemical; water treatment; sewage treatment;
packaging; electronics and computer; personal healthcare and toiletries; cosmetics; dental; non-medical dental; ophthalmic; non-medical ophthalmic; mineral mining and processing; metals mining and processing; quarrying;
aviation; automotive; rail; shipping; space; environmental; soil treatment;
pulp and paper; clothing manufacture; dyes; printing; adhesives; air treatment; solvents; biodefence;
vitamin supplements; cold storage; fibre retting and production; biotechnology; chemical; industrial cleaning products; domestic cleaning products; soaps and detergents; consumer products; forestry; fishing;
leisure; recycling;
plastics; hide, leather and suede; waste management; funeral and undertaking;
fuel; building; energy;
steel; and tobacco industry fields.
[0081] In an example, the ifirst DNA, first phage or vector comprises a CRISPR
array that targets target bacteria, wherein the array comprises one, or two or more spacers (eg, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 20, 30, 40, 50 or more spacers) for targeting the genome of target bacteria.
[0082] In an example, the target bacteria are comprised by an environment as follows. In an example, the environment is a microbiome of a human, eg, the oral cavity microbiome or gut microbiome or the bloodstream. In an example, the environment is not an environment in or on a human. In an example, the environment is not an environment in or on a non-human animal. In an embodiment, the environment is an air environment. In an embodiment, the environment is an agricultural environment. In an embodiment, the environment is an oil or petroleum recovery environment, eg, an oil or petroleum field or well. In an example, the environment is an environment in or on a foodstuff or beverage for human or non-human animal consumption.
[0083] In an example, the environment is a a human or animal microbiome (eg, gut, vaginal, scalp, armpit, skin or oral cavity microbiome). In an example, the target bacteria are comprised by a human or animal microbiome (eg, gut, vaginal, scalp, armpit, skin or oral cavity microbiome).
[0084] In an example, the DNAs, phage or composition of the invention are administered intranasally, topically or orally to a human or non-human animal, or is for such administration. The skilled person aiming to treat a microbiome of the human or animal will be able to determine the best route of administration, depending upon the microbiome of interest. For example, when the microbiome is a gut microbiome, administration can be intranasally or orally.
When the microbiome is a scalp or armpit microbiome, administration can be topically. When the microbiome is in the mouth or throat, the administration can be orally.
[0085] In any use or method herein, in an embodiment the first phage are contacted with the target bacteria at a multiplicity of infection (MOI) of at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600 or 700. For example, the MOI is from 20 to 200, from 20 to 100, fro 50 to 200, from 50 to 100, from 75 to 150, 100 or about 100, or 200 or about 200. In an example, this may be determined by obtaining a sample of the microbiome containing the target bacteria (eg, a sample of a waterway or gut microbiome of a subject) and determining the number of CFU/ml or mg in the sample and using this to titrate the phage dose at the desired MOT to be exposed to the microbiome or administered to the environment or subject to be treated.
[0086] In an example, the environment is harboured by a beverage or water (eg, a waterway or drinking water for human consumption) or soil. The water is optionally in a heating, cooling or industrial system, or in a drinking water storage container.
[0087] In an example, the host and/or target bacteraia are Finnicutes selected from Anaerotruncus, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Anaerococcus, Anaerofilum, Anaerosinus, Anaerostipes, Anaerovorax, Butyrivibrio, Clostridium, Capracoccus, Dehalobacter, Dialister, Dorea, Enterococcus, Ethanoligenens, Faecalibacterium, Fusobacterium, Gracilibacter, Guggenheimella, Hespellia, Lachnobacterium, Lachnospira, Lactobacillus, Leuconostoc, Megamonas, Mitsuokella, Oribacterium, Oxobacter, Papillibacter, Proprionispira,Pseudobutyrivibrio, Pseudoramibacter, Roseburia, Ruminococcus, Sarcina, Seinonella, Shuttleworthia, Sporobacter, Sporobacterium, Streptococcus, Subdoligranulum, Syntrophococcus, Thermobacillus, Turibacter and Weisella.
[0088] In an example, the kit, DNA(s), first phage, helper phage, composition, use or method is for reducing pathogenic infections or for re-balancing gut or oral microbiota eg, for treating or preventing obesity or disease in a human or animal. For example, the first phage, helper phage, composition, use or method is for knocking-down Clostridium dificile or E coli bacteria in a gut microbiota of a human or animal.
[0089] In an example, the packaging signal, NPF and/or HPF consists or comprises SEQ ID NO: 2 or a structural or functional homologue thereof.
[0090] In an example, the packaging signal, NPF and/or HPF consists or comprises SEQ ID NO: 2 or a nucleotide sequence that is at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical thereto.
[0091] In an example, the disease or condition is a cancer, inflammatory or autoimmune disease or condition, eg, obesity, diabetes IBD, a GI tract condition or an oral cavity condition.
[0092] Optionally, the environment is comprised by, or the target bacteria are comprised by, a gut microbiota, skin microbiota, oral cavity microbiota, throat microbiota, hair microbiota, armpit microbiota, vaginal microbiota, rectal microbiota, anal microbiota, ocular microbiota, nasal microbiota, tongue microbiota, lung microbiota, liver microbiota, kidney microbiota, genital microbiota, penile microbiota, scrotal microbiota, mammary gland microbiota, ear microbiota, urethra microbiota, labial microbiota, organ microbiota or dental microbiota.
Optionally, the environment is comprised by, or the target bacteria are comprised by, a plant (eg, a tobacco, crop plant, fruit plant, vegetable plant or tobacco, eg on the surface of a plant or contained in a plant) or by an environment (eg, soil or water or a waterway or acqueous liquid).
[0093] Optionally, the disease or condition of a human or animal subject is selected from (a) A neurodegenerative disease or condition;
(b) A brain disease or condition;
(c) A CNS disease or condition;
(d) Memory loss or impairment;
(e) A heart or cardiovascular disease or condition, eg, heart attack, stroke or atrial fibrillation;
(0 A liver disease or condition;
(g) A kidney disease or condition, eg, chronic kidney disease (CKD);
(h) A pancreas disease or condition;
(i) A lung disease or condition, eg, cystic fibrosis or COPD;
(i) A gastrointestinal disease or condition;
(k) A throat or oral cavity disease or condition;
(1) An ocular disease or condition;
(m) A genital disease or condition, eg, a vaginal, labial, penile or scrotal disease or condition;
(n) A sexually-transmissible disease or condition, eg, gonorrhea, HIV
infection, syphilis or Chlamydia infection;
(o) An ear disease or condition;
(13) A skin disease or condition;
(q) A heart disease or condition;
(r) A nasal disease or condition (s) A haematological disease or condition, eg, anaemia, eg, anaemia of chronic disease or cancer;
(t) A viral infection;
(u) A pathogenic bacterial infection;
(v) A cancer;
(w) An autoimmune disease or condition, eg, SLE;
(x) An inflammatory disease or condition, eg, rheumatoid arthritis, psoriasis, eczema, asthma, ulcerative colitis, colitis, Crohn's disease or IBD;
(y) Autism;
(z) ADHD;
(aa) Bipolar disorder;
(bb) ALS [Amyotrophic Lateral Sclerosis];
(cc) Osteoarthritis;
(dd) A congenital or development defect or condition;
(cc) Miscarriage;
(ft) A blood clotting condition;
(gg) Bronchitis;
(hh) Dry or wet AMD;
(ii) Neovascularisation (eg, of a tumour or in the eye);
Common cold;
(kk) Epilepsy;
(11) Fibrosis, eg, liver or lung fibrosis;
(mm) A fungal disease or condition, eg, thrush;
(nn) A metabolic disease or condition, eg, obesity, anorexia, diabetes, Type I or Type II diabetes.
(oo) Ulcer(s), eg, gastric ulceration or skin ulceration;
(pp) Dry skin;
(qq) Sjogren's syndrome;
(a) Cytokine storm;
(ss) Deafness, hearing loss or impairment;
(tt) Slow or fast metabolism (ie, slower or faster than average for the weight, sex and age of the subject);
(uu) Conception disorder, eg, infertility or low fertility;
(vv) Jaundice;
(ww) Skin rash;
(xx) Kawasaki Disease;
(yy) Lyme Disease;
(zz) An allergy, eg, a nut, grass, pollen, dust mite, cat or dog fur or dander allergy;
(aaa) Malaria, typhoid fever, tuberculosis or cholera;
(bbb) Depression;
(ccc) Mental retardation;
(ddd) Microcephaly;
(eee) Malnutrition;
(fff) Conjunctivitis;
(ggg) Pneumonia;
(hhh) Pulmonary embolism;
(iii) Pulmonary hypertension;
A bone disorder;
(kkk) Sepsis or septic shock;
(111) Sinusitus;
(mmm) Stress (eg, occupational stress);
(nnn) Thalassaemia, anaemia, von Willebrand Disease, or haemophilia;
(000) Shingles or cold sore;
(ppp) Menstruation;
(qqq) Low sperm count.
[0094] NEURODEGENERATIVE OR CNS DISEASES OR CONDITIONS FOR
TREATMENT OR PREVENTION BY THE INVENTION
[0095] In an example, the neurodegenerative or CNS disease or condition is selected from the group consisting of Alzheimer disease , geriopsychosis, Down syndrome, Parkinson's disease, Creutzfeldt-j akob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt- Jakob disease. For example, the disease is Alzheimer disease. For example, the disease is Parkinson syndrome.
[0096] In an example, wherein the method of the invention is practised on a human or animal subject for treating a CNS or neurodegenerative disease or condition, the method causes downregulation of Treg cells in the subject, thereby promoting entry of systemic monocyte-derived macrophages and/or Treg cells across the choroid plexus into the brain of the subject, whereby the disease or condition (eg, Alzheimer's disease) is treated, prevented or progression thereof is reduced.
In an embodiment the method causes an increase of IFN-gamma in the CNS system (eg, in the brain and/or CSF) of the subject. In an example, the method restores nerve fibre and//or reduces the progression of nerve fibre damage. In an example, the method restores nerve myelin and//or reduces the progression of nerve myelin damage. In an example, the method of the invention treats or prevents a disease or condition disclosed in W02015136541 and/or the method can be used with any method disclosed in W02015136541 (the disclosure of this document is incorporated by reference herein in its entirety, eg, for providing disclosure of such methods, diseases, conditions and potential therapeutic agents that can be administered to the subject for effecting treatement and/or prevention of CNS and neurodegenerative diseases and conditions, eg, agents such as immune checkpoint inhibitors, eg, anti-PD-1, anti-PD-L1, anti-TIM3 or other antibodies disclosed therein).
[0097] CANCERS FOR TREATMENT OR PREVENTION BY THE METHOD
[0098] Cancers that may be treated include tumours that are not vascularized, or not substantially vascularized, as well as vascularized tumours. The cancers may comprise non-solid tumours (such as haematological tumours, for example, leukaemias and lymphomas) or may comprise solid tumours.
Types of cancers to be treated with the invention include, but are not limited to, carcinoma, blastoma, and sarcoma, and certain leukaemia or lymphoid malignancies, benign and malignant tumours, and malignancies e.g., sarcomas, carcinomas, and melanomas. Adult tumours/cancers and paediatric tumours/cancers are also included.
[0099] Haematologic cancers are cancers of the blood or bone marrow. Examples of haematological (or haematogenous) cancers include leukaemias, including acute leukaemias (such as acute lymphocytic leukaemia, acute myelocytic leukaemia, acute myelogenous leukaemia and myeloblasts, promyeiocytic, myelomonocytic, monocytic and erythroleukaemia), chronic leukaemias (such as chronic myelocytic (granulocytic) leukaemia, chronic myelogenous leukaemia, and chronic lymphocytic leukaemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and high grade forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myeiodysplastic syndrome, hairy cell leukaemia and myelodysplasia.
[00100] Solid tumours are abnormal masses of tissue that usually do not contain cysts or liquid areas.
Solid tumours can be benign or malignant. Different types of solid tumours are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumours, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumour, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous eel!
carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumour, cervical cancer, testicular tumour, seminoma, bladder carcinoma, melanoma, and CNS tumours (such as a glioma (such as brainstem glioma and mixed gliomas), glioblastoma (also known as glioblastoma multiforme) astrocytoma, CNS lymphoma, germinoma, medu!loblastoma, Schwannoma craniopharyogioma, ependymoma, pineaioma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, neuroblastoma, retinoblastoma and brain metastases).
[00101] AUTOIMMUNE DISEASES FOR TREATMENT OR PREVENTION BY THE
METHOD
1. Acute Disseminated Encephalomyelitis (ADEM) 2. Acute necrotizing hemorrhagic leukoencephalitis 3. Addison's disease 4. Agammaglobulinemia 5. Alopecia areata 6. Amyloidosis 7. Ankylosing spondylitis 8. Anti-GBM/Anti-TBM nephritis 9. Antiphospholipid syndrome (APS) 10. Autoimmune angioedema 11. Autoimmune aplastic anemia 12. Autoimmune dysautonomia 13. Autoimmune hepatitis 14. Autoimmune hyperlipidemia 15. Autoimmune immunodeficiency 16. Autoimmune inner ear disease (AIED) 17. Autoimmune myocarditis 18. Autoimmune oophoritis 19. Autoimmune pancreatitis 20. Autoimmune retinopathy 21. Autoimmune thrombocytopenic putpura (ATP) 22. Autoimmune thyroid disease 23. Autoimmune urticaria 24. Axonal & neuronal neuropathies 25. Balo disease 26. Behcet's disease 27. Bullous pemphigoid 28. Cardiomyopathy 29. Castleman disease 30. Celiac disease 31. Chagas disease 32. Chronic fatigue syndrome 33. Chronic inflammatory demvelinating polyneuropathv (CIDP) 34. Chronic recurrent multifocal ostomvelitis (CRMO) 35. Churg-Strauss syndrome 36. Cicatricial pemphigoid/benign mucosal pemphigoid 37. Crohn's disease 38. Cogans syndrome 39. Cold agglutinin disease 40. Congenital heart block 41. Coxsackie mvocarditis 42. CREST disease 43. Essential mixed cryoglobulincm i a 44. Demyelinating neuropathics 45. Dermatitis herpetiformis 46. Dermatomyositis 47. Devic's disease (neuromyelitis optica) 48. Discoid lupus 49. Dressler's syndrome 50. Endometriosis 51. Eosinophilic esophagitis 52. Eosinophilic fasciitis 53. Erythema nodosum 54. Experimental allergic encephalomyelitis 55. Evans syndrome 56. Fibromyalgia 57. Fibrosing alveolitis 58. Giant cell arteritis (temporal artcritis) 59. Giant cell myocarditis 60. Glomerulonephritis 61. Goodpasture's syndrome 62. Granulomatosis with Polyangiitis (GPM (formerly called Wegener's Granulomatosis) 63. Graves' disease 64. Guillain-Barre syndrome 65. Hashimoto's encephalitis 66. Hashimoto's thyroiditis 67. Hemolytic anemia 68. Hcnoch-Schonlein putpura 69. Herpes gestationis 70. Hvpogammaglobulinemia 71. Idiopathic thrombocvtopenic purpura (ITP) 72. IgA nephropathy 73. IgG4-related sclerosing disease 74. Immunoregulatoty lipoproteins 75. Inclusion body myositis 76. Interstitial cystitis 77. Juvenile arthritis 78. Juvenile diabetes (Type 1 diabetes) 79. Juvenile myositis 80. Kawasaki syndrome 81. Lambert-Eaton syndrome 82. Leukocvtoclastic vasculitis 83. Lichen planus 84. Lichen sclerosus 85. Ligneous conjunctivitis 86. Linear IgA disease (LAD) 87. Lupus (SLE) 88. Lyme disease, chronic 89. Meniere's disease 90. Microscopic polyangiitis 91. Mixed connective tissue disease (MCTD) 92. Mooren's ulcer 93. Mucha-Habermann disease 94. Multiple sclerosis 95. Myasthenia gravis 96. Myositis 97. Narcolepsy 98. Neuromvelitis optica (Devic's) 99. Neutropenia 100. Ocular cicatricial pemphigoid 101. Optic neuritis 102. Palindromic rheumatism 103. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus) 104. Paraneoplastic cerebellar degeneration 105. Paroxysmal nocturnal hemoglobinuria (PNH) 106. Parry Romberg syndrome 107. Parsonnage-Turner syndrome 108. Pars planitis (peripheral uveitis) 109. Pemphigus 110. Peripheral neuropathy 111. Perivenous encephalomyelitis 112. Pernicious anemia 113. POEMS syndrome 114. Polyarteritis nodosa 115. Type I. H. & III autoimmune polvglandular syndromes 116. Polvinyalgia rheumatica 117. Polymyositis 118. Postmvocardial infarction syndrome 119. Postpericardiotomv syndrome
Further Concepts of the invention are as follows:-[0079] The present invention is optionally for an industrial or domestic use, or is used in a method for such use. For example, it is for or used in agriculture, oil or petroleum industry, food or drink industry, clothing industry, packaging industry, electronics industry, computer industry, environmental industry, chemical industry, aeorspace industry, automotive industry, biotechnology industry, medical industry, healthcare industry, dentistry industry, energy industry, consumer products industry, pharmaceutical industry, mining industry, cleaning industry, forestry industry, fishing .. industry, leisure industry, recycling industry, cosmetics industry, plastics industry, pulp or paper industry, textile industry, clothing industry, leather or suede or animal hide industry, tobacco industry or steel industry.
[0080] The present invention is optionally for use in an industry or the environment is an industrial environment, wherein the industry is an industry of a field selected from the group consisting of the medical and healthcare; pharmaceutical; human food; animal food; plant fertilizers; beverage; dairy;
meat processing; agriculture; livestock farming; poultry farming; fish and shellfish farming;
veterinary; oil; gas; petrochemical; water treatment; sewage treatment;
packaging; electronics and computer; personal healthcare and toiletries; cosmetics; dental; non-medical dental; ophthalmic; non-medical ophthalmic; mineral mining and processing; metals mining and processing; quarrying;
aviation; automotive; rail; shipping; space; environmental; soil treatment;
pulp and paper; clothing manufacture; dyes; printing; adhesives; air treatment; solvents; biodefence;
vitamin supplements; cold storage; fibre retting and production; biotechnology; chemical; industrial cleaning products; domestic cleaning products; soaps and detergents; consumer products; forestry; fishing;
leisure; recycling;
plastics; hide, leather and suede; waste management; funeral and undertaking;
fuel; building; energy;
steel; and tobacco industry fields.
[0081] In an example, the ifirst DNA, first phage or vector comprises a CRISPR
array that targets target bacteria, wherein the array comprises one, or two or more spacers (eg, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 20, 30, 40, 50 or more spacers) for targeting the genome of target bacteria.
[0082] In an example, the target bacteria are comprised by an environment as follows. In an example, the environment is a microbiome of a human, eg, the oral cavity microbiome or gut microbiome or the bloodstream. In an example, the environment is not an environment in or on a human. In an example, the environment is not an environment in or on a non-human animal. In an embodiment, the environment is an air environment. In an embodiment, the environment is an agricultural environment. In an embodiment, the environment is an oil or petroleum recovery environment, eg, an oil or petroleum field or well. In an example, the environment is an environment in or on a foodstuff or beverage for human or non-human animal consumption.
[0083] In an example, the environment is a a human or animal microbiome (eg, gut, vaginal, scalp, armpit, skin or oral cavity microbiome). In an example, the target bacteria are comprised by a human or animal microbiome (eg, gut, vaginal, scalp, armpit, skin or oral cavity microbiome).
[0084] In an example, the DNAs, phage or composition of the invention are administered intranasally, topically or orally to a human or non-human animal, or is for such administration. The skilled person aiming to treat a microbiome of the human or animal will be able to determine the best route of administration, depending upon the microbiome of interest. For example, when the microbiome is a gut microbiome, administration can be intranasally or orally.
When the microbiome is a scalp or armpit microbiome, administration can be topically. When the microbiome is in the mouth or throat, the administration can be orally.
[0085] In any use or method herein, in an embodiment the first phage are contacted with the target bacteria at a multiplicity of infection (MOI) of at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600 or 700. For example, the MOI is from 20 to 200, from 20 to 100, fro 50 to 200, from 50 to 100, from 75 to 150, 100 or about 100, or 200 or about 200. In an example, this may be determined by obtaining a sample of the microbiome containing the target bacteria (eg, a sample of a waterway or gut microbiome of a subject) and determining the number of CFU/ml or mg in the sample and using this to titrate the phage dose at the desired MOT to be exposed to the microbiome or administered to the environment or subject to be treated.
[0086] In an example, the environment is harboured by a beverage or water (eg, a waterway or drinking water for human consumption) or soil. The water is optionally in a heating, cooling or industrial system, or in a drinking water storage container.
[0087] In an example, the host and/or target bacteraia are Finnicutes selected from Anaerotruncus, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Anaerococcus, Anaerofilum, Anaerosinus, Anaerostipes, Anaerovorax, Butyrivibrio, Clostridium, Capracoccus, Dehalobacter, Dialister, Dorea, Enterococcus, Ethanoligenens, Faecalibacterium, Fusobacterium, Gracilibacter, Guggenheimella, Hespellia, Lachnobacterium, Lachnospira, Lactobacillus, Leuconostoc, Megamonas, Mitsuokella, Oribacterium, Oxobacter, Papillibacter, Proprionispira,Pseudobutyrivibrio, Pseudoramibacter, Roseburia, Ruminococcus, Sarcina, Seinonella, Shuttleworthia, Sporobacter, Sporobacterium, Streptococcus, Subdoligranulum, Syntrophococcus, Thermobacillus, Turibacter and Weisella.
[0088] In an example, the kit, DNA(s), first phage, helper phage, composition, use or method is for reducing pathogenic infections or for re-balancing gut or oral microbiota eg, for treating or preventing obesity or disease in a human or animal. For example, the first phage, helper phage, composition, use or method is for knocking-down Clostridium dificile or E coli bacteria in a gut microbiota of a human or animal.
[0089] In an example, the packaging signal, NPF and/or HPF consists or comprises SEQ ID NO: 2 or a structural or functional homologue thereof.
[0090] In an example, the packaging signal, NPF and/or HPF consists or comprises SEQ ID NO: 2 or a nucleotide sequence that is at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical thereto.
[0091] In an example, the disease or condition is a cancer, inflammatory or autoimmune disease or condition, eg, obesity, diabetes IBD, a GI tract condition or an oral cavity condition.
[0092] Optionally, the environment is comprised by, or the target bacteria are comprised by, a gut microbiota, skin microbiota, oral cavity microbiota, throat microbiota, hair microbiota, armpit microbiota, vaginal microbiota, rectal microbiota, anal microbiota, ocular microbiota, nasal microbiota, tongue microbiota, lung microbiota, liver microbiota, kidney microbiota, genital microbiota, penile microbiota, scrotal microbiota, mammary gland microbiota, ear microbiota, urethra microbiota, labial microbiota, organ microbiota or dental microbiota.
Optionally, the environment is comprised by, or the target bacteria are comprised by, a plant (eg, a tobacco, crop plant, fruit plant, vegetable plant or tobacco, eg on the surface of a plant or contained in a plant) or by an environment (eg, soil or water or a waterway or acqueous liquid).
[0093] Optionally, the disease or condition of a human or animal subject is selected from (a) A neurodegenerative disease or condition;
(b) A brain disease or condition;
(c) A CNS disease or condition;
(d) Memory loss or impairment;
(e) A heart or cardiovascular disease or condition, eg, heart attack, stroke or atrial fibrillation;
(0 A liver disease or condition;
(g) A kidney disease or condition, eg, chronic kidney disease (CKD);
(h) A pancreas disease or condition;
(i) A lung disease or condition, eg, cystic fibrosis or COPD;
(i) A gastrointestinal disease or condition;
(k) A throat or oral cavity disease or condition;
(1) An ocular disease or condition;
(m) A genital disease or condition, eg, a vaginal, labial, penile or scrotal disease or condition;
(n) A sexually-transmissible disease or condition, eg, gonorrhea, HIV
infection, syphilis or Chlamydia infection;
(o) An ear disease or condition;
(13) A skin disease or condition;
(q) A heart disease or condition;
(r) A nasal disease or condition (s) A haematological disease or condition, eg, anaemia, eg, anaemia of chronic disease or cancer;
(t) A viral infection;
(u) A pathogenic bacterial infection;
(v) A cancer;
(w) An autoimmune disease or condition, eg, SLE;
(x) An inflammatory disease or condition, eg, rheumatoid arthritis, psoriasis, eczema, asthma, ulcerative colitis, colitis, Crohn's disease or IBD;
(y) Autism;
(z) ADHD;
(aa) Bipolar disorder;
(bb) ALS [Amyotrophic Lateral Sclerosis];
(cc) Osteoarthritis;
(dd) A congenital or development defect or condition;
(cc) Miscarriage;
(ft) A blood clotting condition;
(gg) Bronchitis;
(hh) Dry or wet AMD;
(ii) Neovascularisation (eg, of a tumour or in the eye);
Common cold;
(kk) Epilepsy;
(11) Fibrosis, eg, liver or lung fibrosis;
(mm) A fungal disease or condition, eg, thrush;
(nn) A metabolic disease or condition, eg, obesity, anorexia, diabetes, Type I or Type II diabetes.
(oo) Ulcer(s), eg, gastric ulceration or skin ulceration;
(pp) Dry skin;
(qq) Sjogren's syndrome;
(a) Cytokine storm;
(ss) Deafness, hearing loss or impairment;
(tt) Slow or fast metabolism (ie, slower or faster than average for the weight, sex and age of the subject);
(uu) Conception disorder, eg, infertility or low fertility;
(vv) Jaundice;
(ww) Skin rash;
(xx) Kawasaki Disease;
(yy) Lyme Disease;
(zz) An allergy, eg, a nut, grass, pollen, dust mite, cat or dog fur or dander allergy;
(aaa) Malaria, typhoid fever, tuberculosis or cholera;
(bbb) Depression;
(ccc) Mental retardation;
(ddd) Microcephaly;
(eee) Malnutrition;
(fff) Conjunctivitis;
(ggg) Pneumonia;
(hhh) Pulmonary embolism;
(iii) Pulmonary hypertension;
A bone disorder;
(kkk) Sepsis or septic shock;
(111) Sinusitus;
(mmm) Stress (eg, occupational stress);
(nnn) Thalassaemia, anaemia, von Willebrand Disease, or haemophilia;
(000) Shingles or cold sore;
(ppp) Menstruation;
(qqq) Low sperm count.
[0094] NEURODEGENERATIVE OR CNS DISEASES OR CONDITIONS FOR
TREATMENT OR PREVENTION BY THE INVENTION
[0095] In an example, the neurodegenerative or CNS disease or condition is selected from the group consisting of Alzheimer disease , geriopsychosis, Down syndrome, Parkinson's disease, Creutzfeldt-j akob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt- Jakob disease. For example, the disease is Alzheimer disease. For example, the disease is Parkinson syndrome.
[0096] In an example, wherein the method of the invention is practised on a human or animal subject for treating a CNS or neurodegenerative disease or condition, the method causes downregulation of Treg cells in the subject, thereby promoting entry of systemic monocyte-derived macrophages and/or Treg cells across the choroid plexus into the brain of the subject, whereby the disease or condition (eg, Alzheimer's disease) is treated, prevented or progression thereof is reduced.
In an embodiment the method causes an increase of IFN-gamma in the CNS system (eg, in the brain and/or CSF) of the subject. In an example, the method restores nerve fibre and//or reduces the progression of nerve fibre damage. In an example, the method restores nerve myelin and//or reduces the progression of nerve myelin damage. In an example, the method of the invention treats or prevents a disease or condition disclosed in W02015136541 and/or the method can be used with any method disclosed in W02015136541 (the disclosure of this document is incorporated by reference herein in its entirety, eg, for providing disclosure of such methods, diseases, conditions and potential therapeutic agents that can be administered to the subject for effecting treatement and/or prevention of CNS and neurodegenerative diseases and conditions, eg, agents such as immune checkpoint inhibitors, eg, anti-PD-1, anti-PD-L1, anti-TIM3 or other antibodies disclosed therein).
[0097] CANCERS FOR TREATMENT OR PREVENTION BY THE METHOD
[0098] Cancers that may be treated include tumours that are not vascularized, or not substantially vascularized, as well as vascularized tumours. The cancers may comprise non-solid tumours (such as haematological tumours, for example, leukaemias and lymphomas) or may comprise solid tumours.
Types of cancers to be treated with the invention include, but are not limited to, carcinoma, blastoma, and sarcoma, and certain leukaemia or lymphoid malignancies, benign and malignant tumours, and malignancies e.g., sarcomas, carcinomas, and melanomas. Adult tumours/cancers and paediatric tumours/cancers are also included.
[0099] Haematologic cancers are cancers of the blood or bone marrow. Examples of haematological (or haematogenous) cancers include leukaemias, including acute leukaemias (such as acute lymphocytic leukaemia, acute myelocytic leukaemia, acute myelogenous leukaemia and myeloblasts, promyeiocytic, myelomonocytic, monocytic and erythroleukaemia), chronic leukaemias (such as chronic myelocytic (granulocytic) leukaemia, chronic myelogenous leukaemia, and chronic lymphocytic leukaemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and high grade forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myeiodysplastic syndrome, hairy cell leukaemia and myelodysplasia.
[00100] Solid tumours are abnormal masses of tissue that usually do not contain cysts or liquid areas.
Solid tumours can be benign or malignant. Different types of solid tumours are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumours, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumour, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous eel!
carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumour, cervical cancer, testicular tumour, seminoma, bladder carcinoma, melanoma, and CNS tumours (such as a glioma (such as brainstem glioma and mixed gliomas), glioblastoma (also known as glioblastoma multiforme) astrocytoma, CNS lymphoma, germinoma, medu!loblastoma, Schwannoma craniopharyogioma, ependymoma, pineaioma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, neuroblastoma, retinoblastoma and brain metastases).
[00101] AUTOIMMUNE DISEASES FOR TREATMENT OR PREVENTION BY THE
METHOD
1. Acute Disseminated Encephalomyelitis (ADEM) 2. Acute necrotizing hemorrhagic leukoencephalitis 3. Addison's disease 4. Agammaglobulinemia 5. Alopecia areata 6. Amyloidosis 7. Ankylosing spondylitis 8. Anti-GBM/Anti-TBM nephritis 9. Antiphospholipid syndrome (APS) 10. Autoimmune angioedema 11. Autoimmune aplastic anemia 12. Autoimmune dysautonomia 13. Autoimmune hepatitis 14. Autoimmune hyperlipidemia 15. Autoimmune immunodeficiency 16. Autoimmune inner ear disease (AIED) 17. Autoimmune myocarditis 18. Autoimmune oophoritis 19. Autoimmune pancreatitis 20. Autoimmune retinopathy 21. Autoimmune thrombocytopenic putpura (ATP) 22. Autoimmune thyroid disease 23. Autoimmune urticaria 24. Axonal & neuronal neuropathies 25. Balo disease 26. Behcet's disease 27. Bullous pemphigoid 28. Cardiomyopathy 29. Castleman disease 30. Celiac disease 31. Chagas disease 32. Chronic fatigue syndrome 33. Chronic inflammatory demvelinating polyneuropathv (CIDP) 34. Chronic recurrent multifocal ostomvelitis (CRMO) 35. Churg-Strauss syndrome 36. Cicatricial pemphigoid/benign mucosal pemphigoid 37. Crohn's disease 38. Cogans syndrome 39. Cold agglutinin disease 40. Congenital heart block 41. Coxsackie mvocarditis 42. CREST disease 43. Essential mixed cryoglobulincm i a 44. Demyelinating neuropathics 45. Dermatitis herpetiformis 46. Dermatomyositis 47. Devic's disease (neuromyelitis optica) 48. Discoid lupus 49. Dressler's syndrome 50. Endometriosis 51. Eosinophilic esophagitis 52. Eosinophilic fasciitis 53. Erythema nodosum 54. Experimental allergic encephalomyelitis 55. Evans syndrome 56. Fibromyalgia 57. Fibrosing alveolitis 58. Giant cell arteritis (temporal artcritis) 59. Giant cell myocarditis 60. Glomerulonephritis 61. Goodpasture's syndrome 62. Granulomatosis with Polyangiitis (GPM (formerly called Wegener's Granulomatosis) 63. Graves' disease 64. Guillain-Barre syndrome 65. Hashimoto's encephalitis 66. Hashimoto's thyroiditis 67. Hemolytic anemia 68. Hcnoch-Schonlein putpura 69. Herpes gestationis 70. Hvpogammaglobulinemia 71. Idiopathic thrombocvtopenic purpura (ITP) 72. IgA nephropathy 73. IgG4-related sclerosing disease 74. Immunoregulatoty lipoproteins 75. Inclusion body myositis 76. Interstitial cystitis 77. Juvenile arthritis 78. Juvenile diabetes (Type 1 diabetes) 79. Juvenile myositis 80. Kawasaki syndrome 81. Lambert-Eaton syndrome 82. Leukocvtoclastic vasculitis 83. Lichen planus 84. Lichen sclerosus 85. Ligneous conjunctivitis 86. Linear IgA disease (LAD) 87. Lupus (SLE) 88. Lyme disease, chronic 89. Meniere's disease 90. Microscopic polyangiitis 91. Mixed connective tissue disease (MCTD) 92. Mooren's ulcer 93. Mucha-Habermann disease 94. Multiple sclerosis 95. Myasthenia gravis 96. Myositis 97. Narcolepsy 98. Neuromvelitis optica (Devic's) 99. Neutropenia 100. Ocular cicatricial pemphigoid 101. Optic neuritis 102. Palindromic rheumatism 103. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus) 104. Paraneoplastic cerebellar degeneration 105. Paroxysmal nocturnal hemoglobinuria (PNH) 106. Parry Romberg syndrome 107. Parsonnage-Turner syndrome 108. Pars planitis (peripheral uveitis) 109. Pemphigus 110. Peripheral neuropathy 111. Perivenous encephalomyelitis 112. Pernicious anemia 113. POEMS syndrome 114. Polyarteritis nodosa 115. Type I. H. & III autoimmune polvglandular syndromes 116. Polvinyalgia rheumatica 117. Polymyositis 118. Postmvocardial infarction syndrome 119. Postpericardiotomv syndrome
120. Progesterone dermatitis
121. Primary biliary cirrhosis
122. Primary sclerosing cholangitis
123. Psoriasis
124. Psoriatic arthritis
125. Idiopathic pulmonary fibrosis
126. Pyoderma gangrenosum
127. Pure red cell aplasia
128. Raynauds phenomenon
129. Reactive Arthritis
130. Reflex sympathetic dystrophy
131. Reiter's syndrome
132. Relapsing polvchondritis
133. Restless legs syndrome
134. Retroperitoneal fibrosis
135. Rheumatic fever
136. Rheumatoid arthritis
137. Sarcoidosis
138. Schmidt syndrome
139. Scleritis
140. Scleroderma
141. Sjogren's syndrome
142. Sperm & testicular autoimmunity
143. Stiff person syndrome
144. Subacute bacterial endocarditis (SBE)
145. Susac's syndrome
146. Sympathetic ophthalmia
147. Takayasu's arteritis
148. Temporal arteritis/Giant cell arteritis
149. Thrombocytopenic purpura (TTP)
150. Tolosa-Hunt syndrome
151. Transverse myelitis
152. Type 1 diabetes
153. Ulcerative colitis
154. Undifferentiated connective tissue disease (UCTD)
155. Uveitis
156. Vasculitis
157. Vesiculobullous dermatosis
158. Vitiligo
159. Wegener's granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).
[00102] INFLAMMATORY DISEASES FOR TREATMENT OR PREVENTION BY THE
METHOD
1. Alzheimer 2. ankylosing spondylitis 3. arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis) 4. asthma 5. atherosclerosis 6. Crohn's disease 7. colitis 8. dermatitis 9. diverticulitis 10. fibromyalgia 11. hepatitis 12. irritable bowel syndrome (IBS) 13. systemic lupus erythematous (SLE) 14. nephritis 15. Parkinson's disease 16. ulcerative colitis.
[00103] PARAGRAPHS:
By way of example, the invention provides the following Paragraphs (which may optionally be combined with any of the disclosure above):-1. An antibacterial composition comprising a population of first phage, wherein the first phage require helper phage for replication of first phage particles, wherein the helper phage are capable of packaging first phage nucleic acid to produce first phage particles, wherein the first phage are different from the helper phage and the helper phage are incapable themselves of producing helper phage particles, wherein the first phage are capable of infecting target bacteria and each first phage comprises antibacterial means for killing bacteria.
2. The composition of Paragraph 1, wherein at least 95% of phage particles comprised by the composition are first phage particles.
Optionally, the composition comprises helper phage. Optionally, the composition comprises no more than 1 helper phage particle per 1 x 106 or more of phage particles.
Optionally, the composition comprises no more than 1 helper phage particle per 1 x 10' or more of phage particles. Optionally, the composition comprises no more than 1 helper phage particle per 1 x 109 or more of phage particles. Optionally, the composition comprises no more than 1 helper phage particle per 1 x 1010 or more of phage particles.
3. The composition of Paragraph 1 or 2, wherein each first phage comprises one or more components of a CRISPR/Cas system, wherein the component(s) comprise a DNA
sequence encoding a guide RNA (optionally a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria.
4. The composition of any preceding Paragraph, wherein each first phage genome is devoid of genes encoding phage proteins.
5. A composition according to any preceding Paragraph for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a helper phage genome, wherein in the cell the MGE is mobilised using proteins encoded by the helper phage and replication of helper phage is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent, wherein the MGE comprises a modified genomic island, modified pathogenicity island, SaPI (S aureus Pathogenicity Island), V
cholerae PLE (Phage-Like Inducible Chromosomal Island-Like Element) or E coli PLE.
6. A kit comprising (a) A first DNA; and (b) One or more second DNAs;
Wherein (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle comprising a copy of the first DNA;
(ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
(iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle;
and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into phage particles;
wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage (first phage) that comprise the first DNA, wherein the first phage require the second DNA for replication thereof to produce further first phage particles.
7. The kit of Paragraph 6, wherein the phage particle of (i) is capable of infecting a target bacterium, the phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation.
8. The kit of Paragraph 6, wherein the phage particle of (i) is capable of infecting a target bacterium, the phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, or wherein the NSI comprises a regulatory element that is operable in the target bacterium.
9. The kit of Paragraph 8, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genome, or downregulation thereof.
10. The kit of Paragraph 8, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of the target cell, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genome, or upregulation thereofy.
11. The kit of any one of Paragraphs 7, 8 or 9, wherein the NSI encodes a component of a CRISPR/Cas system that is toxic to the target bacterium.
12. The kit of any one of Paragraphs 7, 8 or 9, wherein the NSI comprises engineered antibacterial means for killing target bacteria.
13. The kit of any one of Paragraphs 6 to 12, wherein the packaged phage particle genome is devoid of genes encoding phage proteins.
14. The kit of any one of Paragraphs 6 to 13, wherein the first DNA
comprises none of the structural protein genes.
15. The kit of any one of Paragraphs 6 to 14, wherein the second DNA is devoid of a phage packaging signal.
16. The kit of any one of Paragraphs 6 to 15, wherein each signal is a pac or cos sequence, or is a homologue thereof.
17. The kit of any one of Paragraphs 6 to 16, wherein each signal comprises SEQ ID NO: 2 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99% identical thereto, or is a homologue from a different species.
18. An isolated DNA, wherein the DNA is a first DNA as defined in any one of Paragraphs 6 to 17.
19. The kit or DNA of any one of Paragraphs 6 to 18, wherein the first DNA
is comprised by a vector (optionally, a plasmid, phagemid or shuttle vector).
20. The kit or DNA of any one of Paragraphs 6 to 19, wherein the second DNA
is comprised by a vector (optionally a plasmid, phagemid or shuttle vector), helper phage (optionally a helper phagemid) or is integrated in the genome of a host bacterial cell.
21. A host bacterial cell comprising the first and second DNAs as defined in any one of Paragraphs 6 to 17, 19 and 20; or comprising the DNA of Paragraph 18, 19 or 20.
22. A method of producing a phage composition, the method comprising expressing in a cell of Paragraph 21 the phage proteins, wherein packaged first phage particles are produced that comprise the first DNA, wherein the first phage require the second DNA for replication thereof to produce further first phage; and optionally separating an amount of first phage from cellular material wherein an amount of purified phage is obtained.
In an example, the purified phage are mixed with a pharmaceutically-acceptable excipient, carrier or diluent (eg, an aqueous liquid or water) to produce a pharmaceutical composition.
In an example any composition or kit of the invention is in combination with a label or instructions for use to treat and/or prevent a disease or condition in a human; optionally wherein the label or instructions comprise a marketing authorisation number (eg, an FDA or EMA
authorisation number);
optionally wherein the kit comprises an injection pen or IV container that comprises the first DNA or first phage.
23. The method of Paragraph 22, comprising isolating the first phage particles.
24. A composition (eg, antibacterial composition, eg, for medcial use) comprising a population of first phage particles obtainable by the method of Paragraph 22 or 23.
In an example, the first phage particles are obtained by the method.
In an example, any composition of the invention comprises at least 1 x 103 first phage per ml or mg, such as when the composition is comprised by a fluid (eg, a liquid) or solid.
In an example, any composition of the invention comprises at least 1 x 104 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 105 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 106 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 107 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 10' first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 109 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1010 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1011 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1012 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1013 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1014 first phage per ml or mg.
In an example, any composition of the invention comprises up to 1 x 1014 first phage per ml or mg, such as when the composition is comprised by a fluid (eg, a liquid) or solid.
In an example, any composition of the invention comprises up to 1 x 1013 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 1012 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 1011 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 1010 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 109 first phage per ml or mg.
In an example, any composition of the invention comprises at least 1 x 103 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg, such as when the composition is comprised by a fluid (eg, a liquid) or solid. In an example, any composition of the invention comprises at least 1 x 104 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 105 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 106 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 107 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 108 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 109 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1010 to 1 x le, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1011 to 1 x le, 1 x 1011, 1 x 1012, 1 x 1013 or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1012 to 1 x le, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1013 to 1 x le, 1 x 1011, 1 x 1012, 1 x 1013 or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1014 to 1 x le, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg.
In an example, the composition comprises one or more doses of the first phage for administration to a subject for medical use, eg, to treat or prevent a disease or condition in the subject. In an example, the composition comprises a single dose. In an example, the composition comprises (or comprises at least) 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 doses. In an example, each dose is (or is at least) a 0.5, 1, 2, 3, 4, 5, 10, 20, 25, 30, 40, 50, 75, 100, 125, 200 or 250mg or ml dose comprising said phage (ie, the dose is said amount and comprises phage and an excipient, diluent or carrier for example).
In an example, the composition comprises one or more doses of the first phage for administration to a subject for non-medical use, eg, for agricultural use. In an example, the composition comprises a single dose. In an example, the composition comprises (or comprises at least) 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 doses. In an example, each dose is (or is at least) a 0.5, 1, 2, 3, 4, 5, 10, 20, 25, 30, 40, 50, 75, 100, 125, 200, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 10000, 50000, 100000 mg or ml dose comprising said phage (ie, the dose is said amount and comprises phage and an excipient, diluent or carrier for example). The dose may be dissolved or diluted in a solvent (eg, an aqueous solvent or water) before use for contacting with target bacteria. In an example 1 imperial gallon comprises one dose of the first phage, eg, for agricultural use, such as crop spraying, or for animal or livestock use, such as use as a beverage.
25. The method of Paragraph 22 or 23 or the composition of Paragraph 24, wherein the second DNA is comprised by helper phage DNA and less than 5% of total phage particles comprised by the composition are helper phage particles.
26.
The method or composition of any one of Paragraphs 22 to 24, wherein the second DNA is comprised by helper phage DNA and the composition comprises no more than 1 helper phage particle per 1 x 106 or more of phage particles.
This has been demonstrated in Example 3 and shown to be efficacious for target bacteria killing in Example 4. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 or more of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 10' or more of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 109 or more of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 1010 or more of phage particles.
In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 106 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 108 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 109 of phage particles.
In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 106 to 1 x 109 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 106 to 1 x 108 of phage particles. In an embodiment, the composition comprises no .. more than 1 helper phage particle per 1 x 106 to 1 x 107 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 to 1 x 109 of phage particles.
In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 to 1 x 108 of phage particles.
In an example, the proportion of helper phage is determined as plaque forming units (PFU), eg, PFU/ml of the phage composition comprising said number of phage particles. In example, the proportion of non-helper phage (ie, first phage) is determined as number of transduced units of target bacteria (TFU), eg, TFU/ml of the phage composition. PFU is determined on lawns of a susceptible indicator bacterium while TFU is determined in a transduction assay in which a culture of susceptible .. indicator bacteria is infected with the phage composition ensuring surplus of indicator cells (i.e. at a low multiplicity of infection (MOI < 0.01) and number of transduced cells are determined by plating on selective plates.
Thus, the composition may comprise one or more helper phage particles. The level of helper particles is, however, extremely low. This is beneficial as the composition is relatively pure (and useful, for example, therefore as a medicament). It is also useful as the chances of the first phage being replicated is extremely low, providing the advantages of dosing control of phage, containment of phage (eg, in a human or animal body or an environment), and the lack of phage replication reduces the chances of acquiring undesirable genes (eg, antibiotic resistance genes) by the phage.
27. The composition of any one of Paragraphs 1 to 5, the method of Paragraph 22, 23, 25 or 26 or the composition of Paragraph 24, 25 or 26, wherein each first phage particle comprises a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in a target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA
mediates target cell killing, or downregulation of target cell growth or propagation.
28. The method or composition of Paragraph 27, wherein the NSI encodes a component of a CRISPR/Cas system that is toxic to target cells.
29. The method or composition of Paragraph 28, wherein the component comprises (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR
array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
30. The method or composition of Paragraph 29, wherein the NSI encodes a Cas nuclease and a guide RNA of the system (or wherein the NSI encodes a Cas nuclease and a CRISPR array for producing guide RNA), wherein the guide RNA is capable of targeting the genome of target bacteria, wherein the guide RNA is capable of guiding the Cas in target cells to mediate target cell killing, or downregulation of target cell growth or propagation.
Optionally, the NSI encodes a Cas9, and a tracrRNA and a CRISPR array for producing guide RNA.
31. The method or composition of any one of Paragraphs 1 to 5 and 22 to 30, wherein the first phage particles comprise no phage structural protein genes.
32. The kit, DNA, method or composition of any preceding Paragraph, wherein the first DNA or first phage DNA is comprised by a high copy number plasmid.
Optionally, the first DNA or first phage DNA is comprised by a medium copy number plasmid.
The meaning of low, medium and high copy number on and plasmids is known to the skilled addressee and these are terms of art. As is known by the skilled person, copy number denotes the average number of plasmid copies per cell. For example, a low copy number plasmid is a plasmid that exists in from 1 to 10 copies per bacterial cell in which the plasmid is harboured; a medium copy number plasmid exists in from 11 to 50 (eg, 11 to 40 or 20 to 30 or 40) copies per cell; and a high copy number is >50 (eg, up to 100, 200, 250, 300, 400, 500, 600 or 700) copies per cell. In an example, the plasmid or vector comprising first DNA is a medium copy number plasmid or vector. In an example, the plasmid or vector comprising first DNA is a high copy number plasmid or vector. An example of common on and plasmids is shown in Table 7.
33. The method or composition of Paragraph 27 or any one of Paragraphs 28 to 32 when dependent from Paragraph 27, wherein the NSI comprises engineered antibacterial means for killing target bacteria.
34. The method of composition of Paragraph 33, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease 35. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for administration to a human or animal subject for medical use.
36. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the first phage are capable of infecting and killing the target cells, optionally wherein the infection is a gut microbiome infection.
Optionally, the target cells are E coli cells the first DNA is comprised by a high copy number plasmid.
In an example, the gut microbiome is an upper GI tract microbiome. In an example the target cells are comprised by the upper GI tract of the subject. In an example, the first phage are delivered to the upper GI tract of the subject.
In an example, the gut microbiome is a stomach or small intestine microbiome.
In an example the target cells are comprised by the stomach or small intestine of the subject.
In an example, the first phage are delivered to the stomach or small intestine of the subject.
37. The composition of Paragraph 33 or 34 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by target bacteria and the target bacteria are comprised by the subject (optionally comprised by a gut microbiome), the method comprising administering the composition to the subject, whereby the target bacteria are exposed to the antibacterial means and killed and propagation of the first phage is contained.
38. A method of treating an environment ex vivo, the method comprising exposing the environment to a composition comprising a population of first phage particles, wherein the composition is obtainable by the method of any one of Paragraphs 22, 23 and 25 to 34, or the composition is according to any one of Paragraphs 1 to 5 and 24 to 34, wherein the environment comprises target bacteria and the first phage infect and kill the target bacteria.
39. The method of Paragraph 38, wherein the method is for containing the treatment in the environment.
40. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for controlling the dosing of the first phage treatment in the subject; or the method of Paragraph 38 or 39 for controlling the dosing of the first phage treatment in the environment.
41. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for reducing the risk of acquisition of foreign gene sequence(s) by the first phage in the subject; or the method of Paragraph 38 or 39 for reducing the risk of acquisition of foreign gene sequence(s) by the first phage in the environment.
CONCEPTS:
[00104] The invention provides the following Concepts, as exemplified by Example 6.
1. A host bacterial cell comprising c) A first DNA; and d) One or more second DNAs;
wherein (v) the DNAs together comprise all genes required to produce a transduction particle comprising a copy of the first DNA packaged by phage structural proteins;
(vi) the first DNA is devoid of at least one functional essential gene (eg, encoding a phage structural protein) required to produce the particle; and wherein the one or more second DNAs comprises said functional essential gene(s);
(vii) the first DNA comprises a phage packaging signal for producing the particle; and (viii) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
2. The cell of Concept 1, wherein the host bacterial cell comprises a) said first DNA; and b) said one or more second DNAs;
wherein (i) the DNAs together comprise encode all phage structural proteins required to produce a packaged transduction particle comprising a copy of the first DNA;
(ii) the first DNA encodes none or at least one, but not all, of the structural proteins; and wherein the one or more second DNAs encode the remainder of the structural proteins;
(iii) the first DNA comprises a phage packaging signal for producing the particle; and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
3. The cell of Concept 1, wherein (i) the first DNA is comprised by an episome (eg, a plasmid) that is devoid of said essential or structural protein gene(s) and/or the second DNA is comprised by an episome (eg, a plasmid) or a chromosome of the cell.
4. The cell of Concept 1, 2 or 3, wherein all of said essential genes or phage structural protein genes are comprised by the second DNA and the first DNA is devoid of said genes.
5. The cell of any preceding Concept, wherein the first DNA encodes a guided nuclease or a component of a CRISPR/Cas system (optionally, a crRNA or a guide RNA).
6. The cell of any preceding Concept, wherein the first DNA comprises a phage origin of replication and/or the first DNA comprises phage replication genes and/or phage lysis genes; and/or (ii) the first DNA comprises a phage origin of replication but no bacterial origin of replication.
7. The cell of any preceding Concept, wherein each transduction particle is a non-self replicative transduction particle.
8. The cell of any preceding Concept, wherein each particle comprises a phage tail fibre.
9. The cell of any preceding Concept, wherein the essential genes or structural protein genes;
and packaging signal are genes and a packaging signal of a tailed phage, eg, a P2, T4, T7, Phi92, lambda, K1-5 or 933w phage.
10. The cell of any preceding Concept, wherein the first DNA is comprised by a phage genome, wherein the phage genome is integrated in a plasmid; optionally wherein each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the NSI replaces the essential gene(s) or structural protein gene(s) of the phage.
11. The cell of any preceding Concept, wherein each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation; or (ii) wherein each particle is capable of infecting a target bacterium, the first DNA
comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, or wherein the NSI comprises a regulatory element that is operable in the target bacterium.
12. The cell of Concept 11, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genome, or downregulation thereof.
13. The kit of Concept 11, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of the target cell, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genome, or upregulation thereof.
14. The cell of any preceding Concept, wherein the packaging signal is a pac or cos sequence, or is a homologue thereof; or is a direct terminal repeat (DTR).
15. The cell of any preceding Concept, wherein the packaging signal comprises SEQ ID NO: 2 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99% identical thereto, or is a homologue from a different phage.
16. An isolated DNA, comprising a first DNA as defined in any preceding Concept; or comprising a second DNA as defined in any preceding Concept.
17. The first DNA or the second DNA of any one of Concepts 1 to 15, wherein the DNA is comprised by a plasmid.
18. The second DNA of Concept 16 or 17, wherein the DNA is comprised by a cell, wherein the cell does not comprise the first DNA.
19. A kit comprising a cell as recited in Concept 18, wherein the kit comprises a vector (optionally a plasmid) comprising the first DNA, wherein the vector is not comprised by the cell.
20. The kit of Concept 18 or 19, wherein the cell is a bacterial or archaeal cell.
21. A method of producing a transduction particle composition, the method comprising expressing in a cell of any one of Concepts 1 to 15 phage structural proteins and replicating the first DNA, wherein transduction particles are produced that comprise packaged first DNA; and optionally separating an amount of transduction particles from cellular material wherein an amount of purified transduction particles is obtained.
22. The method of Concept 21, comprising isolating transduction particles.
23. A composition comprising a population of transduction particles obtainable by the method of Concept 21 or 22.
24. The method of Concept 21 or 22 or the composition of Concept 23, wherein the second DNA
is comprised by plasmid DNA and less than 5% of total DNA comprised by the composition is DNA
of said plasmid.
25. The method or composition of any one of Concepts 21 to 24, wherein each transduction particle comprises a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in a target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation.
26. The method or composition of Concept 25, wherein the NSI encodes a guided nuclease or a component of a CRISPR/Cas system that is toxic to target cells.
27. The method or composition of Concept 26, wherein the component comprises (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR
array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
28. The method or composition of Concept 26, wherein the NSI encodes a Cas nuclease and a guide RNA of the system (or wherein the NSI encodes a Cas nuclease and a CRISPR array for producing guide RNA), wherein the guide RNA is capable of targeting the genome of target bacteria, wherein the guide RNA is capable of guiding the Cas in target cells to mediate target cell killing, or downregulation of target cell growth or propagation.
29. The method or composition of Concept 25, wherein the NSI comprises engineered antibacterial means for killing target bacteria.
30. The method or composition of Concept 29, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease 31. The cell of any one of Concepts 1 to 15, the DNA of any one of Concepts 16 to 18, or the composition of any one of Concepts 23 to 30 for administration to a human or animal subject for medical use.
32. The cell of any one of Concepts 1 to 15, the DNA of any one of Concepts 16 to 18, or the composition of any one of Concepts 23 to 30 for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the particles are capable of infecting and killing the target cells, optionally wherein the infection is a gut, blood, lung or uterine tract microbiome infection.
33. The composition of Concept 31 or 32 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by target bacteria and the target bacteria are comprised by the subject (optionally comprised by a gut, blood, lung or uterine tract microbiome), the method comprising administering the composition to the subject, whereby the target bacteria are exposed to antibacterial means encoded by the first DNA and killed, and propagation of the transduction particles is contained.
34. A method of treating an environment ex vivo, the method comprising exposing the environment to a composition comprising a population of particles, wherein the particles are capable of transducing first DNA into the target cells comprised by the environment, the first DNA encoding antibacterial means that is toxic to taraget cells whereby target cells are killed, wherein the composition is obtainable by the method of any one of Concepts 21, 22 and 24 to 30, or the composition is according to any one of Concepts 23 to 30.
35. The method of Concept 34, wherein the method is for containing the treatment in the environment.
36. The composition of any one of Concepts 23 to 30 for controlling in a human or animal subject the dosing of transduction particle treatment of a target bacterial cell infection in the subject, wherein the particles are capable of transducing first DNA into the target cells, the first DNA encoding antibacterial means that is toxic to taraget cells whereby target cells are killed; or the method of Concept 34 or 35 for controlling the dosing of the particle treatment in the environment.
37. The composition of any one of Concepts 23 to 30 for reducing in a human or animal subject the risk of acquisition of foreign gene sequence(s) by the particles in the subject; or the method of Concept 34 or 35 for reducing the risk of acquisition of foreign gene sequence(s) by the particles in the environment.
[00105] Optionally, each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium. For example, the NSI encodes an antimibacterial agent. For example, the NSI encodes a guided nuclease (eg, a Cas, TALEN, zinc finger nuclease or meganuclease). For example, the NSI
encodes a component of a CRISPR/Cas system. For example, the nuclease or system is operable in the target cell to cut a target nucleic acid (DNA or RNA) sequence comprised by the target cell (eg, comprised by a chromosome or episome thereof).
[00106] In an embodiment, an essential gene may be omitted from the first DNA, whereby the first .. DNA is devoid of the essential gene. In another embodiment, the first DNA
may comprise a mutant of the essential gene which does not provide the essential gene function (ie, this is not a functional essential gene). In another embodiment, first DNA may comprise a non-expressible form of the essential gene, eg, wherein a regulatory element of the gene has been deleted or mutated so that the gene does not function, eg, does not express its encoded protein.
.. [00107] Optionally, the essential genes are not phage terminase genes.
Optionally, the first DNA is not devoid of all phage terminase genes. Optionally, the first DNA is not devoid of phage structural protein genes. Optionally, the essential genes are not phage structural protein genes. Optionally, the essential genes are not phage terminase genes and not phage structural protein genes. Optionally, the first DNA does not comprise an origin of replication (on) operable in a bacterial host cell for .. replication of the first DNA (and optionally the first DNA further comprises a pahge orgin of replication).
[00108] Optionally, each particle comprises a tail fibre (eg, a tail fibre comprising one or more tail fibre domains of a wild-type phage).
[00109] Optionally, each particle comprises phage capsid proteins, a packaging signal (comprised by the first DNA) and optionally phage replication gene(s), wherein all of these components are proteins, packaging signal and gene(s) of the same phage (eg, a wild-type phage).
[00110] Optionally, each particle comprises phage capsid proteins, a packaging signal (comprised by the first DNA) and optionally phage replication gene(s), wherein the packaging signal and gene(s) are components of the same phage (eg, a wild-type phage) and the capsid proteins are proteins of a different phage (eg, a wild-type phage).
[00111] Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA
comprises all phage structural protein genes required for packaging first DNA
to produce particles, and for example the packaging signal is a packaging signal of a phage selected from a Caudovirales, Myovirideae, Podovirideae or Siphovirideae phage. Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA comprises all phage structural protein genes required for packaging first DNA to produce particles, and for example the packaging signal is a packaging signal of a phage selected from a P2, Phi92, T7, lambda, 933w, K1-5 and T4 phage.
[00112] Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA
comprises all phage structural protein genes required for packaging first DNA
to produce particles, and for example the phage structural protein genes of the second DNA ae genes of a phage selected from a Caudovirales, Myovirideae, Podovirideae or Siphovirideae phage. Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA comprises all phage structural protein genes required for packaging first DNA to produce particles, and for example the phage structural protein genes of the second DNA ae genes of a phage selected from a P2, Phi92, T7, lambda, 933w, K1-5 and T4 phage.
[00113] The essential or structural protein gene(s) and packaging signal may be structural protein genes and a packaging signal of a tailed phage. Alternatively, the essential or structural protein gene(s) and packaging signal may be essential or structural protein gene(s) and a packaging signal of a temperate phage. Alternatively, the essential or structural protein gene(s) and packaging signal may be essential or structural protein gene(s) and a packaging signal of a lytic phage.
[00114] Optionally, the essential or structural protein gene(s) and packaging signal may be essential or structural protein gene(s) and packaging signal of a P2, T4, T7, Phi92, lambda, K1-5 or 933w phage.
Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a tailed phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a Caudovirales phage.
Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a Myovirideae, Podovirideae or Siphovirideae phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a P2 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a T7 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a Phi92 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a lambda phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a 933w phage.
Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein .. genes and a packaging signal of a K1-5 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a T4 phage.
[00115] Optionally, any phage herein may be a tailed phage. Optionally, any phage herein may be a Caudovirales phage. Optionally, any phage herein may be a Myovirideae, Podovirideae or Siphovirideae phage.
Optionally, any phage herein may be a P2, T4, T7, Phi92, lambda, K1-5 or 933w phage. Optionally, any phage herein may be a P2 phage. Optionally, any phage herein may be a T7 phage.
Optionally, any phage herein may be a Phi92 phage. Optionally, any phage herein may be a lambda phage.
Optionally, any phage herein may be a 933w phage. Optionally, any phage herein may be a K1-5 phage. Optionally, any phage herein may be a T4 phage.
[00116] An essential gene as per the invention may be any nucleic acid sequence (not necessarily encoding a protein) that is required to produce the particle or a phage. In an example, an essential gene encodes a protein.
In an example, the essential gene(s) are not a packaging signal or phage origin of replication.
[00117] For example, each essential gene is selected from = a phage gene encoding a phage structural protein;
= a phage gene encoding a gene expression activator (eg, a RNA polymerase, such as a RNA
polymerase of coliphage T4, T3 or K1-5); gene Q (eg, gene Q of coliphage lambda); gene Rin (eg, Rin of staphylococcal phage NM1), gene ogr (eg, ogr of coliphage P2) or gene delta (eg, delta of coli satellite phage P4));
= a phage RNA metabolism gene (ie, encoding a protein that is comprised by RNA metabolism system of a phage);
= a phage DNA metabolism gene ie, encoding a protein that is comprised by DNA metabolism system of a phage);
= a phage DNA packaging gene (ie, encoding a protein that is comprised by DNA packaging .. system of a phage);
= a phage gene encoding a protein necessary for bacterial cell lysis.
[00118]For example, each essential gene is selected from the following P2 genes (function is given in brackets):
= Gene B (DNA replication);
= Gene Q (portal protein);
= Genes P and M (terminase);
= Genes 0, L and N (capsid);
= Genes X, R, S, v, W, J, I, H, G, Fl, FIT, E, E', T, U, D (tail and tail fiber);
= Genes X, Y, lysA, lysB, lysC (lysis cassette); and = Ogr (activator of late gene expression).
[00119]For example, each essential gene is selected from the following T7 genes (function is given in brackets):
= Gene 1 (RNA polymerase);
= Genes 1.3, 2.5, 3, 3.5, 4a, 5, 6 (DNA and RNA metabolism);
= Genes 6.7, 7.3, 8, 9, 10A, 10b, 14, 15, 16 (capsid and internal core);
= Genes 11, 12, 17 (tail);
= Genes 17.5, 18.5, 18.6, 18.6 (lysis); and = Genes 18 and 19 (terminase).
[00120] The phage is a virus that is capable of infecting a target bacterial cell or the transduction particle is capable of transducing a target bacterial cell, ie, is capable of introducing first DNA or a portion thereof into the target cell.
[00121] In an embodiment, the kit comprises a cell (eg, a bacterial cell) comprising the first and second DNAs. For example, the cell is a bacterial cell, the first DNA is comprised by an episome (eg, plasmid) that is devoid of said essential or structural protein gene(s) and the second DNA is comprised by a chromosome of the cell; and optionally all essential or phage structural protein genes are comprised by the second DNA and the first DNA and episome is devoid of said genes.
Optionally, the first DNA (or portion thereof) encodes a guided nuclease or a component of a CRISPR/Cas system (eg, a Cas, Cascade protein, crRNA, guide RNA or tracrRNA).
Optionally, the first DNA (or portion thereof) encodes a crRNA or a guide RNA.
[00122] Optionally, the first DNA comprises a phage origin of replication.
[00123] Optionally, the transduction particle is a non-self replicative transduction particle.
[00124] Optionally, the first DNA comprises phage replication genes and/or phage lysis genes.
[00125] Optionally, the phage or particle comprises a tail fibre, eg, a tail fibre (or domain thereof) of a wild-type phage that comprises the structural proteins.
[00126] In an alternative to a bacterial cell, the cell is an archaeal cell and the phage is a virus that is capable of infecting archaea or the transduction particle is capable of transducing archaea.
[00127] Optionally, a packaging signal herein is a pac or cos sequence, or is a homologue thereof; or a direct terminal repeat (DTR).
[00128] It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will be able to ascertain using no more than routine study, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. US Patent Application number 15/985,658, PCT/EP2018/082053, all publications and patent applications and all US equivalent patent applications and patents are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
[00105] As used in this specification and claim(s), the words "comprising"
(and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have"
and "has"), "including" (and any form of including, such as "includes" and "include") or "containing"
(and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[00106] The term "or combinations thereof" or similar as used herein refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
[00107] Any part of this disclosure may be read in combination with any other part of the disclosure, unless otherwise apparent from the context.
[00108] All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure.
While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
EXAMPLES
Example 1: Efficient phage CRISPR delivery vehicle production [00109] Background We designed a strategy for efficient production of phage particles comprising components of a CRISPR/Cas system for killing target E coli Nissle strain bacteria. So our phage composition will consist of a lysate primarily containing CRISPR/Cas system components packaged in phage particles which will be devoid of phage protein-encoding sequences and which will have no or a very low proportion of helper phage. Also the strategy will work alternatively in less well 79amster7979ius79 phage/bacterial strain combinations. Worked exemplification is provided in Examples 3 and 4.
[00110] Outline of strategy for CRISPR/Cas component packaging in hitherto unknown phages (a) Identify a high or medium copy number cloning/lshuttle vector (capable of cloning and propagation in a first E coli strain (cloning production strain) and then transfer to a second bacterial host strain of interest (target host strain)), the vector containing an E coli on for replication in the E coli cloning production strain;
(b) Isolate temperate phage against the target host (second) bacterium;
(c) To produce the cloning production strain, identify or engineer a phage production strain of the host target bacteria (or other bacteria) that has an inactive CRISPR/Cas system (eg, a repressed Cas3 or other nuclease) and/or lacks the target protospacer found in the second strain, and which can be infected and lysogenized with the temperate phage; or repress or inactivate the system in the production strain;
(d) In that production strain make a lysogen using the temperate phage (helper phage) .. and test that it can be induced;
(e) Identify the packaging sequence (pac or cos) using PhageTerm (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557969/) on whole genome sequenced phage;
Delete the pac/cos packaging signal sequence in the helper phage in the production strain bacteria;
(g) Incorporate the packaging signal in the shuttle vector along with a CRISPR-array or single gRNA-encoding sequence (and optionally other components of the CRISPR/Cas system, such as a Cas9-encoding nucleotide sequence and optionally tracrRNA-encoding sequence, or Cas3 and/or Cascade-encoding sequence);
(h) Transform the vector into production host strain;
(i) Induce (eg, UV or mitomycin C induce) and harvest phage comprising the CRISPR/Cas component(s). Alternatively, use a system with inducible RecA in trans to simulate SOS
(needs to be activated RecA).
[00111] Example of the above specifically for E coli Nissle using phage P2:
[00112] Nissle is useful due to its GRAS (Generally Regarded as Safe) status and P2 has a relatively broad host range (most E coli, Shigella, Klebsiella, Salmonella in 79amster79 to DNA delivery into e.g. Pseudomonas; Kahn et al 1991, "Bacteriophage P2 and P4", Methods in Enzymology, vol 204, pp264-280).
[00113]We will use pUC19 or other high or medium copy number cloning vector.
Temperate phage P2 can lysogenize Nissle. Most E coli K strains have an inactive CRISPR/Cas system and can be infected by P2 and thus all regular cloning hosts can be used (here exemplified by E coli TOP10).
[00114]P2 is introduced into TOP10 to produce a lysogen. P2 cannot be induced with mitomycin C or UV but we will use the epsilon anti-repressor from the parasite phage P4 that derepresses P2 and makes it go into lytic phase. We will express this gene from an inducible promoter in the production host strain.
[00115] The 325 bp packaging signal sequence of SEQ ID NO: 2 will be used.
[00116] The packaging sequence will be deleted in the P2 prophage of the lysogenic production TOP10 strain.
[00117] A pUC19 shuttle vector encoding a guide RNA that targets the genome of the target Nissle strain (or alternatively comprising a CRISPR array for producing such a guide RNA) will be constructed and the packaging signal SEQ ID NO: 2 will be added. If the target Nissle harbours its own endogenous CRISPR/Cas system, we will use an activation strategy to activate the endogenous Cas3 by including Cas activating genes in the vector. If not, we will include an exogenous Cas3-encoding nucleotide sequence (and optionally one or more nucleotide sequences encoding one or more required Cascade components) in the vector for expression in the target Nissle. We will transform the vector into the TOP10 production strain, induce the P4 anti-repressor and harvest phage comprising the CRISPR/Cas component(s).
[00118] Since the induced (helper) phage DNA does not contain a packaging signal we will be able to isolate particles with only the vector DNA packaged. Thus, we will obtain a composition comprising such phage which can be used to infect target Nissle E coli bacteria and introduce the CRISPR/Cas component(s) therein for killing the target bacteria.
Example 2: MGEs, Genomics Islands etc [00119] Overview of possible different MGE packaging strategies follow.
[00120] Applicable to different types of phages:
= Identify packaging signal and structural genes in the helper phage = Delete packaging signal in helper phage and place on plasmid comprising MGE
= Place both helper and plasmid in production strain = Induce structural gene transcription of helper to get production of helper-phage-packaged MGEs [00121]For using parasitic mobile elements (P4 phage or SaPI etc) activation of helper phage structural genes is done by induction of a helper phage activator obtained from the parasitic element Delta in P4 or one, more or al of ptiA/B/M in SaPI.
[00122]If one wants smaller size particles one can choose to package in a parasite-size capsid (typically 10-20 kb) by including in the MGE or vector P4 Sid and psu or cpmA/B from a SaPI.
[00123] One can use defective helper phages where at least the packaging signal has been removed and structural genes are either on a plasmid or integrated as a cryptic prophage in the production host.
If for some reason one cannot use this approach and need to use functional helper phages, one will include in the MGE or vector the genes on the parasite that hijack the phage packaging machinery to preferentially package parasite DNA (in our case CGVTM) over phage DNA.
[00124]List of the minimal genes one could include on a plasmid vector from P4.
[00125]P4 sequence: see https://www.ncbi.nlm.nih.gov/nuccore/x51522 [00126]Cos packaging site: SEQ ID NO: 3 [00127] The homologous sequence between P2 and P4; this may be used as an alternative packaging signal in the MGE or vector: SQ ID NO: 4 [00128]For small capsid size (packages 11.4kb instead of 33.5 kb) Sid and/or Psu can be included in the MGE or vector:-Sid: SEQ ID NO: 5 Psu: SEQ ID NO: 6 [00129] To activate helper phage P2, Delta from P4 can be included in a host cell genome (provided separately in a host cell, not on the MGE or vector to be packaged) Delta: SEQ ID NO: 7 [00130] Minimum genes to include in the host chromosome/episome from P2.
P2 sequence (acc.number: NC_001895) [00131]Figure 1 shows the genetic map of P2 genome with non-essential genes boxed ¨ one, more or all of these can be excluded (but Cos is always deleted). Cos is deleted and preferably the whole region from int through Cos. This region may, for example, be swapped with a resistance marker while the orf30 and fun(Z) genes are left intact or may be deleted.
[00132] Thus in an embodiment of any aspect herein of the invention, int through to Cos (ie, including int and Cos) are omitted from the helper phage DNA or second DNA or a homologous region is omitted when different phage are used as the basis for the helper phage DNA or second DNA.
The sequences of various stretches of the P2 genome are as follows:-[00133]"Q" through "S": SEQ ID NO: 8 [00134]"V" through "G": SEQ ID NO: 9 [00135] "Fl" through "ogr": SEQ ID NO: 10 [00136]Minimal genes to include from a SaPI on a vector or MGE.
Several different SaPI systems exist. Figure 2 shows one of the well characterized SaPIs (SaPIbov1), which exploits phages phill or phi80a1pha as helper phage. SaPIbov 1 sequence (acc.number:
AF217235.1) Packaging signal [00137]If one uses a defective helper phage with deleted packaging signal one can use that signal from the helper phage and include it in the DNA to be packaged. An example from S. aureus phill (acc. Number: AF424781) is SEQ ID NO: 11.
[00138]For small capsid size (packages 15.8 kb instead of 43.6 kb), one can include cpmA and/or cpmB in the MGE or vector (SEQ ID Nos: 12 and 13).
[00139] To activate helper phage phill one can include one, more or all of ptiA, B and M (provided separately in the production host cell and not on the MGE or vector to be packaged) (SEQ ID Nos:
14-16).
[00140]Minimum genes to include in the host chromosome/episome from phill.
Phill sequence (acc.number: AF424781) [00141]gene #29 (terS) through gene #53 (lysin): SEQ ID NO: 17 [00142]A list of phage that work with SaPIs [00143] Different SaPIs are linked to different helper phages (see Table 2 below) [00144] One can mutate the helper phage to only contain structural genes to direct the phage to package in smaller capsids. If only looking at the genes responsible for small capsid packaging (cpmA
and cpmB) these are highly conserved among staphylococci indicating that they will function to redirect packaging in a variety of phages broader than the list below (Table 2).
Example 3: Design, construction and in vitro efficacy of a synthetic transduction particle delivery platform Executive summary [00145] SA100 is a synthetic DNA delivery vehicle comprising non-self-replicative transduction particles comprising phage coat proteins packaging DNA plasmids that comprise nucleic acid sequences endoding CRISPR/Cas components, wherein the particles are capable of infecting target E
coli host cells to introduce the DNAs therein. Introduced DNAs are then able to be used in the host cells to produce the components. We call such DNAs CRISPR-Guided Vectors (CGVsTm). As shown in this example, we made such particles using a defective helper phage.
Upon production of the synthetic particles we obtain a pure synthetic lysate devoid of any phage nucleic acid encoding phage proteins. We show that this lysate is capable of very efficient delivery of a CGVTM to E. coli in vitro. The particles are non-self-replicative and require the helper phage for replication; thus usefully the lysate is pure and removes the possibility of replication of the particles containing the CGVTM.
This is useful to contain the action of the antibacterial, to allow for more controlled (eg, predetermined) dosing for administration to a human or animal subject or an environement for example, and the elimination of replication in the subject or environment reduces the chances of phage acquiring undesirable genes or traits from surrounding phage or bacteria (eg, undesirable antibiotic resistance genes) ¨ and even then the limitation of particle replication of the invention affords a way of reducing or eliminating spread of such genes or traits. This may be of interest to authorities such as the US FDA or USDA who consider such aspects when approving medicines or antibacterials for use in the environment.
Study objectives [00146] Objective 1: Design and engineer the fully synthetic phage-based CGV
delivery platform SA100.
[00147] Objective 2: Use SA100 to demonstrate CGV delivery to E.coli.
Materials and methods Bacterial strains and growth conditions [00148] We made a bacterial production strain for producing the synthetic SAE100 transduction partiles. E coli strain C-2323 harboring phage P2 was used as starting material for engineering our SA100/CGV production strain (gift from Gail E. Christie at the Virginia Commonwealth University).
Other strains used for testing SA100 and infectivity were EMG-2, C-la and C-1792, (purchased from the Coli Genetic Stock Center http://cgsc2.bio1ogy.ya1e.edu/).
[00149] All bacterial cultures were grown in LB medium supplemented with 2mM
MgCl2. When appropriate, cultures were supplemented with 50 g/mL kanamycin or 50 g/mL
spectinomycin for selection of defective prophage and CGV, respectively. In SA100 infection studies, the medium was supplemented with 2.5 mM CaCl2 to aid adsorption of the SA100 particles to bacterial cells. For induction of the CRISPR/Cas system, cells were exposed to 0.5mM IPTG and 2mM
theophylline.
Construction of defective helper prophage [00150] The pTK-red recombineering plasmid (p'72) was transformed in strain C-2323.
A KamR kanamycin marker gene was amplified using oligos with 50 bp homology to the regions of the P2 prophage immediately up- and downstream of the approximately 10 kbp region of P2 that we wanted to delete (see Figure 3). Following successful replacement of the desired region with the KanR marker gene, the thermosensitive pTK-red recombineering plasmid was cured.
Engineering CGV (p94) for packaging in the SA100 particles [00151] CGV p77 was constructed using plasmid p53 as a template. Plasmid p53 is a plasmid encoding components of a CRISPR/Cas system, the plasmid comprising nucleic acid sequences endoding a tracrRNA and the Cas9 protein from Streptococcus pyogenes (SpCas).
Nucleic acid sequence for produing crRNAs was obtained, expression driven by a plac promoter. The two fragments were assembled using Gibson assembly (NEB E55 10S) and transformed into E. coli competent cells. Assembled p77 plasmid was verified by full sequencing.
[00152] p77 harboring the inducible CRISPR/Cas system was used as the backbone for insertion of a fragment comprising an arabinose inducible promoter transcribing the region sid through cos from the satellite phage P4 (Figure 3).
[00153] Both fragments were PCR amplified and cloned by restriction enzyme cloning. The resulting SA100 packable CGV (p94) was sequence verified.
Production of SA100 packaged CGVs [00154] CGV p94 was transformed into the previously constructed strain harboring the defective prophage thereby generating production strain #189.
[00155] The production strain was grown exponentially for approximately 10 generations in the presence of kanamycin and spectinomycin, ensuring balanced growth of the population. At optical density (0D600) of 1 the culture was induced with 1% arabinose and incubation was continued until optical density measurements were low and stable. After spinning away cell debris the lysate was filtered (0.45 tim) and stored at +4C until further use.
Transduction protocol to determine SA100 titers.
[00156] Determination of titers was done by mixing the SA100 lysate with a suitable bacterial strain ensuring at least 100-fold surplus of bacterial cells in presence of 2.5 mM
CaCl2. Following 30 min incubation, the bacteria were diluted and plated on LB containing spectinomycin for enumeration of bacteria that had received the p94 CGV by transduction. To verify purity of the SA100 lysate, undiluted lysate was spotted on a lawn of bacteria (C-1a) known to support P2 proliferation using standard soft-agar overlay. Absence of plaque formation was used to verify purity.
DNA delivery assay [00157] A transduction protocol was used in which the SA100 lysate was diluted before infecting the bacterial culture to obtain multiplicities of infection (MOT) ranging from 0.01 to 100 effectively spanning a 4 log-ratio of SA100 to bacterial cells.
[00158] Following 30 min infection in the presence of 2.5 mM CaCl2 the bacteria were enumerated on LB plates with and without spectinomycin selection for delivery of the p94 CGV. The obtained numbers were used to calculate the percentage of the population infected at a given MOT.
Results Design of the SA100 vehicle [00159] The overall design of the SA100 E. coli production strain harboring CGV and defective prophage is outlined schematically in Figure 4. We used the native E. coli phage P2 integrated as a prophage on the chromosome of the production strain as our starting material.
In the prophage, we deleted genes that are essential for phage to initiate and carry out its own proliferation thus generating a defective helper phage.
[00102] INFLAMMATORY DISEASES FOR TREATMENT OR PREVENTION BY THE
METHOD
1. Alzheimer 2. ankylosing spondylitis 3. arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis) 4. asthma 5. atherosclerosis 6. Crohn's disease 7. colitis 8. dermatitis 9. diverticulitis 10. fibromyalgia 11. hepatitis 12. irritable bowel syndrome (IBS) 13. systemic lupus erythematous (SLE) 14. nephritis 15. Parkinson's disease 16. ulcerative colitis.
[00103] PARAGRAPHS:
By way of example, the invention provides the following Paragraphs (which may optionally be combined with any of the disclosure above):-1. An antibacterial composition comprising a population of first phage, wherein the first phage require helper phage for replication of first phage particles, wherein the helper phage are capable of packaging first phage nucleic acid to produce first phage particles, wherein the first phage are different from the helper phage and the helper phage are incapable themselves of producing helper phage particles, wherein the first phage are capable of infecting target bacteria and each first phage comprises antibacterial means for killing bacteria.
2. The composition of Paragraph 1, wherein at least 95% of phage particles comprised by the composition are first phage particles.
Optionally, the composition comprises helper phage. Optionally, the composition comprises no more than 1 helper phage particle per 1 x 106 or more of phage particles.
Optionally, the composition comprises no more than 1 helper phage particle per 1 x 10' or more of phage particles. Optionally, the composition comprises no more than 1 helper phage particle per 1 x 109 or more of phage particles. Optionally, the composition comprises no more than 1 helper phage particle per 1 x 1010 or more of phage particles.
3. The composition of Paragraph 1 or 2, wherein each first phage comprises one or more components of a CRISPR/Cas system, wherein the component(s) comprise a DNA
sequence encoding a guide RNA (optionally a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria.
4. The composition of any preceding Paragraph, wherein each first phage genome is devoid of genes encoding phage proteins.
5. A composition according to any preceding Paragraph for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a helper phage genome, wherein in the cell the MGE is mobilised using proteins encoded by the helper phage and replication of helper phage is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent, wherein the MGE comprises a modified genomic island, modified pathogenicity island, SaPI (S aureus Pathogenicity Island), V
cholerae PLE (Phage-Like Inducible Chromosomal Island-Like Element) or E coli PLE.
6. A kit comprising (a) A first DNA; and (b) One or more second DNAs;
Wherein (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle comprising a copy of the first DNA;
(ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
(iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle;
and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into phage particles;
wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage (first phage) that comprise the first DNA, wherein the first phage require the second DNA for replication thereof to produce further first phage particles.
7. The kit of Paragraph 6, wherein the phage particle of (i) is capable of infecting a target bacterium, the phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation.
8. The kit of Paragraph 6, wherein the phage particle of (i) is capable of infecting a target bacterium, the phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, or wherein the NSI comprises a regulatory element that is operable in the target bacterium.
9. The kit of Paragraph 8, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genome, or downregulation thereof.
10. The kit of Paragraph 8, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of the target cell, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genome, or upregulation thereofy.
11. The kit of any one of Paragraphs 7, 8 or 9, wherein the NSI encodes a component of a CRISPR/Cas system that is toxic to the target bacterium.
12. The kit of any one of Paragraphs 7, 8 or 9, wherein the NSI comprises engineered antibacterial means for killing target bacteria.
13. The kit of any one of Paragraphs 6 to 12, wherein the packaged phage particle genome is devoid of genes encoding phage proteins.
14. The kit of any one of Paragraphs 6 to 13, wherein the first DNA
comprises none of the structural protein genes.
15. The kit of any one of Paragraphs 6 to 14, wherein the second DNA is devoid of a phage packaging signal.
16. The kit of any one of Paragraphs 6 to 15, wherein each signal is a pac or cos sequence, or is a homologue thereof.
17. The kit of any one of Paragraphs 6 to 16, wherein each signal comprises SEQ ID NO: 2 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99% identical thereto, or is a homologue from a different species.
18. An isolated DNA, wherein the DNA is a first DNA as defined in any one of Paragraphs 6 to 17.
19. The kit or DNA of any one of Paragraphs 6 to 18, wherein the first DNA
is comprised by a vector (optionally, a plasmid, phagemid or shuttle vector).
20. The kit or DNA of any one of Paragraphs 6 to 19, wherein the second DNA
is comprised by a vector (optionally a plasmid, phagemid or shuttle vector), helper phage (optionally a helper phagemid) or is integrated in the genome of a host bacterial cell.
21. A host bacterial cell comprising the first and second DNAs as defined in any one of Paragraphs 6 to 17, 19 and 20; or comprising the DNA of Paragraph 18, 19 or 20.
22. A method of producing a phage composition, the method comprising expressing in a cell of Paragraph 21 the phage proteins, wherein packaged first phage particles are produced that comprise the first DNA, wherein the first phage require the second DNA for replication thereof to produce further first phage; and optionally separating an amount of first phage from cellular material wherein an amount of purified phage is obtained.
In an example, the purified phage are mixed with a pharmaceutically-acceptable excipient, carrier or diluent (eg, an aqueous liquid or water) to produce a pharmaceutical composition.
In an example any composition or kit of the invention is in combination with a label or instructions for use to treat and/or prevent a disease or condition in a human; optionally wherein the label or instructions comprise a marketing authorisation number (eg, an FDA or EMA
authorisation number);
optionally wherein the kit comprises an injection pen or IV container that comprises the first DNA or first phage.
23. The method of Paragraph 22, comprising isolating the first phage particles.
24. A composition (eg, antibacterial composition, eg, for medcial use) comprising a population of first phage particles obtainable by the method of Paragraph 22 or 23.
In an example, the first phage particles are obtained by the method.
In an example, any composition of the invention comprises at least 1 x 103 first phage per ml or mg, such as when the composition is comprised by a fluid (eg, a liquid) or solid.
In an example, any composition of the invention comprises at least 1 x 104 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 105 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 106 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 107 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 10' first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 109 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1010 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1011 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1012 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1013 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1014 first phage per ml or mg.
In an example, any composition of the invention comprises up to 1 x 1014 first phage per ml or mg, such as when the composition is comprised by a fluid (eg, a liquid) or solid.
In an example, any composition of the invention comprises up to 1 x 1013 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 1012 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 1011 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 1010 first phage per ml or mg. In an example, any composition of the invention comprises up to 1 x 109 first phage per ml or mg.
In an example, any composition of the invention comprises at least 1 x 103 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg, such as when the composition is comprised by a fluid (eg, a liquid) or solid. In an example, any composition of the invention comprises at least 1 x 104 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 105 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 106 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 107 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 108 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 109 to 1 x 1010, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1010 to 1 x le, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1011 to 1 x le, 1 x 1011, 1 x 1012, 1 x 1013 or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1012 to 1 x le, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1013 to 1 x le, 1 x 1011, 1 x 1012, 1 x 1013 or 1 x 1014 first phage per ml or mg. In an example, any composition of the invention comprises at least 1 x 1014 to 1 x le, 1 x 1011, 1 x 1012, 1 x 10" or 1 x 1014 first phage per ml or mg.
In an example, the composition comprises one or more doses of the first phage for administration to a subject for medical use, eg, to treat or prevent a disease or condition in the subject. In an example, the composition comprises a single dose. In an example, the composition comprises (or comprises at least) 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 doses. In an example, each dose is (or is at least) a 0.5, 1, 2, 3, 4, 5, 10, 20, 25, 30, 40, 50, 75, 100, 125, 200 or 250mg or ml dose comprising said phage (ie, the dose is said amount and comprises phage and an excipient, diluent or carrier for example).
In an example, the composition comprises one or more doses of the first phage for administration to a subject for non-medical use, eg, for agricultural use. In an example, the composition comprises a single dose. In an example, the composition comprises (or comprises at least) 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 doses. In an example, each dose is (or is at least) a 0.5, 1, 2, 3, 4, 5, 10, 20, 25, 30, 40, 50, 75, 100, 125, 200, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 10000, 50000, 100000 mg or ml dose comprising said phage (ie, the dose is said amount and comprises phage and an excipient, diluent or carrier for example). The dose may be dissolved or diluted in a solvent (eg, an aqueous solvent or water) before use for contacting with target bacteria. In an example 1 imperial gallon comprises one dose of the first phage, eg, for agricultural use, such as crop spraying, or for animal or livestock use, such as use as a beverage.
25. The method of Paragraph 22 or 23 or the composition of Paragraph 24, wherein the second DNA is comprised by helper phage DNA and less than 5% of total phage particles comprised by the composition are helper phage particles.
26.
The method or composition of any one of Paragraphs 22 to 24, wherein the second DNA is comprised by helper phage DNA and the composition comprises no more than 1 helper phage particle per 1 x 106 or more of phage particles.
This has been demonstrated in Example 3 and shown to be efficacious for target bacteria killing in Example 4. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 or more of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 10' or more of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 109 or more of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 1010 or more of phage particles.
In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 106 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 108 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 109 of phage particles.
In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 106 to 1 x 109 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 106 to 1 x 108 of phage particles. In an embodiment, the composition comprises no .. more than 1 helper phage particle per 1 x 106 to 1 x 107 of phage particles. In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 to 1 x 109 of phage particles.
In an embodiment, the composition comprises no more than 1 helper phage particle per 1 x 107 to 1 x 108 of phage particles.
In an example, the proportion of helper phage is determined as plaque forming units (PFU), eg, PFU/ml of the phage composition comprising said number of phage particles. In example, the proportion of non-helper phage (ie, first phage) is determined as number of transduced units of target bacteria (TFU), eg, TFU/ml of the phage composition. PFU is determined on lawns of a susceptible indicator bacterium while TFU is determined in a transduction assay in which a culture of susceptible .. indicator bacteria is infected with the phage composition ensuring surplus of indicator cells (i.e. at a low multiplicity of infection (MOI < 0.01) and number of transduced cells are determined by plating on selective plates.
Thus, the composition may comprise one or more helper phage particles. The level of helper particles is, however, extremely low. This is beneficial as the composition is relatively pure (and useful, for example, therefore as a medicament). It is also useful as the chances of the first phage being replicated is extremely low, providing the advantages of dosing control of phage, containment of phage (eg, in a human or animal body or an environment), and the lack of phage replication reduces the chances of acquiring undesirable genes (eg, antibiotic resistance genes) by the phage.
27. The composition of any one of Paragraphs 1 to 5, the method of Paragraph 22, 23, 25 or 26 or the composition of Paragraph 24, 25 or 26, wherein each first phage particle comprises a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in a target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA
mediates target cell killing, or downregulation of target cell growth or propagation.
28. The method or composition of Paragraph 27, wherein the NSI encodes a component of a CRISPR/Cas system that is toxic to target cells.
29. The method or composition of Paragraph 28, wherein the component comprises (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR
array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
30. The method or composition of Paragraph 29, wherein the NSI encodes a Cas nuclease and a guide RNA of the system (or wherein the NSI encodes a Cas nuclease and a CRISPR array for producing guide RNA), wherein the guide RNA is capable of targeting the genome of target bacteria, wherein the guide RNA is capable of guiding the Cas in target cells to mediate target cell killing, or downregulation of target cell growth or propagation.
Optionally, the NSI encodes a Cas9, and a tracrRNA and a CRISPR array for producing guide RNA.
31. The method or composition of any one of Paragraphs 1 to 5 and 22 to 30, wherein the first phage particles comprise no phage structural protein genes.
32. The kit, DNA, method or composition of any preceding Paragraph, wherein the first DNA or first phage DNA is comprised by a high copy number plasmid.
Optionally, the first DNA or first phage DNA is comprised by a medium copy number plasmid.
The meaning of low, medium and high copy number on and plasmids is known to the skilled addressee and these are terms of art. As is known by the skilled person, copy number denotes the average number of plasmid copies per cell. For example, a low copy number plasmid is a plasmid that exists in from 1 to 10 copies per bacterial cell in which the plasmid is harboured; a medium copy number plasmid exists in from 11 to 50 (eg, 11 to 40 or 20 to 30 or 40) copies per cell; and a high copy number is >50 (eg, up to 100, 200, 250, 300, 400, 500, 600 or 700) copies per cell. In an example, the plasmid or vector comprising first DNA is a medium copy number plasmid or vector. In an example, the plasmid or vector comprising first DNA is a high copy number plasmid or vector. An example of common on and plasmids is shown in Table 7.
33. The method or composition of Paragraph 27 or any one of Paragraphs 28 to 32 when dependent from Paragraph 27, wherein the NSI comprises engineered antibacterial means for killing target bacteria.
34. The method of composition of Paragraph 33, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease 35. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for administration to a human or animal subject for medical use.
36. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the first phage are capable of infecting and killing the target cells, optionally wherein the infection is a gut microbiome infection.
Optionally, the target cells are E coli cells the first DNA is comprised by a high copy number plasmid.
In an example, the gut microbiome is an upper GI tract microbiome. In an example the target cells are comprised by the upper GI tract of the subject. In an example, the first phage are delivered to the upper GI tract of the subject.
In an example, the gut microbiome is a stomach or small intestine microbiome.
In an example the target cells are comprised by the stomach or small intestine of the subject.
In an example, the first phage are delivered to the stomach or small intestine of the subject.
37. The composition of Paragraph 33 or 34 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by target bacteria and the target bacteria are comprised by the subject (optionally comprised by a gut microbiome), the method comprising administering the composition to the subject, whereby the target bacteria are exposed to the antibacterial means and killed and propagation of the first phage is contained.
38. A method of treating an environment ex vivo, the method comprising exposing the environment to a composition comprising a population of first phage particles, wherein the composition is obtainable by the method of any one of Paragraphs 22, 23 and 25 to 34, or the composition is according to any one of Paragraphs 1 to 5 and 24 to 34, wherein the environment comprises target bacteria and the first phage infect and kill the target bacteria.
39. The method of Paragraph 38, wherein the method is for containing the treatment in the environment.
40. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for controlling the dosing of the first phage treatment in the subject; or the method of Paragraph 38 or 39 for controlling the dosing of the first phage treatment in the environment.
41. The composition of any one of Paragraphs 1 to 5 and 24 to 34 for reducing the risk of acquisition of foreign gene sequence(s) by the first phage in the subject; or the method of Paragraph 38 or 39 for reducing the risk of acquisition of foreign gene sequence(s) by the first phage in the environment.
CONCEPTS:
[00104] The invention provides the following Concepts, as exemplified by Example 6.
1. A host bacterial cell comprising c) A first DNA; and d) One or more second DNAs;
wherein (v) the DNAs together comprise all genes required to produce a transduction particle comprising a copy of the first DNA packaged by phage structural proteins;
(vi) the first DNA is devoid of at least one functional essential gene (eg, encoding a phage structural protein) required to produce the particle; and wherein the one or more second DNAs comprises said functional essential gene(s);
(vii) the first DNA comprises a phage packaging signal for producing the particle; and (viii) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
2. The cell of Concept 1, wherein the host bacterial cell comprises a) said first DNA; and b) said one or more second DNAs;
wherein (i) the DNAs together comprise encode all phage structural proteins required to produce a packaged transduction particle comprising a copy of the first DNA;
(ii) the first DNA encodes none or at least one, but not all, of the structural proteins; and wherein the one or more second DNAs encode the remainder of the structural proteins;
(iii) the first DNA comprises a phage packaging signal for producing the particle; and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA
into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
3. The cell of Concept 1, wherein (i) the first DNA is comprised by an episome (eg, a plasmid) that is devoid of said essential or structural protein gene(s) and/or the second DNA is comprised by an episome (eg, a plasmid) or a chromosome of the cell.
4. The cell of Concept 1, 2 or 3, wherein all of said essential genes or phage structural protein genes are comprised by the second DNA and the first DNA is devoid of said genes.
5. The cell of any preceding Concept, wherein the first DNA encodes a guided nuclease or a component of a CRISPR/Cas system (optionally, a crRNA or a guide RNA).
6. The cell of any preceding Concept, wherein the first DNA comprises a phage origin of replication and/or the first DNA comprises phage replication genes and/or phage lysis genes; and/or (ii) the first DNA comprises a phage origin of replication but no bacterial origin of replication.
7. The cell of any preceding Concept, wherein each transduction particle is a non-self replicative transduction particle.
8. The cell of any preceding Concept, wherein each particle comprises a phage tail fibre.
9. The cell of any preceding Concept, wherein the essential genes or structural protein genes;
and packaging signal are genes and a packaging signal of a tailed phage, eg, a P2, T4, T7, Phi92, lambda, K1-5 or 933w phage.
10. The cell of any preceding Concept, wherein the first DNA is comprised by a phage genome, wherein the phage genome is integrated in a plasmid; optionally wherein each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the NSI replaces the essential gene(s) or structural protein gene(s) of the phage.
11. The cell of any preceding Concept, wherein each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation; or (ii) wherein each particle is capable of infecting a target bacterium, the first DNA
comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, or wherein the NSI comprises a regulatory element that is operable in the target bacterium.
12. The cell of Concept 11, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genome, or downregulation thereof.
13. The kit of Concept 11, wherein the presence in the target bacterium of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of the target cell, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genome, or upregulation thereof.
14. The cell of any preceding Concept, wherein the packaging signal is a pac or cos sequence, or is a homologue thereof; or is a direct terminal repeat (DTR).
15. The cell of any preceding Concept, wherein the packaging signal comprises SEQ ID NO: 2 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99% identical thereto, or is a homologue from a different phage.
16. An isolated DNA, comprising a first DNA as defined in any preceding Concept; or comprising a second DNA as defined in any preceding Concept.
17. The first DNA or the second DNA of any one of Concepts 1 to 15, wherein the DNA is comprised by a plasmid.
18. The second DNA of Concept 16 or 17, wherein the DNA is comprised by a cell, wherein the cell does not comprise the first DNA.
19. A kit comprising a cell as recited in Concept 18, wherein the kit comprises a vector (optionally a plasmid) comprising the first DNA, wherein the vector is not comprised by the cell.
20. The kit of Concept 18 or 19, wherein the cell is a bacterial or archaeal cell.
21. A method of producing a transduction particle composition, the method comprising expressing in a cell of any one of Concepts 1 to 15 phage structural proteins and replicating the first DNA, wherein transduction particles are produced that comprise packaged first DNA; and optionally separating an amount of transduction particles from cellular material wherein an amount of purified transduction particles is obtained.
22. The method of Concept 21, comprising isolating transduction particles.
23. A composition comprising a population of transduction particles obtainable by the method of Concept 21 or 22.
24. The method of Concept 21 or 22 or the composition of Concept 23, wherein the second DNA
is comprised by plasmid DNA and less than 5% of total DNA comprised by the composition is DNA
of said plasmid.
25. The method or composition of any one of Concepts 21 to 24, wherein each transduction particle comprises a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in a target bacterium, wherein the presence in the target bacterium of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation.
26. The method or composition of Concept 25, wherein the NSI encodes a guided nuclease or a component of a CRISPR/Cas system that is toxic to target cells.
27. The method or composition of Concept 26, wherein the component comprises (i) a DNA
sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR
array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria;
(ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
28. The method or composition of Concept 26, wherein the NSI encodes a Cas nuclease and a guide RNA of the system (or wherein the NSI encodes a Cas nuclease and a CRISPR array for producing guide RNA), wherein the guide RNA is capable of targeting the genome of target bacteria, wherein the guide RNA is capable of guiding the Cas in target cells to mediate target cell killing, or downregulation of target cell growth or propagation.
29. The method or composition of Concept 25, wherein the NSI comprises engineered antibacterial means for killing target bacteria.
30. The method or composition of Concept 29, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease 31. The cell of any one of Concepts 1 to 15, the DNA of any one of Concepts 16 to 18, or the composition of any one of Concepts 23 to 30 for administration to a human or animal subject for medical use.
32. The cell of any one of Concepts 1 to 15, the DNA of any one of Concepts 16 to 18, or the composition of any one of Concepts 23 to 30 for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the particles are capable of infecting and killing the target cells, optionally wherein the infection is a gut, blood, lung or uterine tract microbiome infection.
33. The composition of Concept 31 or 32 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by target bacteria and the target bacteria are comprised by the subject (optionally comprised by a gut, blood, lung or uterine tract microbiome), the method comprising administering the composition to the subject, whereby the target bacteria are exposed to antibacterial means encoded by the first DNA and killed, and propagation of the transduction particles is contained.
34. A method of treating an environment ex vivo, the method comprising exposing the environment to a composition comprising a population of particles, wherein the particles are capable of transducing first DNA into the target cells comprised by the environment, the first DNA encoding antibacterial means that is toxic to taraget cells whereby target cells are killed, wherein the composition is obtainable by the method of any one of Concepts 21, 22 and 24 to 30, or the composition is according to any one of Concepts 23 to 30.
35. The method of Concept 34, wherein the method is for containing the treatment in the environment.
36. The composition of any one of Concepts 23 to 30 for controlling in a human or animal subject the dosing of transduction particle treatment of a target bacterial cell infection in the subject, wherein the particles are capable of transducing first DNA into the target cells, the first DNA encoding antibacterial means that is toxic to taraget cells whereby target cells are killed; or the method of Concept 34 or 35 for controlling the dosing of the particle treatment in the environment.
37. The composition of any one of Concepts 23 to 30 for reducing in a human or animal subject the risk of acquisition of foreign gene sequence(s) by the particles in the subject; or the method of Concept 34 or 35 for reducing the risk of acquisition of foreign gene sequence(s) by the particles in the environment.
[00105] Optionally, each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium. For example, the NSI encodes an antimibacterial agent. For example, the NSI encodes a guided nuclease (eg, a Cas, TALEN, zinc finger nuclease or meganuclease). For example, the NSI
encodes a component of a CRISPR/Cas system. For example, the nuclease or system is operable in the target cell to cut a target nucleic acid (DNA or RNA) sequence comprised by the target cell (eg, comprised by a chromosome or episome thereof).
[00106] In an embodiment, an essential gene may be omitted from the first DNA, whereby the first .. DNA is devoid of the essential gene. In another embodiment, the first DNA
may comprise a mutant of the essential gene which does not provide the essential gene function (ie, this is not a functional essential gene). In another embodiment, first DNA may comprise a non-expressible form of the essential gene, eg, wherein a regulatory element of the gene has been deleted or mutated so that the gene does not function, eg, does not express its encoded protein.
.. [00107] Optionally, the essential genes are not phage terminase genes.
Optionally, the first DNA is not devoid of all phage terminase genes. Optionally, the first DNA is not devoid of phage structural protein genes. Optionally, the essential genes are not phage structural protein genes. Optionally, the essential genes are not phage terminase genes and not phage structural protein genes. Optionally, the first DNA does not comprise an origin of replication (on) operable in a bacterial host cell for .. replication of the first DNA (and optionally the first DNA further comprises a pahge orgin of replication).
[00108] Optionally, each particle comprises a tail fibre (eg, a tail fibre comprising one or more tail fibre domains of a wild-type phage).
[00109] Optionally, each particle comprises phage capsid proteins, a packaging signal (comprised by the first DNA) and optionally phage replication gene(s), wherein all of these components are proteins, packaging signal and gene(s) of the same phage (eg, a wild-type phage).
[00110] Optionally, each particle comprises phage capsid proteins, a packaging signal (comprised by the first DNA) and optionally phage replication gene(s), wherein the packaging signal and gene(s) are components of the same phage (eg, a wild-type phage) and the capsid proteins are proteins of a different phage (eg, a wild-type phage).
[00111] Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA
comprises all phage structural protein genes required for packaging first DNA
to produce particles, and for example the packaging signal is a packaging signal of a phage selected from a Caudovirales, Myovirideae, Podovirideae or Siphovirideae phage. Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA comprises all phage structural protein genes required for packaging first DNA to produce particles, and for example the packaging signal is a packaging signal of a phage selected from a P2, Phi92, T7, lambda, 933w, K1-5 and T4 phage.
[00112] Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA
comprises all phage structural protein genes required for packaging first DNA
to produce particles, and for example the phage structural protein genes of the second DNA ae genes of a phage selected from a Caudovirales, Myovirideae, Podovirideae or Siphovirideae phage. Optionally, the first DNA is devoid of all phage structural protein genes and the second DNA comprises all phage structural protein genes required for packaging first DNA to produce particles, and for example the phage structural protein genes of the second DNA ae genes of a phage selected from a P2, Phi92, T7, lambda, 933w, K1-5 and T4 phage.
[00113] The essential or structural protein gene(s) and packaging signal may be structural protein genes and a packaging signal of a tailed phage. Alternatively, the essential or structural protein gene(s) and packaging signal may be essential or structural protein gene(s) and a packaging signal of a temperate phage. Alternatively, the essential or structural protein gene(s) and packaging signal may be essential or structural protein gene(s) and a packaging signal of a lytic phage.
[00114] Optionally, the essential or structural protein gene(s) and packaging signal may be essential or structural protein gene(s) and packaging signal of a P2, T4, T7, Phi92, lambda, K1-5 or 933w phage.
Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a tailed phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a Caudovirales phage.
Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a Myovirideae, Podovirideae or Siphovirideae phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a P2 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a T7 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a Phi92 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a lambda phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a 933w phage.
Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein .. genes and a packaging signal of a K1-5 phage. Optionally, the essential or structural protein genes and packaging signal may be essential or structural protein genes and a packaging signal of a T4 phage.
[00115] Optionally, any phage herein may be a tailed phage. Optionally, any phage herein may be a Caudovirales phage. Optionally, any phage herein may be a Myovirideae, Podovirideae or Siphovirideae phage.
Optionally, any phage herein may be a P2, T4, T7, Phi92, lambda, K1-5 or 933w phage. Optionally, any phage herein may be a P2 phage. Optionally, any phage herein may be a T7 phage.
Optionally, any phage herein may be a Phi92 phage. Optionally, any phage herein may be a lambda phage.
Optionally, any phage herein may be a 933w phage. Optionally, any phage herein may be a K1-5 phage. Optionally, any phage herein may be a T4 phage.
[00116] An essential gene as per the invention may be any nucleic acid sequence (not necessarily encoding a protein) that is required to produce the particle or a phage. In an example, an essential gene encodes a protein.
In an example, the essential gene(s) are not a packaging signal or phage origin of replication.
[00117] For example, each essential gene is selected from = a phage gene encoding a phage structural protein;
= a phage gene encoding a gene expression activator (eg, a RNA polymerase, such as a RNA
polymerase of coliphage T4, T3 or K1-5); gene Q (eg, gene Q of coliphage lambda); gene Rin (eg, Rin of staphylococcal phage NM1), gene ogr (eg, ogr of coliphage P2) or gene delta (eg, delta of coli satellite phage P4));
= a phage RNA metabolism gene (ie, encoding a protein that is comprised by RNA metabolism system of a phage);
= a phage DNA metabolism gene ie, encoding a protein that is comprised by DNA metabolism system of a phage);
= a phage DNA packaging gene (ie, encoding a protein that is comprised by DNA packaging .. system of a phage);
= a phage gene encoding a protein necessary for bacterial cell lysis.
[00118]For example, each essential gene is selected from the following P2 genes (function is given in brackets):
= Gene B (DNA replication);
= Gene Q (portal protein);
= Genes P and M (terminase);
= Genes 0, L and N (capsid);
= Genes X, R, S, v, W, J, I, H, G, Fl, FIT, E, E', T, U, D (tail and tail fiber);
= Genes X, Y, lysA, lysB, lysC (lysis cassette); and = Ogr (activator of late gene expression).
[00119]For example, each essential gene is selected from the following T7 genes (function is given in brackets):
= Gene 1 (RNA polymerase);
= Genes 1.3, 2.5, 3, 3.5, 4a, 5, 6 (DNA and RNA metabolism);
= Genes 6.7, 7.3, 8, 9, 10A, 10b, 14, 15, 16 (capsid and internal core);
= Genes 11, 12, 17 (tail);
= Genes 17.5, 18.5, 18.6, 18.6 (lysis); and = Genes 18 and 19 (terminase).
[00120] The phage is a virus that is capable of infecting a target bacterial cell or the transduction particle is capable of transducing a target bacterial cell, ie, is capable of introducing first DNA or a portion thereof into the target cell.
[00121] In an embodiment, the kit comprises a cell (eg, a bacterial cell) comprising the first and second DNAs. For example, the cell is a bacterial cell, the first DNA is comprised by an episome (eg, plasmid) that is devoid of said essential or structural protein gene(s) and the second DNA is comprised by a chromosome of the cell; and optionally all essential or phage structural protein genes are comprised by the second DNA and the first DNA and episome is devoid of said genes.
Optionally, the first DNA (or portion thereof) encodes a guided nuclease or a component of a CRISPR/Cas system (eg, a Cas, Cascade protein, crRNA, guide RNA or tracrRNA).
Optionally, the first DNA (or portion thereof) encodes a crRNA or a guide RNA.
[00122] Optionally, the first DNA comprises a phage origin of replication.
[00123] Optionally, the transduction particle is a non-self replicative transduction particle.
[00124] Optionally, the first DNA comprises phage replication genes and/or phage lysis genes.
[00125] Optionally, the phage or particle comprises a tail fibre, eg, a tail fibre (or domain thereof) of a wild-type phage that comprises the structural proteins.
[00126] In an alternative to a bacterial cell, the cell is an archaeal cell and the phage is a virus that is capable of infecting archaea or the transduction particle is capable of transducing archaea.
[00127] Optionally, a packaging signal herein is a pac or cos sequence, or is a homologue thereof; or a direct terminal repeat (DTR).
[00128] It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will be able to ascertain using no more than routine study, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. US Patent Application number 15/985,658, PCT/EP2018/082053, all publications and patent applications and all US equivalent patent applications and patents are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
[00105] As used in this specification and claim(s), the words "comprising"
(and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have"
and "has"), "including" (and any form of including, such as "includes" and "include") or "containing"
(and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[00106] The term "or combinations thereof" or similar as used herein refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
[00107] Any part of this disclosure may be read in combination with any other part of the disclosure, unless otherwise apparent from the context.
[00108] All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure.
While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
EXAMPLES
Example 1: Efficient phage CRISPR delivery vehicle production [00109] Background We designed a strategy for efficient production of phage particles comprising components of a CRISPR/Cas system for killing target E coli Nissle strain bacteria. So our phage composition will consist of a lysate primarily containing CRISPR/Cas system components packaged in phage particles which will be devoid of phage protein-encoding sequences and which will have no or a very low proportion of helper phage. Also the strategy will work alternatively in less well 79amster7979ius79 phage/bacterial strain combinations. Worked exemplification is provided in Examples 3 and 4.
[00110] Outline of strategy for CRISPR/Cas component packaging in hitherto unknown phages (a) Identify a high or medium copy number cloning/lshuttle vector (capable of cloning and propagation in a first E coli strain (cloning production strain) and then transfer to a second bacterial host strain of interest (target host strain)), the vector containing an E coli on for replication in the E coli cloning production strain;
(b) Isolate temperate phage against the target host (second) bacterium;
(c) To produce the cloning production strain, identify or engineer a phage production strain of the host target bacteria (or other bacteria) that has an inactive CRISPR/Cas system (eg, a repressed Cas3 or other nuclease) and/or lacks the target protospacer found in the second strain, and which can be infected and lysogenized with the temperate phage; or repress or inactivate the system in the production strain;
(d) In that production strain make a lysogen using the temperate phage (helper phage) .. and test that it can be induced;
(e) Identify the packaging sequence (pac or cos) using PhageTerm (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557969/) on whole genome sequenced phage;
Delete the pac/cos packaging signal sequence in the helper phage in the production strain bacteria;
(g) Incorporate the packaging signal in the shuttle vector along with a CRISPR-array or single gRNA-encoding sequence (and optionally other components of the CRISPR/Cas system, such as a Cas9-encoding nucleotide sequence and optionally tracrRNA-encoding sequence, or Cas3 and/or Cascade-encoding sequence);
(h) Transform the vector into production host strain;
(i) Induce (eg, UV or mitomycin C induce) and harvest phage comprising the CRISPR/Cas component(s). Alternatively, use a system with inducible RecA in trans to simulate SOS
(needs to be activated RecA).
[00111] Example of the above specifically for E coli Nissle using phage P2:
[00112] Nissle is useful due to its GRAS (Generally Regarded as Safe) status and P2 has a relatively broad host range (most E coli, Shigella, Klebsiella, Salmonella in 79amster79 to DNA delivery into e.g. Pseudomonas; Kahn et al 1991, "Bacteriophage P2 and P4", Methods in Enzymology, vol 204, pp264-280).
[00113]We will use pUC19 or other high or medium copy number cloning vector.
Temperate phage P2 can lysogenize Nissle. Most E coli K strains have an inactive CRISPR/Cas system and can be infected by P2 and thus all regular cloning hosts can be used (here exemplified by E coli TOP10).
[00114]P2 is introduced into TOP10 to produce a lysogen. P2 cannot be induced with mitomycin C or UV but we will use the epsilon anti-repressor from the parasite phage P4 that derepresses P2 and makes it go into lytic phase. We will express this gene from an inducible promoter in the production host strain.
[00115] The 325 bp packaging signal sequence of SEQ ID NO: 2 will be used.
[00116] The packaging sequence will be deleted in the P2 prophage of the lysogenic production TOP10 strain.
[00117] A pUC19 shuttle vector encoding a guide RNA that targets the genome of the target Nissle strain (or alternatively comprising a CRISPR array for producing such a guide RNA) will be constructed and the packaging signal SEQ ID NO: 2 will be added. If the target Nissle harbours its own endogenous CRISPR/Cas system, we will use an activation strategy to activate the endogenous Cas3 by including Cas activating genes in the vector. If not, we will include an exogenous Cas3-encoding nucleotide sequence (and optionally one or more nucleotide sequences encoding one or more required Cascade components) in the vector for expression in the target Nissle. We will transform the vector into the TOP10 production strain, induce the P4 anti-repressor and harvest phage comprising the CRISPR/Cas component(s).
[00118] Since the induced (helper) phage DNA does not contain a packaging signal we will be able to isolate particles with only the vector DNA packaged. Thus, we will obtain a composition comprising such phage which can be used to infect target Nissle E coli bacteria and introduce the CRISPR/Cas component(s) therein for killing the target bacteria.
Example 2: MGEs, Genomics Islands etc [00119] Overview of possible different MGE packaging strategies follow.
[00120] Applicable to different types of phages:
= Identify packaging signal and structural genes in the helper phage = Delete packaging signal in helper phage and place on plasmid comprising MGE
= Place both helper and plasmid in production strain = Induce structural gene transcription of helper to get production of helper-phage-packaged MGEs [00121]For using parasitic mobile elements (P4 phage or SaPI etc) activation of helper phage structural genes is done by induction of a helper phage activator obtained from the parasitic element Delta in P4 or one, more or al of ptiA/B/M in SaPI.
[00122]If one wants smaller size particles one can choose to package in a parasite-size capsid (typically 10-20 kb) by including in the MGE or vector P4 Sid and psu or cpmA/B from a SaPI.
[00123] One can use defective helper phages where at least the packaging signal has been removed and structural genes are either on a plasmid or integrated as a cryptic prophage in the production host.
If for some reason one cannot use this approach and need to use functional helper phages, one will include in the MGE or vector the genes on the parasite that hijack the phage packaging machinery to preferentially package parasite DNA (in our case CGVTM) over phage DNA.
[00124]List of the minimal genes one could include on a plasmid vector from P4.
[00125]P4 sequence: see https://www.ncbi.nlm.nih.gov/nuccore/x51522 [00126]Cos packaging site: SEQ ID NO: 3 [00127] The homologous sequence between P2 and P4; this may be used as an alternative packaging signal in the MGE or vector: SQ ID NO: 4 [00128]For small capsid size (packages 11.4kb instead of 33.5 kb) Sid and/or Psu can be included in the MGE or vector:-Sid: SEQ ID NO: 5 Psu: SEQ ID NO: 6 [00129] To activate helper phage P2, Delta from P4 can be included in a host cell genome (provided separately in a host cell, not on the MGE or vector to be packaged) Delta: SEQ ID NO: 7 [00130] Minimum genes to include in the host chromosome/episome from P2.
P2 sequence (acc.number: NC_001895) [00131]Figure 1 shows the genetic map of P2 genome with non-essential genes boxed ¨ one, more or all of these can be excluded (but Cos is always deleted). Cos is deleted and preferably the whole region from int through Cos. This region may, for example, be swapped with a resistance marker while the orf30 and fun(Z) genes are left intact or may be deleted.
[00132] Thus in an embodiment of any aspect herein of the invention, int through to Cos (ie, including int and Cos) are omitted from the helper phage DNA or second DNA or a homologous region is omitted when different phage are used as the basis for the helper phage DNA or second DNA.
The sequences of various stretches of the P2 genome are as follows:-[00133]"Q" through "S": SEQ ID NO: 8 [00134]"V" through "G": SEQ ID NO: 9 [00135] "Fl" through "ogr": SEQ ID NO: 10 [00136]Minimal genes to include from a SaPI on a vector or MGE.
Several different SaPI systems exist. Figure 2 shows one of the well characterized SaPIs (SaPIbov1), which exploits phages phill or phi80a1pha as helper phage. SaPIbov 1 sequence (acc.number:
AF217235.1) Packaging signal [00137]If one uses a defective helper phage with deleted packaging signal one can use that signal from the helper phage and include it in the DNA to be packaged. An example from S. aureus phill (acc. Number: AF424781) is SEQ ID NO: 11.
[00138]For small capsid size (packages 15.8 kb instead of 43.6 kb), one can include cpmA and/or cpmB in the MGE or vector (SEQ ID Nos: 12 and 13).
[00139] To activate helper phage phill one can include one, more or all of ptiA, B and M (provided separately in the production host cell and not on the MGE or vector to be packaged) (SEQ ID Nos:
14-16).
[00140]Minimum genes to include in the host chromosome/episome from phill.
Phill sequence (acc.number: AF424781) [00141]gene #29 (terS) through gene #53 (lysin): SEQ ID NO: 17 [00142]A list of phage that work with SaPIs [00143] Different SaPIs are linked to different helper phages (see Table 2 below) [00144] One can mutate the helper phage to only contain structural genes to direct the phage to package in smaller capsids. If only looking at the genes responsible for small capsid packaging (cpmA
and cpmB) these are highly conserved among staphylococci indicating that they will function to redirect packaging in a variety of phages broader than the list below (Table 2).
Example 3: Design, construction and in vitro efficacy of a synthetic transduction particle delivery platform Executive summary [00145] SA100 is a synthetic DNA delivery vehicle comprising non-self-replicative transduction particles comprising phage coat proteins packaging DNA plasmids that comprise nucleic acid sequences endoding CRISPR/Cas components, wherein the particles are capable of infecting target E
coli host cells to introduce the DNAs therein. Introduced DNAs are then able to be used in the host cells to produce the components. We call such DNAs CRISPR-Guided Vectors (CGVsTm). As shown in this example, we made such particles using a defective helper phage.
Upon production of the synthetic particles we obtain a pure synthetic lysate devoid of any phage nucleic acid encoding phage proteins. We show that this lysate is capable of very efficient delivery of a CGVTM to E. coli in vitro. The particles are non-self-replicative and require the helper phage for replication; thus usefully the lysate is pure and removes the possibility of replication of the particles containing the CGVTM.
This is useful to contain the action of the antibacterial, to allow for more controlled (eg, predetermined) dosing for administration to a human or animal subject or an environement for example, and the elimination of replication in the subject or environment reduces the chances of phage acquiring undesirable genes or traits from surrounding phage or bacteria (eg, undesirable antibiotic resistance genes) ¨ and even then the limitation of particle replication of the invention affords a way of reducing or eliminating spread of such genes or traits. This may be of interest to authorities such as the US FDA or USDA who consider such aspects when approving medicines or antibacterials for use in the environment.
Study objectives [00146] Objective 1: Design and engineer the fully synthetic phage-based CGV
delivery platform SA100.
[00147] Objective 2: Use SA100 to demonstrate CGV delivery to E.coli.
Materials and methods Bacterial strains and growth conditions [00148] We made a bacterial production strain for producing the synthetic SAE100 transduction partiles. E coli strain C-2323 harboring phage P2 was used as starting material for engineering our SA100/CGV production strain (gift from Gail E. Christie at the Virginia Commonwealth University).
Other strains used for testing SA100 and infectivity were EMG-2, C-la and C-1792, (purchased from the Coli Genetic Stock Center http://cgsc2.bio1ogy.ya1e.edu/).
[00149] All bacterial cultures were grown in LB medium supplemented with 2mM
MgCl2. When appropriate, cultures were supplemented with 50 g/mL kanamycin or 50 g/mL
spectinomycin for selection of defective prophage and CGV, respectively. In SA100 infection studies, the medium was supplemented with 2.5 mM CaCl2 to aid adsorption of the SA100 particles to bacterial cells. For induction of the CRISPR/Cas system, cells were exposed to 0.5mM IPTG and 2mM
theophylline.
Construction of defective helper prophage [00150] The pTK-red recombineering plasmid (p'72) was transformed in strain C-2323.
A KamR kanamycin marker gene was amplified using oligos with 50 bp homology to the regions of the P2 prophage immediately up- and downstream of the approximately 10 kbp region of P2 that we wanted to delete (see Figure 3). Following successful replacement of the desired region with the KanR marker gene, the thermosensitive pTK-red recombineering plasmid was cured.
Engineering CGV (p94) for packaging in the SA100 particles [00151] CGV p77 was constructed using plasmid p53 as a template. Plasmid p53 is a plasmid encoding components of a CRISPR/Cas system, the plasmid comprising nucleic acid sequences endoding a tracrRNA and the Cas9 protein from Streptococcus pyogenes (SpCas).
Nucleic acid sequence for produing crRNAs was obtained, expression driven by a plac promoter. The two fragments were assembled using Gibson assembly (NEB E55 10S) and transformed into E. coli competent cells. Assembled p77 plasmid was verified by full sequencing.
[00152] p77 harboring the inducible CRISPR/Cas system was used as the backbone for insertion of a fragment comprising an arabinose inducible promoter transcribing the region sid through cos from the satellite phage P4 (Figure 3).
[00153] Both fragments were PCR amplified and cloned by restriction enzyme cloning. The resulting SA100 packable CGV (p94) was sequence verified.
Production of SA100 packaged CGVs [00154] CGV p94 was transformed into the previously constructed strain harboring the defective prophage thereby generating production strain #189.
[00155] The production strain was grown exponentially for approximately 10 generations in the presence of kanamycin and spectinomycin, ensuring balanced growth of the population. At optical density (0D600) of 1 the culture was induced with 1% arabinose and incubation was continued until optical density measurements were low and stable. After spinning away cell debris the lysate was filtered (0.45 tim) and stored at +4C until further use.
Transduction protocol to determine SA100 titers.
[00156] Determination of titers was done by mixing the SA100 lysate with a suitable bacterial strain ensuring at least 100-fold surplus of bacterial cells in presence of 2.5 mM
CaCl2. Following 30 min incubation, the bacteria were diluted and plated on LB containing spectinomycin for enumeration of bacteria that had received the p94 CGV by transduction. To verify purity of the SA100 lysate, undiluted lysate was spotted on a lawn of bacteria (C-1a) known to support P2 proliferation using standard soft-agar overlay. Absence of plaque formation was used to verify purity.
DNA delivery assay [00157] A transduction protocol was used in which the SA100 lysate was diluted before infecting the bacterial culture to obtain multiplicities of infection (MOT) ranging from 0.01 to 100 effectively spanning a 4 log-ratio of SA100 to bacterial cells.
[00158] Following 30 min infection in the presence of 2.5 mM CaCl2 the bacteria were enumerated on LB plates with and without spectinomycin selection for delivery of the p94 CGV. The obtained numbers were used to calculate the percentage of the population infected at a given MOT.
Results Design of the SA100 vehicle [00159] The overall design of the SA100 E. coli production strain harboring CGV and defective prophage is outlined schematically in Figure 4. We used the native E. coli phage P2 integrated as a prophage on the chromosome of the production strain as our starting material.
In the prophage, we deleted genes that are essential for phage to initiate and carry out its own proliferation thus generating a defective helper phage.
[00160] We then placed expression of the structural genes needed to produce SA100 transduction particles under the control of an inducible promoter allowing us to turn on production of particles.
Finally, we removed the packaging sequence normally used by the phage to package its DNA into the phage particles from the phage DNA and placed it on our CGV (see cos sites shown in Figure 3).
Upon induction of the phage structural genes we got packaging of CGV DNA into the particles that were subsequently released by lysis of the production cells.
Engineering defective helper phage
Finally, we removed the packaging sequence normally used by the phage to package its DNA into the phage particles from the phage DNA and placed it on our CGV (see cos sites shown in Figure 3).
Upon induction of the phage structural genes we got packaging of CGV DNA into the particles that were subsequently released by lysis of the production cells.
Engineering defective helper phage
[00161] E. coli strain C-2323 harboring phage P2 on the chromosome was used as starting material for engineering the production strain with the defective helper phage. A region on the P2 phage comprising integrase, promoters for initiation of phage proliferation, origin of replication, DNA
replication genes and the cos site (DNA sequence 86amster8686i when packaging DNA into phage particles) (see boxed P2 DNA shown in Figure 3), was replaced by a kanamycin marker using recombineering. The site-specific integration of the marker and deletion of approximately 10 kbp of phage DNA was verified by sequencing.
Engineering CGV to enable SA100 packaging
replication genes and the cos site (DNA sequence 86amster8686i when packaging DNA into phage particles) (see boxed P2 DNA shown in Figure 3), was replaced by a kanamycin marker using recombineering. The site-specific integration of the marker and deletion of approximately 10 kbp of phage DNA was verified by sequencing.
Engineering CGV to enable SA100 packaging
[00162] We used a single vector (p77) with the CRIPSR/Cas system expressed from inducible promoters for engineering our SA100 packable CGV.
[00163] To enable activation of the defective P2 helper phage and CGV
packaging into synthetic transduction particles, we cloned the genetic region comprising sid-delta-psu-cos (cos packaging site) from the satellite phage P4 into the p77 plasmid. The cloned P4 region (SEQ ID
NO: 18), which is known to be able to activate the P2 phage was already cloned in another vector p93 where it was expressed from an arabinose inducible promoter. The resulting CGV (p94), containing all elements necessary for P2 activation and SA100 packaging, was verified by complete sequencing. P4 genomic architecture and the region cloned in p94 is shown in the lower box in Figure 3A and the p94 genomic map is shown in Figure 3B.
Production of SA100 packaged CGVs
packaging into synthetic transduction particles, we cloned the genetic region comprising sid-delta-psu-cos (cos packaging site) from the satellite phage P4 into the p77 plasmid. The cloned P4 region (SEQ ID
NO: 18), which is known to be able to activate the P2 phage was already cloned in another vector p93 where it was expressed from an arabinose inducible promoter. The resulting CGV (p94), containing all elements necessary for P2 activation and SA100 packaging, was verified by complete sequencing. P4 genomic architecture and the region cloned in p94 is shown in the lower box in Figure 3A and the p94 genomic map is shown in Figure 3B.
Production of SA100 packaged CGVs
[00164] The p94 CGV was electroporated into the strain harboring the defective prophage resulting in production strain #189.
[00165] SA100 packaged CGVs were produced as described above. Titers of the SA100 packaged CGV was approximately 1010 TFU/mL determined by transduction of SA100 packaged p94 into 3 strains of E. coli. As expected, no contamination of the native P2 phage could be observed (Table 3 below). Accordingly, we can assume a native phage contamination of less than 1 in 1e9 per synthetic particle.
CGV delivery to E. coli using SA100
CGV delivery to E. coli using SA100
[00166] To determine the number of phages required for 100% infection of an E.
coli population, we performed an infection experiment varying the ratio of SA100 particles to bacterial cells, the so-called multiplicity-of-infection (MOT) from 0.01 to 100.
coli population, we performed an infection experiment varying the ratio of SA100 particles to bacterial cells, the so-called multiplicity-of-infection (MOT) from 0.01 to 100.
[00167]We observed that a MOT of 1 meaning one SA100 particle per E. coli cell, was sufficient for 100% infection of the bacterial population (Figure 4).
Discussion and conclusions
Discussion and conclusions
[00168] SA100, a fully synthetic phage-based CGV delivery vehicle was designed and constructed.
Upon expression in a production strain also harboring a compatible CGV, a high titer lysate of SA100 packaged CGVs devoid of native phage contamination was produced. Finally, the obtained SA100 packaged CGVs were efficiently delivered into E. coli.
Example 4: CGV in vitro killing of E. coli following delivery by the SA100 synthetic transduction particle delivery platform Executive summary
Upon expression in a production strain also harboring a compatible CGV, a high titer lysate of SA100 packaged CGVs devoid of native phage contamination was produced. Finally, the obtained SA100 packaged CGVs were efficiently delivered into E. coli.
Example 4: CGV in vitro killing of E. coli following delivery by the SA100 synthetic transduction particle delivery platform Executive summary
[00169]We used the SA100 synthetic DNA delivery vehicle to deliver 87amster8787 CRISPR guided vectors (CGVTM) to two E. coli target strains. Upon induction of the system we could demonstrate up to 4 logs killing of the target population.
Introduction
Introduction
[00170]We have previously engineered the phage-based synthetic DNA delivery vehicle SA100 (Example 3) for delivery of CGVs to E. coli target cells. Here, we 87amster8787 a CGV for delivery by the SA100 vehicle and subsequently tested the efficacy in killing E. coli target cells.
Study objectives
Study objectives
[00171] Objective 1: Optimize CGV for delivery by SA100.
[00172] Objective 2: kill E.coli by SA100 delivered CGVs Materials and methods Bacterial strains and culture conditions
[00173] All bacterial cultures were grown in LB medium supplemented with 2mM
MgCl2. When appropriate, cultures were supplemented with 50 g/mL kanamycin or 50 g/mL
spectinomycin for .. selection of defective prophage and CGV, respectively. In SA100 infection studies, the medium was supplemented with 2.5 mM CaCl2 to aid adsorption of the SA100 particles to bacterial cells. For induction of the CRISPR/Cas system, cells were exposed to 0.5mM IPTG and 2mM
theophylline.
Target strains MG1655_pks and XL1-blue_pks were constructed by recombineering of a 20-nucleotide sequence complementary to the guide RNA spacer sequence in our CGVs into the lacZ
gene of MG1655 and XL1-blue thereby generating target strains MG1655_pks and XL1-blue_pks, respectively.
Production of SA100 packaged CGVs
MgCl2. When appropriate, cultures were supplemented with 50 g/mL kanamycin or 50 g/mL
spectinomycin for .. selection of defective prophage and CGV, respectively. In SA100 infection studies, the medium was supplemented with 2.5 mM CaCl2 to aid adsorption of the SA100 particles to bacterial cells. For induction of the CRISPR/Cas system, cells were exposed to 0.5mM IPTG and 2mM
theophylline.
Target strains MG1655_pks and XL1-blue_pks were constructed by recombineering of a 20-nucleotide sequence complementary to the guide RNA spacer sequence in our CGVs into the lacZ
gene of MG1655 and XL1-blue thereby generating target strains MG1655_pks and XL1-blue_pks, respectively.
Production of SA100 packaged CGVs
[00174] CGVs (p94 and p114) were separately transformed into a respective strain harboring the defective prophage thereby generating production strain #189 and #226, respectively.
[00175] The production strains were grown exponentially for approximately 10 generations in the presence of kanamycin and spectinomycin ensuring balanced growth of the population. At optical density (0D600) of 1 cultures were concentrated x10 and induced with 1%
arabinose and incubation was continued until optical density measurements were low and stable. After spinning away cell debris the lysate was filtered (0.45 tim), further concentrated approximately x4 using Amicon Ultra-15 centrifugal filters and stored at +4C until further use.
CGV delivery and killing
arabinose and incubation was continued until optical density measurements were low and stable. After spinning away cell debris the lysate was filtered (0.45 tim), further concentrated approximately x4 using Amicon Ultra-15 centrifugal filters and stored at +4C until further use.
CGV delivery and killing
[00176] Exponentially growing cultures of the E. coli target strains were infected with SA100 packaged CGVs p94 or p114 at a MOI of 20 in the presence of 2.5mM CaCl2.
[00177] Following 30 min incubation at 37 degreees centigrade, the bacterial cultures were serially diluted and plated on LB plates containing IPTG and theophylline (for inducing the expression of CRISPR/Cas components) to investigate CGV mediated killing or on LB+spectinomycin to investigate CGV delivery to the target populations.
Results Optimising CGV DNA by increasing copy number
Results Optimising CGV DNA by increasing copy number
[00178] CGV p94 was previously shown to be efficiently delivered to E. coli (Example 3). This CGV
contains the CloDF13 origin of replication, in which a single SNP will increase copy number from 7 to 80 according to Stuitje et al. 1981, "Identification of mutations affecting replication control of plasmid Clo DF13", Nature, vol 290, pp264-267. By incorporating the SNP into an oligo used for PCR amplification of the whole CGV, we created p114 containing the mutated CloDF13 on (SEQ ID
NO: 23). Sequence verification was carried out.
CGV delivery by SA100
contains the CloDF13 origin of replication, in which a single SNP will increase copy number from 7 to 80 according to Stuitje et al. 1981, "Identification of mutations affecting replication control of plasmid Clo DF13", Nature, vol 290, pp264-267. By incorporating the SNP into an oligo used for PCR amplification of the whole CGV, we created p114 containing the mutated CloDF13 on (SEQ ID
NO: 23). Sequence verification was carried out.
CGV delivery by SA100
[00179] We previously showed efficient CGV delivery using p94 packaged in SA100 (Example 3).
Here, we compared delivery of CGVs p94 and p114 to MG1655_pks (Fig 6A and additionally p114 delivery to XL1-blue_pks (Fig 6B. Using a multiplicity of infection (MOI) of 20 we demonstrate 100% delivery to the target populations.
Killing efficacy of SA100 delivered CGV
Here, we compared delivery of CGVs p94 and p114 to MG1655_pks (Fig 6A and additionally p114 delivery to XL1-blue_pks (Fig 6B. Using a multiplicity of infection (MOI) of 20 we demonstrate 100% delivery to the target populations.
Killing efficacy of SA100 delivered CGV
[00180] Using the same experimental setup as above (target strains, SA100 packaged CGVs and MOI
of 20) we investigated the ability of the delivered CGVs to kill the target cell upon induction of the expression of the CRISPR/Cas system.
of 20) we investigated the ability of the delivered CGVs to kill the target cell upon induction of the expression of the CRISPR/Cas system.
[00181] The p94 CGV targeting the pks DNA sequence in MG1655_pks was able to reduce the target strain approximately 2 logs while p114 targeting the same sequence reduced the target population approximately 4 logs (Fig 7). The same magnitude of killing was observed when p114 was targeting pks in the XL1-blue_pks target population (Fig 7).
Discussion and conclusions Following SA100 delivery of CGVs to target cells we were able to increase killing of the target population from approximately 2 logs using p94 to 4 logs using p114 probably due to a high copy number CGV.
Example 5: In vivo antibacterial delivery to gut microbiome using non-self-replicative particles & target cell killing in microbiome setting Executive summary
Discussion and conclusions Following SA100 delivery of CGVs to target cells we were able to increase killing of the target population from approximately 2 logs using p94 to 4 logs using p114 probably due to a high copy number CGV.
Example 5: In vivo antibacterial delivery to gut microbiome using non-self-replicative particles & target cell killing in microbiome setting Executive summary
[00182]E. coli AMG1655-pks was used to colonize the murine gut. We show statistically significant delivery of CGVTM pSNP114 into MG1655-PKS by SA100 delivery vehicle (synthetic non-self-replicative phage particles, see Examples 3 and 4). We observered a reduction in survival upon activation of the CGVTM targeting E. coli MG1655-pks.
Introduction
Introduction
[00183] We have previously shown that E. coli ATCC43888 colonizes the a murine gut of NMRI
mice model (data not shown) and that activating of a CRISPR array in E. coli ATCC43888 in the mouse gut reduces survival, where guide RNA produced using the array target the E coli genome for Cas cutting (data not shown). In this Example we set out to assess the survival of a CRISPR/Cas-based antibacterial (a CGVTM) delivered by a Synthetic NanoboioticTM, namely SA100, into MG1655-pks.
Study objective:
mice model (data not shown) and that activating of a CRISPR array in E. coli ATCC43888 in the mouse gut reduces survival, where guide RNA produced using the array target the E coli genome for Cas cutting (data not shown). In this Example we set out to assess the survival of a CRISPR/Cas-based antibacterial (a CGVTM) delivered by a Synthetic NanoboioticTM, namely SA100, into MG1655-pks.
Study objective:
[00184] Establish survival reduction of E. coli MG1655-pks in the murine gut microbiome by delivery of CGVTM pSNP114 with Synthetic Nanoboiotic TM SA100.
Materials and methods
Materials and methods
[00185]E coli was E coli MG1655 with pks fragment inserted, with a strep resistance marker, phylo group A.
[00186] Cells were grown overnight in LB media supplemented with 50 g/mL
spectinomycin. Next day the OD was measured and the cultures were diluted down to 108 CFU/mL.
Vehicle, induced and uninduced groups are shown in Table 4.
= 15 female NMRI mice, 26-30 gram (Taconic) = Inducer solution containing theophylline and L-arabinose Laboratory animal facilities and housing of mice
spectinomycin. Next day the OD was measured and the cultures were diluted down to 108 CFU/mL.
Vehicle, induced and uninduced groups are shown in Table 4.
= 15 female NMRI mice, 26-30 gram (Taconic) = Inducer solution containing theophylline and L-arabinose Laboratory animal facilities and housing of mice
[00187] The temperature was 21 C +/- 2 C and could be regulated by heating and cooling, and light/dark period was in 12-hours intervals of 6 a.m.- 6 p.m./6 p.m ¨ 6 a.m.
Mice had free access to food and to domestic quality drinking water until 3 days prior to the study.
Mice were housed 6-7 mice /cage in the standard facility with bedding from Aspen Wood from Tapvei and paper strands from Sizzle-nest as nesting material until 1 day prior to the study and there after moved into the GMO
facility 1 mouse per cage. The From day 0 the wooden bedding was changed to white paper bedding to facilitate collection of faeces from the cages Preparation of streptomycin drinking water
Mice had free access to food and to domestic quality drinking water until 3 days prior to the study.
Mice were housed 6-7 mice /cage in the standard facility with bedding from Aspen Wood from Tapvei and paper strands from Sizzle-nest as nesting material until 1 day prior to the study and there after moved into the GMO
facility 1 mouse per cage. The From day 0 the wooden bedding was changed to white paper bedding to facilitate collection of faeces from the cages Preparation of streptomycin drinking water
[00188] 6 liters of 5 g/L of streptomycin was prepared by dissolving 6.94 g streptomycin sulphate / L
of sterile water. Mice were given streptomycin water starting day -3 and throughout the study.
Inoculation of mice
of sterile water. Mice were given streptomycin water starting day -3 and throughout the study.
Inoculation of mice
[00189] Inocula was formulated prior to inoculation as ready to use suspensions. Mice were inoculated with 0.25 ml by oral gavage at 8 am day 0. A titre of approximately 10" TFU/ml was used.
Treatment of mice
Treatment of mice
[00190] Mice were dosed with inducers and 10" TFU/mL SA100 by oral gavage at 7 am and 1 pm day 1 and again at 7 am day 2. Inducers were mixed immediately prior to each treatment time point prior to the treatment mice were gavaged with antacid.
Collection of faecal samples from cages
Collection of faecal samples from cages
[00191] Immediately prior to inoculation 0.5 ml faecal samples were collected from cages into three 15 ml Nunc tubes. Day 1 and 2 after inoculation, 0.5 ml faecal samples were collected prior to treatment at 7 am and mice were moved to a new cage. Day 2 after inoculation faecal samples were also collected 4 hours after treatment CFU determination [0019210.5 ml faecal matter was dissolved in 5 ml sterile saline by vortexing multiple times during 1-4 hours. Colony counts were determined by 10 fold serially dilution of the faecal samples in sterile 0.9% NaCl and 20 111_, spots were applied to agar plates. The lower detection limit of faecal samples was 50 CFU/ml. All agar plates were incubated 18-22 hrs at 35 C in ambient air.
[00193] Delivery of the CGV was enumerated by plating on LB + streptomycin +
spectinomycin plates plates. Abudance of the target strain was enumerated by plating on LB
with streptomycin only.
Clinical monitoring of mice [00194] The body weight of the mice were monitored throughout the study and the mice were scored 0 ¨ 6 based on their behavior and clinical signs (Table 5). Mice were euthanized if reaching score 3 or 20% weight loss.
Results [00195]Microbiome analysis of mice prior to inoculation No bacteria was detected in 2 out of 3 of the pooled samples collected prior to inoculation. One of the pooled samples had 6.54 10g10 CFU/ml of small white colonies. MALDI analysis indicated Paenibacillus odorifer with a score value of 1.71 and as second most likely Staphylococcus xylosus with a score value of 1.43 both with a low rank quality. Also in the 2 other pooled samples 3-4 10g10 CFU/ml of small white colonies appeared after 48 hours of incubation.
[00196] At 24 h after inoculation the CFU levels in the faecal samples ranged from 6.1 ¨ 8.6 10g10 CFU/sample as determined on the LB+ strep agar plates. Similar levels were observed day 2 after inoculation. No significant differences were observed with in each of the 2 inoculation groups.
[00197] On the LB+ strep + spec agar plates, no colonies were observed day 1 in in any of the groups.
Day 2 CFU counts ranging from 1 to 5 log10 CFU/sample was observed in the inducer treated groups but not in the vehicle treated groups.
Layout of animal study [00198] Twenty four mice were used in each murine intervention study.
Clinical mice score [00199]Mice did not show any clinical signs of infection or discomfort during the entire study period.
Induction killing of MG1655-pks [00200]Faecal matter extracts were plated out on on plates containing streptomycin to determine the CFU of the E. coli MG1655-PKS strain (Fig 8). Streptomycin CFU counts show no difference between the various treatment groups.
[00201]When plating the faecal samples on spectomycin and streptomycin to determine delivery of CGV pSNP114 (because this CGV carries a spectomycin resistance marker) we observe a significant increase in CFU, and thus CGV delivery, after 48 hours (Fig 9). When the CRISPR system was induced we observed a significant decrease in the mean CFU counts.
Discussion and conclusions [00202]We successfully demonstrated guided nuclease antibacterial (CGVTM) delivery using Synthetic NanobioticTM platform, SA100, into E. coli MG1655-pks in the murine gut model. Thus, delivery of an antibacterial using non-self-replicative particles to a microbiome in vivo was .. established. A statistically significant reduction in CFU counts was observed using the activated CRISPR system on the CGVTM.
Example 6: Production of Transduction Particles By Essential Functions in Trans [00203]Native phage are engineered to convert them into DNA carrier vehicles (transduction particles) for our CRISPR-Guided VectorsTM (CGVs). The particles can transduce target bacterial to introduce the vectors, from which CRISPR/Cas systems or one or more components thereof are expressed.We make use of lytic propagation in which essential helper functions are provided only by the host cell (SA800 & SA900).
SA800 & SA900 [00204] Production of SA800 & SA900 particles is based on lytic propagation on a production host bacterial strain. We engineer native (wild-type) phage by inactivating essential phage functions (e.g.
by deleting structural genes) and adding nucleotide sequences encoding the CRISPR-Cas systems.
[00205]By providing the essential genes on a separate helper plasmid, we can make the CGV-phage hybrid propagate on the production strain. However, CGV propagation is not possible on any other bacterial strains due to the lack of the helper plasmid.
[00206]We refer to Figure 10. To construct a non-self replicative particle comprising a CGV
comprising nucleotide sequences encoding components of a CRISPR-Cas system, we engineer a native phage to contain a phage packaging signal and genes needed for phage DNA replication. The CGV may contain multiple phage genes as long as one or more essential genes are deleted or mutated to make the CGV-phage hybrid non-self replicative on strains not expressing the essential function(s).
In the production strain, this function(s) is provided in trans expressed from a plasmid or the bacterial cell chromosome.
[00207] In one example, the production cell will contain a plasmid with a gene encoding a structural .. phage protein, that is expressed during CGV propagation and packaging. A
vector is constructed comprising a native phage genome in which this gene is mutated and into which are inserted nucleotide sequences encoding components of a CRISPR-Cas system, forming a CGV-phage hybrid.
Thus, the CGV-phage hybrid is non-functional to package the CGV DNA into transduction particles in the absence of the helper function provided in trans.
[00208] In a minimal version, all essential functions (ie, essential for packaging) are carried by the production host cell (eg, on a chromosome or one or more plasmids) except for the phage packaging signal and a phage DNA replication machinery (including phage origin of replication) which are instead carried on the CGV. Importantly, the DNA replication machinery may not need originate from the same phage as the essential genes on the helper plasmid or chromosome. For example, the DNA
replication machinery from phage lambda may be included on a CGV (and used to replicate this) carrying a phage P2 packaging signal and packaged into P2 phage capsids (eg, wherein the capsid proteins are encoded by a helper plasmid or chromosome of the production strain cell).
[00209] The CGV is capable of replicating as a lytic phage (i.e. propagation by infection-lysis-reinfection cycles) on a suitable production host strain carrying the helper function(s). However, in non-production cells such as clinical target bacteria, the phage cannot propagate by the lytic cycle but merely functions as a DNA delivery vehicle, thereby delivering sequences encoding one or more components encoding a CRISPR/Cas component(s) (or alternatively another antibacterial agent or other protein or RNA of interest).
Table 1: Example Bacteria t..) Optionally, the host cells are selected from this Table and/or the target cells are selected from this Table (eg, wherein the host and target cells are of a o t..) o different species; or of the same species but are a different strain or the host cells are engineered but the target cells are wild-type or vice versa).
For example .6.
.6.
the host cells are E coli cells and the target cells are C dificile, E coli, Akkermansia, Enterobacteriacea, Ruminococcus, Faecalibacterium, Firmicutes, n.) oe Bacteroidetes, Salmonella, Klebsiella, Pseudomonas, Acintenobacter or Streptococcus cells.
Abiotrophia Acidocella Actinomyces Alkalilimnicola Aquaspirillum Abiotrophia defectiva Acidocella aminolytica Actinomyces bovis Alkalilimnicola ehrlichii Aquaspirillum polymorphum Acidocella facilis Actinomyces denticolens Aquaspirillum Acaricomes Alkaliphilus Actinomyces europaeus putridiconchylium P
Acaricomes phytoseiuli Acidomonas Alkaliphilus oremlandii Actinomyces georgiae Aquaspirillum serpens 2 Acidomonas methanolica Alkapus ransvaaenss o Actinomyces gerencseriae ;3'lihil t l i vi ?.
Acetitomaculum .
Actinomyces Aquimarina N) Acetitomaculum ruminis Acidothermus Allochromatium , hordeovulneris Aquimarina late rcula Acidothermus cellulolyticus Allochromatium vinosum r., N) Acetivibrio Actinomyces howellii Arcanobacterium li i h Actinomyces yovagnas Acetivibrio cellulolyticus Acidovorax Ac Alloiococcus Arcanobacterium lii i Actinomyces srae Acetivibrio ethanolgignens Acidovorax anthurii Act Alloiococcus otitis haemolyticum Acetivibrio multivorans Acidovorax caeni Actinomyces johnsonii Arcanobacterium pyo genes Actinomyces meyeri Allokutzneria Acidovorax cattleyae Iv n Acetoanaerobium Actinomyces naeslundii Allokutzneria albata 1-3 Acidovorax citrulli Archangium t=1 1-d Acetoanaerobium noterae Actinomyces neuii t..) Acidovorax defluvii Archangium gephyra o t..) o Acidovorax delafieldii Actinomyces odontolyticus 'a o .6.
t..) t..) un Acidovorax facilis Actinomyces oris o t..) Acetobacter Altererythrobacter Arcobacter o Acidovorax konjaci Actinomyces radingae t..) o Acetobacter aceti Altereiythrobacter Arcobacter butzleri Acidovorax temperans Actinomyces slackii .6.
Acetobacter cerevisiae ishigakiensis Arcobacter ciyaerophilus .6.
t...) Acidovorax valerianellae Actinomyces turicensis oe Acetobacter cibinongensis Arcobacter halophilus Actinomyces viscosus Altermonas Acetobacter estunensis Acinetobacter Arcobacter nitrofigilis Altermonas haloplanktis Acetobacter fabarum Acinetobacter baumannii Actinoplanes Arcobacter ski rrowii Altermonas macleodii Acetobacter ghanensis Acinetobacter baylyi Actinoplanes auranticolor Arhodomonas Acetobacter indonesiensis Acinetobacter bouvetii Actinoplanes brasiliensis Alysiella Arhodomonas aquaeolei P
Acetobacter lovaniensis Acinetobacter calcoaceticus Actinoplanes consettensis Alysiella crassa Acetobacter malo rum Acinetobacter gerneri Actinoplanes deccanensis ;3' o Alysiella filifonnis Arsenophonus o, ..
Acetobacter nitrogenifigens Acinetobacter haemolyticus Actinoplanes derwentensis Arsenophonus nasoniae 2' , Acetobacter oeni Acinetobacter johnsonii Actinoplanes digitatis Aminobacter , ""
Acetobacter orientalis Acinetobacter junii Actinoplanes durhamensis Aminobacter aganoensis Acetobacter orleanensis Acinetobacter lwoffi Actinoplanes ferrugineus Aminobacter aminovorans Acetobacter pasteurianus Acinetobacter parvus Actinoplanes globisporus Arthrobacter Aminobacter niigataensis Acetobacter pornorurn Acinetobacter radioresistens Actinoplanes humidus Arthrobacter agilis Acetobacter senegalensis Acinetobacter schindleri Actinoplanes italicus Aminobacterium Arthrobacter albus Iv Acetobacter xylinus Acinetobacter soli Actinoplanes liguriensis Aminobacterium mobile Arthrobacter aurescens n ,-i m Acinetobacter tandoii Actinoplanes lobatus Arthrobacter Iv t..) o Acetobacterium Aminomonas r..) Acinetobacter tjernbergiae Actinoplanes missouriensis chlorophenolicus o 'a Acetobacterium bakii Aminomonas paucivorans o .6.
t..) t..) un Acetobacterium carbinolicum Acinetobacter towneri Actinoplanes palleronii Arthrobacter citreus o t..) Ammoniphilus Acetobacterium dehalogenans Acinetobacter ursingii Actinoplanes philippinensis Arthrobacter ciystallopoietes 2 =
Ammoniphilus oxalaticus Acetobacterium fimetarium Acinetobacter venetianus Actinoplanes rectilineatus Arthrobacter cumminsii c,.) .6.
.6.
hilus oxalivorans r..) Acetobacterium malicum Actinoplanes regularis Ammonip Arthrobacter globiformis oe oraosp Acetobacterium paludosum Acrocarp Actinoplanes Arthrobacter Amphibacillus Acrocarpospora corrugata Acetobacterium tundrae teichomyceticus histidinolovorans Amphibacillus xylanus Acetobacterium wieringae Acrocarpospora Actinoplanes utahensis Arthrobacter ilicis l haa Acetobacterium woodii macrocep Arthrobacter luteus Amphritea Acrocarpospora Actinopolyspora Arthrobacter methylotrophus Amphritea balenae P
Acetofilamentum pleiomorpha Actinopolyspora halophila Arthrobacter mysorens Amphritea japonica Acetofilamentum rigidum Actinopolyspora o Arthrobacter nicotianae 03-' --.1 Actibacter .
mortivallis r., Amycolatopsis Arthrobacter nicotinovorans r.,0 Acetohalobium Actibacter sediminis , Amycolatopsis alba Arthrobacter oxydans Acetohalobium arabaticum Actinosynnema r.,7 r., Amycolatopsis albidoflavus Arthrobacter pascens Actinoalloteichus Actinosynnema mirum Acetomicrobium Actinoalloteichus Amycolatopsis azurea Arthrobacter Acetomicrobium faecale cyanogriseus Actinotalea Amycolatopsis coloradensis phenanthrenivorans Amycolatopsis lurida Arthrobacter Acetomicrobium flavidum Actinoalloteichus Actinotalea fennentans Amycolatopsis mediterranei polychromo genes hymeniacidonis Iv n Acetonema Aerococcus Amycolatopsis rifamycinica Atrhrobacter protophormiae Actinoalloteichus spitiensis t=1 Iv Acetonema longum Aerococcus sanguinicola Amycolatopsis rubida Arthrobacter w o t..) o Aerococcus urinae psychrolactophilus 'a o .6.
r..) t..) un Aerococcus urinaeequi Amycolatopsis sulphurea Arthrobacter ramosus o t..) Acetothermus Actinobaccillus o Aerococcus urinaehominis Amycolatopsis tolypomycina Arthrobacter sulfonivorans t..) o Acetothermus paucivorans Actinobacillus capsulatus Aerococcus viridans Arthrobacter sulfureus c,.) .6.
.6.
Actinobacillus delphinicola Anabaena t..) Arthrobacter uratoxydans oe Acholeplasma Actinobacillus hominis Aeromicrobium Anabaena cylindrica Arthrobacter ureafaciens Acholeplasma axanthum Actinobacillus indolicus Aeromicrobium mythreum Anabaena flos-aquae Arthrobacter viscosus Acholeplasma brassicae Actinobacillus lignieresii Anabaena variabilis Arthrobacter woluwensis Acholeplasma cavigenitalium Aeromonas Actinobacillus minor Acholeplasma equifetale Aeromonas Anaeroarcus Actinobacillus muris Asaia Acholeplasma granularum allosaccharophila Anaeroarcus burkinensis P
Actinobacillus Asaia bogorensis Acholeplasma hippikon Aeromonas bestiarum pleuropneumoniae ;3' o Anaerobaculum .?.
oe Acholeplasma laidlawii Aeromonas caviae Asanoa Actinobacillus porcinus r., Anaerobaculum mobile ,30 , Acholeplasma modicum Aeromonas encheleia Asanoa ferruginea Actinobacillus rossii N) Acholeplasma morum Aeromonas r., Actinobacillus scotiae Anaerobiospirillum Asticcacaulis Acholeplasma multilocale enteropelo genes Actinobacillus seminis Anaerobiospirillum Asticcacaulis biprosthecium Acholeplasma oculi Aeromonas eucrenophila Actinobacillus succinogenes succiniciproducens Asticcacaulis excentricus Acholeplasma palmae Aeromonas ichthiosmia Actinobaccillus suis Anaerobiospirillum thomasii Acholeplasma parvum Aeromonas jandaei Actinobacillus ureae Atopobacter 1-d Acholeplasma pleciae Aeromonas media n Anaerococcus Atopobacter phocae 1-3 Acholeplasma vituli Actinobaculum Aeromonas popoffii t=1 Anaerococcus hydrogenalis Iv t..) o Actinobaculum massiliense Aeromonas sobria t..) Anaerococcus lactolyticus o 'a Actinobaculum schaalii Aeromonas veronii o .6.
t..) t..) un Actinobaculum suis Anaerococcus prevotii o t..) Achromobacter Agrobacterium Atopobium o Actinomyces urinale Anaerococcus tetradius t..) o Achromobacter denitrificans Agrobacterium Atopobium fossor Anaerococcus vaginalis .6.
.6.
Achromobacter insolitus Actinocatenispora gelatinovorum Atopobium minutum r..) oe Achromobacter piechaudii Actinocatenispora rupis Anaerofustis Atopobium parvulum Achromobacter ruhlandii Actinocatenispora Agrococcus Anaerofustis stercorihominis Atopobium rimae Agrococcus citreus Achromobacter spanius thailandica Atopobium vaginae Agrococcus jenensis Anaeromusa Actinocatenispora sera Acidaminobacter Anaeromusa acidaminophila Aureobacterium romonas Acidaminobacter Actinocorallia Ag Aureobacterium barkeri P
Agromonas oligotrophica Anaeromyxobacter hydrogenoformans Actinocorallia aurantiaca ;'3 o Anaeromyxobacter Aurobacterium ..
o Actinocorallia aurea r., Acidaminococcus Agromyces ens r.
dehalogenans Aurobacterium liquefaci3O
, Actinocorallia cavernae Agromyces fucosus Acidaminococcus fermentans Actinocorallia glomerata r.,^' Acidaminococcus intestini Agromyces hippuratus Anaerorhabdus Avibacterium Actinocorallia herbida Agromyces luteolus Anaerorhabdus furcosa Avibacterium avium Actinocorallia libanotica Acidicaldus Agromyces mediolanus Avibacterium gallinarum Actinocorallia longicatena Anaerosinus Acidicaldus organivorans Agromyces ramosus Avibacterium paragallinarum Anaerosinus glycerini Agromyces rhizospherae Avibacterium volantium Actinomadura 1-d Acidimicrobium n ,-i Actinomadura alba Anaerovirgula m Acidimicrobium ferrooxidans Akkermansia Azoarcus 1-d t..) Actinomadura atramentaria o i Anaerovrgula multivorans t..) Akkermansia muciniphila Azoarcus indigens o Actinomadura 'a o .6.
t..) t..) un ban gladeshensis Azoarcus tolulyticus 0 Acidiphilium Albidiferax Ancalomicrobium t..) o Actinomadura catellatispora Azoarcus toluvorans t..) o Acidiphilium acidophilum Actinomadura chibensis Albidiferax ferrireducens Ancalomicrobium adetum .6.
.6.
Acidiphilium angustum Actinomadura chokoriensis Azohydromonas t..) oe Albidovulum Ancylobacter Acidiphilium ciy Azohydromonas australica ptum Actinomadura citrea Albidovulum inexpectatum Ancylobacter aquaticus Azohydromonas lata Acidiphilium multivorum Actinomadura coerulea Acidiphilium organovorum Actinomadura echinospora Alcaligenes Aneurinibacillus Azomonas Acidiphilium rubrum Actinomadura fibrosa Alcaligenes denitrificans Aneurinibacillus Azomonas agilis Actinomadura formosensis Alcaligenes faecalis aneurinilyticus Acidisoma Azomonas insignis P
Actinomadura hibisca i i Aneurinibacillus mgulanus Acidisoma sibiricum Azomonas macrocyto genes 1-, Actinomadura ktjaniata Alcanivorax ;3' o Aneurinibacillus .?.
o Acidisoma tundrae r., Actinomadura latina Alcanivorax borkumensis the rmoaerophilus Azorhizobium ,30 , Actinomadura livida Alcanivorax jadensis o Acidisphaera Azorhizobium caulinodans r, N) Actinomadura Angiococcus Acidisphaera rubrifaciens Algicola luteofluorescens Angiococcus discifonnis Azorhizophilus Algicola bacteriolytica Acidithiobacillus Actinomadura macra Azorhizophilus paspali Angulomicrobium Acidithiobacillus albertensis Actinomadura madurae Alicyclobacillus Angulomicrobium tetraedrale Azospirillum Acidithiobacillus caldus Actinomadura oligospora Iv Alicyclobacillus n Azospirillum brasdense Acidithiobacillus ferrooxidans Actinomadura pelletieri disulfidooxidans Anoxybacillus t=1 Azospirillum halopraeferens Iv Acidithiobacillus thiooxidans Actinomadura rubrobrunea t..) Alicyclobacillus Anoxybacillus pushchinoensis o t..) Azospirillum irakense o Actinomadura rugatobispora 'a o .6.
t..) t..) un Actinomadura umbrina sendaiensis o t..) Acidobacterium Aquabacterium Azotobacter o Actinomadura Alicyclobacillus vulcanalis t..) o Acidobacterium capsulatum Aquabacterium commune Azotobacter beijerinckii verrucosospora .6.
.6.
Alishewanella Aquabacterium parvum Azotobacter chroococcum t...) Actinomadura vinacea oe Alishewanella fetalis Azotobacter nigricans Actinomadura viridilutea Azotobacter salinestris Actinomadura viridis Alkalibacillus Azotobacter vinelandii Actinomadura yumaensis Alkalibacillus haloalkaliphilus P
, 1¨ Bacillus Bacteroides Bibersteinia Borrelia Brevinema o 2 1-, r., [see below] Bacteroides caccae Bibersteinia trehalosi Borrelia afzelii Brevinema andersonii 2 '7 Bacteroides coagulans Borrelia americana 0"
N) Bifidobacterium Brevundimonas "
Bacteroides eggerthii Borrelia burgdorferi Bifidobacterium ado lescentis Brevundimonas alba Bacteroides fragilis Borrelia carolinensis Bacteriovorax Bifidobacterium angulatum Brevundimonas aurantiaca Bacteroides galacturonicus Borrelia coriaceae Bacteriovorax stolpii Bifidobacterium animalis Brevundimonas diminuta Bacteroides helco genes Borrelia garinii Bifidobacterium asteroides Brevundimonas intermedia Bacteroides ovatus Borrelia japonica Iv Bifidobacterium bifidum Brevundimonas subvibrioides n Bacteroides pectinophilus t=1 Bifidobacterium boum Brevundimonas vancanneytii Iv Bacteroides pyo genes t..) o Bifidobacterium breve t..) o Bacteroides salyersiae 'a o .6.
t..) t..) un Bacteroides stercoris Bifidobacterium catenulatum Brevundimonas variabilis 0 t..) Bosea o Bacteroides suis Bifidobacterium choerinum Brevundimonas vesicularis t..) o Bosea minatitlanensis Bacteroides tectus Bifidobacterium coiyneforme c...) .6.
.6.
Bosea thiooxidans Brochothrix t..) Bacteroides thetaiotaomicron Bifidobacterium cuniculi oe Bacteroides uniformis Bifidobacterium dentium Brochothrix campestris Brachybacterium Brochothrix thermosphacta Bacteroides ureolyticus Bifidobacterium gallicum Brachybacterium Bacteroides vulgatus Bifidobacterium gallinarum alimentarium BruceIla Bifidobacterium indicum Balnearium Brachybacterium faecium BruceIla canis Bifidobacterium longum P
Balnearium lithotrophicum Bifi Brachybacterium BruceIla neotomaedobacterium 2 paraconglomeratum 1-, magnumBifidobacterium o .? Bryobacter .
w Balneatrix Brachybacterium rhamnosum r., meiycicum atusre obacter aggg , Balneatrix alpica Brachybacterium Biy , Bifidobacterium minimum 0"
, tyrofermentans r.,"
Balneola Bifidobacterium Burkholderia pseudocatenulatum Burkholderia ambifaria Balneola vulgaris Brachyspira Bifidobacterium Brachyspira alvinipulli Burkholderia andropogonis Barnesiella pseudolongum Burkholderia anthina Brachyspira hyodysenteriae Barnesiella viscericola Bifidobacterium pullorum Brachyspira innocens Burkholderia caledonica Iv n Bifidobacterium ruminantium Burkholderia caiyophylli 1-3 Brachyspira murdochii t=1 Bartonella 1-d Bifidobacterium saeculare Brachyspira pilosicoli Burkholderia cenocepacia t..) o Bartonella alsatica t..) o Bifidobacterium subtile Burkholderia cepacia 'a o .6.
t..) t..) un Bartonella bacilliformis Bifidobacterium Burkholderia cocovenenans o t..) o Bartonella clarridgeiae the rmophilum Burkholderia dolosa t..) o Bartonella doshiae Burkholderia fungorum c,.) .6.
Bradyrhizobium Bilophila .6.
t..) Bartonella elizabethae Burkholderia glathei oe Bilophila wadsworthia Bradyrhizobium canariense Bartonella grahamii Burkholderia glumae Bradyrhizobium elkanii Bartonella henselae Burkholderia graminis Biostraticola Bradyrhizobium japonicum Bartonella rochalimae Burkholderia kururiensis Biostraticola tofi Bradyrhizobium liaoningense Bartonella vinsonii Burkholderia multivorans Bizionia Brenneria Burkholderia phenazinium P
Bavariicoccus Burkholderia plantarii 2 Bizionia argentinensis Brenneria alni Bavariicoccus seileri 1-, Burkholderia pyrrocinia ;3' o Brenneria nigrifluens .2 r., Blastobacter Burkholderia silvatlantica 2' Brenneria quercina Bdellovibrio , Blastobacter capsulatus Burkholderia stabilis Brenneria quercina Bdellovibrio bacteriovorus r.3^' Blastobacter denitrificans Burkholderia thailandensis Brenneria salicis Bdellovibrio exovorus Burkholderia tropica Blastococcus Brevibacillus Burkholderia unamae Beggiatoa Blastococcus aggregatus Brevibacillus agri Burkholderia vietnamiensis Beggiatoa alba Blastococcus saxobsidens Brevibacillus borstelensis Iv n Beijerinckia Brevibacillus brevis Buttiauxella Blastochloris t=1 Buttiauxella agrestis Iv Betjerinckia derxii Brevibacillus centrosporus t..) Blastochloris viridis o t..) b ll iauxea rennerae o Betjerinckia fluminensis Brevibacillus choshinensis Butt 'a o .6.
t..) t..) un Betjerinckia indica Brevibacillus invocatus Buttiauxella ferragutiae o t..) Blastomonas o Betjerinckia mobilis Brevibacillus late rosporus Buttiauxella gaviniae t..) o Blastomonas natatoria Brevibacillus parabrevis Buttiauxella izardii c,.) .6.
Belliella .6.
t..) Brevibacillus reuszeri Buttiauxella noackiae oe Belliella baltica Blastopirellula Buttiauxella warmboldiae Blastopirellula marina Brevibacterium Bellilinea Brevibacterium abidum Butyrivibrio Blautia Bellilinea caldifistulae Brevibacterium album Butyrivibrio fibrisolvens Blautia coccoides Brevibacterium aurantiacum Butyrivibrio hungatei Belnapia Blautia hansenii P
Brevibacterium celere Butyrivibrio proteoclasticus Belnapia moabensis Blautia producta Brevibacterium epidermidis 1-, ;33' o Blautia wexlerae .2 .6.
Brevibacterium Bergeriella , Bergeriella denitrificans Bogoriella frigoritolerans N) Brevibacterium halotolerans r., Bogoriella caseilytica Beutenbergia Brevibacterium iodinum Beutenbergia cavernae Bordetella Brevibacterium linens Bordetella avium Brevibacterium lyticum Bordetella bronchiseptica Brevibacterium mcbrellneri Iv Bordetella hinzii Brevibacterium otitidis n ,-i m Bordetella holmesii Brevibacterium oxydans Iv t..) o Bordetella parapertussis t..) o 'a o .6.
t..) t..) un Bordetella pertussis Brevibacterium paucivorans o tµ.) o Bordetella petrii Brevibacterium stationis tµ.) o Bordetella trematum c,.) .6.
.6.
n.) oe Bacillus B. acidiceler B. aminovorans B. glucanolyticus B. taeanensis B. lautus B. acidicola B. amylolyticus B. gordonae B. tequilensis B. lehensis B. acidiproducens B. andreesenii B. gottheilii B. the rmantarcticus B. lentimorbus P
B. acidocaldarius B. aneurindyncus B. graminis B. the rmoaerophilus B. lentus , ...]
o h li B l th B l l h B
i th B. acidoterrestris B. anracs B. amapaus B.
ermoamyovorans B. ceniformis ..
un r., B. aeolius B. aquimaris B. haloalkaliphilus B. the rmocatenulatus B. ligniniphilus , , , B. aerius B. arenosi B. halochares B. the rmocloacae B. litoralis ' r., r., B. aerophilus B. arseniciselenatis B. halodenitrificans B. the rmocopriae B. locisalis B. agaradhaerens B. arsenicus B. halodurans B. thermodenitrificans B. luciferensis B. agri B. aurantiacus B. halophilus B. the rmoglucosidasius B. luteolus B. aidingensis B. arvi B. halosaccharovorans B. the rmolactis B. luteus B. akibai B. cnyabhattai B.
hemicellulosilyticus B. the rmoleovorans B. macauensis Iv n ,-i B. alcalophilus B. asahii B. hemicentroti B. the rmophilus B. macerans t=1 Iv B. algicola B. atrophaeus B. herbersteinensis B. the rmoruber B. macquariensis tµ.) o tµ.) o B. alginolyticus B. axarquiensis B. horikoshii B. the rmosphaericus B. macyae 'a o .6.
tµ.) tµ.) un B. alkalidiazotrophicus B. azotofixans B. horneckiae B. thiaminolyticus B. malacitensis 0 n.) B. alkalinitrilicus B. azotoformans B. horti B. thioparans B. mannandyticus o t..) o B. alkalisediminis B. badius B. huizhouensis B. thuringiensis B. marisflavi c,.) .6.
.6.
B. alkalitelluris B. barbaricus B. humi B. tianshenii B. marismortui t.) oe B. altitudinis B. bataviensis B. hwajinpoensis B. bypoxylicola B. marmarensis B. alveayuensis B. betjingensis B. idriensis B. tusciae B. massiliensis B. alvei B. benzoevorans B. indicus B. validus B. megaterium B. amyloliquefaciens B. beringensis B. infantis B. vallismortis B. mesonae B. berkeleyi B. infernus B. vedderi B. methanolicus P
= B.
B. beveridgei B. insolitus B. velezensis B. methylotrophicus , a. subsp. Amyloliquefaciens ...]
1-, b i i B ii Bi i Bil B. ogorenss B. nvctae B. vetnamenss B. mguanus 0 o ..
o =
B. a. subsp. Plantarum r., B. boroniphilus B. iranensis B. vireti B. mojavensis '7 B. borstelensis B. isabeliae B. vulcani B. mucilaginosus 0"
r., B. brevis Migula B. isronensis B. wakoensis B. muralis B. dipsosauri B. butanolivorans B. jeotgali B. weihenstephanensis B. murimartini B. drentensis B. canaveralius B. kaustophilus B. xiamenensis B. myco ides B. edaphicus B. carboniphilus B. kobensis B. xiaoxiensis B. naganoensis B. ehimensis B. cecembensis B. kochii B. zhanjiangensis B. nanhaiensis Iv B. eiseniae n B. cellulosilyticus B. kokeshiiformis B. nanhaiisediminis 1-3 B. enclensis t=1 B. peoriae Iv B. centrosporus B. koreensis B. nealsonii t..) o B. endophyticus n.) B. persepolensis o B. cereus B. korlensis B. neidei 'a B. endoradicis o .6.
t..) t..) un B. farraginis B. chagannorensis B. kribbensis B. persicus B. neizhouensis o tµ.) o B. fastidiosus B. chitinolyticus B. krulwichiae B. pervagus B. niabensis tµ.) o B. fengqiuensis B. chondroitinus B. laevolacticus B. plakortidis B. niacini c,.) .6.
.6.
tµ.) B. firmus B. choshinensis B. larvae B. pocheonensis B. novalis oe B. flexus B. chungangensis B. laterosporus B. polygoni B. oceanisediminis B. foraminis B. cibi B. salexigens B. polymyxa B. odysseyi B. fordii B. circulans B. saliphilus B. popilliae B. okhensis B. formosus B. clarkii B. schlegelii B. pseudalcalophilus B. okuhidensis B. fortis B. clausii B. sediminis B. pseudofirmus B. oleronius P
B. fiimarioli B. coagulans B. selenatarsenatis B. pseudomycoides B. oiyzaecorticis , 1-, B. fiiniculus B. coahuilensis B. selenitireducens B. psychrodurans B. oshimensis o ..
B. fiisiformis B. cohnii B. seohaeanensis B. psychrophilus B. pabuli '7 , B. galactophilus B. compost! B. shacheensis B. psychrosaccharolyticus B. pakistanensis r., B. galactosidilyticus B. curdlanolyticus B. shackletonii B. psychrotolerans B. pallidus B. galliciensis B. cycloheptanicus B. siamensis B. pulvifaciens B. pallidus B. gelatini B. cytotoxicus B. silvestris B. pumilus B. panacisoli B. gibsonii B. daliensis B. simplex B. purgationiresistens B. panaciterrae B. ginsengi B. decisifrondis B. siralis B. pycnus B. pantothenticus Iv n B. ginsengihumi B. decolorationis B. smithii B. qingdaonensis B. parabrevis 1-3 t=1 Iv B. ginsengisoli B. deserti B. soli B. qingshengii B. paraflexus tµ.) o tµ.) B. globisporus (eg, B. B. solimangrovi B. reuszeri B. pasteurii 'a o .6.
tµ.) tµ.) un g. subsp. Globisporus; or B. B. solisalsi B. rhizosphaerae B. patagoniensis c;;) t..) g. subsp. Marinus) B. songklensis B. rigui o t..) o B. sonorensis B. runs c,.) .6.
.6.
n.) B. sphaericus B. safensis oe B. sporothermodurans B. salarius B. stearothermophilus B. stratosphericus B. subterraneus B. subtilis (eg, B.
P
s. subsp. Inaquosorum; or B.
1-, s. subsp. Spizizeni;
or B.
o 2 oe N, s. subsp. Subtilis) '7 , Caenimonas Campylobacter Cardiobacterium Catenuloplanes Curtobacterium Caenimonas koreensis Campylobacter coli Cardiobacterium hominis Catenuloplanes atrovinosus Curtobacterium Campylobacter concisus Catenuloplanes castaneus .. albidum Caldalkalibacillus Carnimonas Campylobacter curvus Catenuloplanes crispus Curtobacterium citreus Caldalkalibacillus uzonensis Carnimonas nigrificans Campylobacter fetus Catenuloplanes indicus Iv Campylobacter gracilis Catenuloplanes japonicus n Caldanaerobacter Carnobacterium Campylobacter helveticus Catenuloplanes nepalensis t=1 Iv Caldanaerobacter subterraneus Carnobacterium t..) Campylobacter hominis Catenuloplanes niger o t..) alterfunditum o 'a Campylobacter hyointestinalis o .6.
t..) t..) un Campylobacter jejuni Carnobacterium divergens o t..) Caldanaerobius Chryseobacterium o Campylobacter lari Carnobacterium funditum t...) o Caldanaerobius fijiensis Campylo Chiyseobacterium bacter mucosalis Carnobacterium gallinarum c...) .6.
.6.
Caldanaerobius balustinum t..) Campylobacter rectus Carnobacterium oe polysaccharolyticus Campylobacter showae maltaromaticum Citrobacter Caldanaerobius zeae Campylobacter sputorum Carnobacterium mobile C. amalonaticus Campylobacter upsaliensis Carnobacterium viridans Caldanaerovirga C. braakii Caldanaerovirga acetigignens C. diversus Capnocytophaga Caryophanon P
Capnocytophaga canimorsus Caiyopha C. farmeri non latum Caldicellulosiruptor C. freundii Capnocytophaga cynodegmi Caiyophanon tenue 1-, ;3' o Caldicellulosiruptor bii o C. gillenii .?.
rup esc Capnocytophaga gingivalis r., Caldicellulosiruptor kristjanssonii Catellatospora Catellat C. koseri , Capnocytophaga granulosa 0"1 Caldicellulosiruptor owensensis Catellatospora citrea C. murliniae ,3"1 Capnocytophaga haemolytica Catellatospora C. pasteuriim Capnocytophaga ochracea methionotrophica C. rodentium Capnocytophaga sputigena C. sedlakii Catenococcus C. werkmanii Catenococcus thiocycli Iv C. youngae n ,-i m ,-o Clostridium t..) o t..) o (see below) 'a cA
.6.
t..) t..) un C
t..) Coccochloris o t..) o Coccochloris elabens .6.
.6.
n.) oe Corynebacterium Coiynebacterium flavescens Coiynebacterium variabile Clostridium Clostridium absonum, Clostridium aceticum, Clostridium ace tireducens, Clostridium acetobutylicum, Clostridium acidisoli, Clostridium aciditolerans, P
Clostridium acidurici, Clostridium aerotolerans, Clostridium aestuarii, Clostridium akagii, Clostridium aldenense, Clostridium aldrichii, Clostridium 1-, algidicami, Clostridium algidixylanolyticum, Clostridium algifaecis, Clostridium algoriphilum, Clostridium alkalicellulosi, Clostridium aminophilum, 1-, .
o r., Clostridium aminovalericum, Clostridium amygdalinum, Clostridium amylolyticum, Clostridium arbusti, Clostridium arcticum, Clostridium argentinense, 2 '7 Clostridium asparagiforme, Clostridium aurantibutyricum, Clostridium autoethanogenum, Clostridium baratii, Clostridium barkeri, Clostridium bartlettii, r., Clostridium betjerinckii, Clostridium bifermentans, Clostridium bolteae, Clostridium bomimense, Clostridium botulinum, Clostridium bowmanii, Clostridium biyantii, Clostridium butyricum, Clostridium cadaveris, Clostridium caenicola, Clostridium cam inithermale, Clostridium carboxidivorans, Clostridium camis, Clostridium cavendishii, Clostridium celatum, Clostridium celerecrescens, Clostridium cellobioparum, Clostridium cellulofermentans, Clostridium cellulolyticum, Clostridium cellulosi, Clostridium cellulovorans, Clostridium chartatabidum, Clostridium chauvoei, Clostridium chromiireducens, Clostridium citroniae, Clostridium clariflavum, Clostridium clostridioforme, Clostridium cocco ides, Clostridium cochlearium, Clostridium colletant, Clostridium colicanis, .0 n Clostridium colinum, Clostridium collagenovorans, Clostridium cylindrosporum, Clostridium difficile, Clostridium diolis, Clostridium disporicum, 1-3 t=1 Clostridium drakei, Clostridium durum, Clostridium estertheticum, Clostridium estertheticum estertheticum, Clostridium estertheticum laramiense, Iv t..) o t..) Clostridium fallax, Clostridium felsineum, Clostridium fervidum, Clostridium fimetarium, Clostridium formicaceticum, Clostridium frigidicamis, Clostridium o 'a o .6.
t..) t..) un frigoris, Clostridium ganghwense, Clostridium gasigenes, Clostridium ghonii, Clostridium glycolicum, Clostridium glycyrrhizinilyticum, Clostridium grantii, n.) o Clostridium haemolyticum, Clostridium halophilum, Clostridium hastiforme, Clostridium hathewayi, Clostridium herbivorous, Clostridium hiranonis, tµ.) o Clostridium histolyticum, Clostridium homopropionicum, Clostridium huakuii, Clostridium hungatei, Clostridium hydrogeniformans, Clostridium w .6.
.6.
tµ.) hydroxybenzoicum, Clostridium hylemonae, Clostridium jejuense, Clostridium indolis, Clostridium innocuum, Clostridium intestinale, Clostridium irregulare, oe Clostridium isatidis, Clostridium josui, Clostridium kluyveri, Clostridium lactatifermentans, Clostridium lacusfiyxellense, Clostridium laramiense, Clostridium lavalense, Clostridium lentocellum, Clostridium lentoputrescens, Clostridium leptum, Clostridium limosum, Clostridium litorale, Clostridium lituseburense, Clostridium ljungdahlii, Clostridium lortetii, Clostridium lundense, Clostridium magnum, Clostridium malenominatum, Clostridium mangenotii, Clostridium mayombei, Clostridium methoxybenzovorans, Clostridium methylpentosum, Clostridium neopropionicum, Clostridium nexile, Clostridium nitrophenolicum, Clostridium novyi, Clostridium oceanicum, Clostridium orbiscindens, Clostridium oroticum, Clostridium oxalicum, Clostridium papyrosolvens, Clostridium P
paradoxum, Clostridium paraperfringens (Alias: C. welchii), Clostridium paraputrificum, Clostridium pascui, Clostridium pasteurianum, Clostridium 2 ...]
1-, peptidivorans, Clostridium perenne, Clostridium perfringens, Clostridium pfennigii, Clostridium phytofermentans, Clostridium piliforme, Clostridium 1-, ..
polysaccharolyticum, Clostridium populeti, Clostridium propionicum, Clostridium proteoclasticum, Clostridium proteolyticum, Clostridium psychrophilum, 2 '7 , Clostridium puniceum, Clostridium purinilyticum, Clostridium putrefaciens, Clostridium putrificum, Clostridium quercicolum, Clostridium quinii, Clostridium o r., ramosum, Clostridium rectum, Clostridium roseum, Clostridium saccharobutylicum, Clostridium saccharogumia, Clostridium saccharolyticum, Clostridium saccharoperbutylacetonicum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scatolo genes, Clostridium schirmacherense, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporo genes, Clostridium sporosphaeroides, Clostridium stercorarium, Clostridium stercorarium leptospartum, Clostridium stercorarium stercorarium, Clostridium stercorarium the rmolacticum, Clostridium sticklandii, Clostridium straminisolvens, Clostridium subterminale, Clostridium sufflavum, Clostridium sulfidigenes, Clostridium ,t n symbiosum, Clostridium tagluense, Clostridium tepidiprofundi, Clostridium termitidis, Clostridium tertium, Clostridium tetani, Clostridium tetanomorphum, 1-3 t=1 Iv Clostridium thermaceticum, Clostridium thermautotrophicum, Clostridium thermoalcaliphilum, Clostridium thermobutyricum, Clostridium the rmocellum, t.) o tµ.) o Clostridium thermocopriae, Clostridium thermohydrosulfuricum, Clostridium thermolacticum, Clostridium the rmopalmarium, Clostridium 'a o .6.
tµ.) tµ.) un thermopapyrolyticum, Clostridium thermosaccharolyticum, Clostridium thermosuccinogenes, Clostridium thermosulfurigenes, Clostridium 0 t..) o thiosulfatireducens, Clostridium tyrobutyricum, Clostridium uliginosum, Clostridium ultunense, Clostridium villosum, Clostridium vincentii, Clostridium t...) o viride, Clostridium xylanolyticum, Clostridium xylanovorans c...) .6.
.6.
n.) oe Dactylosporangium Deinococcus Delftia Echinicola Dactylosporangium aurantiacum Deinococcus aerius Delftia acidovorans Echinicola pacifica Dactylosporangium fulvum Deinococcus apachensis Desulfovibrio Echinicola vietnamensis Dactylosporangium matsuzakiense Deinococcus aquaticus Desulfovibrio desulfuricans Dactylosporangium roseum Deinococcus aquatilis Diplococcus Dactylosporangium thailandense Deinococcus caeni Diplococcus pneumoniae P
Dactylosporangium vinaceum Deinococcus radiodurans 1-, t..) Deinococcus radiophilus ..
0"
r., '7 Enterobacter Enterobacter kobei Faecalibacterium Flavobacterium "
E. aero genes E. ludwigii Faecalibacterium prausnitzii Flavobacterium antarctic urn E. amnigenus E. mori Fangia Flavobacterium aquatile E. agglomerans E. nimipressuralis Fangia hongkongensis Flavobacterium E. arachidis E. oiyzae Fastidiosipila aquidurense E. asburiae E. pulveris Fastidiosipila sanguinis Flavobacterium balustinum Iv n E. cancerogenous E. pyrinus Fusobacterium Flavobacterium croceum 1-3 t=1 E. cloacae E. radicincitans Fusobacterium nucleatum Flavobacterium cucumis Iv t..) o t..) E. cowanii E. taylorae Flavobacterium =
'a o .6.
t..) t..) un E. dissolvens E. turicensis daejeonense 0 n.) o E. gergoviae E. sakazakii Enterobacter soli Flavobacterium defluvii r..) o E. helveticus Enterococcus Flavobacterium degerlachei c...) .6.
.6.
t..) E. honnaechei Enterococcus durans Flavobacterium oe E. intermedius Enterococcus faecalis denitrificans Enterococcus faecium Flavobacterium filum Erwinia Flavobacterium flevense Erwinia hapontici Flavobacterium frigidarium Escherichia Flavobacterium mizutaii P
Escherichia coli Flavobacterium 2 -, 1-, okeanokoites 1-, ..
r., N) '7 '8 N) N) Gaetbulibacter Haemophilus Ideonella Janibacter Gaetbulibacter saemankumensis Haemophilus aegyptius Ideonella azotifigens Janibacter anophelis Gallibacterium Haemophilus aphrophilus Idiomarina Janibacter corallicola Gallibacterium anatis Haemophilus felis Idiomarina abyssalis Janibacter limosus Gallicola Haemophilus gallinarum Idiomarina baltica Janibacter melonis Iv n ,-i Gallicola barnesae Haemophilus haemolyticus Idiomarina fontislapidosi Janibacter terrae t=1 Iv Garciella Haemophilus influenzae Idiomarina loihiensis Jannaschia t..) o t..) o Garciella nitratireducens Haemophilus paracuniculus Idiomarina ramblicola Jannaschia cystaugens 'a o .6.
t..) t..) un Geobacillus Haemophilus parahaemolyticus Idiomarina seosinensis Jannaschia helgolandensis r..) o Geobacillus the rmoglucosidasius Haemophilus parainfluenzae Idiomarina zobellii Jannaschia pohangensis r..) o Geobacillus stearothermophilus Haemophilus Ignatzschineria Jannaschia rubra c...) .6.
.6.
t..) Geobacter paraphrohaemolyticus Ignatzschineria larvae oe Geobacter bemidjiensis Haemophilus parasuis Janthinobacterium Geobacter bremensis Haemophilus pittmaniae Ignavigranum Janthinobacterium Geobacter chapellei Hafnia Ignavigranum ruoffiae agaric idamno sum Geobacter grbiciae Hafnia alvei Ilumatobacter Janthinobacterium lividum Geobacter hydrogenophilus Hahella Ilumatobacter fluminis Jejuia P
Geobacter lovleyi Hahella ganghwensis Ilyobacter Jejuia pallidilutea 2 , 1-, Geobacter metallireducens Halalkalibacillus Ilyobacter delafieldii Jeotgalibacillus .
,-, ..
Geobacter pelophilus Halalkalibacillus halophilus Ilyobacter insuetus Jeotgalibacillus 2 '7 Geobacter pickeringii Helicobacter Ilyobacter polytropus alimentarius 0"
r., Geobacter sulfurreducens Helicobacter pylori Ilyobacter tartaricus Jeotgalicoccus Geodermatophilus Jeotgalicoccus halotolerans Geodermatophilus obscurus Gluconacetobacter Gluconacetobacter xylinus Iv n Gordonia m 1-d Gordonia rubripertincta w o t..) o 'a o .6.
t..) t..) un Kaistia Labedella Listeria ivanovii Micrococcus Nesterenkonia o t..) Kaistia adipata Labedella gwakjiensis L. marthii Micrococcus luteus Nesterenkonia holobia o t...) o Kaistia soli Labrenzia L. monocyto genes Micrococcus lylae Nocardia c,.) .6.
.6.
Kangiella Labrenzia aggregata L. newyorkensis Moraxella Nocardia argentinensis t..) oe Kangiella aquimarina Labrenzia alba L. riparia Moraxella bovis Nocardia corallina Kangiella koreensis Labrenzia alexandrii L. rocourtiae Moraxella nonliquefaciens Nocardia Labrenzia marina L. seeligeri Moraxella osloensis otitidiscaviarum Kerstersia Labrys L. weihenstephanensis Nakamurella Kerstersia gyiorum Labiys methylaminiphilus L. welshimeri Nakamurella multipartita P
Kiloniella Labiys miyagiensis Listonella Nannocystis 2 1-, Kiloniella laminariae Labiys monachus Listonella anguillarum Nannocystis pusilla 1-, ..
Klebsiella Labiys okinawensis Macrococcus Natranaerobius 2 '7 , K granulomatis Labiys portucalensis Macrococcus bovicus Natranaerobius 0 r., K oxytoca Marinobacter the rmophilus K pneumoniae Lactobacillus Marinobacter algicola Natranaerobius trueperi K terrigena [see below] Marinobacter biyozoorum Naxibacter K variicola Laceyella Marinobacter flavimaris Naxibacter alkalitolerans Kluyvera Laceyella putida Meiothermus Neisseria 1-d n Kluyvera ascorbata Lechevalieria Meiothermus ruber Neisseria cinerea 1-3 t=1 Iv Lechevalieria aerocolonigenes Neisseria denitrificans w o t..) Legionella Neisseria gonorrhoeae o 'a o .6.
t..) t..) un Kocuria [see below] Methylophilus Neisseria lactamica 0 t..) Kocuria roasea Listeria Methylophilus Neisseria mucosa o r..) o Kocuria varians L. aquatica methylotrophus Neisseria sicca c...) .6.
.6.
Kurthia L. booriae Microbacterium Neisseria subflava t..) oe Kurthia zopfii L. cornellensis Microbacterium Neptunomonas L. fleischmannii ammoniaphilum Neptunomonas japonica L. floridensis Microbacterium arborescens L. grandensis Microbacterium liquefaciens L. grayi Microbacterium oxydans P
L. innocua , -, o r., Lactobacillus , , , ,D
L. acetotolerans L. catenaformis L. mali L. parakefiri L. sakei r., L. acidifarinae L. ceti L. manihotivorans L. paralimentarius L. salivarius L. acidipiscis L. coleohominis L. mindensis L. paraplantarum L. sanfranciscensis L. acidophilus L. collinoides L. mucosae L. pentosus L. satsumensis Lactobacillus agilis L. composti L. murinus L. perolens L. secaliphilus Iv L. algidus L. concavus L. nagelii L. plantarum L. sharpeae n ,-i L. 116amster116116ius L. coryniformis L. namurensis L. pontis L. siliginis t=1 Iv t..) L. amylolyticus L. crispatus L. nantensis L. protectus L. spicheri o t..) o 'a L. amylophilus L. crustorum L. oligofermentans L. psittaci L. suebicus o .6.
t..) t..) un L. amylotrophicus L. curvatus L. oris L. rennini L. thailandensis o r..) L. amylovorus L. delbrueckii subsp. L. panis L. reuteri L. ultunensis o t..) o L. animalis Bulgaricus L. pantheris L. rhamnosus L. vaccinostercus c...) .6.
.6.
L. antri L. delbrueckii subsp. L. parabrevis L. rimae L. vaginalis t..) oe L. 117amster Delbrueckii L. parabuchneri L. rogosae L. versmoldensis L. 117amster117 L. delbrueckii subsp. Lactis L. paracasei L. rossiae L. vini L. bifermentans L. dextrinicus L. paracollinoides L. ruminis L. vitulinus L. brevis L. diolivorans L. parafarraginis L. saerimneri L. zeae L. buchneri L. equi L. homohiochii L. jensenii L. zymae P
L. camelliae L. equigenerosi L. iners L. johnsonii L. gastricus 2 1-, L. casei L. farraginis L. ingluviei L. kalixensis L. ghanensis 1-, ..
L. kitasatonis L. farciminis L. intestinalis L. kefiranofaciens L. graminis 2 '7 L. kunkeei L. fermentum L. fuchuensis L. kefiri L. hammesii , r., L. leichmannii L. fornicalis L. gallinarum L. 117amste L. 117amster L. lindneri L. fructivorans L. gasseri L. helveticus L. harbinensis L. malefermentans L. frumenti L. hilgardii L. hayakitensis Iv n ,-i Legionella t=1 1-d r..) Legionella adelaidensis Legionella drancourtii Candidatus Legionella jeonii Legionella quinlivanii o t..) o 'a Legionella anisa Legionella dresdenensis Legionella jordanis Legionella rowbothamii o .6.
t..) t..) un Legionella beliardensis Legionella drozanskii Legionella lansingensis Legionella rubrilucens 0 t..) o Legionella birminghamensis Legionella dumoffii Legionella londiniensis Legionella sainthelensi t..) o Legionella bozemanae Legionella eiythra Legionella longbeachae Legionella santicrucis c,.) .6.
.6.
t..) Legionella brunensis Legionella fairfieldensis Legionella lytica Legionella shakespearei oe Legionella busanensis Legionella fallonii Legionella maceachernii Legionella spiritensis Legionella cardiaca Legionella feeleii Legionella massiliensis Legionella steelei Legionella cherrii Legionella geestiana Legionella micdadei Legionella steigerwalth Legionella cincinnatiensis Legionella genomospecies Legionella monrovica Legionella taurinensis Legionella clemsonensis Legionella gormanii Legionella moravica Legionella tucsonensis P
Legionella donaldsonii Legionella gratiana Legionella nagasakiensis Legionella tunisiensis 2 1-, Legionella gresilensis Legionella nautarum Legionella wadsworthii 1-, .
Legionella hackeliae Legionella norrlandica Legionella waltersii 2 '7 Legionella impletisoli Legionella oakridgensis Legionella worsleiensis 0"
r., Legionella israelensis Legionella parisiensis Legionella yabuuchiae Legionella jamestowniensis Legionella pittsburghensis Legionella pneumophila Legionella quateirensis Iv n ,-i Oceanibulbus Paenibacillus Prevotella Quadrisphaera m 1-d t..) Oceanibulbus indolifex Paenibacillus thiaminolyticus Prevotella albensis Quadrisphaera granulorum o t..) o 'a Prevotella amnii o .6.
t..) t..) un Oceanicaulis Pantoea Prevotella bergensis Quatrionicoccus 0 n.) o Oceanicaulis alexandrii Pantoea agglomerans Prevotella bivia Quatrionicoccus r..) o Oceanicola Prevotella Prevotella brevis australiensis c,.) .6.
.6.
t..) Oceanicola batsensis Paracoccus Prevotella biyantii oe Oceanicola granulosus Paracoccus alcaliphilus Prevotella buccae Quinella Oceanicola nanhaiensis Paucimonas Prevotella buccalis Quinella ovalis Oceanimonas Paucimonas lemoignei Prevotella copri Oceanimonas baumannii Pectobacterium Prevotella dentalis Ralstonia Oceaniserpentilla Pectobacterium aroidearum Prevotella denticola Ralstonia eutropha P
Oceaniserpentilla haliotis Pectobacterium atrosepticum Prevotella disiens Ralstonia insidiosa 2 ,-, Oceanisphaera Pectobacterium Prevotella histicola Ralstonia mannitolilytica 1-, o r., Oceanisphaera don ghaensis betavasculorum Prevotella intermedia Ralstonia pickettii 2 '7 , Oceanisphaera litoralis Pectobacterium cacticida Prevotella maculosa Ralstonia 0 , Oceanithermus Pectobacterium carnegieana Prevotella marshii pseudosolanacearum Oceanithermus desulfurans Pectobacterium carotovorum Prevotella melaninogenica Ralstonia syzygii Oceanithermus profundus Pectobacterium chiysanthemi Prevotella micans Ralstonia solanacearum Oceanobacillus Pectobacterium cypripedii Prevotella multiformis Ramlibacter Oceanobacillus caeni Pectobacterium rhapontici Prevotella nigrescens Ramlibacter henchirensis Iv n Oceanospirillum Pectobacterium wasabiae Prevotella oralis Ramlibacter tataouinensis 1-3 t=1 Iv Oceanospirillum linum Planococcus Prevotella oris w o t..) o Planococcus citreus Prevotella oulorum 'a o .6.
t..) t..) un Planomicrobium Prevotella pallens Raoultella 0 n.) o Planomicrobium okeanokoites Prevotella salivae Raoultella ornithinolytica t...) o Plesiomonas Prevotella stercorea Raoultella planticola c...) .6.
.6.
t..) Plesiomonas shigelloides Prevotella tannerae Raoultella terrigena oe Proteus Prevotella timonensis Rathayibacter Proteus vulgaris Prevotella veroralis Rathayibacter caricis Providencia Rathayibacter festucae Providencia stuartii Rathayibacter iranicus Pseudomonas Rathayibacter rathayi P
Pseudomonas aeruginosa Rathayibacter toxicus 2 , 1-, Pseudomonas alcaligenes Rathayibacter tritici t..) .
o r., Pseudomonas anguillispetica Rhodobacter '7 , Pseudomonas fluorescens Rhodobacter sphaero ides o r., Pseudoalteromonas Ruegeria haloplanktis Ruegeria gelatinovorans Pseudomonas mendocina Pseudomonas pseudoalcaligenes Iv n Pseudomonas putida t=1 Iv Pseudomonas tutzeri w o t..) o Pseudomonas syringae 'a o .6.
t..) t..) un Psychrobacter o t..) o Psychrobacter faecalis t...) o Psychrobacter c...) .6.
.6.
t..) phenylpyruvicus oe Saccharococcus Sagittula Sanguibacter Stenotrophomonas Tatlockia Saccharococcus the rmophilus Sagittula stellata Sanguibacter keddieii Steno trophomonas Tatlockia maceachernii Sanguibacter suarezii maltophilia Tatlockia micdadei Saccharomonospora Salegentibacter P
Streptococcus Tenacibaculum 2 Saccharomonospora azurea Salegentibacter sale gens Saprospira 1-, Tenacibaculum n . ) 1-, Saccharomonospora cyanea Saprospira grandis r., [also see below]
amylolyticum r.,0 Salimicrobium , Saccharomonospora viridis ' Tenacibaculum discolor '8 Salimicrobium album Sarcina Streptomyces r., Tenacibaculum Saccharophagus Sarcina maxima Streptomyces Salinibacter gallaicum Saccharophagus degradans Sarcina ventriculi achromo genes Tenacibaculum Salinibacter ruber Streptomyces cesalbus Saccharopolyspora Sebaldella lutimaris Salinicoccus Streptomyces cescaepitosus Tenacibaculum Saccharopolyspora eiythraea Sebaldella term itidis Iv Streptomyces cesdiastaticus n Salinicoccus alkaliphilus mesophilum 1-3 Saccharopolyspora gregorii t=1 Streptomyces cesexfoliatus Iv Salinicoccus hispanicus Tenacibaculum Saccharopolyspora hirsuta t..) o Streptomyces fimbriatus t..) Salinicoccus roseus skagerrakense =
Saccharopolyspora hordei 'a Streptomyces fradiae o .6.
t..) t..) un Saccharopolyspora rectivirgula Streptomyces fulvissimus Tepidanaerobacter o t..) Salinispora Serratia o Saccharopolyspora spinosa Streptomyces griseoruber Tepidanaerobacter t...) o Salinispora arenicola Serratia fonticola Saccharopolyspora taberi Streptomyces griseus syntrophicus c...) .6.
.6.
Salinispora tropica Serratia marcescens t..) Streptomyces lavendulae Tepidibacter oe Saccharothrix Streptomyces Tepidibacter Salinivibrio Sphaerotilus Saccharothrix australiensis phaeochromo genes formicigenes Salinivibrio costicola Sphaerotilus natans Saccharothrix coeruleofusca Streptomyces Tepidibacter Saccharothrix espanaensis the rmodiastaticus thalassicus Salmonella Sphingobacterium Saccharothrix longispora Streptomyces tube rcidicus Thermus Salmonella bongori Sphingobacterium multivorum P
Saccharothrix mutabilis Thermus aquaticus Salmonella enterica Saccharothrix syringae -J,-, ermus fiiform Staphylococcus Thlis t..) Salmonella subterranea .i.
t..) Saccharothrix tangerinus r., [see below]
The rmus the Salmonella typhi h hil r.,0 , Saccharothrix texasensis 0"
N) N) Staphylococcus S. arlettae S. microti S. equorum S. schleiferi S. agnetis S. muscae S.
S. sciuri felis S. nepalensis S.
aureus S. fleurettii S. simiae S. auricularis S. pasteuri Iv n S. gallinarum S. simulans 1-3 S. capitis S. petrasii t=1 S. haemolyticus S. stepanovicii Iv t..) S. caprae S. pettenkoferi o t..) S. hominis S. succinus o S. carnosus S. piscifermentans 'a o .6.
t..) t..) un S. caseolyticus S. hyicus S. pseudintermedius S. vitulinus 0 t..) o S. chromo genes S. intermedius S. pseudolugdunensis S. warneri t...) o S. cohnii S. kloosii S. pulvereri S. xylosus c...) .6.
.6.
S. condimenti S. leei S. rostri t..) oe S. delphini S. lentus S. saccharolyticus S. devriesei S. lugdunensis S. saprophyticus S. epidermidis S. lutrae S. lyticans S. massiliensis P
Streptococcus , , t..) .
Streptococcus agalactiae Streptococcus infantarius Streptococcus orisratti Streptococcus the rmophilus ..
N, Streptococcus anginosus Streptococcus iniae Streptococcus parasanguinis Streptococcus sanguinis , , , ,D
, Streptococcus bovis Streptococcus intermedius Streptococcus peroris Streptococcus sobrinus "
N, Streptococcus canis Streptococcus lactarius Streptococcus pneumoniae Streptococcus suis Streptococcus constellatus Streptococcus milleri Streptococcus Streptococcus uberis Streptococcus downei Streptococcus mitis pseudopneumoniae Streptococcus vestibularis Streptococcus dysgalactiae Streptococcus mutans Streptococcus pyo genes Streptococcus viridans Iv Streptococcus equines Streptococcus oralis Streptococcus ratti Streptococcus n ,-i Streptococcus faecalis Streptococcus tigurinus Streptococcus salivariu zooepidemicus t=1 Iv t..) o Streptococcus ferus t..) o 'a o .6.
t..) t..) un C
t..) o t..) o Uliginosibacterium Vagococcus Vibrio Virgibacillus Xanthobacter c,.) .6.
.6.
t..) Vagococcus carniphilus Vibrio aero genes Virgibacillus Xanthobacter agilis oe Uliginosibacterium gangwonense Vagococcus elongatus Vibrio aestuarianus halodenitrificans Xanthobacter Ulvibacter Vagococcus fessus Vibrio albensis Virgibacillus aminoxidans Ulvibacter litoralis Vagococcus fluvialis Vibrio alginolyticus pantothenticus Xanthobacter Umezawaea Vagococcus lutrae Vibrio campbellii autotrophicus Weissella Umezawaea tan gerina Vagococcus salmoninarum Vibrio cholerae Xanthobacter flavus P
Weissella cibaria Undibacterium Vibrio cincinnatiensis Xanthobacter tagetidis 2 ,-, Variovorax Weissella confusa ;3' t..) Undibacterium pigrum Vibrio coralliilyticus Xanthobacter viscosus 2 .6.
r., Variovorax boronicumulans Weissella halotolerans Ureaplasma Vibrio cyclitrophicus Xanthomonas 2' ' 7 Variovorax dokdonensis Weissella hellenica 0"
Ureaplasma urealyticum Vibrio diazotrophicus Xanthomonas , ,3"
Variovorax paradoxus Vibrio fluvialis Weissella kandleri albilineans Variovorax soli Weissella koreensis Ureibacillus Vibrio furnissii Xanthomonas alfalfae Weissella minor Ureibacillus composti Vibrio gazo genes Xanthomonas Veillonella Weissella Ureibacillus suwonensis Vibrio halioticoli arboricola Veillonella atypica aramesenteroides Ureibacillus terrenus Vibrio harveyi p Xanthomonas Iv Veillonella caviae n Weissella soli Ureibacillus the rmophilus Vibrio ichthyoenteri axonopodis t=1 Veillonella criceti Iv Weissella thailandensis t..) Ureibacillus the rmosphaericus Vibrio mediterranei Xanthomonas o Veillonella dispar t..) Weissella viridescens o Vibrio metschnikovii campestris 'a Veillonella montpellierensis o .6.
t..) t..) un Veillonella parvula Vibrio mytili Xanthomonas citri o Williamsia t..) o Veillonella ratti Vibrio natriegens Xanthomonas codiaei r..) o Williamsia marianensis Veillonella rodentium Vibrio navarrensis Xanthomonas c...) .6.
.6.
Williamsia mans t...) Vibrio nereis cucurbitae oe Venenivibrio Williamsia serinedens Vibrio nigripulchritudo Xanthomonas Venenivibrio stagnispumantis Vibrio ordalii euvesicatoria Winogradskyella Vibrio orientalis Xanthomonas fragariae Wino gradskyella Vibrio parahaemolyticus Xanthomonas fuscans thalassocola Verminephrobacter Vibrio pectenicida Xanthomonas gardneri P
Vibrio penaeicida Xanthomonas hortorum Verminephrobacter eiseniae Wolbachia 2 1-, Vibrio proteolyticus Xanthomonas hyacinthi ? ;3' t..) Wolbachia persica ..
un r., Vibrio shilonii Xanthomonas perforans 2 '7 , Vibrio splendidus Xanthomonas phaseoli 0 N) Verrucomicrobium r., Vibrio tubiashii Xanthomonas pisi Verrucomicrobium spinosum Wolinella Vibrio vulnificus Xanthomonas populi Wolinella succino genes Xanthomonas theicola Xanthomonas translucens Iv n ,-i Zobellia m 1-d Zobellia galactanivorans Xanthomonas w o t..) o Zobellia uliginosa vesicatoria 'a o .6.
t..) t..) un C
Zoogloea Xylella t..) o t..) o Zoo gloea ramigera Xylella fastidiosa .6.
Zoo gloea resiniphila Xylophilus .6.
t...) oe Xylophilus ampelinus Xenophilus Yangia Yersinia mollaretii Zooshikella Zobellella Xenophilus azovorans Yangia pacifica Yersinia philomiragia Zooshikella ganghwensis Zobellella denitrificans Xenorhabdus Yersinia pestis Zobellella taiwanensis P
Yaniella Zunongwangia Xenorhabdus beddingii Yersinia pseudotuberculosis 2 , 1-, Yaniella flava Zunongwangia profunda .3 t..) Xenorhabdus bovienii Yersinia rohdei .2 o r., Yaniella halotolerans Xenorhabdus cabanillasii Yersinia ruckeri 2' , Zymobacter Zeaxanthinibacter Xenorhabdus doucetiae , Yeosuana Yokenella Zymobacter palmae Zeaxanthinibacter r.,"
Xenorhabdus griffiniae Yeosuana aromativorans enoshimensis eiensburg Xenorhabdus hominickii Yokenella reg Zymomonas Xenorhabdus koppenhoeferi Yersinia Zymomonas mobilis Zhihengliuella Yonghaparkia Xenorhabdus nematophila Yersinia aldovae Zhihengliuella Yonghaparkia alkaliphila Xenorhabdus poinarii Zymophilus 1-d Yersinia bercovieri halotolerans n ,-i Xylanibacter Zymophilus paucivorans Yersinia enterocolitica Zavarzinia Xylanibacterium t=1 1-d Xylanibacter oiyzae Zymophilus raffinosivorans t..) Yersinia entomophaga Zavarzinia compransoris Xylanibacterium ulmi o t..) o 'a Yersinia frederiksenii o .6.
t..) t..) un .,.., '.-"E3 e) ,'12.; = ,t2 4-=
= ,..4 ,-.=
= 4t = 4t = ,4 = ,4 4.1 4.1 }... }...
TABLE 2: SaPIs Element Staphylococcal genome Baba* Lindsay and Size Inducing Holden' (kb) phages SaP14 S. aureus str. MRSA252 NA SaP14 15.1 Endogenous prophage SaP11028 S. aureus str. NY940 NA NA 15.6 Endogenous prophage SaPlbovl S. aureus str. RF122 vSa2 NA 15.8 91 1 and 80a SaPlbov2 S. aureus str. V329 NA NA 27 80a SaP1m4 S. aureus str. mu50 v5a3 NA 14.4 Endogenous type I prophage SaPlmw2 S. aureus str. mw2 v5a3 SaP13 14.4 Endogenous type II prophage SeP11 S. aureus str. FRI909 NA NA 9.9 Not known ShP12 S. haemolyticus v5h2 NA 16.6 Not known SaP11 S. aureus str. RN4282 vSal NA 15.2 80a and 913 SaP13 S. (WIWI'S' str. COL vSal SaP11 15.6 Not known SaP15 S. aureus str. USA300 NA Na 14.0 Not known SaP1n1 and S. aureus str. n315 and S. v5a4 SaP12 15 80a SaP1m1 aureus str. mu50, respectively type 1 SaP12 S. aureus str. RN3984 NA NA 14.7 80 and 80a SaRlfusB S. aureus European fusidic NA NA 20.7 Not known acid-resistant impetigo clone SaP1122 S. aureus str. RF122 NA NA 17.9 Endogenous prophage SaP16.L S. aureus strains 8325, COL, v5a4 NA 3.14 Not known USA300, M55A476, type II
Newman and mw2 SsP115305 S. saprophyticus str. 15305 vSs15305 NA 16.7 Not known [N/A, not applicable; *Nomenclature proposed by Baba et al; # Nomenclature proposed by Lindsey &
Holden et all Table 3: Titers of SA100 packaged CGVs after production SA100 Native phage strain TFU/mL PFU/mL
EMG2 1.4E+10 n.d C-la 2.2E+10 <20 C-1792 5.2E+09 <20 SUBSTITUTE SHEET (RULE 26) Table 4: Groups (Example 5) Group Preparation (per 500 I) vehicle 139 ul 9% Sod.carb + 361 I H20 SA100 139 ul 9% Sod.carb + 330 I p114 + 31 I H20 SA100 + induction of CRISPR system 170 I Inducers+Sod.carb + 330 I p114 +
Table 5: Clinical Scores Score 0 healthy Score 1 Minor clinical signs of infection (slower movements, light piloerection in the skin) Score 2 Moderate signs of infection (slower movements, slightly pinched eyes, lack of curiosity or changed activity) Score 3 Severe signs of infection (reduced movements, pinched eyes, changed body posture) Score 4 Severe signs of infection (stiff movements, forced ventilation, pinched eyes) Sacrificed.
Score 5 The mouse does not move, is cold, lying on the side. Sacrificed Score 6 The mouse is dead Table 6: Sequences w o SEQ ID NO: DESCRIPTION SEQUENCE
w o i-J
4,.
1 terS nucleotide AATTGGCAGTAAAGTGGCAGTTTTTGATACCTAAAATGAGATATTATGATAGTGTAGGATAT
w oe sequence TGACTATCTTACTGCGTTTCCCTTATCGCAATTAGGAATAAAGGATCTATGTGGGTTGGCTG
ATTATAGCCAATCCTTTTTTAATTTTAAAAAGCGTATAGCGCGAGAGTTGGTGGTAAATGAA
ATGAACGAAAAACAAAAGAGATTCGCAGATGAATATATAATGAATGGATGTAATGGTAAAAA
AG CAG CAATTTCAG CAG GTTATAGTAAGAAAACAG CAGAGTCTTTAG CAAGTCGATTGTTAA
P
GAAATGTTAATGTTTCGGAATATATTAAAGAACGATTAGAACAGATACAAGAAGAGCGTTTA
, , 1¨
.3 =
ATGAGCATTACAGAAGCTTTAGCGTTATCTGCTTCTATTGCTAGAGGAGAACCTCAAGAGGC
, , TTACAGTAAGAAATATGACCATTTAAACGATGAAGTGGAAAAAGAGGTTACTTACACAATCA
, , ,, ,, CACCAACTTTTGAAGAGCGTCAGAGATCTATTGACCACATACTAAAAGTTCATGGTGCGTAT
ATCGACAAAAAAGAAATTACTCAGAAGAATATTGAGATTAATATTGGTGAGTACGATGACGA
AAGTTAAATTAAACTTTAACAAACCATCTAATGTTTTCAACAG
2 Packaging signal GCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGCGTGTCAGTGCAACTGCATTAA
AACCG 1-d n sequence CCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCCAGAAGTTAGTTAATTATTTGTGTAGTCAAAG
t=1 CTTGACTACATACCTCGTTAATACATTG GAG CATAATGAAGAAAATCTATG G CCTATG
GTCCAAAACTGTCTTTTTTGATG G CAC 1-d w o TATCCTGAAAAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTCAGTGTCGCAAGATCCTTAAGAATTC
w o 'a o 4,.
w w vi 3 Cos packaging signal GCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGCGTGTCAGTGCAACTGCATTAA
AACCG
sequence CCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGTTAATTATTTGTGTAGTCAAAG
TGC w o w CTTCAGTACATACCTCGTTAATACATTGGAGCATAATGAAGAAAATCTATGGCCTATGGTC
i-J
4,.
4,.
4 P2/P4 packaging TGCATTAAAACCGCCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGC
w oe signal sequence sid ATGTCTGACCACACTATCCCTGAATATCTGCAACCCGCACTGGCACAACTGGAAAAGGCCAGAGCCGCCCATCTTGAGA
ACGC
CCGCCTGATGGATGAGACCGTCACGGCCATTGAACGGGCAGAGCAGGAAAAAAATGCGCTGGCGCAGGCCGACGGAAAC
GA
CGCTGACGACTGGCGCACGGCCTTTCGTGCAGCCGGTGGTGTCCTGAGCGACGAGCTGAAACAGCGCCACATTGAGCGC
GTG
GCACGCCGGGAGCTGGTACAGGAATATGACAATCTGGCCGTGGTGCTGAATTTCGAACGTGAACGCCTGAAAGGGGCGT
GTG
ACAGCACGGCCACCGCCTACCGGAAGGCACATCATCACCTTCTGAGTCTGTATGCAGAGCATGAGCTGGAACACGCCCT
GAAT P
GAAACCTGTGAGGCGCTTGTCCGGGCAATGCATCTGAGCATTCTGGTACAGGAAAATCCGCTCGCCAACACCACCGGCC
ATCA , 1¨
GGGCTACGTCGCACCGGAAAAGGCTGTCATGCAGCAGGTGAAATCATCGCTGGAACAGAAAATTAAACAGATGCAAATC
AGC , 1¨
CTCACCGGCGAGCCGGTTCTCCGGCTGACCGGACTGTCAGCGGCAACACTCCCGCACATGGATTATGAGGTGGCAGGCA
CACC
GGCACAGCGCAAGGTGTGGCAGGACAAAATAGACCAGCAGGGAGCAGAGCTTAAGGCCAGAGGGCTGCTGTCATGA
, , , , ,, 6 psu ATGGAAAGCACAGCCTTACAGCAGGCCTTTGACACCTGTCAGAATAACAAAGCAGCATGGCTGCAACGCAAAAATGAGC
TGG ,, CAGCGGCCGAACAGGAATATCTGCGGCTTCTGTCAGGAGAAGGCAGAAACGTCAGTCGCCTGGACGAATTACGCAATAT
TATC
GAAGTCAGAAAATGGCAGGTGAATCAGGCCGCCGGTCGTTATATTCGTTCGCATGAAGCCGTTCAGCACATCAGCATCC
GCGA
CCGGCTGAATGATTTTATGCAGCAGCACGGCACAGCACTGGCGGCCGCACTGGCACCGGAGCTGATGGGCTACAGTGAG
CTG
ACGGCCATTGCCCGAAACTGTGCCATACAGCGTGCCACAGATGCCCTGCGTGAAGCCCTTCTGTCCTGGCTTGCGAAGG
GTGA
AAAAATTAATTATTCCGCACAGGATAGCGACATTTTAACGACCATCGGATTCAGGCCTGACGTGGCTTCGGTGGATGAC
AGCC 1-d GTGAAAAATTCACCCCTGCGCAGAACATGATTTTTTCGCGTAAAAGTGCGCAACTGGCATCACGTCAGTCAGTGTAA
n ,-i m ,-o 7 Delta ATGATTTACTGTCCGTCGTGTGGACATGTTGCTCACACCCGTCGCGCACATTTCATGGACGATGGCACCAAGATAATGA
TTGCA w o w CAGTGCCGGAATATTTATTGCTCTGCGACATTTGAAGCGAGTGAAAGCTTTTTCTCTGACAGTAAAGATTCAGGAATGG
AATAC
'a o ATTTCAGGCAAACAGAGATACCGCGATTCACTGACGTCAGCCTCCTGCGGTATGAAACGCCCGAAAAGAATGCTTGTTA
CCGG
w w vi GTGCACGGATCCGGGCTGTGGTCTGGTGTTTAAAACGCTTCAGACCATCAACCGCTTCATTGTCCGCCCGGTCACGCCG
GACG r..) o r..) AACTGGCAGAACGCCTGCATGAAAAACAGGAACTGCCGCCAGTACGGTTAAAAACACAATCATATTCGCTGCGTCTGGA
ATGA
i-J
.6.
.6.
8 Q through S of P2 TCAGTCGTTGTCAGTGTCCAGTGAGTAGTTTTTAAAGCGGATGACCTCCTGACCGAGCCAGCCGTTTATCTCGCGGATC
CTGTC r..) oe CTGTAACGGGATAAGCTCATTGCGGACAAAGACCTTTGCCACTTTCTCAATATCACCCAGCGACCCGACGTTCTCCGGC
TTGCC
ACCCATCAACTGAAAGGGGATGCGGTGCGCGTCCAGCAGGTCAGCGGCGCTGGCTTTTTTGATATTAAAAAAATCGTCC
TTCG
TCGCCACTTCACTGAGGGGGATAATTTTAATGCCGTCGGCTTTCCCCTGTGGGGCATAGAGAAACAGGTTTTTAAAGTT
GTTGC
GGCCTTTCGACTTGACCATGTTTTCGCGAAGCATTTCGATATCGTTGCGATCCTGCACGGCATCGGTGACATACATGAT
GTATCC
GGCATGTGCGCCATTTTCGTAATACTTGCGGCGGAACAACGTGGCCGACTCATTCAGCCAGGCAGAGTTAAGGGCGCTG
AGAT
ATTCCGGCAGGCCGTACAGCTCCTGATTAATATCCGGCTCCAGCAGGTGAAACACGGAGCCGGGCGCGAAGGCTGTCGG
CTC
GTTGAAGGACGGCACCCACCAGTAAACATCCTCTTCCACGCCACGGCGGGTATATTTTGCCGGTGAGGTTTCCAGTCTG
ATGAC P
CTTACCGGTGGTGCTGTAACGCTTTTCCAGAAACGCATTACCGAACACCAGAAAATCCAGCACAAAGCGGCTGAAATCC
TGCT L.
, L.
, 1¨
GGGAAAGCCATGGATGCGGGATAAATGTCGAGGCCAGAATATTGCGTTTGACGTAAATCGGCGAGCTGTGATGCACGGC
AGC .3 .
r..) CCGCAGGCTTTTTGCCAGACCGGTAAAGCTGACCGGTGGCTCATACCATCTGCCGTTACTGATGCACTCGACGTAATCC
AGAAT
, GTCACGGCGGTCGAGTACCGGCACCGGCTCACCAAAGGTGAATGCCTCCATTTTCGGGCCGCTGGCGGTCATTGTTTTT
GCCG , , CAGGTTGCGGTGTTTTCCCTTTTTTCTTGCTCATCAGTAAAACTCCAGAATGGTGGATGTCAGCGGGGTGCTGATACCG
GCGGT
GAGTGGCTCATTTAACAGGGCGTGCATGGTCGCCCAGGCGAGGTCGGCGTGGCTGGCTTCCTCGCTGCGGCTGGCCTCA
TAG
GTGGCGCTGCGTCCGCTGCTGGTCATGGTCTTGCGGATAGCCATAAACGAGCTGGTGATGTCGGTGGCGCTGACGTCGT
ATTC
CAGACAGCCACGGCGGATAACGTCTTTTGCCTTGAGCACCATTGCGGTTTTCATTTCCGGCGTGTAGCGGATATCACGC
GCGGC
GGGATAGAACGAGCGCACGAGCTGGAACACGCCGACACCGAGGCCGGTGGCATCAATACCGATGTATTCGACGTTGTAT
TTT
TCGGTGAGTTTGCGGATGGATTCCGCCTGGGTGGCAAAGTCCATGCCTTTCCACTGGTGACGCTCAAGTATTCTGAATT
TGCCA
1-d CCGGCCACCACCGGCGGTGCCAGTACCACGCATCCGGCGCTGTCGCCACGGTGTGACGGGTCGTAACCAATCCATACCG
GGC n GGGAGCCGAACGGATTGGCGGCAAACGGCGCATAGTCTTCCCATTCTTCCAGCGTGTCGACCATGCAGCGTTGCAGCTC
CTCG t=1 1-d AACGGGAACACCGATGCCTTGTCGTCAACAAATTCACACATGAACAGGTTTTTAAAATCGTCGGCGCTGTTTTCGCGTT
TGAGC r..) o r..) TGCTCAATGTCGAACAGCGTGCAGCCGCCTTTCAGGGCGTCCTCAATGGTGACAATCTGTCGCCACTGGCCGTCCGCAC
AGAG =
'a AAGCCCACCGGCAAGGGCGTTATGACTGACGTCGATTTCCACGCGTTCGGCGGCGCTGGCGCGTCCCCGGTTAAACAGT
TCAC o .6.
r..) r..) un CCGACCAGAACGGGTAGGCGTCGTGCGCCAGCGTGGACGGGGTGGAGAAATAGGTCGAGCGCAGGTGACTCTGTGAGGC
CA
TACCTGATGCCACCTTACGCAGTACCTGAAAATTCGGGATCCAGAAAATCTCATCGACGTACAGGTCGCCGTTATGACT
CTGCG n.) o n.) CGGTGTTGGAGTTGGTGCCGAGAAAAATCAGTTTTGCGCCGTTATTGCCCAGGACAATCGGGTCACCGGTCAGGTCAAC
GTCA
i-J
ACCAGACGGGCAAAGGCGATGATGTATTCGCGGAACACATACGCCTGTGTTTTACTGGCCGACAGAAAAATCTGGTTAT
GACC .6.
.6.
n.) GGTTTTCAGGGCACGCAGCAGCGCCTCGCGGGAAAAATAAAACGTCGCGCCAATCTGGCGGGATTTCAGGATATCGCGG
ATG oe CGGTGCTCAAGCCCGGCACGATACCAGTGCAGCTGATAGTCGAAAGACTGCTCAAAGAAAATCTGCTCCAGCTTTTCGA
TGGC
CTCGTCACTGAAAAAATTCTTTTTCGGTTTGCGCCGTCCGCCTTTGTTACGGTTAGCGACGTTCGGATTAAGGTCTGCC
TCGTTG
CCGGTCTGGCTGTAGCGGTTGACCCGTGCCAGTCGTTCAATCTGGCGTCCCAGCAGGTCAATTTCCTTGAAGTCACCGC
CGGTT
TTCTGTGGTTTGATGATGAGCTGGGTCAGCCGCGCTTCCAGACTCATTTCGACACGGCTGATGGGGGCAACGCTGTCCC
AGCC
GTCGCGCTGTTTCCAGCTCTGCACTGTCGGGCGTTTCATCTGCAACATGGCGGCAATCTGCGGCACGGAAAACCCCTGC
CAGTA
CAGCAGCGCCGCCTGACGACGCGGGTCGTGTAAAAGAGTGGTGTCTGTGGTGATGGTCATGAATACCTCGCCGTGATGA
ATA
P
CACGGCAAGGCTACTGAGTCGCGCCCCGCGATTCGCTAAGGTGCTGTTGTGTCAGTGATAAGCCATCCGGGACTGATGG
CGG
AGGATGCGCATCGTCGGGAAACTGATGCCGACATGTGACTCCTCTAATCACTATTCAGGACTCCTGACAATGGCAAAAA
AAGT
CTCAAAATTCTTTCGTATCGGCGTTGAGGGTGACACCTGTGACGGGCGTGTCATCAGTGCGCAGGATATTCAGGAAATG
.3 AAACCTTTGACCCGCGTGTCTATGGTTGCCGCATTAACCTGGAACATCTGCGCGGCATCCTGCCTGACGGTATTTTTAA
ATGGCGATGTGGCCGAACTGAAGGCCGAAAAGATTGACGATGATTCGGCGCTGAAAGGCAAATGGGCGCTGTTTGCGAA
AAT
.31 .3 CACCCCGACCGATGACCTTATCGCGATGAACAAGGCCGCGCAGAAGGTCTACACCTCAATGGAAATTCAGCCGAACTTT
GCCA
ACACCGGCAAATGTTATCTGGTGGGTCTGGCCGTCACCGATGACCCGGCAAGCCTCGGCACGGAATACCTGGAATTCTG
CCGC
ACGGCAAAACACAACCCCCTGAACCGCTTCAAATTAAGCCCTGAAAACCTGATTTCAGTGGCAACGCCTGTTGAGCTGG
AATTT
GAAGACCTGCCTGAAACCGTGTTCACCGCCCTGACCGAAAAGGTGAAGTCCATTTTTGGCCGCAAACAGGCCAGCGATG
ATGC
CCGTCTGAATGACGTGCATGAAGCGGTGACCGCTGTTGCTGAACATGTGCAGGAAAAACTGAGCGCCACTGAGCAGCGC
CTC
GCTGAGATGGAAACCGCCTTTTCTGCACTTAAGCAGGAGGTGACTGACAGGGCGGATGAAACCAGCCAGGCATTCACCC
GCC
IV
TGAAAAACAGTCTCGACCACACCGAAAGTCTGACCCAGCAGCGCCGCAGCAAAGCCACCGGCGGTGGCGGTGACGCCCT
GAT n GACGAACTGCTGACCGGCGTCAGTCAGTCCGGGAAAACCTTCACGATTAACCCTTAATTTCAGGAAAAACTATGCGCCA
GGAA t=1 tl ACCCGCTTTAAATTTAATGCCTACCTGTCCCGTGTTGCCGAACTGAACGGCATCGACGCCGGTGATGTGTCGAAAAAAT
o GTTGAACCGTCGGTCACCCAGACCCTGATGAACACCATGCAGGAGTCCTCTGACTTTCTGACCCGCATCAATATTGTGC
CGGTC 'a o AGCGAAATGAAAGGGGAAAAAATTGGTATCGGTGTCACCGGCTCCATCGCCAGCACTACCGACACTGCCGGTGGTACCG
AGC tt n.) un GTCAGCCGAAGGACTTCTCGAAGCTGGCGTCAAACAAGTACGAATGCGACCAGATTAACTTCGATTTTTATATCCGCTA
CAAAA
CGCTGGACCTGTGGGCGCGTTATCAGGATTTCCAGCTCCGTATCCGTAACGCCATTATCAAACGCCAGTCCCTTGATTT
CATCAT n.) o n.) GGCCGGTTTTAACGGCGTGAAGCGTGCCGAAACCTCTGACCGCAGCAGCAATCCGATGTTGCAGGATGTGGCGGTCGGC
TGG
i-J
CTGCAGAAATACCGCAATGAAGCACCGGCGCGCGTGATGAGCAAGGTCACTGACGAGGAAGGCCGCACCACCTCTGAGG
TTA .6.
.6.
n.) TCCGCGTGGGTAAGGGCGGTGATTATGCCAGCCTTGATGCACTGGTGATGGATGCGACCAACAACCTGATTGAACCGTG
GTAT oe CAGGAAGACCCTGACCTTGTGGTGATTGTGGGGCGTCAGCTACTGGCGGACAAGTATTTCCCCATCGTCAACAAGGAGC
AGG
ACAACAGCGAAATGCTGGCCGCTGACGTCATCATCAGCCAGAAACGCATCGGTAACCTACCAGCGGTACGCGTCCCGTA
CTTC
CCGGCGGATGCGATGCTCATCACGAAGCTGGAAAACCTGTCCATCTACTACATGGATGACAGCCATCGCCGCGTGATTG
AGGA
AAACCCGAAACTCGACCGCGTGGAGAACTACGAGTCAATGAACATTGATTACGTGGTGGAAGACTACGCCGCCGGTTGT
CTG
GTGGAAAAAATCAAGGTCGGTGACTTCTCCACACCGGCTAAGGCGACCGCAGAGCCGGGAGCGTAACCGATGACGAGTC
CCG
CACAGCGCCACATGATGCGGGTCTCGGCAGCGATGACCGCGCAGCGGGAAGCCGCCCCGCTGCGACATGCAACTGTCTA
TGA
P
GCAGATGCTGGTTAAGCTCGCCGCAGACCAGCGCACACTGAAAGCGATTTACTCAAAAGAGCTGAAGGCCGCAAAAAAA
CGC
GAACTGCTGCCGTTCTGGTTGCCGTGGGTGAACGGCGTGCTGGAGCTGGGCAAAGGTGCACAGGATGACATTCTGATGA
CGG
TCATGCTGTGGCGTCTGGATACCGGCGATATTGCCGGTGCGCTGGAGATTGCCCGTTATGCCCTGAAGTACGGTCTGAC
.6.
.3 CCGGGTAAACACCGCCGTACCCCGCCGTACATGTTCACCGAGGAGGTAGCGCTTGCGGCCATGCGCGCTCACGCTGCCG
GTCTGTGGATACCCGCCTGCTGACGGAGACCCTTGAACTGACCGCCACGGCTGACATGCCTGATGAAGTGCGCGCAAAG
CTGC
.31 .3 ACAAAATCACCGGTCTGTTTCTGCGTGACGGTGGTGATGCCGCCGGTGCGCTGGCGCACCTGCAACGTGCGACACAGCT
CGAC
TGTCAGGCAGGCGTCAAAAAAGAGATTGAACGACTGGAGCGGGAGCTGAAACCGAAGCCGGAGCCGCAGCCCAAAGCGG
CC
ACCCGCGCCCCGCGTAAGACCCGGAGCGTGACACCGGCAAAACGTGGACGCCCGAAAAAGAAAGCCAGTTAACAACCGA
ATG
CGCCCCGCGCCAGGGCGGCACGCCGGTCAGTGACGGTGAATCACCTGACACTGCACCGGCGTCCACCGCCCGACTTTTC
AGAG
GTAGTCATGATGACGCTGATTATTCCGCGAAAGGAGGCTCCCGTGTCCGGTGAGGGTACGGTGGTCATCCCGCAACCGG
CAG
GCGACGAGCCGGTGATTAAAAACACGTTCTTTTTTCCCGATATCGACCCGAAGCGCGTCCGGGAACGTATGCGCCTTGA
GCAG
IV
ACCGTCGCCCCCGCCCGTCTGCGTGAGGCCATCAAGTCAGGCATGGCTGAAACGAATGCGGAGCTGTACGAGTACCGCG
AAC n AGAAAATTGCCGCCGGTTTTACGCGTCTGGCTGACGTCCCGGCGGACGATATCGACGGTGAAAGCATCAAGGTTTTTTA
CTAC t=1 tl GAGCGCGCCGTGTGTGCGATGGCGACCGCGTCGCTTTATGAGCGTTATCGCGGTGTGGATGCCAGTGCGAAAGGCGACA
o AGGCTGACAGCATTGACAGCACCATTGATGAGCTGTGGCGGGATATGCGCTGGGCGGTGGCGCGCATCCAGGGCAAGCC
GC 'a o GCTGCATCGTGAGTCAAATCTGATGAAGACCTTTGCGCTACAGGGCGACACGCTCGACGCCATTTGTGTCCGCTATTAC
GGGC tt n.) un GCACTGAGGGCGTGGTTGAGACCGTGCTCGCCGCAAATCCGGGACTGGCTGAACTGGGGGCGGTGCTGCCACACGGCAC
CG
CCGTCGAACTGCCCGACGTTCAGACCGCGCCCGTGGCTGAAACTGTCAATCTGTGGGAGTAACGCATGACAGCAGAAGA
AAA n.) o n.) AAGCGTCCTGTCGCTTTTCATGATTGGGGTGCTGATTGTTGTCGGCAAGGTGCTTGCCGGTGGTGAACCTATCACCCCG
CGTCT
i-J
GTTTATCGGGCGCATGTTGCTCGGTGGTTTTGTCTCGATGGTTGCCGGTGTTGTTCTGGTGCAGTTTCCTGACCTGTCA
CTGCCA .6.
.6.
n.) GCGGTGTGCGGCATCGGCTCCATGCTGGGTATCGCCGGTTATCAGGTGATTGAGATTGCCATTCAGCGCCGCTTTAAGG
GCAG oe GGGGAAACAGTAATGCCGGTAATTAACACGCATCAGAATATCGCCGCCTTTCTCGACATGCTGGCCGTGTCCGAAGGGA
CGGC
GAATCATCCACTGACGAAAAACCGGGGCTATGACGTGATAGTCACCGGACTGGACGGGAAGCCGGAAATTTTCACCGAC
TAC
AGTGACCACCCGTTCGCACATGGCCGACCGGCGAAGGTGTTTAACCGTCGCGGTGAAAAATCCACGGCCTCCGGTCGCT
ATCA
GCAGCTTTACCTGTTCTGGCCGCATTACCGCAAACAGCTTGCCCTGCCGGATTTCAGTCCGTTGTCACAGGACAGACTC
GCCAT
TCAGTTGATCCGCGAACGCGGAGCACTGGATGACATCCGGGCGGGACGCATTGAGCGCGCCATTTCACGCTGTCGCAAT
ATCT
GGGCGTCCCTGCCGGGTGCCGGTTACGGTCAGCGTGAGCATTCACTGGAAAAACTGGTCACCGTCTGGCGTACCGCTGG
CGG
P
CGTACCGGCTTAAACGGAGTAAATACCATGAAGAAATTATCCCTTTCACTGATGCTGAACGTGTCGCTGGCGCTGATGC
TGGC
ACTGTCCCTGATTTACCCGCAGAGCGTGGCCGTCAATTTTGTCGCTGCCTGGGCGATTCTGGCGACGGTTATCTGTGTG
GTTGC
CGGTGGTGTGGGCGTGTATGCCACTGAGTATGTGCTGGAACGCTACGGGCGGGAGCTGCCGCCGGAATCGCTGGCCGTG
un .3 GATTGTCACGTCGCTGTTTTTGCAGCCGGTGCCGTGGCGCAGACGGGCGGCGGCTCTGGTAGTGGTGGTGGCGACGTTT
CGCTGGTCGCTGCCGGGTGGATTTTTACCGCGCTGATTTATCTTGTGGTGTCGCTGTTTTTCCGGCTGATACGTAAAGC
CTGTC
.31 .3 GTCAGCGTCTTGAGGGGCGGGAACCATGTCAAGGCTGATGATTGTGCTGGTCGTGTTGTTATCGCTGGCGGTGGCCGGT
CTGT
TTCTGGTGAAACACAAAAATGCCAGCCTGCGCGCCTCGCTGGACAGGGCGAACAACGTCGCCAGCGGTCAGCAGACGAC
CAT
CACCATGCTGAAAAATCAGCTTCATGTTGCGCTCACCAGGGCAGATAAAAACGAGCTGGCGCAGGTGGCACTGCGTCAG
GAA
CTGGAGAACGCCGCGAAACGTGAAGCACAGCGCGAGAAAACCATCACGAGGTTACTTAATGAGAACGAAGATTTTCGCC
GCT
GGTACGGTGCTGACCTGCCTGATGCTGTGCGCCGGTTGCACCAGCGCCCCGCCTGCACCGACGCCAGTGATTGTCCCCA
ACGC
ATGCCCGAAAGTGAGCCTTTGCCCGATGCCGGGCAGTGACCCGCAGACGAACGGCGATTTAAGTGCCGATATCCGGCAG
CTT
IV
GAGAACGCGCTGGCACGCTGTGCCAGCCAGGTAAAAATGATTAAACACTGTCAGGACGAAAACGATGCTCAAACCCGAC
AGC n CTGCGCAGGGCGCTGACTGATGCCGTCACGGTGCTGAAAACTAACCCCGATATGCTGCGGATATTCGTGGATAACGGGA
GTAT t=1 tl TGCCTCCACACTGGCGGCGTCGCTGTCATTCGAAAAGCGTTACACGCTCAATGTGATTGTGACCGACTTTACCGGTGAT
o CCTGCTCATTGTGCCGGTGCTGGCGTGGCTGCGGGAAAATCAGCCCGACATCATGACCACCGACGAAGGCCAGAAAAAG
GGC 'a o TTCACGTTTTATGCAGACATCAACAATGACAGCAGCTTTGATATCAGTATCAGCCTGATGCTGACCGAGCGCACGCTGG
TCAGT tt n.) un GAGGTGGACGGCGCACTGCATGTGAAGAATATCTCGGAACCCCCGCCGCCGGAGCCGGTCACCCGCCCGATGGAGCTGT
ATA
TCAATGGCGAACTGGTGAGTAAGTGGGATGAATGAGTTTAAGCGTTTTGAAGACCGGCTGACCGGACTGATTGAATCGC
TGTC n.) o n.) ACCGTCAGGGCGTCGGCGACTGAGTGCCGAACTGGCGAAACGTCTGCGGCAGAGTCAGCAGCGTCGGGTGATGGCACAG
AA
AGCCCCGGACGGCACACCCTACGCGCCACGCCAGCAGCAGAGCGTCAGAAAAAAGACCGGTCGCGTTAAGCGAAAAATG
TTT .6.
.6.
n.) GCGAAACTTATTACCAGTCGTTTTTTGCATATCCGTGCCAGCCCGGAGCAGGCATCAATGGAATTTTACGGCGGGAAGT
CGCC oe GAAAATCGCCAGTGTGCATCAGTTTGGTCTGTCGGAAGAAAACCGGAAAGACGGTAAGAAAATTGATTATCCGGCGCGT
CCCC
TGCTCGGCTTTACCGGTGAGGATGTGCAGATGATTGAAGAGATTATCCTGGCTCACCTTGAGCGTTAG
9 V through G of P2 ATGAACACTCTCGCAAATATTCAGGAACTCGCGCGCGCACTGCGCAACATGATTCGCACTGGCATTATCGTCGAAACCG
ACCTT
AACGCCGGTCGCTGCCGCGTGCAGACCGGCGGCATGTGCACCGACTGGCTTCAGTGGCTGACCCATCGCGCAGGACGTT
CGC
GCACATGGTGGGCACCTTCCGTGGGGGAACAGGTGCTGATTCTGGCCGTGGGTGGTGAACTCGACACGGCGTTCGTTCT
GCC
GGGGATTTATTCCGGCGATAACCCCTCGCCGTCTGTGTCGGCGGATGCCCTGCATATCCGTTTCCCTGACGGGGCGGTG
ATTG P
AATATGAACCCGAAACCAGTGCACTCACGGTAAGCGGAATTAAAACGGCCAGCGTGACGGCTTCCGGTTCTGTTACTGC
CACG L.
, L.
, 1-, GTGCCGGTGGTCATGGTGAAAGCATCAACCCGCGTCACCCTGGACACCCCGGAGGTGGTCTGCACCAACAGGCTGATTA
CCG .3 .
eA
GCACGCTGGAAGTGCAGAAAGGCGGGACGATGCGCGGCAACATTGAACACACCGGCGGTGAACTCTCATCAAACGGTAA
GG
, TACTGCATACCCATAAACACCCCGGCGACAGCGGCGGCACAACCGGGAGTCCTTTATGACAGCGCGTTATCTCGGAATG
AATC , , GCAGTGATGGCCTGACTGTCACTGACCTTGAGCATATCAGCCAGAGTATCGGCGATATCCTGCGCACACCGGTCGGCTC
ACGG
GTGATGCGTCGTGATTACGGCTCGTTGCTGGCGTCAATGATTGACCAGCCGCAGACCCCGGCGCTTGAGTTGCAGATTA
AAGT
CGCCTGTTACATGGCAGTGCTGAAATGGGAACCCCGCGTCACCCTGTCATCCGTCACCACGGCGCGCAGTTTTGACGGG
CGAA
TGACGGTCACGTTAACCGGCCAGCACAACGACACCGGCCAGCCACTTTCATTAACCATCCCTGTGAGTTGAAACCATGC
CGATT
ATCGACCTGAACCAGCTACCCGCACCGGATGTGGTCGAGGAGCTGGACTTTGAAAGCATTCTCGCTGAACGCAAGGCGA
CACT
GATTTCCCTTTACCCGGAAGATCAGCAGGAGGCGGTCGCCCGTACCCTGACACTGGAATCTGAGCCTCTCGTCAAACTG
CTGG
Iv AAGAAAATGCTTATCGTGAGCTTATCTGGCGTCAGCGTGTGAATGAGGCCGCACGGGCGGTGATGCTGGCCTGTGCCGC
CGG n TAATGACCTTGATGTGATTGGTGCCAATTACAACACCACGCGCCTGACTATCACCCCGGCAGATGATTCGACCATCCCG
CCGAC t=1 Iv ACCGGCAGTGATGGAATCTGACACCGATTATCGTCTGCGTATTCAGCAGGCTTTTGAGGGCTTAAGCGTCGCCGGGTCA
GTGG n.) o n.) GAGCCTATCAGTATCATGGTCGCAGTGCTGACGGGCGTGTCGCGGATATTTCTGTCACCAGTCCGTCTCCGGCCTGTGT
CACCA
'a TCTCTGTGCTGTCACGTGAAAATAACGGCGTCGCATCCGAAGACCTGCTGGCTGTGGTGCGTAACGCCCTTAATGGCGA
GGAC eA
.6.
n.) n.) un GTCAGGCCGGTGGCCGACCGCGTGACCGTGCAGTCTGCCGCCATCGTTGAATACCAGATAAACGCCACGCTTTACCTTT
ACCCT
GGTCCCGAAAGCGAACCCATCCGCGCTGCCGCTGTGAAAAAGCTGGAAGCGTATATCACGGCACAGCACCGGCTGGGGC
GCG n.) o n.) ACATCCGTCTGTCTGCCATTTATGCCGCTTTGCATGTGGAAGGTGTGCAGCGTGTCGAACTGGCTGCACCACTGGCCGA
CATCG
i-J
TGCTCAACAGTACGCAGGCGTCTTTCTGTACCGAATACCGCGTCGTGACCGGAGGCTCGGATGAGTGATTCGCGACTGC
TGCC .6.
.6.
n.) GACCGGCTCATCACCGCTTGAGGTCGCCGCCGCAAAAGCCTGTGCGGAAATTGAAAAAACGCCGGTCAGTATTCGTGAA
CTGT oe GGAACCCGGACACCTGTCCGGCAAATCTGCTGCCGTGGCTGGCGTGGGCGTTTTCGGTCGACAGGTGGGATGAAAAGTG
GCC
GGAAGCGACAAAACGCGCCGTTATCCGCGATGCCTATTTCATCCACTGTCATAAGGGCACGATAGGTGCAATCCGGCGT
GTGG
TGGAGCCGCTCGGCTATCTCATCAACGTGACGGAGTGGTGGGAAAACAGTGACCCGCCCGGCACCTTCCGGCTTGATAT
TGGT
GTACTGGAAAGCGGTATCACAGAGGCAATGTATCAGGAAATGGAACGGCTGATTGCTGATGCCAAACCTGCAAGCCGTC
ACC
TTATTGGCCTGAACATTACCCGGGACATTCCCGGCTATCTGTTCGCCGGTGGTGTGGCTTACGACGGCGATGTAATTAC
GGTTT
ACCCCGGATAAGTGAGGAATAATGAGCATAAAATTCAGAACCGTTATCACCACTGCCGGTGCAGCAAAGCTGGCAGCGG
CAA
P
CCGCGCCGGGAAGGCGGAAGGTCGGCATTACCACGATGGCCGTCGGGGATGGCGGTGGTAAATTGCCTGTCCCGGATGC
CG
GACAGACCGGGCTTATCCATGAAGTCTGGCGACATGCGCTGAACAAAATCAGCCAGGACAAACGAAACAGTAATTATAT
TATC
GCCGAGCTGGTTATTCCGCCGGAGGTGGGCGGTTTCTGGATGCGTGAGCTTGGCCTGTACGATGATGCGGGAACGTTAA
--.1 .3 CCGTGGCGAACATGGCCGAAAGCTATAAGCCAGCCCTTGCCGAAGGCTCAGGACGTTGGCAGACCTGTCGCATGGTCAT
GTCAGCAGTGTGGCCTCAGTGGAGCTGACCATTGACACCACAACGGTGATGGCGACGCAGGATTACGTTGATGACAAAA
TTG
.31 .3 CAGAGCACGAACAGTCACGACGTCACCCGGACGCCTCGCTGACAGCAAAAGGTTTTACTCAGTTAAGCAGTGCGACCAA
CAGC
ACGTCTGAAACACTGGCCGCAACGCCGAAAGCGGTAAAGGCCGCGTATGACCTGGCTAACGGGAAATATACCGCACAGG
ACG
CCACCACAGCGCGAAAAGGCCTTGTCCAGCTTAGTAGCGCCACCAACAGCACGTCTGAAACGCTCGCCGCAACACCAAA
AGCC
GTTAAGACGGTAATGGATGAAACGAACAAAAAAGCGCCATTAAACAGCCCTGCACTGACCGGAACGCCAACGACGCCAA
CTG
CGCGACAGGGAACGAATAATACTCAGATCGCAAACACGGCTTTCGTTATGGCCGCGATTGCCGCCCTTGTAGACTCGTC
GCCT
GACGCACTGAATACGCTGAACGAGCTGGCGGCGGCGCTGGGCAATGACCCGAATTTTGCTACCACCATGACTAATGCGC
TTGC
IV
GGGTAAGCAACCGAAAGATGCTACCCTGACGGCGCTGGCGGGGCTTGCTACTGCGGCAGACAGGTTTCCGTATTTTACG
GGG n AATGATGTTGCCAGCCTGGCGACCCTGACAAAAGTCGGGCGGGATATTCTGGCTAAATCGACCGTTGCCGCCGTTATCG
AATA t=1 tl TCTCGGTTTACAGGAAACGGTAAACCGAGCCGGGAACGCCGTGCAAAAAAATGGCGATACCTTGTCCGGTGGACTTACT
o AAAACGACTCAATCCTTGCCTGGATTCGAAATACTGACTGGGCGAAGATTGGATTTAAAAATGATGCCGATGGTGACAC
TGAT 'a o TCATACATGTGGTTTGAAACGGGGGATAACGGCAATGAATATTTCAAATGGAGAAGCCGCCAGAGTACCACAACAAAAG
ACC tt n.) un TGATGACGTTGAAATGGGATGCACTAAATATTCTTGTTAATGCCGTCATTAATGGCTGTTTTGGAGTTGGTACGACGAA
TGCAC
TAGGTGGTAGCTCTATTGTTCTTGGTGATAATGATACCGGATTTAAACAGAATGGAGACGGTATTCTTGATGTTTATGC
TAACA tµ.) o tµ.) GTCAGCGTGTATTCCGTTTTCAGAATGGAGTGGCTATTGCTTTTAAAAATATTCAGGCAGGTGATAGTAAAAAGTTCTC
GCTAT
i-J
CCAGCTCTAATACATCCACGAAGAATATTACCTTTAATTTATGGGGTGCTTCCACCCGTCCAGTGGTTGCAGAGTTAGG
CGATG .6.
.6.
tµ.) AGGCCGGATGGCATTTCTATAGCCAGCGAAATACAGATAACTCGGTAATATTTGCTGTTAACGGTCAGATGCAACCCAG
CAAC oe TGGGGAAATTTTGATTCCCGCTATGTGAAAGATGTTCGCCTGGGTACGCGAGTTGTTCAATTGATGGCGCGAGGTGGTC
GTTA
TGAAAAAGCCGGACACACGATTACCGGATTAAGAATCATTGGTGAAGTAGATGGCGATGATGAAGCCATCTTCAGGCCG
ATA
CAAAAATACATCAATGGCACATGGTATAACGTTGCGCAGGTGTAAGTTATGCAGCATTTAAAGAACATTAAGTCAGGTA
ATCC
AAAAACAAAAGAGCAATATCAGCTAACAAAGAATTTTGATGTTATCTGGTTATGGTCCGAAGACGGAAAAAACTGGTAT
GAGG
AAGTGAAGAACTTTCAGCCAGACACAATAAAGATTGTTTACGATGAAAATAATATTATTGTCGCTATCACCAGAGATGC
TTCAA
CGCTTAATCCTGAAGGTTTTAGCGTTGTTGAGGTTCCTGATATTACCTCCAACCGACGTGCTGACGACTCAGGTAAATG
GATGT
P
TTAAGGATGGTGCTGTGGTTAAACGGATTTATACGGCAGATGAACAGCAACAACAGGCAGAATCACAAAAGGCCGCGTT
ACTT .
, TCCGAAGCGGAAAACGTTATTCAGCCACTGGAACGCGCTGTCAGGCTGAATATGGCGACGGATGAGGAACGTGCACGAC
TGG
...]
1¨
.3 AGTCATGGGAACGTTACAGCGTTCTGGTCAGCCGTGTGGATCCTGCAAATCCTGAATGGCCGGAAATGCCGCAATAA
.
oe , , Fl through ogr of P2 ATGAGTGACTATCATCACGGCGTGCAGGTGCTGGAGATTAACGAGGGCACCCGCGTCATTTCCACCGTATCCACGGCCA
TTGT , , CGGCATGGTCTGCACGGCCAGCGATGCAGATGCGGAAACCTTCCCCCTCAATAAACCTGTGCTGATTACCAATGTGCAG
AGCG
CAATTTCAAAGGCCGGTAAAAAAGGCACGCTGGCGGCATCGTTGCAGGCCATCGCTGACCAGTCAAAACCGGTCACCGT
TGTC
ATGCGCGTGGAAGACGGCACCGGTGATGACGAGGAAACGAAACTCGCGCAGACCGTTTCCAATATCATCGGCACCACCG
ATG
AAAACGGTCAGTACACCGGACTAAAAGCCATGCTGGCGGCGGAGTCGGTAACCGGTGTTAAACCGCGTATTCTCGGCGT
GCC
GGGACTGGATACCAAAGAGGTGGCTGTTGCACTGGCATCAGTCTGTCAGAAGCTGCGTGCTTTCGGGTATATCAGCGCA
TGG
GGCTGTAAAACCATTTCCGAGGTGAAAGCCTATCGTCAGAATTTCAGCCAGCGTGAGCTGATGGTCATCTGGCCGGATT
TCCTC
1-d GCATGGGATACGGTCACCAGTACCACCGCCACCGCGTATGCCACCGCCCGTGCGCTGGGGCTGCGCGCTAAAATCGACC
AGG n ,-i AGCAGGGCTGGCATAAAACGCTGTCCAATGTCGGGGTGAACGGTGTTACCGGCATCAGCGCATCTGTATTCTGGGATTT
GCAG t=1 1-d GAGTCCGGCACCGATGCTGACCTGCTTAACGAGTCAGGCGTCACTACGCTGATTCGCCGCGACGGTTTCCGCTTCTGGG
GTAA tµ.) o tµ.) CCGTACCTGCTCTGATGACCCGCTGTTCCTCTTTGAAAACTACACCCGCACCGCGCAGGTCGTGGCCGACACGATGGCT
GAGGC =
'a GCACATGTGGGCGGTGGACAAGCCCATCACTGCAACGCTGATTCGCGACATCGTTGACGGCATCAATGCCAAATTCCGT
GAGC
.6.
tµ.) tµ.) un TGAAAACAAACGGCTATATCGTGGATGCGACCTGCTGGTTCAGCGAAGAATCCAACGATGCGGAAACCCTCAAGGCCGG
AAA
ACTGTATATCGACTACGACTATACACCGGTGCCTCCTCTCGAAAACCTGACCCTGCGCCAGCGTATTACCGATAAATAC
CTGGC n.) o n.) AAATCTGGTCACCTCGGTTAACAGCAATTAAGGAGCCTGACCGATGGCAATGCCGCGCAAACTCAAGTTAATGAACGTC
TTTCT
i-J
GAACGGCTACAGCTATCAGGGCGTTGCAAAGTCCGTCACGCTGCCAAAACTGACCCGTAAGCTCGAAAACTATCGCGGT
GCGG .6.
.6.
n.) GGATGAACGGCAGCGCACCGGTAGACCTCGGCCTTGATGACGATGCGCTGTCAATGGAGTGGTCGCTCGGTGGCTTCCC
GGA oe TTCGGTTATCTGGGAGCTTTACGCCGCAACCGGTGTGGATGCCGTGCCGATTCGTTTTGCAGGCTCTTACCAGCGCGAC
GATAC
CGGCGAAACGGTGGCCGTCGAAGTGGTCATGCGTGGACGTCAGAAAGAAATCGACACCGGCGAGGGTAAACAGGGAGAA
G
ACACTGAGTCGAAAATCTCCGTGGTCTGCACCTATTTCCGGCTGACGATGGACGGTAAGGAGCTGGTCGAAATTGACAC
CATC
AACATGATTGAGAAGGTGAACGGCGTCGATCGGCTGGAGCAACACCGCCGCAATATCGGCCTGTGATTTTCATCCGGTC
AGCC
TGGCTGGCCGGTTAACCCTGATTCAGAAGTGAGAAAACCATGAACAAAGAAAATGTCATTACCCTGGACAATCCGGTCA
AACG
TGGTGAGCAGGTTATCGAACAGGTCACGCTGATGAAACCCAGTGCCGGGACGCTACGCGGTGTCAGTCTGGCTGCGGTT
GCA
P
AACTCCGAAGTCGATGCACTGATTAAGGTGCTGCCGCGCATGACGGCACCGATGCTGACCGAGCAGGAAGTCGCCGCGC
TGG
AACTGCCTGACCTTGTGGCGCTGGCCGGTAAGGTGGTCGGTTTTTTGTCGCCGAACTCGGTGCAGTGACGTTTCCGAAA
AATC
TCTCGGTCGATGACCTGATGGCGGATGTGGCAGTGATATTTCACTGGCCGCCATCAGAACTGTATCCCATGAGCCTGAC
o .3 CTCATCACATGGCGCGAAAAGGCGCTCCGGCGAAGCGGAAACACGAATGAGTAACAATGTAAAATTACAGGTATTGCTC
GCTGTTGACCAGGCATCCCGCCCGTTTAAATCCATCCGCACAGCGAGCAAGTCGCTGTCGGGGGATATCCGGGAAACAC
AAAA
.31 .3 ATCACTGCGCGAGCTGAACGGTCACGCATCCCGTATTGAGGGATTCCGCAAGACCAGTGCACAGCTCGCCGTGACTGGT
CATG
CACTTGAAAAGGCACGGCAGGAGGCCGAAGCCCTTGCCACACAGTTTAAAAACACCGAACGTCCGACCCGTGCTCAGGC
GAA
AGTCCTGGAATCCGCAAAGCGTGCGGCGGAGGACTTACAGGCGAAATATAACCGCCTGACAGATTCCGTTAAACGCCAG
CAG
CGGGAACTGGCCGCTGTGGGAATTAATACCCGCAATCTTGCACATGATGAGCAGGGACTGAAAAACCGTATCAGTGAAA
CCA
CCGCACAGCTTAACCGTCAGCGTGATGCGCTGGTGCGTGTCAGTGCGCAACAGGCAAAACTTAACGCAGTAAAACAGCG
TTAT
CAGGCCGGAAAGGAACTGGCCGGAAATATGGCCTCAGTGGGCGCTGCCGGTGTGGGGATTGCGGCGGCGGGAACGATGG
C
IV
CGGTGTTAAGCTACTGATGCCCGGTTATGAGTTTGCGCAGAAAAACTCAGAATTACAGGCTGTGATCGGAGTGGCAAAA
GACT n CCGCCGAAATGGCCGCACTCCGCAAGCAGGCGCGCCAGCTCGGCGACAATACCGCCGCCTCGGCAGATGATGCAGCCGG
TGC t=1 tl GCAGATTATTATTGCGAAAGCCGGTGGGGATGTTGATGCCATTCAGGCGGCAACGCCGGTCACGCTGAACATGGCGCTG
o AACCGTCGCACAATGGAAGAAAACGCCGCCCTGCTGATGGGGATGAAATCCGCCTTTCAGCTTTCAAACGATAAGGTCG
CTCA 'a o TATCGGGGATGTTCTCTCCATGACGATGAACAAAACCGCCGCCGATTTTGACGGCATGAGCGATGCGCTGACCTATGCC
GCAC tt n.) un CTGTGGCAAAAAATGCCGGTGTCAGCATTGAAGAAACCGCCGCAATGGTCGGGGCGCTGCATGATGCAAAAATCACAGG
CTC
AATGGCGGGGACGGGAAGCCGTGCCGTGTTAAGCCGCCTGCAGGCACCGACGGGAAAAGCATGGGATGCACTCAAAGAG
CT n.) o n.) TGGAGTGAAAACCTCAGACAGCAAAGGAAACACCCGGCCAATATTTACCATTCTGAAAGAAATGCAGGCCAGTTTTGAG
AAAA
i-J
ACCGGCTCGGTACTGCCCAGCAGGCTGAATACATGAAAACTATTTTCGGGGAGGAGGCCAGCTCAGCCGCTGCCGTGCT
GAT .6.
.6.
n.) GACTGCCGCCTCAACCGGAAAGCTGGACAAACTGACCGCTGCGTTTAAAGCCTCAGACGGGAAGACCGCCGAGCTGGTA
AAT oe ATCATGCAGGACAACCTAGGCGGTGACTTTAAAGCGTTTCAGTCCGCTTATGAGGCGGTGGGGACTGACCTGTTTGACC
AGCA
GGAAGGCGCGCTGCGTAAGCTCACGCAGACGGCCACAAAGTATGTGTTAAAACTCGACGGCTGGATACAGAAAAACAAA
TCA
CTGGCGTCAACCATCGGCATCATTGCCGGCGGTGCACTGGCGCTTACTGGCATCATCGGTGCCATTGGCCTCGTAGCCT
GGCC
GGTTATCACCGGCATCAATGCCATCATCGCGGCAGCAGGCGCAATGGGGGCAGTCTTCACGACGGTTGGCAGTGCTGTT
ATGA
CCGCCATCGGGGCTATTAGCTGGCCGGTTGTGGCCGTGGTGGCTGCCATTGTCGCCGGTGCGTTGCTTATCCGTAAATA
CTGG
GAGCCTGTCAGCGCATTCTTTGGTGGTGTGGTTGAAGGGCTGAAAGCGGCATTTGCGCCGGTGGGGGAACTGTTCACGC
CAC
P
TTAAACCGGTTTTTGACTGGCTGGGCGAAAAGTTACAGGCCGCGTGGCAGTGGTTTAAAAACCTGATTGCCCCGGTCAA
AGCC
ACCCAGGACACCCTGAACCGTTGCCGTGACACGGGCGTCATGTTCGGGCAGGCACTGGCTGACGCGTTGATGCTGCCGC
TTAA
.6.
TGCGTTCAACAAACTGCGCAGTGGTATTGACTGGGTACTGGAAAAACTCGGTGTTATCAACAAAGAGTCAGACACACTT
o .3 AGACCGCCGCCAGAACTCATACCGCCACGTATGGTACCGGTGACTATATTCCGGCGACCAGCTCTTATGCAGGCTATCA
ATCAGCCGGTCACGGCACCGGCTGGCCGCTCTTATGTAGACCAGAGTAAAAACGAATATCACATCAGCCTGACGGGGGG
GAC
.31 .3 TGCGCCGGGGACACAGCTTGACCGCCAGTTACAGGATGCGCTCGAAAAATACGAGCGGGATAAACGTGCGCGCGCCCGT
GCC
AGCATGATGCATGACGGTTAAGGAGGTGACGAAAAATGATGCTCGCGTTAGGTATGTTTGTTTTTATGCGCCAGACGCT
GCCA
CACCAGACCATGCAGCGTGAATCAGATTATCGCTGGCCGTCAAATTCCCGTATCGGTAAACGGGATGCCTTTCAGTTTC
TCGGT
GTGGGTGAGGAAAACATCACGCTGGCCGGTGTGCTTTATCCCGAACTGACCGGCGGCAAGCTGACGATGACCACGCTCA
GGC
TGATGGCAGAGGAGGGGCGGGCGTGGCCGTTGCTGGATGGCACCGGCATGATTTACGGCATGTATGTCATCAGCAGGGT
GA
GTGAAACAGGGAGTATTTTCTTTGCAGACGGCACACCCCGGAAAATTGATTTTACGCTGTCACTCACCCGCGTTGATGA
ATCAC
IV
TGGCCGCGCTTTATGGCGATATCGGTAAACAGGCGGAATCGCTCATCGGTAAGGCCGGCAGTATGGCGACCAGATTCAC
AGG n TATGACGGGGGCGGGATAATGCTGGATGCGCTGACATTTGATGCAGGCAGTACGCTGACGCCGGATTACATGCTGATGC
TCG t=1 tl ACAGCAGGGATATTACCGGCAATATCAGCGACCGTCTGATGAGCATGACCCTGACGGATAACCGGGGCTTTGAGGCTGA
o GCTTGATATTGAACTGAACGATGCCGACGGGCAGGTCGGGCTGCCGGTTCGTGGCGCTGTCCTGACGGTGTATATCGGC
TGG 'a o AAAGGTTTTGCCCTGGTATGCAAAGGGAAATTTACCGTTGATGAGGTTGAACACCGGGGCGCACCGGATGTAGTCACCA
TCCG tt n.) un CGCCCGGAGTGCAGATTTTCGCGGGACGCTCAATTCCCGCCGGGAAGGCTCCTGGCATGACACCACGCTCGGTGCGATT
GTTA
AGGCGATAGCCACCCGTAACAGGCTGGAAGCCAGTGTCGCTCCGTCACTGGCCGGAATAAAAATTCCACACATCGACCA
GTCG t,.) o CAGGAGTCTGATGCGAAATTCCTGACCCGTCTTGCAGAACGCAACGGCGGTGAGGTGTCGGTAAAAATGGGAAAACTGT
TGT
i-J
TTCTCAAAGCGGGGCAGGGAGTGACGGCCAGCGGTAAAAAAATCCCGCAGGTCACCATAACCCGCAGCGACGGCGACCG
CCA
4,.
TCATTTTGCGATTGCTGACCGTGGAGCCTACACCGGTGTAACGGCAAAATGGCTACACACTAAAGACCCGAAGCCGCAA
AAGC oe AGAAGGTAAAACTGAAACGCAAAAAGAAAGAGAAACACCTGCGCGCACTGGAGCACCCGAAAGCGAAACCGGTCAGGCA
GA
AGAAAGCGCCTAAAGTACCGGAAGCGCGTGAAGGTGAATACATGGCCGGTGAGGCTGACAACGTTTTTGCCCTGACCAC
GGT
ATATGCCACGAAAGCGCAGGCCATGCGCGCCGCTCAGGCGAAGTGGGATAAACTGCAACGGGGCGTTGCGGAGTTCTCT
ATC
AGCCTGGCTACCGGTCGGGCAGATATTTACACGGAAACACCGGTCAAAGTGTCTGGCTTTAAGCGCGTCATAGACGAGC
AGG
ACTGGACAATCACTAAGGTGACACATTTTCTGAATAATAGCGGCTTCACGACGTCCTTAGAGCTTGAGGTCAGGCTTTC
TGATG
TGGAGTACGAAACAGAAGATGATGAGTGATGTTTTTGTTTTATCTGTTTGTTTTGTAAGGATAAATTAACTAAAATGGC
ACCAT
P
CAACAAAACCGGAAGAGGTGCTCGCGATGTTTCATTGTCCTTTATGCCAGCATGCCGCACATGCGCGTACAAGTCGCTA
TATCA .
, CTGACACGACAAAAGAGCGTTATCATCAGTGCCAGAACGTGAATTGCAGCGCCACGTTCATCACTTATGAGTCGGTACA
GCGA
_.]
1¨
.3 4,.
TACATCGTGAAGCCGGGAGAAGTCCACGCCGTAAGGCCGCACCCGTTGCCATCAGGGCAGCAAATTATGTGGATGTAA
.
..
1¨
, , 11 S. aureus phi11 ANGATTTANTCC
, , packaging signal 12 cpmA M KTESYF KEYNQFVLDQH KAI QE LEQE R NALESKI
KLDKSTYKQLIM DGQDD KADN LYQATDAD E KKLKALN KR LETKKSVSKEVKY
QKTI E LLKH QS ELSSLYESE KQSAI EKLKKAVDAYN EIIDEIEDIND RYE D EHQQYASVYSQEQLYDD
KEARKALNG H FKE N I FTSFINGN
DLPYEHNNKLFLKC
13 cpmB M KTKYELN NTKKVANAFCLN EE DTN LLI NAVD LD I
KN N M QE ISS E LQQAEQSKQKQYGTTLQN LAKQN RIIK 1-d n 14 ptiA
MDKQQIKDFVCDYHERTRSDVLIDDDINTDEFFSIADENSNEWMADDNIDDHIVKNHLEMIVDRVANDKEFYIFDSLIQ
GRSYQDIS t=1 1-d GVLDCSEQSVRFWYETLLD KIVEVI E
t,.) o o 'a o 4,.
vi 15 ptiB
MESIAEKETYHLPTEHLQVFNVIKNTSNKYITKTKILNQLGYEYNSSNERWLRRVINSLVYDYGYPIGCSYKPSERGYV
IITTEQEKQQA
MRSIKKLADGSMKRYEALKRIEV
w o w o 16 ptiM
MIAYPIRVGSVYRGEQMKLLKTKNCLYYRNGDNKLSEYQLLTQFNPTFINKKIRMCEFQIESMYHMSASTTTCDEMMGV
VSVSYPIE
.6.
.6.
KLVIKIIETKARLQNYKNRSISNMVLLKTVLNHYTEKEQKKVVKYMRSNGRYKPYNVIERLQVDLYQASIKQRSERQKQ
RNIAIENSKIA w oe RVNAYHQSSYVKVV
17 gene #29 (terS) [00119]
through gene #53 atgaacgaaaaacaaaagagattcgcagatgaatatataatgaatggatgtaatggtaaaaaagcagcaattacagcag gttatagtaagaaaacagc (lysin) of phi11 agagtctttagcaagtcgattgttaagaaatgttaatgtttcggaatatattaaagaacgattagaacagatacaagaa gagcgtttaatgagtattacagaagcttta gcgttatctgcttctattgctagaggagaacctcaagaggcttacagtaagaaatatgaccatttaaacgatgaagtgg aaaaagaggttacttacacaatcacacca acttttgaagagcgtcagagatctattgaccacatactaaaagtacatggtgcgtatatcgataaaaaagaaattactc agaagaatattgagattaatattggtgagt P
acgatgacgaaagttaaattaaactttaacaaaccgtctaatgttttcaatagaaacatattcgaaatactaaccaatt acgataacttcactgaagtacattacggtg .
, 1¨
gaggttcgagcggtaagtctcacggcgttatacaaaaagttgtactcaaagcattgcaagattggaaatatcctaggcg tatactgtggcttagaaaagtacaatcaa , .3 .6.
.
w caattaaagatagtttgttcgaagatgttaaagattgtttgataaactttggtatttgggacatgtgcctttggaataa gactgataacaaagttgaattgccaaacggc r., gcagtttttttgtttaaaggattagataacccagagaaaataaagtcgataaaaggcatatcagacatagtcatggaag aagcgtctgaattcacactaaatgattac , , , , acgcaattaacgttgcgtttgagggagcgtaaacacgtgaataagcaaatatttttgatgtttaacccagtatctaaac tgaattgggtttataagtatttctttgaacat r., ggtgaaccaatggaaaatgtcatgattagacaatctagttatcgagataataagtttcttgatgaaatgacacgacaaa acttagagttgttagcaaatcgtaatcca gcatattacaaaatttatgcgttaggtgaatttgctacactagacaaattggttttccctaagtatgaaaaacgtttaa taaataaagatgagttaagacatttaccttct tattttggattggactttggctacgttaatgatcctagtgcttttatacattctaaaatagatgtaaagaaaaagaagt tatacatcattgaagagtatgttaaacaaggt atgctgaatgatgaaatagctaatgtcataaagcaacttggttatgctaaagaagaaattacagcagatagtgcagaac aaaaaagtatagctgaattaaggaatct agggcttaaaaggattttaccaaccaaaaaagggaagggctcggttgtacaagggttacaattcttaatgcaatttgaa atcattgttgatgaacgttgtttcaagact attgaagagtttgacaactacacatggcaaaaggacaaagatacaggtgaatataccaatgaaccagtagatacataca atcattgtatcgattcgttgcgttattca 1-d n gtggaacgattctacagaccggttagaaaacgcacaaatctcagttcgaaagttgacacaataaaatctctaggattat aggagggaacaaatgttaaaagtaaacg 1-3 t=1 aatttgaaacagatacagatctacggggaaacataaattacttatttaatgatgaagccaatgttgtttacacatatga cgggacggaatccgatttattacaaaacgt 1-d w o taatgaagtaagtaaatacattgaacatcacatggattaccaacgacctagattgaaagtgttaagtgattattacgaa ggtaaaactaagaacttagttgagttaac w o -a-, acgacgcaaagaagagtacatggcagataaccgtgtagcgcatgattacgcatcttatattagcgattttatcaacggc tatttcttgggtaatccaattcaatatcaa o .6.
w w vi gatgatgacaaagatgtattagaagttattgaggcgttcaatgatttaaatgatgttgagtcacacaatagatctttag gattagatttgtcaatttatggcaaagcttat gagttaatgattagaaaccaagatgatgaaacgcgtttatacaagagtgatgcaatgagtacttttgtcatatacgaca atacaattgaacgtaatagtatcgcaggc n.) o n.) gttagatatttaagaactaaaccaatagacaagactgacgaagatgaagtgtttacagttgatttattcacttcacacg gtgtttatagatatcttaccagtagaacaa o atggattgaagctcacaccacgtgaaaacggttttgaatcacactctttcgaacgtatgcctattacagaatttagcaa caacgaaagaagaaaaggggattatgag .6.
.6.
n.) aaagtaatcactttaattgatttgtatgataatgctgaatcagatactgctaactatatgagtgatttaaatgacgcta tgttacttattaaaggtaatttaaatttagatc oe ctgtagaagttagaaaacaaaaggaagctaacgtgttgtttttagaaccgactgtttatgctgatagcgaaggtagaga aacagaaggctctgttgatggtggttatat ttataagcaatacgatgtacaaggtaccgaagcttataaagaccgtttaaacagtgatatacacatgtttaccaacacg cctaacatgaaagatgataactttagcgg cactcaatcgggcgaggcaatgaaatacaaattatttggattggaacaacgtactaaaactaaagaaggattgtttact aaagggttaagacgtcgtgctaagttgtt agagacaatacttaaaaatacatggtcgattgacgctaacaaagatttcaatactgttagatacgtatacaacagaaac ttacctaaatcattgattgaagaattaaa agcttatattgattctggtgggaagattagccaaacaactttaatgtctctattctcgttcttccaagaccctgaatta gaagttaagaaaatcgaagaagatgagaaa gaatctattaaaaaagctcaaaaaggtatttataaagaccctagagacatcaatgatgacgaacaagatgatgatacaa aagatactgttgataaaaaggaatgatt P
gtaattgcctaacaaaaacactcaagaatattgggaagaacgcggacgcaaagcaatcgagaatgagttgaagcgtgat aaaactaaagctgaagaaatagaacg .
, tatattgaatatgatgattaagcgcattgaaaaagagatcaatgcgtttattgtcaagtacggagattttgcaggcgtt acattacaagaagcacaaaagattattgat ,, , 1¨
.3 .6.
.
c,.) gagttcgatgtaaaagcgtttcaagaagaagcaaaaagattggtcgaaaacaaggagtttagcgatagagcaaatgaag aattaaagaagtataacacgaaaatg .
r., tatgtatctagagaacagatgttaaagattcaaatagaattcttaattgcttatgcaacagctcaaacagaattatcga tgagggaatatttcgaatcaacagcttatc "
, , , gtgtgttcagtgatcaagcgggtattttaggtgaaggtgtacaagtagctaaagaagttatagatacaatcgttgatac acaatttcatggtgtcgtttggtcagagcga 0 , N, N, ttatggactaataccgaagcaatgaaacaagaagtagaagaaataattgctaatgtagttattagaggtcgacatccta atgaatatgttaaagatatgcgcaagca cttaaataaattcgaaggcacagcacgacaaaagaccgcagcaattaaatcattgctttatacggaatcggcacgtgtt cacgcacaatcaagcattgacagcatga aagaaatttcaccggaaggatattatatgtatattgcaaaaatcgataatagaacaactaaagtatgcaaagggcttaa tggagaaatattcaaagttaaagacgct aaaattggtgttaatttctatcctatgcatatcaattgtcgttcagattgcgctttactacctaaatctatgtggccga aaaaaccaagcaagaaacgaaaaacaaaat acttcggagggaaagtgaaaagcggtgattgatttaaaagtgaagttttttaaaggcaagttagttttgtatgacagta aattaaatgtttggaggatactaatatgag taatactgacaaataccttagagacatagcaagagaattaaaaggtatacgtaaagagttacaaaagcgaaacgaaaca gttattattgatgcaaacttagacagtt 1-0 n taaggtcggcagtattagccgataaagaaaaatcgaaatataatgaacctctcttttaatagctagcacttaattgtgt tggctattttttatgtccaaaacgtgctgatg 1-3 acataaaaagcacgcatggaaaaacagtcgacagactataaatggaggtatatctcatggaagaaaataaacttaagtt taatttgcaattttttgcagaccaatcag t=1 n.) atgatccggacgaaccaggcggagatggtaaaaaaggaaatcctgataagaaagaaaatgacgaaggtactgaaataac tttcacgccagagcaacaaaagaaa =
n.) o gttgatgaaatacttgaacgtcgtgtagcccacgaaaagaaaaaagctgatgagtatgcaaaagaaaaagcagcagaag ctgctaaagaagctgctaaattagcg -a-, c, .6.
aaaatgaacaaggatcaaaaagatgaatatgaacgcgaacaaatggaaaaagaactggaacaattacgttcagaaaaac aattaaacgaaatgcgttcagaagc n.) n.) vi OP OA , (0 OA r0 0 r0 0 OP OA
OD OD ,sr, ,(;)n 0 CLO (0 2 OA tj t,' tc; -u M MI
-uM-our04-,0,0(00(0c0cOutj-- 0 r0 03 (0 -I-' (0 (0 co 4-, (.0 " (13 OD U FO, .iL-' (0 (0 OA 03 co 4_, 4_, (i, 4_, rOtjr0r0rotj4-,(0cou,,?;oroOOrOrOrauSu3r0BOrOut,' -1,- (0 U (0 (13 4-, (0 (0 co 2 U a-, co (0 t; (0 co (0 , -1e,., (0 co op (10 4., (13 4 (0 (0 (0 (0 4-, r0 (0 03 0 0,0 4-, 4-, (0 (.0 (0 CO CO (0s4.4., 4-, r0 03 0 r0 0 (0 4- +., 4-' -' (0 (0 4-, co (0 ,(45, OP co 0 (13Z-r,E; 2 oo (-.
co 0 .(,-9, 2, r ( = 0 -' o(0- 4-,' 2 (.0 (0 4(2 0 4_, 0 3 n, 0, (-0 , 0 00 (.0 2 0,0^ tv ro +, ro 0 u ro r (0 OA 2 (ao (0 a ttotE; u (0 CO 0 U 4-' (0 r.: "M 4- 2 õro' tE; CO
ere CIO -'rir (0 CLO ti' 6) U
,.., .... (xi op 0.0 _ -_ .1-, 4_,-uu-o03c0 =L''(0 w:' 010 co CIO
-u -o (J4- co OP (0 co co -o M OLO M 0-0 co 0 t , ^ .1- ; 00 op 0 (0 ,_,,., .1-; 541 (0 4_, (13 ,(7.),., OP n3 0 0 (0 0 0 OP (.0 co 03 co r0 n3 4.-; OA -3 OD 4-, 4_, ro 0 OD '4. .1-, 4-1 CO 4-, 4-' U
(0 03 0 (0 -1-J .1-; OD 0 (13 hn c0 ,...,(13 U c0 4- M M, (0 ro 0 t,,o ro .0 rr, H r (0 b' OA OA c.71 (0 61 M OD 2 Vo (0 ST MI
0,0 cOr0(0(00.04-,c0-u- m 0,13-aro4-, Ms (0-u .E1 2 : I 2 t Lou .t , BO - u( . 0 c or 0 3 Lo a . 5 , ( . 0 .. , r 0 (. or 0 .. t : , , 4-J( . 0 mu 0 , 00 , 0 . 0( 0 (Z, 0 cjr BO t:), 0 r 0 t :,(13 (31 4-, 4-, 4-, U U CO _ 4_, 03 03 op (i3 u !,7, 4.., n3 CD U 4-1 a-, (0 0,0 0,13 CD 4-',..,0.0op op U 4-, (10 00 03 03 03 co 4_, 03 4_, 4_, _ n3 sam 00 .1-; 4-, OD (xi 4_, 4_, (0 ,,,, 4-, ttO .1_=
(0 4-'õ CO 0 4 (0 CO 013 CO 4-, 4-, U CO '' CO (0 (-0 (-0 OD `(.6" r0 03 03 0 , -..:, 03 .1-; 0 (13 U U 0 0 ,., U .1-; .1-; (0 ,r, U 4-' (0 0 t' `:,' co co co 0 iii "(13 ((3.30 ((.73) (% 03 (a, õ(13 BO
(0 _, (0 4-, (.0 ,,,:, 4_, l:113 c0 U 4-' 0 u CD CO +-, U OP
Ur0C0c0(0(13.t,' M r0+,(0r0a-'n32 2 t,' tE;
(00c0030.0(00(0+-,(04-,c0(0ZrOopur00-uut0'23,,r0(00 0 ---, co 03 03 (a0 4-, op -I-' 0 -u a, 4-, 0 -.It r0 --Ir-:: OW (13 a (0 (0 (13 -u (0 Ms 4-t 0 o mro Ms 0 0 mro 0 4- -, CD ro ...,- CD +., 0 -, ro 0.
CO CD
(13 (13 U ' ' (13 CO .1_= -I-, 0 U 0,0 4-, :i CO
.1-, 0 .1_= 0 0,0 0 j3 if U 4-' CO
0 CO CO 0 0 op op 0 j (0 0 CD (0 (13 4-, (13 (13 (0 0 03 0 Op õ,, 0 (0 co 03 co 4_, t5 03 ti r0 0 r0 r0 OA 0,0 tnn (:(0 OP OLO -o u-' (0 MI co -o co 0 h,-,(13 ,T, co OP 0 s's 4-(-0 ' (0 4--, Op 4-, 03 co 03 03 ..õ.,-, 0- OP 03 0 r0 Ms OA co 0,0 +., (0 MI r0 -u M M 0.0 4t1 0.0 OD ro 0-0 - r0 OP co OO
0 ^ -o co , ss-s" OP -o OP m co 03 0 0 op BO -,O,, co +., +_, (0 co 0.0 op T.0-' , 0 (0 ts, õ, (0 _ .... 4_, hn _ -' OP µ6. MI U (70- ((.,, SIP, (a) 2 0.0 2 "(-0 0,0 0 0.0 (,,, ro (0 4-, t.,, 0 -,t,' s,$).0 t,' co 03 r0 03 (0 -o tr, 4-, (0 (0 0 co (0 0 u .2 co (0 03 +., OP (0 op OP 0 co OP 0 , 0 4_, co , OP , r0 r0 0 op -.1,:,' OW 2 (.0 .1-, 1.T3' (0 (-0 447.,, (:113 CO 0,13 CO t: 0.0 CO (13 OD OD (0 U (a U ,(513 2 ro -(0, op a 0 OA to op OP
(0 0 M
0 -u Ms 0,0 -r; -_,t; co -o 0 0 co S U -^-' , c0 03 OP U op uUr0r0r0 00,0UCCI -(13(13(130,00,0 00(00,0U
(00,00a-,+,+.,+,(13c0UUWCOM cot ''U Ur0r00.0+' (0 U 0 j3 U 0 j3 (X1 (0 CO 03 (0 U .o .o .1.-= 4_, (13 (.0 0 4_, , . 2 0,0 0 4-, +., Ms MI (0 co (0 Ms r0 OA co 'um h n 4- ^ U -' -' OP hn Ms m u -o OP 0-0 0 -o OP (0 4-, }I
0 4- '' OP -o 03 - - r0 OP (0 r0OD 0 OP a-, OP op -Jif (0 (0 a-, 03 OP t.r3 2 ro , (0O 4-, 4-, ,., 0 0 4-, U
,., '' MI MI ' M M (a CD (0 (a0 ta' 2 oo on 0.0 0.0 0 (0 0 .E19 4t: (),., .t,' U U
.F., U (13 (.0 CO (a CO +-= 4=- "jõ.., CO .F. , CO 4- 0 tp r o 4 -J 0 co co co r 0 õ . ,,, s , t; - oõ.., Ms -o 0 03 - r0 co 0 4-, OP s sss 0 03 03 -1--, op ,T, 4-, CO (0 .1-, (0 (-0 CO " s . 4-, 0coo-uhnromo (0- Op4-, 4-, +.,opc0+,0c0 CD 0 4-, (0 co "u 0,0 Op co tf, hn- 03 .':, MI +., hnc 0 MI 2 (ao 2 OP co ro -u (0 0.0 U 4-, +.' (0 (0 2 (-0 (-0 417 +.1 op all u 4,4, 03 OP 4-, OP 4-, 03 a-, CD 8 oo -, 4-, 03 co 03 OP (0 Si? 29 Op 03 1_2 (AO (30 .1-, S19, S. 2 _it, 22:1, (0 t' -(1;r3 (If a t : U ( a 0 ( 0 6' rj (al -r. : µ( . ki 4 - ' B 2 0 (0 (0 2, t,'u 4u ro Lao 0 ,r,(ao -_,t ,,0 n3 eto (0 , ..".õ0 ro (.0 0 (.0 4_, 0 (.0 4-, (0 -, ro - 4-,, (.0 0 A OLO r 0 CD 1 0 O t 0 Z - ,u 0 i jp' r 0 op C ti;
%CI
(0 (0 OA (13 (0 U 4-, (13 0 (13 (13 ,., (13 (0 (13 (13 U OD
(13OP OP 0 op aT,"
4-',..,õ (.0 (.0 0 00 s sa -10, (.0 0 U 0 4-' 03 .1-; a-, (0 03 M tp CtO -u M 0 m OA CO 4-' -' (0 W3 (0 ^ M MI (0 W3 (a r (0 (a CO M
OD U MI (a M U OD (a CO MI r MI OD (0 OD U CO 0 CO rocOopMour0+,03-u-r%0t3u03(003-ur00-000 (0 r0 _,_,4-' OA co OA M r0 (a -u co (a MI co 2 (0 (ao 4-, r 4-, .-t--,' (0 r (ao r "ro (0 0 2 -a -0.13-rorotitirotto0+-,4-Jurou'ro+-' CO 4-, OP
00 4_, 4_, 03 -4-, OP (0 (0 0 0 03 op (0 01:1 4-' 01:1 4-, (0 OP 00 0,0 op .I.J U 4_, (0 r0 (0 r0 hi3 OP 4-, CO 4-j (13 4-, op 4_, 0 OP (0 OP co OP OP 0 , op -1--, OP op (0 4-, 0 0,..õ,(04-,courOuro,,+-,00,0c04-,4-,c00,0000,,c0c0+,00A-u CO CO ro (0 4--' (.0 op op -.1-,-;õ if a, co dA S U (0 4..; u a, all U -,-',.., (0 4.7,j,, 3 '(-0 rom 4-'r 4-'r .).) t --Fi I?, 2 B 4-' co mr(E', Wt.,' tE; (0 r (-0 co 2 (a13 b' 3 (,0-- ro Bo 1-. 4.7_, co (0 su; 4-, 4- 0.0 0 t; 3 03 op 4- op 0 U ST r-: 2 0 (70) OD OD
0.0 MI T^ 010 .1.'.1 ti; (0 õi, it?... t..2 4.5, (0 (0 õ .1-; OP (0 03 (.0 03 0 03 OP 0 r0 4-' OP t;
op op 4-, (.0 op µ(.6-' ',,-u 6uzi (0 .(i2, (0 -,-, (0 (0 ro 0 ttO (.0 4-, 4-' .1-, CO (:)J3 (0 (13 4-, CO U (13 0 U 4_, ,...," _,_, rr, 4.,, (0013 0 4-',,,, õ., t', (13 03 OP 0 co OP
03 OP (0 03 r0 4-, ,..,.," Tip iii ' . +-, OLO co (0 r0 Op _Ls.,, õ..,- õ..,- -F-0 co 0 4-, op r0 n3 -i.i3 OP r0 (10 op ,47', OP ,__,,,s, 0.0 (.0 2 233 3 li 17;j3 -ILI co op srifi O.
(.0 OP r0 (0 4-, s4A, OP L) 0 4-, 03 03 0 0,0 (0 0 (0 op hi3 M 13,0' -(1-15 0 co -13k, 44 (0 2 OD co 1.T3 40 co OP 03 r0 0.04-' CO U CO +-, , (0 0 (.0 0 (13 ,, (.0 ....i 0,0 r tj (.0 (0 0,1:1(0 0 (.0 (0 (.0 0 .1-; .1-, 4_, (0 ,.., õ ,., (0 0 j:, (.0 u , CO _ ^ ro if (.0 (0 03 n3 OP 0 n3 -14 .1-,' 44, U 03 0 (.0 µ,4,u 0,13 4(9 !!! 0 tu3 ,,,, BO
CO (13 0,0 CO CO
(0 C's M OLO Ms 4-' OA 3 ro (0 +, 6'3 -r.,' 0 gup r0 co µ0µ2,1 co ti M u --t--: M
4-' (.0 1::: Bo (.0 0 4_, 03 ,,,,OO 'LI OP Fo-OP op (0 4-, 4-, OA 4_, t,j3 4-, 4,7',., 0,13 CO CO n3 if (13 a-, (xi (0 n3 4-, (0 0 .iL-s 4_, co (.0 Ms 0 OP co co op u tx, U 6A+ +4 U u tx, , 03 OA 0 U 03 op 07 (0 0 j:, I.
4.5, BO 0,0 CO ,4,7',., CO CO U (0 OD (.0 (0 (0 (0 .1-, 0 (0 OD (0 (0 .1-; Op OP 4-, 4_, (.0 4_, .ifj 4- r 0 'Ilt.? ;(.7,)n MI MI (0 MI CO MOD CO CO 0.0 (.0 .t,' (0 (0 CO CO CO (0 () - 4-, (13 0 (.0 4-, 03 op co OP OP r0 (0 CO 4-, (0 'I.' (13 0 (13 (13 (13 013 CO ,., 013 r0 co O, (0 OA op 0.0 CO (0 +., CO Op 4-' CW (0 (0 0 4' U t' U M
CD n3 (0 so 4_, 0 4-, 4-, 0 4_, 0 03 0 (0 OP 0,0 0 rOcOrourOcorour00cOurOc0(04-,00,0c04-,00,0+-,(08+-, CD n3 n3 (.0 n3 (.0 co r0 03 03 n3 ta. OP 03 +, co (.0 4-, (-0 U 4- U (-0 CO
+., (-0 .,., CO .1-, OD (.0 (0 ro co co co co 03 T.-,,, ril u a-, CD 03 (0 co -2-,:,' ro, r0 0,0 r0 0,00,0,(.0(00.00,0c003003'(.6'r4rocOrou.p.,03opT.0-c000,0c0003 0 (0 04_, 4_, 0 (13 (13 u Op 03 4., 4-, (13 (0 opn34_, 03,, (0 OPOPOPOPM
CD 0 OP a-, U .1-, CO CO CO all a-, a-, all U all all a-, .1-, U OP .1-, CO
-' CD+-, , op az) 4_, 0 0 CO .1-; " (0 4-, 0 (:10 0 0 0 ro (0 4_, 0 co 4--;, 4_, 0 0.0 0.0 op 03 0.0 ro ro 0 - +-, CO +., 4- 013 013 -X 4-, 0 0 44f (:10 0 (0 (0 (00 (0 (0 4-, (.0 (0 (0 0 (0 013 01:1 4(9 0 (13 00 013 4-' 4-' 0 -X 0 4- CD 00 00 rj -M, (0 4-' 4-' (0 U 00 CO 0' (0 (0 CO 0 (0 .M, 00 (0 00 W3 r w 4- U 4-, (0 00 4-' 4-, (0 j:( (.0 4., 4_, (00 00 (0 0 (0 .1-, U 4-, .1-, U
(.0 00 ro ro ro ro ro 0 op 0,0 0,0 0 ro 0 co OA 4- ro r0 ro OA Ms 0 00 r,' Ms an 0 co 0 -o OA
-r; 03 r; 0 03 , 0 (0 .t,' 03 -õ,-, r0 op ro 0.0 -a' -(-ro (.0 4(3,ji co ro 2 0 L, , 4.,,,, UJJ (0 0 (00 4.7,4, .1-; -13'D (0 (.0 µØ/ 0 (0 (3j3 4,-! .,., µ2.,_ -4t !.(1,1 0-0 On (a0 (13 0 (a (0 t.,-( r0 (6 0-0 MI '' `rt3 tiE; 0 0 OA .2 tE; Ms ro '6j3 0 ..V.Y
+., 0 0D (,, õ (.0 co ro _03 (.0 (0 co 0.0 t1,0 On +., MI (0 4-, OD -' tl op OA ro 0.0 T.0-' 03 3 -(õ; op (.7) 03 ro 03 w , 03 03 0 op +-, 0 4-, OA
OA 0,0 +-',., t1,0 -' OD (0 (a +., OA ro +., 03 +., ro (0 OA 0 0.0 MI OA ro OA -4-, 0 -o co 0 0 , 0 0.0 +., 2 co co 0 co 4-,õ ,,,,-, 0.0 .t,' 4- (.0 t.,, 3 (-õ, 2 2 .81, (.0 ro -6-3, 03 0 03 4-, a-, 2 CO 0 ro ro -(1.T3, 4(2, ,,,,ji f,...; 1:E; ro 2 4t, (.0 (0 2 0.0 (.0 (.0 (-0 2 (0 (0 "r -4t, 83 -(7, Ms (rao (0 ,(7,0 ((70) co -o,T, ro La0 Ms tE; op ro ro r0 On Ms OA
..., -(y3 CD r ri- (0 0-0 r (0 Ms 2 (0 (0 ro i:5 0 .t,' oh n (a0 (a ti t.) -4t 4_, 0 (0 (00 (.0 .44 (0 r0 00 .4:,,, 4.-,. CD0 (0 is, 0 .1-; (0 4_, CD,,n ¨ 4-, CD(1,3 4_, CD0 4_, 0 4-, 0 "-. U CO 4-, 03 tIA -6- y." 0 tIA 03 U CO
ro 0,0 op (-0 0,0 CO .1-; -14 m 41.1 (0 CO CO 0,0 f,;:', r13 tIA 0 03 03 0,0 .4' (13 r 0 (.0 4-,4-,t1,0-4-,Zt 0 m-t: (10r0+-,+-,0r0-ro Ms roLaOtAro u-o op U (0 co ro ro .1-, 100 (0 iii-:, 0 2 (-0 -,-, 00 4-' CO 0 ((II!, ro ro ob 4-=, ,-,-,-, 0 rts 0 4-' 00 CO U r 00 0,0 00 U op ro 0 ro ro 4-' 8 44:: OA 03 03 '' U U C'.0 CO 4- U
CO õ (00 ro 0 4(1; , (.0 44 õ 03 ro ',I-4 U 4--(13 "Id Bo ro , , 4-, -1--' 013 41.1 0 L' = (0 4¨' s ' 013 .1-; (0 .1_, (0 4-t, (a0 4-' co ro ,Y,,, If -14:: co op t:ID 2 -.If 3 CD U (0 -',, CO CO (0 r 0.0 0 00 4-' CO MI MI MI 0 4' 4-' CO -(-% (0 (0 to co 4-' 4-t:
= -X CO ¶"
44 (.0 .1-; op .(2 (.0 4-, c13. 0.0 OA 4.7,_ .1-; tIA 03 õ., .1-; u. 00 13JS :3,2 to w OA (0 4-, 0 .(,?, 00 (a MI 0 OA 4+7,. ' (II t u OD 0_ 0 :if; tIA 4(3b CO ro ro , (0 4_, 0 0 (ap co õ (.0 00 4_, ro 4-, 00 03 00 4-, _ op 00 03 4-, 2 Bc, to .,,,,, mu -5, (0,0 ,,, mu t,n(-0 00.0 .,-4- (yo (6, 1.1 {05 5 1.,,,,,w3 B .
.,,,, 0 t , zr 0 , ow 2 . . -, , ) - + . ,- ( . 0( = , , , 0 - , ro (.0 ., 0 co '''' 0 00 03 4-, , ro 03 03 tIA m õ, 0 0 03 U 2 4-if -X 4,7.: CO 4.if 2 4-, n,, ,,-, tto aD -+t,' , (0 ro co 0 ro 'or ro to to (a 4-' 0 MI (a 76 010 MI (-1'3 -Ft; (":' co ro 4-, 0 .1-, op 4-, 0 ro 0 4(2, 1-', ro ro 0 4_, ro ro _ co 0 ro ro 0 .1-; (:10 4-, 0 tIA 4-, a-, ro ro ro +-, (.0 -F.E; ro tIA ro 4-, .0 ro ,õ, (0 ro 0 0,0 ro ,:vi _ OA Eo_ z op tIA 4-, 0,0 op 4-' ro (.0 4_, a-, CD OA t:IA ro ro .1.; 0 0-13 (13 ro 44, ow 0 0,0 00 4'6'ro,(0rOrourOoprou,O,Or0(.00(0-(000,13-r:
0 4-, CO -X (.0 0 (-0 +.1 04-, 0 03 co 4-, 4-, (.0 0,0 130 8 (.0 , 0,02 0,:, ro ro .t, ro O m ro ro u 0,0 OA - r, 00 0D 0 Ms ro -o 0 (0 -o ro (13 co an -' roo.OoD-'0 ro mu 0 (-0 4-, co OD ty3 0 03 co .0 ty:, co 0 0 0,0 ro ..... 4_, t.ui op , 00 t,u3 4_, 1_3 03 0 , 03 .2.,,, r0 0 r0 -1-, 4-j 00 U ti CO ro .0 CO
w U U co OD ro ro CD ro (3-13 ES ro F ) (L3 2 ¨ (-0 CS 010 (0 ro 4-' (0 c FoL (a 44:: r0 4-'(6 V.0 - U -it: (0 00 4-, ro 0,0 0(12 ro tf, 1-.6 4-, 00 03 op õ,(13 , 0 a-, _it:
m .,., = CO U (-0 (-0 (0 t: U 0 (a 00 CO r0 0.0 r r r -' uM 4-' (0 (a ti W tiO 4,jj ro co tIA -o .tjr 13 4 - 'MI ( OM t coo ( OM 4 - J+ ' ( 0 , 19 - M ,+ ' UM + '( = 0 ( ,30 ( 0 or III mall g tr 71 c 0(4 : gj t 2 ti 3 rii OD 03 op 03 4-, ro ro tIA .1-; (0 174 4-, ro ro ro , , ro 0.0 ("3 (0 op an u ro -u ro ro CD oproro ro(.0-(; ro 0.0ro.0roro.,(02t50.00 ()rpm 04-,0-c%
^ 0 a-, (0 00 4-, (.0 00 0 op .1-, (0 0 0 OA 0,0 Op 00 4-, 4-, 03 23:, ro 4_, , CO tu3 tu3 CO , 0.0 (0 CO .1-, -1-, (.0 4-' 00 (.0 ro 4., CO tll3 CO -1-, (:11:1 0 4-, m .1-, .1-; tn CO ,_,4-' (13 4-' CO 4-, ,+, 4.if ro ,T, 0 co 0 0 0 co ro (a.,3 0 ro ^ an 0.0 0 0 0.0 +-, ¨ tIA T-, +-' OA ro 03 - 4-, -' - 03 , ro 0 03 ro 03 4-, 03 03 op 4_, 44f (.0 - 00 4_, (.0 (.0 ro 03 4õ-_, 3 , 4_, 4_, tõ:, 4_, 0 4-, ro 4_, ,-.U., ^ 0 'm `rEr on ro (3-13 an +-, (13 co ro ro ro ("3 ro '''' ro 0 4--, a-, all tIA 4-' ro 4-, - MI CO
0 W3 (a 00 U MI OD 4- U U r OA a (4 OD (a0 0 OD CO 4-' t; 0 0 '6'0,000(.0oproZurOtE;r0r0(00roum¨FErroro.20,0op.7)3.0zr0 0 0.0 0 (0 CLO OD +., 0 OD (0 ro r0 0 to 0 4- 0 (.0 s (0 +, tj-Shn mu (.0 -'(.0 to roM
4_, 03 03 4-' 4-' tIA .1-, ro 0.0 0 ro (13 (13 ro ro r^ oc 04-,rorow3couummr04-,-.,tror02,--0.0(10---(0(3(3-0-uu a.0(04-,r04-,uroco-u..00ror0(10+-,(113+-, uõwrOdA,,wro.2030(0 , U CO
ro +-' U (13 (13 , ,., tIA 00 OA op -o ro ro +-, +-, ,444 ro 4-, .T-_, 0 .,, ro co ro ro ro ananu ro-u a.13-' co+, (000-0(04-'(00Øt:r00-04-'0:10.000(0 ro-or04-,(1300,0MrprOm õ., ro (.0 U (13 ojo 0 4-1 Op U (0 4-, 0 (0 4-, ro 4-, 4-, ro ,...., = - 4_, r0 - s '-' 4-, (-0 (0 4- 4-, OA 0 0 0 ro ro ro '.4" co an ro (3-0 an co -' 0 (0 4-, .0 ..__,('3 (1' 4-'.s,õ 4-,_ õ
co a. 4-, c(3 an 4- (a ro ro (a -' 4c; ro op ro op 0 -i.i, ,...., 41J UM -I¨' 0.1 3 MI
4-, tIA co 4_, (.0 .1-; ro (.0 op (0 (.0 õ,ji 0 co 0 ro (0 4-, (00 (00 (.0 4(2, 03 r0 03 o ro op OD ro co 00 4-,õ 03 03 tx0_, r0 co IT CO ,..,(13 ro ro co 0 4-'m +A 2 4-, 03 1-3-(0 -1-' 03 03 03 3 -(i.T3, (.0 0 --- (õ:, 0 6, tu, co co ttO Cr CO (13 4-1 -1--' (.6 445 00 U CO 4-, To 4-, U (13 CO U az, ro u (0 0 ro 0.0 0 1-3 ro a. .t,' co co eto 4,..-.: ,(2, , (0 , eto 44 0.0 ro (0 " r 4uroro--roror0r0""vmuroonr 4-,rouro ro -1-, ro (.0 ro 0 03 4_, 03 op , , U 0 U ro ro 4_, 00 4-, (00 0 (0,0 OD MI 00 0 '' co (0 (00 MI co U CO 0 U U (0 (0 Zy 4-, tIA 03 ro 03 ro op Ms ro r0 _ ro 4-,. t1,13 _ 4F,0 ro ro (.0 (.0 , , ro -u 0 4-, (0 ro co ro ro ro OA 0 0 ro co ;43' OA ro zo, (12 (-0 4-, b' -c% (."op tIA U CO 2 t,,,:, (30 (.0 1=i 00 0 µ6, CO (.32 (0 .0 r, on on a F, .E(,-(3 ro ro 2 MI ((3),0 (rao mr 4- t.) 4- CO 00 (0 (0 CO 3 ',Lk?, -(-% ,t-:
ro (0 ro (3113 (L3 ro ro 0 to c(3 co rLo) ro ro ro (a ..'i 0 '' a4-(L3 ' OA 03 4-' (a U tIA 03 ro tIA 4_, 03 0 ro on ro co n3 .i .14:
0,0 -1-' (.0 CO -1-, ozi .0 ojo op OD 4_, CO -I-' ro --4 0 op 0 4-' 4--' t.E.; tl (00 0 on 0 U (.0 õ 4-' 0 (.0 OA 03 ro CO ojo ro +, ., .. co .0 (0 Y.
0 õ., õ., co .0 CO CO 0 (a ''' (13 ',4 (^ .0 co (.0 4_, ro ,(45, (.0 op tyzi (.0 co 44 if (.0 4_, 0 .,.. t.,ji 0 ¨ (ap (.0 00 co 00 U .iL., CD 2, op 4-, 0 a-, CO -r% ro CO fo OA ro CO to 2 (%0 ro if (Y0D 0.0 r13 OA 03 00 op ro 4.2 4.2 ro r0 03 U On co 03 op 4-, 4-, 00 ro 4_, 03 co 03 03 _, 0 co 4-, 0 4.7.., (.0 (00 4-, (0 0 '' U U (13 0 U3 OD +'/-11 rill (13 4-' (13 '' ro 4-, µ,44 -47.; U (13 co ' ,..., (0 U OD r (0 MI -' '' ".. MI (0 MI 0,0 OD 2 4¨, 0.0 sc,. on -' 0-0 (..) ¨
4_, (.0 1¨,. ro (.0 ro 0.0 (.0 (.0 t, , 3 0 ro 4,74, (.0 (.0 4_, U
ro õ., .0 ro 4-,_ ro ro 4-' (0 U 44 MI 0 4-' 00 (.
MI (13 (0 ". m .1-; (.0 4-, (.0 w (0,0 4-, W .1-; 4-, (00 ro co ., .0 tIA op ro MI ro µ(.6 0 00 Ms (0 ro , 0 Ms 0 -tj op Ms " (.0 03 0 4_, 0 r0 4-, 4_, ttO 47,,, 03 0,0 4_, ttO 4_, 4.7',., 03 0 On O4-.4:, 4,7.,' 00 0 r0 a , op op t-,. 0 pp m ro ro ,..L., 0 0,0 OA 0 47; +., ;:,..,,-, , ro 0 s,.-õ, 0 .,,,L, ., ro ro CD 0 -t; 0 r o -(73 -4._-; Tr, tu 3 0 r o µr 64 4(3 co 0 c 0 2, tll3 ,(6., 4-,, a3 .(i2, ,(6., on 0 0,0 0,0 op 4-, (0 CL:Ihn (13m 2 2 bo 0 0 (-0 To (.0 ?bm 2 (.0 (=:,,' 2 +.,,,,.. (.0 -,,, 0.00 15, 0,0 0D
0 a-a 4--' 0/3 (10 (13 CD, 4-' ro ro ro ro -1-' 053 - 03 OA op _ , 03 00 03 03 -L-_:, 00 0 4-, _ , t,u3 co 4F3, tie., co 1_3 _ 03 co ;=.,": 4-, OA OA w op 03 03 op 0 Ilu.d. 4-, +' co "' 4-, ,,-, 2 (00 4_, 0 .1-, OD UJJ (13 CO co U ojo CO CO 4-, .1-; (0 CO (0 (13 (13 ro co co 0 .1-; 0 4-' U 4-, .1-; ro ro on co ro .1-, CO U (13 U co CO
0 +-,_ On CO CO .1../ (0 (0 CO .I-, a-, CDU CDU CO .I-, CO a-, all OA OA all all OA a-, U 4-, 0.0 a3 4¨, ro U 4_, 4_, (13 '81 4-, (0 õ., 0 ro OD 4-, CO U 44f ro -..17: OD 4-; ro 0 co ro op 4-, ro CO (13 op co ro tie., ro co t,' 00 OP 0 '0'5 co ro tax) .2 U -.it s LO, .1!::
3 (.0 Fe (.0 4-, (0 OP (.0 OP 4-, U 03 ro OP 4-, 4-' U 4F0' oo r 0 -1-, on co ro 4_, .,_, u 0 0 4-' (-)(04-'t:(13 0(10(02--(113.t.,' OD
(23. .L.-! -(.10 4-, y (.0 ro -2-,:: 2 (.0 t) j3 c13 4_, (3.13 4_, U 4-, (0 .Lt: '-' +.1 (13 1?, +-, U on , 4-' (0 U "a (0 (0 0D CO Z3' CO r U (0 to (13 ro ro ro , (13 4.-= 4-, , U ro ,.. 0 CO (.0 03 tu3 03 co 4-, OP rp OP 03 8 on 0 an 4-, (0 (0 c'D an ("0 ro 613 ro ("3 ro t 2, a (II 0=an ro (0 an ro4-'-'-'roro-O.0 um opa.004-,mro op(094-'0-ti+-,,, -' U+., U 4-' r (113 4-' (I' (I' tj (113 4-' utl 4-' 447.: OD (0 t) cati if 1:6' 2 ,,nnro u (0 H 0 ¨,,., nr93 õ., CD (.0 4_, 0 4_, _ 03 4_, _ 0D 4_, 4_, 0.0 ,,,,., , , 4-, (.0 0, 4,7 44=,' co ....,,,, 4_, ¨ ¨ .... 0 4_, CO 03 U "J , , Zuocororom¨urot'ro%4,74?6-' r.; 3 0D 0 (.0 2 (-0 2 g2 3 2 2 0 0,0 oz, 0.0 ., 0D (-0 .:, u (-0 on ,4 ij .1,- - .E.,4 r o t:: (0 - bp OP co +., U co +,, (13 op CO -' 4-, OP OD U (0 U U (73 +,, op tj 03 00 00 CO all ., (0 co 00 03 +., (.0 (0 CO (0 CO r (0 (0 +.; -' CIO (-0 CO 4-= CO :.,' CI -' C1.0 U CO
- ' = CD (100.000U(10+-'03(0U(130,0oU(.0(.0(00,04-' 3 T.0-, u (-0 .õ 0,0 ,,,op-03(.0r003 ,00303ro-ro co co 0 4, CD 4., CP CD MI CO (0 (II
0.0 rn m 0.13 ED
a-, co 4_, CD CD U op oz, .(i2, op 03 0 4t', OP ro 4--' (0 CO OP az 6 ro .03 OP U 4-, +-' (13 OP op ozi CO +-, Op Op 2 r0 2, OP .F., t,' U +a OP 03 ro op op OP ro 'Jr:: -I-' 4_, -ti (.0 (.0 (.0 ox, 0 co , ro ti BO U -ti 03 03 (I,' 0 00 U co r/.9(10t5W30.13COUU U +., 4-' U t,' OD (-0 ,,9 CO U U OD 0 0 OA tj 0.0 0 OA
¨'' ro (134-' tin CO MI (0 '' MI OD OA OD 4-' s ' co ro (0 u co 0 ro opOOro OA
0 ro 03 ro co , 03 03 a-, OP -,,.7,' co 03 4-, OD 2, 03 op OP 00 4_, CO co 4-;
OD 1.74 CO
(.0 co 4_, 0 CO 0 s . (-0 co ril OP 4-; (.0 OP ro a-, +-' CO fo op ro g (0 co co 4-, (.0 ro ro 2, 0 (.0 (.0 , : 4 4_, ro ro ro ro (.0 (.0 ro - ro OA ro 44f ro ttO LI 0 -'-', , u roc to 0 4-, 0.,n3 u 4-',., (10 4-'0, oro -1-'0J3 (30 44(13 4-'0 (0 (-0 (0 U (2i3 .`=,':,. lf, :IL CO }:, -I.' yro õro iii ro 4:, +.1 U
OP 03 U Op +., .2 tj .(e, -0 :.; +-' SIP CO W3 Tz, ki ?LI 0 t, n ti OP -,..,,õ iii +., (0 CO 03 t',õ OP co 03 00 4-; 4,74 (.0 2 (.0 4r2( BO (:,j3 0 (.0 (13 (1.3.. oz, -ti (yo. (.0 ro ro m u (0 0 4,"" u (0 ro 4-= (0 'r6 ro an 4-=
4-' MI CLOt,' (13t,4-' 0.13(0-(3 MI mr (Clj U (a0 0.0 44 -14 0.0 CD 4,-', 0 (53) 44 ro _if 2 q 3 0 (.0 (.0 13 OP OA (0 Tx) 6 CD
r 0 OA OA ro OA (13 CO t:, +., (0 0.0 +., OA 83 2 0 Fe 3 on on .-2, t; ((:0) Fe (,.-0, 0 (-0 (,.-0, 2 -t, 4-, 0 (0 22? (.0 s (.0 ,,,:, 25, 2.9 2 ,:,õ (-õ, -(.6' (0Ø0 t.rõ 4_, 0 , 0 a 3 rp 0D CO 2 ro ".t' 4_, ro c13. CD " op OP 03 oz, 03 3 -,(T,,, ,:, (.0 (.0 u 44 (.0 if 4., 3 2 (0 4_, 44:, CO a, 4-, CD 4-, 030,,COBOopurO3UC044.t,S2UU
CO -' CO CO 010 4-' .F., MI -' ti' r MI
.F., ..t:: MI .F., CIO CO CO 2., r 4_, op ro 4_, ro 4-1 4_, fp .fzi 4_, tu3 ro 0 4-, 0 CO 03 2 03 oz, 1_3 03 03 0 ozi ,-0.1 CO
(0 (0 U OD all tp OD (1 4-, (13 OP 4-' if rill CO (1 (13 cp CO U 0 4-' OP co 4-; al/ 4-' (0 .t: (13 (0 4-' 0 CIO OD CO U r co .F,L 0 t,' oLO .,., CO 4-' CO -',-, ,õ('':' 00 44 +., 0 03 õ, 0.0 4-, OP OP .V.," `ii ,,õ,õ0113 OP OD CO (113 4-',D if ro a mr (0 ro OA Lo tj ,(1:1 ro u LLO (. t: 2 8 mcio ¨ (-0 (-T3 ¨ (-0 0 .(,,, , 0 õ0 ¨ .- (-0 (.0 (.0 0 2 9 op co op - ,9 ro op ro co 0 op 4-, 03 op 0,0 OA 4-' U 0 U 4_, ro ro 0.0 CO õ
,.,-- op , u CD 4-' CD 4-, CD 4-; 4t, ' . CO a-a 0 to 0 (13 44 CO CDco CD CD'4' 0 CD u '' CD W3 -t: r U U (0 ro op (i3 (:,j3 0 tu3 op 223, 4-, 03 tyn ti3 0.-0' OP 2 (.0 0õ
0 0 ¨ 0 0 4- r o õnOPU 4_, 0j34-, 4_, CO 0 mu 4(1.00j303 4,,-,,' (\,!, tu34(101::: 83 .2, ,,.,,, ro (0 U 4-' (0 "" ,000CO `(.',0.0(13+,,UrOCO'co -U+.,4-'+arOCOL4ZrOUO.0 OPcor0(.0Ut,õ.,COUUcoC00003+-,2õc0+,,COOPOPCO+aCOCOCO-CO U 0 , U 03 , ,-, 03 CO 03 a-, U ro 4-' op ,aaa 0 03 03 4-, 4-' 4-, ro 03 U CO on 0,0 4t: 0 (13 U OP op U co , ra 00 4t, (.0 (0 4-, _it:OP OP OP
AM O Pt: ' ' I 3 + ar L3 + 'C 0 + '(..) + ar L3 't r (.- ,f, - '0 3 UM
+ ar L3 (tF, ), 0 + '(-) + -'r 0 c 0U te. )13 = 'M r:t I: I (V + -'(' 0 C
OM L'i 3 i 4_,(-0 to 2 on (.0oz, 0D (-0 -(,0J (.0 ., t: -u ., OPCO+,, CO2t,' ,,, MI co+a, 03 (0 4_, ¨ ro 4-, 4-; .F., 4_, 0 j3 (.0 U (.0 SIP OD U +' OP CO 03 0 613 2, tIZI
T.E; ro .p, ro OA 4-' CO 4-' OD U (0 0 ro 4_, a-a all all ro u U U (V 4-, :lc:: OD (.0 4_, 2, (41_2, ro ms L, -6, a (.0 03 OP 4-, CO U CO op OP ro_ ,9 u 3 0 3 oz, tf, 3 0 õ..(U 4-, CO -I-',õ op CO U
a-, 4t, (.0 4-, 0,13 (:)J3 4-, 4-, 0,0 U OIJJ `-' (.0 oz, co 00 03 op 0,0 OP s . 0.0 ro .i.; 0 t 4-' tn ro 0.0 co -14:' OA (42, 4(9 4-, -1,7',., -1,-',, ((.11.), 4_, _ co (.0 (.0 4_, u 4_, ro 4.-,. co 4_, co .iL.. ro -44 " ' ., 0 '(.'6 -' -' MI +-, 4-' 4- CD (13 OP
4-, 4_, 4-; (.0 OP 4- U oo ro co 0 -1-, co ro 0 4_, co CO U õ, CO 0 (0 .0U a-,(0 -I-'u to õor 4-'(.0 (pro ro 9 4-'M 4-'CLII 4-,+' -1-9 tO ep out:4 .oror oroM ,r0 -1-'(.0(13 oroM 03ur sg3:0 a - ,(r 11 roc roc ro co on 0.0 ro ro .,., (0 ro +, (.0 co , 03 op (.0 +., 4-; 1-3 (.0 ro 0 co OP 4.5, u -1-' (.0 0D 4.5, ozi 4., ro õr., cp cp CO .(iap U fp -I-, 4-' rp OP OP ro U U (SD all (al u op .2 -, oD op ro ro 0 0.,¨ ro OA
ro , um roro.,r0O.0¨ roro rorouopopro-OproW
-4-'0Øt,'-'-'''''''0. O.Or00-0,9roo.Ororoaro um oorl:/+-'ro opm -'0o.o+-,rororot10+-,uroroM., 2,r0+-,uurot,'BOroroo.Oromcor 26µ53 .2ut;',0w3u 0 m 0 ro 0 u 4-, 4_, (-0 2, OP op õro oo 4(3 03 op 4-, 2 ro ro ro OP 4-, 4-' 03 44=,' OP ¨ op 4-, 4-; 4-, on co 0 6" 0 ti ro op OA op Orouti.O(0+-,-0.00Øt,'(04-'opmroo.Oromro 00 OP 0 4(2, OP 4-' CO 44:' 0.0 4-; OP 44:' 2 OP u co OP 03 00 ro 4_, OA co 4-; OP 03 03 (0 (13 CO rp U OP OP rp rp t' 44 CO 03 +-, +-, -' +-, CO (.0 0 U 4-' 03 4_, CO (13 CO 00 (13 4-, CO (0 4-, 4-, OD U 4-' OD OD MI -1-' CO " op .1_= U
MI (13 4-, OA (0 u CO +,, OD 0 co 0 U u 00 4-' t,' CO CO t,' 2 CD 0 r 0 r 0 4- , r o 0 r 0 r 0 o r 0 4 - (- 0 r o r 0 r 0 0.0-+t + - , r 0 .._,- (..) ,,9 0 ro ro 0 -1--, ti-'3 4-, ro ro U U ro (.0 3 (-0 u -,-, (-0 4-, ro -'-' U "rill OP n, 4-, U u OD 4-' .,,, co 4-; U 1.7',.. CO 0 U i. 03 _ 4_, 4_, CO 4-' 0 (13 4-;
ro OA co CO ¨
COCO0,04-,(0`"'OPCOctur0 -co`(.00.0t,'( 0,04-'CO(0-04-'('' ti' (0 U r r COMUMMUCOCOMRICOM
4_, ro , 0 " Op 0 j3 4-1 2 4,,, 4(3 U 4., (.0 ozi 0.0 rp 4-1 , , U ,., n'w CO 0 4-, OP (13 4-, ro 0.0 ro ro ro ro ro ro co 4-' .,, 4-, ro ,-; op ro 0,0 t a ro a, co (.0 u op -' co on +., 0 +, u t,' ro co u 4-, co ozi op , CO 4.5, 0D 4.5, H
0 ro OP 4-',õ 4-, 4-; op 0 CO 4-, .F., (.0 (:)J3 4-; 4-, tk., 4-, 4-; ,..¶., _ ro ro u 4_, ro ro4-' ,,, ro 4_, 4-, co.
4,7.: 2, r0 m 4-, c ro ro -' an on ro '4" ,U ro ro an (0 __co tto (0 Fa' 0.0 an ro 70' 61, 4u an ro L'D ro U 4-; (:113 U U 4-, 4-, 4-; CO OP 4--' op U -,:,-, CO t.-.,:, ,,3 0 4-; (13 4-' 4-' ro 4-, ro 4-, 4-' U U 013 tIZI U 4-, 4-, OD 4-' "" 4-' `-µ,, CO U 4-, U 0.04-, (.0 4-, 0,0 0,0 0,0 4-, 4_, OP 0 4-, CD U OP OP 03 ro 4-, ro 0 4-, ro ro ro ro ro ro 0 4-, OP 4-, a-, a-. CO a-, CO a-, CO CO tll3 CO CO a-, a-. CO tll3 U U
4-, CD CD 0 4-,a-,ouur000 (0 ro 4-, oo .1-; 4_, 03 (0 m r0 r0 oo u , u ro (0 CO 00 ro o co "" co -'' 00 ro co 0.0 ro 0,0 (''' i.3 co co ro ro an (49 3 (0 - t' 0 (0 tin (0 (0 U 4-, u ro 4-' ro a-, MI '' 0 ro -' on ro 2 ro 4-, r 0 u if r 0 .o U (0 4.1: on (0 4-, 4-, ( ) On 'I.- U -' '' (-0 0.0 (0 0.0 (10 (0 (0 CO (11:10.13(13 MI 0.0(0 -' CO 0 MI - (..õ., 4-, U on ro 4-, U On W3 C0 (0.2 te:PrO (0 (13"+-, mtl 76 0,0 r0 te ro 0 00 (0,,, õ.,0 ,õ,(0 r0 B ro (0 2 A On hcM". (0 r U5 4-' (0 U 4-= (0 CO r ". ". "' 4-' ro on (0 u (0 4-, (.0 (0 u u 0 i.i:, ,,.(- (.0 c,- (33 44-, 4_, 4-, (0 CD 03 (:(j3 (:(. On 1.T; U
CO OA 4-' (0 ro u ljz, (0 r0 4F0' oto Fo" ro on r0 ro ro ((.1', o 1.-0' 4-'õ., ro ,4:',.. 01:1 1F .1-; 2 OA ri3 4-' co 00 u on r0 ro ro +, -' on -u an r.,' ro 2 ro µr,Y., r, a t, 0 r 0 +-;
4_, 4_, .1-; (10 ere .1-, 4-, CO u OA m co oo u rou4-, (0 0,00,04-,,,-(0 ooro u (0 ro 4-' 4-' on o o ro - (0 (0 4-, õ., 4-, (0 0 U+' 4- W3r0 (0 U W3(0 0.1:1CW.,, 0M 0%0 p. 0 0 , 0U t : ( MI UM .. t-J+ ' 00.0 3 ro +.,-- -ro Bo (0 ,,,,,r0 ,.0 on (-,, tE; u U 4-, ro .1-; ro o 03 4_, ro u ro 44f, 03 ro a004-, ro monro co, r04-,ro (pro on.F,uro mroc,0-(3'.2("3-(%.t,'ro.F, r0 B 00 I'S u -c; (0 u an (0 0.0 (0 co u (0 4,74 (0 2, t-_,, en , (:to 2 +, 4-= .C,:i U
(0 (10 0.1:1 (0 U "MI -(0' t,en 3 ro on .s,. 2, ro +, 0 u 00 m CO ro m u 4-' r0 4-, .1-=
MI (13 0 on 3 õ.,(13 4-5' 2 (134--10 hrio,orl3U-4-,(00.0(00-13c0 co OA , U
ro op 4-1 ======= ro ro u r0 OA u 0 u 4-, u 4-' oo a, t 41(00.0u6',0 2 3 0 0 0 + , r 0 r 0 r o r o o n + , r o r o ,,,0 r o t: .t,' , . . , r 0 CD, on (0 u (0 on oo t-,, rot, u+,+, onro um .,, 0,13-42-0, 0 on FO. (0 (.0 0 (3,3 o (0 ro u 4-' OA (0 tX, ro 4-' 4-, 4-, (0 u rj 00 4-' +' 4-' MI ro 4_, oo OA ro 4-, hn 4-, U '' CD -,-, m ro (0 m .0 .0 03 (34 CO 03 on o on 4-, ro (0 (0 (I,- (0 , u u ro CO
I. 0 ' s' U U .1-; (0 (0 on (0 t, (13 (13 (0 OA (0 00 ro 4-; ,,., OA (0 :-., ro ro (0 u 4_, 4-, 4-, -u0.0rorouror0robow:,(0(.0ro00`(.'o'roro4Z+,rororo u op ro 4-, U (0 013 (-0 (0 4.5, u .,, 0 j0 (.0 .i., U (-0 t.: CO U On 4-, u ro -' 4-, , (0 2 on on on +-, u ro on ro OA m (0 U 2, ro µ(.6-= t, OA r0 44f, r0 (34 00 on 03 ri3 on -' 4-, OA on 4-, -(% +,4-= CO 4-, (0 on t, -(% ro Z ro a onro U ro 00 -u (0 on 4--, romBO,,u0Orom4-,0,0-ourorOo,ror0 rOro co oprou on u 4_, ro ro 0.0 ro -u -u r0 4-, 4-' (0 MI MI -' 0,0 an 4_, (.0 m op (:,,:, 4_, ,:,,3 õo 4_, ro oo (0 OA ro on 4., "ro 0 2 tr., (0 on o on 4_, u (.0 s_. on 4_, 4_, u u (.0 ro 4_, -+, u (0 on u 0.0 ( 0 co r 0 r o r 0 oo u Ms (0 4-1 on co m 4.5, u 03 -(13js -8J-3, 4-, 03 ro 03 4-, 4.,., ri3 ((.3.. 4-' ri3 ro (0 OA 4- (0 CO
OA
u MI -' ur 4- CO CIO on 00 U OA MU 0 t) CO (73) (0 On (0 a .t,' U CO
r CO CO 4-' CO (0 - CO .1-, .1-; - ro ro O ,õ 4-, 4.,O ro 03 r0 .1-; CO on 4- .F., ., CO ,z, (.0 .,., (0 +
+., ro ro u 0 .,A OA ro 81, CD+, ro 03 CD CD CD CDCD ro 4-, (0 (.0 u U -' (0 .1- = .1-; U
+., ro r0 +, on on co m (0 CDan (0 co (0 OA OA op u ro (0 4-, CDCD(0 (.0 4_, 4_, 4_, õ= 4-, CD(.0 (0 OA co 0 .1-; 4-; 01:1 CO U (0 .t: an -(0 }-!, (0 co 0 (10 00 e, r, 00 +., ro hn 4-, u (0 u " 2 co õr -"r0 BC) ro (0 ''' (1 t,' ' t.') (0 r r to Cr to 4-, OA (0 (4 (0 s ' ro OA m- OA 4-, 4-' .1-; CO co , 0 co on CO 0 4_, 0 on u on oo on 4-, on (0 4_, u , -,_ u ro 00 Ms r0 Ms romr 0.0 'o ,,,,(1 0 (I 0-0 0 2 Ms a, 4-, (0 0 (0 ro ro , .
rOrOror00.0r0-u --rororOuu 4-' on r0 CO 4-, ro an on ro u ro p.,r,r0 u ' 0 -' (0 - -u u u (3-13 u ro on ro u ro ro on OA (0 u u OA 0 on 0 ro 4_, 0 ro ro onro ononro -u hn _ 00 (13 On }I ,,., (13 .II .., 0 (13 0 0j0 On (0 4-' CO (0 On mr r ..6 mW (0 0 (0 tig3 s(1.; tj (0 (1 Z:54 (1301_30(.00 (0 co -I-, OA 4-, (13 (-0 ... ro 03 - 4_, ro 0 03 (34 on ro .1-; CO -1-' (0 ,,,(10 oo .1-; CO (-0 4-, (0 (0 U U 0 (0 u ro 4-, on 4-, -1-' _,_,4-' ' w 0,0 .1-; 0 -L) U On U On (0 on U CO on ',,,.. 4-' OA +., a o 4, :0- r 0 r 0 r o r 0 : -, :, 4- , (0 + , r 0 oo +a r, r, ro +, 4-' u on -' on 4-, +, +, (0 4-, , OS 4-, (-0 (.0 ,,, co ,:u3 (.0 ,z, s. .1-; U (0 on on n3 on 4-= 4-, ,z, r,,(:u3 4-, 0 4-, - -' on (..) 4-, U 4-, (13 4., a-, U co ro ro CO 4., 0 CO (0 4_, 0.0 0.0 ro .(i2 (.0 ro on on 4 d 2 , i i ,- op 0,0 on u ro (0 0 on OA OA 4-, -81 4d 2 233 .-t: ,, (0130 ( 0 .t, v 2 CO (0 (T, u u on ro -' -' ro .,, , ro 4- CO
4- U (0 (0 0 +., on U '' (13 W3 (11:1 U '' 0 0 0 4..-...' (.0 U t u 1-,, OA
,(7,, rill. (4 .t,' CO 00 00 oo ro (0 0.0 (0 4-, (0 Ms U (0 (0 4-' 2 - ro (0 r 0 tE; z (0 (.'; -..-5 z.v 4- ,,, ro ro 0 r 0 4- - t; -J, õ, y. ,, +, on +, -8;3 u , (0 E (0 OA r0 _ 4_, (0 oo 4-, 4-, - m 174' if on OA -653 op - ,,,-, 03 3 (0 on ro 4-, 4-, .1-, (.0 oo oto row mr0 mu 0.0 -' (0 (0 ro 4-, õ., 4-, (0 .1-, OA 4-, 4--' õro -ti ri3 OA m (0 00 (0 r0 4-, ro 1-.,E,' -6' r0 4-, CO 4-' 4-, ".. ".. ,,,u onn3 (0 u- on,rorou 4-, 4_, on ro to +.,ro wro ,(5.),0 -0,0 (29 uu 3 mu mro +.,m, (.0 uro (pro 1_3(0 4-(0 +.,m, mon mu .t' wro '3 .t.6, -ro --' t' 4,õ -(i.T,; 4(9 (0 .,_= (0 (0 u on 3 (0 .(,2 õc, on (.0 u (0 2 OA ro ,:,j3 -(1.T3' _ET (.0 4 = ' + , 70 t . i -I, ro r o On 2 r 0 t; tj -5' ro u 0 4_, on 4_, 4_, u (0 u , (34 ri3 (.0 4, .tian, a-, ro (.0 03 on CO OA on on u r0 0 co u OA m 4-, CO 4-' 'I.' On CO 4-, On 4., ro ro CO On 4., hn OA 44f hn U co (10 CO (0 (0 U co U 0.0 +-' op (0 00 ro :C.," Ms ro -' -+t,' ro ..04 Ms m 4,"' (0 ro +., 4-, ,,..,,r0 u +., on r0 4-, (0 co On õ OA 4-, (0 4-, on (0 03 r 0 u u (3,3 r 0 2, 4 - ' -4t f, 3 - -r% ti;
u (0 ano an r o r o 0,0 co -.,t,' r 0 0.0 4-, 00 mum 0 mumroro,r0(.0(.0u0.0 4-, ro .,., ro 4-' 00 ro an (1 co ("3 u ro 00 -u ro 00 ("3 on ro (1' +, 0.0 u on 4_, (.0 44 ro u (.0 OA (0 r0 m m 4-, (13 ,...., (0 4r2( On u 4_, U on OA
4_, on ro (0 on 44 u on OA ro BO co u ro .(,-9 'rt.,'t; OA r0 ro u Ms 0,0 4-, (0 CO on u ..,u on ro ro (.0 ao ro ro (0 ro .2 t,' 4-, on 00 B ro 4-, 1-21 (0 U ,,,, +.; on ro on +, +, 4-, (0 u an t,' 2 ..), a 2 -,,,' hnr0 a BO ko) r0 mr0 t:,' (0 BO t C to' r0 8 4-m Bo (0 .2 CO
(0 -' co (10 ili (al 2 ro t, ro u (0 +, Ec, ro (0 u an u -u 4- u u 00 4-, CO 4-, r0 u , ro 4-, ro OS ro r0 u 4-, u 4-, +.1 on On u ro ro ro (0 4-1 (0 (13 (0 0 4-, (0 (0 ro CO OS OA
OA ro on ro 0 OA (0 .(,2 ro 0 ,:,z, co oo (0 4-, .1-; 0,0 U 4-' OS (0 (0 OS
OA -I-' (0 (0 -' u ro U (0 223, 2 1::: 233 (0 r0 -6, co t4 2 ro ro if U u ro um ro ro ro ro 4_, 0.0w 4-, ro On 0 (13 (3 on 0 on 4-, ro 2 ro ro (0 OA u ro co on OA 4-, (0 u -' .,., +, ro r0 ro 03 , on 4-, gjo , +, U (0 (.0 4(.T:,' (0 .1-; a-, u On 4-1 4-' 4t1 4-, (13 (0 CO CO (.0 (0 (0 CO oo 4-, r0 On 00 u ro ri3 ro ro 0,0(0-u ro+, co u 0.0+-= onro o 0+,4-, u ro-u o t,'1-2, on r,(113 (13 U -' 4_, on n3 ro (.0 4-, u õ., n3 u ,,., 4_, on .... 4-, u OA . n (13 CO ,,. .1_= u .iL-' CO
co (13 on ro t,' (0 ro (0 (0 ro ro ' an, , r, .L'2, on ro ro '-'a õflon ro µc, (0 (.0 (.0 on on '10 ro ro on 2 00 BO E.0, 0 2 (ojo -E, 0 4., rO co u (0 6.. 44 (.0 ,z, , 3 oo (0 4-, ro ,õ0 2 a 3 1-3 ro (0 oo u 0-0 , u (0 on (,:, ro op +., oo 00 '-"' r0 ' w _ (.0 (.0 õ,., 4.5, (.0 U (-0 U
UtnUr0r0(000(1303(13MU4-'M CO 4- '4,' U CO MI -' (0 .i.7 (0 (0 (0 u ro 4-'_ 4_, u "(13 (0 o 4-, ro ro_ 4-, on u ro 4-, 4-',.r, õ(13 4-'õ., ro (.0 ,z, (0 (0 ,z, .,. 41.1 (0 On .iLl, .,. U
(13 (13 l 1.1 (13 ro on on (0 - - -.,-==, U u co u u 4-, (-0 .iti 4-, 4-, ; 4 .1--, ro ro CD 4-' 4' .-; u (0 4- , (0 ro ro ro CD.,., +, OA r0 r0 +., +., op u +, co op , on CD CD CD CDu 4- on (0 u i.0 4-CO OA rill OA OA OA rill U U rill rill U U U 4-, U U OA U 4-, OA rill 4-, CO 4-, U ro atatcaaaacgaaagaattgttatttaaacgtcgcatcgatataggcggtgtgaataacaactttaaaggagatttcca agaggctgagggtctagatatgtattacg atctagaaacaggacgtaaagcacttctaatcggggtaactattggacctggtaacaacagacatcattcaatttattc tatcggtcaaagaggtgtaaaccaattctt n.) o n.) gaaaaacatcgcacctcaagtatcaatgactgattcaggcggacgtgttaaaccgttaccaatacagaacccagcatat ctaagtgatattacggaagttggtcatta o ctatatctatacgcaagacacacaaaatgcattagatttcccgttaccgaaagcgtttagagatgcagggtggttcttg gatgtactgcctggacactataatggtgctc .6.
.6.
n.) taagacaagtacttaccagaaacagcacaggtagaaatatgcttaaattcgaacgtgtcattgacattttcaataagaa aaacaacggagcatggaatttctgcccgc oe aaaacgccggttattgggaacatatccctaagagtattacaaaattatcagatttaaaaatcgttggtttagatttcta tatcactactgaagaatcaaaccgatttact gattttcctaaagactttaaaggtattgcaggttggatattagaagtaaaatcgaatacaccaggtaatacaacacaag tattaagacgtaataacttcccgtctgcac atcaatttttagttagaaactttggtactggtggcgttggtaaatggagtttattcgaaggaaaggtggttgaataatg gtagtagataatttttcgaaagatgataactt aatcgagttacaaacaacatcacaatataatccggttattgacacaaacatcagtttctatgaatcagatagaggaact ggtgttttaaattttgcagtaactaagaat aacagacccttatctataagttctgaacatgttaaaacatctatcgtgttaaaaaccgatgattataacgtagatagag gcgcttatatttcagacgaattaacgatagt agacgcaattaatgggcgtttgcagtatgtgataccgaatgaatttttaaaacattcaggcaaggtgcatgctcaggca ttctttacacaaaacgggagtaataatgtt P
gttgttgaacgtcaatttagcttcaatattgaaaatgatttagttagtgggtttgatggtataacaaagcttgtttata tcaaatctattcaagatactatcgaagctgtcg .
, gtaaagattttaaccaattaaagcaaaatatggctgatacacaaacgttaatagcaaaagtgaatgatagtgcgacaaa aggcattcaacaaatcgaaatcaagca ,, , 1¨
.3 .6.
.
oe aaacgaagctatacaagctattactgcgacgcaaactagtgcaacacaagctgttacagctgaattcgataaaatagtt gaaaaagagcaagcgatttttgaacgtg .
r., ttaacgaagttgaacaacaaatcaatggcgctgaccttgttaaaggtaattcaacaacgaattggcaaaagtctaaact tacagatgattacggtaaagcaattgaat "
, , , cgtatgagcagtccatagatagcgttttaagcgcagttaacacatctaggattattcatattactaatgcaacagatgc gccagaaaagacggatataggcacgttag 0 , N, N, agaagcctggacaagatggtgttgatgacggttcttcgttcgatgaatcaacttatacatcaagcaaatctggtgtgtt agttgtttatgttgttgataataatactgctc gtgcaacatggtacccagacgattcaaacgatgagtacacaaaatacaaaatctacggcacatggtacccgttttataa aaagaatgatggaaacttaactaagcaa tttgttgaagaaacgtctaacaacgctttaaatcaagctaagcagtatgtagatgataaattcggaacaacgagctggc aacaacataagatgacagaggcgaatgg tcaatcaattcaagttaacttaaataatgcgcaaggcgatttgggatatttaactgctggtaattactatgcaacaaga gtgccggatttaccaggtagcgttgaaagtt atgagggttatttatcggtattcgttaaagatgatacaaacaagctatttaacttcacaccttataactctaaaaagat ttacacacgatcaatcacaaacggcagactt gagcaacagtggacagttcctaatgaacataaatcaacggtattgttcgacggtggcgcaaatggtgtaggtacaacaa tcaatctaactgaaccgtacacaaactat 1-0 n tctattttgttggtaagtggaacttatccaggtggcgttattgagggattcggactaaccgcattacctaacgcgattc aattgagtaaagcgaatgtagttgactcaga 1-3 cggcaacggtggcggtatttatgagtgcttactatccaaaacaagtagcactactttaagaatagataacgatgtgtac tttgatttaggtaaaacatcaggttctgga t=1 n.) gcgaatgccaacaaagttactataactaaaattatggggtggaaataatgaaaatcacagtaaacgataaaaacgaagt tatcggattcgttaatactggcggtttac =
n.) o gcaatagtttagatgtagatgataacaatgtgcctattaaatttaaagaagagttcgaacctagaaagtttgttttcac taacggcgaaattaaatacaatagcaatttc -a-, c, .6.
gaaaaagaagacgtaccgaatgcatcaaaccaacaaagtgcgtcagatttaagtgatgaggaacttcgcggaatggttg cgagtatgcaaatgcaggtggcacaag n.) n.) vi -' u ro 4-, u tw_mtwro (0, m 2 n , n (.0 4-, 0 u m m 4-, 2 op oz, 0 ^ `-µ,' op 03 ro 4-, (0 OP 0 ,,-, au u (II
(0 ' ro o ,õ u r or o 2 . o4 - , or 0 + -=,r 0 t :Thu mop wrill t: 2 .,(0 60 (00A .,co wro -r.103 0D ad + . ,r 0 roro coop row roro co- .,03 0-13 to op U 03 ozi op 03 co -1-' OA oo OA 4-, -' OP OP
r0 co co 4-, OP 03 03 4_, ro CO U CO (-0 CO oo oz, ro ro 4-, U co OP 4-, OP OP 0 OP -' 4-, -' -I-' 4., (-0 M CO CO (-0 4-, CO
Mr C00.00.00.000CCIM'w4-'(-0--.F., ""r 4-' 0,13+,0(13- (0 CO ro ro ro ro ao u co on ,snu r u tto ,..,(1' BO ro ((r o) ,_,(1' õnu -u u ro ao ro 1-3 ro , oz, op ro 03 co ro 4-_,w (1-3.- 3 ( (,0, 4-; 4-, co 44 co u a 3 (0 (0 0 4_, co U
no M co 4-, OD 4-; r0 OP co u .2 :0 m ro tto 0,0 3 oo o ro to V.1 ro ro 0 tE; ro ro t'-', +-, ro ro u -u u (0 u +.,- 0 t OA u Bo t,' co -(0' ro -0 õnnõ4.-iirourorow,u 4-, 233 ',nal, op,c0'-wro,uttOuurr,030 ^ CO co op - õ, 4_, 0D ro co ro u ro 03 (1 r0 tp OP ro ez, op -I-' OP OP op ro '', 4-, u ro (13 OP ro op ro ro OP 4-, ro u ro a, m, (0 u ao 4- on 0,0 +, (.0 ro ao ao õ, (0 +-, OA otO -um oto m 0 u co co 4_, ro on u 4_,urowro- 4_, (0 4-, - ro - 4-, 0 OP o^ p 4_, CO ro u ro 4_, oz, U OA U ro 4-' OA ro ro OA OD OD CIA all U a-, 0 a-, '4.. ro ro co U ro ,.., U U
op ,õ CO op 0 ( 0 op 4., (00,1:1(0rOUCOCCICOCCI.2(10(00.00+.1 -(3"drob'-'sr6uroa.o0.0(0-6' OP ro 03 co U _it, CO a-a (13 tx, t:ll3 4-' u U ty0 0 ro .(i2, ro (0 ro ta ro ro 4.5, co tw 4-, U (0 MI (1 (1 CO MI (113 +' -' MI MI 1-.,) r l:IA CO d.13 CO MI CO
co U 4-' (13 ro ,,c, . 4,74 4(2, 4-' ,,,.,(13 2 (ao n, on n, n, 0 , ro tax) 4., on u 4-, ro m , ro (0 +' 44=,' s . no 111 4`-_,'.. co .,(2, 4_, U u co 4-, OJO b) -1-' 4-, CO 4-' CO CD s ' 4-' U (0 CO nn ro ro 0.0 otO (II (II r 0-0 ro L,:v3 ro (%ro' ro ro ro (0 Lto ro ro ((i,' Oo ro u (0 , u rr,- u ro ror000mmooBorprorouromromm+-,coro+-,0.0,corom-ro, (0 u co 0 u co - õõ Op ro ro on 4-, 4- ro ro ro ro ra m - , a, 0 m u ro ,,,, 4-, 0 CO 4-, 4_, CO OA P. 4_, r CO hnr 'WM 03 4-' U
(0 ro co ro ro (0 4 ao u oo +-, ro 0.13-a CO 0.04-' ..."' ro ''' ao ro -e, u ,r +'ro +-'op ra 0 ra ,õ +., OP OP co co t 4-, U (-0 CO 4_, 4-, CO CO
co ro (13 u oz, 223, 03 co a-, ,,-, OP 4-, u ro ro 4-, co '' +., (113 u U (.
r, U CO
CD on 4., 4-1 co CO 1::: (0 ^ Op 0 0 0 op 0D r0 OP r0 ozi op op 4-, ro OP - +., op U 4., 4--' -I-, 4-, 4_, co OP co (13 ro ro opOPrOc0 4-'rOur0O.PrOcOu Ms op t r 0 2 r, 4-, co+-' MU co+, co CO ClIlt,' TIE; all U+,4-' 2 , + - , r 0 + -, r 0 CO all 0,0 ro rõ, co 0 ri, 2 on CO 4_, on 0 ro ro 0 ro ro CO 4-, OD 4. op 0 op -'(00.0Mco4-'CLCiourOMIcOc0(00-0r0(0+-,(0 0 +., ro OP OP 0 CO op -1-' -' +-' +, U 0 r CD-CD
co ro .i.-; ozi all 4_,z, U CO 1T3' tu3 (.0 4_, no ,.., co 4-, co 4_, U 4_, no 4_, MI 03 4- +, (13 4-' (0 (0 0,0 ca 0 ro ro 0 .,,,,, (.0 ao ro ro OP ro co (.0 , 03 03 u a-a (13 4t: U CO BO 4-' ro 0,0 a, , all ro op OP 4-1 CO ojo (-0 MU (11:1-j CO+, Mr 0,13(0+' (113(0 OD+, CO CO+, COBOU all (044 , op 4-, OP op op OP 4-' op OP ro ro 0 co mu ro (0 co op co OP
" ro ro IT tp co U
U ro ro t 4-, 4-, U U +., OD 4-' +./ MI ' . OD co OP OP t:'- - ro u u -I-, 4--' U
CO 0,0 CO , CO U .t, (10 ro +., CO (-0 co (-0 01:1 44 ,,,, 4_, ojo co co 4_, ,,, oo u CO 0 tn U OD r 0 1-3 CO CA t: (10 (0 co 'cLY., U U OD CO OD (0 2 '44 4-,õ u ao ro =z.,.- ro ro (0 tto ro ro ,-.4, u -' -r; ro t', , õ, OP co +., u op co u OP _,_,=-= OP
-' Ms 0,0 OP ca OD 4-, +., 0,0 tj 0 MI (0 r0 ' OP 'v7 u u ra -' u u OP OP 'El Ms 0 (0 (10 co OA MI OP Ms OA ro ro '10 -0 oo 4-' CO +./ MI (1 -(Lo' MI CO OD U
CO 0 (10 CO ro (0 ro ro ro ro 4-, oz, tx, u ro ro op OP 03 4_, ro ro 2 rõ, (-õ, 03 4_, a-a -!--; U CO ozi op u all a-a (0 CO 4-, ro ro ro 0,0 (0 r, C00.0,...,''4.7,',tf,+4-'01:1C111+,4-JUUCOU0 0c000(0000 0,0 Ms 0 OP ttO .L'f, '-'-'4 op Ms +., (10 r0 MS OP ca -' 0,0 Ms Ms MI OA
OP co (13 CO
ro co ro+,+,4-,ro.,,r0 0 u4-,r0 uttoro-u8r04-,ro , ro u u 0,0 co co 4-, OP oz, co OP co U ro U 2 ,õ ro ro õ OP WI
roc003cOuur00,003-60,0cOur0+,:,;0,0rOurocourorProrou (0 4t, (-0 CO CO OA CO ,..,., OD 0 DOACOUCCI(13(00.t,'+,U(OUUCCIrat' U OD CO MI (10 (0 -,t: 4j CO 0D (0 (13 -(0' -(0j OP 0,0 r0 op (0 OA (o co u U -' co fo 03 oz, 03 0,0 U -I-' oz, (0 4-, _ u 1--,, 4_, 4_, .(1.3, oo 4.2 co u 4_, co 4_, 4_, u co tw I.
U op 0,0 (0 K1 3 , 0 (- 0 t: : 4 i - = , 0 z ; + -=, , 0 0 OP w 4-, Ms ca O
00U 2 -' ,T, 4-, ro ro OP 4-' ro - +., u OP OP 0 - ro ro 4-, 4-, ro OP rill -r, u õ..,"' co a-, (13 4-; CO Cll:1 OD OD (13 4-, OJO co U µ s (13 co ro ro t,o ro CIA (:113 CO /1 a-, 4-' OA ro co 4-, ro a-, op - ^ 4_, 03 4_, 4_, 4_, 4_, (.0 u - õõ co co 4., 4-, co 4_, (-0 4., u OP 4-, OA OD (-0 ro (0 4-, ro m (0 co ''' 4-' u OP OP 03 4-, ro ro 03 OP -4 r0 0,00,0 co 4-, (0 OA, u co - OA U r0 MI OA
on +.1 ClAttOroUoproCCIroro+.1 Uotnr0 op 1-3 U3 OA (10 +.,(0 .000 ror0 (6,0 +-,(0 rou ror %.1:1 Zm ro(10 +-,(0 co 0DM 0,000 _our uU cora (00-0 tn,..,, (00.0 al hj, .6,' ro õ9 ti u44 u 0,0(0,4-,õ,(04:5 um u n, ro ro 4-, OP CO
co tx, (13 u OP -5' ,õ(0 op 1-2, co co 0,0 0,0 mr0 ,T,U ro LI 4t r or 13 r ou 0 3( 1 0 3( 1 4j LW mall (al,(13 ro to .t, Lto u 45.
u , ro -u ro ro - -roun,rorouro 03 OP 03 co ,,,, 0 0 OP co -' +., co OP ,44-' rõR co CO u 4-, ro ro (13 on , 0j3 4-, ro u - ro en (61 (.0 u (.0 ro (0 -0 co 4., ,_,U (0 ro OP 03 ll, -1-',_ 8 4-, 4-',,, 4-, CIIIMU-+.,UU 0,0 0j3 co .1=, tto op u 4_, oz, , . 4_, s . ro U r0 u (10 4-' -' (õ,-,1 op u 0 op co 0 ^ op , (.0 r0 co ro (.0 co (.0 u CD 4_, 4_, U 4-, CO µ...4 co 4_, co ojo u 4_, co 4_, co 4_, 4_, u no hn on õ, co U a-, ro 4-'ro 2 6a0 rpm 4-'u .I.-,t' U U 4-',., 4-'µ , CO 4_,4-' OD 4õ7,' OD OA U
CO CO C13--. CD 0 -0 6' t S 4 - 'a 13 0 u no 4_, co (a rub 3 4C2, 4t,. õ.,`-' tiO co 4-' ,_,"-' CO (:113 -I-' ro U
ro ,..õ r0 0.0 4_, 4_, 4-, 4-, ".. ro ro - 4-' u ro a-, co a-, 'w CO 4., (-0 U 4-' U (0 CO '' OD (1 OD U 4-' CO -' r U
OD oto ro m ro c'D t:,' ro 8 ( , :, ,, um - 6 ,:,õ` 1 2 2 3 s r orc' ,4 - , 3( = 0 s g2 - , .0', , ( . 0 n , n , 0 . 0 4-; OP U ...,, (13 ,,,, , (-0 ro 4-, , , r0 tto µ..,_ u ro 4_, (.0 4_, 0 4_, _ 4-,r0rOWZro+attOurO`' 4-, ,,-, -' MI op 3 0 . 0 t E ; u r 0 , 0 , 0 4 -,c) .2 2 "( = 0 , ow or 0 mu 0 .
om ot, 0 -t:', z s . õ- ' r or 0 + - ',. 0 ,` ' CO a-, CO a-, (0 co .2 0.0 W:Th r ti'o OD U Fcr to 4-' fa (0 CO r ti U (0 CO CO
-6' ro V , ro ro (.0 , TIE; 4., U u (53' ojo ro (-0 oo Op 0 L,^ u OP (13 4-, U 2 U 3 4-, r (13 U OP to op R? F33 2 U - (1 T1; BO 83 If a-, 2 2 0.0 -, u u u oto 0 ro 0 0 on u ro ro ro CO CO (:113 (10 -1--' U
CO U U U U ro oz, CO 4., 4-' m CO (13 u 4-, r CO CO op ro 0j3 (0 CO OP OP u CD 0 c0-(0'corOc uu 4-'CLOMIro U u 4-, CD CD4-, 4-; ...,--(-0 4., (0 l:ll3 Cll:1 U U w CO CO BO u 0 CD CD co co u u 03 0,0 op 0,0 OA u -+t,' u cor0c0u4-,4-,+-,c0OPc0(0c0(00,0000,0urPrOcouut,'-ur0 .,., +., , co r0 -' 4-' r CO OA
(1 on On CO ''" U '' CO r 0 m CO MI
4_, ro 4.5, ,S, ,y 0 OD CO ()J3 (0 ((ro) 4-, op (cil , ro ro z., 4-, 2 - i -=, u .,, ro u r 4-' a (You .,,:i t, -+t: (:Lo -r.: (0 ro co u -m (.2 t 5 a t2, +
- , ( .' 73' "r 0 u r, u +., ca 0.0 ro -.t:,' on 4-, on ti 4- m- u -',õ on Lao t ro - ro (ao (ao oz, co (0 4-' CO (-0 4-' dA 4-, 4-, 4-' 4.D
(-0 , . 4-, - 4-; r (-0 4-, OA
co CO co ro ro 4-, a-, 4., CO -1-' 4-, 4-' -1-' (-0 (-0 ro , a, u 4-, OA 2 0 ro rõ, co OD +./ t,' CO CO CO U CO CO U t: CO (0 +, OP OP .,., OP OP OP .,., u ca +., OP CO
03 rill rill a-, CO CO toiO U U OA CO 03 OP a-, CO CO 4-, (0 t1J3 OA CO a-, a-, co ro a-, U
a-, CO CO CO CO CO OA CO CO CO OA a-, CO CO CO OA CO a-, U OA CO CO CO U 4-, CO CO
0 rn ro (.0 , ro ro u oo oo oo ho ro u 0.0 +, oto B ((:, )3 tj U CO r U CO
2 (II (a ro ro ro OA -' '' OLO -' U CO u (0 r MI r +., U 0 0 I.
0.0 on (0 (0 (.0 oz, moo 2 (0 on u (0 0,3 (0 (ao (ao (ao 0 l5Aro 0+, Fo-ar0 44 0.0(0(000 inn U ¨ ¨ 0 ro bn CO MI ''( ) (0 OA OA +-, CO (0 rn m cO
4-, ty3 oo 4-, -' ¨ hn tto OD a, ro 0 u ,,,¨ m 0 .4¨ ro 4-, u u ro oo ro +, ro u-' - (13 +, CO OA U U it., 0.13 Z.:w (73 (13 Zj co ro Op .1-, ro 0 (0 CO (0 _ 4_, U u , , OA
+-,(00.0(0 -Ot: 1 ( O.O.O.00.0Mr w3 4-'c'0' 3 ?.., (-L0) ti (.0 , (.0 (4 u , 0 (.0 4., 03 0,0 0,0 CO .it', CO 4-, (.0 ,,,, (.0 co (0 (0 ro (0 (0 (0 0.0 (-0 a. 0 (0 (0_ r 0 tE; ti ro 'µ,' 4-, 0 ro oo oo oo u ro co co U MI - La0 OD OD (5.0 (0 U " (0 (5,0 U (0 (5.0 U (0 (0 13;3 ((.11.), 03 co 4(:), 4(:), T.0 ro ro cc, 44 4(2( 0 (.0 (.0 (00 0.0 ro (.0 (.0 0 ro 0 OP
U OP 0 tE; U U U U CO CO t-.,' to +-, (a op (0 4-, (0 CO OP 4t,' 83 OP (0 U 0 CO
.1-; 03 CID oz, 4-, (13 4-, r0 P OA O CO
4-, CO U 03 u 4-, if U u oyo ozi 03 .!..! U 0D co CD m to U co CO
CO U co co 4-, tto ttO , (0 OA 4_, OA .1-; rn _ 4_, -r,r, co .1-; 0 4-, = "' 0,13r CO 0 CO (10(0 +-,.F., tnr0 (0 U U 0.00,13(0 CO U '',....4-' f, -r, +-, , ro sc, op ro ro (-0 4-, oo -u ro u 4, op 1-', U 4-' -' oyo +-' co +-, " CO
CO " 4-, ro u m ro ro .--,:, u ro (13 4-, `-' Op CO OA 03 OA op CO tj OP co oz, 4-' U
U%-",U-to-0003opc0 +.,Opouto ODopOP CO4-, OA
4-,(000.0+.,( C0+.,C0t0LWrOrOopCOOPrOUouUroto(a U
CO . CO m r OD 4-' 4-' U OD (0 r CO 4=- (0 r "..: (-13 CO .2 U CO p.09 hriCd3 OD
t) t.,' (0 '' OD U MI OP -' MI OA CO (0 U CO (13 '' r CO OP 0 U '' (0 L. co OA -r.r, U .,(a 4_,(13 tj 4-= 4-' 2., U 2 - ro t,,o ro 4_, , ro 0.0 ro ¨ ro 4-, = ,-, 0.0 4_, , 0,3 ¨ 4-, õ., .1_=
.1-; l:113 U ,W ro 4t, 1-,. op 4t1 ri3 2 ro tri (13 0 1-', ri3 4-, (13 C1:1 +11 .1., 4-, OD CO U
U 76 di3 CO U(F0) 2 -(,-,-3, co OP (F0) 4-, op OP 4-, 0 -6' 03 CD
2 ao c'ci ro -'((:0' (.0 ti, 0 ro a , as Bo 3 2 (y, w3 (.0 2 ;0.0 murorOm ro so U u C1:1 (.5 t' 4(3 C1:1 T.E; (V .(i2, 44:: 03 (13 (%/3 4-, TIE; 4-' U
C1:1 1553' u ro a 4-, 1.T3' U CO MI (a 2 (:(.0 (:(.0 -' -813 CO OA OP (0 U (V co 2 ao 3 g2 cd:' (:(.0 Bo -(;E; .0 (V (.0 (o:d3 0.0 mr Bo (.0 co -(0' ac9 4-' co -(t:; u -(0' t' u (0 (.0 s.,,o ro .0 (To (0 co (0 u 4-, 0 2 -(.6' (.0 .2 (4 (0 "(0 3 ro+,N32.2+,,,,r0 ro (0, u, 0.0^ 0.0 0.0 4-, ,,,, 0.0 (0 (0 (0 (0 -,,õ _51,0 .L,OO tj 8.0" 0 2 SG (-V
L'; 4r2' 4(2 (0 C(E)1 1-.,) .1-, U OD (13 , C1:1 4_, (0j0 ro r0 rn ro +, -r, 4-' 0 (0 (0 .L'_I -63 '' CO
ro 0 .-t-', OP OA co to OA CO OA OP OA
U CO 03 ro OP (.0 1.T3' 0 CO CO oyo op (.0 2 ,(:),., (0 , -!-,, oz, (.0 õ,:, (0 2 (0 .i.,:,, ti 2 -,,,, (.0 (0 (0 (.0 ,,,, (.0 t 2 (u40.2sz-i2(04-,-.t:: oti_4-,(0 CO OP r0 t, 4_, (-0 -r.,, 0 (6,3, ,,, 0 (.0 0 (.0 .0 (.0 CO 0 ro ro 4(2, co u 2 (.0 ro (.0 (.0 (4 4_, (.0 (13 CO
rOCOOLOCOUM.2 4-'-'+.,d.00ON4-'+-'(-"130.0,,MIZ (-000mU.F.,-rnUt,' CO CO OPOPoprOor00.0000h¨n4-'0OMO.0`"COOprOiirOii (.0 4-, ro 4-, , 4-, ¨ co ro 0 0 .0 OA _ 4-, u +-,OD
CO U +-, 4-' r CO OD OD OD 4-' (0 ". u 3 tn iii3) I CO ti (.0(aci +.,4-' (.0(. .(,..i ro 3 rou u ro ro oo e., õas:, , ,O.0 ro rn to ,,,,O.0 t:,' 1-2, +., cr 0D mCO õ.0 0 (0 (.0 (ao co (0 co co tto 013 (0 .1-; ...A., -.. U co ro -..., 0 3 (4 (.0 4_, a. (0 u (.0 (0 u ri3 (0 CIA CO MI co (0 ..r.: -' 4-, U-',+./.,,..0 (0 W3 OD 0 -' CO U r '' (0 MI ro MI CO
.:,) '' OD `5 '= 0 I. 'thj.' 0 4-' .F., O .0 . = 3 03(-0,,,,r003(.0roro+,ro.0ro.,,(00(04-,,u 4-,ror000,+, = co OD (5.1:1 (11:1 COM 0,0 (0 CO t,'COCCI(5,000tt or 03 (0 03 !TRIMS U fl, 4-, OA co (0 U OA co ro .1-; ,T, n5 .1-; CO OP to ro OP 4-'._ ,., U OA ro co (0 CO U r CO sCj '' " +., CO CO .A.' (0 U
(13 .1-; OP 4-, ¨4-, CO OP -' CO CO
CO
MI 4-' ro CO r0 U Z.,. r0 (0 4-' r0 -u OD OD MI u OD ,(.7?r, u '' op MI u 4-1 +, a-, ro ro op 1:,, 03 U 4-1 U CO Op u ,õ--4 ro op , 0 .0 u oz, OA
CD
CD +., +., op +-, ro _ 0 .,, 0 (13 .t, ro ro u op -F0 U +, OD (13 U C1:1 op ' . CO
op U .1-, co OD (13 "-'.,., 4-, OA 0 co (0 4., 0 ro ro OP .1.., ro 4-' 4-, ro oo 0 ro (13 OA
03 Op to , op 0,0 um co Op +., 0j0 u co +, u rn 4_, .,., 4-, ro ro ao +, 4-, 0 OA op op op oyo 4., OP 4..1 OD (-0 4_, 4-' 4., OD .1-; OD (.0 CO u a-a (1:1 4-' ^ ro CO 4-, (-0 u ro ro ro u 0j3 (13 a-, CO OP 4-, op op co 4-' U 4-, (-0 CO (,.,-. 4-, (13 , OA 4-, U co u OA -I-' co .it', op TIE; .it', CO 03 4., (13 ro u 0.0 OA OA s w ro u (:113 CO oyo OP 44f 44 co u 03 _ 4_, u CO `,.. 0j0 4-, 00 U U (15 0.0 MI CO 4-' +., U +.; CO +., U 0 "m 4-2, C 0 MI, , MI q p t U .,(11 Z 2., , Op ro OD .1-; OD 4-, ,T, 4-, (.., .1_= ¨ ¨ ro =-= to' 4_, 0,0 u 4_, 4-, U C1:1 ri3 CIA (513 U C1:1 +11 C1:1 .;:r (0 (0 OD ro U õ., (13 4., (13 co CO
CO op to 03 0 = 0 OA 4-' op U 4-' OP OP ro ro s- 4_, ro 0 u u "¨ u (.0 4_, 0j0 (:(o ro CO (a .1-; ro ro ro ro 0D 4-,, ro ¨ 4_, (.0 ro õ., 4_, co (.0 co OP co co CO44=,' ro ttO 0.0 ¨, ro OP (13 ro u 4-, .iL' ro -,-, u (13 (13 CO (0 r r CO Z:r ro r rt:' r 2 -' 4-= Cd3 U +-' (a 4-' 4- U rnM 11(7)n r (.7 CO
OP 03 op ro U op (o 0,0 +., CO CO CO +., .t, U CO +., +.1 4-, +., t' U ¨ ¨ -' a..! ,.,., 03 03 op .1-; u ,.õ( 03 OD (0 U .1-; 03 C1:1 C1:1 2 a-, (a) U
ro U CO -1--, U
(µ5'i3 '0'5 03 .1- i B) 0 j3 ( . 0 '0'5 1 f BO (13 BO 4t.1 - = 4- (%) 0 j3 a 4 _, C1:1 4, co (i13,.0 3 ro ti-3' (6,13) (13 0 a, op 0 3 (13 (r-)0 OP OA "t1-8 r (V
w3r0+,t,'4-'0.04-,w3tiouu000.oumu .2 co co 010 u r t co -' co r ro r u OA 4-' ro u ro ro .0 0 +, ro u tto OP o U CO +-, tt, (.0 (0 0,0 (.0 +-, 0,0 t,' (%.0 00 ^ 0,0 t 03 U (13 (5j3 CO (13 C1:1 U 0.0 'a t:: OP -(. a a CO OP (01 CO U
co to CO u ro U 0 03 op (0 ro Li (017'0 gi2 44:: (a 2 29, õc= o 2 0 (.0 0,0 r 0 ti õ0 -(0' w:, (0 (-0 a -(.0' ("3 c'D .0 u r u u co ro ro 4t,' (0 ¨ ,,, 4-, tIA .1-, C1:1 ¨ .1-; 4-, 0.0-rr,+.,(1:1(0MCLOCLOUCOCO
t.1 r U OLO r 4- 0 2 U (0 -' MI -2 a to w3 613 U CO -,..,r, (a0 r0 u ro m (loopt::(.0Urp.00(.00.0(0,0,00,0S,COok7,COUCOroC06-pt) COmr0U-mtor131.2,4-'rou'C'04-'`wr rOrOUO.04-'CO
CD co 03 u OP co op 4-, CO ._,., OP oi3 1T3' 4-, .1-; 0,0 4-, OD U ro u op CO ro 4-, µ6, (0 u (.0 Bo co oo u ro 1,...,.. tto 00 OP ((.1), 2 0 4-, 0 1.T3' CO (0 (0 oto u ro u (0 03 , 03 4_, 03 4t, OA co 41.1 -I-, . 2 (-0 4_, , OA OP CO 0 4-, (4 u 03 ty3 U ro rn u 0.0 oo ro 0 ro r (0 u r op ro .1t .' (a B .(.% r op td3 CO r0 u u ro OD
(.0 op t (0 .1..1 ro oi3 fO, CO op 2 (.0 (.0 4_, u ro 4., (.0 ,(rõ) 4., co (13 -1--' 4-, OP U CO
U CO sowp OP -6,-.0 "(0' CO Z.; 1-2, "(0' +., U Op OP 2, CO OP 0 `(.'6 S co CO
2 2 O. BO CO
-(1-3-3' to ro OP 03 oi3 U U co 4_, CO 4-, .1-,4_, 0 (.0 (0 4_, 0 j3 op 4_, co +., +-, CO MI OA op MI to' '' (0 MI .2 tE; 0 0D ro an tE; U RI r (13 M
.I-; U n3 C1:1 U
UU
4., u CO 0 CO .1.-= U (.0 u (.0 UroM U WCOCOOD
OA dA 4-, CDu (0 0 4-1 1.T3' On (13 03 u CDCD03 CDu 1-3 4-, OA t t.,1 4-, U CD
CDop 4-, (0 (-0 U OA oz, co .1-; 4t,' 03 co 03 4., dA dA 0 4., 4- u o a-o A U U D p U 4-, U CO
co 1-3 op co CO ri3 4t', 4-, 03 fl5 OP 0 j3 op u 0 oi3 4-1 03 OD OA OD 03 0,0 OD CD-(1.T0' 0 rornroror04-,(0Z,,ro(.0+,roo(.01-3(0b) tzl t:: U OA 2 3 (- 0 Bo CO ri, s ' .1_, 4-' 4-' 4-, (0 ,...., CO O CO op o co 0 ro ., CDoo rn CD ii (0., +, 0.0 013 (0 CO, 0+, ''' C1:1 O C1:1 4-, 4-, (13 (13 CO , CO .1-; d A
U d A 4-, ro o CD ro h CDao CD 4-, ^ a-, CD CO OA CD OA CD a-, a-, CD CO CD U U CD OA tll3 CO OA tll3 CO CD
tll3 a-, a-. OA
on w3 co an - co 2, +, an Bo 2 0 (.0 .p, 0 < 0 H u < 0 0 0 u <
ro OA co OA 1-T; -1-' co < 0 < H H H
0.0 -04-'0Opla 03(Or C000Ur 4-' O op MI
OA - '' OAot La 0 < 0 0 (D L9 < H
4-, (0 r on ro ro on 1_3 3 .-,t, (0 4t, (V (0 ro CD m co rill ,õ '=..... U 0 U , õI- (-9 CD
OD OA CO OA -I-' 4-, 0 ro rm. - L7 < U H U L7 L7 H
4_, (0 (-0 tn M U .1-, µ(.6 CO ro .1.t,' CO CIA 65 0 ro -,1.74 on ro ro no H < U < <
01:1 U U CDU CO CD C0 1-3 `6' u g2 < W 0 u W W H < 0 < 0 (0 ro ro 2 4-, ^ 0 OA 4-; tE; ps,-,C4 .1-, tl CO mall (-90uUL-9(-9U<U
4-, , , on rou corn .t., 2 .2 .,-, to on to, .ro. UL7Ho<<L71-uL75 (.1:' O
(0 (10 U r U o ro - 4-' CD H U H < (-CD CD0,0 co ro 4-, ro co U L7 U 0 U y +., < L9 (-9 <
<UULDH 8 <
(-0 OA OD CO ro 4-, all all U ro ro 4-, all op 1(2 8 * u 0 -',..., op õ., ,-, OA co 4-, ^ +-' ro ,,, 0 ,,, - U Q
H < U < W W
2 2 2 .,r 0 'r 0 r ou .t,' flII. t4 0 ro (-0 tton3 4(2, 076, 0.0 2 n, H (D EH < UU LDIL2 (D
(0 CO CO 2 U CO roOA +-, 4-, -0.0 CO OA CO .F., -õ.., U r, 0 , u 44 44 .-.1 < < < (-90,õ(-90<(DE
u op ro U CDs == CO 4-, all OA (13 co a-, co 0 U C-) 0 (-9 U W U
CD co op (13 4_, 4-, CD-I-, OD 4-1 OA co HI-0 00<0 U ' (0 0.0 ' ,-rs -0 CO OA tf, r -',õ, u u u < HI-< H 0 CD4-, 4-, 4-, , ,4-, CO 4-; . s' U 4-' (0 4-' ro (13 U M U
4-, ''' co ro tto ro on 0 H
- 4= 4- < U U
4-, M 4-, U 4-' 4-; u CD0 tto < co 0 0 U U 0 OH <- 0 4; -; (13 0.13 on 0 ttO ro U (13 CO CO U (0 CO CD4-, CO 0 (-0 on 4-, CDCO
OD OD (0 OD -' U U M 4-, U 4- +-'rn OD M U 0 u U U U (-9 - U
ro .1-, M co 4t, (00 OD all a-, On ro ,.õ.,--õH U L7 U u < (-7 I-- 4-; M on M M CO 0 CO CO (0 0U 0 < H W
,_ - U .1= (-0 -, 4-; 4-'õ
O
o (0 pow ro 4-, 4_, t u on ro 4-, 0 -' Op ro L -' ro on u 4= +-, CO -' +-, m (.0 s ''',,.. (D U
OA 4_, .1= CO i.-, .1-, ,-,.. 0 op 4-, (.0 co tu 0 co 0 0 m co j0 .' 0 ro 0 ro OD (.0 +-, ro OD 0 4-, OA
O (%0 2 õc, -(iT,; 4(3 12 T ,,:, if (a tiej a op 1-0, 2 H t)UL7õ<01-UH<Uuu ,1-<U`"Uerl-ro 4-, ro 4-, ro ro o 4-, co 4-, 4_, 4_, 0 (0 H U 0 , r, , ,.., H u - u -.
0 j0 ro 0 0 all U ro 0 0 0 dA U ro MI tiO MI
(13 4-, 4-, 4-; 4_, U 4-, U (-0 .F., (0 (0 ,47',., (0 M
4-; 4-, co co U 0 4-, I-! C0 tto U
u ono roror,ro70$194-,(04-,0 ro f ri Uf)I-ro on u u =-.., < --- (.5 H , .-, (0 (0 U RI OD p , < 5 u 0 H u H u < H
mu 42 2 2 0 0 t i , 2 2 - u u < u < (.9 '9 o < u 0 u 0 < 0 H <
1.,) (.0 _(-0 u tE;
4 - ., (13 ro CO
-(0'CCIa0O.t,'.t:COCO(.000rod.0 Ur0 < ILD(D<L7L9uUUHU<
oHU(D(DUu(D 0. U an4-,+-' 2 0 (0 _ _ . , u u u u , < c,--:, < =-= ,, <
ro (13 (13 ro U all U , U ro H
((7, )3 :,ti CO tf, = U U 4- ' U (10 8 (0 0 u u (49 0 u u < H
CD< op dA 4-, CO
RI r CD ro ro CD
4^ F ' co co co co OA 4-, L. 4-, u (.0 4_, co (0 u t.,-?, ro ro u , 0 u u ro t ro 0 U <
2 4- U U U < (11 U 0 < U U
(.0 , - (.0 ro ro ro U u on OA 0 <000 Lc:c)Q0QL<_S(D<
Qui 4-' U rj U (13 .1-, CO 4-' CO 4-, ro 0 j0 CO co u co CIII U 4-' (:Lo 0 0 -.,,, ,L0 4-; (0 (.0 ro 0 ro U < < L9 "L9 U < <
OD M CO W3 OD (113 +., 2 co op Bo 4t, .1f, 44:: ro õ, -Id 44 .f2 r(.1k8r,.õ,(5,(2u0(.1 (0 .0 u CDu tt0_,_ õ1:10 u ro ttO u 1::: co 4-, 4_, U ro ro u ro tal., .i...-, ro op C0 4.., 4-, ro (13 D -1-' < 0 < < < H 0 U H < U
U U CO O 4_, (0 u 4-0 j0 ; (0 U M 4_, u CD
< I- < L7 < ( D < ( D U ( D <
CO U U CO 013 CO .1-, .1-, CO U CO M a-, U CO
CU
rq u .(0 w .+7 u ,1-0_ ( = 0 0_ 0 ..._... 4_, 013 (11 U CO SD- CO
,-I
ACAGTAAAGATTCAGGAATGGAATACATTTCAGGCAAACAGAGATACCGCGATTCACTGACGTCAGCCTCCTGCGGTAT
GAAA
CGCCCGAAAAGAATGCTTGTTACCGGATATTGTTGTCGGAGATGTAAAGGCCTTGCACTGTCAAGAACATCGCGGCGTC
TGTC w o w TCAGGAAGTCACCGAGCGTTTTTATGTGTGCACGGATCCGGGCTGTGGTCTGGTGTTTAAAACGCTTCAGACCATCAAC
CGCTT
i-J
CATTGTCCGCCCGGTCACGCCGGACGAACTGGCAGAACGCCTGCATGAAAAACAGGAACTGCCGCCAGTACGGTTAAAA
ACA
4,.
w CAATCATATTCGCTGCGTCTGGAATGAGGGCTGCCGGTTAACACCGGCCGTCGCCGCACACCGTATTTTTATTCTTCAG
CATGA oe TGAGAAAGAGATAACGATGGAAAGCACAGCCTTACAGCAGGCCTTTGACACCTGTCAGAATAACAAAGCAGCATGGCTG
CAA
CGCAAAAATGAGCTGGCAGCGGCCGAACAGGAATATCTGCGGCTTCTGTCAGGAGAAGGCAGAAACGTCAGTCGCCTGG
ACG
AATTACGCAATATTATCGAAGTCAGAAAATGGCAGGTGAATCAGGCCGCCGGTCGTTATATTCGTTCGCATGAAGCCGT
TCAG
CACATCAGCATCCGCGACCGGCTGAATGATTTTATGCAGCAGCACGGCACAGCACTGGCGGCCGCACTGGCACCGGAGC
TGA
TGGGCTACAGTGAGCTGACGGCCATTGCCCGAAACTGTGCCATACAGCGTGCCACAGATGCCCTGCGTGAAGCCCTTCT
GTCC
TGGCTTGCGAAGGGTGAAAAAATTAATTATTCCGCACAGGATAGCGACATTTTAACGACCATCGGATTCAGGCCTGACG
TGGC
P
TTCGGTGGATGACAGCCGTGAAAAATTCACCCCTGCGCAGAACATGATTTTTTCGCGTAAAAGTGCGCAACTGGCATCA
CGTC .
, AGTCAGTGTAAAATTCCCCGAAAATCCGCCCGTTTTTACTGAAAAAAGCCATGCATCGATAAGGTGCATGGCTTTGCAT
GCGTT
, 1¨
.3 vi TTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGCGTGTCAGTGCAACTGCATTAAAACCGCCCC
GCAAA .
w GCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGTTAATTATTTGTGTAGTCAAAGTGCCTTCAG
TAC "
, , , ATACCTCGTTAATACATTGGAGCATAATGAAGAAAATCTATGGCCTATGGTCCAAAACTGTCTTTTTTGATGGCACTAT
, N, N, AAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTCAGTGTCGCAAGATC
19 Native P2 (acc nr:
GGCGAGGCGGGGAAAGCACTGCGCGCTGACGGTGGTGCTGATTGTATTTTTTCAGCGTCTCAGCGCGTCGTGACGGCAC
TTA
NC_001895) GTCTGCCCGTTGAGGCGTTGTGTGTCTGCGGGGTGTTTTGTGCGGTGGTGAGCGTGTGAGGGGGGATGACGGGGTGTAA
AA
AAGCCGCCCGCAGGCGGCGATGTTCAGTCGTTGTCAGTGTCCAGTGAGTAGTTTTTAAAGCGGATGACCTCCTGACCGA
GCCA
GCCGTTTATCTCGCGGATCCTGTCCTGTAACGGGATAAGCTCATTGCGGACAAAGACCTTTGCCACTTTCTCAATATCA
CCCAGC
1-d GACCCGACGTTCTCCGGCTTGCCACCCATCAACTGAAAGGGGATGCGGTGCGCGTCCAGCAGGTCAGCGGCGCTGGCTT
TTTT n GATATTAAAAAAATCGTCCTTCGTCGCCACTTCACTGAGGGGGATAATTTTAATGCCGTCGGCTTTCCCCTGTGGGGCA
TAGAG t=1 1-d AAACAGGTTTTTAAAGTTGTTGCGGCCTTTCGACTTGACCATGTTTTCGCGAAGCATTTCGATATCGTTGCGATCCTGC
ACGGCA w o w TCGGTGACATACATGATGTATCCGGCATGTGCGCCATTTTCGTAATACTTGCGGCGGAACAACGTGGCCGACTCATTCA
GCCAG =
'a GCAGAGTTAAGGGCGCTGAGATATTCCGGCAGGCCGTACAGCTCCTGATTAATATCCGGCTCCAGCAGGTGAAACACGG
AGC o 4,.
w w vi CGGGCGCGAAGGCTGTCGGCTCGTTGAAGGACGGCACCCACCAGTAAACATCCTCTTCCACGCCACGGCGGGTATATTT
TGCC
GGTGAGGTTTCCAGTCTGATGACCTTACCGGTGGTGCTGTAACGCTTTTCCAGAAACGCATTACCGAACACCAGAAAAT
CCAGC n.) o n.) ACAAAGCGGCTGAAATCCTGCTGGGAAAGCCATGGATGCGGGATAAATGTCGAGGCCAGAATATTGCGTTTGACGTAAA
TCG
i-J
GCGAGCTGTGATGCACGGCAGCCCGCAGGCTTTTTGCCAGACCGGTAAAGCTGACCGGTGGCTCATACCATCTGCCGTT
ACTG .6.
.6.
n.) ATGCACTCGACGTAATCCAGAATGTCACGGCGGTCGAGTACCGGCACCGGCTCACCAAAGGTGAATGCCTCCATTTTCG
GGCC oe GCTGGCGGTCATTGTTTTTGCCGCAGGTTGCGGTGTTTTCCCTTTTTTCTTGCTCATCAGTAAAACTCCAGAATGGTGG
ATGTCA
GCGGGGTGCTGATACCGGCGGTGAGTGGCTCATTTAACAGGGCGTGCATGGTCGCCCAGGCGAGGTCGGCGTGGCTGGC
TTC
CTCGCTGCGGCTGGCCTCATAGGTGGCGCTGCGTCCGCTGCTGGTCATGGTCTTGCGGATAGCCATAAACGAGCTGGTG
ATGT
CGGTGGCGCTGACGTCGTATTCCAGACAGCCACGGCGGATAACGTCTTTTGCCTTGAGCACCATTGCGGTTTTCATTTC
CGGCG
TGTAGCGGATATCACGCGCGGCGGGATAGAACGAGCGCACGAGCTGGAACACGCCGACACCGAGGCCGGTGGCATCAAT
AC
CGATGTATTCGACGTTGTATTTTTCGGTGAGTTTGCGGATGGATTCCGCCTGGGTGGCAAAGTCCATGCCTTTCCACTG
GTGAC
P
GCTCAAGTATTCTGAATTTGCCACCGGCCACCACCGGCGGTGCCAGTACCACGCATCCGGCGCTGTCGCCACGGTGTGA
CGGG
TCGTAACCAATCCATACCGGGCGGGAGCCGAACGGATTGGCGGCAAACGGCGCATAGTCTTCCCATTCTTCCAGCGTGT
CGAC
un CATGCAGCGTTGCAGCTCCTCGAACGGGAACACCGATGCCTTGTCGTCAACAAATTCACACATGAACAGGTTTTTAAAA
.3 GGCGCTGTTTTCGCGTTTGAGCTGCTCAATGTCGAACAGCGTGCAGCCGCCTTTCAGGGCGTCCTCAATGGTGACAATC
CCACTGGCCGTCCGCACAGAGAAGCCCACCGGCAAGGGCGTTATGACTGACGTCGATTTCCACGCGTTCGGCGGCGCTG
GCG
.31 .3 CGTCCCCGGTTAAACAGTTCACCCGACCAGAACGGGTAGGCGTCGTGCGCCAGCGTGGACGGGGTGGAGAAATAGGTCG
AG
CGCAGGTGACTCTGTGAGGCCATACCTGATGCCACCTTACGCAGTACCTGAAAATTCGGGATCCAGAAAATCTCATCGA
CGTA
CAGGTCGCCGTTATGACTCTGCGCGGTGTTGGAGTTGGTGCCGAGAAAAATCAGTTTTGCGCCGTTATTGCCCAGGACA
ATCG
GGTCACCGGTCAGGTCAACGTCAACCAGACGGGCAAAGGCGATGATGTATTCGCGGAACACATACGCCTGTGTTTTACT
GGCC
GACAGAAAAATCTGGTTATGACCGGTTTTCAGGGCACGCAGCAGCGCCTCGCGGGAAAAATAAAACGTCGCGCCAATCT
GGC
GGGATTTCAGGATATCGCGGATGCGGTGCTCAAGCCCGGCACGATACCAGTGCAGCTGATAGTCGAAAGACTGCTCAAA
GAA
IV
AATCTGCTCCAGCTTTTCGATGGCCTCGTCACTGAAAAAATTCTTTTTCGGTTTGCGCCGTCCGCCTTTGTTACGGTTA
GCGACG n TTCGGATTAAGGTCTGCCTCGTTGCCGGTCTGGCTGTAGCGGTTGACCCGTGCCAGTCGTTCAATCTGGCGTCCCAGCA
GGTCA t=1 tl ATTTCCTTGAAGTCACCGCCGGTTTTCTGTGGTTTGATGATGAGCTGGGTCAGCCGCGCTTCCAGACTCATTTCGACAC
o ATGGGGGCAACGCTGTCCCAGCCGTCGCGCTGTTTCCAGCTCTGCACTGTCGGGCGTTTCATCTGCAACATGGCGGCAA
TCTGC 'a o GGCACGGAAAACCCCTGCCAGTACAGCAGCGCCGCCTGACGACGCGGGTCGTGTAAAAGAGTGGTGTCTGTGGTGATGG
TCA tt n.) un TGAATACCTCGCCGTGATGAATACACGGCAAGGCTACTGAGTCGCGCCCCGCGATTCGCTAAGGTGCTGTTGTGTCAGT
GATA
AGCCATCCGGGACTGATGGCGGAGGATGCGCATCGTCGGGAAACTGATGCCGACATGTGACTCCTCTAATCACTATTCA
GGAC n.) o n.) TCCTGACAATGGCAAAAAAAGTCTCAAAATTCTTTCGTATCGGCGTTGAGGGTGACACCTGTGACGGGCGTGTCATCAG
TGCG
i-J
CAGGATATTCAGGAAATGGCCGAAACCTTTGACCCGCGTGTCTATGGTTGCCGCATTAACCTGGAACATCTGCGCGGCA
TCCT .6.
.6.
n.) GCCTGACGGTATTTTTAAGCGTTATGGCGATGTGGCCGAACTGAAGGCCGAAAAGATTGACGATGATTCGGCGCTGAAA
GGC oe AAATGGGCGCTGTTTGCGAAAATCACCCCGACCGATGACCTTATCGCGATGAACAAGGCCGCGCAGAAGGTCTACACCT
CAAT
GGAAATTCAGCCGAACTTTGCCAACACCGGCAAATGTTATCTGGTGGGTCTGGCCGTCACCGATGACCCGGCAAGCCTC
GGCA
CGGAATACCTGGAATTCTGCCGCACGGCAAAACACAACCCCCTGAACCGCTTCAAATTAAGCCCTGAAAACCTGATTTC
AGTGG
CAACGCCTGTTGAGCTGGAATTTGAAGACCTGCCTGAAACCGTGTTCACCGCCCTGACCGAAAAGGTGAAGTCCATTTT
TGGCC
GCAAACAGGCCAGCGATGATGCCCGTCTGAATGACGTGCATGAAGCGGTGACCGCTGTTGCTGAACATGTGCAGGAAAA
ACT
GAGCGCCACTGAGCAGCGCCTCGCTGAGATGGAAACCGCCTTTTCTGCACTTAAGCAGGAGGTGACTGACAGGGCGGAT
GAA
P
ACCAGCCAGGCATTCACCCGCCTGAAAAACAGTCTCGACCACACCGAAAGTCTGACCCAGCAGCGCCGCAGCAAAGCCA
CCGG
CGGTGGCGGTGACGCCCTGATGACGAACTGCTGACCGGCGTCAGTCAGTCCGGGAAAACCTTCACGATTAACCCTTAAT
TTCA
un GGAAAAACTATGCGCCAGGAAACCCGCTTTAAATTTAATGCCTACCTGTCCCGTGTTGCCGAACTGAACGGCATCGACG
.6.
.3 TGATGTGTCGAAAAAATTCACCGTTGAACCGTCGGTCACCCAGACCCTGATGAACACCATGCAGGAGTCCTCTGACTTT
CCGCATCAATATTGTGCCGGTCAGCGAAATGAAAGGGGAAAAAATTGGTATCGGTGTCACCGGCTCCATCGCCAGCACT
ACCG
.31 .3 ACACTGCCGGTGGTACCGAGCGTCAGCCGAAGGACTTCTCGAAGCTGGCGTCAAACAAGTACGAATGCGACCAGATTAA
CTTC
GATTTTTATATCCGCTACAAAACGCTGGACCTGTGGGCGCGTTATCAGGATTTCCAGCTCCGTATCCGTAACGCCATTA
TCAAAC
GCCAGTCCCTTGATTTCATCATGGCCGGTTTTAACGGCGTGAAGCGTGCCGAAACCTCTGACCGCAGCAGCAATCCGAT
GTTGC
AGGATGTGGCGGTCGGCTGGCTGCAGAAATACCGCAATGAAGCACCGGCGCGCGTGATGAGCAAGGTCACTGACGAGGA
AG
GCCGCACCACCTCTGAGGTTATCCGCGTGGGTAAGGGCGGTGATTATGCCAGCCTTGATGCACTGGTGATGGATGCGAC
CAAC
AACCTGATTGAACCGTGGTATCAGGAAGACCCTGACCTTGTGGTGATTGTGGGGCGTCAGCTACTGGCGGACAAGTATT
TCCC
IV
CATCGTCAACAAGGAGCAGGACAACAGCGAAATGCTGGCCGCTGACGTCATCATCAGCCAGAAACGCATCGGTAACCTA
CCA n GCGGTACGCGTCCCGTACTTCCCGGCGGATGCGATGCTCATCACGAAGCTGGAAAACCTGTCCATCTACTACATGGATG
ACAG t=1 tl CCATCGCCGCGTGATTGAGGAAAACCCGAAACTCGACCGCGTGGAGAACTACGAGTCAATGAACATTGATTACGTGGTG
o GACTACGCCGCCGGTTGTCTGGTGGAAAAAATCAAGGTCGGTGACTTCTCCACACCGGCTAAGGCGACCGCAGAGCCGG
GAG 'a o CGTAACCGATGACGAGTCCCGCACAGCGCCACATGATGCGGGTCTCGGCAGCGATGACCGCGCAGCGGGAAGCCGCCCC
GCT tt n.) un GCGACATGCAACTGTCTATGAGCAGATGCTGGTTAAGCTCGCCGCAGACCAGCGCACACTGAAAGCGATTTACTCAAAA
GAGC
TGAAGGCCGCAAAAAAACGCGAACTGCTGCCGTTCTGGTTGCCGTGGGTGAACGGCGTGCTGGAGCTGGGCAAAGGTGC
AC n.) o n.) AGGATGACATTCTGATGACGGTCATGCTGTGGCGTCTGGATACCGGCGATATTGCCGGTGCGCTGGAGATTGCCCGTTA
TGCC
i-J
CTGAAGTACGGTCTGACCATGCCGGGTAAACACCGCCGTACCCCGCCGTACATGTTCACCGAGGAGGTAGCGCTTGCGG
CCAT .6.
.6.
n.) GCGCGCTCACGCTGCCGGTGAGTCTGTGGATACCCGCCTGCTGACGGAGACCCTTGAACTGACCGCCACGGCTGACATG
CCTG oe ATGAAGTGCGCGCAAAGCTGCACAAAATCACCGGTCTGTTTCTGCGTGACGGTGGTGATGCCGCCGGTGCGCTGGCGCA
CCT
GCAACGTGCGACACAGCTCGACTGTCAGGCAGGCGTCAAAAAAGAGATTGAACGACTGGAGCGGGAGCTGAAACCGAAG
CC
GGAGCCGCAGCCCAAAGCGGCCACCCGCGCCCCGCGTAAGACCCGGAGCGTGACACCGGCAAAACGTGGACGCCCGAAA
AA
GAAAGCCAGTTAACAACCGAATGCGCCCCGCGCCAGGGCGGCACGCCGGTCAGTGACGGTGAATCACCTGACACTGCAC
CGG
CGTCCACCGCCCGACTTTTCAGAGGTAGTCATGATGACGCTGATTATTCCGCGAAAGGAGGCTCCCGTGTCCGGTGAGG
GTAC
GGTGGTCATCCCGCAACCGGCAGGCGACGAGCCGGTGATTAAAAACACGTTCTTTTTTCCCGATATCGACCCGAAGCGC
GTCC
P
GGGAACGTATGCGCCTTGAGCAGACCGTCGCCCCCGCCCGTCTGCGTGAGGCCATCAAGTCAGGCATGGCTGAAACGAA
TGC
GGAGCTGTACGAGTACCGCGAACAGAAAATTGCCGCCGGTTTTACGCGTCTGGCTGACGTCCCGGCGGACGATATCGAC
GGT
un GAAAGCATCAAGGTTTTTTACTACGAGCGCGCCGTGTGTGCGATGGCGACCGCGTCGCTTTATGAGCGTTATCGCGGTG
un .3 TGCCAGTGCGAAAGGCGACAAGAAGGCTGACAGCATTGACAGCACCATTGATGAGCTGTGGCGGGATATGCGCTGGGCG
GGCGCGCATCCAGGGCAAGCCGCGCTGCATCGTGAGTCAAATCTGATGAAGACCTTTGCGCTACAGGGCGACACGCTCG
ACG
.31 .3 CCATTTGTGTCCGCTATTACGGGCGCACTGAGGGCGTGGTTGAGACCGTGCTCGCCGCAAATCCGGGACTGGCTGAACT
GGG
GGCGGTGCTGCCACACGGCACCGCCGTCGAACTGCCCGACGTTCAGACCGCGCCCGTGGCTGAAACTGTCAATCTGTGG
GAG
TAACGCATGACAGCAGAAGAAAAAAGCGTCCTGTCGCTTTTCATGATTGGGGTGCTGATTGTTGTCGGCAAGGTGCTTG
CCGG
TGGTGAACCTATCACCCCGCGTCTGTTTATCGGGCGCATGTTGCTCGGTGGTTTTGTCTCGATGGTTGCCGGTGTTGTT
CTGGT
GCAGTTTCCTGACCTGTCACTGCCAGCGGTGTGCGGCATCGGCTCCATGCTGGGTATCGCCGGTTATCAGGTGATTGAG
ATTG
CCATTCAGCGCCGCTTTAAGGGCAGGGGGAAACAGTAATGCCGGTAATTAACACGCATCAGAATATCGCCGCCTTTCTC
GACA
IV
TGCTGGCCGTGTCCGAAGGGACGGCGAATCATCCACTGACGAAAAACCGGGGCTATGACGTGATAGTCACCGGACTGGA
CGG n GAAGCCGGAAATTTTCACCGACTACAGTGACCACCCGTTCGCACATGGCCGACCGGCGAAGGTGTTTAACCGTCGCGGT
GAAA t=1 tl AATCCACGGCCTCCGGTCGCTATCAGCAGCTTTACCTGTTCTGGCCGCATTACCGCAAACAGCTTGCCCTGCCGGATTT
o GTTGTCACAGGACAGACTCGCCATTCAGTTGATCCGCGAACGCGGAGCACTGGATGACATCCGGGCGGGACGCATTGAG
CGC 'a o GCCATTTCACGCTGTCGCAATATCTGGGCGTCCCTGCCGGGTGCCGGTTACGGTCAGCGTGAGCATTCACTGGAAAAAC
TGGT tt n.) un CACCGTCTGGCGTACCGCTGGCGGCGTACCGGCTTAAACGGAGTAAATACCATGAAGAAATTATCCCTTTCACTGATGC
TGAA
CGTGTCGCTGGCGCTGATGCTGGCACTGTCCCTGATTTACCCGCAGAGCGTGGCCGTCAATTTTGTCGCTGCCTGGGCG
ATTCT n.) o n.) GGCGACGGTTATCTGTGTGGTTGCCGGTGGTGTGGGCGTGTATGCCACTGAGTATGTGCTGGAACGCTACGGGCGGGAG
CTG
i-J
CCGCCGGAATCGCTGGCCGTGAAGATTGTCACGTCGCTGTTTTTGCAGCCGGTGCCGTGGCGCAGACGGGCGGCGGCTC
TGG .6.
.6.
n.) TAGTGGTGGTGGCGACGTTTATCTCGCTGGTCGCTGCCGGGTGGATTTTTACCGCGCTGATTTATCTTGTGGTGTCGCT
GTTTTT oe CCGGCTGATACGTAAAGCCTGTCGTCAGCGTCTTGAGGGGCGGGAACCATGTCAAGGCTGATGATTGTGCTGGTCGTGT
TGTT
ATCGCTGGCGGTGGCCGGTCTGTTTCTGGTGAAACACAAAAATGCCAGCCTGCGCGCCTCGCTGGACAGGGCGAACAAC
GTC
GCCAGCGGTCAGCAGACGACCATCACCATGCTGAAAAATCAGCTTCATGTTGCGCTCACCAGGGCAGATAAAAACGAGC
TGGC
GCAGGTGGCACTGCGTCAGGAACTGGAGAACGCCGCGAAACGTGAAGCACAGCGCGAGAAAACCATCACGAGGTTACTT
AAT
GAGAACGAAGATTTTCGCCGCTGGTACGGTGCTGACCTGCCTGATGCTGTGCGCCGGTTGCACCAGCGCCCCGCCTGCA
CCGA
CGCCAGTGATTGTCCCCAACGCATGCCCGAAAGTGAGCCTTTGCCCGATGCCGGGCAGTGACCCGCAGACGAACGGCGA
TTTA
P
AGTGCCGATATCCGGCAGCTTGAGAACGCGCTGGCACGCTGTGCCAGCCAGGTAAAAATGATTAAACACTGTCAGGACG
AAA
ACGATGCTCAAACCCGACAGCCTGCGCAGGGCGCTGACTGATGCCGTCACGGTGCTGAAAACTAACCCCGATATGCTGC
GGAT
un ATTCGTGGATAACGGGAGTATTGCCTCCACACTGGCGGCGTCGCTGTCATTCGAAAAGCGTTACACGCTCAATGTGATT
o .3 CCGACTTTACCGGTGATTTTGACCTGCTCATTGTGCCGGTGCTGGCGTGGCTGCGGGAAAATCAGCCCGACATCATGAC
GACGAAGGCCAGAAAAAGGGCTTCACGTTTTATGCAGACATCAACAATGACAGCAGCTTTGATATCAGTATCAGCCTGA
TGCT
.31 .3 GACCGAGCGCACGCTGGTCAGTGAGGTGGACGGCGCACTGCATGTGAAGAATATCTCGGAACCCCCGCCGCCGGAGCCG
GTC
ACCCGCCCGATGGAGCTGTATATCAATGGCGAACTGGTGAGTAAGTGGGATGAATGAGTTTAAGCGTTTTGAAGACCGG
CTG
ACCGGACTGATTGAATCGCTGTCACCGTCAGGGCGTCGGCGACTGAGTGCCGAACTGGCGAAACGTCTGCGGCAGAGTC
AGC
AGCGTCGGGTGATGGCACAGAAAGCCCCGGACGGCACACCCTACGCGCCACGCCAGCAGCAGAGCGTCAGAAAAAAGAC
CG
GTCGCGTTAAGCGAAAAATGTTTGCGAAACTTATTACCAGTCGTTTTTTGCATATCCGTGCCAGCCCGGAGCAGGCATC
AATGG
AATTTTACGGCGGGAAGTCGCCGAAAATCGCCAGTGTGCATCAGTTTGGTCTGTCGGAAGAAAACCGGAAAGACGGTAA
GAA
IV
AATTGATTATCCGGCGCGTCCCCTGCTCGGCTTTACCGGTGAGGATGTGCAGATGATTGAAGAGATTATCCTGGCTCAC
CTTGA n GCGTTAGTTTTATCCAGGCAGAGGCTGATGCGCAATTAAACATTGAGCGGCCATGCTGGTCGCTCAATGTTTAGAGGTT
TATG t=1 tl AGTGATTTTTATTTGATGCTTTGTATTCTAAAACCTTCTTATTGGCGTAAAAGAATTTTGTATATGACAGGAATATAAC
o TGAAGTGAAATAGACGAGGGATAGTATTAATAATGCTTTTTTGTGACTGTTATTATCTTTAATCTCCTGGCTTAACCAT
TCGGAG 'a o TCCTCCTCGTTTAGCTGTAAGAGCTTATTGCAGGCGATCTCAGGAAGTGTGTCTTTTATAAATACGTTTTGCAGTCTCT
TGCAAT tt n.) un CGGCAAGGCTATAAGTTTTATTAAATTCAACTGCTTTATTTTTGAAGGATAAAAGAACTTTGTCACTATAAACATAGTA
CATCAT
GTTTTTATATGGTATGCCTGTGGCATCCCTTACTATAACGGATTGTTCGTTGTGTATGTAACATGCGAGGAGAATGTAA
AAAAT n.) o n.) ACTGGCCAGAATTACAATTATTGTTTTAATTATGTGTGGTGGTTTTGTTATGTCACCCCAGATACGAGTAAGGAAAAAA
TACGA
i-J
TGTTTTTAGTTTTCCATCAATCAGTCCCTGCTGTATCATTCTCACATTTTCAATGCCTGATACATTGATTCCGTTAATT
ATTTTAAA .6.
.6.
n.) TAGTTGAATGTCGCGCCACTCGCGGTCAAGTCTTTTTAATTTTTTGTCTGAATATCCAAAATTGAAATAATGTGCAATA
AGCCTC oe ATAAGGTTACTTTTACCAAAGCTAAAAAATGCTAATACTGCAAAGCTACAAAGGAAAAAAACGATTAGCCCCCACACAT
TAGTC
ACATTATAGCTGACCATTACGCTCTCCTTGAATGTTGTCTGGTAGTTCTACAAATGAATCCAGATAGCATAACTTTTAT
ATATTGT
GCAATCTCACATGCATGAACACTCTCGCAAATATTCAGGAACTCGCGCGCGCACTGCGCAACATGATTCGCACTGGCAT
TATCG
TCGAAACCGACCTTAACGCCGGTCGCTGCCGCGTGCAGACCGGCGGCATGTGCACCGACTGGCTTCAGTGGCTGACCCA
TCGC
GCAGGACGTTCGCGCACATGGTGGGCACCTTCCGTGGGGGAACAGGTGCTGATTCTGGCCGTGGGTGGTGAACTCGACA
CGG
CGTTCGTTCTGCCGGGGATTTATTCCGGCGATAACCCCTCGCCGTCTGTGTCGGCGGATGCCCTGCATATCCGTTTCCC
TGACG
P
GGGCGGTGATTGAATATGAACCCGAAACCAGTGCACTCACGGTAAGCGGAATTAAAACGGCCAGCGTGACGGCTTCCGG
TTC
TGTTACTGCCACGGTGCCGGTGGTCATGGTGAAAGCATCAACCCGCGTCACCCTGGACACCCCGGAGGTGGTCTGCACC
AACA
un GGCTGATTACCGGCACGCTGGAAGTGCAGAAAGGCGGGACGATGCGCGGCAACATTGAACACACCGGCGGTGAACTCTC
--.1 .3 AAACGGTAAGGTACTGCATACCCATAAACACCCCGGCGACAGCGGCGGCACAACCGGGAGTCCTTTATGACAGCGCGTT
CGGAATGAATCGCAGTGATGGCCTGACTGTCACTGACCTTGAGCATATCAGCCAGAGTATCGGCGATATCCTGCGCACA
CCGG
.31 .3 TCGGCTCACGGGTGATGCGTCGTGATTACGGCTCGTTGCTGGCGTCAATGATTGACCAGCCGCAGACCCCGGCGCTTGA
GTTG
CAGATTAAAGTCGCCTGTTACATGGCAGTGCTGAAATGGGAACCCCGCGTCACCCTGTCATCCGTCACCACGGCGCGCA
GTTTT
GACGGGCGAATGACGGTCACGTTAACCGGCCAGCACAACGACACCGGCCAGCCACTTTCATTAACCATCCCTGTGAGTT
GAAA
CCATGCCGATTATCGACCTGAACCAGCTACCCGCACCGGATGTGGTCGAGGAGCTGGACTTTGAAAGCATTCTCGCTGA
ACGC
AAGGCGACACTGATTTCCCTTTACCCGGAAGATCAGCAGGAGGCGGTCGCCCGTACCCTGACACTGGAATCTGAGCCTC
TCGT
CAAACTGCTGGAAGAAAATGCTTATCGTGAGCTTATCTGGCGTCAGCGTGTGAATGAGGCCGCACGGGCGGTGATGCTG
GCC
IV
TGTGCCGCCGGTAATGACCTTGATGTGATTGGTGCCAATTACAACACCACGCGCCTGACTATCACCCCGGCAGATGATT
CGACC n ATCCCGCCGACACCGGCAGTGATGGAATCTGACACCGATTATCGTCTGCGTATTCAGCAGGCTTTTGAGGGCTTAAGCG
TCGC t=1 tl CGGGTCAGTGGGAGCCTATCAGTATCATGGTCGCAGTGCTGACGGGCGTGTCGCGGATATTTCTGTCACCAGTCCGTCT
o CCTGTGTCACCATCTCTGTGCTGTCACGTGAAAATAACGGCGTCGCATCCGAAGACCTGCTGGCTGTGGTGCGTAACGC
CCTTA 'a o ATGGCGAGGACGTCAGGCCGGTGGCCGACCGCGTGACCGTGCAGTCTGCCGCCATCGTTGAATACCAGATAAACGCCAC
GCT tt n.) un TTACCTTTACCCTGGTCCCGAAAGCGAACCCATCCGCGCTGCCGCTGTGAAAAAGCTGGAAGCGTATATCACGGCACAG
CACC
GGCTGGGGCGCGACATCCGTCTGTCTGCCATTTATGCCGCTTTGCATGTGGAAGGTGTGCAGCGTGTCGAACTGGCTGC
ACCA n.) o n.) CTGGCCGACATCGTGCTCAACAGTACGCAGGCGTCTTTCTGTACCGAATACCGCGTCGTGACCGGAGGCTCGGATGAGT
GATT
i-J
CGCGACTGCTGCCGACCGGCTCATCACCGCTTGAGGTCGCCGCCGCAAAAGCCTGTGCGGAAATTGAAAAAACGCCGGT
CAG .6.
.6.
n.) TATTCGTGAACTGTGGAACCCGGACACCTGTCCGGCAAATCTGCTGCCGTGGCTGGCGTGGGCGTTTTCGGTCGACAGG
TGGG oe ATGAAAAGTGGCCGGAAGCGACAAAACGCGCCGTTATCCGCGATGCCTATTTCATCCACTGTCATAAGGGCACGATAGG
TGCA
ATCCGGCGTGTGGTGGAGCCGCTCGGCTATCTCATCAACGTGACGGAGTGGTGGGAAAACAGTGACCCGCCCGGCACCT
TCC
GGCTTGATATTGGTGTACTGGAAAGCGGTATCACAGAGGCAATGTATCAGGAAATGGAACGGCTGATTGCTGATGCCAA
ACC
TGCAAGCCGTCACCTTATTGGCCTGAACATTACCCGGGACATTCCCGGCTATCTGTTCGCCGGTGGTGTGGCTTACGAC
GGCGA
TGTAATTACGGTTTACCCCGGATAAGTGAGGAATAATGAGCATAAAATTCAGAACCGTTATCACCACTGCCGGTGCAGC
AAAG
CTGGCAGCGGCAACCGCGCCGGGAAGGCGGAAGGTCGGCATTACCACGATGGCCGTCGGGGATGGCGGTGGTAAATTGC
CT
P
GTCCCGGATGCCGGACAGACCGGGCTTATCCATGAAGTCTGGCGACATGCGCTGAACAAAATCAGCCAGGACAAACGAA
ACA
GTAATTATATTATCGCCGAGCTGGTTATTCCGCCGGAGGTGGGCGGTTTCTGGATGCGTGAGCTTGGCCTGTACGATGA
TGCG
un GGAACGTTAATTGCCGTGGCGAACATGGCCGAAAGCTATAAGCCAGCCCTTGCCGAAGGCTCAGGACGTTGGCAGACCT
oe GCATGGTCATCATCGTCAGCAGTGTGGCCTCAGTGGAGCTGACCATTGACACCACAACGGTGATGGCGACGCAGGATTA
GATGACAAAATTGCAGAGCACGAACAGTCACGACGTCACCCGGACGCCTCGCTGACAGCAAAAGGTTTTACTCAGTTAA
GCAG
.31 .3 TGCGACCAACAGCACGTCTGAAACACTGGCCGCAACGCCGAAAGCGGTAAAGGCCGCGTATGACCTGGCTAACGGGAAA
TAT
ACCGCACAGGACGCCACCACAGCGCGAAAAGGCCTTGTCCAGCTTAGTAGCGCCACCAACAGCACGTCTGAAACGCTCG
CCGC
AACACCAAAAGCCGTTAAGACGGTAATGGATGAAACGAACAAAAAAGCGCCATTAAACAGCCCTGCACTGACCGGAACG
CCA
ACGACGCCAACTGCGCGACAGGGAACGAATAATACTCAGATCGCAAACACGGCTTTCGTTATGGCCGCGATTGCCGCCC
TTGT
AGACTCGTCGCCTGACGCACTGAATACGCTGAACGAGCTGGCGGCGGCGCTGGGCAATGACCCGAATTTTGCTACCACC
ATGA
CTAATGCGCTTGCGGGTAAGCAACCGAAAGATGCTACCCTGACGGCGCTGGCGGGGCTTGCTACTGCGGCAGACAGGTT
TCC
IV
GTATTTTACGGGGAATGATGTTGCCAGCCTGGCGACCCTGACAAAAGTCGGGCGGGATATTCTGGCTAAATCGACCGTT
GCCG n CCGTTATCGAATATCTCGGTTTACAGGAAACGGTAAACCGAGCCGGGAACGCCGTGCAAAAAAATGGCGATACCTTGTC
CGGT t=1 tl GGACTTACTTTTGAAAACGACTCAATCCTTGCCTGGATTCGAAATACTGACTGGGCGAAGATTGGATTTAAAAATGATG
o GGTGACACTGATTCATACATGTGGTTTGAAACGGGGGATAACGGCAATGAATATTTCAAATGGAGAAGCCGCCAGAGTA
CCA 'a o CAACAAAAGACCTGATGACGTTGAAATGGGATGCACTAAATATTCTTGTTAATGCCGTCATTAATGGCTGTTTTGGAGT
TGGTA tt n.) un CGACGAATGCACTAGGTGGTAGCTCTATTGTTCTTGGTGATAATGATACCGGATTTAAACAGAATGGAGACGGTATTCT
TGAT
GTTTATGCTAACAGTCAGCGTGTATTCCGTTTTCAGAATGGAGTGGCTATTGCTTTTAAAAATATTCAGGCAGGTGATA
GTAAA n.) o n.) AAGTTCTCGCTATCCAGCTCTAATACATCCACGAAGAATATTACCTTTAATTTATGGGGTGCTTCCACCCGTCCAGTGG
TTGCAG
i-J
AGTTAGGCGATGAGGCCGGATGGCATTTCTATAGCCAGCGAAATACAGATAACTCGGTAATATTTGCTGTTAACGGTCA
GATG .6.
.6.
n.) CAACCCAGCAACTGGGGAAATTTTGATTCCCGCTATGTGAAAGATGTTCGCCTGGGTACGCGAGTTGTTCAATTGATGG
CGCG oe AGGTGGTCGTTATGAAAAAGCCGGACACACGATTACCGGATTAAGAATCATTGGTGAAGTAGATGGCGATGATGAAGCC
ATC
TTCAGGCCGATACAAAAATACATCAATGGCACATGGTATAACGTTGCGCAGGTGTAAGTTATGCAGCATTTAAAGAACA
TTAA
GTCAGGTAATCCAAAAACAAAAGAGCAATATCAGCTAACAAAGAATTTTGATGTTATCTGGTTATGGTCCGAAGACGGA
AAAA
ACTGGTATGAGGAAGTGAAGAACTTTCAGCCAGACACAATAAAGATTGTTTACGATGAAAATAATATTATTGTCGCTAT
CACCA
GAGATGCTTCAACGCTTAATCCTGAAGGTTTTAGCGTTGTTGAGGTTCCTGATATTACCTCCAACCGACGTGCTGACGA
CTCAG
GTAAATGGATGTTTAAGGATGGTGCTGTGGTTAAACGGATTTATACGGCAGATGAACAGCAACAACAGGCAGAATCACA
AAA
P
GGCCGCGTTACTTTCCGAAGCGGAAAACGTTATTCAGCCACTGGAACGCGCTGTCAGGCTGAATATGGCGACGGATGAG
GAA
CGTGCACGACTGGAGTCATGGGAACGTTACAGCGTTCTGGTCAGCCGTGTGGATCCTGCAAATCCTGAATGGCCGGAAA
TGCC
un GCAATAAGTTGTATGACCTCTGTTGTGAACTTACATATCTATGGCACAGAGTAAAGCCTAATCTGAAGTCCACTCTGTG
o .3 AGCGGACCTTATAAACAAGAACAATGGTCATATCAGTGTGTTTTGATTGCATAGCTAACGTGCGTCTTCCTGTACAGAA
AGATGATAGGGCATAGGAGATGATTATTATCGCGTGTTTTAAAAATAGCTTTCTGCATCAAGTGTCACTTGCGAAGAGG
TATTG
.31 .3 GCGCTATGATTGGCATCACTCAGTTCAGATAATATTTTAAATATTTGGTAAATGTTCAGATTACACAATTCGGTCTGCG
TCCCGT
TAAAATTATCTACTATTAGTTATTACTATGAGGTGAATGGCAAGTGTTTTCCACTCGCCATTTTTGTTTTTTATTTTTT
TAAAGCCT
TTCCGACGTTTAAGGATTTTGCCAAGCCATAAAATATTTGATATTTCATTCCTGTTTTTATTTTTGGTGAGATATTTGC
GTAACTT
CTTTCTCTAAAACACCAACGTATAAACCTATTATTATCTTCGGTTGTTTCTATATAGCATATTACATTGAGACCAAAAA
GAAACTG
AAGGAAGTCATTTGCAGTTGTCATGAATTTTGGTTTTGTTGTGGAAATGGAACTAATATGAGTTTCAAGTTGTTTATAT
GCTAA
GAGGTATTCAGCGTAATCAAAAGTATCTTTTCCAGAGAGGAATTCAAAGAACTTTAAAAAAATCTCATAATGTTCACTT
CCATA
IV
ATAAAATGATAAATGATCTTTTATTTCTCCAAGTAAATAGTTAGAGTAATCTCTTTGCATGCTAGGACTTTCAAAGTCA
TCTAGA n ,-i CTAAATTGATTTTTCCCATCATCACCGCTGGCGTGTGATTTGATAATTTCGAGCATCCGTAATATATCTCTTGGGCGAT
AATATG t=1 tl ACCAGCGAAGGAAATTAATAAATGATGTGGGGTGGTTATAATTATCATGGACGTTGGGTGAATCCCAAGGGAAATAATG
o CCATGCCTGTCCCTTTTTAAGGGCCATGTCTTGCTGAGTCCTAAGCAGATGATCTAATACCTCAAATAATTGAGAGCTA
CGGTG 'a o GTTAACATATTCTGTCCGCCAGTCCAAGAATACTGAATTATCTCTGATTTTTGCGTTTTGATTTTGTAATCCTATGGAT
TCAAATA tt n.) un TATCTGGCCTGATCAAGAGAACGGCCTTCATTCTCCCTTTTCCTCCCTTTATACTTGGGAAGAAATCGTTGTTAATCTC
CCAGACT
GCGTGAGCTAATCCTTTTATACATTCTAGATAATCATCGTATGGAATTGAGGAAGGGCGGATATCAATACCATCGATAA
ATAAA n.) o n.) ATATGATTTTGAGATAAACGTATTTGGCTAAAGGCCTCTTCAAATTTTTTTTGTATATAAAATAAATTTATCTGAAATC
TGCTCTC
i-J
AGAAAAAGATAAAGACTCTCTTTCTTCACCTTTTAAGGTTGCATGCTTATGAAGTAGTTCGGCTGCAACTTTTGACTCT
TGAACA .6.
.6.
n.) AAACTGAGGGCTTGAATTATTTCTGGTGAAAATGCCTTAAGATAATACTCATCTATTGCATCATTAAGTGATGAGAATT
TTGAAT oe AATTTAGTAACTTTGAAATTTTCCCTTCTTTATCTAATACTTGTTTTGATATTAATAAATATAGAATAACTTTCCATAT
GCCAGAGA
AGTCAGACAAATTTAAATGCTTTTCAGATTTAAGAGTGATAAATTTTTGATATTCTGTCTCTCTTATATATTTAGTTGT
AGCTAGC
GTATTGTTAATATTGTTATTTGAGAGATAGATAGAGTATGCGGTTTTACCAGTACCTTTCTCTCCTACAAGAAACGATA
TATTTG
GTTCACATAATCTAGATAGGTGATTATCACGTATGAACACTTTGTTAAGTAATTCTTTATTCTCCCTTCTCTTATAATT
TTCAGCAT
CAGCATAGCCAAGAGTTAGATCTTTGATTGGTATCATTATTACCTCAACTAAAGCAATTGAAAAACATATGGTTATAAA
AACAT
AGCGCTGCTCTGTCGCATATTGTGGATATCAACATATGAAATGTAAAGGAACTATTTGTGGATGAATGAACCGAATCGC
TGTA
P
GCTTCGGTAGTCATCTTTCAGACTTGTATAAATGAACAACTTCCGCTTCTCGCTCAAAGGAAACTGTCAGATTTGATAG
CTTTTG
GGCTATGTAAACTGTCAGTCGGAAAATGAGTGAGTACAAATCAGGGCAGGTGAGCGAATTGCCCGCCTTTTCTTTACCG
GTGG
o TTGTGCTGTCGATTAGCCAACCGGGACAAATAGCCTGACATCTCCGGCGCAACTGAAAATACCACTCACCCATTAACCA
o .3 TTAAACGGATGAGTGACTATCATCACGGCGTGCAGGTGCTGGAGATTAACGAGGGCACCCGCGTCATTTCCACCGTATC
GCCATTGTCGGCATGGTCTGCACGGCCAGCGATGCAGATGCGGAAACCTTCCCCCTCAATAAACCTGTGCTGATTACCA
ATGTG
.31 .3 CAGAGCGCAATTTCAAAGGCCGGTAAAAAAGGCACGCTGGCGGCATCGTTGCAGGCCATCGCTGACCAGTCAAAACCGG
TCA
CCGTTGTCATGCGCGTGGAAGACGGCACCGGTGATGACGAGGAAACGAAACTCGCGCAGACCGTTTCCAATATCATCGG
CAC
CACCGATGAAAACGGTCAGTACACCGGACTAAAAGCCATGCTGGCGGCGGAGTCGGTAACCGGTGTTAAACCGCGTATT
CTC
GGCGTGCCGGGACTGGATACCAAAGAGGTGGCTGTTGCACTGGCATCAGTCTGTCAGAAGCTGCGTGCTTTCGGGTATA
TCA
GCGCATGGGGCTGTAAAACCATTTCCGAGGTGAAAGCCTATCGTCAGAATTTCAGCCAGCGTGAGCTGATGGTCATCTG
GCCG
GATTTCCTCGCATGGGATACGGTCACCAGTACCACCGCCACCGCGTATGCCACCGCCCGTGCGCTGGGGCTGCGCGCTA
AAAT
IV
CGACCAGGAGCAGGGCTGGCATAAAACGCTGTCCAATGTCGGGGTGAACGGTGTTACCGGCATCAGCGCATCTGTATTC
TGG n GATTTGCAGGAGTCCGGCACCGATGCTGACCTGCTTAACGAGTCAGGCGTCACTACGCTGATTCGCCGCGACGGTTTCC
GCTTC t=1 tl TGGGGTAACCGTACCTGCTCTGATGACCCGCTGTTCCTCTTTGAAAACTACACCCGCACCGCGCAGGTCGTGGCCGACA
o GCTGAGGCGCACATGTGGGCGGTGGACAAGCCCATCACTGCAACGCTGATTCGCGACATCGTTGACGGCATCAATGCCA
AATT 'a o CCGTGAGCTGAAAACAAACGGCTATATCGTGGATGCGACCTGCTGGTTCAGCGAAGAATCCAACGATGCGGAAACCCTC
AAG tt n.) un GCCGGAAAACTGTATATCGACTACGACTATACACCGGTGCCTCCTCTCGAAAACCTGACCCTGCGCCAGCGTATTACCG
ATAAA
TACCTGGCAAATCTGGTCACCTCGGTTAACAGCAATTAAGGAGCCTGACCGATGGCAATGCCGCGCAAACTCAAGTTAA
TGAA n.) o n.) CGTCTTTCTGAACGGCTACAGCTATCAGGGCGTTGCAAAGTCCGTCACGCTGCCAAAACTGACCCGTAAGCTCGAAAAC
TATCG
i-J
CGGTGCGGGGATGAACGGCAGCGCACCGGTAGACCTCGGCCTTGATGACGATGCGCTGTCAATGGAGTGGTCGCTCGGT
GGC .6.
.6.
n.) TTCCCGGATTCGGTTATCTGGGAGCTTTACGCCGCAACCGGTGTGGATGCCGTGCCGATTCGTTTTGCAGGCTCTTACC
AGCGC oe GACGATACCGGCGAAACGGTGGCCGTCGAAGTGGTCATGCGTGGACGTCAGAAAGAAATCGACACCGGCGAGGGTAAAC
AG
GGAGAAGACACTGAGTCGAAAATCTCCGTGGTCTGCACCTATTTCCGGCTGACGATGGACGGTAAGGAGCTGGTCGAAA
TTG
ACACCATCAACATGATTGAGAAGGTGAACGGCGTCGATCGGCTGGAGCAACACCGCCGCAATATCGGCCTGTGATTTTC
ATCC
GGTCAGCCTGGCTGGCCGGTTAACCCTGATTCAGAAGTGAGAAAACCATGAACAAAGAAAATGTCATTACCCTGGACAA
TCCG
GTCAAACGTGGTGAGCAGGTTATCGAACAGGTCACGCTGATGAAACCCAGTGCCGGGACGCTACGCGGTGTCAGTCTGG
CTG
CGGTTGCAAACTCCGAAGTCGATGCACTGATTAAGGTGCTGCCGCGCATGACGGCACCGATGCTGACCGAGCAGGAAGT
CGC
P
CGCGCTGGAACTGCCTGACCTTGTGGCGCTGGCCGGTAAGGTGGTCGGTTTTTTGTCGCCGAACTCGGTGCAGTGACGT
TTCC
GAAAAATCTCTCGGTCGATGACCTGATGGCGGATGTGGCAGTGATATTTCACTGGCCGCCATCAGAACTGTATCCCATG
AGCC
o TGACCGAACTCATCACATGGCGCGAAAAGGCGCTCCGGCGAAGCGGAAACACGAATGAGTAACAATGTAAAATTACAGG
1-, .3 TGCTCAGGGCTGTTGACCAGGCATCCCGCCCGTTTAAATCCATCCGCACAGCGAGCAAGTCGCTGTCGGGGGATATCCG
ACACAAAAATCACTGCGCGAGCTGAACGGTCACGCATCCCGTATTGAGGGATTCCGCAAGACCAGTGCACAGCTCGCCG
TGAC
.31 .3 TGGTCATGCACTTGAAAAGGCACGGCAGGAGGCCGAAGCCCTTGCCACACAGTTTAAAAACACCGAACGTCCGACCCGT
GCTC
AGGCGAAAGTCCTGGAATCCGCAAAGCGTGCGGCGGAGGACTTACAGGCGAAATATAACCGCCTGACAGATTCCGTTAA
ACG
CCAGCAGCGGGAACTGGCCGCTGTGGGAATTAATACCCGCAATCTTGCACATGATGAGCAGGGACTGAAAAACCGTATC
AGT
GAAACCACCGCACAGCTTAACCGTCAGCGTGATGCGCTGGTGCGTGTCAGTGCGCAACAGGCAAAACTTAACGCAGTAA
AAC
AGCGTTATCAGGCCGGAAAGGAACTGGCCGGAAATATGGCCTCAGTGGGCGCTGCCGGTGTGGGGATTGCGGCGGCGGG
AA
CGATGGCCGGTGTTAAGCTACTGATGCCCGGTTATGAGTTTGCGCAGAAAAACTCAGAATTACAGGCTGTGATCGGAGT
GGCA
IV
AAAGACTCCGCCGAAATGGCCGCACTCCGCAAGCAGGCGCGCCAGCTCGGCGACAATACCGCCGCCTCGGCAGATGATG
CAG n CCGGTGCGCAGATTATTATTGCGAAAGCCGGTGGGGATGTTGATGCCATTCAGGCGGCAACGCCGGTCACGCTGAACAT
GGC t=1 tl GCTGGCGAACCGTCGCACAATGGAAGAAAACGCCGCCCTGCTGATGGGGATGAAATCCGCCTTTCAGCTTTCAAACGAT
o TCGCTCATATCGGGGATGTTCTCTCCATGACGATGAACAAAACCGCCGCCGATTTTGACGGCATGAGCGATGCGCTGAC
CTAT 'a o GCCGCACCTGTGGCAAAAAATGCCGGTGTCAGCATTGAAGAAACCGCCGCAATGGTCGGGGCGCTGCATGATGCAAAAA
TCA tt n.) un CAGGCTCAATGGCGGGGACGGGAAGCCGTGCCGTGTTAAGCCGCCTGCAGGCACCGACGGGAAAAGCATGGGATGCACT
CA
AAGAGCTTGGAGTGAAAACCTCAGACAGCAAAGGAAACACCCGGCCAATATTTACCATTCTGAAAGAAATGCAGGCCAG
TTTT n.) o n.) GAGAAAAACCGGCTCGGTACTGCCCAGCAGGCTGAATACATGAAAACTATTTTCGGGGAGGAGGCCAGCTCAGCCGCTG
CCG
i-J
TGCTGATGACTGCCGCCTCAACCGGAAAGCTGGACAAACTGACCGCTGCGTTTAAAGCCTCAGACGGGAAGACCGCCGA
GCT .6.
.6.
n.) GGTAAATATCATGCAGGACAACCTAGGCGGTGACTTTAAAGCGTTTCAGTCCGCTTATGAGGCGGTGGGGACTGACCTG
TTTG oe ACCAGCAGGAAGGCGCGCTGCGTAAGCTCACGCAGACGGCCACAAAGTATGTGTTAAAACTCGACGGCTGGATACAGAA
AAA
CAAATCACTGGCGTCAACCATCGGCATCATTGCCGGCGGTGCACTGGCGCTTACTGGCATCATCGGTGCCATTGGCCTC
GTAGC
CTGGCCGGTTATCACCGGCATCAATGCCATCATCGCGGCAGCAGGCGCAATGGGGGCAGTCTTCACGACGGTTGGCAGT
GCT
GTTATGACCGCCATCGGGGCTATTAGCTGGCCGGTTGTGGCCGTGGTGGCTGCCATTGTCGCCGGTGCGTTGCTTATCC
GTAA
ATACTGGGAGCCTGTCAGCGCATTCTTTGGTGGTGTGGTTGAAGGGCTGAAAGCGGCATTTGCGCCGGTGGGGGAACTG
TTC
ACGCCACTTAAACCGGTTTTTGACTGGCTGGGCGAAAAGTTACAGGCCGCGTGGCAGTGGTTTAAAAACCTGATTGCCC
CGGT
P
CAAAGCCACCCAGGACACCCTGAACCGTTGCCGTGACACGGGCGTCATGTTCGGGCAGGCACTGGCTGACGCGTTGATG
CTG
CCGCTTAATGCGTTCAACAAACTGCGCAGTGGTATTGACTGGGTACTGGAAAAACTCGGTGTTATCAACAAAGAGTCAG
ACAC
o ACTTGACCAGACCGCCGCCAGAACTCATACCGCCACGTATGGTACCGGTGACTATATTCCGGCGACCAGCTCTTATGCA
n.) .3 TCAGGCTTATCAGCCGGTCACGGCACCGGCTGGCCGCTCTTATGTAGACCAGAGTAAAAACGAATATCACATCAGCCTG
GGGGGACTGCGCCGGGGACACAGCTTGACCGCCAGTTACAGGATGCGCTCGAAAAATACGAGCGGGATAAACGTGCGCG
CG
.31 .3 CCCGTGCCAGCATGATGCATGACGGTTAAGGAGGTGACGAAAAATGATGCTCGCGTTAGGTATGTTTGTTTTTATGCGC
CAGA
CGCTGCCACACCAGACCATGCAGCGTGAATCAGATTATCGCTGGCCGTCAAATTCCCGTATCGGTAAACGGGATGCCTT
TCAGT
TTCTCGGTGTGGGTGAGGAAAACATCACGCTGGCCGGTGTGCTTTATCCCGAACTGACCGGCGGCAAGCTGACGATGAC
CAC
GCTCAGGCTGATGGCAGAGGAGGGGCGGGCGTGGCCGTTGCTGGATGGCACCGGCATGATTTACGGCATGTATGTCATC
AGC
AGGGTGAGTGAAACAGGGAGTATTTTCTTTGCAGACGGCACACCCCGGAAAATTGATTTTACGCTGTCACTCACCCGCG
TTGA
TGAATCACTGGCCGCGCTTTATGGCGATATCGGTAAACAGGCGGAATCGCTCATCGGTAAGGCCGGCAGTATGGCGACC
AGA
IV
TTCACAGGTATGACGGGGGCGGGATAATGCTGGATGCGCTGACATTTGATGCAGGCAGTACGCTGACGCCGGATTACAT
GCT n GATGCTCGACAGCAGGGATATTACCGGCAATATCAGCGACCGTCTGATGAGCATGACCCTGACGGATAACCGGGGCTTT
GAG t=1 tl GCTGACCAGCTTGATATTGAACTGAACGATGCCGACGGGCAGGTCGGGCTGCCGGTTCGTGGCGCTGTCCTGACGGTGT
o CGGCTGGAAAGGTTTTGCCCTGGTATGCAAAGGGAAATTTACCGTTGATGAGGTTGAACACCGGGGCGCACCGGATGTA
GTC 'a o ACCATCCGCGCCCGGAGTGCAGATTTTCGCGGGACGCTCAATTCCCGCCGGGAAGGCTCCTGGCATGACACCACGCTCG
GTGC tt n.) un GATTGTTAAGGCGATAGCCACCCGTAACAGGCTGGAAGCCAGTGTCGCTCCGTCACTGGCCGGAATAAAAATTCCACAC
ATCG
ACCAGTCGCAGGAGTCTGATGCGAAATTCCTGACCCGTCTTGCAGAACGCAACGGCGGTGAGGTGTCGGTAAAAATGGG
AAA n.) o n.) ACTGTTGTTTCTCAAAGCGGGGCAGGGAGTGACGGCCAGCGGTAAAAAAATCCCGCAGGTCACCATAACCCGCAGCGAC
GGC
i-J
GACCGCCATCATTTTGCGATTGCTGACCGTGGAGCCTACACCGGTGTAACGGCAAAATGGCTACACACTAAAGACCCGA
AGCC .6.
.6.
n.) GCAAAAGCAGAAGGTAAAACTGAAACGCAAAAAGAAAGAGAAACACCTGCGCGCACTGGAGCACCCGAAAGCGAAACCG
GT oe CAGGCAGAAGAAAGCGCCTAAAGTACCGGAAGCGCGTGAAGGTGAATACATGGCCGGTGAGGCTGACAACGTTTTTGCC
CTG
ACCACGGTATATGCCACGAAAGCGCAGGCCATGCGCGCCGCTCAGGCGAAGTGGGATAAACTGCAACGGGGCGTTGCGG
AG
TTCTCTATCAGCCTGGCTACCGGTCGGGCAGATATTTACACGGAAACACCGGTCAAAGTGTCTGGCTTTAAGCGCGTCA
TAGAC
GAGCAGGACTGGACAATCACTAAGGTGACACATTTTCTGAATAATAGCGGCTTCACGACGTCCTTAGAGCTTGAGGTCA
GGCT
TTCTGATGTGGAGTACGAAACAGAAGATGATGAGTGATGTTTTTGTTTTATCTGTTTGTTTTGTAAGGATAAATTAACT
AAAAT
GGCACCATCAACAAAACCGGAAGAGGTGCTCGCGATGTTTCATTGTCCTTTATGCCAGCATGCCGCACATGCGCGTACA
AGTC
P
GCTATATCACTGACACGACAAAAGAGCGTTATCATCAGTGCCAGAACGTGAATTGCAGCGCCACGTTCATCACTTATGA
GTCG
GTACAGCGATACATCGTGAAGCCGGGAGAAGTCCACGCCGTAAGGCCGCACCCGTTGCCATCAGGGCAGCAAATTATGT
GGA
o TGTAATTACAAACAGAAAGCCCCTCAGTCGAGGGGCTTTTTTGTCGATGTGGTCAATGTGTGGACGTGACCAGAAATAA
.3 TTTTATTTCAATTTATTGTACGTAAAAAATAAGCCCGTGTAAGGGAGATTTAGGGTGTCACCAGTAGGGGCTTTCAACG
ATGCGGGTTTGAGCGGCATAAATTACCACTGAAAGCCCTTAAACGTTACTCTACTGTGGACACTGTGTGGACACTCTCG
GCCTC
.31 .3 AGTACCACCTCTTAGCGGATTAAGAGAAATGGCGTCCTGAAGGTACTCTGGCGCAAAATGAGCGTAAACCATAGTTTGC
TCAA
TCCGCGTGTGACCTAGTATCCGTTGTAGCGTGATAATACTTCCTCCATTAATCATGAAATGAGTGGCAAAGCTGTGCCT
TAGTG
CATGTGTGGCTTGCCCCATTGGCAAATCCGGTTTTATTGCTTTCATTGTTCGTCTGAAGCGAGGGTAATCAGCATCAGG
GAATA
AAAAACCTCGTTTGTTATCCGCGATCATTTTGGCAACAGCCTCTGAGATCGGGACGGTGCGTGGTTTGTTTGTTTTCGT
TTTAAC
AAACGTGACGCGGTTATGGATGATATTTTCTGCTTTCAAACGAGCTGCTTCTCCCCAACGTGCTCCTGTACTCAGGCAA
AGAAT
CGCAATCTTTTTATTGTCGCCGTCAAGTGCTGCAAGCAGTAAGGCAATTTCTTCCTGTGTTAGATAGCCTGTTTCTGGT
TTTTCCT
IV
CCTTAAGCCTTTTTGTCCCTCTGATAGGGTGCTCACCAAAGAATAACTCCGCTTCAATCAGGGCTGTAAACATGCCGCT
AATACA n TGTTAAATCACGATTGATACTCGAAGGTTTAATACCCTGACTTCTTCGGGTGGCGCAGTACTGGCTGATAAGCGATTTC
GTAAT t=1 tl TTGAAATGCGCATGGGTCATTCGTTATTTTTGTGAAGATTTCAATTTTTCCAAGATTAGATTTCCCATGCTCTTCGTGT
o TTAAATCCCACCAGATCTGTGTCAGCTCCGACAGACGTCGCTTGTCTGTTGGTTTTGATAGCCATTCTTTATTGTGGTG
GTTGTA 'a o CAACGTGTATTTCTCGAAAGCGACAGCTTCGCTTTTCTTATCAAACTTCCTACGGATGCGTTTTCCATTACGTCCAGTA
GGGCGG tt n.) un ATGTCCACTTCATATCGACCATCATCGAGTTTTTTGATTGCCATCAGAAAACCCTCCGAGTGGTGTGTTTTTTTGCGAC
TACTAAT
CGCTTTTTTCGTGGTGGCTGAAATTTAGCCACCAATAGTAGGCACTTGTGATGAATATATTCACGATGAATTGTTAACC
AGTCTT n.) o n.) TTGACCGGAGTGGGGCGACGTTGTTTCGTTTTGCCCAAAGTGTGCGAGAGCGGGCGCAATTTGCCCGGACTCAGGAGCG
ATC
i-J
TGATTGGTCATGAACCATAAAGTGTATTTGGTGAATTGTGGGGTCTGCAGGATGTTCATCATGACATCTGTTGGAGGTG
TTGA .6.
.6.
n.) ACGACCACTTTCATAGTAACTCAGCGTGCCATACGGAACCCCTGTTAAATCAGCAAGTTGTTGTCTGCTCAAATACTCT
GATTTT oe CGCATTAAGACTATCTTCTCGCTTATCGTGTTTGACATGGTGTTTAGATCTCAATAGTATTTAGTTTAGATGTAGATTG
TTTAGTG
CTTGGATGTGGGCACTAAAAGGCATTATAAGACATTAAACGCAATTCATGAGGGCTAGAGGACGACATGAGCAAGCAAG
TAA
CACTCATGACTGATGCGATTCCTTATCAGGAGTTCGCAAAACTAATAGGAAAATCGACAGGAGCGGTTCGTCGGATGAT
CGAT
AAAGGAAAGCTGCCTGTAATTGATATGACCGATCCACAATCAGCTTCAGGTCGTGCAGGTGAATATTGGGTATACCTTC
CGGC
ATGGAATAACGGACTAAAACTGGCTTATGAAAGCCGCCCTAAAGAGATTCGTGACGGCTGGTTGATGTGGTTAGGTCTC
GGTG
AACCACGTTAAGGAGAACCGTATGAATGAGCCTCGTTGTATTGCTCAGTTACTGCGTAACGAAAGCCCCAGGGCGATTG
ACTT
P
CACCATCACCCACGGTAAGGGGCGTAAGGGAATCATTATCCGCACCAAAAAACAGAGTCCGTTAAAAAAGGCTCTGACC
TTTC
TGAAAAGCCGGAGGGTATGGAAATGACAGTGATGACGCTCAATCTCGTTGAAAAACAGCCAGCAGCTATGCGCCGGATA
ATT
o GGTAAGCATCTTGCCGTTCCTCGCTGGCAGGATACATGTGATTATTATAATCAGATGATGGAGCGCGAACGGTTAACGG
.6.
.3 CTTCCATGCTCAGTTAAAACAGCGTCACGCAACGATGTGTTTTGAAGAAATGAACGACGTCGAACGTGAACGACTGGTA
CAATTGATGAATTGCGTGGTGCATTCTCAAAACGCCGTCAGGTTGGCGCAAGTGAGTATGCATATATTAGTTTTTTAAC
AGTCA
.31 .3 GTCAGCGTCGTACTTTATTTATGCATGCCGGATTGACTGAAAAAGAATTCAACCAGCCATACTGGCGAATTAATGAAGA
GTCAT
GTTACTGGCGTGATGCTTTATTCCGTGCATTACGTGAATTATTCAGTCTGTTTGAGTATGCACCGACAATTCTGACGTC
GGTAAA
ACCGGAGCAATATCTGCATTAAGTAATTAACCAGAGTTTTTAACGCACTTAATTGTGCGGGGCTTCTTTTTGCCTGGAG
AAAGT
TATGCATACAGTTTCTGAAAATCAGTGCGGTATATACGCATTACTGCTGCAACAGGCCAGAACCGAAGCACAGGCCGAC
GCTG
CGACGCGCTTTTCTTCTCATCTTGATGCCATGATTCGCCACATCACAAAGGCGGAGTTATCCCGCGTGGAGATAGTCGA
GCTGC
TCAGTCAGGAGTCGGAAAAATTTCACAATATCGGATTGTCTCGCGGGGAGGTGCTTTGATGTTCTGTTCTCGTGCAGTT
GTATT
IV
ACTGAATAACGCCTTAAAAATCGCCGTTATGAAAAATGGCGATTTGTCTCTTATTCAACTTGGTCTTGATAAAGAAAAA
CGCGA n ,-i AATAACTGAATCTGTTATCGCGATTTATCAGAGTGAATTAAACCTCCTGTCTGATGTGGTCAATTTACTTGTTAAACGC
GCTGTA t=1 tl TTTCACAAGCAAATTTCCTCCGTGGATGAACTGACGAAATTAACGACAGAAATCGCCAGCTATTGCGCTGATGAATTTA
o CTGAACGACAAAAGGAACTGGTAATGCCGGACAACGTAGATTTTATTCAGGAACAACAGGCTGAATTACTGGAGCGCCA
GATT 'a o AACGCGGCAAGGGTAAAACATTGCGGTGCTTCTGCGCTGGTTTGCGAAGAGTGTGACGCGCCAATACCTGCTGCCCGTC
GTGC tt n.) un GGCTTACCCGTCAGCCACGCGTTGTGTTTCCTGTCAGTCAGTCTTTGAAGCAAAAAACAAACATTACCGGAGAACGGCA
TGAG
TATTCGTATTGAAATTGGCGAACGTTATGTCGTTACCAGTGACAGCTTTCAGTTTATTCTCCACGAGAAAAAGAGAGCG
GAAAG n.) o n.) CGGTAAAAACGCCGGTCAGGAATGGCTGGCGGTGGTTGGTTATTACCCGAAATTAAGCCAGCTCGTTTCAGGCCTGATG
CATC
i-J
ACGATATTCTGACCGGAAGCGCAAAGTCTTTTGCTGATTTAAACGTGCAGGTTGAGCAACTCAGCAAGCGTTGTTCAGA
GGCT .6.
.6.
n.) TTTGGCTCATATGGCCGTTAAAGCCTCCGGGCGTTTTGTCCCTCCGTCAGCATTTGCCGCAGGCACCGGTAAGATGTTT
ACCGG oe TGCTTATGCATGGAACGCGCCACGCGAGGCCGTCGGGCGCGAAAGACCCCTTACACGTGACGAGATGCGTCAGATGCAA
GGT
GTTTTATCCACGATTAACCGCCTGCCTTACTTTTTGCGCTCGCTGTTTACTTCACGCTATGACTACATCCGGCGCAATA
AAAGCCC
GGTGCACGGGTTTTATTTCCTCACATCCACTTTTCAGCGTCGTTTATGGCCGCGCATTGAGCGTGTGAATCAGCGCCAT
GAAAT
GAACACCGACGCGTCGTTGCTGTTTCTGGCAGAGCGTGACCACTATGCGCGCCTGCCGGGAATGAATGACAAGGAGCTG
AAA
AAGTTTGCCGCCCGTATCTCATCGCAGCTTTTCATGATGTATGAGGAACTCAGCGATGCCTGGGTGGATGCACATGGCG
AAAA
AGAATCGCTGTTTACGGATGAGGCGCAGGCTCACCTCTATGGTCATGTTGCTGGCGCTGCACGTGCTTTCAATATTTCC
CCGCT
P
TTACTGGAAAAAATACCGTAAAGGACAGATGACCACGAGGCAGGCATATTCTGCCATTGCCCGTCTGTTTAACGATGAG
TGGT
GGACTCATCAGCTCAAAGGCCAGCGTATGCGCTGGCATGAGACGTTACTGATTGCTGTCGGGGAGGTGAATAAAGACCG
TTCT
o CCTTATGCCAGTAAACATGCCATTCGTGATGTGCGTGCACGCCGCCAAGCAAATCTGGAATTTCTTAAATCGTGTGACC
un .3 AACAGGGAAACCGGCGAGCGCATCGACCTTATCAGTAAGGTGATGGGCAGTATTTCTAATCCTGAAATTCGCCGGATGG
GATGAACACCATTGCCGGTATTGAGCGTTACGCCGCCGCAGAGGGTGATGTGGGGATGTTTATCACGCTTACCGCGCCT
TCAA
.31 .3 AGTATCACCCGACACGTCAGGTCGGAAAAGGCGAAAGTAAAACCGTCCAGCTAAATCACGGCTGGAACGATGAGGCATT
TAA
TCCAAAGGATGCGCAGCGTTATCTCTGCCATATCTGGAGCCTGATGCGCACGGCATTCAAAGATAATGATTTACAGGTC
TACG
GTTTGCGTGTCGTCGAGCCACACCACGACGGAACGCCGCACTGGCATATGATGCTTTTTTGTAATCCACGCCAGCGTAA
CCAGA
TTATCGAAATCATGCGTCGCTATGCGCTCAAAGAGGATGGCGACGAAAGAGGAGCCGCGCGAAACCGTTTTCAGGCAAA
ACA
CCTTAACCAGGGCGGTGCTGCGGGGTATATCGCGAAATACATCTCAAAAAACATCGATGGCTATGCACTGGATGGTCAG
CTCG
ATAACGATACCGGCAGACCGCTGAAAGACACTGCTGCGGCTGTTACCGCATGGGCGTCAACGTGGCGCATCCCACAATT
TAAA
IV
ACGGTTGGTCTGCCGACAATGGGGGCTTACCGTGAACTACGCAAATTGCCTCGCGGCGTCAGCATTGCTGATGAGTTTG
ACGA n GCGCGTCGAGGCTGCACGCGCCGCCGCAGACAGTGGTGATTTTGCGTTGTATATCAGCGCGCAGGGTGGGGCAAATGTC
CCG t=1 tl CGCGATTGTCAGACTGTCAGGGTCGCCCGTAGTCCGTCGGATGAGGTTAACGAGTACGAGGAAGAAGTCGAGAGAGTGG
o GGCATTTACGCGCCGCATCTCGGCGCGCGTCATATTCATATCACCAGAACGACGGACTGGCGCATTGTGCCGAAAGTTC
CGGT 'a o CGTTGAGCCTCTGACTTTAAAAAGCGGCATCGCCGCGCCTCGGAGTCCTGTCAATAACTGTGGAAAGCTCACCGGTGGT
GATA tt n.) un CTTCGTTACCGGCTCCCACACCTTCTGAGCACGCCGCAGCAGTGCTTAATCTGGTTGATGACGGTGTTATTGAATGGAA
TGAAC
CGGAGGTCGTGAGGGCGCTCAGGGGCGCATTAAAATACGACATGAGAACGCCAAACCGTCAGCAAAGAAACGGAAGCCC
GT n.) o n.) TAAAACCGCATGAAATTGCACCATCTGCCAGACTGACCAGGTCTGAACGATTGCAGATCACCCGTATCCGCGTTGACCT
TGCTC
i-J
AGAACGGTATCAGGCCTCAGCGATGGGAACTTGAGGCGCTGGCGCGTGGAGCAACCGTAAATTATGACGGGAAAAAATT
CAC .6.
.6.
n.) GTATCCGGTCGCTGATGAGTGGCCGGGATTCTCAACAGTAATGGAGTGGACATGATGGCAAAAATTCACGAGGTAAAGC
TGC oe ACGCAAAATATTTCGACCTTGTACTGGAAGGAAAGAAACGCGCAGAGTTTCGGAAAAAAGATCGTAATTATGAGCGCGG
GGA
CACGTTGATTTTGCATGAATGGGTGCAGGGTGTGTTTACGGGGCGAAAGGTTGAAGCCCGGATAACAGATGTTACTGAC
CTGT
CAGACTGGCTGGAAGATTATGTCTTGCTGCACAGAATACTAGGTGAGATACTGCCGCTGACTGTCAAGCTGGCAGTATC
CTCC
ACATTTTTTATAAATCTAAGGCGAAGAACGGTGGCAATATATTTGCTTTAAATTGTAAATAAGCAAATTATTCTAAGCC
ACAAAT
GATATCAATTGAGTATCGATTTTCGTTCGAATATAACCATAACGCCAAGCGTCAAATGTAAGTCATCTATATGTGATTC
GTATTC
ATATTGGTCAGCATCAGGAGATAGTAAATGCTCTGCTGCTGTAAAAACATCAATTGTAACAGATATATCGTCTGGAATT
TCTTC
P
ATTTAATTCGGATATGTATTTTTTATATTTGTTTTTTAATTTCCTTATCATGTCTTCCTTATGGTGGATTGTAGTGCAG
TAATTTTTT
TTAGTTGAATCATTGTATGAATGGAATGAACAGTTTAATGCTAGGCCAAGACTTGAATTTCCTGTAGGGCCTGTGTGTT
TAAAG
o TATTCAAGATTTCTTCTTATGTCAGAAAATAAAAGACTTTTACAGGGGGCATTTCCTTTAACTTCTATTGCACATATTG
o .3 GAAAAATGGTCTGCTGTCCAATATGGCAATATCAATTCTGCCTGATCTTGTTGTGTTTGTGTTTTTTCTGACAGTTTTT
ATATTTTTTGGGGGTCAGACCGTTTCGATAAAGGAACTGTTGCATTAATGAATTTATTTGTATGGTACTCAAATATAAC
TTTGTA
.31 .3 ATCACCATGGCGAAAAGATTTTATTTCTAACAACGATAGACCTATAGATACGGTAGCTACATATTCAGTGTTTATTTTT
GCACCA
GACCTGAAATCCATTAAATAAGTTGCGTCGGCTGACTTTTTCATTCCATCTTTTACAGCTTTCACAATATCCATGTTAT
TCATATC
AACACCTTTTATATTCCAGAATTATAAATCTTAATGATTGATTTGTTTGTGTGTTTAGGTTACTAGATTGACGTACTTA
TAGCACA
TTCTGATTTTGAAATCACCATCCTTGGGTAAAGCACAGCCTATCACTATTGGTTTAGTACTGTGCTGTAATAGTATCAG
ATTAAG
TTAAATCCATTTTATGAAATCTTCCATTTCATCATATTTTTTTATTACTGCTCTAACATCTTTGCTTTCATCACATAAA
CAATCTAAA
AGACTATCCCATTCAGTTTGTTTTTTACCAAATCCATAAACAGCCTCTATATCACCGGATTTCCATATATAGATTCCGT
TATCTTTC
IV
AATTTTTGATGTATTTCATGTATATGCTTTTGTGTTTTTTCATGGTTACATATTTTGATGAAGTCTTTGCTTGAAATGC
TTTTGAAT n ,-i GACTCAAAAGTAGTAACTTTTGTATTTAAACTAAGCTCTCCTGAGTTGATTGATTCAATCAAAGCAGTCAATAGATTAT
CACATT t=1 tl CAGTACTAAGTAAGTCTTTATGCTCTGTTAATAGAATATTTGATAAGAAATCACAATCAGCTAGAATCCTTGTTTTTAT
o GGCATTGATGATTTGTGACATCTTAAATAAACTACCCTTACCGTCAACGGCAACAATGCAGATTTTACTCGGGTTGAGT
TCATGT 'a o CCGTTAATTTTTTTATAAAGTGCATATAGAACGTTTGTCTCTGTTTTCCCTTCAACAAGCAAAACTTCTTCAGAAAATA
AAAGGTA tt n.) un TGATGAATTAGAAAGCGTGAATGCTGAGTGCAATTGCGGTGATGAAGATTTATATAATTCTTCGATTTTTTCAGATATA
GTCTTC
CTTGCTATGGTTCCATTAGAATCCTTACAAACCTGAATCGCATTTGCTGCATGCTTTGCAGAAAGCATACTGGCTGAGT
GAGTT w o w GATATTATAACCTGATACCCTGATTCACTTAATGTGACAAGTGATTCTCTGACAGAATTAATG
GCTGAAGGGTGTAAATATAAC
i-J
TCAG GTTCATCAATG AAAATCAAAGTGTTTG ATTTTTTTG ATTC G CTGTTTTCTTTTTTTATTTC G GC
CAG GTATTG AATTAATG C
4,.
w CATTTG AATG G AAC GTTGTGTTC CGTG ACCAAATC G G CTG ATATCTCTCATTACCG GTTCATCTTCC
CG AG ACTCAAAAACTTTC oe AG AGTG C CG G ATTTAAATATCTCATCTAATGTCG GTGTG G G AAAGTGTAACTTTACACTTAC GTCAGG
AAAAAATTG GTTTACT
TTTTTATTTACACCTG AGTCTATTTTATTAAG G CTTTCTAATCTGTTCTCACC GTTGTG AG AAAG
ATATTTAC CTATTTCTGATATG
TTTTTTG AAAATTTTTCTTCGTGTTCTTGTTTTATTTCAG AAACAATTG C G G AAAGTATCTTTC
CTATTGTG GTCGTGTTTTTG CAT
TTTGTTG AGTCTTCG ACAG CGTCAG ACATTG CAG G G ATATG AATTG GTTC CG G AAATATATTG G
AG ATTG CAC CATCTATG C CG
CCAGGGTTTTTCTTCCACGTGGTACCGTCATATACATCCAGACTTTTTTTGGCTTTTCCTGTTTCCTTATTAAATTCCT
GTCTTCTT
G CAAAG GTAAG AGTCC CGTCAATTATAAAC G G AG CTATTTTTTGTTG ATTCTCTTCTGTTAACAAAG
ACAG AGTATCATCTGTTA
P
TACCTTG AATAACG C CTTCAACG G ATACG G G GTGTGTAG G ATCGTACACATCTG ATTCTG
AAATCAAAG AG C CATCTAACAG C C .
, ACTTAATTGCTAAGATAATATTTGATTTTCCTGCGTTATTATAACCAACTAAAGCAGTGAAGGGGCGCAAAATAGCCGA
TGTTG
, 1¨
.3 o ACTTACAAG AACG AAAGTTG CTAATTG
AAACTG AAG CAAG AC GTACAGTCATTATTTTTC CTTAAATGTG CTATTTGTATG CAAT .
G AGTTCATACG AAACG CTTTTTTACATTTTATAGTCGTTGCATTCAAG G GTG CATG AG ATTG CATTAAG
G G AAACTGTG ATATG "
, , , GCTTGGCTTTTGACTGGAAATACTGATGGCTCATTAGTTTTATTAAGGTGCATTAAAACCG CC CC GTG AAGCG
, N, N, GCGGGGAAAGCAC
20 Native P4 (acc nr:
TTTGCCGCTGCCGCCGGGACCGGTCACCTCCAGAAAGAGCTGCCAGTCGTAGCGGTTTGCCAGCACCATAAACAGTGCA
GCCA
X51522) GAATCACGTCGCGTTTTTCCGCACGGCCACCGGCGGCACGGTCAAGCCAGCGCCAGAAGGCGGGGGCGTGGGTTTCCAG
CGT
TTCACCGTCCACCGGCGGGGTGAAATCCACATCGCACAGGGTGCGCATCCAGTGTGACGGACTGTGCGGGTGGAACGTG
CCG
TTCTGCGTGTCGAGCACGCCGTTACGAAAGCCAATCAGGCGGCGGGAGGGGGCTTCCTGCTGCGGAATAATCAGCTTCA
GGG
1-d TATCCACCACGGAGGCCACCTTCCCGGAGGAGAACGGCGCACGCAGACGCTGAAACAGCCCGGCCACATCCCGGGCAAA
GTC n CTGTGGCGGCAGCACCTTCCAGACACCATTTTCATAGCGGGACAGAAGCTGGCCGTTGGCATCGACCGCGAGCGCCTCG
CCGT t=1 1-d AATGCTCATAGATACGCATGGCCTTTTCGCTGGTACTCATGGCGGAAAACTCCGCTTCGCTCATGGTGTCGAACGGGCT
TTCAG w o w CCGGTGGCCGGATGGCATCGTAAATGGCCTTACGGGTGGCCTCCCCGCCGTACTGCGTGAAGGCATCATTCCAGTCACC
GAAG =
'a ACCGGCGGCAGGGCAACAACACCTTCACACGCATCTGCGGCTGCGGCGGCTTTTTTCTGGCCGTCACCACTGAGGTCAC
GGTC o 4,.
w w vi AGCGGCAAGGACAATCTGACAGGCGGGGTGCTTCTGCCGGGCAAGGCTGGCCAGAGAAAGGAGGTTCACGGAAGAAAGC
G
CCACCATCACCGTTTCACCGGTCAGGTGATGTACGGTAAGTGCGGTCGCGTATCCCTCCGCTATCCACAGACGTTTTCC
GGCCT n.) o n.) GATTCTGTCCTTCAAGGGTGTGACAGGTGCCCCTGACCTGTCCGCCTTTCAGGGTGCGCTTACGGCCGTCAGCACTGAT
TAACT
i-J
GAAGGTTAACCAGTTCGCCGCTGTCGTCATACAGTGGCACCACAAGGTCACCGGCGCGCCAGCTCACGCCACCGGCTCT
GTGT .6.
.6.
n.) GTGCCGGTCAGCATCCGGCATTCCCGGCCGGGAAAGCCCTTGCGGGTCAGGTAGGCGTTACCGGTTCCGGTACGGGTTT
TCGC oe CATCAGGGTTTGTGCCAGTGCGGCGGCGTTCTTCCGGGCAGCGTCTGTTTCATCAACGGCGGCGGTCGTCACTGCCGGG
TCAG
CCGGTGGCAGGCTGCCGGTCACGGCAGCCACCTTTGCGGCCGCGTCGGACGGGGAAACACCAAAAACCTTTTCAACCAG
TTTC
AGGCCGTCACCGGCACCACACTGATTGCAGTACCAGGTGCCGCGCCCCTCCCTGTCATCAAAACGGAAGCGGTCACTCC
CGCC
ACAGACCGGACAGGGCTGATGACGGTTCTTCAGCACCTGAATCCCCAGCGCCGGGAGAATACGCGGCCAGTGGCCGAGC
GCA
TGGCTGACGGTGGCGGTTACGTTCATTTTCATGGTGTTGTTCTCCTTCAGTGCAGTACCGGCGCTTTTATGTGACGGGC
ACAGA
GTTCATCCATCACAACCAGCCCGAGAAAGGACAGCGACGGCGCGGCCTTCAGGGGGCCGGATTCCATTAAATCTTCCAG
CAGG
P
GCACAGGCTATCTGACGCCCTTTTTCCTCACCGTGCTGGCGCAGATAAAAGCCTTCCAGCTCAGCGGCGATGGCCGCCT
CCAGT
GACTCAAGGGTGAGATGCGGGTAGCGGTGCTGACGTTCGCACACGGTCAGCCAGGCACAGGCGACAGCGCGACGGTAAA
GG
o GCAGCGCGTAAGACGGGCGGTAAGGGTGTTTTCATTTGCTTTTCTCCCTGTGACAGATGACTGCATTCCGTGCCGGTTG
oe ACTGATAAGGCATATCTGCGTCTCCTGAAGACGTGCGTATCCCTGCGCGAATACGCACATTTAATTTTTCGGGGGTCGT
ATTACAGATAATTGCGGTAACTGTTATCCGGGGTGGTTTCCGGGTCAGGCTCCGTGCGGGGAATTTCCCGCCATTCCCG
CGCCA
.31 .3 CCGGTGCTGCCCGGCTGACCGGAACAGTGTCCTGCGGGTAAATATCCAGATATTTTTCCCGCCATTTCTGTAATTCCGG
GTCTC
CGGCCATTTCTTTCAGTACCGCATGCCGGTTTACGGGGCTGCGTTTAAACAGGTCAGGACGGTCACAGGTAAATTCCCG
CAGA
AAACGCCCCAGCGGGATGTCTGTGGTGCGTCCGTCAGCGAGGATACGCACAAGGATACTGAATTTACGGCGGTACGGGT
TCC
AGACAATGTCCGGGCAGCGGTACGGCATTTCCCACGGAATACCGTCTTCCAGAATGCCGACCACGGCCACATCGGGAAA
ACCG
GCAGAACGGTAAATCTCACCGGGCTGGGGAAAATCAAACATGCGTCCTGTCTCCCCGGTCTTTCTGCTGGGCGAGAAAA
TCGC
GGCACAGGCCTTTGGCTTTCAGCTCATTCAGCACAAAATCAATATCTTCATTCAGGTAGCTGAAAATATGTGGAATGTA
GAGCT
IV
GATGCAGGCCGGAGAGTTCACGGTGAATCAAATCACCCCCAACAAACCGGGATACGGCGCTGGCGCGGTTGAGCTTATG
GTA n AGCCTCAATGCTGAGGTGTTCACGGGCGTCATGACGCGCTGAGACGGTCTGAGGGGCTTTTTTATTACGCACGGGACAC
CTCC t=1 tl ACCACCGGCAGACGGGCAGCAAGGGAGAGCACATAGTCACGGACAAGGGAACGGCGGGCACTGCGTTCATCACCGGCGA
o GTGCGAAGCATACAGATACGGGGATGACGGTCTGCGCGACGGACAGCCGCAAACACAAAGACAAATTCAGGGTGTGAGG
GG 'a o GTAAGGGTTGTAGCCATGATGGCAGCCTCCTGTGAATAGCAAATAACGCTATCGCCGGAGTTCTCACGCTCGATGGCGA
TAGC tt n.) un CCAGACGGGGGTGAGAATACCGGCTTCACAGGATACCGGCCAGCCCGGAGGCTGCCCCGCCTGAGCTACCATTGACTCT
GCG
GCATAATGAGCGGACGCGGGCAGGATGCACGGAATGCCATCTGCACGACTGACCACACACCACACCATAATCTGGCGCT
CTGT n.) o n.) GGCATTGATTGCGACACAAAAAAAGACGCGTGGCGCGTCATATGTCGCCTGTGAATTGCTCGGGTTCTCACGCCCGGCT
GCCG
i-J
ATTTTGCGGCAGGCGAAAAACTATATCCGCAAATGCCGGAAAAAGGCAAGCCAGAAAAAGGGAGTTTTTGCAGAGCGGG
CAT .6.
.6.
n.) CATCATGCGTCGTACCCCCGTTTGCGTCCGGCAATGCGTCCGGCCATCCATGCGGTGACTTCAGAGTGCAGCCAGGCCA
CATTT oe TTACCGCCAAGACTCACCTGCGGCGGAAATTCCCCCTTACGGATGAGTTCGTAGATGGTCGAGCGTGACAGGCCGCACA
GGTG
CATCACTTCCGGCACACGTAAAAAACGCTCCTGCGTGATGTCCGGCAGCGGCATCAGTGGCGTCACTGGGGCGGGAGAC
GGG
GAAGAAAAAACAGCTTGCATCGGGCTACCTCGTTAATGTCCATACAGCACCGGATAAGTCCGTCCGGCTTCGGGTAGCG
CTTT
ATTTTGTGAATATTTTCAGCAGACGCAACAGGGGGGATTTGTTCAGGCTGTCTTACAATGGCTGTGTGTTTTTTGTTCA
TCTCCA
CTTAAAGTCATTTAAAGCCACTTAAAGCAATTTGTAATTTTTATAGTGAAATACAAATCGTTTCTTCTTATTCATTCCC
GGCGAAT
TAATAAAAACAAACAGTAGTAAACAGCACAAAAAGCCCATCAACGGGTGAACAGTGGTGAACAGACGGTGAACAGTCAT
TAC
P
TGCGATTGTTCACCCTTTAACTTACTGTATTACTTATCTTTTTTATTAAGGTGAACAGAGGTGAACAGTAAAATATAAA
AAAACA
AACAGTAAGCCGGTTTTTCCTGCGACCTTTTCCTGGCTTGCCGGTCTGAGGATGAGTCTCCTGTGTCAGGGCTGGCACA
TCTGC
o AATGCGTCGTGTTGTTGTCCGGTGTACGTCACAATTTTCTTAACCTGAAGTGACGAGGAGCCGGAAAATGTCTGACCAC
o .3 CCCTGAATATCTGCAACCCGCACTGGCACAACTGGAAAAGGCCAGAGCCGCCCATCTTGAGAACGCCCGCCTGATGGAT
CCGTCACGGCCATTGAACGGGCAGAGCAGGAAAAAAATGCGCTGGCGCAGGCCGACGGAAACGACGCTGACGACTGGCG
CA
.31 .3 CGGCCTTTCGTGCAGCCGGTGGTGTCCTGAGCGACGAGCTGAAACAGCGCCACATTGAGCGCGTGGCACGCCGGGAGCT
GGT
ACAGGAATATGACAATCTGGCCGTGGTGCTGAATTTCGAACGTGAACGCCTGAAAGGGGCGTGTGACAGCACGGCCACC
GCC
TACCGGAAGGCACATCATCACCTTCTGAGTCTGTATGCAGAGCATGAGCTGGAACACGCCCTGAATGAAACCTGTGAGG
CGCT
TGTCCGGGCAATGCATCTGAGCATTCTGGTACAGGAAAATCCGCTCGCCAACACCACCGGCCATCAGGGCTACGTCGCA
CCGG
AAAAGGCTGTCATGCAGCAGGTGAAATCATCGCTGGAACAGAAAATTAAACAGATGCAAATCAGCCTCACCGGCGAGCC
GGT
TCTCCGGCTGACCGGACTGTCAGCGGCAACACTCCCGCACATGGATTATGAGGTGGCAGGCACACCGGCACAGCGCAAG
GTG
IV
TGGCAGGACAAAATAGACCAGCAGGGAGCAGAGCTTAAGGCCAGAGGGCTGCTGTCATGATTTACTGTCCGTCGTGTGG
ACA n TGTTGCTCACACCCGTCGCGCACATTTCATGGACGATGGCACCAAGATAATGATTGCACAGTGCCGGAATATTTATTGC
TCTGC t=1 tl GACATTTGAAGCGAGTGAAAGCTTTTTCTCTGACAGTAAAGATTCAGGAATGGAATACATTTCAGGCAAACAGAGATAC
o ATTCACTGACGTCAGCCTCCTGCGGTATGAAACGCCCGAAAAGAATGCTTGTTACCGGATATTGTTGTCGGAGATGTAA
AGGC 'a o CTTGCACTGTCAAGAACATCGCGGCGTCTGTCTCAGGAAGTCACCGAGCGTTTTTATGTGTGCACGGATCCGGGCTGTG
GTCT tt n.) un GGTGTTTAAAACGCTTCAGACCATCAACCGCTTCATTGTCCGCCCGGTCACGCCGGACGAACTGGCAGAACGCCTGCAT
GAAA
AACAGGAACTGCCGCCAGTACGGTTAAAAACACAATCATATTCGCTGCGTCTGGAATGAGGGCTGCCGGTTAACACCGG
CCGT n.) o n.) CGCCGCACACCGTATTTTTATTCTTCAGCATGATGAGAAAGAGATAACGATGGAAAGCACAGCCTTACAGCAGGCCTTT
GACAC
i-J
CTGTCAGAATAACAAAGCAGCATGGCTGCAACGCAAAAATGAGCTGGCAGCGGCCGAACAGGAATATCTGCGGCTTCTG
TCA .6.
.6.
n.) GGAGAAGGCAGAAACGTCAGTCGCCTGGACGAATTACGCAATATTATCGAAGTCAGAAAATGGCAGGTGAATCAGGCCG
CCG oe GTCGTTATATTCGTTCGCATGAAGCCGTTCAGCACATCAGCATCCGCGACCGGCTGAATGATTTTATGCAGCAGCACGG
CACAG
CACTGGCGGCCGCACTGGCACCGGAGCTGATGGGCTACAGTGAGCTGACGGCCATTGCCCGAAACTGTGCCATACAGCG
TGC
CACAGATGCCCTGCGTGAAGCCCTTCTGTCCTGGCTTGCGAAGGGTGAAAAAATTAATTATTCCGCACAGGATAGCGAC
ATTTT
AACGACCATCGGATTCAGGCCTGACGTGGCTTCGGTGGATGACAGCCGTGAAAAATTCACCCCTGCGCAGAACATGATT
TTTT
CGCGTAAAAGTGCGCAACTGGCATCACGTCAGTCAGTGTAAAATTCCCCGAAAATCCGCCCGTTTTTACTGAAAAAAGC
CATGC
ATCGATAAGGTGCATGGCTTTGCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGC
GTGTC
P
AGTGCAACTGCATTAAAACCGCCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGT
TA
ATTATTTGTGTAGTCAAAGTGCCTTCAGTACATACCTCGTTAATACATTGGAGCATAATGAAGAAAATCTATGGCCTAT
GGTCC
--.1 AAAACTGTCTTTTTTGATGGCACTATCCTGAAAAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTCAGTGTCG
o .3 TCCTTAAGAATTCGTGGCATGAGAGAGTTAAAGGATGCTGAATCATGTATATGGATTAATTGGCGTTGTTGGGACCATA
CTATTGCTACTAGCTTCATCCGCAACCAAGATATTTCACAATGGTTGCTCGTTTGTTCTGGATGGTTAGCTGCTTTACT
TATTGGA
.31 .3 TGGTTTACACACAGAACGATTAAAGCAATTAGCAACAACCACACGAATGTTATAAAAAGTAATATGGAGGTAATCAACA
GTCA
TAATGAATCCAATCAAAACTTGATGGCTGAAAACAAAGAATTGATTAAAGAACTTGCAAGAACTTCAGAACAGAAAGAG
AAGA
TGGAAAGTATAGCTGCTTATCTTGCTACTCAGAACCCCCAAATTAACGCTATGCCAAGAACAGCAAGCCGACCAGAAAA
TATCG
ATTCGGAGGCTAATTAAATATGAAAGTATATTTTGAAAATTACTCATACTATCCAGCCCTAAGAACACGATCAGCAGAA
ATGAC
CGGACTGAATAATTTATCATATGAGAATAAGAAAAAAATATTACCTTTAATTTCTTTGGGGAAATGGCCTCGCTCGGAA
GAAAT
ACAGGTATCGTTAGATAAAAGTTTAGAAGTGATGAGTAATCTCCCATTTATTTTGGATGTCACAAAGGATAATTCTCAT
CATTGC
IV
GCGTCAAGCTTCGAACTACTCTCTCCTGAGAATGGTTTTAAAAACTGGATAGAGTTTTGTTCCAGAAATGATAATATTA
TTCCAG n ,-i TAGTCCAGATGCCGGATTCAGCAAAACTTAGAGATATATCTATCCAAGCCAGGGTTTTAGAGGAACTTAAAGGTTCAAT
TGCAT t=1 tl TTAGAATTAGAAATCTAAATACAGACATTAATAAAACCCTGACGTCACTAGTATCGATGAACTCTCCAGAAAATGCCAT
o CATAGATTTGGGCTACATTAGAGGGAATGTATCTGCTATAACAGCTGCAGCAATAAATTCGATTAATCAGATTAGAACT
GAGAT 'a o TCCTGAAGCCATAATTAGTGTGCTAGCAACAAGCTTCCCTAGTTCAGTTACAAATTTTTGCCGTGAAAATGGACAGTCC
GGATA tt n.) un TATTGATGTTATTGAGAGAGAATTGCATCAAAATATTGGTGGAAGTGATGTCGCTATTTATGGCGATCATGGTTCAATT
CATTC
AGTAGTGTATGACAACATAATTGGGCGATATGTTCCTAGAATTGATATAGCGTTAAATGATTCATGGTATTTCGAGCGC
CGCCC n.) o n.) TGGGATGAATAAAGAAGGGTTCATTGAAGCTGCGAAATCAATTTTGGCAGAGTATCCACATTATCAAAGGGAGGACTCT
TGG
i-J
GGAGCTGCAATGATAAGAAATGCTGCTATAGGGGATATAGCAGGTATGGGAAGTCCAGCTAAATGGATTGCTGTTCGAG
TGA .6.
.6.
n.) ATCTACACTTAAATAAGCAAATTGAGCTATCTGAAGCTCTACAGTATGGCTTTGATCATGATGAGGAAGATCTTATCTA
ATAAA oe AAACTAGGGAAGGTTAGCCTTCCCTAGCCCACAACCCTTTTAAGTACTTTTTCCGGAATATAGGAAACATCATCGCCAT
ATTTCC
TAACTATAGAGTCAACATCAACCTTATGGTATTCATTTAAAGATTTCTCCGAACAAGCCTTAAACTCAAACTTAACCAA
AGAATT
ATTCCTTCTTTTAGCTTTGCTCAATAAGGCAAGATCGTTTATAGATATTTCTTGATTACCATGGAGTCTAGATAAAAAA
TCATTAG
ATGTCGCATGATACCTATTTTTAATAGATGTAATGACAAATTCTCTAATCTTGTTTAAAGATAACTTAGATGCCAAAAC
CTCAAG
ACAATCCCTATGTAGTTCATTTGAAAATGTAATTCCATACTGATTAAGCAGATCTTTAAGCTCAGACTTAAGCAAAAAA
CCCAAA
TAAACAAATTTATTTAAGCGAGAGCAAACCCTTCCTTTTTGAATTATTTTAAAGCGTACGCTACTATTATTAGATTGAA
ATTCTAC
P
AACGCCAACATCTGATGAAACCCGTTTAGATACTTCACTGGTAAATTTTGGCGCGCACACAATTGTAACTTTTTCGAAG
CTAGAT
TTAAAAATTTTTAACTGACCATCCAAGCGCTTAAGAGAGTCAAAATCGCTTTTTATTTCAAAAGCTTGTAGGCTTCCAT
TGGCAA
--.1 TAGCCAAATCAGCTCTTCTGCTCCAGTTAGCAACAACCATTTCATTAATGATCGTTGCATCACTAAGCATGCCTTTTTT
1-, .3 CATTCAATTAGGGCTATTTTAACTTCCTGCTCTCGCAATAACTCAGCCATGTTAATCACACTCACTTCACGTTGATTTT
GCAACTAACAATTAAAAACTCCAGATTATGTTACTTAACACTCATTTTAAAAATCAACCAATAACTATTTTTATTTAAG
TATTTCTT
.31 .3 TGTATTTTGAATAATCATAAGGCTAATATATTTATTACGGTTCATATCCAAATAATCAGCCCACCACTGCATCATTAAA
CGCCGC
TCATCCAAATGCTCGGAGGTATGGATATATGCCGCACGTACATTATTACGCTCTGAGTGGCTCAGTTGCCTCTCTATCG
CGTCAT
CACTCCATAACCCCGACTCCCCCAACGCACCACGCGCCATAGTCCTAAACCCATGCCCACACACCTCGGTTTTAGTATC
ATAGCC
CATCGCACGCAATGCGCTGTTTACCGTGTTTTCACTCATAACCTTAGTTGCGTCATGATCCCCCGGAAAAAGCAGCTCT
TTATCA
CCACTAATCTGCTTTAACTGGTTTAATAAAATCATCGCCTGTCGACTAAGCGGAACGATATGTTCCTCTTTCATCTTCA
TGCCTCG
GTACGAATAACGCACACCTTTAATTTCTTCTCGCTTTGCAGGTATACGCCAAAGAGATTTATCGAAGTCGAATTCATCC
CAACGT
IV
GCGAAACGTAATTCACTGGAACGCACAAAAGTTAGCAAGGAAAGCTTGACCGCAATCCGTGTCATTACACGGCCACGAT
ATGC n ,-i AGCAAGACGTGCAAGAAACTCAGGGAATCGGCTAGAAGGTAAAGCAGGGTAATGTCGCGCTTTGGTTGTCGATAGCGCA
CCA t=1 tl GCCATATCGCTGGCTGGATTTGAGTCGATGTAATCGTTCTGTACGGCATAACGCATAATGGCTGTGACGCGCTGTTGCA
o CTGAGCGACATCGTGTTTGCCACTGGCATCAACTTTTTTAATCGGGGCTAACAGGTGGCTGGTTTTAAGCTGCCGAATG
TCGGA 'a o CGAACCGATATGAGGGAATATATAAAGCTCAAGATAGCGAAGAACGCGCGATCGATGGTCTTCACTCCAGCGCTTGTTA
CTGG tt n.) un CATGCCATTCTCGGGCGATAGCTTCAAAAGTATATGCCCCCGAATTCTCGGCCCGAGCTTCTTTTTGTACGACTTTTGG
GTCTAT
GCCCTGTACTAAAAGCTTTTTAGCTTCATCGCGTTTTGCTCTTGCCTGAGCAAGCGTCACAGTAGGCCAAACACCAAAC
GCAAG w o w ACGATCCTCTTTTTTGTCAGAGGGACGTCTGTATTTCATGCGCCAGTATTTGGAACCTTTGGCCGAAACCTCAAGATAC
AAACCA
i-J
CCACCATCGGCCATTTTGTAGGTTTTGTCTTTTGGCTTTGCGGTCTCGACCTGTCTGGCGTTGAGCTTCATTTGGGGGC
ACATTT
4,.
w CTAATCGAAGTTAAGATGCCCCCAATTATGCCCCCAATGATATCCGGATTTCAACGGACAACCTCGGAAGACGCAGGAC
GAAA oe AAATCGCTGCAAGCATTGATTTTAAAGGGATATTTGGACTTTCTCGGATGGTCTTGGAAGTAAGAATGGTGCCGAAGGC
CGGA
CTCAAACATCAAAATAAGTTAATGATAAAAAACAAATAATAAAACACAACAATGAAATATGCCCCCTTTTGTGCCCCCA
CTGTTT
TTCTGACCAATCTATTTTCAGCCCATCAATAAATCGGAAAGTTAAATCATTTTTAATCAGTAAGTTTGGATCCGTAGCT
CGGATC
CAAACCAGTGCATCTTTTATCCACATAAAAAATTTTTTTTCGAAAGAACTGTTCACACTGTTCACCTTTCTGTTTTCTC
CTTTTATT
TCAGAGTGATAGGTGGTGAATAATGGGTGAAGGGTGAACATTCGATTCTTCACCTCCGGCATTCTGCCGATGTGACTCA
TACC
GGTGATTAATCCTCCGCACTGAAATCACTCAGGAAGAAAAAAGTTTTTTTTGATTTGATTGTTCACACTGTTCACCTTT
CGTTTTT
P
CTCTTTTAATTTCAGTGTGATAACGGGTGAATATACGGTGAAGGGTGAACAGTGGATTGTTCACCTTCGGGGGATATCG
GGAT .
, AAAAAAAGACCGGCAGATGCCGGTCAGGTGGGTCAGGCTGTTGTAGGGTCGTCACATTTTGG CAG
CCAGTCGCCGTAGCTTTC
, 1¨
.3 CTCTTTCAGCGTCAGGTTGGTCTGTATCCCCTGTTTGGTATGGCGTTTCTCGTAATTCAGTCCGTATTCCTTCAGCATC
ACCGGCA .
w GCCCCAGCCCGAACATTTTCAGACTGAGTACATTCCGGTAGCCGTTTGCCTCCATGTAGGCCAGATAGGCGTGATAGAG
GTATT "
, , , TACGGTAATTGCGCGGGATGATACTGGCGTTCCCCATATACATGCCGCTGGTCTGCGGCAGGGTTTCCAGATAGCCGAT
, N, N, TCAAACGTCGGGTCGGCATCCCGTTTGATGTTCAGTGCCTCGTCTGAGTTCTGCTGGGACTGAAGCAGTGACCGGGCGA
GCAT
CGGGTCGCTGAACTTCTGCATCAGGTGACGCACGATGACCGCCAGCTCGCGGGTGATTTTGTCCTTAAGCTGCGGGTCG
CGCT
CCTGCGGGGCTATCTGTTCCGGGAAGTGAATAATCACCCGTCGGCGTGACACGCCGCCGCTGCGGTCGGTGAAGCGCAT
CGG
GTTATTGTTCACGGCCAGAATCACCGCCGGGATGTGCGTGGAGTACGCATCCCGGTATTTCGGGTCAACGGACACCGCA
TCGC
CGCCGGTGATGGCCTTGAGTCCGGCACCGTCGCCGCTCCATTTTTCCTGGTCCGGCAGGCGTATCAGTGAGAAGCCAGT
TAAC
GCGGCACGTTCACGCGGGGATTCCAGCGTCTCGATGGTGGCCGACGTGGCGTTATCCTCCCCGGCCAGCAGGGTGGCTA
TTTC 1-d GGCCATGATACT
n ,-i m ,-o 21 Sequence removed TTTGAGCGGCATAAATTACCACTGAAAGCCCTTAAACGTTACTCTACTGTGGACACTGTGTGGACACTCTCGG
CCTCAGTACCA w o w from P2 (replaced CCTCTTAGCGGATTAAGAGAAATGGCGTCCTGAAGGTACTCTGGCGCAAAATGAGCGTAAACCATAGTTTGCTCAATCC
GCGT =
'a GTGACCTAGTATCCGTTGTAGCGTGATAATACTTCCTCCATTAATCATGAAATGAGTGGCAAAGCTGTGCCTTAGTGCA
TGTGT o 4,.
w w vi with kanamycin GGCTTGCCCCATTGGCAAATCCGGTTTTATTGCTTTCATTGTTCGTCTGAAGCGAGGGTAATCAGCATCAGGGAATAAA
AAACC
marker; Example 3) TCGTTTGTTATCCGCGATCATTTTGGCAACAGCCTCTGAGATCGGGACGGTGCGTGGTTTGTTTGTTTTCGTTTTAACA
AACGTG w o w ACGCGGTTATGGATGATATTTTCTGCTTTCAAACGAGCTGCTTCTCCCCAACGTGCTCCTGTACTCAGGCAAAGAATCG
CAATCT
i-J
TTTTATTGTCGCCGTCAAGTGCTGCAAGCAGTAAGGCAATTTCTTCCTGTGTTAGATAGCCTGTTTCTGGTTTTTCCTC
CTTAAGC
4,.
w CTTTTTGTCCCTCTGATAGGGTGCTCACCAAAGAATAACTCCGCTTCAATCAGGGCTGTAAACATGCCGCTAATACATG
TTAAAT oe CACGATTGATACTCGAAGGTTTAATACCCTGACTTCTTCGGGTGGCGCAGTACTGGCTGATAAGCGATTTCGTAATTTG
AAATG
CCAAGATTAGATTTCCCATGCTCTTCGTGTTTACCCTTTAAATCCC
ACCAGATCTGTGTCAGCTCCGACAGACGTCGCTTGTCTGTTGGTTTTGATAGCCATTCTTTATTGTGGTGGTTGTACAA
CGTGTA
TTTCTCGAAAGCGACAGCTTCGCTTTTCTTATCAAACTTCCTACGGATGCGTTTTCCATTACGTCCAGTAGGGCGGATG
TCCACT
TCATATCGACCATCATCGAGTTTTTTGATTGCCATCAGAAAACCCTCCGAGTGGTGTGTTTTTTTGCGACTACTAATCG
CTTTTTT
CGTGGTGGCTGAAATTTAGCCACCAATAGTAGGCACTTGTGATGAATATATTCACGATGAATTGTTAACCAGTCTTTTG
ACCGG
P
AGTGGGGCGACGTTGTTTCGTTTTGCCCAAAGTGTGCGAGAGCGGGCGCAATTTGCCCGGACTCAGGAGCGATCTGATT
GGTC .
, ATGAACCATAAAGTGTATTTG GTGAATTGTG G G GTCTG CAG GATGTTCATCATGACATCTGTTG G AG
GTGTTG AACGACCACTT
, 1¨
.3 TCATAGTAACTCAGCGTGCCATACGGAACCCCTGTTAAATCAGCAAGTTGTTGTCTGCTCAAATACTCTGATTTTCGCA
TTAAGA .
CTATCTTCTCGCTTATCGTGTTTGACATGGTGTTTAGATCTCAATAGTATTTAGTTTAGATGTAGATTGTTTAGTGCTT
GGATGTG "
, , , GGCACTAAAAGGCATTATAAGACATTAAACGCAATTCATGAGGGCTAGAGGACGACATGAGCAAGCAAGTAACACTCAT
, N, N, TGATGCGATTCCTTATCAGGAGTTCGCAAAACTAATAGGAAAATCGACAGGAGCGGTTCGTCGGATGATCGATAAAGGA
AAG
CTGCCTGTAATTGATATGACCGATCCACAATCAGCTTCAGGTCGTGCAGGTGAATATTGGGTATACCTTCCGGCATGGA
ATAAC
GGACTAAAACTGGCTTATGAAAGCCGCCCTAAAGAGATTCGTGACGGCTGGTTGATGTGGTTAGGTCTCGGTGAACCAC
GTTA
AGGAGAACCGTATGAATGAGCCTCGTTGTATTGCTCAGTTACTGCGTAACGAAAGCCCCAGGGCGATTGACTTCACCAT
CACC
CACGGTAAGGGGCGTAAGGGAATCATTATCCGCACCAAAAAACAGAGTCCGTTAAAAAAGGCTCTGACCTTTCTGAAAA
GCCG
GAGGGTATGGAAATGACAGTGATGACGCTCAATCTCGTTGAAAAACAGCCAGCAGCTATGCGCCGGATAATTGGTAAGC
ATCT 1-d TGCCGTTCCTCGCTGGCAGGATACATGTGATTATTATAATCAGATGATGGAGCGCGAACGGTTAACGGTTTGCTTCCAT
GCTCA n ,-i GTTAAAACAGCGTCACGCAACGATGTGTTTTGAAGAAATGAACGACGTCGAACGTGAACGACTGGTATGTGCAATTGAT
GAAT t=1 1-d w TGCGTGGTGCATTCTCAAAACGCCGTCAGGTTGGCGCAAGTGAGTATGCATATATTAGTTTTTTAACAGTCAGTCAGCG
TCGTA =
w o CTTTATTTATGCATGCCGGATTGACTGAAAAAGAATTCAACCAGCCATACTGGCGAATTAATGAAGAGTCATGTTACTG
GCGTG 'a o ATG CTTTATTCCGTG CATTACGTGAATTATTCAGTCTGTTTGAGTATG
CACCGACAATTCTGACGTCGGTAAAACCG GAG CAAT
w w vi ATCTGCATTAAGTAATTAACCAGAGTTTTTAACGCACTTAATTGTGCGGGGCTTCTTTTTGCCTGGAGAAAGTTATGCA
TACAGT
TTCTGAAAATCAGTGCGGTATATACGCATTACTGCTGCAACAGGCCAGAACCGAAGCACAGGCCGACGCTGCGACGCGC
TTTT n.) o n.) CTTCTCATCTTGATGCCATGATTCGCCACATCACAAAGGCGGAGTTATCCCGCGTGGAGATAGTCGAGCTGCTCAGTCA
GGAGT
i-J
CGGAAAAATTTCACAATATCGGATTGTCTCGCGGGGAGGTGCTTTGATGTTCTGTTCTCGTGCAGTTGTATTACTGAAT
AACGC .6.
.6.
n.) CTTAAAAATCGCCGTTATGAAAAATGGCGATTTGTCTCTTATTCAACTTGGTCTTGATAAAGAAAAACGCGAAATAACT
GAATC oe TGTTATCGCGATTTATCAGAGTGAATTAAACCTCCTGTCTGATGTGGTCAATTTACTTGTTAAACGCGCTGTATTTCAC
AAGCAA
ATTTCCTCCGTGGATGAACTGACGAAATTAACGACAGAAATCGCCAGCTATTGCGCTGATGAATTTAAAAAACTGAACG
ACAA
AAGGAACTGGTAATGCCGGACAACGTAGATTTTATTCAGGAACAACAGGCTGAATTACTGGAGCGCCAGATTAACGCGG
CAA
GGGTAAAACATTGCGGTGCTTCTGCGCTGGTTTGCGAAGAGTGTGACGCGCCAATACCTGCTGCCCGTCGTGCGGCTTA
CCCG
TCAGCCACGCGTTGTGTTTCCTGTCAGTCAGTCTTTGAAGCAAAAAACAAACATTACCGGAGAACGGCATGAGTATTCG
TATTG
AAATTGGCGAACGTTATGTCGTTACCAGTGACAGCTTTCAGTTTATTCTCCACGAGAAAAAGAGAGCGGAAAGCGGTAA
AAAC
P
GCCGGTCAGGAATGGCTGGCGGTGGTTGGTTATTACCCGAAATTAAGCCAGCTCGTTTCAGGCCTGATGCATCACGATA
TTCT
GACCGGAAGCGCAAAGTCTTTTGCTGATTTAAACGTGCAGGTTGAGCAACTCAGCAAGCGTTGTTCAGAGGCTTTTGGC
TCAT
--.1 ATGGCCGTTAAAGCCTCCGGGCGTTTTGTCCCTCCGTCAGCATTTGCCGCAGGCACCGGTAAGATGTTTACCGGTGCTT
.6.
.3 TGGAACGCGCCACGCGAGGCCGTCGGGCGCGAAAGACCCCTTACACGTGACGAGATGCGTCAGATGCAAGGTGTTTTAT
CGATTAACCGCCTGCCTTACTTTTTGCGCTCGCTGTTTACTTCACGCTATGACTACATCCGGCGCAATAAAAGCCCGGT
GCACGG
.31 .3 GTTTTATTTCCTCACATCCACTTTTCAGCGTCGTTTATGGCCGCGCATTGAGCGTGTGAATCAGCGCCATGAAATGAAC
ACCGAC
GCGTCGTTGCTGTTTCTGGCAGAGCGTGACCACTATGCGCGCCTGCCGGGAATGAATGACAAGGAGCTGAAAAAGTTTG
CCG
CCCGTATCTCATCGCAGCTTTTCATGATGTATGAGGAACTCAGCGATGCCTGGGTGGATGCACATGGCGAAAAAGAATC
GCTG
TTTACGGATGAGGCGCAGGCTCACCTCTATGGTCATGTTGCTGGCGCTGCACGTGCTTTCAATATTTCCCCGCTTTACT
GGAAA
AAATACCGTAAAGGACAGATGACCACGAGGCAGGCATATTCTGCCATTGCCCGTCTGTTTAACGATGAGTGGTGGACTC
ATCA
GCTCAAAGGCCAGCGTATGCGCTGGCATGAGACGTTACTGATTGCTGTCGGGGAGGTGAATAAAGACCGTTCTCCTTAT
GCCA
IV
GTAAACATGCCATTCGTGATGTGCGTGCACGCCGCCAAGCAAATCTGGAATTTCTTAAATCGTGTGACCTTGAAAACAG
GGAA n ACCGGCGAGCGCATCGACCTTATCAGTAAGGTGATGGGCAGTATTTCTAATCCTGAAATTCGCCGGATGGAGCTGATGA
ACAC t=1 tl CATTGCCGGTATTGAGCGTTACGCCGCCGCAGAGGGTGATGTGGGGATGTTTATCACGCTTACCGCGCCTTCAAAGTAT
o CGACACGTCAGGTCGGAAAAGGCGAAAGTAAAACCGTCCAGCTAAATCACGGCTGGAACGATGAGGCATTTAATCCAAA
GGA 'a o TGCGCAGCGTTATCTCTGCCATATCTGGAGCCTGATGCGCACGGCATTCAAAGATAATGATTTACAGGTCTACGGTTTG
CGTGT tt n.) un CGTCGAGCCACACCACGACGGAACGCCGCACTGGCATATGATGCTTTTTTGTAATCCACGCCAGCGTAACCAGATTATC
GAAAT
CATGCGTCGCTATGCGCTCAAAGAGGATGGCGACGAAAGAGGAGCCGCGCGAAACCGTTTTCAGGCAAAACACCTTAAC
CAG n.) o n.) GGCGGTGCTGCGGGGTATATCGCGAAATACATCTCAAAAAACATCGATGGCTATGCACTGGATGGTCAGCTCGATAACG
ATAC
i-J
CGGCAGACCGCTGAAAGACACTGCTGCGGCTGTTACCGCATGGGCGTCAACGTGGCGCATCCCACAATTTAAAACGGTT
GGTC .6.
.6.
n.) TGCCGACAATGGGGGCTTACCGTGAACTACGCAAATTGCCTCGCGGCGTCAGCATTGCTGATGAGTTTGACGAGCGCGT
CGAG oe GCTGCACGCGCCGCCGCAGACAGTGGTGATTTTGCGTTGTATATCAGCGCGCAGGGTGGGGCAAATGTCCCGCGCGATT
GTC
AGACTGTCAGGGTCGCCCGTAGTCCGTCGGATGAGGTTAACGAGTACGAGGAAGAAGTCGAGAGAGTGGTCGGCATTTA
CGC
GCCGCATCTCGGCGCGCGTCATATTCATATCACCAGAACGACGGACTGGCGCATTGTGCCGAAAGTTCCGGTCGTTGAG
CCTC
TGACTTTAAAAAGCGGCATCGCCGCGCCTCGGAGTCCTGTCAATAACTGTGGAAAGCTCACCGGTGGTGATACTTCGTT
ACCG
GCTCCCACACCTTCTGAGCACGCCGCAGCAGTGCTTAATCTGGTTGATGACGGTGTTATTGAATGGAATGAACCGGAGG
TCGT
GAGGGCGCTCAGGGGCGCATTAAAATACGACATGAGAACGCCAAACCGTCAGCAAAGAAACGGAAGCCCGTTAAAACCG
CAT
P
GAAATTGCACCATCTGCCAGACTGACCAGGTCTGAACGATTGCAGATCACCCGTATCCGCGTTGACCTTGCTCAGAACG
GTATC
AGGCCTCAGCGATGGGAACTTGAGGCGCTGGCGCGTGGAGCAACCGTAAATTATGACGGGAAAAAATTCACGTATCCGG
TCG
--.1 CTGATGAGTGGCCGGGATTCTCAACAGTAATGGAGTGGACATGATGGCAAAAATTCACGAGGTAAAGCTGCACGCAAAA
un .3 TTCGACCTTGTACTGGAAGGAAAGAAACGCGCAGAGTTTCGGAAAAAAGATCGTAATTATGAGCGCGGGGACACGTTGA
TGCATGAATGGGTGCAGGGTGTGTTTACGGGGCGAAAGGTTGAAGCCCGGATAACAGATGTTACTGACCTGTCAGACTG
GCT
.31 .3 GGAAGATTATGTCTTGCTGCACAGAATACTAGGTGAGATACTGCCGCTGACTGTCAAGCTGGCAGTATCCTCCACATTT
TTTAT
AAATCTAAGGCGAAGAACGGTGGCAATATATTTGCTTTAAATTGTAAATAAGCAAATTATTCTAAGCCACAAATGATAT
CAATT
GAGTATCGATTTTCGTTCGAATATAACCATAACGCCAAGCGTCAAATGTAAGTCATCTATATGTGATTCGTATTCATAT
TGGTCA
GCATCAGGAGATAGTAAATGCTCTGCTGCTGTAAAAACATCAATTGTAACAGATATATCGTCTGGAATTTCTTCATTTA
ATTCGG
ATTGTATGAATGGAATGAACAGTTTAATGCTAGGCCAAGACTTGAATTTCCTGTAGGGCCTGTGTGTTTAAAGTATTCA
AGATT
IV
TCTTCTTATGTCAGAAAATAAAAGACTTTTACAGGGGGCATTTCCTTTAACTTCTATTGCACATATTGGAATGTCGAAA
AATGGT n ,-i CTGCTGTCCAATATGGCAATATCAATTCTGCCTGATCTTGTTGTGTTTGTGTTTTTTCTGACAGTTTTTTTTGAGAATA
TTTTTTGG t=1 tl GGGTCAGACCGTTTCGATAAAGGAACTGTTGCATTAATGAATTTATTTGTATGGTACTCAAATATAACTTTGTAATCAC
o GAAAAGATTTTATTTCTAACAACGATAGACCTATAGATACGGTAGCTACATATTCAGTGTTTATTTTTGCACCAGACCT
GAAATC 'a o CATTAAATAAGTTGCGTCGGCTGACTTTTTCATTCCATCTTTTACAGCTTTCACAATATCCATGTTATTCATATCAACA
CCTTTTAT tt n.) un ATTCCAGAATTATAAATCTTAATGATTGATTTGTTTGTGTGTTTAGGTTACTAGATTGACGTACTTATAGCACATTCTG
ATTTTGA
AATC AC CATC CTT G G GTAAAG C AC AG CCTATCACTATTG G TTTA G TACTG T G CTG
TAATAG TAT CA G ATTAA G TTAAATC C ATTT n.) o n.) ATTACTGCTCTAACATCTTTGCTTTCATCACATAAACAATCTAAAAGACTATCCCA
i-J
TTCAGTTTGTTTTTTACCAAATCCATAAACAGCCTCTATATCACCGGATTTCCATATATAGATTCCGTTATCTTTCAAT
TTTTGATG .6.
.6.
n.) TATTTCATGTATATG CTTTT GT G TTTTTTCATG GTTACATATTTTGATGAAGTCTTTG CTTGAAATG
CTTTTG AATG A CTCAAAA G oe TA G TAACTTTTG TATTTAAACTAAG CTCTC CTG A GTTG ATTG ATT CAATC AAAG C AG T CAATA
G ATTATC AC ATT CA GTA CTAA G
TAAGTCTTTATG CTCTGTTAATAGAATATTTGATAAGAAATCACAATCAG CTAGAATCCTTGTTTTTATG C C G
AT G G CATTGATG
ATTTGTG AC AT CTTAAATAAA CTAC CCTTACC GTC AACG G CAA CAATG CAGATTTTACTCG G
GTTGAGTTCATGTCCGTTAATTT
TTTTATAAAGTG C ATATA G AAC G TTT GT CT CTG TTTTC C CTT CAAC AA G
CAAAACTTCTTCAGAAAATAAAAG GTATGATGAATT
AG AAAG CGTGAATG CTG AG TG CAATTG CG GTGATG AAGATTTATATAATTCTTC G ATTTTTTC AG
ATATAGTCTTCCTTG CTATG
GTTCCATTAGAATCCTTACAAACCTGAATCG CATTTG CTGCATG CTTTG CAGAAAG CATACTG G CTG
AGTG AG TTG ATATTATA
P
AC CTG ATAC CCTG ATTCA CTTAATGTG AC AA GTG ATTCT CTG ACAG AATTAATG G CTGAAG G
GTGTAAATATAA CT CAG GTTC A
TCAATGAAAATCAAAGTGTTTGATTTTTTTG ATTCG CTGTTTTCTTTTTTTATTTCG G C CA G G TATTG
AATTAATG CCATTTGAAT L."
--.1 GGAACGTTGTGTTCCGTGACCAAATCGGCTGATATCTCTCATTACCGGTTCATCTTCCCGAGACTCAAAAACTTTCAGA
o .3 G GATTTAAATATCTCATCTAATGTCG GT G TG G G AAAG T G TAACTTTA CA CTTAC GT CA G G
AC AC CT G AG T CTATTTTATTAA G G CTTT CTAATCTG TT CTC AC C G TT GT G A G AAAG
ATATTTA C CTATTTCTG ATAT G TTTTTTG A
.31 .3 AAATTTTTCTTC GTG TTCTTG TTTTATTTC AG AAA CAATTG C G G AAAG TAT CTTTC CTATTGTG
GTCGTGTTTTTG CATTTTG TTG A
GTCTTCGACAG CGTCAGACATTG CAG G GATATGAATTGGTTCCG GAAATATATTG G AG ATTG CAC
CATCTATG C CG CCAG G GT
TTTTCTTCCACGTGGTACCGTCATATACATCCAGACTTTTTTTGGCTTTTCCTGTTTCCTTATTAAATTCCTGTCTTCT
TGCAAAGG
TAAG AGTC CC GT CAATTATAAACG GAG CTATTTTTTGTTG ATTCTCTTCTG TTAA CAAAGACAG AG
TAT CATCTGTTATAC CTTG
AATAACGCCTTCAACGGATACGGGGTGTGTAGGATCGTACACATCTGATTCTGAAATCAAAGAGCCATCTAACAGCCAC
TTAAT
TG CTAAGATAATATTTGATTTTCCTGCGTTATTATAACCAACTAAAG CAGTGAAG G G G CG CAAAATAG C
CG ATG TTG ACTTA CA
IV
AG AAC G AAAG TTG CTAATTG AAA CT G AA G CAAG A C G TACA G TC ATTATTTTT C
CTTAAAT G TG CTATTTG TAT G CAATG AG TTC n ,-i ATACGAAACGCTTTTTTACATTTTATAGTCGTTGCATTCAAGGGTGCATGAGATTGCATTAAGGGAAACTGTGATATGG
CTTGG t=1 tl CTTTTGACTG GAAATACTGATG G CTCATTAGTTTTATTAAG GTG CATTAAAACCG C CC CGTG AAG
o 'a o .6.
n.) n.) un AAAGCACGGCGAGGCGGGGAAAGCACTGCGCGCTGACGGTGGTGCTGATTGTATTTTTTCAGCGTCTCAGCGCGTCGTG
ACG
GCACTTAGTCTGCCCGTTGAGGCGTTGTGTGTCTGCGGGGTGTTTTGTGCGGTGGT
w o w o 22 WilcktypecloDF13 GCGCTGCGGACACATACAAAGTTACCCACAGATTCCGTGGATAAGCAGGGGACTAACATGTGAGGCAAAACAGCAGGGC
CGC
w 4.
4.
on GCCGGTGGCGTTTTTCCATAGGCTCCGCCCTCCTGCCAGAGTTCACATAAACAGACGCTTTTCCGGTGCATCTGTGGGA
GCCGT w m GAGGCTCAACCATGAATCTGACAGTACGGGCGAAACCCGACAGGACTTAAAGATCCCCACCGTTTCCGGCGGGTCGCTC
CCTC
TTGCGCTCTCCTGTTCCGACCCTGCCGTTTACCGGATACCTGTTCCGCCTTTCTCCCTTACGGGAAGTGTGGCGCTTTC
TCATAGC
TCACACACTGGTATCTCGGCTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTAAGCAAGAACTCCCCGTTCAGCCCGA
CTGCT
GCGCCTTATCCGGTAACTGTTCACTTGAGTCCAACCCGGAAAAGCACGGTAAAACGCCACTGGCAGCAGCCATTGGTAA
CTGG
GAGTTCGCAGAGGATTTGTTTAGCTAAACACGCGGTTGCTCTTGAAGTGTGCGCCAAAGTCCGGCTACACTGGAAGGAC
AGAT
TTGGTTGCTGTGCTCTGCGAAAGCCAGTTACCACGGTTAAGCAGTTCCCCAACTGACTTAACCTTCGATCAAACCACCT
CCCCAG
GTGGTTTTTTCGTTTACAGGGCAAAAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATC
P
.
, 1-, 23 MutantcloDF13ori GCGCTGCGGACACATACAAAGTTACCCACAGATTCCGTGGATAAGCAGGGGACTAACATGTGAGGCAAAACAGCAGGGC
CGC , --.1 (higher copy number GCCGGTGGCGTTTTTCCATAGGCTCCGCCCTCCTGCCAGAGTTCACATAAACAGACGCTTTTCCGGTGCATCTGTGGGA
GCCGT
on cloD13_cop3;
GAGGCTCAACCATGAATCTGACAGTACGGGCGAAACCCGACAGGACTTAAAGATCCCCACCGTTTCCGGCGGGTCGCTC
CCTC , , , , single mutation TTGCGCTCTCCTGTTCCGACCCTGCCGTTTACCGGATACCTGTTCCGCCTTTCTCCCTTACGGGAAGTGTGGCGCTTTC
TCATAGC
versusmMcktypeis TCACACACTGGTATCTCGGCTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTAAGCAAGAACTCCCCGTTCAGCCCGA
CTGCT
shown underlined GCGCCTTATCCGGTAACTGTTCACTTGAGTCCAACCCGGAAAAGCACGGTAAAACGCCACTGGCAGCAGCCATTGGTAA
CTGG
andinbold GAGTTCGCAGAGGATTTGTTTAGCTAAACACGCGGTTGCTCTTGAAGTGTGCGCCAAAGTCCGGCTACACTGGAAGGAC
AGAT
TTGGTTGCTGTGCTCTGCGAAATCCAGTTACCACGGTTAAGCAGTTCCCCAACTGACTTAACCTTCGATCAAACCACCT
CCCCAG
GTGGTTTTTTCGTTTACAGGGCAAAAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATC
Iv n ,-i m ,-o t..) =
t..) =
'a c., 4,.
w w u, Table 7: Example Plasmids and Copy Numbers w _______________________________________________________________________________ ________________________________________ <
w i Common Vectors Copy Number OF11 Incompatibliity Group Control t.) OC
pUC -500-700 0,481 (derivative) A Relaxed pBR322 -15-20 pME31 A Relaxed PET -15-20 pBR322 A Relaxed pG EX -15-20 pBR322 A Relaxed pColE1 -15-20 ColE1 A Relaxed 0 IpR6K -15-20 R6 K ' C Stringent .
.
oe ,pACYC -10 p15A
B Relaxed .
0 ..
i ..
i IpSC101 -5 pSC 101 C Stringent ipB1Liescript -300-500 0 1E1 (derivative) and Fl"
A Relaxed pGENI -300-500 pUC and Fl -A Relaxed .0 n ,-3 ril .0 w <
F, t.) t.) !A
[00193] Delivery of the CGV was enumerated by plating on LB + streptomycin +
spectinomycin plates plates. Abudance of the target strain was enumerated by plating on LB
with streptomycin only.
Clinical monitoring of mice [00194] The body weight of the mice were monitored throughout the study and the mice were scored 0 ¨ 6 based on their behavior and clinical signs (Table 5). Mice were euthanized if reaching score 3 or 20% weight loss.
Results [00195]Microbiome analysis of mice prior to inoculation No bacteria was detected in 2 out of 3 of the pooled samples collected prior to inoculation. One of the pooled samples had 6.54 10g10 CFU/ml of small white colonies. MALDI analysis indicated Paenibacillus odorifer with a score value of 1.71 and as second most likely Staphylococcus xylosus with a score value of 1.43 both with a low rank quality. Also in the 2 other pooled samples 3-4 10g10 CFU/ml of small white colonies appeared after 48 hours of incubation.
[00196] At 24 h after inoculation the CFU levels in the faecal samples ranged from 6.1 ¨ 8.6 10g10 CFU/sample as determined on the LB+ strep agar plates. Similar levels were observed day 2 after inoculation. No significant differences were observed with in each of the 2 inoculation groups.
[00197] On the LB+ strep + spec agar plates, no colonies were observed day 1 in in any of the groups.
Day 2 CFU counts ranging from 1 to 5 log10 CFU/sample was observed in the inducer treated groups but not in the vehicle treated groups.
Layout of animal study [00198] Twenty four mice were used in each murine intervention study.
Clinical mice score [00199]Mice did not show any clinical signs of infection or discomfort during the entire study period.
Induction killing of MG1655-pks [00200]Faecal matter extracts were plated out on on plates containing streptomycin to determine the CFU of the E. coli MG1655-PKS strain (Fig 8). Streptomycin CFU counts show no difference between the various treatment groups.
[00201]When plating the faecal samples on spectomycin and streptomycin to determine delivery of CGV pSNP114 (because this CGV carries a spectomycin resistance marker) we observe a significant increase in CFU, and thus CGV delivery, after 48 hours (Fig 9). When the CRISPR system was induced we observed a significant decrease in the mean CFU counts.
Discussion and conclusions [00202]We successfully demonstrated guided nuclease antibacterial (CGVTM) delivery using Synthetic NanobioticTM platform, SA100, into E. coli MG1655-pks in the murine gut model. Thus, delivery of an antibacterial using non-self-replicative particles to a microbiome in vivo was .. established. A statistically significant reduction in CFU counts was observed using the activated CRISPR system on the CGVTM.
Example 6: Production of Transduction Particles By Essential Functions in Trans [00203]Native phage are engineered to convert them into DNA carrier vehicles (transduction particles) for our CRISPR-Guided VectorsTM (CGVs). The particles can transduce target bacterial to introduce the vectors, from which CRISPR/Cas systems or one or more components thereof are expressed.We make use of lytic propagation in which essential helper functions are provided only by the host cell (SA800 & SA900).
SA800 & SA900 [00204] Production of SA800 & SA900 particles is based on lytic propagation on a production host bacterial strain. We engineer native (wild-type) phage by inactivating essential phage functions (e.g.
by deleting structural genes) and adding nucleotide sequences encoding the CRISPR-Cas systems.
[00205]By providing the essential genes on a separate helper plasmid, we can make the CGV-phage hybrid propagate on the production strain. However, CGV propagation is not possible on any other bacterial strains due to the lack of the helper plasmid.
[00206]We refer to Figure 10. To construct a non-self replicative particle comprising a CGV
comprising nucleotide sequences encoding components of a CRISPR-Cas system, we engineer a native phage to contain a phage packaging signal and genes needed for phage DNA replication. The CGV may contain multiple phage genes as long as one or more essential genes are deleted or mutated to make the CGV-phage hybrid non-self replicative on strains not expressing the essential function(s).
In the production strain, this function(s) is provided in trans expressed from a plasmid or the bacterial cell chromosome.
[00207] In one example, the production cell will contain a plasmid with a gene encoding a structural .. phage protein, that is expressed during CGV propagation and packaging. A
vector is constructed comprising a native phage genome in which this gene is mutated and into which are inserted nucleotide sequences encoding components of a CRISPR-Cas system, forming a CGV-phage hybrid.
Thus, the CGV-phage hybrid is non-functional to package the CGV DNA into transduction particles in the absence of the helper function provided in trans.
[00208] In a minimal version, all essential functions (ie, essential for packaging) are carried by the production host cell (eg, on a chromosome or one or more plasmids) except for the phage packaging signal and a phage DNA replication machinery (including phage origin of replication) which are instead carried on the CGV. Importantly, the DNA replication machinery may not need originate from the same phage as the essential genes on the helper plasmid or chromosome. For example, the DNA
replication machinery from phage lambda may be included on a CGV (and used to replicate this) carrying a phage P2 packaging signal and packaged into P2 phage capsids (eg, wherein the capsid proteins are encoded by a helper plasmid or chromosome of the production strain cell).
[00209] The CGV is capable of replicating as a lytic phage (i.e. propagation by infection-lysis-reinfection cycles) on a suitable production host strain carrying the helper function(s). However, in non-production cells such as clinical target bacteria, the phage cannot propagate by the lytic cycle but merely functions as a DNA delivery vehicle, thereby delivering sequences encoding one or more components encoding a CRISPR/Cas component(s) (or alternatively another antibacterial agent or other protein or RNA of interest).
Table 1: Example Bacteria t..) Optionally, the host cells are selected from this Table and/or the target cells are selected from this Table (eg, wherein the host and target cells are of a o t..) o different species; or of the same species but are a different strain or the host cells are engineered but the target cells are wild-type or vice versa).
For example .6.
.6.
the host cells are E coli cells and the target cells are C dificile, E coli, Akkermansia, Enterobacteriacea, Ruminococcus, Faecalibacterium, Firmicutes, n.) oe Bacteroidetes, Salmonella, Klebsiella, Pseudomonas, Acintenobacter or Streptococcus cells.
Abiotrophia Acidocella Actinomyces Alkalilimnicola Aquaspirillum Abiotrophia defectiva Acidocella aminolytica Actinomyces bovis Alkalilimnicola ehrlichii Aquaspirillum polymorphum Acidocella facilis Actinomyces denticolens Aquaspirillum Acaricomes Alkaliphilus Actinomyces europaeus putridiconchylium P
Acaricomes phytoseiuli Acidomonas Alkaliphilus oremlandii Actinomyces georgiae Aquaspirillum serpens 2 Acidomonas methanolica Alkapus ransvaaenss o Actinomyces gerencseriae ;3'lihil t l i vi ?.
Acetitomaculum .
Actinomyces Aquimarina N) Acetitomaculum ruminis Acidothermus Allochromatium , hordeovulneris Aquimarina late rcula Acidothermus cellulolyticus Allochromatium vinosum r., N) Acetivibrio Actinomyces howellii Arcanobacterium li i h Actinomyces yovagnas Acetivibrio cellulolyticus Acidovorax Ac Alloiococcus Arcanobacterium lii i Actinomyces srae Acetivibrio ethanolgignens Acidovorax anthurii Act Alloiococcus otitis haemolyticum Acetivibrio multivorans Acidovorax caeni Actinomyces johnsonii Arcanobacterium pyo genes Actinomyces meyeri Allokutzneria Acidovorax cattleyae Iv n Acetoanaerobium Actinomyces naeslundii Allokutzneria albata 1-3 Acidovorax citrulli Archangium t=1 1-d Acetoanaerobium noterae Actinomyces neuii t..) Acidovorax defluvii Archangium gephyra o t..) o Acidovorax delafieldii Actinomyces odontolyticus 'a o .6.
t..) t..) un Acidovorax facilis Actinomyces oris o t..) Acetobacter Altererythrobacter Arcobacter o Acidovorax konjaci Actinomyces radingae t..) o Acetobacter aceti Altereiythrobacter Arcobacter butzleri Acidovorax temperans Actinomyces slackii .6.
Acetobacter cerevisiae ishigakiensis Arcobacter ciyaerophilus .6.
t...) Acidovorax valerianellae Actinomyces turicensis oe Acetobacter cibinongensis Arcobacter halophilus Actinomyces viscosus Altermonas Acetobacter estunensis Acinetobacter Arcobacter nitrofigilis Altermonas haloplanktis Acetobacter fabarum Acinetobacter baumannii Actinoplanes Arcobacter ski rrowii Altermonas macleodii Acetobacter ghanensis Acinetobacter baylyi Actinoplanes auranticolor Arhodomonas Acetobacter indonesiensis Acinetobacter bouvetii Actinoplanes brasiliensis Alysiella Arhodomonas aquaeolei P
Acetobacter lovaniensis Acinetobacter calcoaceticus Actinoplanes consettensis Alysiella crassa Acetobacter malo rum Acinetobacter gerneri Actinoplanes deccanensis ;3' o Alysiella filifonnis Arsenophonus o, ..
Acetobacter nitrogenifigens Acinetobacter haemolyticus Actinoplanes derwentensis Arsenophonus nasoniae 2' , Acetobacter oeni Acinetobacter johnsonii Actinoplanes digitatis Aminobacter , ""
Acetobacter orientalis Acinetobacter junii Actinoplanes durhamensis Aminobacter aganoensis Acetobacter orleanensis Acinetobacter lwoffi Actinoplanes ferrugineus Aminobacter aminovorans Acetobacter pasteurianus Acinetobacter parvus Actinoplanes globisporus Arthrobacter Aminobacter niigataensis Acetobacter pornorurn Acinetobacter radioresistens Actinoplanes humidus Arthrobacter agilis Acetobacter senegalensis Acinetobacter schindleri Actinoplanes italicus Aminobacterium Arthrobacter albus Iv Acetobacter xylinus Acinetobacter soli Actinoplanes liguriensis Aminobacterium mobile Arthrobacter aurescens n ,-i m Acinetobacter tandoii Actinoplanes lobatus Arthrobacter Iv t..) o Acetobacterium Aminomonas r..) Acinetobacter tjernbergiae Actinoplanes missouriensis chlorophenolicus o 'a Acetobacterium bakii Aminomonas paucivorans o .6.
t..) t..) un Acetobacterium carbinolicum Acinetobacter towneri Actinoplanes palleronii Arthrobacter citreus o t..) Ammoniphilus Acetobacterium dehalogenans Acinetobacter ursingii Actinoplanes philippinensis Arthrobacter ciystallopoietes 2 =
Ammoniphilus oxalaticus Acetobacterium fimetarium Acinetobacter venetianus Actinoplanes rectilineatus Arthrobacter cumminsii c,.) .6.
.6.
hilus oxalivorans r..) Acetobacterium malicum Actinoplanes regularis Ammonip Arthrobacter globiformis oe oraosp Acetobacterium paludosum Acrocarp Actinoplanes Arthrobacter Amphibacillus Acrocarpospora corrugata Acetobacterium tundrae teichomyceticus histidinolovorans Amphibacillus xylanus Acetobacterium wieringae Acrocarpospora Actinoplanes utahensis Arthrobacter ilicis l haa Acetobacterium woodii macrocep Arthrobacter luteus Amphritea Acrocarpospora Actinopolyspora Arthrobacter methylotrophus Amphritea balenae P
Acetofilamentum pleiomorpha Actinopolyspora halophila Arthrobacter mysorens Amphritea japonica Acetofilamentum rigidum Actinopolyspora o Arthrobacter nicotianae 03-' --.1 Actibacter .
mortivallis r., Amycolatopsis Arthrobacter nicotinovorans r.,0 Acetohalobium Actibacter sediminis , Amycolatopsis alba Arthrobacter oxydans Acetohalobium arabaticum Actinosynnema r.,7 r., Amycolatopsis albidoflavus Arthrobacter pascens Actinoalloteichus Actinosynnema mirum Acetomicrobium Actinoalloteichus Amycolatopsis azurea Arthrobacter Acetomicrobium faecale cyanogriseus Actinotalea Amycolatopsis coloradensis phenanthrenivorans Amycolatopsis lurida Arthrobacter Acetomicrobium flavidum Actinoalloteichus Actinotalea fennentans Amycolatopsis mediterranei polychromo genes hymeniacidonis Iv n Acetonema Aerococcus Amycolatopsis rifamycinica Atrhrobacter protophormiae Actinoalloteichus spitiensis t=1 Iv Acetonema longum Aerococcus sanguinicola Amycolatopsis rubida Arthrobacter w o t..) o Aerococcus urinae psychrolactophilus 'a o .6.
r..) t..) un Aerococcus urinaeequi Amycolatopsis sulphurea Arthrobacter ramosus o t..) Acetothermus Actinobaccillus o Aerococcus urinaehominis Amycolatopsis tolypomycina Arthrobacter sulfonivorans t..) o Acetothermus paucivorans Actinobacillus capsulatus Aerococcus viridans Arthrobacter sulfureus c,.) .6.
.6.
Actinobacillus delphinicola Anabaena t..) Arthrobacter uratoxydans oe Acholeplasma Actinobacillus hominis Aeromicrobium Anabaena cylindrica Arthrobacter ureafaciens Acholeplasma axanthum Actinobacillus indolicus Aeromicrobium mythreum Anabaena flos-aquae Arthrobacter viscosus Acholeplasma brassicae Actinobacillus lignieresii Anabaena variabilis Arthrobacter woluwensis Acholeplasma cavigenitalium Aeromonas Actinobacillus minor Acholeplasma equifetale Aeromonas Anaeroarcus Actinobacillus muris Asaia Acholeplasma granularum allosaccharophila Anaeroarcus burkinensis P
Actinobacillus Asaia bogorensis Acholeplasma hippikon Aeromonas bestiarum pleuropneumoniae ;3' o Anaerobaculum .?.
oe Acholeplasma laidlawii Aeromonas caviae Asanoa Actinobacillus porcinus r., Anaerobaculum mobile ,30 , Acholeplasma modicum Aeromonas encheleia Asanoa ferruginea Actinobacillus rossii N) Acholeplasma morum Aeromonas r., Actinobacillus scotiae Anaerobiospirillum Asticcacaulis Acholeplasma multilocale enteropelo genes Actinobacillus seminis Anaerobiospirillum Asticcacaulis biprosthecium Acholeplasma oculi Aeromonas eucrenophila Actinobacillus succinogenes succiniciproducens Asticcacaulis excentricus Acholeplasma palmae Aeromonas ichthiosmia Actinobaccillus suis Anaerobiospirillum thomasii Acholeplasma parvum Aeromonas jandaei Actinobacillus ureae Atopobacter 1-d Acholeplasma pleciae Aeromonas media n Anaerococcus Atopobacter phocae 1-3 Acholeplasma vituli Actinobaculum Aeromonas popoffii t=1 Anaerococcus hydrogenalis Iv t..) o Actinobaculum massiliense Aeromonas sobria t..) Anaerococcus lactolyticus o 'a Actinobaculum schaalii Aeromonas veronii o .6.
t..) t..) un Actinobaculum suis Anaerococcus prevotii o t..) Achromobacter Agrobacterium Atopobium o Actinomyces urinale Anaerococcus tetradius t..) o Achromobacter denitrificans Agrobacterium Atopobium fossor Anaerococcus vaginalis .6.
.6.
Achromobacter insolitus Actinocatenispora gelatinovorum Atopobium minutum r..) oe Achromobacter piechaudii Actinocatenispora rupis Anaerofustis Atopobium parvulum Achromobacter ruhlandii Actinocatenispora Agrococcus Anaerofustis stercorihominis Atopobium rimae Agrococcus citreus Achromobacter spanius thailandica Atopobium vaginae Agrococcus jenensis Anaeromusa Actinocatenispora sera Acidaminobacter Anaeromusa acidaminophila Aureobacterium romonas Acidaminobacter Actinocorallia Ag Aureobacterium barkeri P
Agromonas oligotrophica Anaeromyxobacter hydrogenoformans Actinocorallia aurantiaca ;'3 o Anaeromyxobacter Aurobacterium ..
o Actinocorallia aurea r., Acidaminococcus Agromyces ens r.
dehalogenans Aurobacterium liquefaci3O
, Actinocorallia cavernae Agromyces fucosus Acidaminococcus fermentans Actinocorallia glomerata r.,^' Acidaminococcus intestini Agromyces hippuratus Anaerorhabdus Avibacterium Actinocorallia herbida Agromyces luteolus Anaerorhabdus furcosa Avibacterium avium Actinocorallia libanotica Acidicaldus Agromyces mediolanus Avibacterium gallinarum Actinocorallia longicatena Anaerosinus Acidicaldus organivorans Agromyces ramosus Avibacterium paragallinarum Anaerosinus glycerini Agromyces rhizospherae Avibacterium volantium Actinomadura 1-d Acidimicrobium n ,-i Actinomadura alba Anaerovirgula m Acidimicrobium ferrooxidans Akkermansia Azoarcus 1-d t..) Actinomadura atramentaria o i Anaerovrgula multivorans t..) Akkermansia muciniphila Azoarcus indigens o Actinomadura 'a o .6.
t..) t..) un ban gladeshensis Azoarcus tolulyticus 0 Acidiphilium Albidiferax Ancalomicrobium t..) o Actinomadura catellatispora Azoarcus toluvorans t..) o Acidiphilium acidophilum Actinomadura chibensis Albidiferax ferrireducens Ancalomicrobium adetum .6.
.6.
Acidiphilium angustum Actinomadura chokoriensis Azohydromonas t..) oe Albidovulum Ancylobacter Acidiphilium ciy Azohydromonas australica ptum Actinomadura citrea Albidovulum inexpectatum Ancylobacter aquaticus Azohydromonas lata Acidiphilium multivorum Actinomadura coerulea Acidiphilium organovorum Actinomadura echinospora Alcaligenes Aneurinibacillus Azomonas Acidiphilium rubrum Actinomadura fibrosa Alcaligenes denitrificans Aneurinibacillus Azomonas agilis Actinomadura formosensis Alcaligenes faecalis aneurinilyticus Acidisoma Azomonas insignis P
Actinomadura hibisca i i Aneurinibacillus mgulanus Acidisoma sibiricum Azomonas macrocyto genes 1-, Actinomadura ktjaniata Alcanivorax ;3' o Aneurinibacillus .?.
o Acidisoma tundrae r., Actinomadura latina Alcanivorax borkumensis the rmoaerophilus Azorhizobium ,30 , Actinomadura livida Alcanivorax jadensis o Acidisphaera Azorhizobium caulinodans r, N) Actinomadura Angiococcus Acidisphaera rubrifaciens Algicola luteofluorescens Angiococcus discifonnis Azorhizophilus Algicola bacteriolytica Acidithiobacillus Actinomadura macra Azorhizophilus paspali Angulomicrobium Acidithiobacillus albertensis Actinomadura madurae Alicyclobacillus Angulomicrobium tetraedrale Azospirillum Acidithiobacillus caldus Actinomadura oligospora Iv Alicyclobacillus n Azospirillum brasdense Acidithiobacillus ferrooxidans Actinomadura pelletieri disulfidooxidans Anoxybacillus t=1 Azospirillum halopraeferens Iv Acidithiobacillus thiooxidans Actinomadura rubrobrunea t..) Alicyclobacillus Anoxybacillus pushchinoensis o t..) Azospirillum irakense o Actinomadura rugatobispora 'a o .6.
t..) t..) un Actinomadura umbrina sendaiensis o t..) Acidobacterium Aquabacterium Azotobacter o Actinomadura Alicyclobacillus vulcanalis t..) o Acidobacterium capsulatum Aquabacterium commune Azotobacter beijerinckii verrucosospora .6.
.6.
Alishewanella Aquabacterium parvum Azotobacter chroococcum t...) Actinomadura vinacea oe Alishewanella fetalis Azotobacter nigricans Actinomadura viridilutea Azotobacter salinestris Actinomadura viridis Alkalibacillus Azotobacter vinelandii Actinomadura yumaensis Alkalibacillus haloalkaliphilus P
, 1¨ Bacillus Bacteroides Bibersteinia Borrelia Brevinema o 2 1-, r., [see below] Bacteroides caccae Bibersteinia trehalosi Borrelia afzelii Brevinema andersonii 2 '7 Bacteroides coagulans Borrelia americana 0"
N) Bifidobacterium Brevundimonas "
Bacteroides eggerthii Borrelia burgdorferi Bifidobacterium ado lescentis Brevundimonas alba Bacteroides fragilis Borrelia carolinensis Bacteriovorax Bifidobacterium angulatum Brevundimonas aurantiaca Bacteroides galacturonicus Borrelia coriaceae Bacteriovorax stolpii Bifidobacterium animalis Brevundimonas diminuta Bacteroides helco genes Borrelia garinii Bifidobacterium asteroides Brevundimonas intermedia Bacteroides ovatus Borrelia japonica Iv Bifidobacterium bifidum Brevundimonas subvibrioides n Bacteroides pectinophilus t=1 Bifidobacterium boum Brevundimonas vancanneytii Iv Bacteroides pyo genes t..) o Bifidobacterium breve t..) o Bacteroides salyersiae 'a o .6.
t..) t..) un Bacteroides stercoris Bifidobacterium catenulatum Brevundimonas variabilis 0 t..) Bosea o Bacteroides suis Bifidobacterium choerinum Brevundimonas vesicularis t..) o Bosea minatitlanensis Bacteroides tectus Bifidobacterium coiyneforme c...) .6.
.6.
Bosea thiooxidans Brochothrix t..) Bacteroides thetaiotaomicron Bifidobacterium cuniculi oe Bacteroides uniformis Bifidobacterium dentium Brochothrix campestris Brachybacterium Brochothrix thermosphacta Bacteroides ureolyticus Bifidobacterium gallicum Brachybacterium Bacteroides vulgatus Bifidobacterium gallinarum alimentarium BruceIla Bifidobacterium indicum Balnearium Brachybacterium faecium BruceIla canis Bifidobacterium longum P
Balnearium lithotrophicum Bifi Brachybacterium BruceIla neotomaedobacterium 2 paraconglomeratum 1-, magnumBifidobacterium o .? Bryobacter .
w Balneatrix Brachybacterium rhamnosum r., meiycicum atusre obacter aggg , Balneatrix alpica Brachybacterium Biy , Bifidobacterium minimum 0"
, tyrofermentans r.,"
Balneola Bifidobacterium Burkholderia pseudocatenulatum Burkholderia ambifaria Balneola vulgaris Brachyspira Bifidobacterium Brachyspira alvinipulli Burkholderia andropogonis Barnesiella pseudolongum Burkholderia anthina Brachyspira hyodysenteriae Barnesiella viscericola Bifidobacterium pullorum Brachyspira innocens Burkholderia caledonica Iv n Bifidobacterium ruminantium Burkholderia caiyophylli 1-3 Brachyspira murdochii t=1 Bartonella 1-d Bifidobacterium saeculare Brachyspira pilosicoli Burkholderia cenocepacia t..) o Bartonella alsatica t..) o Bifidobacterium subtile Burkholderia cepacia 'a o .6.
t..) t..) un Bartonella bacilliformis Bifidobacterium Burkholderia cocovenenans o t..) o Bartonella clarridgeiae the rmophilum Burkholderia dolosa t..) o Bartonella doshiae Burkholderia fungorum c,.) .6.
Bradyrhizobium Bilophila .6.
t..) Bartonella elizabethae Burkholderia glathei oe Bilophila wadsworthia Bradyrhizobium canariense Bartonella grahamii Burkholderia glumae Bradyrhizobium elkanii Bartonella henselae Burkholderia graminis Biostraticola Bradyrhizobium japonicum Bartonella rochalimae Burkholderia kururiensis Biostraticola tofi Bradyrhizobium liaoningense Bartonella vinsonii Burkholderia multivorans Bizionia Brenneria Burkholderia phenazinium P
Bavariicoccus Burkholderia plantarii 2 Bizionia argentinensis Brenneria alni Bavariicoccus seileri 1-, Burkholderia pyrrocinia ;3' o Brenneria nigrifluens .2 r., Blastobacter Burkholderia silvatlantica 2' Brenneria quercina Bdellovibrio , Blastobacter capsulatus Burkholderia stabilis Brenneria quercina Bdellovibrio bacteriovorus r.3^' Blastobacter denitrificans Burkholderia thailandensis Brenneria salicis Bdellovibrio exovorus Burkholderia tropica Blastococcus Brevibacillus Burkholderia unamae Beggiatoa Blastococcus aggregatus Brevibacillus agri Burkholderia vietnamiensis Beggiatoa alba Blastococcus saxobsidens Brevibacillus borstelensis Iv n Beijerinckia Brevibacillus brevis Buttiauxella Blastochloris t=1 Buttiauxella agrestis Iv Betjerinckia derxii Brevibacillus centrosporus t..) Blastochloris viridis o t..) b ll iauxea rennerae o Betjerinckia fluminensis Brevibacillus choshinensis Butt 'a o .6.
t..) t..) un Betjerinckia indica Brevibacillus invocatus Buttiauxella ferragutiae o t..) Blastomonas o Betjerinckia mobilis Brevibacillus late rosporus Buttiauxella gaviniae t..) o Blastomonas natatoria Brevibacillus parabrevis Buttiauxella izardii c,.) .6.
Belliella .6.
t..) Brevibacillus reuszeri Buttiauxella noackiae oe Belliella baltica Blastopirellula Buttiauxella warmboldiae Blastopirellula marina Brevibacterium Bellilinea Brevibacterium abidum Butyrivibrio Blautia Bellilinea caldifistulae Brevibacterium album Butyrivibrio fibrisolvens Blautia coccoides Brevibacterium aurantiacum Butyrivibrio hungatei Belnapia Blautia hansenii P
Brevibacterium celere Butyrivibrio proteoclasticus Belnapia moabensis Blautia producta Brevibacterium epidermidis 1-, ;33' o Blautia wexlerae .2 .6.
Brevibacterium Bergeriella , Bergeriella denitrificans Bogoriella frigoritolerans N) Brevibacterium halotolerans r., Bogoriella caseilytica Beutenbergia Brevibacterium iodinum Beutenbergia cavernae Bordetella Brevibacterium linens Bordetella avium Brevibacterium lyticum Bordetella bronchiseptica Brevibacterium mcbrellneri Iv Bordetella hinzii Brevibacterium otitidis n ,-i m Bordetella holmesii Brevibacterium oxydans Iv t..) o Bordetella parapertussis t..) o 'a o .6.
t..) t..) un Bordetella pertussis Brevibacterium paucivorans o tµ.) o Bordetella petrii Brevibacterium stationis tµ.) o Bordetella trematum c,.) .6.
.6.
n.) oe Bacillus B. acidiceler B. aminovorans B. glucanolyticus B. taeanensis B. lautus B. acidicola B. amylolyticus B. gordonae B. tequilensis B. lehensis B. acidiproducens B. andreesenii B. gottheilii B. the rmantarcticus B. lentimorbus P
B. acidocaldarius B. aneurindyncus B. graminis B. the rmoaerophilus B. lentus , ...]
o h li B l th B l l h B
i th B. acidoterrestris B. anracs B. amapaus B.
ermoamyovorans B. ceniformis ..
un r., B. aeolius B. aquimaris B. haloalkaliphilus B. the rmocatenulatus B. ligniniphilus , , , B. aerius B. arenosi B. halochares B. the rmocloacae B. litoralis ' r., r., B. aerophilus B. arseniciselenatis B. halodenitrificans B. the rmocopriae B. locisalis B. agaradhaerens B. arsenicus B. halodurans B. thermodenitrificans B. luciferensis B. agri B. aurantiacus B. halophilus B. the rmoglucosidasius B. luteolus B. aidingensis B. arvi B. halosaccharovorans B. the rmolactis B. luteus B. akibai B. cnyabhattai B.
hemicellulosilyticus B. the rmoleovorans B. macauensis Iv n ,-i B. alcalophilus B. asahii B. hemicentroti B. the rmophilus B. macerans t=1 Iv B. algicola B. atrophaeus B. herbersteinensis B. the rmoruber B. macquariensis tµ.) o tµ.) o B. alginolyticus B. axarquiensis B. horikoshii B. the rmosphaericus B. macyae 'a o .6.
tµ.) tµ.) un B. alkalidiazotrophicus B. azotofixans B. horneckiae B. thiaminolyticus B. malacitensis 0 n.) B. alkalinitrilicus B. azotoformans B. horti B. thioparans B. mannandyticus o t..) o B. alkalisediminis B. badius B. huizhouensis B. thuringiensis B. marisflavi c,.) .6.
.6.
B. alkalitelluris B. barbaricus B. humi B. tianshenii B. marismortui t.) oe B. altitudinis B. bataviensis B. hwajinpoensis B. bypoxylicola B. marmarensis B. alveayuensis B. betjingensis B. idriensis B. tusciae B. massiliensis B. alvei B. benzoevorans B. indicus B. validus B. megaterium B. amyloliquefaciens B. beringensis B. infantis B. vallismortis B. mesonae B. berkeleyi B. infernus B. vedderi B. methanolicus P
= B.
B. beveridgei B. insolitus B. velezensis B. methylotrophicus , a. subsp. Amyloliquefaciens ...]
1-, b i i B ii Bi i Bil B. ogorenss B. nvctae B. vetnamenss B. mguanus 0 o ..
o =
B. a. subsp. Plantarum r., B. boroniphilus B. iranensis B. vireti B. mojavensis '7 B. borstelensis B. isabeliae B. vulcani B. mucilaginosus 0"
r., B. brevis Migula B. isronensis B. wakoensis B. muralis B. dipsosauri B. butanolivorans B. jeotgali B. weihenstephanensis B. murimartini B. drentensis B. canaveralius B. kaustophilus B. xiamenensis B. myco ides B. edaphicus B. carboniphilus B. kobensis B. xiaoxiensis B. naganoensis B. ehimensis B. cecembensis B. kochii B. zhanjiangensis B. nanhaiensis Iv B. eiseniae n B. cellulosilyticus B. kokeshiiformis B. nanhaiisediminis 1-3 B. enclensis t=1 B. peoriae Iv B. centrosporus B. koreensis B. nealsonii t..) o B. endophyticus n.) B. persepolensis o B. cereus B. korlensis B. neidei 'a B. endoradicis o .6.
t..) t..) un B. farraginis B. chagannorensis B. kribbensis B. persicus B. neizhouensis o tµ.) o B. fastidiosus B. chitinolyticus B. krulwichiae B. pervagus B. niabensis tµ.) o B. fengqiuensis B. chondroitinus B. laevolacticus B. plakortidis B. niacini c,.) .6.
.6.
tµ.) B. firmus B. choshinensis B. larvae B. pocheonensis B. novalis oe B. flexus B. chungangensis B. laterosporus B. polygoni B. oceanisediminis B. foraminis B. cibi B. salexigens B. polymyxa B. odysseyi B. fordii B. circulans B. saliphilus B. popilliae B. okhensis B. formosus B. clarkii B. schlegelii B. pseudalcalophilus B. okuhidensis B. fortis B. clausii B. sediminis B. pseudofirmus B. oleronius P
B. fiimarioli B. coagulans B. selenatarsenatis B. pseudomycoides B. oiyzaecorticis , 1-, B. fiiniculus B. coahuilensis B. selenitireducens B. psychrodurans B. oshimensis o ..
B. fiisiformis B. cohnii B. seohaeanensis B. psychrophilus B. pabuli '7 , B. galactophilus B. compost! B. shacheensis B. psychrosaccharolyticus B. pakistanensis r., B. galactosidilyticus B. curdlanolyticus B. shackletonii B. psychrotolerans B. pallidus B. galliciensis B. cycloheptanicus B. siamensis B. pulvifaciens B. pallidus B. gelatini B. cytotoxicus B. silvestris B. pumilus B. panacisoli B. gibsonii B. daliensis B. simplex B. purgationiresistens B. panaciterrae B. ginsengi B. decisifrondis B. siralis B. pycnus B. pantothenticus Iv n B. ginsengihumi B. decolorationis B. smithii B. qingdaonensis B. parabrevis 1-3 t=1 Iv B. ginsengisoli B. deserti B. soli B. qingshengii B. paraflexus tµ.) o tµ.) B. globisporus (eg, B. B. solimangrovi B. reuszeri B. pasteurii 'a o .6.
tµ.) tµ.) un g. subsp. Globisporus; or B. B. solisalsi B. rhizosphaerae B. patagoniensis c;;) t..) g. subsp. Marinus) B. songklensis B. rigui o t..) o B. sonorensis B. runs c,.) .6.
.6.
n.) B. sphaericus B. safensis oe B. sporothermodurans B. salarius B. stearothermophilus B. stratosphericus B. subterraneus B. subtilis (eg, B.
P
s. subsp. Inaquosorum; or B.
1-, s. subsp. Spizizeni;
or B.
o 2 oe N, s. subsp. Subtilis) '7 , Caenimonas Campylobacter Cardiobacterium Catenuloplanes Curtobacterium Caenimonas koreensis Campylobacter coli Cardiobacterium hominis Catenuloplanes atrovinosus Curtobacterium Campylobacter concisus Catenuloplanes castaneus .. albidum Caldalkalibacillus Carnimonas Campylobacter curvus Catenuloplanes crispus Curtobacterium citreus Caldalkalibacillus uzonensis Carnimonas nigrificans Campylobacter fetus Catenuloplanes indicus Iv Campylobacter gracilis Catenuloplanes japonicus n Caldanaerobacter Carnobacterium Campylobacter helveticus Catenuloplanes nepalensis t=1 Iv Caldanaerobacter subterraneus Carnobacterium t..) Campylobacter hominis Catenuloplanes niger o t..) alterfunditum o 'a Campylobacter hyointestinalis o .6.
t..) t..) un Campylobacter jejuni Carnobacterium divergens o t..) Caldanaerobius Chryseobacterium o Campylobacter lari Carnobacterium funditum t...) o Caldanaerobius fijiensis Campylo Chiyseobacterium bacter mucosalis Carnobacterium gallinarum c...) .6.
.6.
Caldanaerobius balustinum t..) Campylobacter rectus Carnobacterium oe polysaccharolyticus Campylobacter showae maltaromaticum Citrobacter Caldanaerobius zeae Campylobacter sputorum Carnobacterium mobile C. amalonaticus Campylobacter upsaliensis Carnobacterium viridans Caldanaerovirga C. braakii Caldanaerovirga acetigignens C. diversus Capnocytophaga Caryophanon P
Capnocytophaga canimorsus Caiyopha C. farmeri non latum Caldicellulosiruptor C. freundii Capnocytophaga cynodegmi Caiyophanon tenue 1-, ;3' o Caldicellulosiruptor bii o C. gillenii .?.
rup esc Capnocytophaga gingivalis r., Caldicellulosiruptor kristjanssonii Catellatospora Catellat C. koseri , Capnocytophaga granulosa 0"1 Caldicellulosiruptor owensensis Catellatospora citrea C. murliniae ,3"1 Capnocytophaga haemolytica Catellatospora C. pasteuriim Capnocytophaga ochracea methionotrophica C. rodentium Capnocytophaga sputigena C. sedlakii Catenococcus C. werkmanii Catenococcus thiocycli Iv C. youngae n ,-i m ,-o Clostridium t..) o t..) o (see below) 'a cA
.6.
t..) t..) un C
t..) Coccochloris o t..) o Coccochloris elabens .6.
.6.
n.) oe Corynebacterium Coiynebacterium flavescens Coiynebacterium variabile Clostridium Clostridium absonum, Clostridium aceticum, Clostridium ace tireducens, Clostridium acetobutylicum, Clostridium acidisoli, Clostridium aciditolerans, P
Clostridium acidurici, Clostridium aerotolerans, Clostridium aestuarii, Clostridium akagii, Clostridium aldenense, Clostridium aldrichii, Clostridium 1-, algidicami, Clostridium algidixylanolyticum, Clostridium algifaecis, Clostridium algoriphilum, Clostridium alkalicellulosi, Clostridium aminophilum, 1-, .
o r., Clostridium aminovalericum, Clostridium amygdalinum, Clostridium amylolyticum, Clostridium arbusti, Clostridium arcticum, Clostridium argentinense, 2 '7 Clostridium asparagiforme, Clostridium aurantibutyricum, Clostridium autoethanogenum, Clostridium baratii, Clostridium barkeri, Clostridium bartlettii, r., Clostridium betjerinckii, Clostridium bifermentans, Clostridium bolteae, Clostridium bomimense, Clostridium botulinum, Clostridium bowmanii, Clostridium biyantii, Clostridium butyricum, Clostridium cadaveris, Clostridium caenicola, Clostridium cam inithermale, Clostridium carboxidivorans, Clostridium camis, Clostridium cavendishii, Clostridium celatum, Clostridium celerecrescens, Clostridium cellobioparum, Clostridium cellulofermentans, Clostridium cellulolyticum, Clostridium cellulosi, Clostridium cellulovorans, Clostridium chartatabidum, Clostridium chauvoei, Clostridium chromiireducens, Clostridium citroniae, Clostridium clariflavum, Clostridium clostridioforme, Clostridium cocco ides, Clostridium cochlearium, Clostridium colletant, Clostridium colicanis, .0 n Clostridium colinum, Clostridium collagenovorans, Clostridium cylindrosporum, Clostridium difficile, Clostridium diolis, Clostridium disporicum, 1-3 t=1 Clostridium drakei, Clostridium durum, Clostridium estertheticum, Clostridium estertheticum estertheticum, Clostridium estertheticum laramiense, Iv t..) o t..) Clostridium fallax, Clostridium felsineum, Clostridium fervidum, Clostridium fimetarium, Clostridium formicaceticum, Clostridium frigidicamis, Clostridium o 'a o .6.
t..) t..) un frigoris, Clostridium ganghwense, Clostridium gasigenes, Clostridium ghonii, Clostridium glycolicum, Clostridium glycyrrhizinilyticum, Clostridium grantii, n.) o Clostridium haemolyticum, Clostridium halophilum, Clostridium hastiforme, Clostridium hathewayi, Clostridium herbivorous, Clostridium hiranonis, tµ.) o Clostridium histolyticum, Clostridium homopropionicum, Clostridium huakuii, Clostridium hungatei, Clostridium hydrogeniformans, Clostridium w .6.
.6.
tµ.) hydroxybenzoicum, Clostridium hylemonae, Clostridium jejuense, Clostridium indolis, Clostridium innocuum, Clostridium intestinale, Clostridium irregulare, oe Clostridium isatidis, Clostridium josui, Clostridium kluyveri, Clostridium lactatifermentans, Clostridium lacusfiyxellense, Clostridium laramiense, Clostridium lavalense, Clostridium lentocellum, Clostridium lentoputrescens, Clostridium leptum, Clostridium limosum, Clostridium litorale, Clostridium lituseburense, Clostridium ljungdahlii, Clostridium lortetii, Clostridium lundense, Clostridium magnum, Clostridium malenominatum, Clostridium mangenotii, Clostridium mayombei, Clostridium methoxybenzovorans, Clostridium methylpentosum, Clostridium neopropionicum, Clostridium nexile, Clostridium nitrophenolicum, Clostridium novyi, Clostridium oceanicum, Clostridium orbiscindens, Clostridium oroticum, Clostridium oxalicum, Clostridium papyrosolvens, Clostridium P
paradoxum, Clostridium paraperfringens (Alias: C. welchii), Clostridium paraputrificum, Clostridium pascui, Clostridium pasteurianum, Clostridium 2 ...]
1-, peptidivorans, Clostridium perenne, Clostridium perfringens, Clostridium pfennigii, Clostridium phytofermentans, Clostridium piliforme, Clostridium 1-, ..
polysaccharolyticum, Clostridium populeti, Clostridium propionicum, Clostridium proteoclasticum, Clostridium proteolyticum, Clostridium psychrophilum, 2 '7 , Clostridium puniceum, Clostridium purinilyticum, Clostridium putrefaciens, Clostridium putrificum, Clostridium quercicolum, Clostridium quinii, Clostridium o r., ramosum, Clostridium rectum, Clostridium roseum, Clostridium saccharobutylicum, Clostridium saccharogumia, Clostridium saccharolyticum, Clostridium saccharoperbutylacetonicum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scatolo genes, Clostridium schirmacherense, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporo genes, Clostridium sporosphaeroides, Clostridium stercorarium, Clostridium stercorarium leptospartum, Clostridium stercorarium stercorarium, Clostridium stercorarium the rmolacticum, Clostridium sticklandii, Clostridium straminisolvens, Clostridium subterminale, Clostridium sufflavum, Clostridium sulfidigenes, Clostridium ,t n symbiosum, Clostridium tagluense, Clostridium tepidiprofundi, Clostridium termitidis, Clostridium tertium, Clostridium tetani, Clostridium tetanomorphum, 1-3 t=1 Iv Clostridium thermaceticum, Clostridium thermautotrophicum, Clostridium thermoalcaliphilum, Clostridium thermobutyricum, Clostridium the rmocellum, t.) o tµ.) o Clostridium thermocopriae, Clostridium thermohydrosulfuricum, Clostridium thermolacticum, Clostridium the rmopalmarium, Clostridium 'a o .6.
tµ.) tµ.) un thermopapyrolyticum, Clostridium thermosaccharolyticum, Clostridium thermosuccinogenes, Clostridium thermosulfurigenes, Clostridium 0 t..) o thiosulfatireducens, Clostridium tyrobutyricum, Clostridium uliginosum, Clostridium ultunense, Clostridium villosum, Clostridium vincentii, Clostridium t...) o viride, Clostridium xylanolyticum, Clostridium xylanovorans c...) .6.
.6.
n.) oe Dactylosporangium Deinococcus Delftia Echinicola Dactylosporangium aurantiacum Deinococcus aerius Delftia acidovorans Echinicola pacifica Dactylosporangium fulvum Deinococcus apachensis Desulfovibrio Echinicola vietnamensis Dactylosporangium matsuzakiense Deinococcus aquaticus Desulfovibrio desulfuricans Dactylosporangium roseum Deinococcus aquatilis Diplococcus Dactylosporangium thailandense Deinococcus caeni Diplococcus pneumoniae P
Dactylosporangium vinaceum Deinococcus radiodurans 1-, t..) Deinococcus radiophilus ..
0"
r., '7 Enterobacter Enterobacter kobei Faecalibacterium Flavobacterium "
E. aero genes E. ludwigii Faecalibacterium prausnitzii Flavobacterium antarctic urn E. amnigenus E. mori Fangia Flavobacterium aquatile E. agglomerans E. nimipressuralis Fangia hongkongensis Flavobacterium E. arachidis E. oiyzae Fastidiosipila aquidurense E. asburiae E. pulveris Fastidiosipila sanguinis Flavobacterium balustinum Iv n E. cancerogenous E. pyrinus Fusobacterium Flavobacterium croceum 1-3 t=1 E. cloacae E. radicincitans Fusobacterium nucleatum Flavobacterium cucumis Iv t..) o t..) E. cowanii E. taylorae Flavobacterium =
'a o .6.
t..) t..) un E. dissolvens E. turicensis daejeonense 0 n.) o E. gergoviae E. sakazakii Enterobacter soli Flavobacterium defluvii r..) o E. helveticus Enterococcus Flavobacterium degerlachei c...) .6.
.6.
t..) E. honnaechei Enterococcus durans Flavobacterium oe E. intermedius Enterococcus faecalis denitrificans Enterococcus faecium Flavobacterium filum Erwinia Flavobacterium flevense Erwinia hapontici Flavobacterium frigidarium Escherichia Flavobacterium mizutaii P
Escherichia coli Flavobacterium 2 -, 1-, okeanokoites 1-, ..
r., N) '7 '8 N) N) Gaetbulibacter Haemophilus Ideonella Janibacter Gaetbulibacter saemankumensis Haemophilus aegyptius Ideonella azotifigens Janibacter anophelis Gallibacterium Haemophilus aphrophilus Idiomarina Janibacter corallicola Gallibacterium anatis Haemophilus felis Idiomarina abyssalis Janibacter limosus Gallicola Haemophilus gallinarum Idiomarina baltica Janibacter melonis Iv n ,-i Gallicola barnesae Haemophilus haemolyticus Idiomarina fontislapidosi Janibacter terrae t=1 Iv Garciella Haemophilus influenzae Idiomarina loihiensis Jannaschia t..) o t..) o Garciella nitratireducens Haemophilus paracuniculus Idiomarina ramblicola Jannaschia cystaugens 'a o .6.
t..) t..) un Geobacillus Haemophilus parahaemolyticus Idiomarina seosinensis Jannaschia helgolandensis r..) o Geobacillus the rmoglucosidasius Haemophilus parainfluenzae Idiomarina zobellii Jannaschia pohangensis r..) o Geobacillus stearothermophilus Haemophilus Ignatzschineria Jannaschia rubra c...) .6.
.6.
t..) Geobacter paraphrohaemolyticus Ignatzschineria larvae oe Geobacter bemidjiensis Haemophilus parasuis Janthinobacterium Geobacter bremensis Haemophilus pittmaniae Ignavigranum Janthinobacterium Geobacter chapellei Hafnia Ignavigranum ruoffiae agaric idamno sum Geobacter grbiciae Hafnia alvei Ilumatobacter Janthinobacterium lividum Geobacter hydrogenophilus Hahella Ilumatobacter fluminis Jejuia P
Geobacter lovleyi Hahella ganghwensis Ilyobacter Jejuia pallidilutea 2 , 1-, Geobacter metallireducens Halalkalibacillus Ilyobacter delafieldii Jeotgalibacillus .
,-, ..
Geobacter pelophilus Halalkalibacillus halophilus Ilyobacter insuetus Jeotgalibacillus 2 '7 Geobacter pickeringii Helicobacter Ilyobacter polytropus alimentarius 0"
r., Geobacter sulfurreducens Helicobacter pylori Ilyobacter tartaricus Jeotgalicoccus Geodermatophilus Jeotgalicoccus halotolerans Geodermatophilus obscurus Gluconacetobacter Gluconacetobacter xylinus Iv n Gordonia m 1-d Gordonia rubripertincta w o t..) o 'a o .6.
t..) t..) un Kaistia Labedella Listeria ivanovii Micrococcus Nesterenkonia o t..) Kaistia adipata Labedella gwakjiensis L. marthii Micrococcus luteus Nesterenkonia holobia o t...) o Kaistia soli Labrenzia L. monocyto genes Micrococcus lylae Nocardia c,.) .6.
.6.
Kangiella Labrenzia aggregata L. newyorkensis Moraxella Nocardia argentinensis t..) oe Kangiella aquimarina Labrenzia alba L. riparia Moraxella bovis Nocardia corallina Kangiella koreensis Labrenzia alexandrii L. rocourtiae Moraxella nonliquefaciens Nocardia Labrenzia marina L. seeligeri Moraxella osloensis otitidiscaviarum Kerstersia Labrys L. weihenstephanensis Nakamurella Kerstersia gyiorum Labiys methylaminiphilus L. welshimeri Nakamurella multipartita P
Kiloniella Labiys miyagiensis Listonella Nannocystis 2 1-, Kiloniella laminariae Labiys monachus Listonella anguillarum Nannocystis pusilla 1-, ..
Klebsiella Labiys okinawensis Macrococcus Natranaerobius 2 '7 , K granulomatis Labiys portucalensis Macrococcus bovicus Natranaerobius 0 r., K oxytoca Marinobacter the rmophilus K pneumoniae Lactobacillus Marinobacter algicola Natranaerobius trueperi K terrigena [see below] Marinobacter biyozoorum Naxibacter K variicola Laceyella Marinobacter flavimaris Naxibacter alkalitolerans Kluyvera Laceyella putida Meiothermus Neisseria 1-d n Kluyvera ascorbata Lechevalieria Meiothermus ruber Neisseria cinerea 1-3 t=1 Iv Lechevalieria aerocolonigenes Neisseria denitrificans w o t..) Legionella Neisseria gonorrhoeae o 'a o .6.
t..) t..) un Kocuria [see below] Methylophilus Neisseria lactamica 0 t..) Kocuria roasea Listeria Methylophilus Neisseria mucosa o r..) o Kocuria varians L. aquatica methylotrophus Neisseria sicca c...) .6.
.6.
Kurthia L. booriae Microbacterium Neisseria subflava t..) oe Kurthia zopfii L. cornellensis Microbacterium Neptunomonas L. fleischmannii ammoniaphilum Neptunomonas japonica L. floridensis Microbacterium arborescens L. grandensis Microbacterium liquefaciens L. grayi Microbacterium oxydans P
L. innocua , -, o r., Lactobacillus , , , ,D
L. acetotolerans L. catenaformis L. mali L. parakefiri L. sakei r., L. acidifarinae L. ceti L. manihotivorans L. paralimentarius L. salivarius L. acidipiscis L. coleohominis L. mindensis L. paraplantarum L. sanfranciscensis L. acidophilus L. collinoides L. mucosae L. pentosus L. satsumensis Lactobacillus agilis L. composti L. murinus L. perolens L. secaliphilus Iv L. algidus L. concavus L. nagelii L. plantarum L. sharpeae n ,-i L. 116amster116116ius L. coryniformis L. namurensis L. pontis L. siliginis t=1 Iv t..) L. amylolyticus L. crispatus L. nantensis L. protectus L. spicheri o t..) o 'a L. amylophilus L. crustorum L. oligofermentans L. psittaci L. suebicus o .6.
t..) t..) un L. amylotrophicus L. curvatus L. oris L. rennini L. thailandensis o r..) L. amylovorus L. delbrueckii subsp. L. panis L. reuteri L. ultunensis o t..) o L. animalis Bulgaricus L. pantheris L. rhamnosus L. vaccinostercus c...) .6.
.6.
L. antri L. delbrueckii subsp. L. parabrevis L. rimae L. vaginalis t..) oe L. 117amster Delbrueckii L. parabuchneri L. rogosae L. versmoldensis L. 117amster117 L. delbrueckii subsp. Lactis L. paracasei L. rossiae L. vini L. bifermentans L. dextrinicus L. paracollinoides L. ruminis L. vitulinus L. brevis L. diolivorans L. parafarraginis L. saerimneri L. zeae L. buchneri L. equi L. homohiochii L. jensenii L. zymae P
L. camelliae L. equigenerosi L. iners L. johnsonii L. gastricus 2 1-, L. casei L. farraginis L. ingluviei L. kalixensis L. ghanensis 1-, ..
L. kitasatonis L. farciminis L. intestinalis L. kefiranofaciens L. graminis 2 '7 L. kunkeei L. fermentum L. fuchuensis L. kefiri L. hammesii , r., L. leichmannii L. fornicalis L. gallinarum L. 117amste L. 117amster L. lindneri L. fructivorans L. gasseri L. helveticus L. harbinensis L. malefermentans L. frumenti L. hilgardii L. hayakitensis Iv n ,-i Legionella t=1 1-d r..) Legionella adelaidensis Legionella drancourtii Candidatus Legionella jeonii Legionella quinlivanii o t..) o 'a Legionella anisa Legionella dresdenensis Legionella jordanis Legionella rowbothamii o .6.
t..) t..) un Legionella beliardensis Legionella drozanskii Legionella lansingensis Legionella rubrilucens 0 t..) o Legionella birminghamensis Legionella dumoffii Legionella londiniensis Legionella sainthelensi t..) o Legionella bozemanae Legionella eiythra Legionella longbeachae Legionella santicrucis c,.) .6.
.6.
t..) Legionella brunensis Legionella fairfieldensis Legionella lytica Legionella shakespearei oe Legionella busanensis Legionella fallonii Legionella maceachernii Legionella spiritensis Legionella cardiaca Legionella feeleii Legionella massiliensis Legionella steelei Legionella cherrii Legionella geestiana Legionella micdadei Legionella steigerwalth Legionella cincinnatiensis Legionella genomospecies Legionella monrovica Legionella taurinensis Legionella clemsonensis Legionella gormanii Legionella moravica Legionella tucsonensis P
Legionella donaldsonii Legionella gratiana Legionella nagasakiensis Legionella tunisiensis 2 1-, Legionella gresilensis Legionella nautarum Legionella wadsworthii 1-, .
Legionella hackeliae Legionella norrlandica Legionella waltersii 2 '7 Legionella impletisoli Legionella oakridgensis Legionella worsleiensis 0"
r., Legionella israelensis Legionella parisiensis Legionella yabuuchiae Legionella jamestowniensis Legionella pittsburghensis Legionella pneumophila Legionella quateirensis Iv n ,-i Oceanibulbus Paenibacillus Prevotella Quadrisphaera m 1-d t..) Oceanibulbus indolifex Paenibacillus thiaminolyticus Prevotella albensis Quadrisphaera granulorum o t..) o 'a Prevotella amnii o .6.
t..) t..) un Oceanicaulis Pantoea Prevotella bergensis Quatrionicoccus 0 n.) o Oceanicaulis alexandrii Pantoea agglomerans Prevotella bivia Quatrionicoccus r..) o Oceanicola Prevotella Prevotella brevis australiensis c,.) .6.
.6.
t..) Oceanicola batsensis Paracoccus Prevotella biyantii oe Oceanicola granulosus Paracoccus alcaliphilus Prevotella buccae Quinella Oceanicola nanhaiensis Paucimonas Prevotella buccalis Quinella ovalis Oceanimonas Paucimonas lemoignei Prevotella copri Oceanimonas baumannii Pectobacterium Prevotella dentalis Ralstonia Oceaniserpentilla Pectobacterium aroidearum Prevotella denticola Ralstonia eutropha P
Oceaniserpentilla haliotis Pectobacterium atrosepticum Prevotella disiens Ralstonia insidiosa 2 ,-, Oceanisphaera Pectobacterium Prevotella histicola Ralstonia mannitolilytica 1-, o r., Oceanisphaera don ghaensis betavasculorum Prevotella intermedia Ralstonia pickettii 2 '7 , Oceanisphaera litoralis Pectobacterium cacticida Prevotella maculosa Ralstonia 0 , Oceanithermus Pectobacterium carnegieana Prevotella marshii pseudosolanacearum Oceanithermus desulfurans Pectobacterium carotovorum Prevotella melaninogenica Ralstonia syzygii Oceanithermus profundus Pectobacterium chiysanthemi Prevotella micans Ralstonia solanacearum Oceanobacillus Pectobacterium cypripedii Prevotella multiformis Ramlibacter Oceanobacillus caeni Pectobacterium rhapontici Prevotella nigrescens Ramlibacter henchirensis Iv n Oceanospirillum Pectobacterium wasabiae Prevotella oralis Ramlibacter tataouinensis 1-3 t=1 Iv Oceanospirillum linum Planococcus Prevotella oris w o t..) o Planococcus citreus Prevotella oulorum 'a o .6.
t..) t..) un Planomicrobium Prevotella pallens Raoultella 0 n.) o Planomicrobium okeanokoites Prevotella salivae Raoultella ornithinolytica t...) o Plesiomonas Prevotella stercorea Raoultella planticola c...) .6.
.6.
t..) Plesiomonas shigelloides Prevotella tannerae Raoultella terrigena oe Proteus Prevotella timonensis Rathayibacter Proteus vulgaris Prevotella veroralis Rathayibacter caricis Providencia Rathayibacter festucae Providencia stuartii Rathayibacter iranicus Pseudomonas Rathayibacter rathayi P
Pseudomonas aeruginosa Rathayibacter toxicus 2 , 1-, Pseudomonas alcaligenes Rathayibacter tritici t..) .
o r., Pseudomonas anguillispetica Rhodobacter '7 , Pseudomonas fluorescens Rhodobacter sphaero ides o r., Pseudoalteromonas Ruegeria haloplanktis Ruegeria gelatinovorans Pseudomonas mendocina Pseudomonas pseudoalcaligenes Iv n Pseudomonas putida t=1 Iv Pseudomonas tutzeri w o t..) o Pseudomonas syringae 'a o .6.
t..) t..) un Psychrobacter o t..) o Psychrobacter faecalis t...) o Psychrobacter c...) .6.
.6.
t..) phenylpyruvicus oe Saccharococcus Sagittula Sanguibacter Stenotrophomonas Tatlockia Saccharococcus the rmophilus Sagittula stellata Sanguibacter keddieii Steno trophomonas Tatlockia maceachernii Sanguibacter suarezii maltophilia Tatlockia micdadei Saccharomonospora Salegentibacter P
Streptococcus Tenacibaculum 2 Saccharomonospora azurea Salegentibacter sale gens Saprospira 1-, Tenacibaculum n . ) 1-, Saccharomonospora cyanea Saprospira grandis r., [also see below]
amylolyticum r.,0 Salimicrobium , Saccharomonospora viridis ' Tenacibaculum discolor '8 Salimicrobium album Sarcina Streptomyces r., Tenacibaculum Saccharophagus Sarcina maxima Streptomyces Salinibacter gallaicum Saccharophagus degradans Sarcina ventriculi achromo genes Tenacibaculum Salinibacter ruber Streptomyces cesalbus Saccharopolyspora Sebaldella lutimaris Salinicoccus Streptomyces cescaepitosus Tenacibaculum Saccharopolyspora eiythraea Sebaldella term itidis Iv Streptomyces cesdiastaticus n Salinicoccus alkaliphilus mesophilum 1-3 Saccharopolyspora gregorii t=1 Streptomyces cesexfoliatus Iv Salinicoccus hispanicus Tenacibaculum Saccharopolyspora hirsuta t..) o Streptomyces fimbriatus t..) Salinicoccus roseus skagerrakense =
Saccharopolyspora hordei 'a Streptomyces fradiae o .6.
t..) t..) un Saccharopolyspora rectivirgula Streptomyces fulvissimus Tepidanaerobacter o t..) Salinispora Serratia o Saccharopolyspora spinosa Streptomyces griseoruber Tepidanaerobacter t...) o Salinispora arenicola Serratia fonticola Saccharopolyspora taberi Streptomyces griseus syntrophicus c...) .6.
.6.
Salinispora tropica Serratia marcescens t..) Streptomyces lavendulae Tepidibacter oe Saccharothrix Streptomyces Tepidibacter Salinivibrio Sphaerotilus Saccharothrix australiensis phaeochromo genes formicigenes Salinivibrio costicola Sphaerotilus natans Saccharothrix coeruleofusca Streptomyces Tepidibacter Saccharothrix espanaensis the rmodiastaticus thalassicus Salmonella Sphingobacterium Saccharothrix longispora Streptomyces tube rcidicus Thermus Salmonella bongori Sphingobacterium multivorum P
Saccharothrix mutabilis Thermus aquaticus Salmonella enterica Saccharothrix syringae -J,-, ermus fiiform Staphylococcus Thlis t..) Salmonella subterranea .i.
t..) Saccharothrix tangerinus r., [see below]
The rmus the Salmonella typhi h hil r.,0 , Saccharothrix texasensis 0"
N) N) Staphylococcus S. arlettae S. microti S. equorum S. schleiferi S. agnetis S. muscae S.
S. sciuri felis S. nepalensis S.
aureus S. fleurettii S. simiae S. auricularis S. pasteuri Iv n S. gallinarum S. simulans 1-3 S. capitis S. petrasii t=1 S. haemolyticus S. stepanovicii Iv t..) S. caprae S. pettenkoferi o t..) S. hominis S. succinus o S. carnosus S. piscifermentans 'a o .6.
t..) t..) un S. caseolyticus S. hyicus S. pseudintermedius S. vitulinus 0 t..) o S. chromo genes S. intermedius S. pseudolugdunensis S. warneri t...) o S. cohnii S. kloosii S. pulvereri S. xylosus c...) .6.
.6.
S. condimenti S. leei S. rostri t..) oe S. delphini S. lentus S. saccharolyticus S. devriesei S. lugdunensis S. saprophyticus S. epidermidis S. lutrae S. lyticans S. massiliensis P
Streptococcus , , t..) .
Streptococcus agalactiae Streptococcus infantarius Streptococcus orisratti Streptococcus the rmophilus ..
N, Streptococcus anginosus Streptococcus iniae Streptococcus parasanguinis Streptococcus sanguinis , , , ,D
, Streptococcus bovis Streptococcus intermedius Streptococcus peroris Streptococcus sobrinus "
N, Streptococcus canis Streptococcus lactarius Streptococcus pneumoniae Streptococcus suis Streptococcus constellatus Streptococcus milleri Streptococcus Streptococcus uberis Streptococcus downei Streptococcus mitis pseudopneumoniae Streptococcus vestibularis Streptococcus dysgalactiae Streptococcus mutans Streptococcus pyo genes Streptococcus viridans Iv Streptococcus equines Streptococcus oralis Streptococcus ratti Streptococcus n ,-i Streptococcus faecalis Streptococcus tigurinus Streptococcus salivariu zooepidemicus t=1 Iv t..) o Streptococcus ferus t..) o 'a o .6.
t..) t..) un C
t..) o t..) o Uliginosibacterium Vagococcus Vibrio Virgibacillus Xanthobacter c,.) .6.
.6.
t..) Vagococcus carniphilus Vibrio aero genes Virgibacillus Xanthobacter agilis oe Uliginosibacterium gangwonense Vagococcus elongatus Vibrio aestuarianus halodenitrificans Xanthobacter Ulvibacter Vagococcus fessus Vibrio albensis Virgibacillus aminoxidans Ulvibacter litoralis Vagococcus fluvialis Vibrio alginolyticus pantothenticus Xanthobacter Umezawaea Vagococcus lutrae Vibrio campbellii autotrophicus Weissella Umezawaea tan gerina Vagococcus salmoninarum Vibrio cholerae Xanthobacter flavus P
Weissella cibaria Undibacterium Vibrio cincinnatiensis Xanthobacter tagetidis 2 ,-, Variovorax Weissella confusa ;3' t..) Undibacterium pigrum Vibrio coralliilyticus Xanthobacter viscosus 2 .6.
r., Variovorax boronicumulans Weissella halotolerans Ureaplasma Vibrio cyclitrophicus Xanthomonas 2' ' 7 Variovorax dokdonensis Weissella hellenica 0"
Ureaplasma urealyticum Vibrio diazotrophicus Xanthomonas , ,3"
Variovorax paradoxus Vibrio fluvialis Weissella kandleri albilineans Variovorax soli Weissella koreensis Ureibacillus Vibrio furnissii Xanthomonas alfalfae Weissella minor Ureibacillus composti Vibrio gazo genes Xanthomonas Veillonella Weissella Ureibacillus suwonensis Vibrio halioticoli arboricola Veillonella atypica aramesenteroides Ureibacillus terrenus Vibrio harveyi p Xanthomonas Iv Veillonella caviae n Weissella soli Ureibacillus the rmophilus Vibrio ichthyoenteri axonopodis t=1 Veillonella criceti Iv Weissella thailandensis t..) Ureibacillus the rmosphaericus Vibrio mediterranei Xanthomonas o Veillonella dispar t..) Weissella viridescens o Vibrio metschnikovii campestris 'a Veillonella montpellierensis o .6.
t..) t..) un Veillonella parvula Vibrio mytili Xanthomonas citri o Williamsia t..) o Veillonella ratti Vibrio natriegens Xanthomonas codiaei r..) o Williamsia marianensis Veillonella rodentium Vibrio navarrensis Xanthomonas c...) .6.
.6.
Williamsia mans t...) Vibrio nereis cucurbitae oe Venenivibrio Williamsia serinedens Vibrio nigripulchritudo Xanthomonas Venenivibrio stagnispumantis Vibrio ordalii euvesicatoria Winogradskyella Vibrio orientalis Xanthomonas fragariae Wino gradskyella Vibrio parahaemolyticus Xanthomonas fuscans thalassocola Verminephrobacter Vibrio pectenicida Xanthomonas gardneri P
Vibrio penaeicida Xanthomonas hortorum Verminephrobacter eiseniae Wolbachia 2 1-, Vibrio proteolyticus Xanthomonas hyacinthi ? ;3' t..) Wolbachia persica ..
un r., Vibrio shilonii Xanthomonas perforans 2 '7 , Vibrio splendidus Xanthomonas phaseoli 0 N) Verrucomicrobium r., Vibrio tubiashii Xanthomonas pisi Verrucomicrobium spinosum Wolinella Vibrio vulnificus Xanthomonas populi Wolinella succino genes Xanthomonas theicola Xanthomonas translucens Iv n ,-i Zobellia m 1-d Zobellia galactanivorans Xanthomonas w o t..) o Zobellia uliginosa vesicatoria 'a o .6.
t..) t..) un C
Zoogloea Xylella t..) o t..) o Zoo gloea ramigera Xylella fastidiosa .6.
Zoo gloea resiniphila Xylophilus .6.
t...) oe Xylophilus ampelinus Xenophilus Yangia Yersinia mollaretii Zooshikella Zobellella Xenophilus azovorans Yangia pacifica Yersinia philomiragia Zooshikella ganghwensis Zobellella denitrificans Xenorhabdus Yersinia pestis Zobellella taiwanensis P
Yaniella Zunongwangia Xenorhabdus beddingii Yersinia pseudotuberculosis 2 , 1-, Yaniella flava Zunongwangia profunda .3 t..) Xenorhabdus bovienii Yersinia rohdei .2 o r., Yaniella halotolerans Xenorhabdus cabanillasii Yersinia ruckeri 2' , Zymobacter Zeaxanthinibacter Xenorhabdus doucetiae , Yeosuana Yokenella Zymobacter palmae Zeaxanthinibacter r.,"
Xenorhabdus griffiniae Yeosuana aromativorans enoshimensis eiensburg Xenorhabdus hominickii Yokenella reg Zymomonas Xenorhabdus koppenhoeferi Yersinia Zymomonas mobilis Zhihengliuella Yonghaparkia Xenorhabdus nematophila Yersinia aldovae Zhihengliuella Yonghaparkia alkaliphila Xenorhabdus poinarii Zymophilus 1-d Yersinia bercovieri halotolerans n ,-i Xylanibacter Zymophilus paucivorans Yersinia enterocolitica Zavarzinia Xylanibacterium t=1 1-d Xylanibacter oiyzae Zymophilus raffinosivorans t..) Yersinia entomophaga Zavarzinia compransoris Xylanibacterium ulmi o t..) o 'a Yersinia frederiksenii o .6.
t..) t..) un .,.., '.-"E3 e) ,'12.; = ,t2 4-=
= ,..4 ,-.=
= 4t = 4t = ,4 = ,4 4.1 4.1 }... }...
TABLE 2: SaPIs Element Staphylococcal genome Baba* Lindsay and Size Inducing Holden' (kb) phages SaP14 S. aureus str. MRSA252 NA SaP14 15.1 Endogenous prophage SaP11028 S. aureus str. NY940 NA NA 15.6 Endogenous prophage SaPlbovl S. aureus str. RF122 vSa2 NA 15.8 91 1 and 80a SaPlbov2 S. aureus str. V329 NA NA 27 80a SaP1m4 S. aureus str. mu50 v5a3 NA 14.4 Endogenous type I prophage SaPlmw2 S. aureus str. mw2 v5a3 SaP13 14.4 Endogenous type II prophage SeP11 S. aureus str. FRI909 NA NA 9.9 Not known ShP12 S. haemolyticus v5h2 NA 16.6 Not known SaP11 S. aureus str. RN4282 vSal NA 15.2 80a and 913 SaP13 S. (WIWI'S' str. COL vSal SaP11 15.6 Not known SaP15 S. aureus str. USA300 NA Na 14.0 Not known SaP1n1 and S. aureus str. n315 and S. v5a4 SaP12 15 80a SaP1m1 aureus str. mu50, respectively type 1 SaP12 S. aureus str. RN3984 NA NA 14.7 80 and 80a SaRlfusB S. aureus European fusidic NA NA 20.7 Not known acid-resistant impetigo clone SaP1122 S. aureus str. RF122 NA NA 17.9 Endogenous prophage SaP16.L S. aureus strains 8325, COL, v5a4 NA 3.14 Not known USA300, M55A476, type II
Newman and mw2 SsP115305 S. saprophyticus str. 15305 vSs15305 NA 16.7 Not known [N/A, not applicable; *Nomenclature proposed by Baba et al; # Nomenclature proposed by Lindsey &
Holden et all Table 3: Titers of SA100 packaged CGVs after production SA100 Native phage strain TFU/mL PFU/mL
EMG2 1.4E+10 n.d C-la 2.2E+10 <20 C-1792 5.2E+09 <20 SUBSTITUTE SHEET (RULE 26) Table 4: Groups (Example 5) Group Preparation (per 500 I) vehicle 139 ul 9% Sod.carb + 361 I H20 SA100 139 ul 9% Sod.carb + 330 I p114 + 31 I H20 SA100 + induction of CRISPR system 170 I Inducers+Sod.carb + 330 I p114 +
Table 5: Clinical Scores Score 0 healthy Score 1 Minor clinical signs of infection (slower movements, light piloerection in the skin) Score 2 Moderate signs of infection (slower movements, slightly pinched eyes, lack of curiosity or changed activity) Score 3 Severe signs of infection (reduced movements, pinched eyes, changed body posture) Score 4 Severe signs of infection (stiff movements, forced ventilation, pinched eyes) Sacrificed.
Score 5 The mouse does not move, is cold, lying on the side. Sacrificed Score 6 The mouse is dead Table 6: Sequences w o SEQ ID NO: DESCRIPTION SEQUENCE
w o i-J
4,.
1 terS nucleotide AATTGGCAGTAAAGTGGCAGTTTTTGATACCTAAAATGAGATATTATGATAGTGTAGGATAT
w oe sequence TGACTATCTTACTGCGTTTCCCTTATCGCAATTAGGAATAAAGGATCTATGTGGGTTGGCTG
ATTATAGCCAATCCTTTTTTAATTTTAAAAAGCGTATAGCGCGAGAGTTGGTGGTAAATGAA
ATGAACGAAAAACAAAAGAGATTCGCAGATGAATATATAATGAATGGATGTAATGGTAAAAA
AG CAG CAATTTCAG CAG GTTATAGTAAGAAAACAG CAGAGTCTTTAG CAAGTCGATTGTTAA
P
GAAATGTTAATGTTTCGGAATATATTAAAGAACGATTAGAACAGATACAAGAAGAGCGTTTA
, , 1¨
.3 =
ATGAGCATTACAGAAGCTTTAGCGTTATCTGCTTCTATTGCTAGAGGAGAACCTCAAGAGGC
, , TTACAGTAAGAAATATGACCATTTAAACGATGAAGTGGAAAAAGAGGTTACTTACACAATCA
, , ,, ,, CACCAACTTTTGAAGAGCGTCAGAGATCTATTGACCACATACTAAAAGTTCATGGTGCGTAT
ATCGACAAAAAAGAAATTACTCAGAAGAATATTGAGATTAATATTGGTGAGTACGATGACGA
AAGTTAAATTAAACTTTAACAAACCATCTAATGTTTTCAACAG
2 Packaging signal GCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGCGTGTCAGTGCAACTGCATTAA
AACCG 1-d n sequence CCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCCAGAAGTTAGTTAATTATTTGTGTAGTCAAAG
t=1 CTTGACTACATACCTCGTTAATACATTG GAG CATAATGAAGAAAATCTATG G CCTATG
GTCCAAAACTGTCTTTTTTGATG G CAC 1-d w o TATCCTGAAAAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTCAGTGTCGCAAGATCCTTAAGAATTC
w o 'a o 4,.
w w vi 3 Cos packaging signal GCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGCGTGTCAGTGCAACTGCATTAA
AACCG
sequence CCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGTTAATTATTTGTGTAGTCAAAG
TGC w o w CTTCAGTACATACCTCGTTAATACATTGGAGCATAATGAAGAAAATCTATGGCCTATGGTC
i-J
4,.
4,.
4 P2/P4 packaging TGCATTAAAACCGCCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGC
w oe signal sequence sid ATGTCTGACCACACTATCCCTGAATATCTGCAACCCGCACTGGCACAACTGGAAAAGGCCAGAGCCGCCCATCTTGAGA
ACGC
CCGCCTGATGGATGAGACCGTCACGGCCATTGAACGGGCAGAGCAGGAAAAAAATGCGCTGGCGCAGGCCGACGGAAAC
GA
CGCTGACGACTGGCGCACGGCCTTTCGTGCAGCCGGTGGTGTCCTGAGCGACGAGCTGAAACAGCGCCACATTGAGCGC
GTG
GCACGCCGGGAGCTGGTACAGGAATATGACAATCTGGCCGTGGTGCTGAATTTCGAACGTGAACGCCTGAAAGGGGCGT
GTG
ACAGCACGGCCACCGCCTACCGGAAGGCACATCATCACCTTCTGAGTCTGTATGCAGAGCATGAGCTGGAACACGCCCT
GAAT P
GAAACCTGTGAGGCGCTTGTCCGGGCAATGCATCTGAGCATTCTGGTACAGGAAAATCCGCTCGCCAACACCACCGGCC
ATCA , 1¨
GGGCTACGTCGCACCGGAAAAGGCTGTCATGCAGCAGGTGAAATCATCGCTGGAACAGAAAATTAAACAGATGCAAATC
AGC , 1¨
CTCACCGGCGAGCCGGTTCTCCGGCTGACCGGACTGTCAGCGGCAACACTCCCGCACATGGATTATGAGGTGGCAGGCA
CACC
GGCACAGCGCAAGGTGTGGCAGGACAAAATAGACCAGCAGGGAGCAGAGCTTAAGGCCAGAGGGCTGCTGTCATGA
, , , , ,, 6 psu ATGGAAAGCACAGCCTTACAGCAGGCCTTTGACACCTGTCAGAATAACAAAGCAGCATGGCTGCAACGCAAAAATGAGC
TGG ,, CAGCGGCCGAACAGGAATATCTGCGGCTTCTGTCAGGAGAAGGCAGAAACGTCAGTCGCCTGGACGAATTACGCAATAT
TATC
GAAGTCAGAAAATGGCAGGTGAATCAGGCCGCCGGTCGTTATATTCGTTCGCATGAAGCCGTTCAGCACATCAGCATCC
GCGA
CCGGCTGAATGATTTTATGCAGCAGCACGGCACAGCACTGGCGGCCGCACTGGCACCGGAGCTGATGGGCTACAGTGAG
CTG
ACGGCCATTGCCCGAAACTGTGCCATACAGCGTGCCACAGATGCCCTGCGTGAAGCCCTTCTGTCCTGGCTTGCGAAGG
GTGA
AAAAATTAATTATTCCGCACAGGATAGCGACATTTTAACGACCATCGGATTCAGGCCTGACGTGGCTTCGGTGGATGAC
AGCC 1-d GTGAAAAATTCACCCCTGCGCAGAACATGATTTTTTCGCGTAAAAGTGCGCAACTGGCATCACGTCAGTCAGTGTAA
n ,-i m ,-o 7 Delta ATGATTTACTGTCCGTCGTGTGGACATGTTGCTCACACCCGTCGCGCACATTTCATGGACGATGGCACCAAGATAATGA
TTGCA w o w CAGTGCCGGAATATTTATTGCTCTGCGACATTTGAAGCGAGTGAAAGCTTTTTCTCTGACAGTAAAGATTCAGGAATGG
AATAC
'a o ATTTCAGGCAAACAGAGATACCGCGATTCACTGACGTCAGCCTCCTGCGGTATGAAACGCCCGAAAAGAATGCTTGTTA
CCGG
w w vi GTGCACGGATCCGGGCTGTGGTCTGGTGTTTAAAACGCTTCAGACCATCAACCGCTTCATTGTCCGCCCGGTCACGCCG
GACG r..) o r..) AACTGGCAGAACGCCTGCATGAAAAACAGGAACTGCCGCCAGTACGGTTAAAAACACAATCATATTCGCTGCGTCTGGA
ATGA
i-J
.6.
.6.
8 Q through S of P2 TCAGTCGTTGTCAGTGTCCAGTGAGTAGTTTTTAAAGCGGATGACCTCCTGACCGAGCCAGCCGTTTATCTCGCGGATC
CTGTC r..) oe CTGTAACGGGATAAGCTCATTGCGGACAAAGACCTTTGCCACTTTCTCAATATCACCCAGCGACCCGACGTTCTCCGGC
TTGCC
ACCCATCAACTGAAAGGGGATGCGGTGCGCGTCCAGCAGGTCAGCGGCGCTGGCTTTTTTGATATTAAAAAAATCGTCC
TTCG
TCGCCACTTCACTGAGGGGGATAATTTTAATGCCGTCGGCTTTCCCCTGTGGGGCATAGAGAAACAGGTTTTTAAAGTT
GTTGC
GGCCTTTCGACTTGACCATGTTTTCGCGAAGCATTTCGATATCGTTGCGATCCTGCACGGCATCGGTGACATACATGAT
GTATCC
GGCATGTGCGCCATTTTCGTAATACTTGCGGCGGAACAACGTGGCCGACTCATTCAGCCAGGCAGAGTTAAGGGCGCTG
AGAT
ATTCCGGCAGGCCGTACAGCTCCTGATTAATATCCGGCTCCAGCAGGTGAAACACGGAGCCGGGCGCGAAGGCTGTCGG
CTC
GTTGAAGGACGGCACCCACCAGTAAACATCCTCTTCCACGCCACGGCGGGTATATTTTGCCGGTGAGGTTTCCAGTCTG
ATGAC P
CTTACCGGTGGTGCTGTAACGCTTTTCCAGAAACGCATTACCGAACACCAGAAAATCCAGCACAAAGCGGCTGAAATCC
TGCT L.
, L.
, 1¨
GGGAAAGCCATGGATGCGGGATAAATGTCGAGGCCAGAATATTGCGTTTGACGTAAATCGGCGAGCTGTGATGCACGGC
AGC .3 .
r..) CCGCAGGCTTTTTGCCAGACCGGTAAAGCTGACCGGTGGCTCATACCATCTGCCGTTACTGATGCACTCGACGTAATCC
AGAAT
, GTCACGGCGGTCGAGTACCGGCACCGGCTCACCAAAGGTGAATGCCTCCATTTTCGGGCCGCTGGCGGTCATTGTTTTT
GCCG , , CAGGTTGCGGTGTTTTCCCTTTTTTCTTGCTCATCAGTAAAACTCCAGAATGGTGGATGTCAGCGGGGTGCTGATACCG
GCGGT
GAGTGGCTCATTTAACAGGGCGTGCATGGTCGCCCAGGCGAGGTCGGCGTGGCTGGCTTCCTCGCTGCGGCTGGCCTCA
TAG
GTGGCGCTGCGTCCGCTGCTGGTCATGGTCTTGCGGATAGCCATAAACGAGCTGGTGATGTCGGTGGCGCTGACGTCGT
ATTC
CAGACAGCCACGGCGGATAACGTCTTTTGCCTTGAGCACCATTGCGGTTTTCATTTCCGGCGTGTAGCGGATATCACGC
GCGGC
GGGATAGAACGAGCGCACGAGCTGGAACACGCCGACACCGAGGCCGGTGGCATCAATACCGATGTATTCGACGTTGTAT
TTT
TCGGTGAGTTTGCGGATGGATTCCGCCTGGGTGGCAAAGTCCATGCCTTTCCACTGGTGACGCTCAAGTATTCTGAATT
TGCCA
1-d CCGGCCACCACCGGCGGTGCCAGTACCACGCATCCGGCGCTGTCGCCACGGTGTGACGGGTCGTAACCAATCCATACCG
GGC n GGGAGCCGAACGGATTGGCGGCAAACGGCGCATAGTCTTCCCATTCTTCCAGCGTGTCGACCATGCAGCGTTGCAGCTC
CTCG t=1 1-d AACGGGAACACCGATGCCTTGTCGTCAACAAATTCACACATGAACAGGTTTTTAAAATCGTCGGCGCTGTTTTCGCGTT
TGAGC r..) o r..) TGCTCAATGTCGAACAGCGTGCAGCCGCCTTTCAGGGCGTCCTCAATGGTGACAATCTGTCGCCACTGGCCGTCCGCAC
AGAG =
'a AAGCCCACCGGCAAGGGCGTTATGACTGACGTCGATTTCCACGCGTTCGGCGGCGCTGGCGCGTCCCCGGTTAAACAGT
TCAC o .6.
r..) r..) un CCGACCAGAACGGGTAGGCGTCGTGCGCCAGCGTGGACGGGGTGGAGAAATAGGTCGAGCGCAGGTGACTCTGTGAGGC
CA
TACCTGATGCCACCTTACGCAGTACCTGAAAATTCGGGATCCAGAAAATCTCATCGACGTACAGGTCGCCGTTATGACT
CTGCG n.) o n.) CGGTGTTGGAGTTGGTGCCGAGAAAAATCAGTTTTGCGCCGTTATTGCCCAGGACAATCGGGTCACCGGTCAGGTCAAC
GTCA
i-J
ACCAGACGGGCAAAGGCGATGATGTATTCGCGGAACACATACGCCTGTGTTTTACTGGCCGACAGAAAAATCTGGTTAT
GACC .6.
.6.
n.) GGTTTTCAGGGCACGCAGCAGCGCCTCGCGGGAAAAATAAAACGTCGCGCCAATCTGGCGGGATTTCAGGATATCGCGG
ATG oe CGGTGCTCAAGCCCGGCACGATACCAGTGCAGCTGATAGTCGAAAGACTGCTCAAAGAAAATCTGCTCCAGCTTTTCGA
TGGC
CTCGTCACTGAAAAAATTCTTTTTCGGTTTGCGCCGTCCGCCTTTGTTACGGTTAGCGACGTTCGGATTAAGGTCTGCC
TCGTTG
CCGGTCTGGCTGTAGCGGTTGACCCGTGCCAGTCGTTCAATCTGGCGTCCCAGCAGGTCAATTTCCTTGAAGTCACCGC
CGGTT
TTCTGTGGTTTGATGATGAGCTGGGTCAGCCGCGCTTCCAGACTCATTTCGACACGGCTGATGGGGGCAACGCTGTCCC
AGCC
GTCGCGCTGTTTCCAGCTCTGCACTGTCGGGCGTTTCATCTGCAACATGGCGGCAATCTGCGGCACGGAAAACCCCTGC
CAGTA
CAGCAGCGCCGCCTGACGACGCGGGTCGTGTAAAAGAGTGGTGTCTGTGGTGATGGTCATGAATACCTCGCCGTGATGA
ATA
P
CACGGCAAGGCTACTGAGTCGCGCCCCGCGATTCGCTAAGGTGCTGTTGTGTCAGTGATAAGCCATCCGGGACTGATGG
CGG
AGGATGCGCATCGTCGGGAAACTGATGCCGACATGTGACTCCTCTAATCACTATTCAGGACTCCTGACAATGGCAAAAA
AAGT
CTCAAAATTCTTTCGTATCGGCGTTGAGGGTGACACCTGTGACGGGCGTGTCATCAGTGCGCAGGATATTCAGGAAATG
.3 AAACCTTTGACCCGCGTGTCTATGGTTGCCGCATTAACCTGGAACATCTGCGCGGCATCCTGCCTGACGGTATTTTTAA
ATGGCGATGTGGCCGAACTGAAGGCCGAAAAGATTGACGATGATTCGGCGCTGAAAGGCAAATGGGCGCTGTTTGCGAA
AAT
.31 .3 CACCCCGACCGATGACCTTATCGCGATGAACAAGGCCGCGCAGAAGGTCTACACCTCAATGGAAATTCAGCCGAACTTT
GCCA
ACACCGGCAAATGTTATCTGGTGGGTCTGGCCGTCACCGATGACCCGGCAAGCCTCGGCACGGAATACCTGGAATTCTG
CCGC
ACGGCAAAACACAACCCCCTGAACCGCTTCAAATTAAGCCCTGAAAACCTGATTTCAGTGGCAACGCCTGTTGAGCTGG
AATTT
GAAGACCTGCCTGAAACCGTGTTCACCGCCCTGACCGAAAAGGTGAAGTCCATTTTTGGCCGCAAACAGGCCAGCGATG
ATGC
CCGTCTGAATGACGTGCATGAAGCGGTGACCGCTGTTGCTGAACATGTGCAGGAAAAACTGAGCGCCACTGAGCAGCGC
CTC
GCTGAGATGGAAACCGCCTTTTCTGCACTTAAGCAGGAGGTGACTGACAGGGCGGATGAAACCAGCCAGGCATTCACCC
GCC
IV
TGAAAAACAGTCTCGACCACACCGAAAGTCTGACCCAGCAGCGCCGCAGCAAAGCCACCGGCGGTGGCGGTGACGCCCT
GAT n GACGAACTGCTGACCGGCGTCAGTCAGTCCGGGAAAACCTTCACGATTAACCCTTAATTTCAGGAAAAACTATGCGCCA
GGAA t=1 tl ACCCGCTTTAAATTTAATGCCTACCTGTCCCGTGTTGCCGAACTGAACGGCATCGACGCCGGTGATGTGTCGAAAAAAT
o GTTGAACCGTCGGTCACCCAGACCCTGATGAACACCATGCAGGAGTCCTCTGACTTTCTGACCCGCATCAATATTGTGC
CGGTC 'a o AGCGAAATGAAAGGGGAAAAAATTGGTATCGGTGTCACCGGCTCCATCGCCAGCACTACCGACACTGCCGGTGGTACCG
AGC tt n.) un GTCAGCCGAAGGACTTCTCGAAGCTGGCGTCAAACAAGTACGAATGCGACCAGATTAACTTCGATTTTTATATCCGCTA
CAAAA
CGCTGGACCTGTGGGCGCGTTATCAGGATTTCCAGCTCCGTATCCGTAACGCCATTATCAAACGCCAGTCCCTTGATTT
CATCAT n.) o n.) GGCCGGTTTTAACGGCGTGAAGCGTGCCGAAACCTCTGACCGCAGCAGCAATCCGATGTTGCAGGATGTGGCGGTCGGC
TGG
i-J
CTGCAGAAATACCGCAATGAAGCACCGGCGCGCGTGATGAGCAAGGTCACTGACGAGGAAGGCCGCACCACCTCTGAGG
TTA .6.
.6.
n.) TCCGCGTGGGTAAGGGCGGTGATTATGCCAGCCTTGATGCACTGGTGATGGATGCGACCAACAACCTGATTGAACCGTG
GTAT oe CAGGAAGACCCTGACCTTGTGGTGATTGTGGGGCGTCAGCTACTGGCGGACAAGTATTTCCCCATCGTCAACAAGGAGC
AGG
ACAACAGCGAAATGCTGGCCGCTGACGTCATCATCAGCCAGAAACGCATCGGTAACCTACCAGCGGTACGCGTCCCGTA
CTTC
CCGGCGGATGCGATGCTCATCACGAAGCTGGAAAACCTGTCCATCTACTACATGGATGACAGCCATCGCCGCGTGATTG
AGGA
AAACCCGAAACTCGACCGCGTGGAGAACTACGAGTCAATGAACATTGATTACGTGGTGGAAGACTACGCCGCCGGTTGT
CTG
GTGGAAAAAATCAAGGTCGGTGACTTCTCCACACCGGCTAAGGCGACCGCAGAGCCGGGAGCGTAACCGATGACGAGTC
CCG
CACAGCGCCACATGATGCGGGTCTCGGCAGCGATGACCGCGCAGCGGGAAGCCGCCCCGCTGCGACATGCAACTGTCTA
TGA
P
GCAGATGCTGGTTAAGCTCGCCGCAGACCAGCGCACACTGAAAGCGATTTACTCAAAAGAGCTGAAGGCCGCAAAAAAA
CGC
GAACTGCTGCCGTTCTGGTTGCCGTGGGTGAACGGCGTGCTGGAGCTGGGCAAAGGTGCACAGGATGACATTCTGATGA
CGG
TCATGCTGTGGCGTCTGGATACCGGCGATATTGCCGGTGCGCTGGAGATTGCCCGTTATGCCCTGAAGTACGGTCTGAC
.6.
.3 CCGGGTAAACACCGCCGTACCCCGCCGTACATGTTCACCGAGGAGGTAGCGCTTGCGGCCATGCGCGCTCACGCTGCCG
GTCTGTGGATACCCGCCTGCTGACGGAGACCCTTGAACTGACCGCCACGGCTGACATGCCTGATGAAGTGCGCGCAAAG
CTGC
.31 .3 ACAAAATCACCGGTCTGTTTCTGCGTGACGGTGGTGATGCCGCCGGTGCGCTGGCGCACCTGCAACGTGCGACACAGCT
CGAC
TGTCAGGCAGGCGTCAAAAAAGAGATTGAACGACTGGAGCGGGAGCTGAAACCGAAGCCGGAGCCGCAGCCCAAAGCGG
CC
ACCCGCGCCCCGCGTAAGACCCGGAGCGTGACACCGGCAAAACGTGGACGCCCGAAAAAGAAAGCCAGTTAACAACCGA
ATG
CGCCCCGCGCCAGGGCGGCACGCCGGTCAGTGACGGTGAATCACCTGACACTGCACCGGCGTCCACCGCCCGACTTTTC
AGAG
GTAGTCATGATGACGCTGATTATTCCGCGAAAGGAGGCTCCCGTGTCCGGTGAGGGTACGGTGGTCATCCCGCAACCGG
CAG
GCGACGAGCCGGTGATTAAAAACACGTTCTTTTTTCCCGATATCGACCCGAAGCGCGTCCGGGAACGTATGCGCCTTGA
GCAG
IV
ACCGTCGCCCCCGCCCGTCTGCGTGAGGCCATCAAGTCAGGCATGGCTGAAACGAATGCGGAGCTGTACGAGTACCGCG
AAC n AGAAAATTGCCGCCGGTTTTACGCGTCTGGCTGACGTCCCGGCGGACGATATCGACGGTGAAAGCATCAAGGTTTTTTA
CTAC t=1 tl GAGCGCGCCGTGTGTGCGATGGCGACCGCGTCGCTTTATGAGCGTTATCGCGGTGTGGATGCCAGTGCGAAAGGCGACA
o AGGCTGACAGCATTGACAGCACCATTGATGAGCTGTGGCGGGATATGCGCTGGGCGGTGGCGCGCATCCAGGGCAAGCC
GC 'a o GCTGCATCGTGAGTCAAATCTGATGAAGACCTTTGCGCTACAGGGCGACACGCTCGACGCCATTTGTGTCCGCTATTAC
GGGC tt n.) un GCACTGAGGGCGTGGTTGAGACCGTGCTCGCCGCAAATCCGGGACTGGCTGAACTGGGGGCGGTGCTGCCACACGGCAC
CG
CCGTCGAACTGCCCGACGTTCAGACCGCGCCCGTGGCTGAAACTGTCAATCTGTGGGAGTAACGCATGACAGCAGAAGA
AAA n.) o n.) AAGCGTCCTGTCGCTTTTCATGATTGGGGTGCTGATTGTTGTCGGCAAGGTGCTTGCCGGTGGTGAACCTATCACCCCG
CGTCT
i-J
GTTTATCGGGCGCATGTTGCTCGGTGGTTTTGTCTCGATGGTTGCCGGTGTTGTTCTGGTGCAGTTTCCTGACCTGTCA
CTGCCA .6.
.6.
n.) GCGGTGTGCGGCATCGGCTCCATGCTGGGTATCGCCGGTTATCAGGTGATTGAGATTGCCATTCAGCGCCGCTTTAAGG
GCAG oe GGGGAAACAGTAATGCCGGTAATTAACACGCATCAGAATATCGCCGCCTTTCTCGACATGCTGGCCGTGTCCGAAGGGA
CGGC
GAATCATCCACTGACGAAAAACCGGGGCTATGACGTGATAGTCACCGGACTGGACGGGAAGCCGGAAATTTTCACCGAC
TAC
AGTGACCACCCGTTCGCACATGGCCGACCGGCGAAGGTGTTTAACCGTCGCGGTGAAAAATCCACGGCCTCCGGTCGCT
ATCA
GCAGCTTTACCTGTTCTGGCCGCATTACCGCAAACAGCTTGCCCTGCCGGATTTCAGTCCGTTGTCACAGGACAGACTC
GCCAT
TCAGTTGATCCGCGAACGCGGAGCACTGGATGACATCCGGGCGGGACGCATTGAGCGCGCCATTTCACGCTGTCGCAAT
ATCT
GGGCGTCCCTGCCGGGTGCCGGTTACGGTCAGCGTGAGCATTCACTGGAAAAACTGGTCACCGTCTGGCGTACCGCTGG
CGG
P
CGTACCGGCTTAAACGGAGTAAATACCATGAAGAAATTATCCCTTTCACTGATGCTGAACGTGTCGCTGGCGCTGATGC
TGGC
ACTGTCCCTGATTTACCCGCAGAGCGTGGCCGTCAATTTTGTCGCTGCCTGGGCGATTCTGGCGACGGTTATCTGTGTG
GTTGC
CGGTGGTGTGGGCGTGTATGCCACTGAGTATGTGCTGGAACGCTACGGGCGGGAGCTGCCGCCGGAATCGCTGGCCGTG
un .3 GATTGTCACGTCGCTGTTTTTGCAGCCGGTGCCGTGGCGCAGACGGGCGGCGGCTCTGGTAGTGGTGGTGGCGACGTTT
CGCTGGTCGCTGCCGGGTGGATTTTTACCGCGCTGATTTATCTTGTGGTGTCGCTGTTTTTCCGGCTGATACGTAAAGC
CTGTC
.31 .3 GTCAGCGTCTTGAGGGGCGGGAACCATGTCAAGGCTGATGATTGTGCTGGTCGTGTTGTTATCGCTGGCGGTGGCCGGT
CTGT
TTCTGGTGAAACACAAAAATGCCAGCCTGCGCGCCTCGCTGGACAGGGCGAACAACGTCGCCAGCGGTCAGCAGACGAC
CAT
CACCATGCTGAAAAATCAGCTTCATGTTGCGCTCACCAGGGCAGATAAAAACGAGCTGGCGCAGGTGGCACTGCGTCAG
GAA
CTGGAGAACGCCGCGAAACGTGAAGCACAGCGCGAGAAAACCATCACGAGGTTACTTAATGAGAACGAAGATTTTCGCC
GCT
GGTACGGTGCTGACCTGCCTGATGCTGTGCGCCGGTTGCACCAGCGCCCCGCCTGCACCGACGCCAGTGATTGTCCCCA
ACGC
ATGCCCGAAAGTGAGCCTTTGCCCGATGCCGGGCAGTGACCCGCAGACGAACGGCGATTTAAGTGCCGATATCCGGCAG
CTT
IV
GAGAACGCGCTGGCACGCTGTGCCAGCCAGGTAAAAATGATTAAACACTGTCAGGACGAAAACGATGCTCAAACCCGAC
AGC n CTGCGCAGGGCGCTGACTGATGCCGTCACGGTGCTGAAAACTAACCCCGATATGCTGCGGATATTCGTGGATAACGGGA
GTAT t=1 tl TGCCTCCACACTGGCGGCGTCGCTGTCATTCGAAAAGCGTTACACGCTCAATGTGATTGTGACCGACTTTACCGGTGAT
o CCTGCTCATTGTGCCGGTGCTGGCGTGGCTGCGGGAAAATCAGCCCGACATCATGACCACCGACGAAGGCCAGAAAAAG
GGC 'a o TTCACGTTTTATGCAGACATCAACAATGACAGCAGCTTTGATATCAGTATCAGCCTGATGCTGACCGAGCGCACGCTGG
TCAGT tt n.) un GAGGTGGACGGCGCACTGCATGTGAAGAATATCTCGGAACCCCCGCCGCCGGAGCCGGTCACCCGCCCGATGGAGCTGT
ATA
TCAATGGCGAACTGGTGAGTAAGTGGGATGAATGAGTTTAAGCGTTTTGAAGACCGGCTGACCGGACTGATTGAATCGC
TGTC n.) o n.) ACCGTCAGGGCGTCGGCGACTGAGTGCCGAACTGGCGAAACGTCTGCGGCAGAGTCAGCAGCGTCGGGTGATGGCACAG
AA
AGCCCCGGACGGCACACCCTACGCGCCACGCCAGCAGCAGAGCGTCAGAAAAAAGACCGGTCGCGTTAAGCGAAAAATG
TTT .6.
.6.
n.) GCGAAACTTATTACCAGTCGTTTTTTGCATATCCGTGCCAGCCCGGAGCAGGCATCAATGGAATTTTACGGCGGGAAGT
CGCC oe GAAAATCGCCAGTGTGCATCAGTTTGGTCTGTCGGAAGAAAACCGGAAAGACGGTAAGAAAATTGATTATCCGGCGCGT
CCCC
TGCTCGGCTTTACCGGTGAGGATGTGCAGATGATTGAAGAGATTATCCTGGCTCACCTTGAGCGTTAG
9 V through G of P2 ATGAACACTCTCGCAAATATTCAGGAACTCGCGCGCGCACTGCGCAACATGATTCGCACTGGCATTATCGTCGAAACCG
ACCTT
AACGCCGGTCGCTGCCGCGTGCAGACCGGCGGCATGTGCACCGACTGGCTTCAGTGGCTGACCCATCGCGCAGGACGTT
CGC
GCACATGGTGGGCACCTTCCGTGGGGGAACAGGTGCTGATTCTGGCCGTGGGTGGTGAACTCGACACGGCGTTCGTTCT
GCC
GGGGATTTATTCCGGCGATAACCCCTCGCCGTCTGTGTCGGCGGATGCCCTGCATATCCGTTTCCCTGACGGGGCGGTG
ATTG P
AATATGAACCCGAAACCAGTGCACTCACGGTAAGCGGAATTAAAACGGCCAGCGTGACGGCTTCCGGTTCTGTTACTGC
CACG L.
, L.
, 1-, GTGCCGGTGGTCATGGTGAAAGCATCAACCCGCGTCACCCTGGACACCCCGGAGGTGGTCTGCACCAACAGGCTGATTA
CCG .3 .
eA
GCACGCTGGAAGTGCAGAAAGGCGGGACGATGCGCGGCAACATTGAACACACCGGCGGTGAACTCTCATCAAACGGTAA
GG
, TACTGCATACCCATAAACACCCCGGCGACAGCGGCGGCACAACCGGGAGTCCTTTATGACAGCGCGTTATCTCGGAATG
AATC , , GCAGTGATGGCCTGACTGTCACTGACCTTGAGCATATCAGCCAGAGTATCGGCGATATCCTGCGCACACCGGTCGGCTC
ACGG
GTGATGCGTCGTGATTACGGCTCGTTGCTGGCGTCAATGATTGACCAGCCGCAGACCCCGGCGCTTGAGTTGCAGATTA
AAGT
CGCCTGTTACATGGCAGTGCTGAAATGGGAACCCCGCGTCACCCTGTCATCCGTCACCACGGCGCGCAGTTTTGACGGG
CGAA
TGACGGTCACGTTAACCGGCCAGCACAACGACACCGGCCAGCCACTTTCATTAACCATCCCTGTGAGTTGAAACCATGC
CGATT
ATCGACCTGAACCAGCTACCCGCACCGGATGTGGTCGAGGAGCTGGACTTTGAAAGCATTCTCGCTGAACGCAAGGCGA
CACT
GATTTCCCTTTACCCGGAAGATCAGCAGGAGGCGGTCGCCCGTACCCTGACACTGGAATCTGAGCCTCTCGTCAAACTG
CTGG
Iv AAGAAAATGCTTATCGTGAGCTTATCTGGCGTCAGCGTGTGAATGAGGCCGCACGGGCGGTGATGCTGGCCTGTGCCGC
CGG n TAATGACCTTGATGTGATTGGTGCCAATTACAACACCACGCGCCTGACTATCACCCCGGCAGATGATTCGACCATCCCG
CCGAC t=1 Iv ACCGGCAGTGATGGAATCTGACACCGATTATCGTCTGCGTATTCAGCAGGCTTTTGAGGGCTTAAGCGTCGCCGGGTCA
GTGG n.) o n.) GAGCCTATCAGTATCATGGTCGCAGTGCTGACGGGCGTGTCGCGGATATTTCTGTCACCAGTCCGTCTCCGGCCTGTGT
CACCA
'a TCTCTGTGCTGTCACGTGAAAATAACGGCGTCGCATCCGAAGACCTGCTGGCTGTGGTGCGTAACGCCCTTAATGGCGA
GGAC eA
.6.
n.) n.) un GTCAGGCCGGTGGCCGACCGCGTGACCGTGCAGTCTGCCGCCATCGTTGAATACCAGATAAACGCCACGCTTTACCTTT
ACCCT
GGTCCCGAAAGCGAACCCATCCGCGCTGCCGCTGTGAAAAAGCTGGAAGCGTATATCACGGCACAGCACCGGCTGGGGC
GCG n.) o n.) ACATCCGTCTGTCTGCCATTTATGCCGCTTTGCATGTGGAAGGTGTGCAGCGTGTCGAACTGGCTGCACCACTGGCCGA
CATCG
i-J
TGCTCAACAGTACGCAGGCGTCTTTCTGTACCGAATACCGCGTCGTGACCGGAGGCTCGGATGAGTGATTCGCGACTGC
TGCC .6.
.6.
n.) GACCGGCTCATCACCGCTTGAGGTCGCCGCCGCAAAAGCCTGTGCGGAAATTGAAAAAACGCCGGTCAGTATTCGTGAA
CTGT oe GGAACCCGGACACCTGTCCGGCAAATCTGCTGCCGTGGCTGGCGTGGGCGTTTTCGGTCGACAGGTGGGATGAAAAGTG
GCC
GGAAGCGACAAAACGCGCCGTTATCCGCGATGCCTATTTCATCCACTGTCATAAGGGCACGATAGGTGCAATCCGGCGT
GTGG
TGGAGCCGCTCGGCTATCTCATCAACGTGACGGAGTGGTGGGAAAACAGTGACCCGCCCGGCACCTTCCGGCTTGATAT
TGGT
GTACTGGAAAGCGGTATCACAGAGGCAATGTATCAGGAAATGGAACGGCTGATTGCTGATGCCAAACCTGCAAGCCGTC
ACC
TTATTGGCCTGAACATTACCCGGGACATTCCCGGCTATCTGTTCGCCGGTGGTGTGGCTTACGACGGCGATGTAATTAC
GGTTT
ACCCCGGATAAGTGAGGAATAATGAGCATAAAATTCAGAACCGTTATCACCACTGCCGGTGCAGCAAAGCTGGCAGCGG
CAA
P
CCGCGCCGGGAAGGCGGAAGGTCGGCATTACCACGATGGCCGTCGGGGATGGCGGTGGTAAATTGCCTGTCCCGGATGC
CG
GACAGACCGGGCTTATCCATGAAGTCTGGCGACATGCGCTGAACAAAATCAGCCAGGACAAACGAAACAGTAATTATAT
TATC
GCCGAGCTGGTTATTCCGCCGGAGGTGGGCGGTTTCTGGATGCGTGAGCTTGGCCTGTACGATGATGCGGGAACGTTAA
--.1 .3 CCGTGGCGAACATGGCCGAAAGCTATAAGCCAGCCCTTGCCGAAGGCTCAGGACGTTGGCAGACCTGTCGCATGGTCAT
GTCAGCAGTGTGGCCTCAGTGGAGCTGACCATTGACACCACAACGGTGATGGCGACGCAGGATTACGTTGATGACAAAA
TTG
.31 .3 CAGAGCACGAACAGTCACGACGTCACCCGGACGCCTCGCTGACAGCAAAAGGTTTTACTCAGTTAAGCAGTGCGACCAA
CAGC
ACGTCTGAAACACTGGCCGCAACGCCGAAAGCGGTAAAGGCCGCGTATGACCTGGCTAACGGGAAATATACCGCACAGG
ACG
CCACCACAGCGCGAAAAGGCCTTGTCCAGCTTAGTAGCGCCACCAACAGCACGTCTGAAACGCTCGCCGCAACACCAAA
AGCC
GTTAAGACGGTAATGGATGAAACGAACAAAAAAGCGCCATTAAACAGCCCTGCACTGACCGGAACGCCAACGACGCCAA
CTG
CGCGACAGGGAACGAATAATACTCAGATCGCAAACACGGCTTTCGTTATGGCCGCGATTGCCGCCCTTGTAGACTCGTC
GCCT
GACGCACTGAATACGCTGAACGAGCTGGCGGCGGCGCTGGGCAATGACCCGAATTTTGCTACCACCATGACTAATGCGC
TTGC
IV
GGGTAAGCAACCGAAAGATGCTACCCTGACGGCGCTGGCGGGGCTTGCTACTGCGGCAGACAGGTTTCCGTATTTTACG
GGG n AATGATGTTGCCAGCCTGGCGACCCTGACAAAAGTCGGGCGGGATATTCTGGCTAAATCGACCGTTGCCGCCGTTATCG
AATA t=1 tl TCTCGGTTTACAGGAAACGGTAAACCGAGCCGGGAACGCCGTGCAAAAAAATGGCGATACCTTGTCCGGTGGACTTACT
o AAAACGACTCAATCCTTGCCTGGATTCGAAATACTGACTGGGCGAAGATTGGATTTAAAAATGATGCCGATGGTGACAC
TGAT 'a o TCATACATGTGGTTTGAAACGGGGGATAACGGCAATGAATATTTCAAATGGAGAAGCCGCCAGAGTACCACAACAAAAG
ACC tt n.) un TGATGACGTTGAAATGGGATGCACTAAATATTCTTGTTAATGCCGTCATTAATGGCTGTTTTGGAGTTGGTACGACGAA
TGCAC
TAGGTGGTAGCTCTATTGTTCTTGGTGATAATGATACCGGATTTAAACAGAATGGAGACGGTATTCTTGATGTTTATGC
TAACA tµ.) o tµ.) GTCAGCGTGTATTCCGTTTTCAGAATGGAGTGGCTATTGCTTTTAAAAATATTCAGGCAGGTGATAGTAAAAAGTTCTC
GCTAT
i-J
CCAGCTCTAATACATCCACGAAGAATATTACCTTTAATTTATGGGGTGCTTCCACCCGTCCAGTGGTTGCAGAGTTAGG
CGATG .6.
.6.
tµ.) AGGCCGGATGGCATTTCTATAGCCAGCGAAATACAGATAACTCGGTAATATTTGCTGTTAACGGTCAGATGCAACCCAG
CAAC oe TGGGGAAATTTTGATTCCCGCTATGTGAAAGATGTTCGCCTGGGTACGCGAGTTGTTCAATTGATGGCGCGAGGTGGTC
GTTA
TGAAAAAGCCGGACACACGATTACCGGATTAAGAATCATTGGTGAAGTAGATGGCGATGATGAAGCCATCTTCAGGCCG
ATA
CAAAAATACATCAATGGCACATGGTATAACGTTGCGCAGGTGTAAGTTATGCAGCATTTAAAGAACATTAAGTCAGGTA
ATCC
AAAAACAAAAGAGCAATATCAGCTAACAAAGAATTTTGATGTTATCTGGTTATGGTCCGAAGACGGAAAAAACTGGTAT
GAGG
AAGTGAAGAACTTTCAGCCAGACACAATAAAGATTGTTTACGATGAAAATAATATTATTGTCGCTATCACCAGAGATGC
TTCAA
CGCTTAATCCTGAAGGTTTTAGCGTTGTTGAGGTTCCTGATATTACCTCCAACCGACGTGCTGACGACTCAGGTAAATG
GATGT
P
TTAAGGATGGTGCTGTGGTTAAACGGATTTATACGGCAGATGAACAGCAACAACAGGCAGAATCACAAAAGGCCGCGTT
ACTT .
, TCCGAAGCGGAAAACGTTATTCAGCCACTGGAACGCGCTGTCAGGCTGAATATGGCGACGGATGAGGAACGTGCACGAC
TGG
...]
1¨
.3 AGTCATGGGAACGTTACAGCGTTCTGGTCAGCCGTGTGGATCCTGCAAATCCTGAATGGCCGGAAATGCCGCAATAA
.
oe , , Fl through ogr of P2 ATGAGTGACTATCATCACGGCGTGCAGGTGCTGGAGATTAACGAGGGCACCCGCGTCATTTCCACCGTATCCACGGCCA
TTGT , , CGGCATGGTCTGCACGGCCAGCGATGCAGATGCGGAAACCTTCCCCCTCAATAAACCTGTGCTGATTACCAATGTGCAG
AGCG
CAATTTCAAAGGCCGGTAAAAAAGGCACGCTGGCGGCATCGTTGCAGGCCATCGCTGACCAGTCAAAACCGGTCACCGT
TGTC
ATGCGCGTGGAAGACGGCACCGGTGATGACGAGGAAACGAAACTCGCGCAGACCGTTTCCAATATCATCGGCACCACCG
ATG
AAAACGGTCAGTACACCGGACTAAAAGCCATGCTGGCGGCGGAGTCGGTAACCGGTGTTAAACCGCGTATTCTCGGCGT
GCC
GGGACTGGATACCAAAGAGGTGGCTGTTGCACTGGCATCAGTCTGTCAGAAGCTGCGTGCTTTCGGGTATATCAGCGCA
TGG
GGCTGTAAAACCATTTCCGAGGTGAAAGCCTATCGTCAGAATTTCAGCCAGCGTGAGCTGATGGTCATCTGGCCGGATT
TCCTC
1-d GCATGGGATACGGTCACCAGTACCACCGCCACCGCGTATGCCACCGCCCGTGCGCTGGGGCTGCGCGCTAAAATCGACC
AGG n ,-i AGCAGGGCTGGCATAAAACGCTGTCCAATGTCGGGGTGAACGGTGTTACCGGCATCAGCGCATCTGTATTCTGGGATTT
GCAG t=1 1-d GAGTCCGGCACCGATGCTGACCTGCTTAACGAGTCAGGCGTCACTACGCTGATTCGCCGCGACGGTTTCCGCTTCTGGG
GTAA tµ.) o tµ.) CCGTACCTGCTCTGATGACCCGCTGTTCCTCTTTGAAAACTACACCCGCACCGCGCAGGTCGTGGCCGACACGATGGCT
GAGGC =
'a GCACATGTGGGCGGTGGACAAGCCCATCACTGCAACGCTGATTCGCGACATCGTTGACGGCATCAATGCCAAATTCCGT
GAGC
.6.
tµ.) tµ.) un TGAAAACAAACGGCTATATCGTGGATGCGACCTGCTGGTTCAGCGAAGAATCCAACGATGCGGAAACCCTCAAGGCCGG
AAA
ACTGTATATCGACTACGACTATACACCGGTGCCTCCTCTCGAAAACCTGACCCTGCGCCAGCGTATTACCGATAAATAC
CTGGC n.) o n.) AAATCTGGTCACCTCGGTTAACAGCAATTAAGGAGCCTGACCGATGGCAATGCCGCGCAAACTCAAGTTAATGAACGTC
TTTCT
i-J
GAACGGCTACAGCTATCAGGGCGTTGCAAAGTCCGTCACGCTGCCAAAACTGACCCGTAAGCTCGAAAACTATCGCGGT
GCGG .6.
.6.
n.) GGATGAACGGCAGCGCACCGGTAGACCTCGGCCTTGATGACGATGCGCTGTCAATGGAGTGGTCGCTCGGTGGCTTCCC
GGA oe TTCGGTTATCTGGGAGCTTTACGCCGCAACCGGTGTGGATGCCGTGCCGATTCGTTTTGCAGGCTCTTACCAGCGCGAC
GATAC
CGGCGAAACGGTGGCCGTCGAAGTGGTCATGCGTGGACGTCAGAAAGAAATCGACACCGGCGAGGGTAAACAGGGAGAA
G
ACACTGAGTCGAAAATCTCCGTGGTCTGCACCTATTTCCGGCTGACGATGGACGGTAAGGAGCTGGTCGAAATTGACAC
CATC
AACATGATTGAGAAGGTGAACGGCGTCGATCGGCTGGAGCAACACCGCCGCAATATCGGCCTGTGATTTTCATCCGGTC
AGCC
TGGCTGGCCGGTTAACCCTGATTCAGAAGTGAGAAAACCATGAACAAAGAAAATGTCATTACCCTGGACAATCCGGTCA
AACG
TGGTGAGCAGGTTATCGAACAGGTCACGCTGATGAAACCCAGTGCCGGGACGCTACGCGGTGTCAGTCTGGCTGCGGTT
GCA
P
AACTCCGAAGTCGATGCACTGATTAAGGTGCTGCCGCGCATGACGGCACCGATGCTGACCGAGCAGGAAGTCGCCGCGC
TGG
AACTGCCTGACCTTGTGGCGCTGGCCGGTAAGGTGGTCGGTTTTTTGTCGCCGAACTCGGTGCAGTGACGTTTCCGAAA
AATC
TCTCGGTCGATGACCTGATGGCGGATGTGGCAGTGATATTTCACTGGCCGCCATCAGAACTGTATCCCATGAGCCTGAC
o .3 CTCATCACATGGCGCGAAAAGGCGCTCCGGCGAAGCGGAAACACGAATGAGTAACAATGTAAAATTACAGGTATTGCTC
GCTGTTGACCAGGCATCCCGCCCGTTTAAATCCATCCGCACAGCGAGCAAGTCGCTGTCGGGGGATATCCGGGAAACAC
AAAA
.31 .3 ATCACTGCGCGAGCTGAACGGTCACGCATCCCGTATTGAGGGATTCCGCAAGACCAGTGCACAGCTCGCCGTGACTGGT
CATG
CACTTGAAAAGGCACGGCAGGAGGCCGAAGCCCTTGCCACACAGTTTAAAAACACCGAACGTCCGACCCGTGCTCAGGC
GAA
AGTCCTGGAATCCGCAAAGCGTGCGGCGGAGGACTTACAGGCGAAATATAACCGCCTGACAGATTCCGTTAAACGCCAG
CAG
CGGGAACTGGCCGCTGTGGGAATTAATACCCGCAATCTTGCACATGATGAGCAGGGACTGAAAAACCGTATCAGTGAAA
CCA
CCGCACAGCTTAACCGTCAGCGTGATGCGCTGGTGCGTGTCAGTGCGCAACAGGCAAAACTTAACGCAGTAAAACAGCG
TTAT
CAGGCCGGAAAGGAACTGGCCGGAAATATGGCCTCAGTGGGCGCTGCCGGTGTGGGGATTGCGGCGGCGGGAACGATGG
C
IV
CGGTGTTAAGCTACTGATGCCCGGTTATGAGTTTGCGCAGAAAAACTCAGAATTACAGGCTGTGATCGGAGTGGCAAAA
GACT n CCGCCGAAATGGCCGCACTCCGCAAGCAGGCGCGCCAGCTCGGCGACAATACCGCCGCCTCGGCAGATGATGCAGCCGG
TGC t=1 tl GCAGATTATTATTGCGAAAGCCGGTGGGGATGTTGATGCCATTCAGGCGGCAACGCCGGTCACGCTGAACATGGCGCTG
o AACCGTCGCACAATGGAAGAAAACGCCGCCCTGCTGATGGGGATGAAATCCGCCTTTCAGCTTTCAAACGATAAGGTCG
CTCA 'a o TATCGGGGATGTTCTCTCCATGACGATGAACAAAACCGCCGCCGATTTTGACGGCATGAGCGATGCGCTGACCTATGCC
GCAC tt n.) un CTGTGGCAAAAAATGCCGGTGTCAGCATTGAAGAAACCGCCGCAATGGTCGGGGCGCTGCATGATGCAAAAATCACAGG
CTC
AATGGCGGGGACGGGAAGCCGTGCCGTGTTAAGCCGCCTGCAGGCACCGACGGGAAAAGCATGGGATGCACTCAAAGAG
CT n.) o n.) TGGAGTGAAAACCTCAGACAGCAAAGGAAACACCCGGCCAATATTTACCATTCTGAAAGAAATGCAGGCCAGTTTTGAG
AAAA
i-J
ACCGGCTCGGTACTGCCCAGCAGGCTGAATACATGAAAACTATTTTCGGGGAGGAGGCCAGCTCAGCCGCTGCCGTGCT
GAT .6.
.6.
n.) GACTGCCGCCTCAACCGGAAAGCTGGACAAACTGACCGCTGCGTTTAAAGCCTCAGACGGGAAGACCGCCGAGCTGGTA
AAT oe ATCATGCAGGACAACCTAGGCGGTGACTTTAAAGCGTTTCAGTCCGCTTATGAGGCGGTGGGGACTGACCTGTTTGACC
AGCA
GGAAGGCGCGCTGCGTAAGCTCACGCAGACGGCCACAAAGTATGTGTTAAAACTCGACGGCTGGATACAGAAAAACAAA
TCA
CTGGCGTCAACCATCGGCATCATTGCCGGCGGTGCACTGGCGCTTACTGGCATCATCGGTGCCATTGGCCTCGTAGCCT
GGCC
GGTTATCACCGGCATCAATGCCATCATCGCGGCAGCAGGCGCAATGGGGGCAGTCTTCACGACGGTTGGCAGTGCTGTT
ATGA
CCGCCATCGGGGCTATTAGCTGGCCGGTTGTGGCCGTGGTGGCTGCCATTGTCGCCGGTGCGTTGCTTATCCGTAAATA
CTGG
GAGCCTGTCAGCGCATTCTTTGGTGGTGTGGTTGAAGGGCTGAAAGCGGCATTTGCGCCGGTGGGGGAACTGTTCACGC
CAC
P
TTAAACCGGTTTTTGACTGGCTGGGCGAAAAGTTACAGGCCGCGTGGCAGTGGTTTAAAAACCTGATTGCCCCGGTCAA
AGCC
ACCCAGGACACCCTGAACCGTTGCCGTGACACGGGCGTCATGTTCGGGCAGGCACTGGCTGACGCGTTGATGCTGCCGC
TTAA
.6.
TGCGTTCAACAAACTGCGCAGTGGTATTGACTGGGTACTGGAAAAACTCGGTGTTATCAACAAAGAGTCAGACACACTT
o .3 AGACCGCCGCCAGAACTCATACCGCCACGTATGGTACCGGTGACTATATTCCGGCGACCAGCTCTTATGCAGGCTATCA
ATCAGCCGGTCACGGCACCGGCTGGCCGCTCTTATGTAGACCAGAGTAAAAACGAATATCACATCAGCCTGACGGGGGG
GAC
.31 .3 TGCGCCGGGGACACAGCTTGACCGCCAGTTACAGGATGCGCTCGAAAAATACGAGCGGGATAAACGTGCGCGCGCCCGT
GCC
AGCATGATGCATGACGGTTAAGGAGGTGACGAAAAATGATGCTCGCGTTAGGTATGTTTGTTTTTATGCGCCAGACGCT
GCCA
CACCAGACCATGCAGCGTGAATCAGATTATCGCTGGCCGTCAAATTCCCGTATCGGTAAACGGGATGCCTTTCAGTTTC
TCGGT
GTGGGTGAGGAAAACATCACGCTGGCCGGTGTGCTTTATCCCGAACTGACCGGCGGCAAGCTGACGATGACCACGCTCA
GGC
TGATGGCAGAGGAGGGGCGGGCGTGGCCGTTGCTGGATGGCACCGGCATGATTTACGGCATGTATGTCATCAGCAGGGT
GA
GTGAAACAGGGAGTATTTTCTTTGCAGACGGCACACCCCGGAAAATTGATTTTACGCTGTCACTCACCCGCGTTGATGA
ATCAC
IV
TGGCCGCGCTTTATGGCGATATCGGTAAACAGGCGGAATCGCTCATCGGTAAGGCCGGCAGTATGGCGACCAGATTCAC
AGG n TATGACGGGGGCGGGATAATGCTGGATGCGCTGACATTTGATGCAGGCAGTACGCTGACGCCGGATTACATGCTGATGC
TCG t=1 tl ACAGCAGGGATATTACCGGCAATATCAGCGACCGTCTGATGAGCATGACCCTGACGGATAACCGGGGCTTTGAGGCTGA
o GCTTGATATTGAACTGAACGATGCCGACGGGCAGGTCGGGCTGCCGGTTCGTGGCGCTGTCCTGACGGTGTATATCGGC
TGG 'a o AAAGGTTTTGCCCTGGTATGCAAAGGGAAATTTACCGTTGATGAGGTTGAACACCGGGGCGCACCGGATGTAGTCACCA
TCCG tt n.) un CGCCCGGAGTGCAGATTTTCGCGGGACGCTCAATTCCCGCCGGGAAGGCTCCTGGCATGACACCACGCTCGGTGCGATT
GTTA
AGGCGATAGCCACCCGTAACAGGCTGGAAGCCAGTGTCGCTCCGTCACTGGCCGGAATAAAAATTCCACACATCGACCA
GTCG t,.) o CAGGAGTCTGATGCGAAATTCCTGACCCGTCTTGCAGAACGCAACGGCGGTGAGGTGTCGGTAAAAATGGGAAAACTGT
TGT
i-J
TTCTCAAAGCGGGGCAGGGAGTGACGGCCAGCGGTAAAAAAATCCCGCAGGTCACCATAACCCGCAGCGACGGCGACCG
CCA
4,.
TCATTTTGCGATTGCTGACCGTGGAGCCTACACCGGTGTAACGGCAAAATGGCTACACACTAAAGACCCGAAGCCGCAA
AAGC oe AGAAGGTAAAACTGAAACGCAAAAAGAAAGAGAAACACCTGCGCGCACTGGAGCACCCGAAAGCGAAACCGGTCAGGCA
GA
AGAAAGCGCCTAAAGTACCGGAAGCGCGTGAAGGTGAATACATGGCCGGTGAGGCTGACAACGTTTTTGCCCTGACCAC
GGT
ATATGCCACGAAAGCGCAGGCCATGCGCGCCGCTCAGGCGAAGTGGGATAAACTGCAACGGGGCGTTGCGGAGTTCTCT
ATC
AGCCTGGCTACCGGTCGGGCAGATATTTACACGGAAACACCGGTCAAAGTGTCTGGCTTTAAGCGCGTCATAGACGAGC
AGG
ACTGGACAATCACTAAGGTGACACATTTTCTGAATAATAGCGGCTTCACGACGTCCTTAGAGCTTGAGGTCAGGCTTTC
TGATG
TGGAGTACGAAACAGAAGATGATGAGTGATGTTTTTGTTTTATCTGTTTGTTTTGTAAGGATAAATTAACTAAAATGGC
ACCAT
P
CAACAAAACCGGAAGAGGTGCTCGCGATGTTTCATTGTCCTTTATGCCAGCATGCCGCACATGCGCGTACAAGTCGCTA
TATCA .
, CTGACACGACAAAAGAGCGTTATCATCAGTGCCAGAACGTGAATTGCAGCGCCACGTTCATCACTTATGAGTCGGTACA
GCGA
_.]
1¨
.3 4,.
TACATCGTGAAGCCGGGAGAAGTCCACGCCGTAAGGCCGCACCCGTTGCCATCAGGGCAGCAAATTATGTGGATGTAA
.
..
1¨
, , 11 S. aureus phi11 ANGATTTANTCC
, , packaging signal 12 cpmA M KTESYF KEYNQFVLDQH KAI QE LEQE R NALESKI
KLDKSTYKQLIM DGQDD KADN LYQATDAD E KKLKALN KR LETKKSVSKEVKY
QKTI E LLKH QS ELSSLYESE KQSAI EKLKKAVDAYN EIIDEIEDIND RYE D EHQQYASVYSQEQLYDD
KEARKALNG H FKE N I FTSFINGN
DLPYEHNNKLFLKC
13 cpmB M KTKYELN NTKKVANAFCLN EE DTN LLI NAVD LD I
KN N M QE ISS E LQQAEQSKQKQYGTTLQN LAKQN RIIK 1-d n 14 ptiA
MDKQQIKDFVCDYHERTRSDVLIDDDINTDEFFSIADENSNEWMADDNIDDHIVKNHLEMIVDRVANDKEFYIFDSLIQ
GRSYQDIS t=1 1-d GVLDCSEQSVRFWYETLLD KIVEVI E
t,.) o o 'a o 4,.
vi 15 ptiB
MESIAEKETYHLPTEHLQVFNVIKNTSNKYITKTKILNQLGYEYNSSNERWLRRVINSLVYDYGYPIGCSYKPSERGYV
IITTEQEKQQA
MRSIKKLADGSMKRYEALKRIEV
w o w o 16 ptiM
MIAYPIRVGSVYRGEQMKLLKTKNCLYYRNGDNKLSEYQLLTQFNPTFINKKIRMCEFQIESMYHMSASTTTCDEMMGV
VSVSYPIE
.6.
.6.
KLVIKIIETKARLQNYKNRSISNMVLLKTVLNHYTEKEQKKVVKYMRSNGRYKPYNVIERLQVDLYQASIKQRSERQKQ
RNIAIENSKIA w oe RVNAYHQSSYVKVV
17 gene #29 (terS) [00119]
through gene #53 atgaacgaaaaacaaaagagattcgcagatgaatatataatgaatggatgtaatggtaaaaaagcagcaattacagcag gttatagtaagaaaacagc (lysin) of phi11 agagtctttagcaagtcgattgttaagaaatgttaatgtttcggaatatattaaagaacgattagaacagatacaagaa gagcgtttaatgagtattacagaagcttta gcgttatctgcttctattgctagaggagaacctcaagaggcttacagtaagaaatatgaccatttaaacgatgaagtgg aaaaagaggttacttacacaatcacacca acttttgaagagcgtcagagatctattgaccacatactaaaagtacatggtgcgtatatcgataaaaaagaaattactc agaagaatattgagattaatattggtgagt P
acgatgacgaaagttaaattaaactttaacaaaccgtctaatgttttcaatagaaacatattcgaaatactaaccaatt acgataacttcactgaagtacattacggtg .
, 1¨
gaggttcgagcggtaagtctcacggcgttatacaaaaagttgtactcaaagcattgcaagattggaaatatcctaggcg tatactgtggcttagaaaagtacaatcaa , .3 .6.
.
w caattaaagatagtttgttcgaagatgttaaagattgtttgataaactttggtatttgggacatgtgcctttggaataa gactgataacaaagttgaattgccaaacggc r., gcagtttttttgtttaaaggattagataacccagagaaaataaagtcgataaaaggcatatcagacatagtcatggaag aagcgtctgaattcacactaaatgattac , , , , acgcaattaacgttgcgtttgagggagcgtaaacacgtgaataagcaaatatttttgatgtttaacccagtatctaaac tgaattgggtttataagtatttctttgaacat r., ggtgaaccaatggaaaatgtcatgattagacaatctagttatcgagataataagtttcttgatgaaatgacacgacaaa acttagagttgttagcaaatcgtaatcca gcatattacaaaatttatgcgttaggtgaatttgctacactagacaaattggttttccctaagtatgaaaaacgtttaa taaataaagatgagttaagacatttaccttct tattttggattggactttggctacgttaatgatcctagtgcttttatacattctaaaatagatgtaaagaaaaagaagt tatacatcattgaagagtatgttaaacaaggt atgctgaatgatgaaatagctaatgtcataaagcaacttggttatgctaaagaagaaattacagcagatagtgcagaac aaaaaagtatagctgaattaaggaatct agggcttaaaaggattttaccaaccaaaaaagggaagggctcggttgtacaagggttacaattcttaatgcaatttgaa atcattgttgatgaacgttgtttcaagact attgaagagtttgacaactacacatggcaaaaggacaaagatacaggtgaatataccaatgaaccagtagatacataca atcattgtatcgattcgttgcgttattca 1-d n gtggaacgattctacagaccggttagaaaacgcacaaatctcagttcgaaagttgacacaataaaatctctaggattat aggagggaacaaatgttaaaagtaaacg 1-3 t=1 aatttgaaacagatacagatctacggggaaacataaattacttatttaatgatgaagccaatgttgtttacacatatga cgggacggaatccgatttattacaaaacgt 1-d w o taatgaagtaagtaaatacattgaacatcacatggattaccaacgacctagattgaaagtgttaagtgattattacgaa ggtaaaactaagaacttagttgagttaac w o -a-, acgacgcaaagaagagtacatggcagataaccgtgtagcgcatgattacgcatcttatattagcgattttatcaacggc tatttcttgggtaatccaattcaatatcaa o .6.
w w vi gatgatgacaaagatgtattagaagttattgaggcgttcaatgatttaaatgatgttgagtcacacaatagatctttag gattagatttgtcaatttatggcaaagcttat gagttaatgattagaaaccaagatgatgaaacgcgtttatacaagagtgatgcaatgagtacttttgtcatatacgaca atacaattgaacgtaatagtatcgcaggc n.) o n.) gttagatatttaagaactaaaccaatagacaagactgacgaagatgaagtgtttacagttgatttattcacttcacacg gtgtttatagatatcttaccagtagaacaa o atggattgaagctcacaccacgtgaaaacggttttgaatcacactctttcgaacgtatgcctattacagaatttagcaa caacgaaagaagaaaaggggattatgag .6.
.6.
n.) aaagtaatcactttaattgatttgtatgataatgctgaatcagatactgctaactatatgagtgatttaaatgacgcta tgttacttattaaaggtaatttaaatttagatc oe ctgtagaagttagaaaacaaaaggaagctaacgtgttgtttttagaaccgactgtttatgctgatagcgaaggtagaga aacagaaggctctgttgatggtggttatat ttataagcaatacgatgtacaaggtaccgaagcttataaagaccgtttaaacagtgatatacacatgtttaccaacacg cctaacatgaaagatgataactttagcgg cactcaatcgggcgaggcaatgaaatacaaattatttggattggaacaacgtactaaaactaaagaaggattgtttact aaagggttaagacgtcgtgctaagttgtt agagacaatacttaaaaatacatggtcgattgacgctaacaaagatttcaatactgttagatacgtatacaacagaaac ttacctaaatcattgattgaagaattaaa agcttatattgattctggtgggaagattagccaaacaactttaatgtctctattctcgttcttccaagaccctgaatta gaagttaagaaaatcgaagaagatgagaaa gaatctattaaaaaagctcaaaaaggtatttataaagaccctagagacatcaatgatgacgaacaagatgatgatacaa aagatactgttgataaaaaggaatgatt P
gtaattgcctaacaaaaacactcaagaatattgggaagaacgcggacgcaaagcaatcgagaatgagttgaagcgtgat aaaactaaagctgaagaaatagaacg .
, tatattgaatatgatgattaagcgcattgaaaaagagatcaatgcgtttattgtcaagtacggagattttgcaggcgtt acattacaagaagcacaaaagattattgat ,, , 1¨
.3 .6.
.
c,.) gagttcgatgtaaaagcgtttcaagaagaagcaaaaagattggtcgaaaacaaggagtttagcgatagagcaaatgaag aattaaagaagtataacacgaaaatg .
r., tatgtatctagagaacagatgttaaagattcaaatagaattcttaattgcttatgcaacagctcaaacagaattatcga tgagggaatatttcgaatcaacagcttatc "
, , , gtgtgttcagtgatcaagcgggtattttaggtgaaggtgtacaagtagctaaagaagttatagatacaatcgttgatac acaatttcatggtgtcgtttggtcagagcga 0 , N, N, ttatggactaataccgaagcaatgaaacaagaagtagaagaaataattgctaatgtagttattagaggtcgacatccta atgaatatgttaaagatatgcgcaagca cttaaataaattcgaaggcacagcacgacaaaagaccgcagcaattaaatcattgctttatacggaatcggcacgtgtt cacgcacaatcaagcattgacagcatga aagaaatttcaccggaaggatattatatgtatattgcaaaaatcgataatagaacaactaaagtatgcaaagggcttaa tggagaaatattcaaagttaaagacgct aaaattggtgttaatttctatcctatgcatatcaattgtcgttcagattgcgctttactacctaaatctatgtggccga aaaaaccaagcaagaaacgaaaaacaaaat acttcggagggaaagtgaaaagcggtgattgatttaaaagtgaagttttttaaaggcaagttagttttgtatgacagta aattaaatgtttggaggatactaatatgag taatactgacaaataccttagagacatagcaagagaattaaaaggtatacgtaaagagttacaaaagcgaaacgaaaca gttattattgatgcaaacttagacagtt 1-0 n taaggtcggcagtattagccgataaagaaaaatcgaaatataatgaacctctcttttaatagctagcacttaattgtgt tggctattttttatgtccaaaacgtgctgatg 1-3 acataaaaagcacgcatggaaaaacagtcgacagactataaatggaggtatatctcatggaagaaaataaacttaagtt taatttgcaattttttgcagaccaatcag t=1 n.) atgatccggacgaaccaggcggagatggtaaaaaaggaaatcctgataagaaagaaaatgacgaaggtactgaaataac tttcacgccagagcaacaaaagaaa =
n.) o gttgatgaaatacttgaacgtcgtgtagcccacgaaaagaaaaaagctgatgagtatgcaaaagaaaaagcagcagaag ctgctaaagaagctgctaaattagcg -a-, c, .6.
aaaatgaacaaggatcaaaaagatgaatatgaacgcgaacaaatggaaaaagaactggaacaattacgttcagaaaaac aattaaacgaaatgcgttcagaagc n.) n.) vi OP OA , (0 OA r0 0 r0 0 OP OA
OD OD ,sr, ,(;)n 0 CLO (0 2 OA tj t,' tc; -u M MI
-uM-our04-,0,0(00(0c0cOutj-- 0 r0 03 (0 -I-' (0 (0 co 4-, (.0 " (13 OD U FO, .iL-' (0 (0 OA 03 co 4_, 4_, (i, 4_, rOtjr0r0rotj4-,(0cou,,?;oroOOrOrOrauSu3r0BOrOut,' -1,- (0 U (0 (13 4-, (0 (0 co 2 U a-, co (0 t; (0 co (0 , -1e,., (0 co op (10 4., (13 4 (0 (0 (0 (0 4-, r0 (0 03 0 0,0 4-, 4-, (0 (.0 (0 CO CO (0s4.4., 4-, r0 03 0 r0 0 (0 4- +., 4-' -' (0 (0 4-, co (0 ,(45, OP co 0 (13Z-r,E; 2 oo (-.
co 0 .(,-9, 2, r ( = 0 -' o(0- 4-,' 2 (.0 (0 4(2 0 4_, 0 3 n, 0, (-0 , 0 00 (.0 2 0,0^ tv ro +, ro 0 u ro r (0 OA 2 (ao (0 a ttotE; u (0 CO 0 U 4-' (0 r.: "M 4- 2 õro' tE; CO
ere CIO -'rir (0 CLO ti' 6) U
,.., .... (xi op 0.0 _ -_ .1-, 4_,-uu-o03c0 =L''(0 w:' 010 co CIO
-u -o (J4- co OP (0 co co -o M OLO M 0-0 co 0 t , ^ .1- ; 00 op 0 (0 ,_,,., .1-; 541 (0 4_, (13 ,(7.),., OP n3 0 0 (0 0 0 OP (.0 co 03 co r0 n3 4.-; OA -3 OD 4-, 4_, ro 0 OD '4. .1-, 4-1 CO 4-, 4-' U
(0 03 0 (0 -1-J .1-; OD 0 (13 hn c0 ,...,(13 U c0 4- M M, (0 ro 0 t,,o ro .0 rr, H r (0 b' OA OA c.71 (0 61 M OD 2 Vo (0 ST MI
0,0 cOr0(0(00.04-,c0-u- m 0,13-aro4-, Ms (0-u .E1 2 : I 2 t Lou .t , BO - u( . 0 c or 0 3 Lo a . 5 , ( . 0 .. , r 0 (. or 0 .. t : , , 4-J( . 0 mu 0 , 00 , 0 . 0( 0 (Z, 0 cjr BO t:), 0 r 0 t :,(13 (31 4-, 4-, 4-, U U CO _ 4_, 03 03 op (i3 u !,7, 4.., n3 CD U 4-1 a-, (0 0,0 0,13 CD 4-',..,0.0op op U 4-, (10 00 03 03 03 co 4_, 03 4_, 4_, _ n3 sam 00 .1-; 4-, OD (xi 4_, 4_, (0 ,,,, 4-, ttO .1_=
(0 4-'õ CO 0 4 (0 CO 013 CO 4-, 4-, U CO '' CO (0 (-0 (-0 OD `(.6" r0 03 03 0 , -..:, 03 .1-; 0 (13 U U 0 0 ,., U .1-; .1-; (0 ,r, U 4-' (0 0 t' `:,' co co co 0 iii "(13 ((3.30 ((.73) (% 03 (a, õ(13 BO
(0 _, (0 4-, (.0 ,,,:, 4_, l:113 c0 U 4-' 0 u CD CO +-, U OP
Ur0C0c0(0(13.t,' M r0+,(0r0a-'n32 2 t,' tE;
(00c0030.0(00(0+-,(04-,c0(0ZrOopur00-uut0'23,,r0(00 0 ---, co 03 03 (a0 4-, op -I-' 0 -u a, 4-, 0 -.It r0 --Ir-:: OW (13 a (0 (0 (13 -u (0 Ms 4-t 0 o mro Ms 0 0 mro 0 4- -, CD ro ...,- CD +., 0 -, ro 0.
CO CD
(13 (13 U ' ' (13 CO .1_= -I-, 0 U 0,0 4-, :i CO
.1-, 0 .1_= 0 0,0 0 j3 if U 4-' CO
0 CO CO 0 0 op op 0 j (0 0 CD (0 (13 4-, (13 (13 (0 0 03 0 Op õ,, 0 (0 co 03 co 4_, t5 03 ti r0 0 r0 r0 OA 0,0 tnn (:(0 OP OLO -o u-' (0 MI co -o co 0 h,-,(13 ,T, co OP 0 s's 4-(-0 ' (0 4--, Op 4-, 03 co 03 03 ..õ.,-, 0- OP 03 0 r0 Ms OA co 0,0 +., (0 MI r0 -u M M 0.0 4t1 0.0 OD ro 0-0 - r0 OP co OO
0 ^ -o co , ss-s" OP -o OP m co 03 0 0 op BO -,O,, co +., +_, (0 co 0.0 op T.0-' , 0 (0 ts, õ, (0 _ .... 4_, hn _ -' OP µ6. MI U (70- ((.,, SIP, (a) 2 0.0 2 "(-0 0,0 0 0.0 (,,, ro (0 4-, t.,, 0 -,t,' s,$).0 t,' co 03 r0 03 (0 -o tr, 4-, (0 (0 0 co (0 0 u .2 co (0 03 +., OP (0 op OP 0 co OP 0 , 0 4_, co , OP , r0 r0 0 op -.1,:,' OW 2 (.0 .1-, 1.T3' (0 (-0 447.,, (:113 CO 0,13 CO t: 0.0 CO (13 OD OD (0 U (a U ,(513 2 ro -(0, op a 0 OA to op OP
(0 0 M
0 -u Ms 0,0 -r; -_,t; co -o 0 0 co S U -^-' , c0 03 OP U op uUr0r0r0 00,0UCCI -(13(13(130,00,0 00(00,0U
(00,00a-,+,+.,+,(13c0UUWCOM cot ''U Ur0r00.0+' (0 U 0 j3 U 0 j3 (X1 (0 CO 03 (0 U .o .o .1.-= 4_, (13 (.0 0 4_, , . 2 0,0 0 4-, +., Ms MI (0 co (0 Ms r0 OA co 'um h n 4- ^ U -' -' OP hn Ms m u -o OP 0-0 0 -o OP (0 4-, }I
0 4- '' OP -o 03 - - r0 OP (0 r0OD 0 OP a-, OP op -Jif (0 (0 a-, 03 OP t.r3 2 ro , (0O 4-, 4-, ,., 0 0 4-, U
,., '' MI MI ' M M (a CD (0 (a0 ta' 2 oo on 0.0 0.0 0 (0 0 .E19 4t: (),., .t,' U U
.F., U (13 (.0 CO (a CO +-= 4=- "jõ.., CO .F. , CO 4- 0 tp r o 4 -J 0 co co co r 0 õ . ,,, s , t; - oõ.., Ms -o 0 03 - r0 co 0 4-, OP s sss 0 03 03 -1--, op ,T, 4-, CO (0 .1-, (0 (-0 CO " s . 4-, 0coo-uhnromo (0- Op4-, 4-, +.,opc0+,0c0 CD 0 4-, (0 co "u 0,0 Op co tf, hn- 03 .':, MI +., hnc 0 MI 2 (ao 2 OP co ro -u (0 0.0 U 4-, +.' (0 (0 2 (-0 (-0 417 +.1 op all u 4,4, 03 OP 4-, OP 4-, 03 a-, CD 8 oo -, 4-, 03 co 03 OP (0 Si? 29 Op 03 1_2 (AO (30 .1-, S19, S. 2 _it, 22:1, (0 t' -(1;r3 (If a t : U ( a 0 ( 0 6' rj (al -r. : µ( . ki 4 - ' B 2 0 (0 (0 2, t,'u 4u ro Lao 0 ,r,(ao -_,t ,,0 n3 eto (0 , ..".õ0 ro (.0 0 (.0 4_, 0 (.0 4-, (0 -, ro - 4-,, (.0 0 A OLO r 0 CD 1 0 O t 0 Z - ,u 0 i jp' r 0 op C ti;
%CI
(0 (0 OA (13 (0 U 4-, (13 0 (13 (13 ,., (13 (0 (13 (13 U OD
(13OP OP 0 op aT,"
4-',..,õ (.0 (.0 0 00 s sa -10, (.0 0 U 0 4-' 03 .1-; a-, (0 03 M tp CtO -u M 0 m OA CO 4-' -' (0 W3 (0 ^ M MI (0 W3 (a r (0 (a CO M
OD U MI (a M U OD (a CO MI r MI OD (0 OD U CO 0 CO rocOopMour0+,03-u-r%0t3u03(003-ur00-000 (0 r0 _,_,4-' OA co OA M r0 (a -u co (a MI co 2 (0 (ao 4-, r 4-, .-t--,' (0 r (ao r "ro (0 0 2 -a -0.13-rorotitirotto0+-,4-Jurou'ro+-' CO 4-, OP
00 4_, 4_, 03 -4-, OP (0 (0 0 0 03 op (0 01:1 4-' 01:1 4-, (0 OP 00 0,0 op .I.J U 4_, (0 r0 (0 r0 hi3 OP 4-, CO 4-j (13 4-, op 4_, 0 OP (0 OP co OP OP 0 , op -1--, OP op (0 4-, 0 0,..õ,(04-,courOuro,,+-,00,0c04-,4-,c00,0000,,c0c0+,00A-u CO CO ro (0 4--' (.0 op op -.1-,-;õ if a, co dA S U (0 4..; u a, all U -,-',.., (0 4.7,j,, 3 '(-0 rom 4-'r 4-'r .).) t --Fi I?, 2 B 4-' co mr(E', Wt.,' tE; (0 r (-0 co 2 (a13 b' 3 (,0-- ro Bo 1-. 4.7_, co (0 su; 4-, 4- 0.0 0 t; 3 03 op 4- op 0 U ST r-: 2 0 (70) OD OD
0.0 MI T^ 010 .1.'.1 ti; (0 õi, it?... t..2 4.5, (0 (0 õ .1-; OP (0 03 (.0 03 0 03 OP 0 r0 4-' OP t;
op op 4-, (.0 op µ(.6-' ',,-u 6uzi (0 .(i2, (0 -,-, (0 (0 ro 0 ttO (.0 4-, 4-' .1-, CO (:)J3 (0 (13 4-, CO U (13 0 U 4_, ,...," _,_, rr, 4.,, (0013 0 4-',,,, õ., t', (13 03 OP 0 co OP
03 OP (0 03 r0 4-, ,..,.," Tip iii ' . +-, OLO co (0 r0 Op _Ls.,, õ..,- õ..,- -F-0 co 0 4-, op r0 n3 -i.i3 OP r0 (10 op ,47', OP ,__,,,s, 0.0 (.0 2 233 3 li 17;j3 -ILI co op srifi O.
(.0 OP r0 (0 4-, s4A, OP L) 0 4-, 03 03 0 0,0 (0 0 (0 op hi3 M 13,0' -(1-15 0 co -13k, 44 (0 2 OD co 1.T3 40 co OP 03 r0 0.04-' CO U CO +-, , (0 0 (.0 0 (13 ,, (.0 ....i 0,0 r tj (.0 (0 0,1:1(0 0 (.0 (0 (.0 0 .1-; .1-, 4_, (0 ,.., õ ,., (0 0 j:, (.0 u , CO _ ^ ro if (.0 (0 03 n3 OP 0 n3 -14 .1-,' 44, U 03 0 (.0 µ,4,u 0,13 4(9 !!! 0 tu3 ,,,, BO
CO (13 0,0 CO CO
(0 C's M OLO Ms 4-' OA 3 ro (0 +, 6'3 -r.,' 0 gup r0 co µ0µ2,1 co ti M u --t--: M
4-' (.0 1::: Bo (.0 0 4_, 03 ,,,,OO 'LI OP Fo-OP op (0 4-, 4-, OA 4_, t,j3 4-, 4,7',., 0,13 CO CO n3 if (13 a-, (xi (0 n3 4-, (0 0 .iL-s 4_, co (.0 Ms 0 OP co co op u tx, U 6A+ +4 U u tx, , 03 OA 0 U 03 op 07 (0 0 j:, I.
4.5, BO 0,0 CO ,4,7',., CO CO U (0 OD (.0 (0 (0 (0 .1-, 0 (0 OD (0 (0 .1-; Op OP 4-, 4_, (.0 4_, .ifj 4- r 0 'Ilt.? ;(.7,)n MI MI (0 MI CO MOD CO CO 0.0 (.0 .t,' (0 (0 CO CO CO (0 () - 4-, (13 0 (.0 4-, 03 op co OP OP r0 (0 CO 4-, (0 'I.' (13 0 (13 (13 (13 013 CO ,., 013 r0 co O, (0 OA op 0.0 CO (0 +., CO Op 4-' CW (0 (0 0 4' U t' U M
CD n3 (0 so 4_, 0 4-, 4-, 0 4_, 0 03 0 (0 OP 0,0 0 rOcOrourOcorour00cOurOc0(04-,00,0c04-,00,0+-,(08+-, CD n3 n3 (.0 n3 (.0 co r0 03 03 n3 ta. OP 03 +, co (.0 4-, (-0 U 4- U (-0 CO
+., (-0 .,., CO .1-, OD (.0 (0 ro co co co co 03 T.-,,, ril u a-, CD 03 (0 co -2-,:,' ro, r0 0,0 r0 0,00,0,(.0(00.00,0c003003'(.6'r4rocOrou.p.,03opT.0-c000,0c0003 0 (0 04_, 4_, 0 (13 (13 u Op 03 4., 4-, (13 (0 opn34_, 03,, (0 OPOPOPOPM
CD 0 OP a-, U .1-, CO CO CO all a-, a-, all U all all a-, .1-, U OP .1-, CO
-' CD+-, , op az) 4_, 0 0 CO .1-; " (0 4-, 0 (:10 0 0 0 ro (0 4_, 0 co 4--;, 4_, 0 0.0 0.0 op 03 0.0 ro ro 0 - +-, CO +., 4- 013 013 -X 4-, 0 0 44f (:10 0 (0 (0 (00 (0 (0 4-, (.0 (0 (0 0 (0 013 01:1 4(9 0 (13 00 013 4-' 4-' 0 -X 0 4- CD 00 00 rj -M, (0 4-' 4-' (0 U 00 CO 0' (0 (0 CO 0 (0 .M, 00 (0 00 W3 r w 4- U 4-, (0 00 4-' 4-, (0 j:( (.0 4., 4_, (00 00 (0 0 (0 .1-, U 4-, .1-, U
(.0 00 ro ro ro ro ro 0 op 0,0 0,0 0 ro 0 co OA 4- ro r0 ro OA Ms 0 00 r,' Ms an 0 co 0 -o OA
-r; 03 r; 0 03 , 0 (0 .t,' 03 -õ,-, r0 op ro 0.0 -a' -(-ro (.0 4(3,ji co ro 2 0 L, , 4.,,,, UJJ (0 0 (00 4.7,4, .1-; -13'D (0 (.0 µØ/ 0 (0 (3j3 4,-! .,., µ2.,_ -4t !.(1,1 0-0 On (a0 (13 0 (a (0 t.,-( r0 (6 0-0 MI '' `rt3 tiE; 0 0 OA .2 tE; Ms ro '6j3 0 ..V.Y
+., 0 0D (,, õ (.0 co ro _03 (.0 (0 co 0.0 t1,0 On +., MI (0 4-, OD -' tl op OA ro 0.0 T.0-' 03 3 -(õ; op (.7) 03 ro 03 w , 03 03 0 op +-, 0 4-, OA
OA 0,0 +-',., t1,0 -' OD (0 (a +., OA ro +., 03 +., ro (0 OA 0 0.0 MI OA ro OA -4-, 0 -o co 0 0 , 0 0.0 +., 2 co co 0 co 4-,õ ,,,,-, 0.0 .t,' 4- (.0 t.,, 3 (-õ, 2 2 .81, (.0 ro -6-3, 03 0 03 4-, a-, 2 CO 0 ro ro -(1.T3, 4(2, ,,,,ji f,...; 1:E; ro 2 4t, (.0 (0 2 0.0 (.0 (.0 (-0 2 (0 (0 "r -4t, 83 -(7, Ms (rao (0 ,(7,0 ((70) co -o,T, ro La0 Ms tE; op ro ro r0 On Ms OA
..., -(y3 CD r ri- (0 0-0 r (0 Ms 2 (0 (0 ro i:5 0 .t,' oh n (a0 (a ti t.) -4t 4_, 0 (0 (00 (.0 .44 (0 r0 00 .4:,,, 4.-,. CD0 (0 is, 0 .1-; (0 4_, CD,,n ¨ 4-, CD(1,3 4_, CD0 4_, 0 4-, 0 "-. U CO 4-, 03 tIA -6- y." 0 tIA 03 U CO
ro 0,0 op (-0 0,0 CO .1-; -14 m 41.1 (0 CO CO 0,0 f,;:', r13 tIA 0 03 03 0,0 .4' (13 r 0 (.0 4-,4-,t1,0-4-,Zt 0 m-t: (10r0+-,+-,0r0-ro Ms roLaOtAro u-o op U (0 co ro ro .1-, 100 (0 iii-:, 0 2 (-0 -,-, 00 4-' CO 0 ((II!, ro ro ob 4-=, ,-,-,-, 0 rts 0 4-' 00 CO U r 00 0,0 00 U op ro 0 ro ro 4-' 8 44:: OA 03 03 '' U U C'.0 CO 4- U
CO õ (00 ro 0 4(1; , (.0 44 õ 03 ro ',I-4 U 4--(13 "Id Bo ro , , 4-, -1--' 013 41.1 0 L' = (0 4¨' s ' 013 .1-; (0 .1_, (0 4-t, (a0 4-' co ro ,Y,,, If -14:: co op t:ID 2 -.If 3 CD U (0 -',, CO CO (0 r 0.0 0 00 4-' CO MI MI MI 0 4' 4-' CO -(-% (0 (0 to co 4-' 4-t:
= -X CO ¶"
44 (.0 .1-; op .(2 (.0 4-, c13. 0.0 OA 4.7,_ .1-; tIA 03 õ., .1-; u. 00 13JS :3,2 to w OA (0 4-, 0 .(,?, 00 (a MI 0 OA 4+7,. ' (II t u OD 0_ 0 :if; tIA 4(3b CO ro ro , (0 4_, 0 0 (ap co õ (.0 00 4_, ro 4-, 00 03 00 4-, _ op 00 03 4-, 2 Bc, to .,,,,, mu -5, (0,0 ,,, mu t,n(-0 00.0 .,-4- (yo (6, 1.1 {05 5 1.,,,,,w3 B .
.,,,, 0 t , zr 0 , ow 2 . . -, , ) - + . ,- ( . 0( = , , , 0 - , ro (.0 ., 0 co '''' 0 00 03 4-, , ro 03 03 tIA m õ, 0 0 03 U 2 4-if -X 4,7.: CO 4.if 2 4-, n,, ,,-, tto aD -+t,' , (0 ro co 0 ro 'or ro to to (a 4-' 0 MI (a 76 010 MI (-1'3 -Ft; (":' co ro 4-, 0 .1-, op 4-, 0 ro 0 4(2, 1-', ro ro 0 4_, ro ro _ co 0 ro ro 0 .1-; (:10 4-, 0 tIA 4-, a-, ro ro ro +-, (.0 -F.E; ro tIA ro 4-, .0 ro ,õ, (0 ro 0 0,0 ro ,:vi _ OA Eo_ z op tIA 4-, 0,0 op 4-' ro (.0 4_, a-, CD OA t:IA ro ro .1.; 0 0-13 (13 ro 44, ow 0 0,0 00 4'6'ro,(0rOrourOoprou,O,Or0(.00(0-(000,13-r:
0 4-, CO -X (.0 0 (-0 +.1 04-, 0 03 co 4-, 4-, (.0 0,0 130 8 (.0 , 0,02 0,:, ro ro .t, ro O m ro ro u 0,0 OA - r, 00 0D 0 Ms ro -o 0 (0 -o ro (13 co an -' roo.OoD-'0 ro mu 0 (-0 4-, co OD ty3 0 03 co .0 ty:, co 0 0 0,0 ro ..... 4_, t.ui op , 00 t,u3 4_, 1_3 03 0 , 03 .2.,,, r0 0 r0 -1-, 4-j 00 U ti CO ro .0 CO
w U U co OD ro ro CD ro (3-13 ES ro F ) (L3 2 ¨ (-0 CS 010 (0 ro 4-' (0 c FoL (a 44:: r0 4-'(6 V.0 - U -it: (0 00 4-, ro 0,0 0(12 ro tf, 1-.6 4-, 00 03 op õ,(13 , 0 a-, _it:
m .,., = CO U (-0 (-0 (0 t: U 0 (a 00 CO r0 0.0 r r r -' uM 4-' (0 (a ti W tiO 4,jj ro co tIA -o .tjr 13 4 - 'MI ( OM t coo ( OM 4 - J+ ' ( 0 , 19 - M ,+ ' UM + '( = 0 ( ,30 ( 0 or III mall g tr 71 c 0(4 : gj t 2 ti 3 rii OD 03 op 03 4-, ro ro tIA .1-; (0 174 4-, ro ro ro , , ro 0.0 ("3 (0 op an u ro -u ro ro CD oproro ro(.0-(; ro 0.0ro.0roro.,(02t50.00 ()rpm 04-,0-c%
^ 0 a-, (0 00 4-, (.0 00 0 op .1-, (0 0 0 OA 0,0 Op 00 4-, 4-, 03 23:, ro 4_, , CO tu3 tu3 CO , 0.0 (0 CO .1-, -1-, (.0 4-' 00 (.0 ro 4., CO tll3 CO -1-, (:11:1 0 4-, m .1-, .1-; tn CO ,_,4-' (13 4-' CO 4-, ,+, 4.if ro ,T, 0 co 0 0 0 co ro (a.,3 0 ro ^ an 0.0 0 0 0.0 +-, ¨ tIA T-, +-' OA ro 03 - 4-, -' - 03 , ro 0 03 ro 03 4-, 03 03 op 4_, 44f (.0 - 00 4_, (.0 (.0 ro 03 4õ-_, 3 , 4_, 4_, tõ:, 4_, 0 4-, ro 4_, ,-.U., ^ 0 'm `rEr on ro (3-13 an +-, (13 co ro ro ro ("3 ro '''' ro 0 4--, a-, all tIA 4-' ro 4-, - MI CO
0 W3 (a 00 U MI OD 4- U U r OA a (4 OD (a0 0 OD CO 4-' t; 0 0 '6'0,000(.0oproZurOtE;r0r0(00roum¨FErroro.20,0op.7)3.0zr0 0 0.0 0 (0 CLO OD +., 0 OD (0 ro r0 0 to 0 4- 0 (.0 s (0 +, tj-Shn mu (.0 -'(.0 to roM
4_, 03 03 4-' 4-' tIA .1-, ro 0.0 0 ro (13 (13 ro ro r^ oc 04-,rorow3couummr04-,-.,tror02,--0.0(10---(0(3(3-0-uu a.0(04-,r04-,uroco-u..00ror0(10+-,(113+-, uõwrOdA,,wro.2030(0 , U CO
ro +-' U (13 (13 , ,., tIA 00 OA op -o ro ro +-, +-, ,444 ro 4-, .T-_, 0 .,, ro co ro ro ro ananu ro-u a.13-' co+, (000-0(04-'(00Øt:r00-04-'0:10.000(0 ro-or04-,(1300,0MrprOm õ., ro (.0 U (13 ojo 0 4-1 Op U (0 4-, 0 (0 4-, ro 4-, 4-, ro ,...., = - 4_, r0 - s '-' 4-, (-0 (0 4- 4-, OA 0 0 0 ro ro ro '.4" co an ro (3-0 an co -' 0 (0 4-, .0 ..__,('3 (1' 4-'.s,õ 4-,_ õ
co a. 4-, c(3 an 4- (a ro ro (a -' 4c; ro op ro op 0 -i.i, ,...., 41J UM -I¨' 0.1 3 MI
4-, tIA co 4_, (.0 .1-; ro (.0 op (0 (.0 õ,ji 0 co 0 ro (0 4-, (00 (00 (.0 4(2, 03 r0 03 o ro op OD ro co 00 4-,õ 03 03 tx0_, r0 co IT CO ,..,(13 ro ro co 0 4-'m +A 2 4-, 03 1-3-(0 -1-' 03 03 03 3 -(i.T3, (.0 0 --- (õ:, 0 6, tu, co co ttO Cr CO (13 4-1 -1--' (.6 445 00 U CO 4-, To 4-, U (13 CO U az, ro u (0 0 ro 0.0 0 1-3 ro a. .t,' co co eto 4,..-.: ,(2, , (0 , eto 44 0.0 ro (0 " r 4uroro--roror0r0""vmuroonr 4-,rouro ro -1-, ro (.0 ro 0 03 4_, 03 op , , U 0 U ro ro 4_, 00 4-, (00 0 (0,0 OD MI 00 0 '' co (0 (00 MI co U CO 0 U U (0 (0 Zy 4-, tIA 03 ro 03 ro op Ms ro r0 _ ro 4-,. t1,13 _ 4F,0 ro ro (.0 (.0 , , ro -u 0 4-, (0 ro co ro ro ro OA 0 0 ro co ;43' OA ro zo, (12 (-0 4-, b' -c% (."op tIA U CO 2 t,,,:, (30 (.0 1=i 00 0 µ6, CO (.32 (0 .0 r, on on a F, .E(,-(3 ro ro 2 MI ((3),0 (rao mr 4- t.) 4- CO 00 (0 (0 CO 3 ',Lk?, -(-% ,t-:
ro (0 ro (3113 (L3 ro ro 0 to c(3 co rLo) ro ro ro (a ..'i 0 '' a4-(L3 ' OA 03 4-' (a U tIA 03 ro tIA 4_, 03 0 ro on ro co n3 .i .14:
0,0 -1-' (.0 CO -1-, ozi .0 ojo op OD 4_, CO -I-' ro --4 0 op 0 4-' 4--' t.E.; tl (00 0 on 0 U (.0 õ 4-' 0 (.0 OA 03 ro CO ojo ro +, ., .. co .0 (0 Y.
0 õ., õ., co .0 CO CO 0 (a ''' (13 ',4 (^ .0 co (.0 4_, ro ,(45, (.0 op tyzi (.0 co 44 if (.0 4_, 0 .,.. t.,ji 0 ¨ (ap (.0 00 co 00 U .iL., CD 2, op 4-, 0 a-, CO -r% ro CO fo OA ro CO to 2 (%0 ro if (Y0D 0.0 r13 OA 03 00 op ro 4.2 4.2 ro r0 03 U On co 03 op 4-, 4-, 00 ro 4_, 03 co 03 03 _, 0 co 4-, 0 4.7.., (.0 (00 4-, (0 0 '' U U (13 0 U3 OD +'/-11 rill (13 4-' (13 '' ro 4-, µ,44 -47.; U (13 co ' ,..., (0 U OD r (0 MI -' '' ".. MI (0 MI 0,0 OD 2 4¨, 0.0 sc,. on -' 0-0 (..) ¨
4_, (.0 1¨,. ro (.0 ro 0.0 (.0 (.0 t, , 3 0 ro 4,74, (.0 (.0 4_, U
ro õ., .0 ro 4-,_ ro ro 4-' (0 U 44 MI 0 4-' 00 (.
MI (13 (0 ". m .1-; (.0 4-, (.0 w (0,0 4-, W .1-; 4-, (00 ro co ., .0 tIA op ro MI ro µ(.6 0 00 Ms (0 ro , 0 Ms 0 -tj op Ms " (.0 03 0 4_, 0 r0 4-, 4_, ttO 47,,, 03 0,0 4_, ttO 4_, 4.7',., 03 0 On O4-.4:, 4,7.,' 00 0 r0 a , op op t-,. 0 pp m ro ro ,..L., 0 0,0 OA 0 47; +., ;:,..,,-, , ro 0 s,.-õ, 0 .,,,L, ., ro ro CD 0 -t; 0 r o -(73 -4._-; Tr, tu 3 0 r o µr 64 4(3 co 0 c 0 2, tll3 ,(6., 4-,, a3 .(i2, ,(6., on 0 0,0 0,0 op 4-, (0 CL:Ihn (13m 2 2 bo 0 0 (-0 To (.0 ?bm 2 (.0 (=:,,' 2 +.,,,,.. (.0 -,,, 0.00 15, 0,0 0D
0 a-a 4--' 0/3 (10 (13 CD, 4-' ro ro ro ro -1-' 053 - 03 OA op _ , 03 00 03 03 -L-_:, 00 0 4-, _ , t,u3 co 4F3, tie., co 1_3 _ 03 co ;=.,": 4-, OA OA w op 03 03 op 0 Ilu.d. 4-, +' co "' 4-, ,,-, 2 (00 4_, 0 .1-, OD UJJ (13 CO co U ojo CO CO 4-, .1-; (0 CO (0 (13 (13 ro co co 0 .1-; 0 4-' U 4-, .1-; ro ro on co ro .1-, CO U (13 U co CO
0 +-,_ On CO CO .1../ (0 (0 CO .I-, a-, CDU CDU CO .I-, CO a-, all OA OA all all OA a-, U 4-, 0.0 a3 4¨, ro U 4_, 4_, (13 '81 4-, (0 õ., 0 ro OD 4-, CO U 44f ro -..17: OD 4-; ro 0 co ro op 4-, ro CO (13 op co ro tie., ro co t,' 00 OP 0 '0'5 co ro tax) .2 U -.it s LO, .1!::
3 (.0 Fe (.0 4-, (0 OP (.0 OP 4-, U 03 ro OP 4-, 4-' U 4F0' oo r 0 -1-, on co ro 4_, .,_, u 0 0 4-' (-)(04-'t:(13 0(10(02--(113.t.,' OD
(23. .L.-! -(.10 4-, y (.0 ro -2-,:: 2 (.0 t) j3 c13 4_, (3.13 4_, U 4-, (0 .Lt: '-' +.1 (13 1?, +-, U on , 4-' (0 U "a (0 (0 0D CO Z3' CO r U (0 to (13 ro ro ro , (13 4.-= 4-, , U ro ,.. 0 CO (.0 03 tu3 03 co 4-, OP rp OP 03 8 on 0 an 4-, (0 (0 c'D an ("0 ro 613 ro ("3 ro t 2, a (II 0=an ro (0 an ro4-'-'-'roro-O.0 um opa.004-,mro op(094-'0-ti+-,,, -' U+., U 4-' r (113 4-' (I' (I' tj (113 4-' utl 4-' 447.: OD (0 t) cati if 1:6' 2 ,,nnro u (0 H 0 ¨,,., nr93 õ., CD (.0 4_, 0 4_, _ 03 4_, _ 0D 4_, 4_, 0.0 ,,,,., , , 4-, (.0 0, 4,7 44=,' co ....,,,, 4_, ¨ ¨ .... 0 4_, CO 03 U "J , , Zuocororom¨urot'ro%4,74?6-' r.; 3 0D 0 (.0 2 (-0 2 g2 3 2 2 0 0,0 oz, 0.0 ., 0D (-0 .:, u (-0 on ,4 ij .1,- - .E.,4 r o t:: (0 - bp OP co +., U co +,, (13 op CO -' 4-, OP OD U (0 U U (73 +,, op tj 03 00 00 CO all ., (0 co 00 03 +., (.0 (0 CO (0 CO r (0 (0 +.; -' CIO (-0 CO 4-= CO :.,' CI -' C1.0 U CO
- ' = CD (100.000U(10+-'03(0U(130,0oU(.0(.0(00,04-' 3 T.0-, u (-0 .õ 0,0 ,,,op-03(.0r003 ,00303ro-ro co co 0 4, CD 4., CP CD MI CO (0 (II
0.0 rn m 0.13 ED
a-, co 4_, CD CD U op oz, .(i2, op 03 0 4t', OP ro 4--' (0 CO OP az 6 ro .03 OP U 4-, +-' (13 OP op ozi CO +-, Op Op 2 r0 2, OP .F., t,' U +a OP 03 ro op op OP ro 'Jr:: -I-' 4_, -ti (.0 (.0 (.0 ox, 0 co , ro ti BO U -ti 03 03 (I,' 0 00 U co r/.9(10t5W30.13COUU U +., 4-' U t,' OD (-0 ,,9 CO U U OD 0 0 OA tj 0.0 0 OA
¨'' ro (134-' tin CO MI (0 '' MI OD OA OD 4-' s ' co ro (0 u co 0 ro opOOro OA
0 ro 03 ro co , 03 03 a-, OP -,,.7,' co 03 4-, OD 2, 03 op OP 00 4_, CO co 4-;
OD 1.74 CO
(.0 co 4_, 0 CO 0 s . (-0 co ril OP 4-; (.0 OP ro a-, +-' CO fo op ro g (0 co co 4-, (.0 ro ro 2, 0 (.0 (.0 , : 4 4_, ro ro ro ro (.0 (.0 ro - ro OA ro 44f ro ttO LI 0 -'-', , u roc to 0 4-, 0.,n3 u 4-',., (10 4-'0, oro -1-'0J3 (30 44(13 4-'0 (0 (-0 (0 U (2i3 .`=,':,. lf, :IL CO }:, -I.' yro õro iii ro 4:, +.1 U
OP 03 U Op +., .2 tj .(e, -0 :.; +-' SIP CO W3 Tz, ki ?LI 0 t, n ti OP -,..,,õ iii +., (0 CO 03 t',õ OP co 03 00 4-; 4,74 (.0 2 (.0 4r2( BO (:,j3 0 (.0 (13 (1.3.. oz, -ti (yo. (.0 ro ro m u (0 0 4,"" u (0 ro 4-= (0 'r6 ro an 4-=
4-' MI CLOt,' (13t,4-' 0.13(0-(3 MI mr (Clj U (a0 0.0 44 -14 0.0 CD 4,-', 0 (53) 44 ro _if 2 q 3 0 (.0 (.0 13 OP OA (0 Tx) 6 CD
r 0 OA OA ro OA (13 CO t:, +., (0 0.0 +., OA 83 2 0 Fe 3 on on .-2, t; ((:0) Fe (,.-0, 0 (-0 (,.-0, 2 -t, 4-, 0 (0 22? (.0 s (.0 ,,,:, 25, 2.9 2 ,:,õ (-õ, -(.6' (0Ø0 t.rõ 4_, 0 , 0 a 3 rp 0D CO 2 ro ".t' 4_, ro c13. CD " op OP 03 oz, 03 3 -,(T,,, ,:, (.0 (.0 u 44 (.0 if 4., 3 2 (0 4_, 44:, CO a, 4-, CD 4-, 030,,COBOopurO3UC044.t,S2UU
CO -' CO CO 010 4-' .F., MI -' ti' r MI
.F., ..t:: MI .F., CIO CO CO 2., r 4_, op ro 4_, ro 4-1 4_, fp .fzi 4_, tu3 ro 0 4-, 0 CO 03 2 03 oz, 1_3 03 03 0 ozi ,-0.1 CO
(0 (0 U OD all tp OD (1 4-, (13 OP 4-' if rill CO (1 (13 cp CO U 0 4-' OP co 4-; al/ 4-' (0 .t: (13 (0 4-' 0 CIO OD CO U r co .F,L 0 t,' oLO .,., CO 4-' CO -',-, ,õ('':' 00 44 +., 0 03 õ, 0.0 4-, OP OP .V.," `ii ,,õ,õ0113 OP OD CO (113 4-',D if ro a mr (0 ro OA Lo tj ,(1:1 ro u LLO (. t: 2 8 mcio ¨ (-0 (-T3 ¨ (-0 0 .(,,, , 0 õ0 ¨ .- (-0 (.0 (.0 0 2 9 op co op - ,9 ro op ro co 0 op 4-, 03 op 0,0 OA 4-' U 0 U 4_, ro ro 0.0 CO õ
,.,-- op , u CD 4-' CD 4-, CD 4-; 4t, ' . CO a-a 0 to 0 (13 44 CO CDco CD CD'4' 0 CD u '' CD W3 -t: r U U (0 ro op (i3 (:,j3 0 tu3 op 223, 4-, 03 tyn ti3 0.-0' OP 2 (.0 0õ
0 0 ¨ 0 0 4- r o õnOPU 4_, 0j34-, 4_, CO 0 mu 4(1.00j303 4,,-,,' (\,!, tu34(101::: 83 .2, ,,.,,, ro (0 U 4-' (0 "" ,000CO `(.',0.0(13+,,UrOCO'co -U+.,4-'+arOCOL4ZrOUO.0 OPcor0(.0Ut,õ.,COUUcoC00003+-,2õc0+,,COOPOPCO+aCOCOCO-CO U 0 , U 03 , ,-, 03 CO 03 a-, U ro 4-' op ,aaa 0 03 03 4-, 4-' 4-, ro 03 U CO on 0,0 4t: 0 (13 U OP op U co , ra 00 4t, (.0 (0 4-, _it:OP OP OP
AM O Pt: ' ' I 3 + ar L3 + 'C 0 + '(..) + ar L3 't r (.- ,f, - '0 3 UM
+ ar L3 (tF, ), 0 + '(-) + -'r 0 c 0U te. )13 = 'M r:t I: I (V + -'(' 0 C
OM L'i 3 i 4_,(-0 to 2 on (.0oz, 0D (-0 -(,0J (.0 ., t: -u ., OPCO+,, CO2t,' ,,, MI co+a, 03 (0 4_, ¨ ro 4-, 4-; .F., 4_, 0 j3 (.0 U (.0 SIP OD U +' OP CO 03 0 613 2, tIZI
T.E; ro .p, ro OA 4-' CO 4-' OD U (0 0 ro 4_, a-a all all ro u U U (V 4-, :lc:: OD (.0 4_, 2, (41_2, ro ms L, -6, a (.0 03 OP 4-, CO U CO op OP ro_ ,9 u 3 0 3 oz, tf, 3 0 õ..(U 4-, CO -I-',õ op CO U
a-, 4t, (.0 4-, 0,13 (:)J3 4-, 4-, 0,0 U OIJJ `-' (.0 oz, co 00 03 op 0,0 OP s . 0.0 ro .i.; 0 t 4-' tn ro 0.0 co -14:' OA (42, 4(9 4-, -1,7',., -1,-',, ((.11.), 4_, _ co (.0 (.0 4_, u 4_, ro 4.-,. co 4_, co .iL.. ro -44 " ' ., 0 '(.'6 -' -' MI +-, 4-' 4- CD (13 OP
4-, 4_, 4-; (.0 OP 4- U oo ro co 0 -1-, co ro 0 4_, co CO U õ, CO 0 (0 .0U a-,(0 -I-'u to õor 4-'(.0 (pro ro 9 4-'M 4-'CLII 4-,+' -1-9 tO ep out:4 .oror oroM ,r0 -1-'(.0(13 oroM 03ur sg3:0 a - ,(r 11 roc roc ro co on 0.0 ro ro .,., (0 ro +, (.0 co , 03 op (.0 +., 4-; 1-3 (.0 ro 0 co OP 4.5, u -1-' (.0 0D 4.5, ozi 4., ro õr., cp cp CO .(iap U fp -I-, 4-' rp OP OP ro U U (SD all (al u op .2 -, oD op ro ro 0 0.,¨ ro OA
ro , um roro.,r0O.0¨ roro rorouopopro-OproW
-4-'0Øt,'-'-'''''''0. O.Or00-0,9roo.Ororoaro um oorl:/+-'ro opm -'0o.o+-,rororot10+-,uroroM., 2,r0+-,uurot,'BOroroo.Oromcor 26µ53 .2ut;',0w3u 0 m 0 ro 0 u 4-, 4_, (-0 2, OP op õro oo 4(3 03 op 4-, 2 ro ro ro OP 4-, 4-' 03 44=,' OP ¨ op 4-, 4-; 4-, on co 0 6" 0 ti ro op OA op Orouti.O(0+-,-0.00Øt,'(04-'opmroo.Oromro 00 OP 0 4(2, OP 4-' CO 44:' 0.0 4-; OP 44:' 2 OP u co OP 03 00 ro 4_, OA co 4-; OP 03 03 (0 (13 CO rp U OP OP rp rp t' 44 CO 03 +-, +-, -' +-, CO (.0 0 U 4-' 03 4_, CO (13 CO 00 (13 4-, CO (0 4-, 4-, OD U 4-' OD OD MI -1-' CO " op .1_= U
MI (13 4-, OA (0 u CO +,, OD 0 co 0 U u 00 4-' t,' CO CO t,' 2 CD 0 r 0 r 0 4- , r o 0 r 0 r 0 o r 0 4 - (- 0 r o r 0 r 0 0.0-+t + - , r 0 .._,- (..) ,,9 0 ro ro 0 -1--, ti-'3 4-, ro ro U U ro (.0 3 (-0 u -,-, (-0 4-, ro -'-' U "rill OP n, 4-, U u OD 4-' .,,, co 4-; U 1.7',.. CO 0 U i. 03 _ 4_, 4_, CO 4-' 0 (13 4-;
ro OA co CO ¨
COCO0,04-,(0`"'OPCOctur0 -co`(.00.0t,'( 0,04-'CO(0-04-'('' ti' (0 U r r COMUMMUCOCOMRICOM
4_, ro , 0 " Op 0 j3 4-1 2 4,,, 4(3 U 4., (.0 ozi 0.0 rp 4-1 , , U ,., n'w CO 0 4-, OP (13 4-, ro 0.0 ro ro ro ro ro ro co 4-' .,, 4-, ro ,-; op ro 0,0 t a ro a, co (.0 u op -' co on +., 0 +, u t,' ro co u 4-, co ozi op , CO 4.5, 0D 4.5, H
0 ro OP 4-',õ 4-, 4-; op 0 CO 4-, .F., (.0 (:)J3 4-; 4-, tk., 4-, 4-; ,..¶., _ ro ro u 4_, ro ro4-' ,,, ro 4_, 4-, co.
4,7.: 2, r0 m 4-, c ro ro -' an on ro '4" ,U ro ro an (0 __co tto (0 Fa' 0.0 an ro 70' 61, 4u an ro L'D ro U 4-; (:113 U U 4-, 4-, 4-; CO OP 4--' op U -,:,-, CO t.-.,:, ,,3 0 4-; (13 4-' 4-' ro 4-, ro 4-, 4-' U U 013 tIZI U 4-, 4-, OD 4-' "" 4-' `-µ,, CO U 4-, U 0.04-, (.0 4-, 0,0 0,0 0,0 4-, 4_, OP 0 4-, CD U OP OP 03 ro 4-, ro 0 4-, ro ro ro ro ro ro 0 4-, OP 4-, a-, a-. CO a-, CO a-, CO CO tll3 CO CO a-, a-. CO tll3 U U
4-, CD CD 0 4-,a-,ouur000 (0 ro 4-, oo .1-; 4_, 03 (0 m r0 r0 oo u , u ro (0 CO 00 ro o co "" co -'' 00 ro co 0.0 ro 0,0 (''' i.3 co co ro ro an (49 3 (0 - t' 0 (0 tin (0 (0 U 4-, u ro 4-' ro a-, MI '' 0 ro -' on ro 2 ro 4-, r 0 u if r 0 .o U (0 4.1: on (0 4-, 4-, ( ) On 'I.- U -' '' (-0 0.0 (0 0.0 (10 (0 (0 CO (11:10.13(13 MI 0.0(0 -' CO 0 MI - (..õ., 4-, U on ro 4-, U On W3 C0 (0.2 te:PrO (0 (13"+-, mtl 76 0,0 r0 te ro 0 00 (0,,, õ.,0 ,õ,(0 r0 B ro (0 2 A On hcM". (0 r U5 4-' (0 U 4-= (0 CO r ". ". "' 4-' ro on (0 u (0 4-, (.0 (0 u u 0 i.i:, ,,.(- (.0 c,- (33 44-, 4_, 4-, (0 CD 03 (:(j3 (:(. On 1.T; U
CO OA 4-' (0 ro u ljz, (0 r0 4F0' oto Fo" ro on r0 ro ro ((.1', o 1.-0' 4-'õ., ro ,4:',.. 01:1 1F .1-; 2 OA ri3 4-' co 00 u on r0 ro ro +, -' on -u an r.,' ro 2 ro µr,Y., r, a t, 0 r 0 +-;
4_, 4_, .1-; (10 ere .1-, 4-, CO u OA m co oo u rou4-, (0 0,00,04-,,,-(0 ooro u (0 ro 4-' 4-' on o o ro - (0 (0 4-, õ., 4-, (0 0 U+' 4- W3r0 (0 U W3(0 0.1:1CW.,, 0M 0%0 p. 0 0 , 0U t : ( MI UM .. t-J+ ' 00.0 3 ro +.,-- -ro Bo (0 ,,,,,r0 ,.0 on (-,, tE; u U 4-, ro .1-; ro o 03 4_, ro u ro 44f, 03 ro a004-, ro monro co, r04-,ro (pro on.F,uro mroc,0-(3'.2("3-(%.t,'ro.F, r0 B 00 I'S u -c; (0 u an (0 0.0 (0 co u (0 4,74 (0 2, t-_,, en , (:to 2 +, 4-= .C,:i U
(0 (10 0.1:1 (0 U "MI -(0' t,en 3 ro on .s,. 2, ro +, 0 u 00 m CO ro m u 4-' r0 4-, .1-=
MI (13 0 on 3 õ.,(13 4-5' 2 (134--10 hrio,orl3U-4-,(00.0(00-13c0 co OA , U
ro op 4-1 ======= ro ro u r0 OA u 0 u 4-, u 4-' oo a, t 41(00.0u6',0 2 3 0 0 0 + , r 0 r 0 r o r o o n + , r o r o ,,,0 r o t: .t,' , . . , r 0 CD, on (0 u (0 on oo t-,, rot, u+,+, onro um .,, 0,13-42-0, 0 on FO. (0 (.0 0 (3,3 o (0 ro u 4-' OA (0 tX, ro 4-' 4-, 4-, (0 u rj 00 4-' +' 4-' MI ro 4_, oo OA ro 4-, hn 4-, U '' CD -,-, m ro (0 m .0 .0 03 (34 CO 03 on o on 4-, ro (0 (0 (I,- (0 , u u ro CO
I. 0 ' s' U U .1-; (0 (0 on (0 t, (13 (13 (0 OA (0 00 ro 4-; ,,., OA (0 :-., ro ro (0 u 4_, 4-, 4-, -u0.0rorouror0robow:,(0(.0ro00`(.'o'roro4Z+,rororo u op ro 4-, U (0 013 (-0 (0 4.5, u .,, 0 j0 (.0 .i., U (-0 t.: CO U On 4-, u ro -' 4-, , (0 2 on on on +-, u ro on ro OA m (0 U 2, ro µ(.6-= t, OA r0 44f, r0 (34 00 on 03 ri3 on -' 4-, OA on 4-, -(% +,4-= CO 4-, (0 on t, -(% ro Z ro a onro U ro 00 -u (0 on 4--, romBO,,u0Orom4-,0,0-ourorOo,ror0 rOro co oprou on u 4_, ro ro 0.0 ro -u -u r0 4-, 4-' (0 MI MI -' 0,0 an 4_, (.0 m op (:,,:, 4_, ,:,,3 õo 4_, ro oo (0 OA ro on 4., "ro 0 2 tr., (0 on o on 4_, u (.0 s_. on 4_, 4_, u u (.0 ro 4_, -+, u (0 on u 0.0 ( 0 co r 0 r o r 0 oo u Ms (0 4-1 on co m 4.5, u 03 -(13js -8J-3, 4-, 03 ro 03 4-, 4.,., ri3 ((.3.. 4-' ri3 ro (0 OA 4- (0 CO
OA
u MI -' ur 4- CO CIO on 00 U OA MU 0 t) CO (73) (0 On (0 a .t,' U CO
r CO CO 4-' CO (0 - CO .1-, .1-; - ro ro O ,õ 4-, 4.,O ro 03 r0 .1-; CO on 4- .F., ., CO ,z, (.0 .,., (0 +
+., ro ro u 0 .,A OA ro 81, CD+, ro 03 CD CD CD CDCD ro 4-, (0 (.0 u U -' (0 .1- = .1-; U
+., ro r0 +, on on co m (0 CDan (0 co (0 OA OA op u ro (0 4-, CDCD(0 (.0 4_, 4_, 4_, õ= 4-, CD(.0 (0 OA co 0 .1-; 4-; 01:1 CO U (0 .t: an -(0 }-!, (0 co 0 (10 00 e, r, 00 +., ro hn 4-, u (0 u " 2 co õr -"r0 BC) ro (0 ''' (1 t,' ' t.') (0 r r to Cr to 4-, OA (0 (4 (0 s ' ro OA m- OA 4-, 4-' .1-; CO co , 0 co on CO 0 4_, 0 on u on oo on 4-, on (0 4_, u , -,_ u ro 00 Ms r0 Ms romr 0.0 'o ,,,,(1 0 (I 0-0 0 2 Ms a, 4-, (0 0 (0 ro ro , .
rOrOror00.0r0-u --rororOuu 4-' on r0 CO 4-, ro an on ro u ro p.,r,r0 u ' 0 -' (0 - -u u u (3-13 u ro on ro u ro ro on OA (0 u u OA 0 on 0 ro 4_, 0 ro ro onro ononro -u hn _ 00 (13 On }I ,,., (13 .II .., 0 (13 0 0j0 On (0 4-' CO (0 On mr r ..6 mW (0 0 (0 tig3 s(1.; tj (0 (1 Z:54 (1301_30(.00 (0 co -I-, OA 4-, (13 (-0 ... ro 03 - 4_, ro 0 03 (34 on ro .1-; CO -1-' (0 ,,,(10 oo .1-; CO (-0 4-, (0 (0 U U 0 (0 u ro 4-, on 4-, -1-' _,_,4-' ' w 0,0 .1-; 0 -L) U On U On (0 on U CO on ',,,.. 4-' OA +., a o 4, :0- r 0 r 0 r o r 0 : -, :, 4- , (0 + , r 0 oo +a r, r, ro +, 4-' u on -' on 4-, +, +, (0 4-, , OS 4-, (-0 (.0 ,,, co ,:u3 (.0 ,z, s. .1-; U (0 on on n3 on 4-= 4-, ,z, r,,(:u3 4-, 0 4-, - -' on (..) 4-, U 4-, (13 4., a-, U co ro ro CO 4., 0 CO (0 4_, 0.0 0.0 ro .(i2 (.0 ro on on 4 d 2 , i i ,- op 0,0 on u ro (0 0 on OA OA 4-, -81 4d 2 233 .-t: ,, (0130 ( 0 .t, v 2 CO (0 (T, u u on ro -' -' ro .,, , ro 4- CO
4- U (0 (0 0 +., on U '' (13 W3 (11:1 U '' 0 0 0 4..-...' (.0 U t u 1-,, OA
,(7,, rill. (4 .t,' CO 00 00 oo ro (0 0.0 (0 4-, (0 Ms U (0 (0 4-' 2 - ro (0 r 0 tE; z (0 (.'; -..-5 z.v 4- ,,, ro ro 0 r 0 4- - t; -J, õ, y. ,, +, on +, -8;3 u , (0 E (0 OA r0 _ 4_, (0 oo 4-, 4-, - m 174' if on OA -653 op - ,,,-, 03 3 (0 on ro 4-, 4-, .1-, (.0 oo oto row mr0 mu 0.0 -' (0 (0 ro 4-, õ., 4-, (0 .1-, OA 4-, 4--' õro -ti ri3 OA m (0 00 (0 r0 4-, ro 1-.,E,' -6' r0 4-, CO 4-' 4-, ".. ".. ,,,u onn3 (0 u- on,rorou 4-, 4_, on ro to +.,ro wro ,(5.),0 -0,0 (29 uu 3 mu mro +.,m, (.0 uro (pro 1_3(0 4-(0 +.,m, mon mu .t' wro '3 .t.6, -ro --' t' 4,õ -(i.T,; 4(9 (0 .,_= (0 (0 u on 3 (0 .(,2 õc, on (.0 u (0 2 OA ro ,:,j3 -(1.T3' _ET (.0 4 = ' + , 70 t . i -I, ro r o On 2 r 0 t; tj -5' ro u 0 4_, on 4_, 4_, u (0 u , (34 ri3 (.0 4, .tian, a-, ro (.0 03 on CO OA on on u r0 0 co u OA m 4-, CO 4-' 'I.' On CO 4-, On 4., ro ro CO On 4., hn OA 44f hn U co (10 CO (0 (0 U co U 0.0 +-' op (0 00 ro :C.," Ms ro -' -+t,' ro ..04 Ms m 4,"' (0 ro +., 4-, ,,..,,r0 u +., on r0 4-, (0 co On õ OA 4-, (0 4-, on (0 03 r 0 u u (3,3 r 0 2, 4 - ' -4t f, 3 - -r% ti;
u (0 ano an r o r o 0,0 co -.,t,' r 0 0.0 4-, 00 mum 0 mumroro,r0(.0(.0u0.0 4-, ro .,., ro 4-' 00 ro an (1 co ("3 u ro 00 -u ro 00 ("3 on ro (1' +, 0.0 u on 4_, (.0 44 ro u (.0 OA (0 r0 m m 4-, (13 ,...., (0 4r2( On u 4_, U on OA
4_, on ro (0 on 44 u on OA ro BO co u ro .(,-9 'rt.,'t; OA r0 ro u Ms 0,0 4-, (0 CO on u ..,u on ro ro (.0 ao ro ro (0 ro .2 t,' 4-, on 00 B ro 4-, 1-21 (0 U ,,,, +.; on ro on +, +, 4-, (0 u an t,' 2 ..), a 2 -,,,' hnr0 a BO ko) r0 mr0 t:,' (0 BO t C to' r0 8 4-m Bo (0 .2 CO
(0 -' co (10 ili (al 2 ro t, ro u (0 +, Ec, ro (0 u an u -u 4- u u 00 4-, CO 4-, r0 u , ro 4-, ro OS ro r0 u 4-, u 4-, +.1 on On u ro ro ro (0 4-1 (0 (13 (0 0 4-, (0 (0 ro CO OS OA
OA ro on ro 0 OA (0 .(,2 ro 0 ,:,z, co oo (0 4-, .1-; 0,0 U 4-' OS (0 (0 OS
OA -I-' (0 (0 -' u ro U (0 223, 2 1::: 233 (0 r0 -6, co t4 2 ro ro if U u ro um ro ro ro ro 4_, 0.0w 4-, ro On 0 (13 (3 on 0 on 4-, ro 2 ro ro (0 OA u ro co on OA 4-, (0 u -' .,., +, ro r0 ro 03 , on 4-, gjo , +, U (0 (.0 4(.T:,' (0 .1-; a-, u On 4-1 4-' 4t1 4-, (13 (0 CO CO (.0 (0 (0 CO oo 4-, r0 On 00 u ro ri3 ro ro 0,0(0-u ro+, co u 0.0+-= onro o 0+,4-, u ro-u o t,'1-2, on r,(113 (13 U -' 4_, on n3 ro (.0 4-, u õ., n3 u ,,., 4_, on .... 4-, u OA . n (13 CO ,,. .1_= u .iL-' CO
co (13 on ro t,' (0 ro (0 (0 ro ro ' an, , r, .L'2, on ro ro '-'a õflon ro µc, (0 (.0 (.0 on on '10 ro ro on 2 00 BO E.0, 0 2 (ojo -E, 0 4., rO co u (0 6.. 44 (.0 ,z, , 3 oo (0 4-, ro ,õ0 2 a 3 1-3 ro (0 oo u 0-0 , u (0 on (,:, ro op +., oo 00 '-"' r0 ' w _ (.0 (.0 õ,., 4.5, (.0 U (-0 U
UtnUr0r0(000(1303(13MU4-'M CO 4- '4,' U CO MI -' (0 .i.7 (0 (0 (0 u ro 4-'_ 4_, u "(13 (0 o 4-, ro ro_ 4-, on u ro 4-, 4-',.r, õ(13 4-'õ., ro (.0 ,z, (0 (0 ,z, .,. 41.1 (0 On .iLl, .,. U
(13 (13 l 1.1 (13 ro on on (0 - - -.,-==, U u co u u 4-, (-0 .iti 4-, 4-, ; 4 .1--, ro ro CD 4-' 4' .-; u (0 4- , (0 ro ro ro CD.,., +, OA r0 r0 +., +., op u +, co op , on CD CD CD CDu 4- on (0 u i.0 4-CO OA rill OA OA OA rill U U rill rill U U U 4-, U U OA U 4-, OA rill 4-, CO 4-, U ro atatcaaaacgaaagaattgttatttaaacgtcgcatcgatataggcggtgtgaataacaactttaaaggagatttcca agaggctgagggtctagatatgtattacg atctagaaacaggacgtaaagcacttctaatcggggtaactattggacctggtaacaacagacatcattcaatttattc tatcggtcaaagaggtgtaaaccaattctt n.) o n.) gaaaaacatcgcacctcaagtatcaatgactgattcaggcggacgtgttaaaccgttaccaatacagaacccagcatat ctaagtgatattacggaagttggtcatta o ctatatctatacgcaagacacacaaaatgcattagatttcccgttaccgaaagcgtttagagatgcagggtggttcttg gatgtactgcctggacactataatggtgctc .6.
.6.
n.) taagacaagtacttaccagaaacagcacaggtagaaatatgcttaaattcgaacgtgtcattgacattttcaataagaa aaacaacggagcatggaatttctgcccgc oe aaaacgccggttattgggaacatatccctaagagtattacaaaattatcagatttaaaaatcgttggtttagatttcta tatcactactgaagaatcaaaccgatttact gattttcctaaagactttaaaggtattgcaggttggatattagaagtaaaatcgaatacaccaggtaatacaacacaag tattaagacgtaataacttcccgtctgcac atcaatttttagttagaaactttggtactggtggcgttggtaaatggagtttattcgaaggaaaggtggttgaataatg gtagtagataatttttcgaaagatgataactt aatcgagttacaaacaacatcacaatataatccggttattgacacaaacatcagtttctatgaatcagatagaggaact ggtgttttaaattttgcagtaactaagaat aacagacccttatctataagttctgaacatgttaaaacatctatcgtgttaaaaaccgatgattataacgtagatagag gcgcttatatttcagacgaattaacgatagt agacgcaattaatgggcgtttgcagtatgtgataccgaatgaatttttaaaacattcaggcaaggtgcatgctcaggca ttctttacacaaaacgggagtaataatgtt P
gttgttgaacgtcaatttagcttcaatattgaaaatgatttagttagtgggtttgatggtataacaaagcttgtttata tcaaatctattcaagatactatcgaagctgtcg .
, gtaaagattttaaccaattaaagcaaaatatggctgatacacaaacgttaatagcaaaagtgaatgatagtgcgacaaa aggcattcaacaaatcgaaatcaagca ,, , 1¨
.3 .6.
.
oe aaacgaagctatacaagctattactgcgacgcaaactagtgcaacacaagctgttacagctgaattcgataaaatagtt gaaaaagagcaagcgatttttgaacgtg .
r., ttaacgaagttgaacaacaaatcaatggcgctgaccttgttaaaggtaattcaacaacgaattggcaaaagtctaaact tacagatgattacggtaaagcaattgaat "
, , , cgtatgagcagtccatagatagcgttttaagcgcagttaacacatctaggattattcatattactaatgcaacagatgc gccagaaaagacggatataggcacgttag 0 , N, N, agaagcctggacaagatggtgttgatgacggttcttcgttcgatgaatcaacttatacatcaagcaaatctggtgtgtt agttgtttatgttgttgataataatactgctc gtgcaacatggtacccagacgattcaaacgatgagtacacaaaatacaaaatctacggcacatggtacccgttttataa aaagaatgatggaaacttaactaagcaa tttgttgaagaaacgtctaacaacgctttaaatcaagctaagcagtatgtagatgataaattcggaacaacgagctggc aacaacataagatgacagaggcgaatgg tcaatcaattcaagttaacttaaataatgcgcaaggcgatttgggatatttaactgctggtaattactatgcaacaaga gtgccggatttaccaggtagcgttgaaagtt atgagggttatttatcggtattcgttaaagatgatacaaacaagctatttaacttcacaccttataactctaaaaagat ttacacacgatcaatcacaaacggcagactt gagcaacagtggacagttcctaatgaacataaatcaacggtattgttcgacggtggcgcaaatggtgtaggtacaacaa tcaatctaactgaaccgtacacaaactat 1-0 n tctattttgttggtaagtggaacttatccaggtggcgttattgagggattcggactaaccgcattacctaacgcgattc aattgagtaaagcgaatgtagttgactcaga 1-3 cggcaacggtggcggtatttatgagtgcttactatccaaaacaagtagcactactttaagaatagataacgatgtgtac tttgatttaggtaaaacatcaggttctgga t=1 n.) gcgaatgccaacaaagttactataactaaaattatggggtggaaataatgaaaatcacagtaaacgataaaaacgaagt tatcggattcgttaatactggcggtttac =
n.) o gcaatagtttagatgtagatgataacaatgtgcctattaaatttaaagaagagttcgaacctagaaagtttgttttcac taacggcgaaattaaatacaatagcaatttc -a-, c, .6.
gaaaaagaagacgtaccgaatgcatcaaaccaacaaagtgcgtcagatttaagtgatgaggaacttcgcggaatggttg cgagtatgcaaatgcaggtggcacaag n.) n.) vi -' u ro 4-, u tw_mtwro (0, m 2 n , n (.0 4-, 0 u m m 4-, 2 op oz, 0 ^ `-µ,' op 03 ro 4-, (0 OP 0 ,,-, au u (II
(0 ' ro o ,õ u r or o 2 . o4 - , or 0 + -=,r 0 t :Thu mop wrill t: 2 .,(0 60 (00A .,co wro -r.103 0D ad + . ,r 0 roro coop row roro co- .,03 0-13 to op U 03 ozi op 03 co -1-' OA oo OA 4-, -' OP OP
r0 co co 4-, OP 03 03 4_, ro CO U CO (-0 CO oo oz, ro ro 4-, U co OP 4-, OP OP 0 OP -' 4-, -' -I-' 4., (-0 M CO CO (-0 4-, CO
Mr C00.00.00.000CCIM'w4-'(-0--.F., ""r 4-' 0,13+,0(13- (0 CO ro ro ro ro ao u co on ,snu r u tto ,..,(1' BO ro ((r o) ,_,(1' õnu -u u ro ao ro 1-3 ro , oz, op ro 03 co ro 4-_,w (1-3.- 3 ( (,0, 4-; 4-, co 44 co u a 3 (0 (0 0 4_, co U
no M co 4-, OD 4-; r0 OP co u .2 :0 m ro tto 0,0 3 oo o ro to V.1 ro ro 0 tE; ro ro t'-', +-, ro ro u -u u (0 u +.,- 0 t OA u Bo t,' co -(0' ro -0 õnnõ4.-iirourorow,u 4-, 233 ',nal, op,c0'-wro,uttOuurr,030 ^ CO co op - õ, 4_, 0D ro co ro u ro 03 (1 r0 tp OP ro ez, op -I-' OP OP op ro '', 4-, u ro (13 OP ro op ro ro OP 4-, ro u ro a, m, (0 u ao 4- on 0,0 +, (.0 ro ao ao õ, (0 +-, OA otO -um oto m 0 u co co 4_, ro on u 4_,urowro- 4_, (0 4-, - ro - 4-, 0 OP o^ p 4_, CO ro u ro 4_, oz, U OA U ro 4-' OA ro ro OA OD OD CIA all U a-, 0 a-, '4.. ro ro co U ro ,.., U U
op ,õ CO op 0 ( 0 op 4., (00,1:1(0rOUCOCCICOCCI.2(10(00.00+.1 -(3"drob'-'sr6uroa.o0.0(0-6' OP ro 03 co U _it, CO a-a (13 tx, t:ll3 4-' u U ty0 0 ro .(i2, ro (0 ro ta ro ro 4.5, co tw 4-, U (0 MI (1 (1 CO MI (113 +' -' MI MI 1-.,) r l:IA CO d.13 CO MI CO
co U 4-' (13 ro ,,c, . 4,74 4(2, 4-' ,,,.,(13 2 (ao n, on n, n, 0 , ro tax) 4., on u 4-, ro m , ro (0 +' 44=,' s . no 111 4`-_,'.. co .,(2, 4_, U u co 4-, OJO b) -1-' 4-, CO 4-' CO CD s ' 4-' U (0 CO nn ro ro 0.0 otO (II (II r 0-0 ro L,:v3 ro (%ro' ro ro ro (0 Lto ro ro ((i,' Oo ro u (0 , u rr,- u ro ror000mmooBorprorouromromm+-,coro+-,0.0,corom-ro, (0 u co 0 u co - õõ Op ro ro on 4-, 4- ro ro ro ro ra m - , a, 0 m u ro ,,,, 4-, 0 CO 4-, 4_, CO OA P. 4_, r CO hnr 'WM 03 4-' U
(0 ro co ro ro (0 4 ao u oo +-, ro 0.13-a CO 0.04-' ..."' ro ''' ao ro -e, u ,r +'ro +-'op ra 0 ra ,õ +., OP OP co co t 4-, U (-0 CO 4_, 4-, CO CO
co ro (13 u oz, 223, 03 co a-, ,,-, OP 4-, u ro ro 4-, co '' +., (113 u U (.
r, U CO
CD on 4., 4-1 co CO 1::: (0 ^ Op 0 0 0 op 0D r0 OP r0 ozi op op 4-, ro OP - +., op U 4., 4--' -I-, 4-, 4_, co OP co (13 ro ro opOPrOc0 4-'rOur0O.PrOcOu Ms op t r 0 2 r, 4-, co+-' MU co+, co CO ClIlt,' TIE; all U+,4-' 2 , + - , r 0 + -, r 0 CO all 0,0 ro rõ, co 0 ri, 2 on CO 4_, on 0 ro ro 0 ro ro CO 4-, OD 4. op 0 op -'(00.0Mco4-'CLCiourOMIcOc0(00-0r0(0+-,(0 0 +., ro OP OP 0 CO op -1-' -' +-' +, U 0 r CD-CD
co ro .i.-; ozi all 4_,z, U CO 1T3' tu3 (.0 4_, no ,.., co 4-, co 4_, U 4_, no 4_, MI 03 4- +, (13 4-' (0 (0 0,0 ca 0 ro ro 0 .,,,,, (.0 ao ro ro OP ro co (.0 , 03 03 u a-a (13 4t: U CO BO 4-' ro 0,0 a, , all ro op OP 4-1 CO ojo (-0 MU (11:1-j CO+, Mr 0,13(0+' (113(0 OD+, CO CO+, COBOU all (044 , op 4-, OP op op OP 4-' op OP ro ro 0 co mu ro (0 co op co OP
" ro ro IT tp co U
U ro ro t 4-, 4-, U U +., OD 4-' +./ MI ' . OD co OP OP t:'- - ro u u -I-, 4--' U
CO 0,0 CO , CO U .t, (10 ro +., CO (-0 co (-0 01:1 44 ,,,, 4_, ojo co co 4_, ,,, oo u CO 0 tn U OD r 0 1-3 CO CA t: (10 (0 co 'cLY., U U OD CO OD (0 2 '44 4-,õ u ao ro =z.,.- ro ro (0 tto ro ro ,-.4, u -' -r; ro t', , õ, OP co +., u op co u OP _,_,=-= OP
-' Ms 0,0 OP ca OD 4-, +., 0,0 tj 0 MI (0 r0 ' OP 'v7 u u ra -' u u OP OP 'El Ms 0 (0 (10 co OA MI OP Ms OA ro ro '10 -0 oo 4-' CO +./ MI (1 -(Lo' MI CO OD U
CO 0 (10 CO ro (0 ro ro ro ro 4-, oz, tx, u ro ro op OP 03 4_, ro ro 2 rõ, (-õ, 03 4_, a-a -!--; U CO ozi op u all a-a (0 CO 4-, ro ro ro 0,0 (0 r, C00.0,...,''4.7,',tf,+4-'01:1C111+,4-JUUCOU0 0c000(0000 0,0 Ms 0 OP ttO .L'f, '-'-'4 op Ms +., (10 r0 MS OP ca -' 0,0 Ms Ms MI OA
OP co (13 CO
ro co ro+,+,4-,ro.,,r0 0 u4-,r0 uttoro-u8r04-,ro , ro u u 0,0 co co 4-, OP oz, co OP co U ro U 2 ,õ ro ro õ OP WI
roc003cOuur00,003-60,0cOur0+,:,;0,0rOurocourorProrou (0 4t, (-0 CO CO OA CO ,..,., OD 0 DOACOUCCI(13(00.t,'+,U(OUUCCIrat' U OD CO MI (10 (0 -,t: 4j CO 0D (0 (13 -(0' -(0j OP 0,0 r0 op (0 OA (o co u U -' co fo 03 oz, 03 0,0 U -I-' oz, (0 4-, _ u 1--,, 4_, 4_, .(1.3, oo 4.2 co u 4_, co 4_, 4_, u co tw I.
U op 0,0 (0 K1 3 , 0 (- 0 t: : 4 i - = , 0 z ; + -=, , 0 0 OP w 4-, Ms ca O
00U 2 -' ,T, 4-, ro ro OP 4-' ro - +., u OP OP 0 - ro ro 4-, 4-, ro OP rill -r, u õ..,"' co a-, (13 4-; CO Cll:1 OD OD (13 4-, OJO co U µ s (13 co ro ro t,o ro CIA (:113 CO /1 a-, 4-' OA ro co 4-, ro a-, op - ^ 4_, 03 4_, 4_, 4_, 4_, (.0 u - õõ co co 4., 4-, co 4_, (-0 4., u OP 4-, OA OD (-0 ro (0 4-, ro m (0 co ''' 4-' u OP OP 03 4-, ro ro 03 OP -4 r0 0,00,0 co 4-, (0 OA, u co - OA U r0 MI OA
on +.1 ClAttOroUoproCCIroro+.1 Uotnr0 op 1-3 U3 OA (10 +.,(0 .000 ror0 (6,0 +-,(0 rou ror %.1:1 Zm ro(10 +-,(0 co 0DM 0,000 _our uU cora (00-0 tn,..,, (00.0 al hj, .6,' ro õ9 ti u44 u 0,0(0,4-,õ,(04:5 um u n, ro ro 4-, OP CO
co tx, (13 u OP -5' ,õ(0 op 1-2, co co 0,0 0,0 mr0 ,T,U ro LI 4t r or 13 r ou 0 3( 1 0 3( 1 4j LW mall (al,(13 ro to .t, Lto u 45.
u , ro -u ro ro - -roun,rorouro 03 OP 03 co ,,,, 0 0 OP co -' +., co OP ,44-' rõR co CO u 4-, ro ro (13 on , 0j3 4-, ro u - ro en (61 (.0 u (.0 ro (0 -0 co 4., ,_,U (0 ro OP 03 ll, -1-',_ 8 4-, 4-',,, 4-, CIIIMU-+.,UU 0,0 0j3 co .1=, tto op u 4_, oz, , . 4_, s . ro U r0 u (10 4-' -' (õ,-,1 op u 0 op co 0 ^ op , (.0 r0 co ro (.0 co (.0 u CD 4_, 4_, U 4-, CO µ...4 co 4_, co ojo u 4_, co 4_, co 4_, 4_, u no hn on õ, co U a-, ro 4-'ro 2 6a0 rpm 4-'u .I.-,t' U U 4-',., 4-'µ , CO 4_,4-' OD 4õ7,' OD OA U
CO CO C13--. CD 0 -0 6' t S 4 - 'a 13 0 u no 4_, co (a rub 3 4C2, 4t,. õ.,`-' tiO co 4-' ,_,"-' CO (:113 -I-' ro U
ro ,..õ r0 0.0 4_, 4_, 4-, 4-, ".. ro ro - 4-' u ro a-, co a-, 'w CO 4., (-0 U 4-' U (0 CO '' OD (1 OD U 4-' CO -' r U
OD oto ro m ro c'D t:,' ro 8 ( , :, ,, um - 6 ,:,õ` 1 2 2 3 s r orc' ,4 - , 3( = 0 s g2 - , .0', , ( . 0 n , n , 0 . 0 4-; OP U ...,, (13 ,,,, , (-0 ro 4-, , , r0 tto µ..,_ u ro 4_, (.0 4_, 0 4_, _ 4-,r0rOWZro+attOurO`' 4-, ,,-, -' MI op 3 0 . 0 t E ; u r 0 , 0 , 0 4 -,c) .2 2 "( = 0 , ow or 0 mu 0 .
om ot, 0 -t:', z s . õ- ' r or 0 + - ',. 0 ,` ' CO a-, CO a-, (0 co .2 0.0 W:Th r ti'o OD U Fcr to 4-' fa (0 CO r ti U (0 CO CO
-6' ro V , ro ro (.0 , TIE; 4., U u (53' ojo ro (-0 oo Op 0 L,^ u OP (13 4-, U 2 U 3 4-, r (13 U OP to op R? F33 2 U - (1 T1; BO 83 If a-, 2 2 0.0 -, u u u oto 0 ro 0 0 on u ro ro ro CO CO (:113 (10 -1--' U
CO U U U U ro oz, CO 4., 4-' m CO (13 u 4-, r CO CO op ro 0j3 (0 CO OP OP u CD 0 c0-(0'corOc uu 4-'CLOMIro U u 4-, CD CD4-, 4-; ...,--(-0 4., (0 l:ll3 Cll:1 U U w CO CO BO u 0 CD CD co co u u 03 0,0 op 0,0 OA u -+t,' u cor0c0u4-,4-,+-,c0OPc0(0c0(00,0000,0urPrOcouut,'-ur0 .,., +., , co r0 -' 4-' r CO OA
(1 on On CO ''" U '' CO r 0 m CO MI
4_, ro 4.5, ,S, ,y 0 OD CO ()J3 (0 ((ro) 4-, op (cil , ro ro z., 4-, 2 - i -=, u .,, ro u r 4-' a (You .,,:i t, -+t: (:Lo -r.: (0 ro co u -m (.2 t 5 a t2, +
- , ( .' 73' "r 0 u r, u +., ca 0.0 ro -.t:,' on 4-, on ti 4- m- u -',õ on Lao t ro - ro (ao (ao oz, co (0 4-' CO (-0 4-' dA 4-, 4-, 4-' 4.D
(-0 , . 4-, - 4-; r (-0 4-, OA
co CO co ro ro 4-, a-, 4., CO -1-' 4-, 4-' -1-' (-0 (-0 ro , a, u 4-, OA 2 0 ro rõ, co OD +./ t,' CO CO CO U CO CO U t: CO (0 +, OP OP .,., OP OP OP .,., u ca +., OP CO
03 rill rill a-, CO CO toiO U U OA CO 03 OP a-, CO CO 4-, (0 t1J3 OA CO a-, a-, co ro a-, U
a-, CO CO CO CO CO OA CO CO CO OA a-, CO CO CO OA CO a-, U OA CO CO CO U 4-, CO CO
0 rn ro (.0 , ro ro u oo oo oo ho ro u 0.0 +, oto B ((:, )3 tj U CO r U CO
2 (II (a ro ro ro OA -' '' OLO -' U CO u (0 r MI r +., U 0 0 I.
0.0 on (0 (0 (.0 oz, moo 2 (0 on u (0 0,3 (0 (ao (ao (ao 0 l5Aro 0+, Fo-ar0 44 0.0(0(000 inn U ¨ ¨ 0 ro bn CO MI ''( ) (0 OA OA +-, CO (0 rn m cO
4-, ty3 oo 4-, -' ¨ hn tto OD a, ro 0 u ,,,¨ m 0 .4¨ ro 4-, u u ro oo ro +, ro u-' - (13 +, CO OA U U it., 0.13 Z.:w (73 (13 Zj co ro Op .1-, ro 0 (0 CO (0 _ 4_, U u , , OA
+-,(00.0(0 -Ot: 1 ( O.O.O.00.0Mr w3 4-'c'0' 3 ?.., (-L0) ti (.0 , (.0 (4 u , 0 (.0 4., 03 0,0 0,0 CO .it', CO 4-, (.0 ,,,, (.0 co (0 (0 ro (0 (0 (0 0.0 (-0 a. 0 (0 (0_ r 0 tE; ti ro 'µ,' 4-, 0 ro oo oo oo u ro co co U MI - La0 OD OD (5.0 (0 U " (0 (5,0 U (0 (5.0 U (0 (0 13;3 ((.11.), 03 co 4(:), 4(:), T.0 ro ro cc, 44 4(2( 0 (.0 (.0 (00 0.0 ro (.0 (.0 0 ro 0 OP
U OP 0 tE; U U U U CO CO t-.,' to +-, (a op (0 4-, (0 CO OP 4t,' 83 OP (0 U 0 CO
.1-; 03 CID oz, 4-, (13 4-, r0 P OA O CO
4-, CO U 03 u 4-, if U u oyo ozi 03 .!..! U 0D co CD m to U co CO
CO U co co 4-, tto ttO , (0 OA 4_, OA .1-; rn _ 4_, -r,r, co .1-; 0 4-, = "' 0,13r CO 0 CO (10(0 +-,.F., tnr0 (0 U U 0.00,13(0 CO U '',....4-' f, -r, +-, , ro sc, op ro ro (-0 4-, oo -u ro u 4, op 1-', U 4-' -' oyo +-' co +-, " CO
CO " 4-, ro u m ro ro .--,:, u ro (13 4-, `-' Op CO OA 03 OA op CO tj OP co oz, 4-' U
U%-",U-to-0003opc0 +.,Opouto ODopOP CO4-, OA
4-,(000.0+.,( C0+.,C0t0LWrOrOopCOOPrOUouUroto(a U
CO . CO m r OD 4-' 4-' U OD (0 r CO 4=- (0 r "..: (-13 CO .2 U CO p.09 hriCd3 OD
t) t.,' (0 '' OD U MI OP -' MI OA CO (0 U CO (13 '' r CO OP 0 U '' (0 L. co OA -r.r, U .,(a 4_,(13 tj 4-= 4-' 2., U 2 - ro t,,o ro 4_, , ro 0.0 ro ¨ ro 4-, = ,-, 0.0 4_, , 0,3 ¨ 4-, õ., .1_=
.1-; l:113 U ,W ro 4t, 1-,. op 4t1 ri3 2 ro tri (13 0 1-', ri3 4-, (13 C1:1 +11 .1., 4-, OD CO U
U 76 di3 CO U(F0) 2 -(,-,-3, co OP (F0) 4-, op OP 4-, 0 -6' 03 CD
2 ao c'ci ro -'((:0' (.0 ti, 0 ro a , as Bo 3 2 (y, w3 (.0 2 ;0.0 murorOm ro so U u C1:1 (.5 t' 4(3 C1:1 T.E; (V .(i2, 44:: 03 (13 (%/3 4-, TIE; 4-' U
C1:1 1553' u ro a 4-, 1.T3' U CO MI (a 2 (:(.0 (:(.0 -' -813 CO OA OP (0 U (V co 2 ao 3 g2 cd:' (:(.0 Bo -(;E; .0 (V (.0 (o:d3 0.0 mr Bo (.0 co -(0' ac9 4-' co -(t:; u -(0' t' u (0 (.0 s.,,o ro .0 (To (0 co (0 u 4-, 0 2 -(.6' (.0 .2 (4 (0 "(0 3 ro+,N32.2+,,,,r0 ro (0, u, 0.0^ 0.0 0.0 4-, ,,,, 0.0 (0 (0 (0 (0 -,,õ _51,0 .L,OO tj 8.0" 0 2 SG (-V
L'; 4r2' 4(2 (0 C(E)1 1-.,) .1-, U OD (13 , C1:1 4_, (0j0 ro r0 rn ro +, -r, 4-' 0 (0 (0 .L'_I -63 '' CO
ro 0 .-t-', OP OA co to OA CO OA OP OA
U CO 03 ro OP (.0 1.T3' 0 CO CO oyo op (.0 2 ,(:),., (0 , -!-,, oz, (.0 õ,:, (0 2 (0 .i.,:,, ti 2 -,,,, (.0 (0 (0 (.0 ,,,, (.0 t 2 (u40.2sz-i2(04-,-.t:: oti_4-,(0 CO OP r0 t, 4_, (-0 -r.,, 0 (6,3, ,,, 0 (.0 0 (.0 .0 (.0 CO 0 ro ro 4(2, co u 2 (.0 ro (.0 (.0 (4 4_, (.0 (13 CO
rOCOOLOCOUM.2 4-'-'+.,d.00ON4-'+-'(-"130.0,,MIZ (-000mU.F.,-rnUt,' CO CO OPOPoprOor00.0000h¨n4-'0OMO.0`"COOprOiirOii (.0 4-, ro 4-, , 4-, ¨ co ro 0 0 .0 OA _ 4-, u +-,OD
CO U +-, 4-' r CO OD OD OD 4-' (0 ". u 3 tn iii3) I CO ti (.0(aci +.,4-' (.0(. .(,..i ro 3 rou u ro ro oo e., õas:, , ,O.0 ro rn to ,,,,O.0 t:,' 1-2, +., cr 0D mCO õ.0 0 (0 (.0 (ao co (0 co co tto 013 (0 .1-; ...A., -.. U co ro -..., 0 3 (4 (.0 4_, a. (0 u (.0 (0 u ri3 (0 CIA CO MI co (0 ..r.: -' 4-, U-',+./.,,..0 (0 W3 OD 0 -' CO U r '' (0 MI ro MI CO
.:,) '' OD `5 '= 0 I. 'thj.' 0 4-' .F., O .0 . = 3 03(-0,,,,r003(.0roro+,ro.0ro.,,(00(04-,,u 4-,ror000,+, = co OD (5.1:1 (11:1 COM 0,0 (0 CO t,'COCCI(5,000tt or 03 (0 03 !TRIMS U fl, 4-, OA co (0 U OA co ro .1-; ,T, n5 .1-; CO OP to ro OP 4-'._ ,., U OA ro co (0 CO U r CO sCj '' " +., CO CO .A.' (0 U
(13 .1-; OP 4-, ¨4-, CO OP -' CO CO
CO
MI 4-' ro CO r0 U Z.,. r0 (0 4-' r0 -u OD OD MI u OD ,(.7?r, u '' op MI u 4-1 +, a-, ro ro op 1:,, 03 U 4-1 U CO Op u ,õ--4 ro op , 0 .0 u oz, OA
CD
CD +., +., op +-, ro _ 0 .,, 0 (13 .t, ro ro u op -F0 U +, OD (13 U C1:1 op ' . CO
op U .1-, co OD (13 "-'.,., 4-, OA 0 co (0 4., 0 ro ro OP .1.., ro 4-' 4-, ro oo 0 ro (13 OA
03 Op to , op 0,0 um co Op +., 0j0 u co +, u rn 4_, .,., 4-, ro ro ao +, 4-, 0 OA op op op oyo 4., OP 4..1 OD (-0 4_, 4-' 4., OD .1-; OD (.0 CO u a-a (1:1 4-' ^ ro CO 4-, (-0 u ro ro ro u 0j3 (13 a-, CO OP 4-, op op co 4-' U 4-, (-0 CO (,.,-. 4-, (13 , OA 4-, U co u OA -I-' co .it', op TIE; .it', CO 03 4., (13 ro u 0.0 OA OA s w ro u (:113 CO oyo OP 44f 44 co u 03 _ 4_, u CO `,.. 0j0 4-, 00 U U (15 0.0 MI CO 4-' +., U +.; CO +., U 0 "m 4-2, C 0 MI, , MI q p t U .,(11 Z 2., , Op ro OD .1-; OD 4-, ,T, 4-, (.., .1_= ¨ ¨ ro =-= to' 4_, 0,0 u 4_, 4-, U C1:1 ri3 CIA (513 U C1:1 +11 C1:1 .;:r (0 (0 OD ro U õ., (13 4., (13 co CO
CO op to 03 0 = 0 OA 4-' op U 4-' OP OP ro ro s- 4_, ro 0 u u "¨ u (.0 4_, 0j0 (:(o ro CO (a .1-; ro ro ro ro 0D 4-,, ro ¨ 4_, (.0 ro õ., 4_, co (.0 co OP co co CO44=,' ro ttO 0.0 ¨, ro OP (13 ro u 4-, .iL' ro -,-, u (13 (13 CO (0 r r CO Z:r ro r rt:' r 2 -' 4-= Cd3 U +-' (a 4-' 4- U rnM 11(7)n r (.7 CO
OP 03 op ro U op (o 0,0 +., CO CO CO +., .t, U CO +., +.1 4-, +., t' U ¨ ¨ -' a..! ,.,., 03 03 op .1-; u ,.õ( 03 OD (0 U .1-; 03 C1:1 C1:1 2 a-, (a) U
ro U CO -1--, U
(µ5'i3 '0'5 03 .1- i B) 0 j3 ( . 0 '0'5 1 f BO (13 BO 4t.1 - = 4- (%) 0 j3 a 4 _, C1:1 4, co (i13,.0 3 ro ti-3' (6,13) (13 0 a, op 0 3 (13 (r-)0 OP OA "t1-8 r (V
w3r0+,t,'4-'0.04-,w3tiouu000.oumu .2 co co 010 u r t co -' co r ro r u OA 4-' ro u ro ro .0 0 +, ro u tto OP o U CO +-, tt, (.0 (0 0,0 (.0 +-, 0,0 t,' (%.0 00 ^ 0,0 t 03 U (13 (5j3 CO (13 C1:1 U 0.0 'a t:: OP -(. a a CO OP (01 CO U
co to CO u ro U 0 03 op (0 ro Li (017'0 gi2 44:: (a 2 29, õc= o 2 0 (.0 0,0 r 0 ti õ0 -(0' w:, (0 (-0 a -(.0' ("3 c'D .0 u r u u co ro ro 4t,' (0 ¨ ,,, 4-, tIA .1-, C1:1 ¨ .1-; 4-, 0.0-rr,+.,(1:1(0MCLOCLOUCOCO
t.1 r U OLO r 4- 0 2 U (0 -' MI -2 a to w3 613 U CO -,..,r, (a0 r0 u ro m (loopt::(.0Urp.00(.00.0(0,0,00,0S,COok7,COUCOroC06-pt) COmr0U-mtor131.2,4-'rou'C'04-'`wr rOrOUO.04-'CO
CD co 03 u OP co op 4-, CO ._,., OP oi3 1T3' 4-, .1-; 0,0 4-, OD U ro u op CO ro 4-, µ6, (0 u (.0 Bo co oo u ro 1,...,.. tto 00 OP ((.1), 2 0 4-, 0 1.T3' CO (0 (0 oto u ro u (0 03 , 03 4_, 03 4t, OA co 41.1 -I-, . 2 (-0 4_, , OA OP CO 0 4-, (4 u 03 ty3 U ro rn u 0.0 oo ro 0 ro r (0 u r op ro .1t .' (a B .(.% r op td3 CO r0 u u ro OD
(.0 op t (0 .1..1 ro oi3 fO, CO op 2 (.0 (.0 4_, u ro 4., (.0 ,(rõ) 4., co (13 -1--' 4-, OP U CO
U CO sowp OP -6,-.0 "(0' CO Z.; 1-2, "(0' +., U Op OP 2, CO OP 0 `(.'6 S co CO
2 2 O. BO CO
-(1-3-3' to ro OP 03 oi3 U U co 4_, CO 4-, .1-,4_, 0 (.0 (0 4_, 0 j3 op 4_, co +., +-, CO MI OA op MI to' '' (0 MI .2 tE; 0 0D ro an tE; U RI r (13 M
.I-; U n3 C1:1 U
UU
4., u CO 0 CO .1.-= U (.0 u (.0 UroM U WCOCOOD
OA dA 4-, CDu (0 0 4-1 1.T3' On (13 03 u CDCD03 CDu 1-3 4-, OA t t.,1 4-, U CD
CDop 4-, (0 (-0 U OA oz, co .1-; 4t,' 03 co 03 4., dA dA 0 4., 4- u o a-o A U U D p U 4-, U CO
co 1-3 op co CO ri3 4t', 4-, 03 fl5 OP 0 j3 op u 0 oi3 4-1 03 OD OA OD 03 0,0 OD CD-(1.T0' 0 rornroror04-,(0Z,,ro(.0+,roo(.01-3(0b) tzl t:: U OA 2 3 (- 0 Bo CO ri, s ' .1_, 4-' 4-' 4-, (0 ,...., CO O CO op o co 0 ro ., CDoo rn CD ii (0., +, 0.0 013 (0 CO, 0+, ''' C1:1 O C1:1 4-, 4-, (13 (13 CO , CO .1-; d A
U d A 4-, ro o CD ro h CDao CD 4-, ^ a-, CD CO OA CD OA CD a-, a-, CD CO CD U U CD OA tll3 CO OA tll3 CO CD
tll3 a-, a-. OA
on w3 co an - co 2, +, an Bo 2 0 (.0 .p, 0 < 0 H u < 0 0 0 u <
ro OA co OA 1-T; -1-' co < 0 < H H H
0.0 -04-'0Opla 03(Or C000Ur 4-' O op MI
OA - '' OAot La 0 < 0 0 (D L9 < H
4-, (0 r on ro ro on 1_3 3 .-,t, (0 4t, (V (0 ro CD m co rill ,õ '=..... U 0 U , õI- (-9 CD
OD OA CO OA -I-' 4-, 0 ro rm. - L7 < U H U L7 L7 H
4_, (0 (-0 tn M U .1-, µ(.6 CO ro .1.t,' CO CIA 65 0 ro -,1.74 on ro ro no H < U < <
01:1 U U CDU CO CD C0 1-3 `6' u g2 < W 0 u W W H < 0 < 0 (0 ro ro 2 4-, ^ 0 OA 4-; tE; ps,-,C4 .1-, tl CO mall (-90uUL-9(-9U<U
4-, , , on rou corn .t., 2 .2 .,-, to on to, .ro. UL7Ho<<L71-uL75 (.1:' O
(0 (10 U r U o ro - 4-' CD H U H < (-CD CD0,0 co ro 4-, ro co U L7 U 0 U y +., < L9 (-9 <
<UULDH 8 <
(-0 OA OD CO ro 4-, all all U ro ro 4-, all op 1(2 8 * u 0 -',..., op õ., ,-, OA co 4-, ^ +-' ro ,,, 0 ,,, - U Q
H < U < W W
2 2 2 .,r 0 'r 0 r ou .t,' flII. t4 0 ro (-0 tton3 4(2, 076, 0.0 2 n, H (D EH < UU LDIL2 (D
(0 CO CO 2 U CO roOA +-, 4-, -0.0 CO OA CO .F., -õ.., U r, 0 , u 44 44 .-.1 < < < (-90,õ(-90<(DE
u op ro U CDs == CO 4-, all OA (13 co a-, co 0 U C-) 0 (-9 U W U
CD co op (13 4_, 4-, CD-I-, OD 4-1 OA co HI-0 00<0 U ' (0 0.0 ' ,-rs -0 CO OA tf, r -',õ, u u u < HI-< H 0 CD4-, 4-, 4-, , ,4-, CO 4-; . s' U 4-' (0 4-' ro (13 U M U
4-, ''' co ro tto ro on 0 H
- 4= 4- < U U
4-, M 4-, U 4-' 4-; u CD0 tto < co 0 0 U U 0 OH <- 0 4; -; (13 0.13 on 0 ttO ro U (13 CO CO U (0 CO CD4-, CO 0 (-0 on 4-, CDCO
OD OD (0 OD -' U U M 4-, U 4- +-'rn OD M U 0 u U U U (-9 - U
ro .1-, M co 4t, (00 OD all a-, On ro ,.õ.,--õH U L7 U u < (-7 I-- 4-; M on M M CO 0 CO CO (0 0U 0 < H W
,_ - U .1= (-0 -, 4-; 4-'õ
O
o (0 pow ro 4-, 4_, t u on ro 4-, 0 -' Op ro L -' ro on u 4= +-, CO -' +-, m (.0 s ''',,.. (D U
OA 4_, .1= CO i.-, .1-, ,-,.. 0 op 4-, (.0 co tu 0 co 0 0 m co j0 .' 0 ro 0 ro OD (.0 +-, ro OD 0 4-, OA
O (%0 2 õc, -(iT,; 4(3 12 T ,,:, if (a tiej a op 1-0, 2 H t)UL7õ<01-UH<Uuu ,1-<U`"Uerl-ro 4-, ro 4-, ro ro o 4-, co 4-, 4_, 4_, 0 (0 H U 0 , r, , ,.., H u - u -.
0 j0 ro 0 0 all U ro 0 0 0 dA U ro MI tiO MI
(13 4-, 4-, 4-; 4_, U 4-, U (-0 .F., (0 (0 ,47',., (0 M
4-; 4-, co co U 0 4-, I-! C0 tto U
u ono roror,ro70$194-,(04-,0 ro f ri Uf)I-ro on u u =-.., < --- (.5 H , .-, (0 (0 U RI OD p , < 5 u 0 H u H u < H
mu 42 2 2 0 0 t i , 2 2 - u u < u < (.9 '9 o < u 0 u 0 < 0 H <
1.,) (.0 _(-0 u tE;
4 - ., (13 ro CO
-(0'CCIa0O.t,'.t:COCO(.000rod.0 Ur0 < ILD(D<L7L9uUUHU<
oHU(D(DUu(D 0. U an4-,+-' 2 0 (0 _ _ . , u u u u , < c,--:, < =-= ,, <
ro (13 (13 ro U all U , U ro H
((7, )3 :,ti CO tf, = U U 4- ' U (10 8 (0 0 u u (49 0 u u < H
CD< op dA 4-, CO
RI r CD ro ro CD
4^ F ' co co co co OA 4-, L. 4-, u (.0 4_, co (0 u t.,-?, ro ro u , 0 u u ro t ro 0 U <
2 4- U U U < (11 U 0 < U U
(.0 , - (.0 ro ro ro U u on OA 0 <000 Lc:c)Q0QL<_S(D<
Qui 4-' U rj U (13 .1-, CO 4-' CO 4-, ro 0 j0 CO co u co CIII U 4-' (:Lo 0 0 -.,,, ,L0 4-; (0 (.0 ro 0 ro U < < L9 "L9 U < <
OD M CO W3 OD (113 +., 2 co op Bo 4t, .1f, 44:: ro õ, -Id 44 .f2 r(.1k8r,.õ,(5,(2u0(.1 (0 .0 u CDu tt0_,_ õ1:10 u ro ttO u 1::: co 4-, 4_, U ro ro u ro tal., .i...-, ro op C0 4.., 4-, ro (13 D -1-' < 0 < < < H 0 U H < U
U U CO O 4_, (0 u 4-0 j0 ; (0 U M 4_, u CD
< I- < L7 < ( D < ( D U ( D <
CO U U CO 013 CO .1-, .1-, CO U CO M a-, U CO
CU
rq u .(0 w .+7 u ,1-0_ ( = 0 0_ 0 ..._... 4_, 013 (11 U CO SD- CO
,-I
ACAGTAAAGATTCAGGAATGGAATACATTTCAGGCAAACAGAGATACCGCGATTCACTGACGTCAGCCTCCTGCGGTAT
GAAA
CGCCCGAAAAGAATGCTTGTTACCGGATATTGTTGTCGGAGATGTAAAGGCCTTGCACTGTCAAGAACATCGCGGCGTC
TGTC w o w TCAGGAAGTCACCGAGCGTTTTTATGTGTGCACGGATCCGGGCTGTGGTCTGGTGTTTAAAACGCTTCAGACCATCAAC
CGCTT
i-J
CATTGTCCGCCCGGTCACGCCGGACGAACTGGCAGAACGCCTGCATGAAAAACAGGAACTGCCGCCAGTACGGTTAAAA
ACA
4,.
w CAATCATATTCGCTGCGTCTGGAATGAGGGCTGCCGGTTAACACCGGCCGTCGCCGCACACCGTATTTTTATTCTTCAG
CATGA oe TGAGAAAGAGATAACGATGGAAAGCACAGCCTTACAGCAGGCCTTTGACACCTGTCAGAATAACAAAGCAGCATGGCTG
CAA
CGCAAAAATGAGCTGGCAGCGGCCGAACAGGAATATCTGCGGCTTCTGTCAGGAGAAGGCAGAAACGTCAGTCGCCTGG
ACG
AATTACGCAATATTATCGAAGTCAGAAAATGGCAGGTGAATCAGGCCGCCGGTCGTTATATTCGTTCGCATGAAGCCGT
TCAG
CACATCAGCATCCGCGACCGGCTGAATGATTTTATGCAGCAGCACGGCACAGCACTGGCGGCCGCACTGGCACCGGAGC
TGA
TGGGCTACAGTGAGCTGACGGCCATTGCCCGAAACTGTGCCATACAGCGTGCCACAGATGCCCTGCGTGAAGCCCTTCT
GTCC
TGGCTTGCGAAGGGTGAAAAAATTAATTATTCCGCACAGGATAGCGACATTTTAACGACCATCGGATTCAGGCCTGACG
TGGC
P
TTCGGTGGATGACAGCCGTGAAAAATTCACCCCTGCGCAGAACATGATTTTTTCGCGTAAAAGTGCGCAACTGGCATCA
CGTC .
, AGTCAGTGTAAAATTCCCCGAAAATCCGCCCGTTTTTACTGAAAAAAGCCATGCATCGATAAGGTGCATGGCTTTGCAT
GCGTT
, 1¨
.3 vi TTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGCGTGTCAGTGCAACTGCATTAAAACCGCCCC
GCAAA .
w GCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGTTAATTATTTGTGTAGTCAAAGTGCCTTCAG
TAC "
, , , ATACCTCGTTAATACATTGGAGCATAATGAAGAAAATCTATGGCCTATGGTCCAAAACTGTCTTTTTTGATGGCACTAT
, N, N, AAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTCAGTGTCGCAAGATC
19 Native P2 (acc nr:
GGCGAGGCGGGGAAAGCACTGCGCGCTGACGGTGGTGCTGATTGTATTTTTTCAGCGTCTCAGCGCGTCGTGACGGCAC
TTA
NC_001895) GTCTGCCCGTTGAGGCGTTGTGTGTCTGCGGGGTGTTTTGTGCGGTGGTGAGCGTGTGAGGGGGGATGACGGGGTGTAA
AA
AAGCCGCCCGCAGGCGGCGATGTTCAGTCGTTGTCAGTGTCCAGTGAGTAGTTTTTAAAGCGGATGACCTCCTGACCGA
GCCA
GCCGTTTATCTCGCGGATCCTGTCCTGTAACGGGATAAGCTCATTGCGGACAAAGACCTTTGCCACTTTCTCAATATCA
CCCAGC
1-d GACCCGACGTTCTCCGGCTTGCCACCCATCAACTGAAAGGGGATGCGGTGCGCGTCCAGCAGGTCAGCGGCGCTGGCTT
TTTT n GATATTAAAAAAATCGTCCTTCGTCGCCACTTCACTGAGGGGGATAATTTTAATGCCGTCGGCTTTCCCCTGTGGGGCA
TAGAG t=1 1-d AAACAGGTTTTTAAAGTTGTTGCGGCCTTTCGACTTGACCATGTTTTCGCGAAGCATTTCGATATCGTTGCGATCCTGC
ACGGCA w o w TCGGTGACATACATGATGTATCCGGCATGTGCGCCATTTTCGTAATACTTGCGGCGGAACAACGTGGCCGACTCATTCA
GCCAG =
'a GCAGAGTTAAGGGCGCTGAGATATTCCGGCAGGCCGTACAGCTCCTGATTAATATCCGGCTCCAGCAGGTGAAACACGG
AGC o 4,.
w w vi CGGGCGCGAAGGCTGTCGGCTCGTTGAAGGACGGCACCCACCAGTAAACATCCTCTTCCACGCCACGGCGGGTATATTT
TGCC
GGTGAGGTTTCCAGTCTGATGACCTTACCGGTGGTGCTGTAACGCTTTTCCAGAAACGCATTACCGAACACCAGAAAAT
CCAGC n.) o n.) ACAAAGCGGCTGAAATCCTGCTGGGAAAGCCATGGATGCGGGATAAATGTCGAGGCCAGAATATTGCGTTTGACGTAAA
TCG
i-J
GCGAGCTGTGATGCACGGCAGCCCGCAGGCTTTTTGCCAGACCGGTAAAGCTGACCGGTGGCTCATACCATCTGCCGTT
ACTG .6.
.6.
n.) ATGCACTCGACGTAATCCAGAATGTCACGGCGGTCGAGTACCGGCACCGGCTCACCAAAGGTGAATGCCTCCATTTTCG
GGCC oe GCTGGCGGTCATTGTTTTTGCCGCAGGTTGCGGTGTTTTCCCTTTTTTCTTGCTCATCAGTAAAACTCCAGAATGGTGG
ATGTCA
GCGGGGTGCTGATACCGGCGGTGAGTGGCTCATTTAACAGGGCGTGCATGGTCGCCCAGGCGAGGTCGGCGTGGCTGGC
TTC
CTCGCTGCGGCTGGCCTCATAGGTGGCGCTGCGTCCGCTGCTGGTCATGGTCTTGCGGATAGCCATAAACGAGCTGGTG
ATGT
CGGTGGCGCTGACGTCGTATTCCAGACAGCCACGGCGGATAACGTCTTTTGCCTTGAGCACCATTGCGGTTTTCATTTC
CGGCG
TGTAGCGGATATCACGCGCGGCGGGATAGAACGAGCGCACGAGCTGGAACACGCCGACACCGAGGCCGGTGGCATCAAT
AC
CGATGTATTCGACGTTGTATTTTTCGGTGAGTTTGCGGATGGATTCCGCCTGGGTGGCAAAGTCCATGCCTTTCCACTG
GTGAC
P
GCTCAAGTATTCTGAATTTGCCACCGGCCACCACCGGCGGTGCCAGTACCACGCATCCGGCGCTGTCGCCACGGTGTGA
CGGG
TCGTAACCAATCCATACCGGGCGGGAGCCGAACGGATTGGCGGCAAACGGCGCATAGTCTTCCCATTCTTCCAGCGTGT
CGAC
un CATGCAGCGTTGCAGCTCCTCGAACGGGAACACCGATGCCTTGTCGTCAACAAATTCACACATGAACAGGTTTTTAAAA
.3 GGCGCTGTTTTCGCGTTTGAGCTGCTCAATGTCGAACAGCGTGCAGCCGCCTTTCAGGGCGTCCTCAATGGTGACAATC
CCACTGGCCGTCCGCACAGAGAAGCCCACCGGCAAGGGCGTTATGACTGACGTCGATTTCCACGCGTTCGGCGGCGCTG
GCG
.31 .3 CGTCCCCGGTTAAACAGTTCACCCGACCAGAACGGGTAGGCGTCGTGCGCCAGCGTGGACGGGGTGGAGAAATAGGTCG
AG
CGCAGGTGACTCTGTGAGGCCATACCTGATGCCACCTTACGCAGTACCTGAAAATTCGGGATCCAGAAAATCTCATCGA
CGTA
CAGGTCGCCGTTATGACTCTGCGCGGTGTTGGAGTTGGTGCCGAGAAAAATCAGTTTTGCGCCGTTATTGCCCAGGACA
ATCG
GGTCACCGGTCAGGTCAACGTCAACCAGACGGGCAAAGGCGATGATGTATTCGCGGAACACATACGCCTGTGTTTTACT
GGCC
GACAGAAAAATCTGGTTATGACCGGTTTTCAGGGCACGCAGCAGCGCCTCGCGGGAAAAATAAAACGTCGCGCCAATCT
GGC
GGGATTTCAGGATATCGCGGATGCGGTGCTCAAGCCCGGCACGATACCAGTGCAGCTGATAGTCGAAAGACTGCTCAAA
GAA
IV
AATCTGCTCCAGCTTTTCGATGGCCTCGTCACTGAAAAAATTCTTTTTCGGTTTGCGCCGTCCGCCTTTGTTACGGTTA
GCGACG n TTCGGATTAAGGTCTGCCTCGTTGCCGGTCTGGCTGTAGCGGTTGACCCGTGCCAGTCGTTCAATCTGGCGTCCCAGCA
GGTCA t=1 tl ATTTCCTTGAAGTCACCGCCGGTTTTCTGTGGTTTGATGATGAGCTGGGTCAGCCGCGCTTCCAGACTCATTTCGACAC
o ATGGGGGCAACGCTGTCCCAGCCGTCGCGCTGTTTCCAGCTCTGCACTGTCGGGCGTTTCATCTGCAACATGGCGGCAA
TCTGC 'a o GGCACGGAAAACCCCTGCCAGTACAGCAGCGCCGCCTGACGACGCGGGTCGTGTAAAAGAGTGGTGTCTGTGGTGATGG
TCA tt n.) un TGAATACCTCGCCGTGATGAATACACGGCAAGGCTACTGAGTCGCGCCCCGCGATTCGCTAAGGTGCTGTTGTGTCAGT
GATA
AGCCATCCGGGACTGATGGCGGAGGATGCGCATCGTCGGGAAACTGATGCCGACATGTGACTCCTCTAATCACTATTCA
GGAC n.) o n.) TCCTGACAATGGCAAAAAAAGTCTCAAAATTCTTTCGTATCGGCGTTGAGGGTGACACCTGTGACGGGCGTGTCATCAG
TGCG
i-J
CAGGATATTCAGGAAATGGCCGAAACCTTTGACCCGCGTGTCTATGGTTGCCGCATTAACCTGGAACATCTGCGCGGCA
TCCT .6.
.6.
n.) GCCTGACGGTATTTTTAAGCGTTATGGCGATGTGGCCGAACTGAAGGCCGAAAAGATTGACGATGATTCGGCGCTGAAA
GGC oe AAATGGGCGCTGTTTGCGAAAATCACCCCGACCGATGACCTTATCGCGATGAACAAGGCCGCGCAGAAGGTCTACACCT
CAAT
GGAAATTCAGCCGAACTTTGCCAACACCGGCAAATGTTATCTGGTGGGTCTGGCCGTCACCGATGACCCGGCAAGCCTC
GGCA
CGGAATACCTGGAATTCTGCCGCACGGCAAAACACAACCCCCTGAACCGCTTCAAATTAAGCCCTGAAAACCTGATTTC
AGTGG
CAACGCCTGTTGAGCTGGAATTTGAAGACCTGCCTGAAACCGTGTTCACCGCCCTGACCGAAAAGGTGAAGTCCATTTT
TGGCC
GCAAACAGGCCAGCGATGATGCCCGTCTGAATGACGTGCATGAAGCGGTGACCGCTGTTGCTGAACATGTGCAGGAAAA
ACT
GAGCGCCACTGAGCAGCGCCTCGCTGAGATGGAAACCGCCTTTTCTGCACTTAAGCAGGAGGTGACTGACAGGGCGGAT
GAA
P
ACCAGCCAGGCATTCACCCGCCTGAAAAACAGTCTCGACCACACCGAAAGTCTGACCCAGCAGCGCCGCAGCAAAGCCA
CCGG
CGGTGGCGGTGACGCCCTGATGACGAACTGCTGACCGGCGTCAGTCAGTCCGGGAAAACCTTCACGATTAACCCTTAAT
TTCA
un GGAAAAACTATGCGCCAGGAAACCCGCTTTAAATTTAATGCCTACCTGTCCCGTGTTGCCGAACTGAACGGCATCGACG
.6.
.3 TGATGTGTCGAAAAAATTCACCGTTGAACCGTCGGTCACCCAGACCCTGATGAACACCATGCAGGAGTCCTCTGACTTT
CCGCATCAATATTGTGCCGGTCAGCGAAATGAAAGGGGAAAAAATTGGTATCGGTGTCACCGGCTCCATCGCCAGCACT
ACCG
.31 .3 ACACTGCCGGTGGTACCGAGCGTCAGCCGAAGGACTTCTCGAAGCTGGCGTCAAACAAGTACGAATGCGACCAGATTAA
CTTC
GATTTTTATATCCGCTACAAAACGCTGGACCTGTGGGCGCGTTATCAGGATTTCCAGCTCCGTATCCGTAACGCCATTA
TCAAAC
GCCAGTCCCTTGATTTCATCATGGCCGGTTTTAACGGCGTGAAGCGTGCCGAAACCTCTGACCGCAGCAGCAATCCGAT
GTTGC
AGGATGTGGCGGTCGGCTGGCTGCAGAAATACCGCAATGAAGCACCGGCGCGCGTGATGAGCAAGGTCACTGACGAGGA
AG
GCCGCACCACCTCTGAGGTTATCCGCGTGGGTAAGGGCGGTGATTATGCCAGCCTTGATGCACTGGTGATGGATGCGAC
CAAC
AACCTGATTGAACCGTGGTATCAGGAAGACCCTGACCTTGTGGTGATTGTGGGGCGTCAGCTACTGGCGGACAAGTATT
TCCC
IV
CATCGTCAACAAGGAGCAGGACAACAGCGAAATGCTGGCCGCTGACGTCATCATCAGCCAGAAACGCATCGGTAACCTA
CCA n GCGGTACGCGTCCCGTACTTCCCGGCGGATGCGATGCTCATCACGAAGCTGGAAAACCTGTCCATCTACTACATGGATG
ACAG t=1 tl CCATCGCCGCGTGATTGAGGAAAACCCGAAACTCGACCGCGTGGAGAACTACGAGTCAATGAACATTGATTACGTGGTG
o GACTACGCCGCCGGTTGTCTGGTGGAAAAAATCAAGGTCGGTGACTTCTCCACACCGGCTAAGGCGACCGCAGAGCCGG
GAG 'a o CGTAACCGATGACGAGTCCCGCACAGCGCCACATGATGCGGGTCTCGGCAGCGATGACCGCGCAGCGGGAAGCCGCCCC
GCT tt n.) un GCGACATGCAACTGTCTATGAGCAGATGCTGGTTAAGCTCGCCGCAGACCAGCGCACACTGAAAGCGATTTACTCAAAA
GAGC
TGAAGGCCGCAAAAAAACGCGAACTGCTGCCGTTCTGGTTGCCGTGGGTGAACGGCGTGCTGGAGCTGGGCAAAGGTGC
AC n.) o n.) AGGATGACATTCTGATGACGGTCATGCTGTGGCGTCTGGATACCGGCGATATTGCCGGTGCGCTGGAGATTGCCCGTTA
TGCC
i-J
CTGAAGTACGGTCTGACCATGCCGGGTAAACACCGCCGTACCCCGCCGTACATGTTCACCGAGGAGGTAGCGCTTGCGG
CCAT .6.
.6.
n.) GCGCGCTCACGCTGCCGGTGAGTCTGTGGATACCCGCCTGCTGACGGAGACCCTTGAACTGACCGCCACGGCTGACATG
CCTG oe ATGAAGTGCGCGCAAAGCTGCACAAAATCACCGGTCTGTTTCTGCGTGACGGTGGTGATGCCGCCGGTGCGCTGGCGCA
CCT
GCAACGTGCGACACAGCTCGACTGTCAGGCAGGCGTCAAAAAAGAGATTGAACGACTGGAGCGGGAGCTGAAACCGAAG
CC
GGAGCCGCAGCCCAAAGCGGCCACCCGCGCCCCGCGTAAGACCCGGAGCGTGACACCGGCAAAACGTGGACGCCCGAAA
AA
GAAAGCCAGTTAACAACCGAATGCGCCCCGCGCCAGGGCGGCACGCCGGTCAGTGACGGTGAATCACCTGACACTGCAC
CGG
CGTCCACCGCCCGACTTTTCAGAGGTAGTCATGATGACGCTGATTATTCCGCGAAAGGAGGCTCCCGTGTCCGGTGAGG
GTAC
GGTGGTCATCCCGCAACCGGCAGGCGACGAGCCGGTGATTAAAAACACGTTCTTTTTTCCCGATATCGACCCGAAGCGC
GTCC
P
GGGAACGTATGCGCCTTGAGCAGACCGTCGCCCCCGCCCGTCTGCGTGAGGCCATCAAGTCAGGCATGGCTGAAACGAA
TGC
GGAGCTGTACGAGTACCGCGAACAGAAAATTGCCGCCGGTTTTACGCGTCTGGCTGACGTCCCGGCGGACGATATCGAC
GGT
un GAAAGCATCAAGGTTTTTTACTACGAGCGCGCCGTGTGTGCGATGGCGACCGCGTCGCTTTATGAGCGTTATCGCGGTG
un .3 TGCCAGTGCGAAAGGCGACAAGAAGGCTGACAGCATTGACAGCACCATTGATGAGCTGTGGCGGGATATGCGCTGGGCG
GGCGCGCATCCAGGGCAAGCCGCGCTGCATCGTGAGTCAAATCTGATGAAGACCTTTGCGCTACAGGGCGACACGCTCG
ACG
.31 .3 CCATTTGTGTCCGCTATTACGGGCGCACTGAGGGCGTGGTTGAGACCGTGCTCGCCGCAAATCCGGGACTGGCTGAACT
GGG
GGCGGTGCTGCCACACGGCACCGCCGTCGAACTGCCCGACGTTCAGACCGCGCCCGTGGCTGAAACTGTCAATCTGTGG
GAG
TAACGCATGACAGCAGAAGAAAAAAGCGTCCTGTCGCTTTTCATGATTGGGGTGCTGATTGTTGTCGGCAAGGTGCTTG
CCGG
TGGTGAACCTATCACCCCGCGTCTGTTTATCGGGCGCATGTTGCTCGGTGGTTTTGTCTCGATGGTTGCCGGTGTTGTT
CTGGT
GCAGTTTCCTGACCTGTCACTGCCAGCGGTGTGCGGCATCGGCTCCATGCTGGGTATCGCCGGTTATCAGGTGATTGAG
ATTG
CCATTCAGCGCCGCTTTAAGGGCAGGGGGAAACAGTAATGCCGGTAATTAACACGCATCAGAATATCGCCGCCTTTCTC
GACA
IV
TGCTGGCCGTGTCCGAAGGGACGGCGAATCATCCACTGACGAAAAACCGGGGCTATGACGTGATAGTCACCGGACTGGA
CGG n GAAGCCGGAAATTTTCACCGACTACAGTGACCACCCGTTCGCACATGGCCGACCGGCGAAGGTGTTTAACCGTCGCGGT
GAAA t=1 tl AATCCACGGCCTCCGGTCGCTATCAGCAGCTTTACCTGTTCTGGCCGCATTACCGCAAACAGCTTGCCCTGCCGGATTT
o GTTGTCACAGGACAGACTCGCCATTCAGTTGATCCGCGAACGCGGAGCACTGGATGACATCCGGGCGGGACGCATTGAG
CGC 'a o GCCATTTCACGCTGTCGCAATATCTGGGCGTCCCTGCCGGGTGCCGGTTACGGTCAGCGTGAGCATTCACTGGAAAAAC
TGGT tt n.) un CACCGTCTGGCGTACCGCTGGCGGCGTACCGGCTTAAACGGAGTAAATACCATGAAGAAATTATCCCTTTCACTGATGC
TGAA
CGTGTCGCTGGCGCTGATGCTGGCACTGTCCCTGATTTACCCGCAGAGCGTGGCCGTCAATTTTGTCGCTGCCTGGGCG
ATTCT n.) o n.) GGCGACGGTTATCTGTGTGGTTGCCGGTGGTGTGGGCGTGTATGCCACTGAGTATGTGCTGGAACGCTACGGGCGGGAG
CTG
i-J
CCGCCGGAATCGCTGGCCGTGAAGATTGTCACGTCGCTGTTTTTGCAGCCGGTGCCGTGGCGCAGACGGGCGGCGGCTC
TGG .6.
.6.
n.) TAGTGGTGGTGGCGACGTTTATCTCGCTGGTCGCTGCCGGGTGGATTTTTACCGCGCTGATTTATCTTGTGGTGTCGCT
GTTTTT oe CCGGCTGATACGTAAAGCCTGTCGTCAGCGTCTTGAGGGGCGGGAACCATGTCAAGGCTGATGATTGTGCTGGTCGTGT
TGTT
ATCGCTGGCGGTGGCCGGTCTGTTTCTGGTGAAACACAAAAATGCCAGCCTGCGCGCCTCGCTGGACAGGGCGAACAAC
GTC
GCCAGCGGTCAGCAGACGACCATCACCATGCTGAAAAATCAGCTTCATGTTGCGCTCACCAGGGCAGATAAAAACGAGC
TGGC
GCAGGTGGCACTGCGTCAGGAACTGGAGAACGCCGCGAAACGTGAAGCACAGCGCGAGAAAACCATCACGAGGTTACTT
AAT
GAGAACGAAGATTTTCGCCGCTGGTACGGTGCTGACCTGCCTGATGCTGTGCGCCGGTTGCACCAGCGCCCCGCCTGCA
CCGA
CGCCAGTGATTGTCCCCAACGCATGCCCGAAAGTGAGCCTTTGCCCGATGCCGGGCAGTGACCCGCAGACGAACGGCGA
TTTA
P
AGTGCCGATATCCGGCAGCTTGAGAACGCGCTGGCACGCTGTGCCAGCCAGGTAAAAATGATTAAACACTGTCAGGACG
AAA
ACGATGCTCAAACCCGACAGCCTGCGCAGGGCGCTGACTGATGCCGTCACGGTGCTGAAAACTAACCCCGATATGCTGC
GGAT
un ATTCGTGGATAACGGGAGTATTGCCTCCACACTGGCGGCGTCGCTGTCATTCGAAAAGCGTTACACGCTCAATGTGATT
o .3 CCGACTTTACCGGTGATTTTGACCTGCTCATTGTGCCGGTGCTGGCGTGGCTGCGGGAAAATCAGCCCGACATCATGAC
GACGAAGGCCAGAAAAAGGGCTTCACGTTTTATGCAGACATCAACAATGACAGCAGCTTTGATATCAGTATCAGCCTGA
TGCT
.31 .3 GACCGAGCGCACGCTGGTCAGTGAGGTGGACGGCGCACTGCATGTGAAGAATATCTCGGAACCCCCGCCGCCGGAGCCG
GTC
ACCCGCCCGATGGAGCTGTATATCAATGGCGAACTGGTGAGTAAGTGGGATGAATGAGTTTAAGCGTTTTGAAGACCGG
CTG
ACCGGACTGATTGAATCGCTGTCACCGTCAGGGCGTCGGCGACTGAGTGCCGAACTGGCGAAACGTCTGCGGCAGAGTC
AGC
AGCGTCGGGTGATGGCACAGAAAGCCCCGGACGGCACACCCTACGCGCCACGCCAGCAGCAGAGCGTCAGAAAAAAGAC
CG
GTCGCGTTAAGCGAAAAATGTTTGCGAAACTTATTACCAGTCGTTTTTTGCATATCCGTGCCAGCCCGGAGCAGGCATC
AATGG
AATTTTACGGCGGGAAGTCGCCGAAAATCGCCAGTGTGCATCAGTTTGGTCTGTCGGAAGAAAACCGGAAAGACGGTAA
GAA
IV
AATTGATTATCCGGCGCGTCCCCTGCTCGGCTTTACCGGTGAGGATGTGCAGATGATTGAAGAGATTATCCTGGCTCAC
CTTGA n GCGTTAGTTTTATCCAGGCAGAGGCTGATGCGCAATTAAACATTGAGCGGCCATGCTGGTCGCTCAATGTTTAGAGGTT
TATG t=1 tl AGTGATTTTTATTTGATGCTTTGTATTCTAAAACCTTCTTATTGGCGTAAAAGAATTTTGTATATGACAGGAATATAAC
o TGAAGTGAAATAGACGAGGGATAGTATTAATAATGCTTTTTTGTGACTGTTATTATCTTTAATCTCCTGGCTTAACCAT
TCGGAG 'a o TCCTCCTCGTTTAGCTGTAAGAGCTTATTGCAGGCGATCTCAGGAAGTGTGTCTTTTATAAATACGTTTTGCAGTCTCT
TGCAAT tt n.) un CGGCAAGGCTATAAGTTTTATTAAATTCAACTGCTTTATTTTTGAAGGATAAAAGAACTTTGTCACTATAAACATAGTA
CATCAT
GTTTTTATATGGTATGCCTGTGGCATCCCTTACTATAACGGATTGTTCGTTGTGTATGTAACATGCGAGGAGAATGTAA
AAAAT n.) o n.) ACTGGCCAGAATTACAATTATTGTTTTAATTATGTGTGGTGGTTTTGTTATGTCACCCCAGATACGAGTAAGGAAAAAA
TACGA
i-J
TGTTTTTAGTTTTCCATCAATCAGTCCCTGCTGTATCATTCTCACATTTTCAATGCCTGATACATTGATTCCGTTAATT
ATTTTAAA .6.
.6.
n.) TAGTTGAATGTCGCGCCACTCGCGGTCAAGTCTTTTTAATTTTTTGTCTGAATATCCAAAATTGAAATAATGTGCAATA
AGCCTC oe ATAAGGTTACTTTTACCAAAGCTAAAAAATGCTAATACTGCAAAGCTACAAAGGAAAAAAACGATTAGCCCCCACACAT
TAGTC
ACATTATAGCTGACCATTACGCTCTCCTTGAATGTTGTCTGGTAGTTCTACAAATGAATCCAGATAGCATAACTTTTAT
ATATTGT
GCAATCTCACATGCATGAACACTCTCGCAAATATTCAGGAACTCGCGCGCGCACTGCGCAACATGATTCGCACTGGCAT
TATCG
TCGAAACCGACCTTAACGCCGGTCGCTGCCGCGTGCAGACCGGCGGCATGTGCACCGACTGGCTTCAGTGGCTGACCCA
TCGC
GCAGGACGTTCGCGCACATGGTGGGCACCTTCCGTGGGGGAACAGGTGCTGATTCTGGCCGTGGGTGGTGAACTCGACA
CGG
CGTTCGTTCTGCCGGGGATTTATTCCGGCGATAACCCCTCGCCGTCTGTGTCGGCGGATGCCCTGCATATCCGTTTCCC
TGACG
P
GGGCGGTGATTGAATATGAACCCGAAACCAGTGCACTCACGGTAAGCGGAATTAAAACGGCCAGCGTGACGGCTTCCGG
TTC
TGTTACTGCCACGGTGCCGGTGGTCATGGTGAAAGCATCAACCCGCGTCACCCTGGACACCCCGGAGGTGGTCTGCACC
AACA
un GGCTGATTACCGGCACGCTGGAAGTGCAGAAAGGCGGGACGATGCGCGGCAACATTGAACACACCGGCGGTGAACTCTC
--.1 .3 AAACGGTAAGGTACTGCATACCCATAAACACCCCGGCGACAGCGGCGGCACAACCGGGAGTCCTTTATGACAGCGCGTT
CGGAATGAATCGCAGTGATGGCCTGACTGTCACTGACCTTGAGCATATCAGCCAGAGTATCGGCGATATCCTGCGCACA
CCGG
.31 .3 TCGGCTCACGGGTGATGCGTCGTGATTACGGCTCGTTGCTGGCGTCAATGATTGACCAGCCGCAGACCCCGGCGCTTGA
GTTG
CAGATTAAAGTCGCCTGTTACATGGCAGTGCTGAAATGGGAACCCCGCGTCACCCTGTCATCCGTCACCACGGCGCGCA
GTTTT
GACGGGCGAATGACGGTCACGTTAACCGGCCAGCACAACGACACCGGCCAGCCACTTTCATTAACCATCCCTGTGAGTT
GAAA
CCATGCCGATTATCGACCTGAACCAGCTACCCGCACCGGATGTGGTCGAGGAGCTGGACTTTGAAAGCATTCTCGCTGA
ACGC
AAGGCGACACTGATTTCCCTTTACCCGGAAGATCAGCAGGAGGCGGTCGCCCGTACCCTGACACTGGAATCTGAGCCTC
TCGT
CAAACTGCTGGAAGAAAATGCTTATCGTGAGCTTATCTGGCGTCAGCGTGTGAATGAGGCCGCACGGGCGGTGATGCTG
GCC
IV
TGTGCCGCCGGTAATGACCTTGATGTGATTGGTGCCAATTACAACACCACGCGCCTGACTATCACCCCGGCAGATGATT
CGACC n ATCCCGCCGACACCGGCAGTGATGGAATCTGACACCGATTATCGTCTGCGTATTCAGCAGGCTTTTGAGGGCTTAAGCG
TCGC t=1 tl CGGGTCAGTGGGAGCCTATCAGTATCATGGTCGCAGTGCTGACGGGCGTGTCGCGGATATTTCTGTCACCAGTCCGTCT
o CCTGTGTCACCATCTCTGTGCTGTCACGTGAAAATAACGGCGTCGCATCCGAAGACCTGCTGGCTGTGGTGCGTAACGC
CCTTA 'a o ATGGCGAGGACGTCAGGCCGGTGGCCGACCGCGTGACCGTGCAGTCTGCCGCCATCGTTGAATACCAGATAAACGCCAC
GCT tt n.) un TTACCTTTACCCTGGTCCCGAAAGCGAACCCATCCGCGCTGCCGCTGTGAAAAAGCTGGAAGCGTATATCACGGCACAG
CACC
GGCTGGGGCGCGACATCCGTCTGTCTGCCATTTATGCCGCTTTGCATGTGGAAGGTGTGCAGCGTGTCGAACTGGCTGC
ACCA n.) o n.) CTGGCCGACATCGTGCTCAACAGTACGCAGGCGTCTTTCTGTACCGAATACCGCGTCGTGACCGGAGGCTCGGATGAGT
GATT
i-J
CGCGACTGCTGCCGACCGGCTCATCACCGCTTGAGGTCGCCGCCGCAAAAGCCTGTGCGGAAATTGAAAAAACGCCGGT
CAG .6.
.6.
n.) TATTCGTGAACTGTGGAACCCGGACACCTGTCCGGCAAATCTGCTGCCGTGGCTGGCGTGGGCGTTTTCGGTCGACAGG
TGGG oe ATGAAAAGTGGCCGGAAGCGACAAAACGCGCCGTTATCCGCGATGCCTATTTCATCCACTGTCATAAGGGCACGATAGG
TGCA
ATCCGGCGTGTGGTGGAGCCGCTCGGCTATCTCATCAACGTGACGGAGTGGTGGGAAAACAGTGACCCGCCCGGCACCT
TCC
GGCTTGATATTGGTGTACTGGAAAGCGGTATCACAGAGGCAATGTATCAGGAAATGGAACGGCTGATTGCTGATGCCAA
ACC
TGCAAGCCGTCACCTTATTGGCCTGAACATTACCCGGGACATTCCCGGCTATCTGTTCGCCGGTGGTGTGGCTTACGAC
GGCGA
TGTAATTACGGTTTACCCCGGATAAGTGAGGAATAATGAGCATAAAATTCAGAACCGTTATCACCACTGCCGGTGCAGC
AAAG
CTGGCAGCGGCAACCGCGCCGGGAAGGCGGAAGGTCGGCATTACCACGATGGCCGTCGGGGATGGCGGTGGTAAATTGC
CT
P
GTCCCGGATGCCGGACAGACCGGGCTTATCCATGAAGTCTGGCGACATGCGCTGAACAAAATCAGCCAGGACAAACGAA
ACA
GTAATTATATTATCGCCGAGCTGGTTATTCCGCCGGAGGTGGGCGGTTTCTGGATGCGTGAGCTTGGCCTGTACGATGA
TGCG
un GGAACGTTAATTGCCGTGGCGAACATGGCCGAAAGCTATAAGCCAGCCCTTGCCGAAGGCTCAGGACGTTGGCAGACCT
oe GCATGGTCATCATCGTCAGCAGTGTGGCCTCAGTGGAGCTGACCATTGACACCACAACGGTGATGGCGACGCAGGATTA
GATGACAAAATTGCAGAGCACGAACAGTCACGACGTCACCCGGACGCCTCGCTGACAGCAAAAGGTTTTACTCAGTTAA
GCAG
.31 .3 TGCGACCAACAGCACGTCTGAAACACTGGCCGCAACGCCGAAAGCGGTAAAGGCCGCGTATGACCTGGCTAACGGGAAA
TAT
ACCGCACAGGACGCCACCACAGCGCGAAAAGGCCTTGTCCAGCTTAGTAGCGCCACCAACAGCACGTCTGAAACGCTCG
CCGC
AACACCAAAAGCCGTTAAGACGGTAATGGATGAAACGAACAAAAAAGCGCCATTAAACAGCCCTGCACTGACCGGAACG
CCA
ACGACGCCAACTGCGCGACAGGGAACGAATAATACTCAGATCGCAAACACGGCTTTCGTTATGGCCGCGATTGCCGCCC
TTGT
AGACTCGTCGCCTGACGCACTGAATACGCTGAACGAGCTGGCGGCGGCGCTGGGCAATGACCCGAATTTTGCTACCACC
ATGA
CTAATGCGCTTGCGGGTAAGCAACCGAAAGATGCTACCCTGACGGCGCTGGCGGGGCTTGCTACTGCGGCAGACAGGTT
TCC
IV
GTATTTTACGGGGAATGATGTTGCCAGCCTGGCGACCCTGACAAAAGTCGGGCGGGATATTCTGGCTAAATCGACCGTT
GCCG n CCGTTATCGAATATCTCGGTTTACAGGAAACGGTAAACCGAGCCGGGAACGCCGTGCAAAAAAATGGCGATACCTTGTC
CGGT t=1 tl GGACTTACTTTTGAAAACGACTCAATCCTTGCCTGGATTCGAAATACTGACTGGGCGAAGATTGGATTTAAAAATGATG
o GGTGACACTGATTCATACATGTGGTTTGAAACGGGGGATAACGGCAATGAATATTTCAAATGGAGAAGCCGCCAGAGTA
CCA 'a o CAACAAAAGACCTGATGACGTTGAAATGGGATGCACTAAATATTCTTGTTAATGCCGTCATTAATGGCTGTTTTGGAGT
TGGTA tt n.) un CGACGAATGCACTAGGTGGTAGCTCTATTGTTCTTGGTGATAATGATACCGGATTTAAACAGAATGGAGACGGTATTCT
TGAT
GTTTATGCTAACAGTCAGCGTGTATTCCGTTTTCAGAATGGAGTGGCTATTGCTTTTAAAAATATTCAGGCAGGTGATA
GTAAA n.) o n.) AAGTTCTCGCTATCCAGCTCTAATACATCCACGAAGAATATTACCTTTAATTTATGGGGTGCTTCCACCCGTCCAGTGG
TTGCAG
i-J
AGTTAGGCGATGAGGCCGGATGGCATTTCTATAGCCAGCGAAATACAGATAACTCGGTAATATTTGCTGTTAACGGTCA
GATG .6.
.6.
n.) CAACCCAGCAACTGGGGAAATTTTGATTCCCGCTATGTGAAAGATGTTCGCCTGGGTACGCGAGTTGTTCAATTGATGG
CGCG oe AGGTGGTCGTTATGAAAAAGCCGGACACACGATTACCGGATTAAGAATCATTGGTGAAGTAGATGGCGATGATGAAGCC
ATC
TTCAGGCCGATACAAAAATACATCAATGGCACATGGTATAACGTTGCGCAGGTGTAAGTTATGCAGCATTTAAAGAACA
TTAA
GTCAGGTAATCCAAAAACAAAAGAGCAATATCAGCTAACAAAGAATTTTGATGTTATCTGGTTATGGTCCGAAGACGGA
AAAA
ACTGGTATGAGGAAGTGAAGAACTTTCAGCCAGACACAATAAAGATTGTTTACGATGAAAATAATATTATTGTCGCTAT
CACCA
GAGATGCTTCAACGCTTAATCCTGAAGGTTTTAGCGTTGTTGAGGTTCCTGATATTACCTCCAACCGACGTGCTGACGA
CTCAG
GTAAATGGATGTTTAAGGATGGTGCTGTGGTTAAACGGATTTATACGGCAGATGAACAGCAACAACAGGCAGAATCACA
AAA
P
GGCCGCGTTACTTTCCGAAGCGGAAAACGTTATTCAGCCACTGGAACGCGCTGTCAGGCTGAATATGGCGACGGATGAG
GAA
CGTGCACGACTGGAGTCATGGGAACGTTACAGCGTTCTGGTCAGCCGTGTGGATCCTGCAAATCCTGAATGGCCGGAAA
TGCC
un GCAATAAGTTGTATGACCTCTGTTGTGAACTTACATATCTATGGCACAGAGTAAAGCCTAATCTGAAGTCCACTCTGTG
o .3 AGCGGACCTTATAAACAAGAACAATGGTCATATCAGTGTGTTTTGATTGCATAGCTAACGTGCGTCTTCCTGTACAGAA
AGATGATAGGGCATAGGAGATGATTATTATCGCGTGTTTTAAAAATAGCTTTCTGCATCAAGTGTCACTTGCGAAGAGG
TATTG
.31 .3 GCGCTATGATTGGCATCACTCAGTTCAGATAATATTTTAAATATTTGGTAAATGTTCAGATTACACAATTCGGTCTGCG
TCCCGT
TAAAATTATCTACTATTAGTTATTACTATGAGGTGAATGGCAAGTGTTTTCCACTCGCCATTTTTGTTTTTTATTTTTT
TAAAGCCT
TTCCGACGTTTAAGGATTTTGCCAAGCCATAAAATATTTGATATTTCATTCCTGTTTTTATTTTTGGTGAGATATTTGC
GTAACTT
CTTTCTCTAAAACACCAACGTATAAACCTATTATTATCTTCGGTTGTTTCTATATAGCATATTACATTGAGACCAAAAA
GAAACTG
AAGGAAGTCATTTGCAGTTGTCATGAATTTTGGTTTTGTTGTGGAAATGGAACTAATATGAGTTTCAAGTTGTTTATAT
GCTAA
GAGGTATTCAGCGTAATCAAAAGTATCTTTTCCAGAGAGGAATTCAAAGAACTTTAAAAAAATCTCATAATGTTCACTT
CCATA
IV
ATAAAATGATAAATGATCTTTTATTTCTCCAAGTAAATAGTTAGAGTAATCTCTTTGCATGCTAGGACTTTCAAAGTCA
TCTAGA n ,-i CTAAATTGATTTTTCCCATCATCACCGCTGGCGTGTGATTTGATAATTTCGAGCATCCGTAATATATCTCTTGGGCGAT
AATATG t=1 tl ACCAGCGAAGGAAATTAATAAATGATGTGGGGTGGTTATAATTATCATGGACGTTGGGTGAATCCCAAGGGAAATAATG
o CCATGCCTGTCCCTTTTTAAGGGCCATGTCTTGCTGAGTCCTAAGCAGATGATCTAATACCTCAAATAATTGAGAGCTA
CGGTG 'a o GTTAACATATTCTGTCCGCCAGTCCAAGAATACTGAATTATCTCTGATTTTTGCGTTTTGATTTTGTAATCCTATGGAT
TCAAATA tt n.) un TATCTGGCCTGATCAAGAGAACGGCCTTCATTCTCCCTTTTCCTCCCTTTATACTTGGGAAGAAATCGTTGTTAATCTC
CCAGACT
GCGTGAGCTAATCCTTTTATACATTCTAGATAATCATCGTATGGAATTGAGGAAGGGCGGATATCAATACCATCGATAA
ATAAA n.) o n.) ATATGATTTTGAGATAAACGTATTTGGCTAAAGGCCTCTTCAAATTTTTTTTGTATATAAAATAAATTTATCTGAAATC
TGCTCTC
i-J
AGAAAAAGATAAAGACTCTCTTTCTTCACCTTTTAAGGTTGCATGCTTATGAAGTAGTTCGGCTGCAACTTTTGACTCT
TGAACA .6.
.6.
n.) AAACTGAGGGCTTGAATTATTTCTGGTGAAAATGCCTTAAGATAATACTCATCTATTGCATCATTAAGTGATGAGAATT
TTGAAT oe AATTTAGTAACTTTGAAATTTTCCCTTCTTTATCTAATACTTGTTTTGATATTAATAAATATAGAATAACTTTCCATAT
GCCAGAGA
AGTCAGACAAATTTAAATGCTTTTCAGATTTAAGAGTGATAAATTTTTGATATTCTGTCTCTCTTATATATTTAGTTGT
AGCTAGC
GTATTGTTAATATTGTTATTTGAGAGATAGATAGAGTATGCGGTTTTACCAGTACCTTTCTCTCCTACAAGAAACGATA
TATTTG
GTTCACATAATCTAGATAGGTGATTATCACGTATGAACACTTTGTTAAGTAATTCTTTATTCTCCCTTCTCTTATAATT
TTCAGCAT
CAGCATAGCCAAGAGTTAGATCTTTGATTGGTATCATTATTACCTCAACTAAAGCAATTGAAAAACATATGGTTATAAA
AACAT
AGCGCTGCTCTGTCGCATATTGTGGATATCAACATATGAAATGTAAAGGAACTATTTGTGGATGAATGAACCGAATCGC
TGTA
P
GCTTCGGTAGTCATCTTTCAGACTTGTATAAATGAACAACTTCCGCTTCTCGCTCAAAGGAAACTGTCAGATTTGATAG
CTTTTG
GGCTATGTAAACTGTCAGTCGGAAAATGAGTGAGTACAAATCAGGGCAGGTGAGCGAATTGCCCGCCTTTTCTTTACCG
GTGG
o TTGTGCTGTCGATTAGCCAACCGGGACAAATAGCCTGACATCTCCGGCGCAACTGAAAATACCACTCACCCATTAACCA
o .3 TTAAACGGATGAGTGACTATCATCACGGCGTGCAGGTGCTGGAGATTAACGAGGGCACCCGCGTCATTTCCACCGTATC
GCCATTGTCGGCATGGTCTGCACGGCCAGCGATGCAGATGCGGAAACCTTCCCCCTCAATAAACCTGTGCTGATTACCA
ATGTG
.31 .3 CAGAGCGCAATTTCAAAGGCCGGTAAAAAAGGCACGCTGGCGGCATCGTTGCAGGCCATCGCTGACCAGTCAAAACCGG
TCA
CCGTTGTCATGCGCGTGGAAGACGGCACCGGTGATGACGAGGAAACGAAACTCGCGCAGACCGTTTCCAATATCATCGG
CAC
CACCGATGAAAACGGTCAGTACACCGGACTAAAAGCCATGCTGGCGGCGGAGTCGGTAACCGGTGTTAAACCGCGTATT
CTC
GGCGTGCCGGGACTGGATACCAAAGAGGTGGCTGTTGCACTGGCATCAGTCTGTCAGAAGCTGCGTGCTTTCGGGTATA
TCA
GCGCATGGGGCTGTAAAACCATTTCCGAGGTGAAAGCCTATCGTCAGAATTTCAGCCAGCGTGAGCTGATGGTCATCTG
GCCG
GATTTCCTCGCATGGGATACGGTCACCAGTACCACCGCCACCGCGTATGCCACCGCCCGTGCGCTGGGGCTGCGCGCTA
AAAT
IV
CGACCAGGAGCAGGGCTGGCATAAAACGCTGTCCAATGTCGGGGTGAACGGTGTTACCGGCATCAGCGCATCTGTATTC
TGG n GATTTGCAGGAGTCCGGCACCGATGCTGACCTGCTTAACGAGTCAGGCGTCACTACGCTGATTCGCCGCGACGGTTTCC
GCTTC t=1 tl TGGGGTAACCGTACCTGCTCTGATGACCCGCTGTTCCTCTTTGAAAACTACACCCGCACCGCGCAGGTCGTGGCCGACA
o GCTGAGGCGCACATGTGGGCGGTGGACAAGCCCATCACTGCAACGCTGATTCGCGACATCGTTGACGGCATCAATGCCA
AATT 'a o CCGTGAGCTGAAAACAAACGGCTATATCGTGGATGCGACCTGCTGGTTCAGCGAAGAATCCAACGATGCGGAAACCCTC
AAG tt n.) un GCCGGAAAACTGTATATCGACTACGACTATACACCGGTGCCTCCTCTCGAAAACCTGACCCTGCGCCAGCGTATTACCG
ATAAA
TACCTGGCAAATCTGGTCACCTCGGTTAACAGCAATTAAGGAGCCTGACCGATGGCAATGCCGCGCAAACTCAAGTTAA
TGAA n.) o n.) CGTCTTTCTGAACGGCTACAGCTATCAGGGCGTTGCAAAGTCCGTCACGCTGCCAAAACTGACCCGTAAGCTCGAAAAC
TATCG
i-J
CGGTGCGGGGATGAACGGCAGCGCACCGGTAGACCTCGGCCTTGATGACGATGCGCTGTCAATGGAGTGGTCGCTCGGT
GGC .6.
.6.
n.) TTCCCGGATTCGGTTATCTGGGAGCTTTACGCCGCAACCGGTGTGGATGCCGTGCCGATTCGTTTTGCAGGCTCTTACC
AGCGC oe GACGATACCGGCGAAACGGTGGCCGTCGAAGTGGTCATGCGTGGACGTCAGAAAGAAATCGACACCGGCGAGGGTAAAC
AG
GGAGAAGACACTGAGTCGAAAATCTCCGTGGTCTGCACCTATTTCCGGCTGACGATGGACGGTAAGGAGCTGGTCGAAA
TTG
ACACCATCAACATGATTGAGAAGGTGAACGGCGTCGATCGGCTGGAGCAACACCGCCGCAATATCGGCCTGTGATTTTC
ATCC
GGTCAGCCTGGCTGGCCGGTTAACCCTGATTCAGAAGTGAGAAAACCATGAACAAAGAAAATGTCATTACCCTGGACAA
TCCG
GTCAAACGTGGTGAGCAGGTTATCGAACAGGTCACGCTGATGAAACCCAGTGCCGGGACGCTACGCGGTGTCAGTCTGG
CTG
CGGTTGCAAACTCCGAAGTCGATGCACTGATTAAGGTGCTGCCGCGCATGACGGCACCGATGCTGACCGAGCAGGAAGT
CGC
P
CGCGCTGGAACTGCCTGACCTTGTGGCGCTGGCCGGTAAGGTGGTCGGTTTTTTGTCGCCGAACTCGGTGCAGTGACGT
TTCC
GAAAAATCTCTCGGTCGATGACCTGATGGCGGATGTGGCAGTGATATTTCACTGGCCGCCATCAGAACTGTATCCCATG
AGCC
o TGACCGAACTCATCACATGGCGCGAAAAGGCGCTCCGGCGAAGCGGAAACACGAATGAGTAACAATGTAAAATTACAGG
1-, .3 TGCTCAGGGCTGTTGACCAGGCATCCCGCCCGTTTAAATCCATCCGCACAGCGAGCAAGTCGCTGTCGGGGGATATCCG
ACACAAAAATCACTGCGCGAGCTGAACGGTCACGCATCCCGTATTGAGGGATTCCGCAAGACCAGTGCACAGCTCGCCG
TGAC
.31 .3 TGGTCATGCACTTGAAAAGGCACGGCAGGAGGCCGAAGCCCTTGCCACACAGTTTAAAAACACCGAACGTCCGACCCGT
GCTC
AGGCGAAAGTCCTGGAATCCGCAAAGCGTGCGGCGGAGGACTTACAGGCGAAATATAACCGCCTGACAGATTCCGTTAA
ACG
CCAGCAGCGGGAACTGGCCGCTGTGGGAATTAATACCCGCAATCTTGCACATGATGAGCAGGGACTGAAAAACCGTATC
AGT
GAAACCACCGCACAGCTTAACCGTCAGCGTGATGCGCTGGTGCGTGTCAGTGCGCAACAGGCAAAACTTAACGCAGTAA
AAC
AGCGTTATCAGGCCGGAAAGGAACTGGCCGGAAATATGGCCTCAGTGGGCGCTGCCGGTGTGGGGATTGCGGCGGCGGG
AA
CGATGGCCGGTGTTAAGCTACTGATGCCCGGTTATGAGTTTGCGCAGAAAAACTCAGAATTACAGGCTGTGATCGGAGT
GGCA
IV
AAAGACTCCGCCGAAATGGCCGCACTCCGCAAGCAGGCGCGCCAGCTCGGCGACAATACCGCCGCCTCGGCAGATGATG
CAG n CCGGTGCGCAGATTATTATTGCGAAAGCCGGTGGGGATGTTGATGCCATTCAGGCGGCAACGCCGGTCACGCTGAACAT
GGC t=1 tl GCTGGCGAACCGTCGCACAATGGAAGAAAACGCCGCCCTGCTGATGGGGATGAAATCCGCCTTTCAGCTTTCAAACGAT
o TCGCTCATATCGGGGATGTTCTCTCCATGACGATGAACAAAACCGCCGCCGATTTTGACGGCATGAGCGATGCGCTGAC
CTAT 'a o GCCGCACCTGTGGCAAAAAATGCCGGTGTCAGCATTGAAGAAACCGCCGCAATGGTCGGGGCGCTGCATGATGCAAAAA
TCA tt n.) un CAGGCTCAATGGCGGGGACGGGAAGCCGTGCCGTGTTAAGCCGCCTGCAGGCACCGACGGGAAAAGCATGGGATGCACT
CA
AAGAGCTTGGAGTGAAAACCTCAGACAGCAAAGGAAACACCCGGCCAATATTTACCATTCTGAAAGAAATGCAGGCCAG
TTTT n.) o n.) GAGAAAAACCGGCTCGGTACTGCCCAGCAGGCTGAATACATGAAAACTATTTTCGGGGAGGAGGCCAGCTCAGCCGCTG
CCG
i-J
TGCTGATGACTGCCGCCTCAACCGGAAAGCTGGACAAACTGACCGCTGCGTTTAAAGCCTCAGACGGGAAGACCGCCGA
GCT .6.
.6.
n.) GGTAAATATCATGCAGGACAACCTAGGCGGTGACTTTAAAGCGTTTCAGTCCGCTTATGAGGCGGTGGGGACTGACCTG
TTTG oe ACCAGCAGGAAGGCGCGCTGCGTAAGCTCACGCAGACGGCCACAAAGTATGTGTTAAAACTCGACGGCTGGATACAGAA
AAA
CAAATCACTGGCGTCAACCATCGGCATCATTGCCGGCGGTGCACTGGCGCTTACTGGCATCATCGGTGCCATTGGCCTC
GTAGC
CTGGCCGGTTATCACCGGCATCAATGCCATCATCGCGGCAGCAGGCGCAATGGGGGCAGTCTTCACGACGGTTGGCAGT
GCT
GTTATGACCGCCATCGGGGCTATTAGCTGGCCGGTTGTGGCCGTGGTGGCTGCCATTGTCGCCGGTGCGTTGCTTATCC
GTAA
ATACTGGGAGCCTGTCAGCGCATTCTTTGGTGGTGTGGTTGAAGGGCTGAAAGCGGCATTTGCGCCGGTGGGGGAACTG
TTC
ACGCCACTTAAACCGGTTTTTGACTGGCTGGGCGAAAAGTTACAGGCCGCGTGGCAGTGGTTTAAAAACCTGATTGCCC
CGGT
P
CAAAGCCACCCAGGACACCCTGAACCGTTGCCGTGACACGGGCGTCATGTTCGGGCAGGCACTGGCTGACGCGTTGATG
CTG
CCGCTTAATGCGTTCAACAAACTGCGCAGTGGTATTGACTGGGTACTGGAAAAACTCGGTGTTATCAACAAAGAGTCAG
ACAC
o ACTTGACCAGACCGCCGCCAGAACTCATACCGCCACGTATGGTACCGGTGACTATATTCCGGCGACCAGCTCTTATGCA
n.) .3 TCAGGCTTATCAGCCGGTCACGGCACCGGCTGGCCGCTCTTATGTAGACCAGAGTAAAAACGAATATCACATCAGCCTG
GGGGGACTGCGCCGGGGACACAGCTTGACCGCCAGTTACAGGATGCGCTCGAAAAATACGAGCGGGATAAACGTGCGCG
CG
.31 .3 CCCGTGCCAGCATGATGCATGACGGTTAAGGAGGTGACGAAAAATGATGCTCGCGTTAGGTATGTTTGTTTTTATGCGC
CAGA
CGCTGCCACACCAGACCATGCAGCGTGAATCAGATTATCGCTGGCCGTCAAATTCCCGTATCGGTAAACGGGATGCCTT
TCAGT
TTCTCGGTGTGGGTGAGGAAAACATCACGCTGGCCGGTGTGCTTTATCCCGAACTGACCGGCGGCAAGCTGACGATGAC
CAC
GCTCAGGCTGATGGCAGAGGAGGGGCGGGCGTGGCCGTTGCTGGATGGCACCGGCATGATTTACGGCATGTATGTCATC
AGC
AGGGTGAGTGAAACAGGGAGTATTTTCTTTGCAGACGGCACACCCCGGAAAATTGATTTTACGCTGTCACTCACCCGCG
TTGA
TGAATCACTGGCCGCGCTTTATGGCGATATCGGTAAACAGGCGGAATCGCTCATCGGTAAGGCCGGCAGTATGGCGACC
AGA
IV
TTCACAGGTATGACGGGGGCGGGATAATGCTGGATGCGCTGACATTTGATGCAGGCAGTACGCTGACGCCGGATTACAT
GCT n GATGCTCGACAGCAGGGATATTACCGGCAATATCAGCGACCGTCTGATGAGCATGACCCTGACGGATAACCGGGGCTTT
GAG t=1 tl GCTGACCAGCTTGATATTGAACTGAACGATGCCGACGGGCAGGTCGGGCTGCCGGTTCGTGGCGCTGTCCTGACGGTGT
o CGGCTGGAAAGGTTTTGCCCTGGTATGCAAAGGGAAATTTACCGTTGATGAGGTTGAACACCGGGGCGCACCGGATGTA
GTC 'a o ACCATCCGCGCCCGGAGTGCAGATTTTCGCGGGACGCTCAATTCCCGCCGGGAAGGCTCCTGGCATGACACCACGCTCG
GTGC tt n.) un GATTGTTAAGGCGATAGCCACCCGTAACAGGCTGGAAGCCAGTGTCGCTCCGTCACTGGCCGGAATAAAAATTCCACAC
ATCG
ACCAGTCGCAGGAGTCTGATGCGAAATTCCTGACCCGTCTTGCAGAACGCAACGGCGGTGAGGTGTCGGTAAAAATGGG
AAA n.) o n.) ACTGTTGTTTCTCAAAGCGGGGCAGGGAGTGACGGCCAGCGGTAAAAAAATCCCGCAGGTCACCATAACCCGCAGCGAC
GGC
i-J
GACCGCCATCATTTTGCGATTGCTGACCGTGGAGCCTACACCGGTGTAACGGCAAAATGGCTACACACTAAAGACCCGA
AGCC .6.
.6.
n.) GCAAAAGCAGAAGGTAAAACTGAAACGCAAAAAGAAAGAGAAACACCTGCGCGCACTGGAGCACCCGAAAGCGAAACCG
GT oe CAGGCAGAAGAAAGCGCCTAAAGTACCGGAAGCGCGTGAAGGTGAATACATGGCCGGTGAGGCTGACAACGTTTTTGCC
CTG
ACCACGGTATATGCCACGAAAGCGCAGGCCATGCGCGCCGCTCAGGCGAAGTGGGATAAACTGCAACGGGGCGTTGCGG
AG
TTCTCTATCAGCCTGGCTACCGGTCGGGCAGATATTTACACGGAAACACCGGTCAAAGTGTCTGGCTTTAAGCGCGTCA
TAGAC
GAGCAGGACTGGACAATCACTAAGGTGACACATTTTCTGAATAATAGCGGCTTCACGACGTCCTTAGAGCTTGAGGTCA
GGCT
TTCTGATGTGGAGTACGAAACAGAAGATGATGAGTGATGTTTTTGTTTTATCTGTTTGTTTTGTAAGGATAAATTAACT
AAAAT
GGCACCATCAACAAAACCGGAAGAGGTGCTCGCGATGTTTCATTGTCCTTTATGCCAGCATGCCGCACATGCGCGTACA
AGTC
P
GCTATATCACTGACACGACAAAAGAGCGTTATCATCAGTGCCAGAACGTGAATTGCAGCGCCACGTTCATCACTTATGA
GTCG
GTACAGCGATACATCGTGAAGCCGGGAGAAGTCCACGCCGTAAGGCCGCACCCGTTGCCATCAGGGCAGCAAATTATGT
GGA
o TGTAATTACAAACAGAAAGCCCCTCAGTCGAGGGGCTTTTTTGTCGATGTGGTCAATGTGTGGACGTGACCAGAAATAA
.3 TTTTATTTCAATTTATTGTACGTAAAAAATAAGCCCGTGTAAGGGAGATTTAGGGTGTCACCAGTAGGGGCTTTCAACG
ATGCGGGTTTGAGCGGCATAAATTACCACTGAAAGCCCTTAAACGTTACTCTACTGTGGACACTGTGTGGACACTCTCG
GCCTC
.31 .3 AGTACCACCTCTTAGCGGATTAAGAGAAATGGCGTCCTGAAGGTACTCTGGCGCAAAATGAGCGTAAACCATAGTTTGC
TCAA
TCCGCGTGTGACCTAGTATCCGTTGTAGCGTGATAATACTTCCTCCATTAATCATGAAATGAGTGGCAAAGCTGTGCCT
TAGTG
CATGTGTGGCTTGCCCCATTGGCAAATCCGGTTTTATTGCTTTCATTGTTCGTCTGAAGCGAGGGTAATCAGCATCAGG
GAATA
AAAAACCTCGTTTGTTATCCGCGATCATTTTGGCAACAGCCTCTGAGATCGGGACGGTGCGTGGTTTGTTTGTTTTCGT
TTTAAC
AAACGTGACGCGGTTATGGATGATATTTTCTGCTTTCAAACGAGCTGCTTCTCCCCAACGTGCTCCTGTACTCAGGCAA
AGAAT
CGCAATCTTTTTATTGTCGCCGTCAAGTGCTGCAAGCAGTAAGGCAATTTCTTCCTGTGTTAGATAGCCTGTTTCTGGT
TTTTCCT
IV
CCTTAAGCCTTTTTGTCCCTCTGATAGGGTGCTCACCAAAGAATAACTCCGCTTCAATCAGGGCTGTAAACATGCCGCT
AATACA n TGTTAAATCACGATTGATACTCGAAGGTTTAATACCCTGACTTCTTCGGGTGGCGCAGTACTGGCTGATAAGCGATTTC
GTAAT t=1 tl TTGAAATGCGCATGGGTCATTCGTTATTTTTGTGAAGATTTCAATTTTTCCAAGATTAGATTTCCCATGCTCTTCGTGT
o TTAAATCCCACCAGATCTGTGTCAGCTCCGACAGACGTCGCTTGTCTGTTGGTTTTGATAGCCATTCTTTATTGTGGTG
GTTGTA 'a o CAACGTGTATTTCTCGAAAGCGACAGCTTCGCTTTTCTTATCAAACTTCCTACGGATGCGTTTTCCATTACGTCCAGTA
GGGCGG tt n.) un ATGTCCACTTCATATCGACCATCATCGAGTTTTTTGATTGCCATCAGAAAACCCTCCGAGTGGTGTGTTTTTTTGCGAC
TACTAAT
CGCTTTTTTCGTGGTGGCTGAAATTTAGCCACCAATAGTAGGCACTTGTGATGAATATATTCACGATGAATTGTTAACC
AGTCTT n.) o n.) TTGACCGGAGTGGGGCGACGTTGTTTCGTTTTGCCCAAAGTGTGCGAGAGCGGGCGCAATTTGCCCGGACTCAGGAGCG
ATC
i-J
TGATTGGTCATGAACCATAAAGTGTATTTGGTGAATTGTGGGGTCTGCAGGATGTTCATCATGACATCTGTTGGAGGTG
TTGA .6.
.6.
n.) ACGACCACTTTCATAGTAACTCAGCGTGCCATACGGAACCCCTGTTAAATCAGCAAGTTGTTGTCTGCTCAAATACTCT
GATTTT oe CGCATTAAGACTATCTTCTCGCTTATCGTGTTTGACATGGTGTTTAGATCTCAATAGTATTTAGTTTAGATGTAGATTG
TTTAGTG
CTTGGATGTGGGCACTAAAAGGCATTATAAGACATTAAACGCAATTCATGAGGGCTAGAGGACGACATGAGCAAGCAAG
TAA
CACTCATGACTGATGCGATTCCTTATCAGGAGTTCGCAAAACTAATAGGAAAATCGACAGGAGCGGTTCGTCGGATGAT
CGAT
AAAGGAAAGCTGCCTGTAATTGATATGACCGATCCACAATCAGCTTCAGGTCGTGCAGGTGAATATTGGGTATACCTTC
CGGC
ATGGAATAACGGACTAAAACTGGCTTATGAAAGCCGCCCTAAAGAGATTCGTGACGGCTGGTTGATGTGGTTAGGTCTC
GGTG
AACCACGTTAAGGAGAACCGTATGAATGAGCCTCGTTGTATTGCTCAGTTACTGCGTAACGAAAGCCCCAGGGCGATTG
ACTT
P
CACCATCACCCACGGTAAGGGGCGTAAGGGAATCATTATCCGCACCAAAAAACAGAGTCCGTTAAAAAAGGCTCTGACC
TTTC
TGAAAAGCCGGAGGGTATGGAAATGACAGTGATGACGCTCAATCTCGTTGAAAAACAGCCAGCAGCTATGCGCCGGATA
ATT
o GGTAAGCATCTTGCCGTTCCTCGCTGGCAGGATACATGTGATTATTATAATCAGATGATGGAGCGCGAACGGTTAACGG
.6.
.3 CTTCCATGCTCAGTTAAAACAGCGTCACGCAACGATGTGTTTTGAAGAAATGAACGACGTCGAACGTGAACGACTGGTA
CAATTGATGAATTGCGTGGTGCATTCTCAAAACGCCGTCAGGTTGGCGCAAGTGAGTATGCATATATTAGTTTTTTAAC
AGTCA
.31 .3 GTCAGCGTCGTACTTTATTTATGCATGCCGGATTGACTGAAAAAGAATTCAACCAGCCATACTGGCGAATTAATGAAGA
GTCAT
GTTACTGGCGTGATGCTTTATTCCGTGCATTACGTGAATTATTCAGTCTGTTTGAGTATGCACCGACAATTCTGACGTC
GGTAAA
ACCGGAGCAATATCTGCATTAAGTAATTAACCAGAGTTTTTAACGCACTTAATTGTGCGGGGCTTCTTTTTGCCTGGAG
AAAGT
TATGCATACAGTTTCTGAAAATCAGTGCGGTATATACGCATTACTGCTGCAACAGGCCAGAACCGAAGCACAGGCCGAC
GCTG
CGACGCGCTTTTCTTCTCATCTTGATGCCATGATTCGCCACATCACAAAGGCGGAGTTATCCCGCGTGGAGATAGTCGA
GCTGC
TCAGTCAGGAGTCGGAAAAATTTCACAATATCGGATTGTCTCGCGGGGAGGTGCTTTGATGTTCTGTTCTCGTGCAGTT
GTATT
IV
ACTGAATAACGCCTTAAAAATCGCCGTTATGAAAAATGGCGATTTGTCTCTTATTCAACTTGGTCTTGATAAAGAAAAA
CGCGA n ,-i AATAACTGAATCTGTTATCGCGATTTATCAGAGTGAATTAAACCTCCTGTCTGATGTGGTCAATTTACTTGTTAAACGC
GCTGTA t=1 tl TTTCACAAGCAAATTTCCTCCGTGGATGAACTGACGAAATTAACGACAGAAATCGCCAGCTATTGCGCTGATGAATTTA
o CTGAACGACAAAAGGAACTGGTAATGCCGGACAACGTAGATTTTATTCAGGAACAACAGGCTGAATTACTGGAGCGCCA
GATT 'a o AACGCGGCAAGGGTAAAACATTGCGGTGCTTCTGCGCTGGTTTGCGAAGAGTGTGACGCGCCAATACCTGCTGCCCGTC
GTGC tt n.) un GGCTTACCCGTCAGCCACGCGTTGTGTTTCCTGTCAGTCAGTCTTTGAAGCAAAAAACAAACATTACCGGAGAACGGCA
TGAG
TATTCGTATTGAAATTGGCGAACGTTATGTCGTTACCAGTGACAGCTTTCAGTTTATTCTCCACGAGAAAAAGAGAGCG
GAAAG n.) o n.) CGGTAAAAACGCCGGTCAGGAATGGCTGGCGGTGGTTGGTTATTACCCGAAATTAAGCCAGCTCGTTTCAGGCCTGATG
CATC
i-J
ACGATATTCTGACCGGAAGCGCAAAGTCTTTTGCTGATTTAAACGTGCAGGTTGAGCAACTCAGCAAGCGTTGTTCAGA
GGCT .6.
.6.
n.) TTTGGCTCATATGGCCGTTAAAGCCTCCGGGCGTTTTGTCCCTCCGTCAGCATTTGCCGCAGGCACCGGTAAGATGTTT
ACCGG oe TGCTTATGCATGGAACGCGCCACGCGAGGCCGTCGGGCGCGAAAGACCCCTTACACGTGACGAGATGCGTCAGATGCAA
GGT
GTTTTATCCACGATTAACCGCCTGCCTTACTTTTTGCGCTCGCTGTTTACTTCACGCTATGACTACATCCGGCGCAATA
AAAGCCC
GGTGCACGGGTTTTATTTCCTCACATCCACTTTTCAGCGTCGTTTATGGCCGCGCATTGAGCGTGTGAATCAGCGCCAT
GAAAT
GAACACCGACGCGTCGTTGCTGTTTCTGGCAGAGCGTGACCACTATGCGCGCCTGCCGGGAATGAATGACAAGGAGCTG
AAA
AAGTTTGCCGCCCGTATCTCATCGCAGCTTTTCATGATGTATGAGGAACTCAGCGATGCCTGGGTGGATGCACATGGCG
AAAA
AGAATCGCTGTTTACGGATGAGGCGCAGGCTCACCTCTATGGTCATGTTGCTGGCGCTGCACGTGCTTTCAATATTTCC
CCGCT
P
TTACTGGAAAAAATACCGTAAAGGACAGATGACCACGAGGCAGGCATATTCTGCCATTGCCCGTCTGTTTAACGATGAG
TGGT
GGACTCATCAGCTCAAAGGCCAGCGTATGCGCTGGCATGAGACGTTACTGATTGCTGTCGGGGAGGTGAATAAAGACCG
TTCT
o CCTTATGCCAGTAAACATGCCATTCGTGATGTGCGTGCACGCCGCCAAGCAAATCTGGAATTTCTTAAATCGTGTGACC
un .3 AACAGGGAAACCGGCGAGCGCATCGACCTTATCAGTAAGGTGATGGGCAGTATTTCTAATCCTGAAATTCGCCGGATGG
GATGAACACCATTGCCGGTATTGAGCGTTACGCCGCCGCAGAGGGTGATGTGGGGATGTTTATCACGCTTACCGCGCCT
TCAA
.31 .3 AGTATCACCCGACACGTCAGGTCGGAAAAGGCGAAAGTAAAACCGTCCAGCTAAATCACGGCTGGAACGATGAGGCATT
TAA
TCCAAAGGATGCGCAGCGTTATCTCTGCCATATCTGGAGCCTGATGCGCACGGCATTCAAAGATAATGATTTACAGGTC
TACG
GTTTGCGTGTCGTCGAGCCACACCACGACGGAACGCCGCACTGGCATATGATGCTTTTTTGTAATCCACGCCAGCGTAA
CCAGA
TTATCGAAATCATGCGTCGCTATGCGCTCAAAGAGGATGGCGACGAAAGAGGAGCCGCGCGAAACCGTTTTCAGGCAAA
ACA
CCTTAACCAGGGCGGTGCTGCGGGGTATATCGCGAAATACATCTCAAAAAACATCGATGGCTATGCACTGGATGGTCAG
CTCG
ATAACGATACCGGCAGACCGCTGAAAGACACTGCTGCGGCTGTTACCGCATGGGCGTCAACGTGGCGCATCCCACAATT
TAAA
IV
ACGGTTGGTCTGCCGACAATGGGGGCTTACCGTGAACTACGCAAATTGCCTCGCGGCGTCAGCATTGCTGATGAGTTTG
ACGA n GCGCGTCGAGGCTGCACGCGCCGCCGCAGACAGTGGTGATTTTGCGTTGTATATCAGCGCGCAGGGTGGGGCAAATGTC
CCG t=1 tl CGCGATTGTCAGACTGTCAGGGTCGCCCGTAGTCCGTCGGATGAGGTTAACGAGTACGAGGAAGAAGTCGAGAGAGTGG
o GGCATTTACGCGCCGCATCTCGGCGCGCGTCATATTCATATCACCAGAACGACGGACTGGCGCATTGTGCCGAAAGTTC
CGGT 'a o CGTTGAGCCTCTGACTTTAAAAAGCGGCATCGCCGCGCCTCGGAGTCCTGTCAATAACTGTGGAAAGCTCACCGGTGGT
GATA tt n.) un CTTCGTTACCGGCTCCCACACCTTCTGAGCACGCCGCAGCAGTGCTTAATCTGGTTGATGACGGTGTTATTGAATGGAA
TGAAC
CGGAGGTCGTGAGGGCGCTCAGGGGCGCATTAAAATACGACATGAGAACGCCAAACCGTCAGCAAAGAAACGGAAGCCC
GT n.) o n.) TAAAACCGCATGAAATTGCACCATCTGCCAGACTGACCAGGTCTGAACGATTGCAGATCACCCGTATCCGCGTTGACCT
TGCTC
i-J
AGAACGGTATCAGGCCTCAGCGATGGGAACTTGAGGCGCTGGCGCGTGGAGCAACCGTAAATTATGACGGGAAAAAATT
CAC .6.
.6.
n.) GTATCCGGTCGCTGATGAGTGGCCGGGATTCTCAACAGTAATGGAGTGGACATGATGGCAAAAATTCACGAGGTAAAGC
TGC oe ACGCAAAATATTTCGACCTTGTACTGGAAGGAAAGAAACGCGCAGAGTTTCGGAAAAAAGATCGTAATTATGAGCGCGG
GGA
CACGTTGATTTTGCATGAATGGGTGCAGGGTGTGTTTACGGGGCGAAAGGTTGAAGCCCGGATAACAGATGTTACTGAC
CTGT
CAGACTGGCTGGAAGATTATGTCTTGCTGCACAGAATACTAGGTGAGATACTGCCGCTGACTGTCAAGCTGGCAGTATC
CTCC
ACATTTTTTATAAATCTAAGGCGAAGAACGGTGGCAATATATTTGCTTTAAATTGTAAATAAGCAAATTATTCTAAGCC
ACAAAT
GATATCAATTGAGTATCGATTTTCGTTCGAATATAACCATAACGCCAAGCGTCAAATGTAAGTCATCTATATGTGATTC
GTATTC
ATATTGGTCAGCATCAGGAGATAGTAAATGCTCTGCTGCTGTAAAAACATCAATTGTAACAGATATATCGTCTGGAATT
TCTTC
P
ATTTAATTCGGATATGTATTTTTTATATTTGTTTTTTAATTTCCTTATCATGTCTTCCTTATGGTGGATTGTAGTGCAG
TAATTTTTT
TTAGTTGAATCATTGTATGAATGGAATGAACAGTTTAATGCTAGGCCAAGACTTGAATTTCCTGTAGGGCCTGTGTGTT
TAAAG
o TATTCAAGATTTCTTCTTATGTCAGAAAATAAAAGACTTTTACAGGGGGCATTTCCTTTAACTTCTATTGCACATATTG
o .3 GAAAAATGGTCTGCTGTCCAATATGGCAATATCAATTCTGCCTGATCTTGTTGTGTTTGTGTTTTTTCTGACAGTTTTT
ATATTTTTTGGGGGTCAGACCGTTTCGATAAAGGAACTGTTGCATTAATGAATTTATTTGTATGGTACTCAAATATAAC
TTTGTA
.31 .3 ATCACCATGGCGAAAAGATTTTATTTCTAACAACGATAGACCTATAGATACGGTAGCTACATATTCAGTGTTTATTTTT
GCACCA
GACCTGAAATCCATTAAATAAGTTGCGTCGGCTGACTTTTTCATTCCATCTTTTACAGCTTTCACAATATCCATGTTAT
TCATATC
AACACCTTTTATATTCCAGAATTATAAATCTTAATGATTGATTTGTTTGTGTGTTTAGGTTACTAGATTGACGTACTTA
TAGCACA
TTCTGATTTTGAAATCACCATCCTTGGGTAAAGCACAGCCTATCACTATTGGTTTAGTACTGTGCTGTAATAGTATCAG
ATTAAG
TTAAATCCATTTTATGAAATCTTCCATTTCATCATATTTTTTTATTACTGCTCTAACATCTTTGCTTTCATCACATAAA
CAATCTAAA
AGACTATCCCATTCAGTTTGTTTTTTACCAAATCCATAAACAGCCTCTATATCACCGGATTTCCATATATAGATTCCGT
TATCTTTC
IV
AATTTTTGATGTATTTCATGTATATGCTTTTGTGTTTTTTCATGGTTACATATTTTGATGAAGTCTTTGCTTGAAATGC
TTTTGAAT n ,-i GACTCAAAAGTAGTAACTTTTGTATTTAAACTAAGCTCTCCTGAGTTGATTGATTCAATCAAAGCAGTCAATAGATTAT
CACATT t=1 tl CAGTACTAAGTAAGTCTTTATGCTCTGTTAATAGAATATTTGATAAGAAATCACAATCAGCTAGAATCCTTGTTTTTAT
o GGCATTGATGATTTGTGACATCTTAAATAAACTACCCTTACCGTCAACGGCAACAATGCAGATTTTACTCGGGTTGAGT
TCATGT 'a o CCGTTAATTTTTTTATAAAGTGCATATAGAACGTTTGTCTCTGTTTTCCCTTCAACAAGCAAAACTTCTTCAGAAAATA
AAAGGTA tt n.) un TGATGAATTAGAAAGCGTGAATGCTGAGTGCAATTGCGGTGATGAAGATTTATATAATTCTTCGATTTTTTCAGATATA
GTCTTC
CTTGCTATGGTTCCATTAGAATCCTTACAAACCTGAATCGCATTTGCTGCATGCTTTGCAGAAAGCATACTGGCTGAGT
GAGTT w o w GATATTATAACCTGATACCCTGATTCACTTAATGTGACAAGTGATTCTCTGACAGAATTAATG
GCTGAAGGGTGTAAATATAAC
i-J
TCAG GTTCATCAATG AAAATCAAAGTGTTTG ATTTTTTTG ATTC G CTGTTTTCTTTTTTTATTTC G GC
CAG GTATTG AATTAATG C
4,.
w CATTTG AATG G AAC GTTGTGTTC CGTG ACCAAATC G G CTG ATATCTCTCATTACCG GTTCATCTTCC
CG AG ACTCAAAAACTTTC oe AG AGTG C CG G ATTTAAATATCTCATCTAATGTCG GTGTG G G AAAGTGTAACTTTACACTTAC GTCAGG
AAAAAATTG GTTTACT
TTTTTATTTACACCTG AGTCTATTTTATTAAG G CTTTCTAATCTGTTCTCACC GTTGTG AG AAAG
ATATTTAC CTATTTCTGATATG
TTTTTTG AAAATTTTTCTTCGTGTTCTTGTTTTATTTCAG AAACAATTG C G G AAAGTATCTTTC
CTATTGTG GTCGTGTTTTTG CAT
TTTGTTG AGTCTTCG ACAG CGTCAG ACATTG CAG G G ATATG AATTG GTTC CG G AAATATATTG G
AG ATTG CAC CATCTATG C CG
CCAGGGTTTTTCTTCCACGTGGTACCGTCATATACATCCAGACTTTTTTTGGCTTTTCCTGTTTCCTTATTAAATTCCT
GTCTTCTT
G CAAAG GTAAG AGTCC CGTCAATTATAAAC G G AG CTATTTTTTGTTG ATTCTCTTCTGTTAACAAAG
ACAG AGTATCATCTGTTA
P
TACCTTG AATAACG C CTTCAACG G ATACG G G GTGTGTAG G ATCGTACACATCTG ATTCTG
AAATCAAAG AG C CATCTAACAG C C .
, ACTTAATTGCTAAGATAATATTTGATTTTCCTGCGTTATTATAACCAACTAAAGCAGTGAAGGGGCGCAAAATAGCCGA
TGTTG
, 1¨
.3 o ACTTACAAG AACG AAAGTTG CTAATTG
AAACTG AAG CAAG AC GTACAGTCATTATTTTTC CTTAAATGTG CTATTTGTATG CAAT .
G AGTTCATACG AAACG CTTTTTTACATTTTATAGTCGTTGCATTCAAG G GTG CATG AG ATTG CATTAAG
G G AAACTGTG ATATG "
, , , GCTTGGCTTTTGACTGGAAATACTGATGGCTCATTAGTTTTATTAAGGTGCATTAAAACCG CC CC GTG AAGCG
, N, N, GCGGGGAAAGCAC
20 Native P4 (acc nr:
TTTGCCGCTGCCGCCGGGACCGGTCACCTCCAGAAAGAGCTGCCAGTCGTAGCGGTTTGCCAGCACCATAAACAGTGCA
GCCA
X51522) GAATCACGTCGCGTTTTTCCGCACGGCCACCGGCGGCACGGTCAAGCCAGCGCCAGAAGGCGGGGGCGTGGGTTTCCAG
CGT
TTCACCGTCCACCGGCGGGGTGAAATCCACATCGCACAGGGTGCGCATCCAGTGTGACGGACTGTGCGGGTGGAACGTG
CCG
TTCTGCGTGTCGAGCACGCCGTTACGAAAGCCAATCAGGCGGCGGGAGGGGGCTTCCTGCTGCGGAATAATCAGCTTCA
GGG
1-d TATCCACCACGGAGGCCACCTTCCCGGAGGAGAACGGCGCACGCAGACGCTGAAACAGCCCGGCCACATCCCGGGCAAA
GTC n CTGTGGCGGCAGCACCTTCCAGACACCATTTTCATAGCGGGACAGAAGCTGGCCGTTGGCATCGACCGCGAGCGCCTCG
CCGT t=1 1-d AATGCTCATAGATACGCATGGCCTTTTCGCTGGTACTCATGGCGGAAAACTCCGCTTCGCTCATGGTGTCGAACGGGCT
TTCAG w o w CCGGTGGCCGGATGGCATCGTAAATGGCCTTACGGGTGGCCTCCCCGCCGTACTGCGTGAAGGCATCATTCCAGTCACC
GAAG =
'a ACCGGCGGCAGGGCAACAACACCTTCACACGCATCTGCGGCTGCGGCGGCTTTTTTCTGGCCGTCACCACTGAGGTCAC
GGTC o 4,.
w w vi AGCGGCAAGGACAATCTGACAGGCGGGGTGCTTCTGCCGGGCAAGGCTGGCCAGAGAAAGGAGGTTCACGGAAGAAAGC
G
CCACCATCACCGTTTCACCGGTCAGGTGATGTACGGTAAGTGCGGTCGCGTATCCCTCCGCTATCCACAGACGTTTTCC
GGCCT n.) o n.) GATTCTGTCCTTCAAGGGTGTGACAGGTGCCCCTGACCTGTCCGCCTTTCAGGGTGCGCTTACGGCCGTCAGCACTGAT
TAACT
i-J
GAAGGTTAACCAGTTCGCCGCTGTCGTCATACAGTGGCACCACAAGGTCACCGGCGCGCCAGCTCACGCCACCGGCTCT
GTGT .6.
.6.
n.) GTGCCGGTCAGCATCCGGCATTCCCGGCCGGGAAAGCCCTTGCGGGTCAGGTAGGCGTTACCGGTTCCGGTACGGGTTT
TCGC oe CATCAGGGTTTGTGCCAGTGCGGCGGCGTTCTTCCGGGCAGCGTCTGTTTCATCAACGGCGGCGGTCGTCACTGCCGGG
TCAG
CCGGTGGCAGGCTGCCGGTCACGGCAGCCACCTTTGCGGCCGCGTCGGACGGGGAAACACCAAAAACCTTTTCAACCAG
TTTC
AGGCCGTCACCGGCACCACACTGATTGCAGTACCAGGTGCCGCGCCCCTCCCTGTCATCAAAACGGAAGCGGTCACTCC
CGCC
ACAGACCGGACAGGGCTGATGACGGTTCTTCAGCACCTGAATCCCCAGCGCCGGGAGAATACGCGGCCAGTGGCCGAGC
GCA
TGGCTGACGGTGGCGGTTACGTTCATTTTCATGGTGTTGTTCTCCTTCAGTGCAGTACCGGCGCTTTTATGTGACGGGC
ACAGA
GTTCATCCATCACAACCAGCCCGAGAAAGGACAGCGACGGCGCGGCCTTCAGGGGGCCGGATTCCATTAAATCTTCCAG
CAGG
P
GCACAGGCTATCTGACGCCCTTTTTCCTCACCGTGCTGGCGCAGATAAAAGCCTTCCAGCTCAGCGGCGATGGCCGCCT
CCAGT
GACTCAAGGGTGAGATGCGGGTAGCGGTGCTGACGTTCGCACACGGTCAGCCAGGCACAGGCGACAGCGCGACGGTAAA
GG
o GCAGCGCGTAAGACGGGCGGTAAGGGTGTTTTCATTTGCTTTTCTCCCTGTGACAGATGACTGCATTCCGTGCCGGTTG
oe ACTGATAAGGCATATCTGCGTCTCCTGAAGACGTGCGTATCCCTGCGCGAATACGCACATTTAATTTTTCGGGGGTCGT
ATTACAGATAATTGCGGTAACTGTTATCCGGGGTGGTTTCCGGGTCAGGCTCCGTGCGGGGAATTTCCCGCCATTCCCG
CGCCA
.31 .3 CCGGTGCTGCCCGGCTGACCGGAACAGTGTCCTGCGGGTAAATATCCAGATATTTTTCCCGCCATTTCTGTAATTCCGG
GTCTC
CGGCCATTTCTTTCAGTACCGCATGCCGGTTTACGGGGCTGCGTTTAAACAGGTCAGGACGGTCACAGGTAAATTCCCG
CAGA
AAACGCCCCAGCGGGATGTCTGTGGTGCGTCCGTCAGCGAGGATACGCACAAGGATACTGAATTTACGGCGGTACGGGT
TCC
AGACAATGTCCGGGCAGCGGTACGGCATTTCCCACGGAATACCGTCTTCCAGAATGCCGACCACGGCCACATCGGGAAA
ACCG
GCAGAACGGTAAATCTCACCGGGCTGGGGAAAATCAAACATGCGTCCTGTCTCCCCGGTCTTTCTGCTGGGCGAGAAAA
TCGC
GGCACAGGCCTTTGGCTTTCAGCTCATTCAGCACAAAATCAATATCTTCATTCAGGTAGCTGAAAATATGTGGAATGTA
GAGCT
IV
GATGCAGGCCGGAGAGTTCACGGTGAATCAAATCACCCCCAACAAACCGGGATACGGCGCTGGCGCGGTTGAGCTTATG
GTA n AGCCTCAATGCTGAGGTGTTCACGGGCGTCATGACGCGCTGAGACGGTCTGAGGGGCTTTTTTATTACGCACGGGACAC
CTCC t=1 tl ACCACCGGCAGACGGGCAGCAAGGGAGAGCACATAGTCACGGACAAGGGAACGGCGGGCACTGCGTTCATCACCGGCGA
o GTGCGAAGCATACAGATACGGGGATGACGGTCTGCGCGACGGACAGCCGCAAACACAAAGACAAATTCAGGGTGTGAGG
GG 'a o GTAAGGGTTGTAGCCATGATGGCAGCCTCCTGTGAATAGCAAATAACGCTATCGCCGGAGTTCTCACGCTCGATGGCGA
TAGC tt n.) un CCAGACGGGGGTGAGAATACCGGCTTCACAGGATACCGGCCAGCCCGGAGGCTGCCCCGCCTGAGCTACCATTGACTCT
GCG
GCATAATGAGCGGACGCGGGCAGGATGCACGGAATGCCATCTGCACGACTGACCACACACCACACCATAATCTGGCGCT
CTGT n.) o n.) GGCATTGATTGCGACACAAAAAAAGACGCGTGGCGCGTCATATGTCGCCTGTGAATTGCTCGGGTTCTCACGCCCGGCT
GCCG
i-J
ATTTTGCGGCAGGCGAAAAACTATATCCGCAAATGCCGGAAAAAGGCAAGCCAGAAAAAGGGAGTTTTTGCAGAGCGGG
CAT .6.
.6.
n.) CATCATGCGTCGTACCCCCGTTTGCGTCCGGCAATGCGTCCGGCCATCCATGCGGTGACTTCAGAGTGCAGCCAGGCCA
CATTT oe TTACCGCCAAGACTCACCTGCGGCGGAAATTCCCCCTTACGGATGAGTTCGTAGATGGTCGAGCGTGACAGGCCGCACA
GGTG
CATCACTTCCGGCACACGTAAAAAACGCTCCTGCGTGATGTCCGGCAGCGGCATCAGTGGCGTCACTGGGGCGGGAGAC
GGG
GAAGAAAAAACAGCTTGCATCGGGCTACCTCGTTAATGTCCATACAGCACCGGATAAGTCCGTCCGGCTTCGGGTAGCG
CTTT
ATTTTGTGAATATTTTCAGCAGACGCAACAGGGGGGATTTGTTCAGGCTGTCTTACAATGGCTGTGTGTTTTTTGTTCA
TCTCCA
CTTAAAGTCATTTAAAGCCACTTAAAGCAATTTGTAATTTTTATAGTGAAATACAAATCGTTTCTTCTTATTCATTCCC
GGCGAAT
TAATAAAAACAAACAGTAGTAAACAGCACAAAAAGCCCATCAACGGGTGAACAGTGGTGAACAGACGGTGAACAGTCAT
TAC
P
TGCGATTGTTCACCCTTTAACTTACTGTATTACTTATCTTTTTTATTAAGGTGAACAGAGGTGAACAGTAAAATATAAA
AAAACA
AACAGTAAGCCGGTTTTTCCTGCGACCTTTTCCTGGCTTGCCGGTCTGAGGATGAGTCTCCTGTGTCAGGGCTGGCACA
TCTGC
o AATGCGTCGTGTTGTTGTCCGGTGTACGTCACAATTTTCTTAACCTGAAGTGACGAGGAGCCGGAAAATGTCTGACCAC
o .3 CCCTGAATATCTGCAACCCGCACTGGCACAACTGGAAAAGGCCAGAGCCGCCCATCTTGAGAACGCCCGCCTGATGGAT
CCGTCACGGCCATTGAACGGGCAGAGCAGGAAAAAAATGCGCTGGCGCAGGCCGACGGAAACGACGCTGACGACTGGCG
CA
.31 .3 CGGCCTTTCGTGCAGCCGGTGGTGTCCTGAGCGACGAGCTGAAACAGCGCCACATTGAGCGCGTGGCACGCCGGGAGCT
GGT
ACAGGAATATGACAATCTGGCCGTGGTGCTGAATTTCGAACGTGAACGCCTGAAAGGGGCGTGTGACAGCACGGCCACC
GCC
TACCGGAAGGCACATCATCACCTTCTGAGTCTGTATGCAGAGCATGAGCTGGAACACGCCCTGAATGAAACCTGTGAGG
CGCT
TGTCCGGGCAATGCATCTGAGCATTCTGGTACAGGAAAATCCGCTCGCCAACACCACCGGCCATCAGGGCTACGTCGCA
CCGG
AAAAGGCTGTCATGCAGCAGGTGAAATCATCGCTGGAACAGAAAATTAAACAGATGCAAATCAGCCTCACCGGCGAGCC
GGT
TCTCCGGCTGACCGGACTGTCAGCGGCAACACTCCCGCACATGGATTATGAGGTGGCAGGCACACCGGCACAGCGCAAG
GTG
IV
TGGCAGGACAAAATAGACCAGCAGGGAGCAGAGCTTAAGGCCAGAGGGCTGCTGTCATGATTTACTGTCCGTCGTGTGG
ACA n TGTTGCTCACACCCGTCGCGCACATTTCATGGACGATGGCACCAAGATAATGATTGCACAGTGCCGGAATATTTATTGC
TCTGC t=1 tl GACATTTGAAGCGAGTGAAAGCTTTTTCTCTGACAGTAAAGATTCAGGAATGGAATACATTTCAGGCAAACAGAGATAC
o ATTCACTGACGTCAGCCTCCTGCGGTATGAAACGCCCGAAAAGAATGCTTGTTACCGGATATTGTTGTCGGAGATGTAA
AGGC 'a o CTTGCACTGTCAAGAACATCGCGGCGTCTGTCTCAGGAAGTCACCGAGCGTTTTTATGTGTGCACGGATCCGGGCTGTG
GTCT tt n.) un GGTGTTTAAAACGCTTCAGACCATCAACCGCTTCATTGTCCGCCCGGTCACGCCGGACGAACTGGCAGAACGCCTGCAT
GAAA
AACAGGAACTGCCGCCAGTACGGTTAAAAACACAATCATATTCGCTGCGTCTGGAATGAGGGCTGCCGGTTAACACCGG
CCGT n.) o n.) CGCCGCACACCGTATTTTTATTCTTCAGCATGATGAGAAAGAGATAACGATGGAAAGCACAGCCTTACAGCAGGCCTTT
GACAC
i-J
CTGTCAGAATAACAAAGCAGCATGGCTGCAACGCAAAAATGAGCTGGCAGCGGCCGAACAGGAATATCTGCGGCTTCTG
TCA .6.
.6.
n.) GGAGAAGGCAGAAACGTCAGTCGCCTGGACGAATTACGCAATATTATCGAAGTCAGAAAATGGCAGGTGAATCAGGCCG
CCG oe GTCGTTATATTCGTTCGCATGAAGCCGTTCAGCACATCAGCATCCGCGACCGGCTGAATGATTTTATGCAGCAGCACGG
CACAG
CACTGGCGGCCGCACTGGCACCGGAGCTGATGGGCTACAGTGAGCTGACGGCCATTGCCCGAAACTGTGCCATACAGCG
TGC
CACAGATGCCCTGCGTGAAGCCCTTCTGTCCTGGCTTGCGAAGGGTGAAAAAATTAATTATTCCGCACAGGATAGCGAC
ATTTT
AACGACCATCGGATTCAGGCCTGACGTGGCTTCGGTGGATGACAGCCGTGAAAAATTCACCCCTGCGCAGAACATGATT
TTTT
CGCGTAAAAGTGCGCAACTGGCATCACGTCAGTCAGTGTAAAATTCCCCGAAAATCCGCCCGTTTTTACTGAAAAAAGC
CATGC
ATCGATAAGGTGCATGGCTTTGCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCGGTCTGAGC
GTGTC
P
AGTGCAACTGCATTAAAACCGCCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGT
TA
ATTATTTGTGTAGTCAAAGTGCCTTCAGTACATACCTCGTTAATACATTGGAGCATAATGAAGAAAATCTATGGCCTAT
GGTCC
--.1 AAAACTGTCTTTTTTGATGGCACTATCCTGAAAAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTCAGTGTCG
o .3 TCCTTAAGAATTCGTGGCATGAGAGAGTTAAAGGATGCTGAATCATGTATATGGATTAATTGGCGTTGTTGGGACCATA
CTATTGCTACTAGCTTCATCCGCAACCAAGATATTTCACAATGGTTGCTCGTTTGTTCTGGATGGTTAGCTGCTTTACT
TATTGGA
.31 .3 TGGTTTACACACAGAACGATTAAAGCAATTAGCAACAACCACACGAATGTTATAAAAAGTAATATGGAGGTAATCAACA
GTCA
TAATGAATCCAATCAAAACTTGATGGCTGAAAACAAAGAATTGATTAAAGAACTTGCAAGAACTTCAGAACAGAAAGAG
AAGA
TGGAAAGTATAGCTGCTTATCTTGCTACTCAGAACCCCCAAATTAACGCTATGCCAAGAACAGCAAGCCGACCAGAAAA
TATCG
ATTCGGAGGCTAATTAAATATGAAAGTATATTTTGAAAATTACTCATACTATCCAGCCCTAAGAACACGATCAGCAGAA
ATGAC
CGGACTGAATAATTTATCATATGAGAATAAGAAAAAAATATTACCTTTAATTTCTTTGGGGAAATGGCCTCGCTCGGAA
GAAAT
ACAGGTATCGTTAGATAAAAGTTTAGAAGTGATGAGTAATCTCCCATTTATTTTGGATGTCACAAAGGATAATTCTCAT
CATTGC
IV
GCGTCAAGCTTCGAACTACTCTCTCCTGAGAATGGTTTTAAAAACTGGATAGAGTTTTGTTCCAGAAATGATAATATTA
TTCCAG n ,-i TAGTCCAGATGCCGGATTCAGCAAAACTTAGAGATATATCTATCCAAGCCAGGGTTTTAGAGGAACTTAAAGGTTCAAT
TGCAT t=1 tl TTAGAATTAGAAATCTAAATACAGACATTAATAAAACCCTGACGTCACTAGTATCGATGAACTCTCCAGAAAATGCCAT
o CATAGATTTGGGCTACATTAGAGGGAATGTATCTGCTATAACAGCTGCAGCAATAAATTCGATTAATCAGATTAGAACT
GAGAT 'a o TCCTGAAGCCATAATTAGTGTGCTAGCAACAAGCTTCCCTAGTTCAGTTACAAATTTTTGCCGTGAAAATGGACAGTCC
GGATA tt n.) un TATTGATGTTATTGAGAGAGAATTGCATCAAAATATTGGTGGAAGTGATGTCGCTATTTATGGCGATCATGGTTCAATT
CATTC
AGTAGTGTATGACAACATAATTGGGCGATATGTTCCTAGAATTGATATAGCGTTAAATGATTCATGGTATTTCGAGCGC
CGCCC n.) o n.) TGGGATGAATAAAGAAGGGTTCATTGAAGCTGCGAAATCAATTTTGGCAGAGTATCCACATTATCAAAGGGAGGACTCT
TGG
i-J
GGAGCTGCAATGATAAGAAATGCTGCTATAGGGGATATAGCAGGTATGGGAAGTCCAGCTAAATGGATTGCTGTTCGAG
TGA .6.
.6.
n.) ATCTACACTTAAATAAGCAAATTGAGCTATCTGAAGCTCTACAGTATGGCTTTGATCATGATGAGGAAGATCTTATCTA
ATAAA oe AAACTAGGGAAGGTTAGCCTTCCCTAGCCCACAACCCTTTTAAGTACTTTTTCCGGAATATAGGAAACATCATCGCCAT
ATTTCC
TAACTATAGAGTCAACATCAACCTTATGGTATTCATTTAAAGATTTCTCCGAACAAGCCTTAAACTCAAACTTAACCAA
AGAATT
ATTCCTTCTTTTAGCTTTGCTCAATAAGGCAAGATCGTTTATAGATATTTCTTGATTACCATGGAGTCTAGATAAAAAA
TCATTAG
ATGTCGCATGATACCTATTTTTAATAGATGTAATGACAAATTCTCTAATCTTGTTTAAAGATAACTTAGATGCCAAAAC
CTCAAG
ACAATCCCTATGTAGTTCATTTGAAAATGTAATTCCATACTGATTAAGCAGATCTTTAAGCTCAGACTTAAGCAAAAAA
CCCAAA
TAAACAAATTTATTTAAGCGAGAGCAAACCCTTCCTTTTTGAATTATTTTAAAGCGTACGCTACTATTATTAGATTGAA
ATTCTAC
P
AACGCCAACATCTGATGAAACCCGTTTAGATACTTCACTGGTAAATTTTGGCGCGCACACAATTGTAACTTTTTCGAAG
CTAGAT
TTAAAAATTTTTAACTGACCATCCAAGCGCTTAAGAGAGTCAAAATCGCTTTTTATTTCAAAAGCTTGTAGGCTTCCAT
TGGCAA
--.1 TAGCCAAATCAGCTCTTCTGCTCCAGTTAGCAACAACCATTTCATTAATGATCGTTGCATCACTAAGCATGCCTTTTTT
1-, .3 CATTCAATTAGGGCTATTTTAACTTCCTGCTCTCGCAATAACTCAGCCATGTTAATCACACTCACTTCACGTTGATTTT
GCAACTAACAATTAAAAACTCCAGATTATGTTACTTAACACTCATTTTAAAAATCAACCAATAACTATTTTTATTTAAG
TATTTCTT
.31 .3 TGTATTTTGAATAATCATAAGGCTAATATATTTATTACGGTTCATATCCAAATAATCAGCCCACCACTGCATCATTAAA
CGCCGC
TCATCCAAATGCTCGGAGGTATGGATATATGCCGCACGTACATTATTACGCTCTGAGTGGCTCAGTTGCCTCTCTATCG
CGTCAT
CACTCCATAACCCCGACTCCCCCAACGCACCACGCGCCATAGTCCTAAACCCATGCCCACACACCTCGGTTTTAGTATC
ATAGCC
CATCGCACGCAATGCGCTGTTTACCGTGTTTTCACTCATAACCTTAGTTGCGTCATGATCCCCCGGAAAAAGCAGCTCT
TTATCA
CCACTAATCTGCTTTAACTGGTTTAATAAAATCATCGCCTGTCGACTAAGCGGAACGATATGTTCCTCTTTCATCTTCA
TGCCTCG
GTACGAATAACGCACACCTTTAATTTCTTCTCGCTTTGCAGGTATACGCCAAAGAGATTTATCGAAGTCGAATTCATCC
CAACGT
IV
GCGAAACGTAATTCACTGGAACGCACAAAAGTTAGCAAGGAAAGCTTGACCGCAATCCGTGTCATTACACGGCCACGAT
ATGC n ,-i AGCAAGACGTGCAAGAAACTCAGGGAATCGGCTAGAAGGTAAAGCAGGGTAATGTCGCGCTTTGGTTGTCGATAGCGCA
CCA t=1 tl GCCATATCGCTGGCTGGATTTGAGTCGATGTAATCGTTCTGTACGGCATAACGCATAATGGCTGTGACGCGCTGTTGCA
o CTGAGCGACATCGTGTTTGCCACTGGCATCAACTTTTTTAATCGGGGCTAACAGGTGGCTGGTTTTAAGCTGCCGAATG
TCGGA 'a o CGAACCGATATGAGGGAATATATAAAGCTCAAGATAGCGAAGAACGCGCGATCGATGGTCTTCACTCCAGCGCTTGTTA
CTGG tt n.) un CATGCCATTCTCGGGCGATAGCTTCAAAAGTATATGCCCCCGAATTCTCGGCCCGAGCTTCTTTTTGTACGACTTTTGG
GTCTAT
GCCCTGTACTAAAAGCTTTTTAGCTTCATCGCGTTTTGCTCTTGCCTGAGCAAGCGTCACAGTAGGCCAAACACCAAAC
GCAAG w o w ACGATCCTCTTTTTTGTCAGAGGGACGTCTGTATTTCATGCGCCAGTATTTGGAACCTTTGGCCGAAACCTCAAGATAC
AAACCA
i-J
CCACCATCGGCCATTTTGTAGGTTTTGTCTTTTGGCTTTGCGGTCTCGACCTGTCTGGCGTTGAGCTTCATTTGGGGGC
ACATTT
4,.
w CTAATCGAAGTTAAGATGCCCCCAATTATGCCCCCAATGATATCCGGATTTCAACGGACAACCTCGGAAGACGCAGGAC
GAAA oe AAATCGCTGCAAGCATTGATTTTAAAGGGATATTTGGACTTTCTCGGATGGTCTTGGAAGTAAGAATGGTGCCGAAGGC
CGGA
CTCAAACATCAAAATAAGTTAATGATAAAAAACAAATAATAAAACACAACAATGAAATATGCCCCCTTTTGTGCCCCCA
CTGTTT
TTCTGACCAATCTATTTTCAGCCCATCAATAAATCGGAAAGTTAAATCATTTTTAATCAGTAAGTTTGGATCCGTAGCT
CGGATC
CAAACCAGTGCATCTTTTATCCACATAAAAAATTTTTTTTCGAAAGAACTGTTCACACTGTTCACCTTTCTGTTTTCTC
CTTTTATT
TCAGAGTGATAGGTGGTGAATAATGGGTGAAGGGTGAACATTCGATTCTTCACCTCCGGCATTCTGCCGATGTGACTCA
TACC
GGTGATTAATCCTCCGCACTGAAATCACTCAGGAAGAAAAAAGTTTTTTTTGATTTGATTGTTCACACTGTTCACCTTT
CGTTTTT
P
CTCTTTTAATTTCAGTGTGATAACGGGTGAATATACGGTGAAGGGTGAACAGTGGATTGTTCACCTTCGGGGGATATCG
GGAT .
, AAAAAAAGACCGGCAGATGCCGGTCAGGTGGGTCAGGCTGTTGTAGGGTCGTCACATTTTGG CAG
CCAGTCGCCGTAGCTTTC
, 1¨
.3 CTCTTTCAGCGTCAGGTTGGTCTGTATCCCCTGTTTGGTATGGCGTTTCTCGTAATTCAGTCCGTATTCCTTCAGCATC
ACCGGCA .
w GCCCCAGCCCGAACATTTTCAGACTGAGTACATTCCGGTAGCCGTTTGCCTCCATGTAGGCCAGATAGGCGTGATAGAG
GTATT "
, , , TACGGTAATTGCGCGGGATGATACTGGCGTTCCCCATATACATGCCGCTGGTCTGCGGCAGGGTTTCCAGATAGCCGAT
, N, N, TCAAACGTCGGGTCGGCATCCCGTTTGATGTTCAGTGCCTCGTCTGAGTTCTGCTGGGACTGAAGCAGTGACCGGGCGA
GCAT
CGGGTCGCTGAACTTCTGCATCAGGTGACGCACGATGACCGCCAGCTCGCGGGTGATTTTGTCCTTAAGCTGCGGGTCG
CGCT
CCTGCGGGGCTATCTGTTCCGGGAAGTGAATAATCACCCGTCGGCGTGACACGCCGCCGCTGCGGTCGGTGAAGCGCAT
CGG
GTTATTGTTCACGGCCAGAATCACCGCCGGGATGTGCGTGGAGTACGCATCCCGGTATTTCGGGTCAACGGACACCGCA
TCGC
CGCCGGTGATGGCCTTGAGTCCGGCACCGTCGCCGCTCCATTTTTCCTGGTCCGGCAGGCGTATCAGTGAGAAGCCAGT
TAAC
GCGGCACGTTCACGCGGGGATTCCAGCGTCTCGATGGTGGCCGACGTGGCGTTATCCTCCCCGGCCAGCAGGGTGGCTA
TTTC 1-d GGCCATGATACT
n ,-i m ,-o 21 Sequence removed TTTGAGCGGCATAAATTACCACTGAAAGCCCTTAAACGTTACTCTACTGTGGACACTGTGTGGACACTCTCGG
CCTCAGTACCA w o w from P2 (replaced CCTCTTAGCGGATTAAGAGAAATGGCGTCCTGAAGGTACTCTGGCGCAAAATGAGCGTAAACCATAGTTTGCTCAATCC
GCGT =
'a GTGACCTAGTATCCGTTGTAGCGTGATAATACTTCCTCCATTAATCATGAAATGAGTGGCAAAGCTGTGCCTTAGTGCA
TGTGT o 4,.
w w vi with kanamycin GGCTTGCCCCATTGGCAAATCCGGTTTTATTGCTTTCATTGTTCGTCTGAAGCGAGGGTAATCAGCATCAGGGAATAAA
AAACC
marker; Example 3) TCGTTTGTTATCCGCGATCATTTTGGCAACAGCCTCTGAGATCGGGACGGTGCGTGGTTTGTTTGTTTTCGTTTTAACA
AACGTG w o w ACGCGGTTATGGATGATATTTTCTGCTTTCAAACGAGCTGCTTCTCCCCAACGTGCTCCTGTACTCAGGCAAAGAATCG
CAATCT
i-J
TTTTATTGTCGCCGTCAAGTGCTGCAAGCAGTAAGGCAATTTCTTCCTGTGTTAGATAGCCTGTTTCTGGTTTTTCCTC
CTTAAGC
4,.
w CTTTTTGTCCCTCTGATAGGGTGCTCACCAAAGAATAACTCCGCTTCAATCAGGGCTGTAAACATGCCGCTAATACATG
TTAAAT oe CACGATTGATACTCGAAGGTTTAATACCCTGACTTCTTCGGGTGGCGCAGTACTGGCTGATAAGCGATTTCGTAATTTG
AAATG
CCAAGATTAGATTTCCCATGCTCTTCGTGTTTACCCTTTAAATCCC
ACCAGATCTGTGTCAGCTCCGACAGACGTCGCTTGTCTGTTGGTTTTGATAGCCATTCTTTATTGTGGTGGTTGTACAA
CGTGTA
TTTCTCGAAAGCGACAGCTTCGCTTTTCTTATCAAACTTCCTACGGATGCGTTTTCCATTACGTCCAGTAGGGCGGATG
TCCACT
TCATATCGACCATCATCGAGTTTTTTGATTGCCATCAGAAAACCCTCCGAGTGGTGTGTTTTTTTGCGACTACTAATCG
CTTTTTT
CGTGGTGGCTGAAATTTAGCCACCAATAGTAGGCACTTGTGATGAATATATTCACGATGAATTGTTAACCAGTCTTTTG
ACCGG
P
AGTGGGGCGACGTTGTTTCGTTTTGCCCAAAGTGTGCGAGAGCGGGCGCAATTTGCCCGGACTCAGGAGCGATCTGATT
GGTC .
, ATGAACCATAAAGTGTATTTG GTGAATTGTG G G GTCTG CAG GATGTTCATCATGACATCTGTTG G AG
GTGTTG AACGACCACTT
, 1¨
.3 TCATAGTAACTCAGCGTGCCATACGGAACCCCTGTTAAATCAGCAAGTTGTTGTCTGCTCAAATACTCTGATTTTCGCA
TTAAGA .
CTATCTTCTCGCTTATCGTGTTTGACATGGTGTTTAGATCTCAATAGTATTTAGTTTAGATGTAGATTGTTTAGTGCTT
GGATGTG "
, , , GGCACTAAAAGGCATTATAAGACATTAAACGCAATTCATGAGGGCTAGAGGACGACATGAGCAAGCAAGTAACACTCAT
, N, N, TGATGCGATTCCTTATCAGGAGTTCGCAAAACTAATAGGAAAATCGACAGGAGCGGTTCGTCGGATGATCGATAAAGGA
AAG
CTGCCTGTAATTGATATGACCGATCCACAATCAGCTTCAGGTCGTGCAGGTGAATATTGGGTATACCTTCCGGCATGGA
ATAAC
GGACTAAAACTGGCTTATGAAAGCCGCCCTAAAGAGATTCGTGACGGCTGGTTGATGTGGTTAGGTCTCGGTGAACCAC
GTTA
AGGAGAACCGTATGAATGAGCCTCGTTGTATTGCTCAGTTACTGCGTAACGAAAGCCCCAGGGCGATTGACTTCACCAT
CACC
CACGGTAAGGGGCGTAAGGGAATCATTATCCGCACCAAAAAACAGAGTCCGTTAAAAAAGGCTCTGACCTTTCTGAAAA
GCCG
GAGGGTATGGAAATGACAGTGATGACGCTCAATCTCGTTGAAAAACAGCCAGCAGCTATGCGCCGGATAATTGGTAAGC
ATCT 1-d TGCCGTTCCTCGCTGGCAGGATACATGTGATTATTATAATCAGATGATGGAGCGCGAACGGTTAACGGTTTGCTTCCAT
GCTCA n ,-i GTTAAAACAGCGTCACGCAACGATGTGTTTTGAAGAAATGAACGACGTCGAACGTGAACGACTGGTATGTGCAATTGAT
GAAT t=1 1-d w TGCGTGGTGCATTCTCAAAACGCCGTCAGGTTGGCGCAAGTGAGTATGCATATATTAGTTTTTTAACAGTCAGTCAGCG
TCGTA =
w o CTTTATTTATGCATGCCGGATTGACTGAAAAAGAATTCAACCAGCCATACTGGCGAATTAATGAAGAGTCATGTTACTG
GCGTG 'a o ATG CTTTATTCCGTG CATTACGTGAATTATTCAGTCTGTTTGAGTATG
CACCGACAATTCTGACGTCGGTAAAACCG GAG CAAT
w w vi ATCTGCATTAAGTAATTAACCAGAGTTTTTAACGCACTTAATTGTGCGGGGCTTCTTTTTGCCTGGAGAAAGTTATGCA
TACAGT
TTCTGAAAATCAGTGCGGTATATACGCATTACTGCTGCAACAGGCCAGAACCGAAGCACAGGCCGACGCTGCGACGCGC
TTTT n.) o n.) CTTCTCATCTTGATGCCATGATTCGCCACATCACAAAGGCGGAGTTATCCCGCGTGGAGATAGTCGAGCTGCTCAGTCA
GGAGT
i-J
CGGAAAAATTTCACAATATCGGATTGTCTCGCGGGGAGGTGCTTTGATGTTCTGTTCTCGTGCAGTTGTATTACTGAAT
AACGC .6.
.6.
n.) CTTAAAAATCGCCGTTATGAAAAATGGCGATTTGTCTCTTATTCAACTTGGTCTTGATAAAGAAAAACGCGAAATAACT
GAATC oe TGTTATCGCGATTTATCAGAGTGAATTAAACCTCCTGTCTGATGTGGTCAATTTACTTGTTAAACGCGCTGTATTTCAC
AAGCAA
ATTTCCTCCGTGGATGAACTGACGAAATTAACGACAGAAATCGCCAGCTATTGCGCTGATGAATTTAAAAAACTGAACG
ACAA
AAGGAACTGGTAATGCCGGACAACGTAGATTTTATTCAGGAACAACAGGCTGAATTACTGGAGCGCCAGATTAACGCGG
CAA
GGGTAAAACATTGCGGTGCTTCTGCGCTGGTTTGCGAAGAGTGTGACGCGCCAATACCTGCTGCCCGTCGTGCGGCTTA
CCCG
TCAGCCACGCGTTGTGTTTCCTGTCAGTCAGTCTTTGAAGCAAAAAACAAACATTACCGGAGAACGGCATGAGTATTCG
TATTG
AAATTGGCGAACGTTATGTCGTTACCAGTGACAGCTTTCAGTTTATTCTCCACGAGAAAAAGAGAGCGGAAAGCGGTAA
AAAC
P
GCCGGTCAGGAATGGCTGGCGGTGGTTGGTTATTACCCGAAATTAAGCCAGCTCGTTTCAGGCCTGATGCATCACGATA
TTCT
GACCGGAAGCGCAAAGTCTTTTGCTGATTTAAACGTGCAGGTTGAGCAACTCAGCAAGCGTTGTTCAGAGGCTTTTGGC
TCAT
--.1 ATGGCCGTTAAAGCCTCCGGGCGTTTTGTCCCTCCGTCAGCATTTGCCGCAGGCACCGGTAAGATGTTTACCGGTGCTT
.6.
.3 TGGAACGCGCCACGCGAGGCCGTCGGGCGCGAAAGACCCCTTACACGTGACGAGATGCGTCAGATGCAAGGTGTTTTAT
CGATTAACCGCCTGCCTTACTTTTTGCGCTCGCTGTTTACTTCACGCTATGACTACATCCGGCGCAATAAAAGCCCGGT
GCACGG
.31 .3 GTTTTATTTCCTCACATCCACTTTTCAGCGTCGTTTATGGCCGCGCATTGAGCGTGTGAATCAGCGCCATGAAATGAAC
ACCGAC
GCGTCGTTGCTGTTTCTGGCAGAGCGTGACCACTATGCGCGCCTGCCGGGAATGAATGACAAGGAGCTGAAAAAGTTTG
CCG
CCCGTATCTCATCGCAGCTTTTCATGATGTATGAGGAACTCAGCGATGCCTGGGTGGATGCACATGGCGAAAAAGAATC
GCTG
TTTACGGATGAGGCGCAGGCTCACCTCTATGGTCATGTTGCTGGCGCTGCACGTGCTTTCAATATTTCCCCGCTTTACT
GGAAA
AAATACCGTAAAGGACAGATGACCACGAGGCAGGCATATTCTGCCATTGCCCGTCTGTTTAACGATGAGTGGTGGACTC
ATCA
GCTCAAAGGCCAGCGTATGCGCTGGCATGAGACGTTACTGATTGCTGTCGGGGAGGTGAATAAAGACCGTTCTCCTTAT
GCCA
IV
GTAAACATGCCATTCGTGATGTGCGTGCACGCCGCCAAGCAAATCTGGAATTTCTTAAATCGTGTGACCTTGAAAACAG
GGAA n ACCGGCGAGCGCATCGACCTTATCAGTAAGGTGATGGGCAGTATTTCTAATCCTGAAATTCGCCGGATGGAGCTGATGA
ACAC t=1 tl CATTGCCGGTATTGAGCGTTACGCCGCCGCAGAGGGTGATGTGGGGATGTTTATCACGCTTACCGCGCCTTCAAAGTAT
o CGACACGTCAGGTCGGAAAAGGCGAAAGTAAAACCGTCCAGCTAAATCACGGCTGGAACGATGAGGCATTTAATCCAAA
GGA 'a o TGCGCAGCGTTATCTCTGCCATATCTGGAGCCTGATGCGCACGGCATTCAAAGATAATGATTTACAGGTCTACGGTTTG
CGTGT tt n.) un CGTCGAGCCACACCACGACGGAACGCCGCACTGGCATATGATGCTTTTTTGTAATCCACGCCAGCGTAACCAGATTATC
GAAAT
CATGCGTCGCTATGCGCTCAAAGAGGATGGCGACGAAAGAGGAGCCGCGCGAAACCGTTTTCAGGCAAAACACCTTAAC
CAG n.) o n.) GGCGGTGCTGCGGGGTATATCGCGAAATACATCTCAAAAAACATCGATGGCTATGCACTGGATGGTCAGCTCGATAACG
ATAC
i-J
CGGCAGACCGCTGAAAGACACTGCTGCGGCTGTTACCGCATGGGCGTCAACGTGGCGCATCCCACAATTTAAAACGGTT
GGTC .6.
.6.
n.) TGCCGACAATGGGGGCTTACCGTGAACTACGCAAATTGCCTCGCGGCGTCAGCATTGCTGATGAGTTTGACGAGCGCGT
CGAG oe GCTGCACGCGCCGCCGCAGACAGTGGTGATTTTGCGTTGTATATCAGCGCGCAGGGTGGGGCAAATGTCCCGCGCGATT
GTC
AGACTGTCAGGGTCGCCCGTAGTCCGTCGGATGAGGTTAACGAGTACGAGGAAGAAGTCGAGAGAGTGGTCGGCATTTA
CGC
GCCGCATCTCGGCGCGCGTCATATTCATATCACCAGAACGACGGACTGGCGCATTGTGCCGAAAGTTCCGGTCGTTGAG
CCTC
TGACTTTAAAAAGCGGCATCGCCGCGCCTCGGAGTCCTGTCAATAACTGTGGAAAGCTCACCGGTGGTGATACTTCGTT
ACCG
GCTCCCACACCTTCTGAGCACGCCGCAGCAGTGCTTAATCTGGTTGATGACGGTGTTATTGAATGGAATGAACCGGAGG
TCGT
GAGGGCGCTCAGGGGCGCATTAAAATACGACATGAGAACGCCAAACCGTCAGCAAAGAAACGGAAGCCCGTTAAAACCG
CAT
P
GAAATTGCACCATCTGCCAGACTGACCAGGTCTGAACGATTGCAGATCACCCGTATCCGCGTTGACCTTGCTCAGAACG
GTATC
AGGCCTCAGCGATGGGAACTTGAGGCGCTGGCGCGTGGAGCAACCGTAAATTATGACGGGAAAAAATTCACGTATCCGG
TCG
--.1 CTGATGAGTGGCCGGGATTCTCAACAGTAATGGAGTGGACATGATGGCAAAAATTCACGAGGTAAAGCTGCACGCAAAA
un .3 TTCGACCTTGTACTGGAAGGAAAGAAACGCGCAGAGTTTCGGAAAAAAGATCGTAATTATGAGCGCGGGGACACGTTGA
TGCATGAATGGGTGCAGGGTGTGTTTACGGGGCGAAAGGTTGAAGCCCGGATAACAGATGTTACTGACCTGTCAGACTG
GCT
.31 .3 GGAAGATTATGTCTTGCTGCACAGAATACTAGGTGAGATACTGCCGCTGACTGTCAAGCTGGCAGTATCCTCCACATTT
TTTAT
AAATCTAAGGCGAAGAACGGTGGCAATATATTTGCTTTAAATTGTAAATAAGCAAATTATTCTAAGCCACAAATGATAT
CAATT
GAGTATCGATTTTCGTTCGAATATAACCATAACGCCAAGCGTCAAATGTAAGTCATCTATATGTGATTCGTATTCATAT
TGGTCA
GCATCAGGAGATAGTAAATGCTCTGCTGCTGTAAAAACATCAATTGTAACAGATATATCGTCTGGAATTTCTTCATTTA
ATTCGG
ATTGTATGAATGGAATGAACAGTTTAATGCTAGGCCAAGACTTGAATTTCCTGTAGGGCCTGTGTGTTTAAAGTATTCA
AGATT
IV
TCTTCTTATGTCAGAAAATAAAAGACTTTTACAGGGGGCATTTCCTTTAACTTCTATTGCACATATTGGAATGTCGAAA
AATGGT n ,-i CTGCTGTCCAATATGGCAATATCAATTCTGCCTGATCTTGTTGTGTTTGTGTTTTTTCTGACAGTTTTTTTTGAGAATA
TTTTTTGG t=1 tl GGGTCAGACCGTTTCGATAAAGGAACTGTTGCATTAATGAATTTATTTGTATGGTACTCAAATATAACTTTGTAATCAC
o GAAAAGATTTTATTTCTAACAACGATAGACCTATAGATACGGTAGCTACATATTCAGTGTTTATTTTTGCACCAGACCT
GAAATC 'a o CATTAAATAAGTTGCGTCGGCTGACTTTTTCATTCCATCTTTTACAGCTTTCACAATATCCATGTTATTCATATCAACA
CCTTTTAT tt n.) un ATTCCAGAATTATAAATCTTAATGATTGATTTGTTTGTGTGTTTAGGTTACTAGATTGACGTACTTATAGCACATTCTG
ATTTTGA
AATC AC CATC CTT G G GTAAAG C AC AG CCTATCACTATTG G TTTA G TACTG T G CTG
TAATAG TAT CA G ATTAA G TTAAATC C ATTT n.) o n.) ATTACTGCTCTAACATCTTTGCTTTCATCACATAAACAATCTAAAAGACTATCCCA
i-J
TTCAGTTTGTTTTTTACCAAATCCATAAACAGCCTCTATATCACCGGATTTCCATATATAGATTCCGTTATCTTTCAAT
TTTTGATG .6.
.6.
n.) TATTTCATGTATATG CTTTT GT G TTTTTTCATG GTTACATATTTTGATGAAGTCTTTG CTTGAAATG
CTTTTG AATG A CTCAAAA G oe TA G TAACTTTTG TATTTAAACTAAG CTCTC CTG A GTTG ATTG ATT CAATC AAAG C AG T CAATA
G ATTATC AC ATT CA GTA CTAA G
TAAGTCTTTATG CTCTGTTAATAGAATATTTGATAAGAAATCACAATCAG CTAGAATCCTTGTTTTTATG C C G
AT G G CATTGATG
ATTTGTG AC AT CTTAAATAAA CTAC CCTTACC GTC AACG G CAA CAATG CAGATTTTACTCG G
GTTGAGTTCATGTCCGTTAATTT
TTTTATAAAGTG C ATATA G AAC G TTT GT CT CTG TTTTC C CTT CAAC AA G
CAAAACTTCTTCAGAAAATAAAAG GTATGATGAATT
AG AAAG CGTGAATG CTG AG TG CAATTG CG GTGATG AAGATTTATATAATTCTTC G ATTTTTTC AG
ATATAGTCTTCCTTG CTATG
GTTCCATTAGAATCCTTACAAACCTGAATCG CATTTG CTGCATG CTTTG CAGAAAG CATACTG G CTG
AGTG AG TTG ATATTATA
P
AC CTG ATAC CCTG ATTCA CTTAATGTG AC AA GTG ATTCT CTG ACAG AATTAATG G CTGAAG G
GTGTAAATATAA CT CAG GTTC A
TCAATGAAAATCAAAGTGTTTGATTTTTTTG ATTCG CTGTTTTCTTTTTTTATTTCG G C CA G G TATTG
AATTAATG CCATTTGAAT L."
--.1 GGAACGTTGTGTTCCGTGACCAAATCGGCTGATATCTCTCATTACCGGTTCATCTTCCCGAGACTCAAAAACTTTCAGA
o .3 G GATTTAAATATCTCATCTAATGTCG GT G TG G G AAAG T G TAACTTTA CA CTTAC GT CA G G
AC AC CT G AG T CTATTTTATTAA G G CTTT CTAATCTG TT CTC AC C G TT GT G A G AAAG
ATATTTA C CTATTTCTG ATAT G TTTTTTG A
.31 .3 AAATTTTTCTTC GTG TTCTTG TTTTATTTC AG AAA CAATTG C G G AAAG TAT CTTTC CTATTGTG
GTCGTGTTTTTG CATTTTG TTG A
GTCTTCGACAG CGTCAGACATTG CAG G GATATGAATTGGTTCCG GAAATATATTG G AG ATTG CAC
CATCTATG C CG CCAG G GT
TTTTCTTCCACGTGGTACCGTCATATACATCCAGACTTTTTTTGGCTTTTCCTGTTTCCTTATTAAATTCCTGTCTTCT
TGCAAAGG
TAAG AGTC CC GT CAATTATAAACG GAG CTATTTTTTGTTG ATTCTCTTCTG TTAA CAAAGACAG AG
TAT CATCTGTTATAC CTTG
AATAACGCCTTCAACGGATACGGGGTGTGTAGGATCGTACACATCTGATTCTGAAATCAAAGAGCCATCTAACAGCCAC
TTAAT
TG CTAAGATAATATTTGATTTTCCTGCGTTATTATAACCAACTAAAG CAGTGAAG G G G CG CAAAATAG C
CG ATG TTG ACTTA CA
IV
AG AAC G AAAG TTG CTAATTG AAA CT G AA G CAAG A C G TACA G TC ATTATTTTT C
CTTAAAT G TG CTATTTG TAT G CAATG AG TTC n ,-i ATACGAAACGCTTTTTTACATTTTATAGTCGTTGCATTCAAGGGTGCATGAGATTGCATTAAGGGAAACTGTGATATGG
CTTGG t=1 tl CTTTTGACTG GAAATACTGATG G CTCATTAGTTTTATTAAG GTG CATTAAAACCG C CC CGTG AAG
o 'a o .6.
n.) n.) un AAAGCACGGCGAGGCGGGGAAAGCACTGCGCGCTGACGGTGGTGCTGATTGTATTTTTTCAGCGTCTCAGCGCGTCGTG
ACG
GCACTTAGTCTGCCCGTTGAGGCGTTGTGTGTCTGCGGGGTGTTTTGTGCGGTGGT
w o w o 22 WilcktypecloDF13 GCGCTGCGGACACATACAAAGTTACCCACAGATTCCGTGGATAAGCAGGGGACTAACATGTGAGGCAAAACAGCAGGGC
CGC
w 4.
4.
on GCCGGTGGCGTTTTTCCATAGGCTCCGCCCTCCTGCCAGAGTTCACATAAACAGACGCTTTTCCGGTGCATCTGTGGGA
GCCGT w m GAGGCTCAACCATGAATCTGACAGTACGGGCGAAACCCGACAGGACTTAAAGATCCCCACCGTTTCCGGCGGGTCGCTC
CCTC
TTGCGCTCTCCTGTTCCGACCCTGCCGTTTACCGGATACCTGTTCCGCCTTTCTCCCTTACGGGAAGTGTGGCGCTTTC
TCATAGC
TCACACACTGGTATCTCGGCTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTAAGCAAGAACTCCCCGTTCAGCCCGA
CTGCT
GCGCCTTATCCGGTAACTGTTCACTTGAGTCCAACCCGGAAAAGCACGGTAAAACGCCACTGGCAGCAGCCATTGGTAA
CTGG
GAGTTCGCAGAGGATTTGTTTAGCTAAACACGCGGTTGCTCTTGAAGTGTGCGCCAAAGTCCGGCTACACTGGAAGGAC
AGAT
TTGGTTGCTGTGCTCTGCGAAAGCCAGTTACCACGGTTAAGCAGTTCCCCAACTGACTTAACCTTCGATCAAACCACCT
CCCCAG
GTGGTTTTTTCGTTTACAGGGCAAAAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATC
P
.
, 1-, 23 MutantcloDF13ori GCGCTGCGGACACATACAAAGTTACCCACAGATTCCGTGGATAAGCAGGGGACTAACATGTGAGGCAAAACAGCAGGGC
CGC , --.1 (higher copy number GCCGGTGGCGTTTTTCCATAGGCTCCGCCCTCCTGCCAGAGTTCACATAAACAGACGCTTTTCCGGTGCATCTGTGGGA
GCCGT
on cloD13_cop3;
GAGGCTCAACCATGAATCTGACAGTACGGGCGAAACCCGACAGGACTTAAAGATCCCCACCGTTTCCGGCGGGTCGCTC
CCTC , , , , single mutation TTGCGCTCTCCTGTTCCGACCCTGCCGTTTACCGGATACCTGTTCCGCCTTTCTCCCTTACGGGAAGTGTGGCGCTTTC
TCATAGC
versusmMcktypeis TCACACACTGGTATCTCGGCTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTAAGCAAGAACTCCCCGTTCAGCCCGA
CTGCT
shown underlined GCGCCTTATCCGGTAACTGTTCACTTGAGTCCAACCCGGAAAAGCACGGTAAAACGCCACTGGCAGCAGCCATTGGTAA
CTGG
andinbold GAGTTCGCAGAGGATTTGTTTAGCTAAACACGCGGTTGCTCTTGAAGTGTGCGCCAAAGTCCGGCTACACTGGAAGGAC
AGAT
TTGGTTGCTGTGCTCTGCGAAATCCAGTTACCACGGTTAAGCAGTTCCCCAACTGACTTAACCTTCGATCAAACCACCT
CCCCAG
GTGGTTTTTTCGTTTACAGGGCAAAAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATC
Iv n ,-i m ,-o t..) =
t..) =
'a c., 4,.
w w u, Table 7: Example Plasmids and Copy Numbers w _______________________________________________________________________________ ________________________________________ <
w i Common Vectors Copy Number OF11 Incompatibliity Group Control t.) OC
pUC -500-700 0,481 (derivative) A Relaxed pBR322 -15-20 pME31 A Relaxed PET -15-20 pBR322 A Relaxed pG EX -15-20 pBR322 A Relaxed pColE1 -15-20 ColE1 A Relaxed 0 IpR6K -15-20 R6 K ' C Stringent .
.
oe ,pACYC -10 p15A
B Relaxed .
0 ..
i ..
i IpSC101 -5 pSC 101 C Stringent ipB1Liescript -300-500 0 1E1 (derivative) and Fl"
A Relaxed pGENI -300-500 pUC and Fl -A Relaxed .0 n ,-3 ril .0 w <
F, t.) t.) !A
Claims (24)
1. A host bacterial cell comprising a) a first DNA; and b) one or more second DNAs;
wherein (i) the DNAs together comprise all genes required to produce a transduction particle comprising a copy of the first DNA packaged by phage structural proteins;
(ii) the first DNA is devoid of at least one functional essential gene required to produce the particle; and wherein the one or more second DNAs comprises said functional essential gene(s);
(iii) the first DNA comprises a phage packaging signal for producing the particle; and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
wherein (i) the DNAs together comprise all genes required to produce a transduction particle comprising a copy of the first DNA packaged by phage structural proteins;
(ii) the first DNA is devoid of at least one functional essential gene required to produce the particle; and wherein the one or more second DNAs comprises said functional essential gene(s);
(iii) the first DNA comprises a phage packaging signal for producing the particle; and (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA into transduction particles;
wherein the second DNA is required for packaging first DNA to produce particles, wherein the DNAs are operable in the cell for producing transduction particles comprising phage structural proteins that package copies of the first DNA.
2. The cell of claim 1, wherein the DNAs together encode all phage structural proteins required to produce a packaged transduction particle comprising a copy of the first DNA;
wherein the first DNA
encodes none or at least one, but not all, of the structural proteins; and wherein the one or more second DNAs encode the remainder of the structural proteins.
wherein the first DNA
encodes none or at least one, but not all, of the structural proteins; and wherein the one or more second DNAs encode the remainder of the structural proteins.
3. The cell of claim 1 or 2, wherein the first DNA is comprised by an episome that is devoid of said essential or structural protein gene(s) and/or the second DNA is comprised by an episome or a chromosome of the cell.
4. The cell of any preceding claim, wherein all of said essential genes or phage structural protein genes are comprised by the second DNA and the first DNA is devoid of said genes.
5. The cell of any preceding claim, wherein the first DNA encodes a guided nuclease or a component of a CRISPR/Cas system (optionally, a crRNA or a guide RNA).
6. The cell of any preceding claim, wherein the first DNA comprises a phage origin of replication and/or the first DNA comprises phage replication genes and phage lysis genes.
7. The cell of any preceding claim, wherein each transduction particle is a non-self replicative transduction particle.
8. The cell of any preceding claim, wherein the essential genes, structural protein genes and packaging signal are genes and a packaging signal of a tailed phage, optionally a P2, T4, T7, Phi92, lambda, K 1-or 933w phage.
9. The cell of any preceding claim, wherein the first DNA is comprised by a phage genome, wherein the phage genome is integrated in a plasmid; optionally wherein each particle is capable of infecting a target bacterium, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the NSI replaces the essential gene(s) or structural protein gene(s) of the phage.
10. The cell of any preceding claim, wherein each particle is capable of infecting a target bacterial cell, the first DNA comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, wherein the presence in the target cell of the NSI-encoded protein or RNA mediates target cell killing, or downregulation of target cell growth or propagation, optionally wherein the NSI encodes a guided nuclease or a component of a CRISPR/Cas system that is toxic to the target cell.
11. The cell of any preceding claim, wherein the packaging signal is a pac or cos sequence, or is a homologue thereof; or wherein the packaging signal is a direct terminal repeat (DTR).
12. The cell of any preceding claim, wherein the packaging signal comprises SEQ ID NO: 2 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99% identical thereto, or is a homologue thereof from a different phage.
13. An isolated DNA, comprising a first DNA as defined in any preceding claim;
or comprising a second DNA as defined in any preceding claim, optionally wherein the isolated DNA is comprised by a plasmid.
or comprising a second DNA as defined in any preceding claim, optionally wherein the isolated DNA is comprised by a plasmid.
14. A kit comprising (a) a cell wherein the cell comprises a second DNA as defined in any one of claims 1 to 12, but the cell does not comprise the first DNA as defined in any one of claims 1 to 12; and (b) a vector (optionally a plasmid) comprising the first DNA, wherein the vector is not comprised by the cell;
optionally, wherein the cell is a bacterial or archaeal cell.
optionally, wherein the cell is a bacterial or archaeal cell.
15. A method of producing a transduction particle composition, the method comprising expressing phage structural proteins in a cell and replicating in the cell first DNA, wherein transduction particles are produced that comprise packaged first DNA; and optionally separating an amount of transduction particles from cellular material wherein an amount of purified transduction particles is obtained, wherein the cell is a cell of any one of claims 1 to 12 when dependent from claim 2.
16. A composition comprising a population of transduction particles obtainable by the method of claim 15.
17. The method of claim 15 or the composition of claim 16, wherein the second DNA is comprised by plasmid DNA and less than 5% of total DNA comprised by the composition is DNA
of said plasmid.
of said plasmid.
18. The cell, DNA or composition of any one of claims 1 to 13, 16 and 17 for administration to a human or animal subject for medical use.
19. The cell, DNA or composition of any one of claims 1 to 13, 16 and 17 for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the particles are capable of infecting and killing the target cells, optionally wherein the infection is a gut, blood, lung or uterine tract microbiome infection.
20. The cell, DNA or composition of any one of claims 1 to 13, 16 and 17 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by target bacteria and the target bacteria are comprised by the subject (optionally comprised by a gut, blood, lung or uterine tract microbiome), the method comprising administering the composition to the subject, whereby the target bacteria are exposed to antibacterial means encoded by the first DNA and killed, and propagation of the transduction particles is contained.
21. The composition of claim 16 or 17 for controlling in a human or animal subject the dosing of transduction particle treatment of a target bacterial cell infection in the subject, wherein the particles are capable of transducing first DNA into the target cells, the first DNA
encoding antibacterial means that is toxic to target cells whereby target cells are killed.
encoding antibacterial means that is toxic to target cells whereby target cells are killed.
22. The composition of claim 18, 19, 20 or 21 for reducing the risk of acquisition of foreign gene sequence(s) by the particles in the subject.
23. A method of treating an environment ex vivo, the method comprising exposing the environment to a composition comprising a population of particles, wherein the particles are capable of transducing first DNA into target cells comprised by the environment, the first DNA
encoding antibacterial means that is toxic to target cells whereby target cells are killed, wherein the composition is a composition according to claim 16 or 17.
encoding antibacterial means that is toxic to target cells whereby target cells are killed, wherein the composition is a composition according to claim 16 or 17.
24. The method of claim 23, wherein the method is for (a) containing the treatment in the environment;
(b) reducing the risk of acquisition of foreign gene sequence(s) by the particles in the environment; and/or (c) controlling the dosing of the particle treatment in the environment.
(b) reducing the risk of acquisition of foreign gene sequence(s) by the particles in the environment; and/or (c) controlling the dosing of the particle treatment in the environment.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1907242.0A GB201907242D0 (en) | 2019-05-22 | 2019-05-22 | Dna methods etc ii |
GB1907242.0 | 2019-05-22 | ||
PCT/EP2020/064225 WO2020234428A1 (en) | 2019-05-22 | 2020-05-21 | Phage and transduction particles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3137804A1 true CA3137804A1 (en) | 2020-11-26 |
Family
ID=67385351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3137804A Pending CA3137804A1 (en) | 2019-05-22 | 2020-05-21 | Phage and transduction particles |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3973052A1 (en) |
JP (1) | JP2022542742A (en) |
CN (1) | CN114144517A (en) |
AU (1) | AU2020278898A1 (en) |
CA (1) | CA3137804A1 (en) |
GB (1) | GB201907242D0 (en) |
SG (1) | SG11202111779PA (en) |
WO (1) | WO2020234428A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112391357A (en) * | 2019-08-14 | 2021-02-23 | 宁波大学 | Aeromonas sobria efficient lytic phage vB _ AsoP-yong and application thereof |
CN115418324B (en) * | 2020-07-15 | 2023-09-01 | 北京工商大学 | New strain of Mei Zeshi bacteria of North Industrial and commercial and application thereof |
CN113046328B (en) * | 2021-04-13 | 2023-07-25 | 吉林大学 | Stellera suppurative phage and medical application thereof |
WO2023056413A1 (en) * | 2021-09-30 | 2023-04-06 | Board Of Regents, The University Of Texas System | Engineered vectors and organisms containing the same for isoflavone conversion in the gut |
CN114934059B (en) * | 2022-03-04 | 2023-02-21 | 深圳先进技术研究院 | Method for simplifying phage genome framework in high flux |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1677834B1 (en) * | 2003-10-06 | 2014-01-08 | Gangagen, Inc. | Defined dose therapeutic phage |
US10351452B2 (en) * | 2014-01-29 | 2019-07-16 | Synphagen Llc | Compositions for in vivo expression of therapeutic sequences in the microbiome |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
WO2017009399A1 (en) * | 2015-07-13 | 2017-01-19 | Institut Pasteur | Improving sequence-specific antimicrobials by blocking dna repair |
-
2019
- 2019-05-22 GB GBGB1907242.0A patent/GB201907242D0/en not_active Ceased
-
2020
- 2020-05-21 SG SG11202111779PA patent/SG11202111779PA/en unknown
- 2020-05-21 CN CN202080052941.3A patent/CN114144517A/en active Pending
- 2020-05-21 JP JP2021569069A patent/JP2022542742A/en active Pending
- 2020-05-21 WO PCT/EP2020/064225 patent/WO2020234428A1/en unknown
- 2020-05-21 AU AU2020278898A patent/AU2020278898A1/en not_active Abandoned
- 2020-05-21 CA CA3137804A patent/CA3137804A1/en active Pending
- 2020-05-21 EP EP20727987.8A patent/EP3973052A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
SG11202111779PA (en) | 2021-12-30 |
WO2020234428A1 (en) | 2020-11-26 |
GB201907242D0 (en) | 2019-07-03 |
EP3973052A1 (en) | 2022-03-30 |
AU2020278898A1 (en) | 2021-12-16 |
CN114144517A (en) | 2022-03-04 |
JP2022542742A (en) | 2022-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3137804A1 (en) | Phage and transduction particles | |
US20230330167A1 (en) | Phage and transduction particles | |
US11788085B2 (en) | Treating and preventing microbial infections | |
US11629350B2 (en) | Single-vector type I vectors | |
EP3645716A2 (en) | Altering microbial populations&modifying microbiota | |
BR112020019418A2 (en) | treatment and prevention of microbial infections | |
US20220162270A1 (en) | Methods, uses & compositions | |
EP3909644A1 (en) | Host bacterium specific nanoparticle | |
US20220226396A1 (en) | Antibacterial agents & methods | |
EP4217473A2 (en) | Synthetic viruses | |
CA3171200A1 (en) | Multiplex crispr/cas system for modifying cell genomes | |
US20220275380A1 (en) | Plasmids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220907 |
|
EEER | Examination request |
Effective date: 20220907 |
|
EEER | Examination request |
Effective date: 20220907 |
|
EEER | Examination request |
Effective date: 20220907 |